FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Xu, HY
Yang, YJ
Tang, XR
Sabatine, M
Wiviott, S
AF Xu, Haiyan
Yang, YueJin
Tang, Xinran
Sabatine, Marc
Wiviott, Stephen
TI ACUTE MYOCARDIAL INFARCTION CARE ACROSS THREE LEVELS OF HOSPITALS IN
CHINA: A REPORT FROM THE CHINA ACUTE MYOCARDIAL INFARCTION REGISTRY
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT Scientific Session of the American-College-of-Cardiology (ACC)
CY MAR 14-16, 2015
CL San Diego, CA
SP Amer Coll Cardiol
C1 Fuwai Hosp, Beijing, Peoples R China.
TIMI Study Grp, Boston, MA USA.
NR 0
TC 0
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAR 17
PY 2015
VL 65
IS 10
SU S
MA 1175-068
BP A137
EP A137
DI 10.1016/S0735-1097(15)60137-1
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DL0ND
UT WOS:000375328800138
ER
PT J
AU Young, M
Kennedy, K
Yeh, R
AF Young, Michael
Kennedy, Kevin
Yeh, Robert
TI NATIONAL UTILIZATION PATTERNS OF TRANSCATHETER AORTIC VALVE REPLACEMENT
SHORTLY AFTER DEVICE APPROVAL
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT Scientific Session of the American-College-of-Cardiology (ACC)
CY MAR 14-16, 2015
CL San Diego, CA
SP Amer Coll Cardiol
C1 Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAR 17
PY 2015
VL 65
IS 10
SU S
MA 1261-348
BP A2030
EP A2030
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DL0ND
UT WOS:000375328802352
ER
PT J
AU Elder, GA
Sosa, MAG
De Gasperi, R
Stone, JR
Dickstein, DL
Haghighi, F
Hof, PR
Ahlers, ST
AF Elder, Gregory A.
Sosa, Miguel A. Gama
De Gasperi, Rita
Stone, James Radford
Dickstein, Dara L.
Haghighi, Fatemeh
Hof, Patrick R.
Ahlers, Stephen T.
TI Vascular and inflammatory factors in the pathophysiology of
blast-induced brain injury
SO FRONTIERS IN NEUROLOGY
LA English
DT Review
DE animal models; blast; inflammation; traumatic brain injury; vascular
pathology
ID CENTRAL-NERVOUS-SYSTEM; POSTTRAUMATIC-STRESS-DISORDER; CHRONIC TRAUMATIC
ENCEPHALOPATHY; MISSILE EXTREMITY IMPACT; PRESSURE WAVE INJURIES;
TIME-DEPENDENT CHANGES; NON-PENETRATIVE BLAST; SHOCK-WAVE; RAT MODEL;
INDUCED NEUROTRAUMA
AB Blast-related traumatic brain injury (TBI) has received much recent attention because of its frequency in the conflicts in Iraq and Afghanistan. This renewed interest has led to a rapid expansion of clinical and animal studies related to blast. In humans, high-level blast exposure is associated with a prominent hemorrhagic component. In animal models, blast exerts a variety of effects on the nervous system including vascular and inflammatory effects that can be seen with even low-level blast exposures which produce minimal or no neuronal pathology. Acutely, blast exposure in animals causes prominent vasospasm and decreased cerebral blood flow along with blood-brain barrier breakdown and increased vascular permeability. Besides direct effects on the central nervous system, evidence supports a role fora thoracically mediated effect of blast; whereby, pressure waves transmitted through the systemic circulation damage the brain. Chronically, a vascular pathology has been observed that is associated with alterations of the vascular extracellular matrix. Sustained microglial and astroglial reactions occur after blast exposure. Markers of a central and peripheral inflammatory response are found for sustained periods after blast injury and include elevation of inflammatory cytokines and other inflammatory mediators. At low levels of blast exposure, a microvascular pathology has been observed in the presence of an otherwise normal brain parenchyma, suggesting that the vasculature may be selectively vulnerable to blast injury. Chronic immune activation in brain following vascular injury may lead to neurobehavioral changes in the absence of direct neuronal pathology. Strategies aimed at preventing or reversing vascular damage or modulating the immune response may improve the chronic neuropsychiatric symptoms associated with blast-related TBI.
C1 [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA.
[Elder, Gregory A.; Sosa, Miguel A. Gama; De Gasperi, Rita; Haghighi, Fatemeh] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.
[Elder, Gregory A.; Sosa, Miguel A. Gama; De Gasperi, Rita; Dickstein, Dara L.; Haghighi, Fatemeh; Hof, Patrick R.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.
[Sosa, Miguel A. Gama; De Gasperi, Rita; Haghighi, Fatemeh] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, Bronx, NY 10468 USA.
[Stone, James Radford] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA USA.
[Stone, James Radford] Univ Virginia, Dept Neurosurg, Charlottesville, VA USA.
[Dickstein, Dara L.; Haghighi, Fatemeh; Hof, Patrick R.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA.
[Dickstein, Dara L.; Hof, Patrick R.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Care, New York, NY 10029 USA.
[Ahlers, Stephen T.] Naval Med Res Ctr, Dept Neurotrauma, Operat & Undersea Med Directorate, Silver Spring, MD USA.
RP Elder, GA (reprint author), James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, 3E16,130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM gregory.elder@va.gov
FU Department of Veterans Affairs; Veterans Health Administration;
Rehabilitation Research and Development Service [1I01RX000179-01,
1I01RX000996-01]
FX The authors have received research support from the Department of
Veterans Affairs, Veterans Health Administration, Rehabilitation
Research and Development Service Awards 1I01RX000179-01 and
1I01RX000996-01. The views expressed in this article are those of the
authors and do not necessarily reflect the official policy or position
of the Department of the Navy, Department of Defense, nor the U.S.
Government. STA is a military service member (or employe of the U.S.
Government). This work was prepared as part of his official duties.
Title 17 U.S.C. 105 provides that copyright protection under this title
is not available for any work of the United States Government. Title 17
U.S.C. 101 defines a U.S. Government work as a work prepared by a
military service member or employe of the U.S. Government as part of
that person's official duties.
NR 147
TC 9
Z9 10
U1 3
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD MAR 16
PY 2015
VL 6
AR UNSP 48
DI 10.3389/fneur.2015.00048
PG 22
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CU8CX
UT WOS:000363769900001
PM 25852632
ER
PT J
AU Ross, JM
Coxe, S
Schuster, RM
Rojas, A
Gonzalez, R
AF Ross, J. Megan
Coxe, Stefany
Schuster, Randi M.
Rojas, Angelica
Gonzalez, Raul
TI The moderating effects of cannabis use and decision making on the
relationship between conduct disorder and risky sexual behavior
SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY
LA English
DT Article
DE Conduct disorder; Risky sexual behavior; Cannabis; Decision making
ID LIFE-COURSE-PERSISTENT; VENTROMEDIAL PREFRONTAL CORTEX; LIMITED
ANTISOCIAL PATHWAYS; ADOLESCENT SUBSTANCE USE; YOUNG-ADULTS;
UNITED-STATES; CHILDHOOD PREDICTORS; TAKING BEHAVIOR; GAMBLING TASK;
MARIJUANA USE
AB Risky sexual behavior (RSB) is a current public health concern affecting adolescents and young adults. Conduct disorder, cannabis use, and decision-making (DM) ability are interrelated constructs that are relevant to RSB; however, there is little research on the association of DM and RSB. Participants were 79 cannabis users assessed through self-report measures of RSB and mental health and a timeline follow-back procedure for substance use. DM ability was assessed via the Iowa Gambling Task. We found that more conduct disorder symptoms accounted for unique variance in measures of overall RSB and an earlier initiation of oral sex, even when taking into account DM and cannabis use. Amount of cannabis use and DM ability moderated the relationships between number of conduct disorder symptoms and number of oral sex partners and age of initiation for vaginal sex. An increase in conduct disorder symptoms was associated with more oral sex partners when DM was poor and fewer partners when DM was better; however, this relationship was only present at higher levels of cannabis use. Furthermore, when DM was poor, more conduct disorder symptoms predicted a younger age of initiation of vaginal sex, with the age decreasing as amount of cannabis use increased. Determining how DM influences RSB may assist in the identification of novel treatment approaches to reduce engagement in RSB.
C1 [Ross, J. Megan; Coxe, Stefany; Rojas, Angelica; Gonzalez, Raul] Florida Int Univ, Dept Psychol, Ctr Children & Families, Miami, FL 33199 USA.
[Schuster, Randi M.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, Boston, MA 02114 USA.
RP Ross, JM (reprint author), Florida Int Univ, Ctr Children & Families, 11200 SW 8th St,AHC1 Rm 140, Miami, FL 33199 USA.
EM jmross@fiu.edu
FU National Institute on Drug Abuse [K23 DA023560, R01 DA031176, R01
DA033156]
FX This work was supported by the National Institute on Drug Abuse [grant
number K23 DA023560], [grant number R01 DA031176], [grant number R01
DA033156] (PI: R. Gonzalez).
NR 76
TC 1
Z9 1
U1 4
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1380-3395
EI 1744-411X
J9 J CLIN EXP NEUROPSYC
JI J. Clin. Exp. Neuropsychol.
PD MAR 16
PY 2015
VL 37
IS 3
BP 303
EP 315
DI 10.1080/13803395.2015.1010489
PG 13
WC Psychology, Clinical; Clinical Neurology; Psychology
SC Psychology; Neurosciences & Neurology
GA CI7FV
UT WOS:000354929200007
PM 25832553
ER
PT J
AU Gard, T
Taquet, M
Dixit, R
Holzel, BK
Dickerson, BC
Lazar, SW
AF Gard, Tim
Taquet, Maxime
Dixit, Rohan
Hoelzel, Britta K.
Dickerson, Bradford C.
Lazar, Sara W.
TI Greater widespread functional connectivity of the caudate in older
adults who practice kripalu yoga and vipassana meditation than in
controls
SO FRONTIERS IN HUMAN NEUROSCIENCE
LA English
DT Article
DE caudate; functional connectivity; graph theory; degree centrality; yoga;
mindfulness meditation; aging; basal ganglia-thalamocortical circuits
ID STRESS REDUCTION PROGRAM; BRAIN GABA LEVELS; BASAL GANGLIA;
INDIVIDUAL-DIFFERENCES; NETWORK CONNECTIVITY; TERM MEDITATION;
WORKING-MEMORY; RESTING STATE; MINDFULNESS; CIRCUITS
AB There has been a growing interest in understanding how contemplative practices affect brain functional organization. However, most studies have restricted their exploration to predefined networks. Furthermore, scientific comparisons of different contemplative traditions are largely lacking. Here we explored differences in whole brain resting state functional connectivity between experienced yoga practitioners, experienced meditators, and matched controls. Analyses were repeated in an independent sample of experienced meditators and matched controls. Analyses utilizing Network Based Statistics (Zalesky et al., 2010) revealed difference components for yoga practitioners > controls and meditators > controls in which the right caudate was a central node. Follow up analyses revealed that yoga practitioners and meditators had significantly greater degree centrality in the caudate than controls. This greater degree centrality was not driven by single connections but by greater connectivity between the caudate and numerous brain regions. Findings of greater caudate connectivity in meditators than in controls was replicated in an independent dataset. These findings suggest that yoga and meditation practitioners have stronger functional connectivity within basal ganglia cortico-thalamic feedback loops than non practitioners. Although we could not provide evidence for its mechanistic role, this greater connectivity might be related to the often reported effects of meditation and yoga on behavioral flexibility, mental health, and well-being.
C1 [Gard, Tim; Hoelzel, Britta K.; Dickerson, Bradford C.; Lazar, Sara W.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA.
[Gard, Tim] Univ Giessen, Bender Inst Neuroimaging, D-35390 Giessen, Germany.
[Gard, Tim] Maastricht Univ, Fac Psychol & Neurosci, NL-6200 MD Maastricht, Netherlands.
[Taquet, Maxime] Catholic Univ Louvain, Inst Informat & Commun Elect, Louvain La Neuve, Belgium.
[Taquet, Maxime] Catholic Univ Louvain, Inst Appl Math, Louvain La Neuve, Belgium.
[Dixit, Rohan] BrainBot, San Francisco, CA USA.
[Hoelzel, Britta K.] Tech Univ Munich, Klinikum Rechts Isar, Dept Neuroradiol, D-80290 Munich, Germany.
RP Gard, T (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA.
EM tgard@nmr.mgh.harvard.edu
RI Lazar, Sara/G-3809-2012
OI Lazar, Sara/0000-0003-1126-8363
FU NIH [R21AT003673, K01AT00694, R01AT006344]; Kripalu Institute for
Extraordinary Living; Shared Instrumentation Grants [1S10RR023401,
S10RR019307, 1S10RR023043]
FX This study was funded by NIH award R21AT003673, K01AT00694, and
R01AT006344, and awards from the Kripalu Institute for Extraordinary
Living, Sarah Hancock, and Jeff Walker. The project was made possible by
the resources provided by Shared Instrumentation Grants 1S10RR023401,
S10RR019307, and 1S10RR023043. We also would like to thank all
participants for their contribution.
NR 72
TC 2
Z9 2
U1 6
U2 33
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5161
J9 FRONT HUM NEUROSCI
JI Front. Hum. Neurosci.
PD MAR 16
PY 2015
VL 9
AR UNSP 137
DI 10.3339/fnhum.2015.DD137
PG 12
WC Neurosciences; Psychology
SC Neurosciences & Neurology; Psychology
GA CF3XJ
UT WOS:000352482100001
PM 25852521
ER
PT J
AU Pereira, RC
Juppner, H
Gales, B
Salusky, IB
Wesseling-Perry, K
AF Pereira, Renata C.
Jueppner, Harald
Gales, Barbara
Salusky, Isidro B.
Wesseling-Perry, Katherine
TI Osteocytic Protein Expression Response to Doxercalciferol Therapy in
Pediatric Dialysis Patients
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR 23; DENTIN MATRIX PROTEIN-1; CHRONIC KIDNEY-DISEASE;
C-TERMINAL FRAGMENT; PARATHYROID-HORMONE; SECONDARY HYPERPARATHYROIDISM;
PHOSPHATE HOMEOSTASIS; RENAL OSTEODYSTROPHY; BREAST-CARCINOMA;
GENE-EXPRESSION
AB Background
Osteocytic protein expression is dysregulated in CKD and is affected by changes in mineral metabolism; however the effects of active vitamin D sterol therapy on osteocyte protein expression in advanced CKD is unknown.
Methods
Eleven pediatric patients with end stage kidney disease underwent bone biopsy, were treated for 8 months with doxercalciferol, and then underwent a second bone biopsy. Bone expression of fibroblast growth factor 23 (FGF23), dentin matrix protein 1 (DMP1), and sclerostin were determined by immunohistochemistry and quantified by Ariol Scanning. Western blot analysis and qRT-PCR was performed on bone abstracts of a subset of study subjects to determine the nature (i.e. size) of FGF23 and DMP1 in bone before and after therapy.
Results
As assessed by immunohistochemistry, bone FGF23, DMP1 and sclerostin protein all increased with therapy. In the case of FGF23, this increase was due to an increase in the full-length molecule without the appearance of FGF23 fragments. DMP1 was present primarily in its full-length formin healthy controls while 57kDa and 37kDa fragments of DMP1 were apparent in bone of dialysis patients at baseline and the 57 kDa appeared to decrease with therapy.
Conclusion
Marked changes in osteocytic protein expression accompany doxercalciferol therapy, potentially impacting bone mineralization and the skeletal response to PTH. The effects of these bone changes on long-term outcomes remain to be determined.
C1 [Pereira, Renata C.; Gales, Barbara; Salusky, Isidro B.; Wesseling-Perry, Katherine] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA.
[Jueppner, Harald] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Jueppner, Harald] Massachusetts Gen Hosp, Pediat Nephrol Unit, Boston, MA 02114 USA.
[Jueppner, Harald] Harvard Univ, Sch Med, Boston, MA USA.
RP Wesseling-Perry, K (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA.
EM kwesseling@mednet.ucla.edu
FU USPHS [DK-67563, DK-35423, DK-080984, PO-1DK11794]; CTSI [UL1
TR-000124]; Casey Lee Ball Foundation
FX This work was supported in part by USPHS grants DK-67563, DK-35423,
DK-080984, PO-1DK11794, and CTSI grant UL1 TR-000124 and funds from the
Casey Lee Ball Foundation. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 37
TC 6
Z9 6
U1 2
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 16
PY 2015
VL 10
IS 3
AR e0120856
DI 10.1371/journal.pone.0120856
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CD6EY
UT WOS:000351183500195
PM 25774916
ER
PT J
AU Kim, DK
Lee, J
Kim, SR
Choi, DS
Yoon, YJ
Kim, JH
Go, G
Nhung, D
Hong, K
Jang, SC
Kim, SH
Park, KS
Kim, OY
Park, HT
Seo, JH
Aikawa, E
Baj-Krzyworzeka, M
van Balkom, BWM
Belting, M
Blanc, L
Bond, V
Bongiovanni, A
Borras, FE
Buee, L
Buzas, EI
Cheng, L
Clayton, A
Cocucci, E
Dela Cruz, CS
Desiderio, DM
Di Vizio, D
Ekstrom, K
Falcon-Perez, JM
Gardiner, C
Giebel, B
Greening, DW
Gross, JC
Gupta, D
Hendrix, A
Hill, AF
Hill, MM
Hoen, EN
Hwang, DW
Inal, J
Jagannadham, MV
Jayachandran, M
Jee, YK
Jorgensen, M
Kim, KP
Kim, YK
Kislinger, T
Lasser, C
Lee, DS
Lee, H
van Leeuwen, J
Lener, T
Liu, ML
Lotvall, J
Marcilla, A
Mathivanan, S
Moller, A
Morhayim, J
Mullier, F
Nazarenko, I
Nieuwland, R
Nunes, DN
Pang, K
Park, J
Patel, T
Pocsfalvi, G
del Portillo, H
Putz, U
Ramirez, MI
Rodrigues, ML
Roh, TY
Royo, F
Sahoo, S
Schiffelers, R
Sharma, S
Siljander, P
Simpson, RJ
Soekmadji, C
Stahl, P
Stensballe, A
Stepien, E
Tahara, H
Trummer, A
Valadi, H
Vella, LJ
Wai, SN
Witwer, K
Yanez-Mo, M
Youn, H
Zeidler, R
Gho, YS
AF Kim, Dae-Kyum
Lee, Jaewook
Kim, Sae Rom
Choi, Dong-Sic
Yoon, Yae Jin
Kim, Ji Hyun
Go, Gyeongyun
Nhung, Dinh
Hong, Kahye
Jang, Su Chul
Kim, Si-Hyun
Park, Kyong-Su
Kim, Oh Youn
Park, Hyun Taek
Seo, Ji Hye
Aikawa, Elena
Baj-Krzyworzeka, Monika
van Balkom, Bas W. M.
Belting, Mattias
Blanc, Lionel
Bond, Vincent
Bongiovanni, Antonella
Borras, Francesc E.
Buee, Luc
Buzas, Edit I.
Cheng, Lesley
Clayton, Aled
Cocucci, Emanuele
Dela Cruz, Charles S.
Desiderio, Dominic M.
Di Vizio, Dolores
Ekstrom, Karin
Falcon-Perez, Juan M.
Gardiner, Chris
Giebel, Bernd
Greening, David W.
Gross, Julia Christina
Gupta, Dwijendra
Hendrix, An
Hill, Andrew F.
Hill, Michelle M.
Hoen, Esther Nolte-'t
Hwang, Do Won
Inal, Jameel
Jagannadham, Medicharla V.
Jayachandran, Muthuvel
Jee, Young-Koo
Jorgensen, Malene
Kim, Kwang Pyo
Kim, Yoon-Keun
Kislinger, Thomas
Lasser, Cecilia
Lee, Dong Soo
Lee, Hakmo
van Leeuwen, Johannes
Lener, Thomas
Liu, Ming-Lin
Lotvall, Jan
Marcilla, Antonio
Mathivanan, Suresh
Moeller, Andreas
Morhayim, Jess
Mullier, Francois
Nazarenko, Irina
Nieuwland, Rienk
Nunes, Diana N.
Pang, Ken
Park, Jaesung
Patel, Tushar
Pocsfalvi, Gabriella
del Portillo, Hernando
Putz, Ulrich
Ramirez, Marcel I.
Rodrigues, Marcio L.
Roh, Tae-Young
Royo, Felix
Sahoo, Susmita
Schiffelers, Raymond
Sharma, Shivani
Siljander, Pia
Simpson, Richard J.
Soekmadji, Carolina
Stahl, Philip
Stensballe, Allan
Stepien, Ewa
Tahara, Hidetoshi
Trummer, Arne
Valadi, Hadi
Vella, Laura J.
Wai, Sun Nyunt
Witwer, Kenneth
Yanez-Mo, Maria
Youn, Hyewon
Zeidler, Reinhard
Gho, Yong Song
TI EVpedia: a community web portal for extracellular vesicles research
SO BIOINFORMATICS
LA English
DT Article
ID MEMBRANE-VESICLES; PROTEOMIC ANALYSIS; EXOSOMES; MICROPARTICLES; CANCER;
CELLS; DELIVERY; PLASMA; PROSTASOMES; EXPRESSION
AB Motivation: Extracellular vesicles (EVs) are spherical bilayered proteolipids, harboring various bioactive molecules. Due to the complexity of the vesicular nomenclatures and components, online searches for EV-related publications and vesicular components are currently challenging.
Results: We present an improved version of EVpedia, a public database for EVs research. This community web portal contains a database of publications and vesicular components, identification of orthologous vesicular components, bioinformatic tools and a personalized function. EVpedia includes 6879 publications, 172 080 vesicular components from 263 high-throughput datasets, and has been accessed more than 65 000 times from more than 750 cities. In addition, about 350 members from 73 international research groups have participated in developing EVpedia. This free web-based database might serve as a useful resource to stimulate the emerging field of EV research.
C1 [Kim, Dae-Kyum; Lee, Jaewook; Kim, Sae Rom; Choi, Dong-Sic; Kim, Ji Hyun; Go, Gyeongyun; Nhung, Dinh; Hong, Kahye; Jang, Su Chul; Kim, Si-Hyun; Park, Kyong-Su; Kim, Oh Youn; Park, Hyun Taek; Seo, Ji Hye; Roh, Tae-Young; Gho, Yong Song] Pohang Univ Sci & Technol, Dept Life Sci, Pohang, South Korea.
[Yoon, Yae Jin; Roh, Tae-Young] Pohang Univ Sci & Technol, Div Integrat Biosci & Biotechnol, Pohang, South Korea.
[Aikawa, Elena] Harvard Univ, Sch Med, Brigham & Womens Hosp, Cardiovasc Med, Boston, MA USA.
[Baj-Krzyworzeka, Monika] Jagiellonian Univ, Coll Med, Polish Amer Inst Paediat, Dept Clin Immunol, Krakow, Poland.
[van Balkom, Bas W. M.] Univ Med Ctr Utrecht, Dept Hypertens & Nephrol, Utrecht, Netherlands.
[Belting, Mattias] Lund Univ, Dept Clin Sci, Sect Oncol, Lund, Sweden.
[Blanc, Lionel] Feinstein Inst Med Res, Manhasset, NY USA.
[Bond, Vincent] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA.
[Bongiovanni, Antonella] CNR, Inst Biomed & Mol Immunol IBIM, Palermo, Italy.
[Borras, Francesc E.] Germans Trias & Pujol Univ Hosp, Germans Trias & Pujol Res Inst, Innovat Vesicles & Cells Applicat Therapy, Badalona, Spain.
[Buee, Luc] INSERM, JEAN PIERRE Aubert Res Ctr, UMR837, F-59045 Lille, France.
[Buzas, Edit I.] Semmelweis Univ, Dept Genet Cell & Immunobiol, H-1085 Budapest, Hungary.
[Cheng, Lesley; Hill, Andrew F.] Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst BIO21, Melbourne, Vic, Australia.
[Clayton, Aled] Cardiff Univ, Sch Med, Velindre Canc Ctr, Inst Canc & Genet, Cardiff CF10 3AX, S Glam, Wales.
[Cocucci, Emanuele] Harvard Univ, Sch Med, Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
[Cocucci, Emanuele] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA.
[Dela Cruz, Charles S.] Yale Univ, Sch Med, Dept Internal Med, Sect Pulm Crit Care & Sleep Med, New Haven, CT 06510 USA.
[Desiderio, Dominic M.] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Neurol, Memphis, TN USA.
[Di Vizio, Dolores] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Canc Biol Program, Los Angeles, CA 90048 USA.
[Ekstrom, Karin] Univ Gothenburg, Inst Clin Sci, Dept Biomat, Sahlgrenska Acad, Gothenburg, Sweden.
[Ekstrom, Karin] BIOMATCELL VINN Excellence Ctr Biomat & Cell Ther, Gothenburg, Sweden.
[Falcon-Perez, Juan M.; Royo, Felix] IKERBASQUE Res Fdn, Metabol Unit, CIC BioGUNE, Derio, Bizkaia, Spain.
[Gardiner, Chris] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford, England.
[Giebel, Bernd] Univ Duisburg Essen, Univ Hosp Essen, Inst Transfus Med, Essen, Germany.
[Greening, David W.; Mathivanan, Suresh; Simpson, Richard J.] La Trobe Univ, La Trobe Inst Mol Sci LIMS, Melbourne, Vic, Australia.
[Gross, Julia Christina] German Canc Res Ctr, Div Signaling & Funct Genom, Heidelberg, Germany.
[Gupta, Dwijendra] Jai Prakash Univ, Chapra, Bihar, India.
[Hendrix, An] Ghent Univ Hosp, Dept Radiat Oncol & Expt Canc Res, Lab Expt Canc Res, Ghent, Belgium.
[Hill, Michelle M.] Univ Queensland, Translat Res Inst, Diamantina Inst, Brisbane, Qld, Australia.
[Hoen, Esther Nolte-'t] Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, Utrecht, Netherlands.
[Hwang, Do Won; Lee, Dong Soo; Youn, Hyewon] Seoul Natl Univ, Coll Med, Dept Nucl Med, Seoul, South Korea.
[Inal, Jameel] London Metropolitan Univ, Fac Life Sci & Comp, Cellular & Mol Immunol Res Ctr, London, England.
[Jagannadham, Medicharla V.] CSIR, Ctr Cellular & Mol Biol, Hyderabad, Andhra Pradesh, India.
[Jayachandran, Muthuvel] Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN USA.
[Jee, Young-Koo] Dankook Univ, Coll Med, Dept Internal Med, Cheonan, South Korea.
[Jorgensen, Malene] Aalborg Univ Hosp, Dept Clin Immunol, Aalborg, Denmark.
[Kim, Kwang Pyo] Kyung Hee Univ, Dept Appl Chem, Yongin, South Korea.
[Kim, Yoon-Keun] Ewha Womans Univ, Med Ctr, Seoul, South Korea.
[Kislinger, Thomas] Ontario Canc Inst, Toronto, ON M4X 1K9, Canada.
[Lasser, Cecilia; Lotvall, Jan] Univ Gothenburg, Sahlgrenska Acad, Krefting Res Ctr, Gothenburg, Sweden.
[Lee, Hakmo] Seoul Natl Univ Hosp, Biomed Res Inst, Seoul 110744, South Korea.
[van Leeuwen, Johannes; Morhayim, Jess] Erasmus Univ, Med Ctr, Dept Internal Med, Rotterdam, Netherlands.
[Lener, Thomas] Paracelsus Med Univ, Univ Hosp Salzburg, Dept Blood Grp Serol & Transfus Med, Salzburg, Austria.
[Lener, Thomas] Paracelsus Med Univ, Spinal Cord Injury & Tissue Regenerat Ctr Salzbur, Salzburg, Austria.
[Liu, Ming-Lin] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Liu, Ming-Lin] Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19122 USA.
[Marcilla, Antonio] Univ Valencia, Dept Biol Celular & Parasitol, Area Parasitol, Valencia, Spain.
[Moeller, Andreas] QIMR Berghofer Med Res Inst, Tumour Microenvironm Lab, Herston, Qld, Australia.
[Mullier, Francois] Catholic Univ Louvain, Hematol Lab, Namur Thrombosis & Hemostasis Ctr, NARILIS,CHU Dinant Godinne UCL Namur, Louvain, Belgium.
[Mullier, Francois] Univ Namur, Dept Pharm, NARILIS, Namur Thrombosis & Hemostasis Ctr, Naumr, Belgium.
[Nazarenko, Irina] Med Ctr Univ Freiburg, Inst Environm Hlth Sci, Freiburg, Germany.
[Nazarenko, Irina] Med Ctr Univ Freiburg, Hosp Infect Control, Freiburg, Germany.
[Nieuwland, Rienk] Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, NL-1105 AZ Amsterdam, Netherlands.
[Nunes, Diana N.] AC Camargo Canc Ctr, Lab Med Genom, Sao Paulo, Brazil.
[Pang, Ken] Walter & Eliza Hall Inst Med Res, Inflammat Div, Parkville, Vic, Australia.
[Pang, Ken] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia.
[Park, Jaesung] Pohang Univ Sci & Technol, Dept Mech Engn, Pohang, South Korea.
[Patel, Tushar] Mayo Clin, Dept Transplantat & Canc Biol, Jacksonville, FL 32224 USA.
[Pocsfalvi, Gabriella] Natl Res Council Italy, Mass Spectrometry & Prote, Inst Biosci & Bior, Naples, Italy.
[del Portillo, Hernando] Barcelona Ctr Int Hlth Res, ICREA, Barcelona, Spain.
[Putz, Ulrich] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia.
[Ramirez, Marcel I.] Fundacao Oswaldo Cruz, Lab Mol Biol Parasites & Vectors, Rio De Janeiro, Brazil.
[Rodrigues, Marcio L.] Univ Fed Rio de Janeiro, Paulo Goes Microbiol Inst, Rio De Janeiro, Brazil.
[Rodrigues, Marcio L.] Fundacao Oswaldo Cruz, Ctr Technol Dev Hlth CDTS, Rio De Janeiro, Brazil.
[Sahoo, Susmita] Icahn Sch Med Mt Sinai, Cardiovasc Res Inst, New York, NY 10029 USA.
[Schiffelers, Raymond] Univ Med Ctr Utrecht, Dept Clin Chem & Hematol, Utrecht, Netherlands.
[Sharma, Shivani] Univ Calif Los Angeles, Calif Nanosyst Inst, Los Angeles, CA USA.
[Siljander, Pia] Univ Helsinki, Dept Biosci, Div Biochem & Biotechnol, Helsinki, Finland.
[Soekmadji, Carolina] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4001, Australia.
[Stahl, Philip] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.
[Stensballe, Allan] Aalborg Univ, Dept Hlth Sci & Technol, Aalborg, Denmark.
[Stepien, Ewa] Jagiellonian Univ, Dept Med Phys, Krakow, Poland.
[Tahara, Hidetoshi] Hiroshima Univ, Grad Sch Biomed Sci, Dept Cellular & Mol Biol, Hiroshima, Japan.
[Trummer, Arne] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany.
[Valadi, Hadi] Univ Gothenburg, Sahlgrenska Acad, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden.
[Vella, Laura J.] Austin Hosp, Ludwig Inst Canc Res Melbourne, Heidelberg, Vic 3084, Australia.
[Wai, Sun Nyunt] Umea Univ, Dept Mol Biol, Umea, Sweden.
[Witwer, Kenneth] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD USA.
[Yanez-Mo, Maria] Inst Invest Sanitaria Princesa, Hosp Santa Cristina, Unidad Invest, Madrid, Spain.
[Zeidler, Reinhard] Univ Munich, Dept Otorhinolaryngol, Helmholtz Zentrum Munchen, Munich, Germany.
[Zeidler, Reinhard] Univ Munich, Res Grp Gene Vectors, Helmholtz Zentrum Munchen, Munich, Germany.
RP Gho, YS (reprint author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang, South Korea.
EM ysgho@postech.ac.kr
RI Inal, Jameel/G-2995-2010; Nazarenko, Irina/E-5714-2010; Witwer,
Kenneth/G-1626-2013; Rodrigues, Marcio/J-3727-2013; BUEE,
Luc/B-3126-2010; Hill, Andrew/B-4527-2009; Hill, Michelle M/G-4417-2010;
Mathivanan, Suresh/D-2045-2009; Trummer, Arne/J-5203-2015; Nunes,
Diana/A-7867-2010; marcilla, antonio/F-9996-2010; Moller,
Andreas/O-1063-2015; patel, tushar/J-3976-2013; Royo, Felix/A-7198-2015;
Greening, David/E-9138-2016; Falcon-Perez, Juan/F-5920-2011
OI Blanc, Lionel/0000-0002-0185-6260; Stepien, Ewa/0000-0003-3589-1715;
Vella, Laura/0000-0002-1869-6291; Gardiner, Chris/0000-0002-2318-0062;
Mullier, Francois/0000-0001-6947-6099; Jang, Su
Chul/0000-0003-3326-1007; Siljander, Pia/0000-0003-2326-5821; Inal,
Jameel/0000-0002-7200-0363; Lotvall, Jan/0000-0001-9195-9249; Jee,
Young-Koo/0000-0001-5800-8038; Pocsfalvi, Gabriella/0000-0001-6065-3853;
Yanez-Mo, Maria/0000-0001-7484-2866; bongiovanni,
antonella/0000-0002-0307-4043; Choi, Dong-Sic/0000-0002-2516-5616; Youn,
Hyewon/0000-0003-1006-2689; Falcon-Perez, Juan M/0000-0003-3133-0670;
Ekstrom, Karin/0000-0001-7808-4572; BORRAS, FRANCESC
E./0000-0003-4038-1912; Witwer, Kenneth/0000-0003-1664-4233; Rodrigues,
Marcio/0000-0002-6081-3439; BUEE, Luc/0000-0002-6261-4230; Hill,
Andrew/0000-0001-5581-2354; Hill, Michelle M/0000-0003-1134-0951;
Mathivanan, Suresh/0000-0002-7290-5795; marcilla,
antonio/0000-0003-0004-0531; patel, tushar/0000-0001-7021-9532; Royo,
Felix/0000-0001-9769-4165;
FU National Research Foundation of Korea (NRF) grant - Korea government
(MSIP) [2014-023004]; Ministry of Health and Welfare grant - Korea
government [A120273]; KRIBB Research Initiative Program; National Junior
Research Fellowship [2014-048579]; BK21 PLUS program - Ministry of
Education, Science and Technology, Republic of Korea [10Z20130012243]
FX This work was supported by the National Research Foundation of Korea
(NRF) grant funded by the Korea government (MSIP) [No. 2014-023004], the
Ministry of Health and Welfare grant funded by the Korea government [No.
A120273] and a grant from KRIBB Research Initiative Program. D.-K. K is
supported by a National Junior Research Fellowship [No. 2014-048579] and
Y. J. Y by BK21 PLUS program [10Z20130012243] funded by Ministry of
Education, Science and Technology, Republic of Korea.
NR 49
TC 41
Z9 42
U1 10
U2 39
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
EI 1460-2059
J9 BIOINFORMATICS
JI Bioinformatics
PD MAR 15
PY 2015
VL 31
IS 6
BP 933
EP 939
DI 10.1093/bioinformatics/btu741
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Computer Science, Interdisciplinary Applications; Mathematical &
Computational Biology; Statistics & Probability
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Computer Science; Mathematical & Computational Biology; Mathematics
GA CF0XW
UT WOS:000352268900018
PM 25388151
ER
PT J
AU Volz, MS
Suarez-Contreras, V
Portilla, ALS
Fregni, F
AF Volz, Magdalena Sarah
Suarez-Contreras, Vanessa
Portilla, Andrea L. Santos
Fregni, Felipe
TI Mental imagery-induced attention modulates pain perception and cortical
excitability
SO BMC NEUROSCIENCE
LA English
DT Article
DE Pain; Attention; Mental imagery; Pain catastrophizing; Cortical
excitability
ID TRANSCRANIAL MAGNETIC STIMULATION; PHANTOM LIMB PAIN; MOTOR CORTEX
DISINHIBITION; NEUROPATHIC PAIN; PURDUE PEGBOARD; INTRACORTICAL
INHIBITION; EVOKED-POTENTIALS; MYOFASCIAL PAIN; NORMATIVE DATA; SILENT
PERIOD
AB Background: Mental imagery is a powerful method of altering brain activity and behavioral outcomes, such as performance of cognition and motor skills. Further, attention and distraction can modulate pain-related neuronal networks and the perception of pain. This exploratory study examined the effects of mental imagery-induced attention on pressure pain threshold and cortical plasticity using transcranial magnetic stimulation (TMS). This blinded, randomized, and parallel-design trial comprised 30 healthy right-handed male subjects. Exploratory statistical analyses were performed using ANOVA and t-tests for pain and TMS assessments. Pearson's correlation was used to analyze the association between changes in pain threshold and cortical excitability.
Results: In the analysis of pain outcomes, there was no significant interaction effect on pain between group versus time. In an exploratory analysis, we only observed a significant effect of group for the targeted left hand (ANOVA with pain threshold as the dependent variable and time and group as independent variables). Although there was only a within-group effect of mental imagery on pain, further analyses showed a significant positive correlation of changes in pain threshold and cortical excitability (motor-evoked potentials via TMS).
Conclusions: Mental imagery has a minor effect on pain modulation in healthy subjects. Its effects appear to differ compared with chronic pain, leading to a small decrease in pain threshold. Assessments of cortical excitability confirmed that these effects are related to the modulation of pain-related cortical circuits. These exploratory findings suggest that neuronal plasticity is influenced by pain and that the mental imagery effects on pain depend on the state of central sensitization.
C1 [Volz, Magdalena Sarah; Suarez-Contreras, Vanessa; Portilla, Andrea L. Santos; Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil,Lab Neuromodulat, Boston, MA 02114 USA.
[Volz, Magdalena Sarah; Suarez-Contreras, Vanessa; Portilla, Andrea L. Santos; Fregni, Felipe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
[Volz, Magdalena Sarah] Charite, D-13353 Berlin, Germany.
[Fregni, Felipe] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA USA.
RP Fregni, F (reprint author), Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil,Lab Neuromodulat, 125 Nashua St 727, Boston, MA 02114 USA.
EM fregni.felipe@mgh.harvard.edu
FU NIH [1R21DK81773-1A1]
FX This study was also supported by a NIH grant 1R21DK81773-1A1.
NR 59
TC 3
Z9 3
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2202
J9 BMC NEUROSCI
JI BMC Neurosci.
PD MAR 15
PY 2015
VL 16
AR 15
DI 10.1186/s12868-015-0146-6
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA CF0UE
UT WOS:000352258900001
PM 25887060
ER
PT J
AU Chen, EJ
Sowalsky, AG
Gao, S
Cai, CM
Voznesensky, O
Schaefer, R
Loda, M
True, LD
Ye, HH
Troncoso, P
Lis, RL
Kantoff, PW
Montgomery, RB
Nelson, PS
Bubley, GJ
Balk, SP
Taplin, ME
AF Chen, Eddy J.
Sowalsky, Adam G.
Gao, Shuai
Cai, Changmeng
Voznesensky, Olga
Schaefer, Rachel
Loda, Massimo
True, Lawrence D.
Ye, Huihui
Troncoso, Patricia
Lis, Rosina L.
Kantoff, Philip W.
Montgomery, Robert B.
Nelson, Peter S.
Bubley, Glenn J.
Balk, Steven P.
Taplin, Mary-Ellen
TI Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects
for Progesterone Responsive Mutant Androgen Receptors
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID TUMOR-GROWTH; CELL-LINE; MUTATION; BICALUTAMIDE; PROGRESSION;
EXPRESSION; STEROIDOGENESIS; TESTOSTERONE; DUTASTERIDE; INHIBITORS
AB Purpose: The CYP17A1 inhibitor abiraterone markedly reduces androgen precursors and is thereby effective in castration-resistant prostate cancer (CRPC). However, abiraterone increases progesterone, which can activate certain mutant androgen receptors (AR) identified previously in flutamide-resistant tumors. Therefore, we sought to determine if CYP17A1 inhibitor treatment selects for progesterone-activated mutant ARs.
Experimental Design: AR was examined by targeted sequencing in metastatic tumor biopsies from 18 patients with CRPC who were progressing on a CYP17A1 inhibitor (17 on abiraterone, 1 on ketoconazole), alone or in combination with dutasteride, and by whole-exome sequencing in residual tumor in one patient treated with neoadjuvant leuprolide plus abiraterone.
Results: The progesterone-activated T878A-mutant AR was present at high allele frequency in 3 of the 18 CRPC cases. It was also present in one focus of resistant tumor in the neoadjuvant-treated patient, but not in a second clonally related resistant focus that instead had lost one copy of PTEN and both copies of CHD1. The T878A mutation appeared to be less common in the subset of patients with CRPC treated with abiraterone plus dutasteride, and transfection studies showed that dutasteride was a more potent direct antagonist of the T878A versus the wild-type AR.
Conclusions: These findings indicate that selection for tumor cells expressing progesterone-activated mutant ARs is a mechanism of resistance to CYP17A1 inhibition. (C) 2014 AACR.
C1 [Chen, Eddy J.; Sowalsky, Adam G.; Gao, Shuai; Cai, Changmeng; Voznesensky, Olga; Schaefer, Rachel; Ye, Huihui; Bubley, Glenn J.; Balk, Steven P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Loda, Massimo; Lis, Rosina L.; Kantoff, Philip W.; Taplin, Mary-Ellen] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[True, Lawrence D.; Montgomery, Robert B.; Nelson, Peter S.] Univ Washington, Seattle, WA 98195 USA.
[Troncoso, Patricia] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
RP Balk, SP (reprint author), Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02115 USA.
EM sbalk@bidmc.harvard.edu; mary_taplin@dfci.harvard.edu
RI Sowalsky, Adam/K-1485-2013;
OI Sowalsky, Adam/0000-0003-2760-1853; Cai, Changmeng/0000-0002-8701-2586
FU NIH [P01 CA163227, K99 CA166507, SPORE P50 CA090381, SPORE P50 CA097186,
T32 CA081156]; Department of Defense Prostate Cancer Research Program
[W81XWH 13 1 0267, W81XWH 11 1 0295, W81XWH 10 1 0590, W81XWH 08-1-0414,
W81XWH-07-1-0443]; DF/HCC Mazzone Award; Prostate Cancer Foundation;
Ortho Biotech Oncology Research and Development (unit of Cougar
Biotechnology, now Janssen Research Development)
FX This work was supported by grants from the NIH (P01 CA163227, K99
CA166507, Dana-Farber/Harvard Cancer Center SPORE P50 CA090381, Pacific
Northwest Prostate Cancer SPORE P50 CA097186, and T32 CA081156), the
Department of Defense Prostate Cancer Research Program (W81XWH 13 1
0267, W81XWH 11 1 0295, W81XWH 10 1 0590, W81XWH 08-1-0414, and
W81XWH-07-1-0443), a DF/HCC Mazzone Award, and by generous support
through Challenge Awards from the Prostate Cancer Foundation. The
abiraterone clinical trials were supported by Ortho Biotech Oncology
Research and Development (unit of Cougar Biotechnology, now Janssen
Research & Development).
NR 31
TC 43
Z9 43
U1 3
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR 15
PY 2015
VL 21
IS 6
BP 1273
EP 1280
DI 10.1158/1078-0432.CCR-14-1220
PG 8
WC Oncology
SC Oncology
GA CE8DJ
UT WOS:000352071200007
PM 25320358
ER
PT J
AU Heidari, P
Deng, F
Esfahani, SA
Leece, AK
Shoup, TM
Vasdev, N
Mahmood, U
AF Heidari, Pedram
Deng, Francis
Esfahani, Shadi A.
Leece, Alicia K.
Shoup, Timothy M.
Vasdev, Neil
Mahmood, Umar
TI Pharmacodynamic Imaging Guides Dosing of a Selective Estrogen Receptor
Degrader
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ADVANCED BREAST-CANCER; POSITRON-EMISSION-TOMOGRAPHY; POSTMENOPAUSAL
WOMEN; ENDOCRINE THERAPY; PHASE-II; ANTIESTROGEN ICI-182780; AROMATASE
INHIBITORS; HORMONE SENSITIVITY; PRECLINICAL MODEL; DOUBLE-BLIND
AB Purpose: Estrogen receptor (ER) targeting is key in management of receptor-positive breast cancer. Currently, there are no methods to optimize anti-ER therapy dosing. This study assesses the use of 16 alpha-F-18-fluoroestradiol (F-18-FES) PET for fulvestrant dose optimization in a preclinical ER+ breast cancer model.
Experimental Design: In vitro, F-18-FES retention was compared with ER alpha protein expression (ELISA) and ESR1 mRNA transcription (qPCR) in MCF7 cells (ER+) after treatment with different fulvestrant doses. MCF7 xenografts were grown in ovariectomized nude mice and assigned to vehicle, low-(0.05 mg), medium-(0.5 mg), or high-dose (5 mg) fulvestrant treatment groups (5-7 per group). Two and 3 days after fulvestrant treatment, PET/CT was performed using F-18-FES and F-18-FDG, respectively. ER expression was assessed by immunohistochemistry, ELISA, and qPCR on xenografts. Tumor proliferation was assessed using Ki67 immunohistochemistry.
Results: In vitro, we observed a parallel graded reduction in F-18-FES uptake and ER expression with increased fulvestrant doses, despite enhancement of ER mRNA transcription. In xenografts, ER expression significantly decreased with increased fulvestrant dose, despite similar mRNA expression and Ki67 staining among the treatment groups. We observed a significant dose-dependent reduction of F-18-FES PET mean standardized uptake value (SUVmean) with fulvestrant treatment but no significant difference among the treatment groups in F-18-FDG PET SUVmean.
Conclusions: We demonstrated that F-18-FES uptake mirrors the dose-dependent changes in functional ER expression with fulvestrant resulting in ER degradation and/or blockade; these precede changes in tumor metabolism and proliferation. Quantitative F-18-FES PET may be useful for tracking early efficacy of ER blockade/degradation and guiding ER-targeted therapy dosing in patients with breast cancer. (C)2015 AACR.
C1 [Heidari, Pedram; Deng, Francis; Esfahani, Shadi A.; Leece, Alicia K.; Mahmood, Umar] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Deng, Francis] Washington Univ, Sch Med, St Louis, MO USA.
[Shoup, Timothy M.; Vasdev, Neil] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
RP Mahmood, U (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
EM umahmood@mgh.harvard.edu
OI Deng, Francis/0000-0003-3117-5076
FU Society for Nuclear Medicine and Molecular Imaging; Washington
University School of Medicine Dean's Fellowship; [U01CA084301];
[P50CA127003]
FX This work was supported by U01CA084301 and P50CA127003. F. Deng
supported by a Bradley-Alavi Student Fellowship from the Society for
Nuclear Medicine and Molecular Imaging and a Washington University
School of Medicine Dean's Fellowship.
NR 39
TC 8
Z9 8
U1 1
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR 15
PY 2015
VL 21
IS 6
BP 1340
EP 1347
DI 10.1158/1078-0432.CCR-14-1178
PG 8
WC Oncology
SC Oncology
GA CE8DJ
UT WOS:000352071200015
PM 25609068
ER
PT J
AU Li, YY
Hanna, GJ
Laga, AC
Haddad, RI
Lorch, JH
Hammerman, PS
AF Li, Yvonne Y.
Hanna, Glenn J.
Laga, Alvaro C.
Haddad, Robert I.
Lorch, Jochen H.
Hammerman, Peter S.
TI Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ORGAN-TRANSPLANT RECIPIENTS; GROWTH-FACTOR-RECEPTOR; COPY-NUMBER
ALTERATION; NF-KAPPA-B; RAS MUTATIONS; SKIN-CANCER; LUNG ADENOCARCINOMA;
SOMATIC MUTATIONS; CARD11 MUTATIONS; POINT MUTATIONS
AB Purpose: A rare 5% of cutaneous squamous cell carcinomas (cSCC) metastasize, lack FDA-approved therapies, and carry a poor prognosis. Our aim was to identify recurrent genomic alterations in this little-studied population of metastatic cSCCs.
Experimental Design: We performed targeted sequencing of 504 cancer-associated genes on lymph node metastases in 29 patients with cSCC and identified mutations and somatic copy-number alterations associated with metastatic cSCC. We determined significantly mutated, deleted, and amplified genes and associated genomic alterations with clinical variables.
Results: The cSCC genome is heterogeneous with widely varying numbers of genomic alterations and does not appear to be associated with human papillomavirus. We found previously identified recurrently altered genes (TP53, CDKN2A, NOTCH1/2) but also a wide spectrum of oncogenic mutations affecting RAS/RTK/PI3K, squamous differentiation, cell cycle, and chromatin remodeling pathway genes. Specific mutations in known oncogenic drivers and pathways were correlated with inferior patient outcomes. Our results suggest potential therapeutic targets in metastatic cSCC, including PIK3CA, FGFR3, BRAF, and EGFR, similar to those reported in SCCs of the lung and head and neck, suggesting that clinical trials could be developed to accrue patients with SCCs from multiple sites of origin.
Conclusions: We have genomically characterized a rare cohort of 29 metastatic cSCCs and identified a diverse array of oncogenic alterations that can guide future studies of this disease. (C) 2015 AACR.
C1 [Li, Yvonne Y.; Haddad, Robert I.; Lorch, Jochen H.; Hammerman, Peter S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Li, Yvonne Y.] Broad Inst, Cambridge, MA USA.
[Hanna, Glenn J.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Laga, Alvaro C.] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA.
[Haddad, Robert I.; Lorch, Jochen H.; Hammerman, Peter S.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Haddad, Robert I.; Lorch, Jochen H.; Hammerman, Peter S.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Hammerman, PS (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM Jochen_Lorch@dfci.harvard.edu; Peter_Hammerman@dfci.harvard.edu
FU NCI [K08 CA163677]; Friends of Dana Farber Grant
FX P.S. Hammerman is supported by NCI K08 CA163677. J.H. Lorch is supported
by a Friends of Dana Farber Grant.
NR 65
TC 27
Z9 27
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR 15
PY 2015
VL 21
IS 6
BP 1447
EP 1456
DI 10.1158/1078-0432.CCR-14-1773
PG 10
WC Oncology
SC Oncology
GA CE8DJ
UT WOS:000352071200026
PM 25589618
ER
PT J
AU Rodrigues, LU
Rider, L
Nieto, C
Romero, L
Karimpour-Fard, A
Loda, M
Lucia, MS
Wu, M
Shi, LH
Cimic, A
Sirintrapun, SJ
Nolley, R
Pac, C
Chen, HT
Peehl, DM
Xu, JF
Liu, WN
Costello, JC
Cramer, SD
AF Rodrigues, Lindsey Ulkus
Rider, Leah
Nieto, Cera
Romero, Lina
Karimpour-Fard, Anis
Loda, Massimo
Lucia, M. Scott
Wu, Min
Shi, Lihong
Cimic, Adela
Sirintrapun, S. Joseph
Nolley, Rosalie
Pac, Colton
Chen, Haitao
Peehl, Donna M.
Xu, Jianfeng
Liu, Wennuan
Costello, James C.
Cramer, Scott D.
TI Coordinate Loss of MAP3K7 and CHD1 Promotes Aggressive Prostate Cancer
SO CANCER RESEARCH
LA English
DT Article
ID MEDIATED CELL-ADHESION; I-KAPPA-B; MESENCHYMAL TRANSITION; E-CADHERIN;
PSA RECURRENCE; KINASE TAK1; EXPRESSION; CARCINOMA; PATHWAY;
NEUROENDOCRINE
AB Prostate cancer subtypes are poorly defined and functional validation of drivers of ETS rearrangement-negative prostate cancer has not been conducted. Here, we identified an ETS- subtype of aggressive prostate cancer (ERG-MAP3K7(dcl)CHD1(dcl)) and used a novel developmental model and a cell line xenograft model to show that cosuppression of MAP3K7 and CHD1 expression promotes aggressive disease. Analyses of publicly available prostate cancer datasets revealed that MAP3K7 and CHD1 were significantly codeleted in 10% to 20% of localized tumors and combined loss correlated with poor disease-free survival. To evaluate the functional impact of dual MAP3K7-CHD1 loss, we suppressed Map3k7 and/or Chd1 expression in mouse prostate epithelial progenitor/stem cells (PrP/SC) and performed tissue recombination experiments in vivo. Dual shMap3k7-shChd1 PrP/SC recombinants displayed massive glandular atypia with regions of prostatic intraepithelial neoplasia and carcinoma apparent. Combined Map3k7-Chd1 suppression greatly disrupted normal prostatic lineage differentiation; dual recombinants displayed significant androgen receptor loss, increased neuroendocrine differentiation, and increased neural differentiation. Clinical samples with dual MAP3K7-CHD1 loss also displayed neuroendocrine and neural characteristics. In addition, dual Map3k7-Chd1 suppression promoted E-cadherin loss and mucin production in recombinants. MAP3K7 and CHD1 protein loss also correlated with Gleason grade and E-cadherin loss in clinical samples. To further validate the phenotype observed in the PrP/SC model, we suppressed MAP3K7 and/or CHD1 expression in LNCaP prostate cancer cells. Dual shMAP3K7-shCHD1 LNCaP xenografts displayed increased tumor growth and decreased survival compared with shControl, shMAP3K7, and shCHD1 xenografts. Collectively, these data identify coordinate loss of MAP3K7 and CHD1 as a unique driver of aggressive prostate cancer development.
C1 [Rodrigues, Lindsey Ulkus; Rider, Leah; Nieto, Cera; Romero, Lina; Karimpour-Fard, Anis; Wu, Min; Pac, Colton; Costello, James C.; Cramer, Scott D.] Univ Colorado, Dept Pharmacol, Aurora, CO 80045 USA.
[Rodrigues, Lindsey Ulkus; Shi, Lihong] Wake Forest Univ, Dept Canc Biol, Winston Salem, NC 27109 USA.
[Loda, Massimo] Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA.
[Lucia, M. Scott] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA.
[Cimic, Adela; Sirintrapun, S. Joseph] Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27103 USA.
[Nolley, Rosalie; Peehl, Donna M.] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA.
[Chen, Haitao] Fudan Univ, Ctr Genet Epidemiol, Shanghai 200433, Peoples R China.
[Xu, Jianfeng; Liu, Wennuan] Wake Forest Univ, Ctr Canc Genom, Winston Salem, NC 27109 USA.
[Xu, Jianfeng; Liu, Wennuan] Wake Forest Univ, Ctr Genom & Personalized Med Res, Winston Salem, NC 27109 USA.
RP Cramer, SD (reprint author), Univ Colorado, Anschutz Med Campus,12801 East 17th Ave, Aurora, CO 80045 USA.
EM scott.cramer@ucdenver.edu
FU [R01 CA129418]; [W81XWH-12-10188]
FX This study was supported by grant numbers R01 CA129418; W81XWH-12-10188.
NR 49
TC 15
Z9 15
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 15
PY 2015
VL 75
IS 6
BP 1021
EP 1034
DI 10.1158/0008-5472.CAN-14-1596
PG 14
WC Oncology
SC Oncology
GA CE6IZ
UT WOS:000351941400012
PM 25770290
ER
PT J
AU Spurgeon, ME
Cheng, JW
Bronson, RT
Lambert, PF
DeCaprio, JA
AF Spurgeon, Megan E.
Cheng, Jingwei
Bronson, Roderick T.
Lambert, Paul F.
DeCaprio, James A.
TI Tumorigenic Activity of Merkel Cell Polyomavirus T Antigens Expressed in
the Stratified Epithelium of Mice
SO CANCER RESEARCH
LA English
DT Article
ID PAPILLOMAVIRUS TYPE-16 E7; TRANSGENIC MICE; MOUSE MODEL; GENE;
CARCINOMAS; IDENTIFICATION; SKIN; CARCINOGENESIS; REPLICATION;
PROGRESSION
AB Merkel cell polyomavirus (MCPyV) is frequently associated with Merkel cell carcinoma (MCC), a highly aggressive neuroendocrine skin cancer. Most MCC tumors contain integrated copies of the viral genome with persistent expression of the MCPyV large T (LT) and small T (ST) antigen. MCPyV isolated from MCC typically contains wild-type ST but truncated forms of LT that retain the N-terminus but delete the C-terminus and render LT incapable of supporting virus replication. To determine the oncogenic activity of MCC tumor-derived T antigens in vivo, a conditional, tissue-specific mouse model was developed. Keratin 14-mediated Cre recombinase expression induced expression of MCPyV T antigens in stratified squamous epithelial cells and Merkel cells of the skin epidermis. Mice expressing MCPyV T antigens developed hyperplasia, hyperkeratosis, and acanthosis of the skin with additional abnormalities in whisker pads, footpads, and eyes. Nearly half of the mice also developed cutaneous papillomas. Evidence for neoplastic progression within stratified epithelia included increased cellular proliferation, unscheduled DNA synthesis, increased E2F-responsive genes levels, disrupted differentiation, and presence of a DNA damage response. These results indicate that MCPyV T antigens are tumorigenic in vivo, consistent with their suspected etiologic role in human cancer.
C1 [Spurgeon, Megan E.; Lambert, Paul F.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Oncol, McArdle Lab Canc Res, Madison, WI USA.
[Cheng, Jingwei; DeCaprio, James A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Cheng, Jingwei; DeCaprio, James A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Cheng, Jingwei; DeCaprio, James A.] Harvard Univ, Sch Med, Boston, MA USA.
[Bronson, Roderick T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
RP DeCaprio, JA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM james_decaprio@dfci.harvard.edu
FU U.S. Public Health Service [R01 CA63113, R01 CA173023, P01 CA050661, P01
CA022443]; University of Wisconsin Investigative Dermatology Training
Program [T32AR055893]; National Institute of Allergy and Infectious
Diseases T32 Training Program [AI078985]
FX This work was supported in part by U.S. Public Health Service grants R01
CA63113, R01 CA173023, and P01 CA050661 (J.A. DeCaprio) and P01 CA022443
(P.F. Lambert). M.E. Spurgeon was supported by the University of
Wisconsin Investigative Dermatology Training Program T32AR055893 and the
National Institute of Allergy and Infectious Diseases T32 Training
Program AI078985.
NR 47
TC 12
Z9 12
U1 1
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 15
PY 2015
VL 75
IS 6
BP 1068
EP 1079
DI 10.1158/0008-5472.CAN-14-2425
PG 12
WC Oncology
SC Oncology
GA CE6IZ
UT WOS:000351941400016
PM 25596282
ER
PT J
AU Arvold, ND
Catalano, PJ
AF Arvold, Nils D.
Catalano, Paul J.
TI Local Therapies for Brain Metastases, Competing Risks, and Overall
Survival
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Editorial Material
ID CELL LUNG-CANCER; STEREOTACTIC RADIOSURGERY; RADIATION-THERAPY;
ONCOLOGY-GROUP; PHASE-III; SURGICAL RESECTION; RADIOTHERAPY; TRIAL;
FAILURE
C1 [Arvold, Nils D.] Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA.
[Catalano, Paul J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Cambridge, MA 02138 USA.
[Catalano, Paul J.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
RP Arvold, ND (reprint author), Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, 75 Francis St,ASB1-L2, Boston, MA 02115 USA.
EM narvold@partners.org
NR 17
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAR 15
PY 2015
VL 91
IS 4
BP 718
EP 720
DI 10.1016/j.ijrobp.2014.12.003
PG 3
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CE3NN
UT WOS:000351733500009
PM 25752383
ER
PT J
AU Chandra, RA
Miller, CL
Skolny, MN
Warren, LEG
Horick, N
Jammallo, LS
Sadek, BT
Shenouda, MN
O'Toole, J
Specht, MC
Taghian, AG
AF Chandra, Ravi A.
Miller, Cynthia L.
Skolny, Melissa N.
Warren, Laura E. G.
Horick, Nora
Jammallo, Lauren S.
Sadek, Betro T.
Shenouda, Mina N.
O'Toole, Jean
Specht, Michelle C.
Taghian, Alphonse G.
TI Radiation Therapy Risk Factors for Development of Lymphedema in Patients
Treated With Regional Lymph Node Irradiation for Breast Cancer
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID PREMENOPAUSAL WOMEN; RADIOTHERAPY; CHEMOTHERAPY
AB Purpose: We previously evaluated the risk of breast cancer-related lymphedema (LE) with the addition of regional lymph node irradiation (RLNR) and found an increased risk when RLNR is used. Here we analyze the association of technical radiation therapy (RT) factors in RLNR patients with the risk of LE development.
Methods and Materials: From 2005 to 2012, we prospectively screened 1476 women for LE who underwent surgery for breast cancer. Among 1507 breasts treated, 172 received RLNR and had complete technical data for analysis. RLNR was delivered as supraclavicular (SC) irradiation (69% [118 of 172 patients]) or SC plus posterior axillary boost (PAB) (31% [54 of 172]). Bilateral arm volume measurements were performed pre-and postoperatively. Patients' RT plans were analyzed for SC field lateral border (relative to the humeral head), total dose to SC, RT fraction size, beam energy, and type of tangent (normal vs wide). Cox proportional hazards models were used to analyze associated risk factors for LE.
Results: Median postoperative follow-up was 29.3 months (range: 4.9-74.1 months). The 2-year cumulative incidence of LE was 22% (95% confidence interval [CI]: 15%-32%) for SC and 20% (95% CI: 11%-37%) for SC plus PAB (SC+PAB). None of the analyzed variables was significantly associated with LE risk (extent of humeral head: P=.74 for <1/3 vs >2/3, PZ. 41 for 1/3 to 2/3 vs >2/3; P=.40 for fraction size of 1.8 Gy vs 2.0 Gy; P=. 57 for beam energy 6 MV vs 10 MV; P=. 74 for tangent type wide vs regular; P=. 66 for SC vs SC+PAB). Only pretreatment body mass index (hazard ratio [HR]: 1.09; 95% CI: 1.04-1.15, P=. 0007) and the use of axillary lymph node dissection (HR: 7.08, 95% CI: 0.98-51.40, P=. 05) were associated with risk of subsequent LE development.
Conclusions: Of the RT parameters tested, none was associated with an increased risk of LE development. This study underscores the need for future work investigating alternative RLNR risk factors for LE. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Chandra, Ravi A.; Warren, Laura E. G.] Harvard Radiat Oncol Program, Boston, MA USA.
[Miller, Cynthia L.] Harvard Univ, Sch Med, Boston, MA USA.
[Skolny, Melissa N.; Jammallo, Lauren S.; Sadek, Betro T.; Shenouda, Mina N.; Taghian, Alphonse G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Horick, Nora] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA.
[O'Toole, Jean] Massachusetts Gen Hosp, Dept Phys & Occupat Therapy, Boston, MA 02114 USA.
[Specht, Michelle C.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA.
RP Taghian, AG (reprint author), 100 Blossom St, Boston, MA 02114 USA.
EM ataghian@partners.org
RI Sadek, Betro/I-7734-2013
OI Sadek, Betro/0000-0003-0119-7207
FU National Cancer Institute [R01CA139118, P50CA089393]; Adele McKinnon
Research Fund for Breast Cancer-Related Lymphedema
FX The study described was supported by Award Number R01CA139118 (AGT),
Award Number P50CA089393 (AGT) from the National Cancer Institute and
the Adele McKinnon Research Fund for Breast Cancer-Related Lymphedema.
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Cancer
Institute or the National Institutes of Health.
NR 14
TC 9
Z9 9
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAR 15
PY 2015
VL 91
IS 4
BP 760
EP 764
DI 10.1016/j.ijrobp.2014.12.029
PG 5
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CE3NN
UT WOS:000351733500015
PM 25752389
ER
PT J
AU Chen, AB
AF Chen, Aileen B.
TI Fate of Manuscripts Rejected From the Red Journal In Reply
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Letter
ID DEFINITIVE PRIMARY THERAPY; CELL LUNG-CANCER
C1 Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
RP Chen, AB (reprint author), Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
OI Chen, Aileen/0000-0002-5385-3360
NR 2
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAR 15
PY 2015
VL 91
IS 4
BP 880
EP 881
DI 10.1016/j.ijrobp.2014.12.015
PG 3
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CE3NN
UT WOS:000351733500034
PM 25752408
ER
PT J
AU De Luca, G
van't Hof, AWJ
Gibson, CM
Cutlip, D
Zeymer, U
Noc, M
Maioli, M
Zorman, S
Gabriel, HM
Emre, A
Rakowski, T
Gyongyosi, M
Huber, K
Bellandi, F
Dudek, D
AF De Luca, Giuseppe
van't Hof, Arnoud W. J.
Gibson, C. Michael
Cutlip, Donald
Zeymer, Uwe
Noc, Marko
Maioli, Mauro
Zorman, Simona
Gabriel, H. Mesquita
Emre, Ayse
Rakowski, Tomasz
Gyongyosi, Maryann
Huber, Kurt
Bellandi, Francesco
Dudek, Dariusz
CA EGYPT Cooperation
TI Impact of Time from Symptom Onset to Drug Administration on Outcome in
Patients Undergoing Glycoprotein IIb-IIIa Facilitated Primary
Angioplasty (from the EGYPT Cooperation)
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID ELEVATION MYOCARDIAL-INFARCTION; PERCUTANEOUS CORONARY INTERVENTION;
RANDOMIZED-TRIALS; DATA METAANALYSIS; STEMI PATIENTS; TO-TREATMENT;
REPERFUSION; SIZE; INHIBITORS; MORTALITY
AB Contrasting data have been so far reported on facilitation with glycoprotein Jib-IIIa inhibitors (GpIIbIIIa) in patients who underwent primary percutaneous coronary intervention. However, it has been demonstrated a time-dependent composition of coronary thrombus in ST-segment elevation myocardial infarction, with more platelets in the first hours. Subsequently, the benefits of early administration of GpIIbIIIa may be affected by the time from symptoms onset to GpIIbIIIa, that therefore is the am of this study. Our population is represented by 814 patients who underwent GpIIbIIIa facilitated primary angioplasty included in the Early glycoprotein lib-IIIa inhibitors in primary angioplasty database. Patients were divided according to quartiles of time from symptom onset to GpIIbIIIa administration (565 minutes; 65 to 100 minutes; 101 to 178 minutes; and >178 minutes). Myocardial perfusion was evaluated by myocardial blush grade and ST-segment resolution. Time from symptoms onset to GpIIbIIIa was linearly associated with hypertension, diabetes, hypercholesterolemia, and previous myocardial infarction but inversely associated with smoking. Abciximab was more often administrated later from symptoms onset. Time from symptoms onset to GpIIbIIIa was significantly associated with the rate of preprocedural recanalization (thrombolysis in myocardial infarction [TIMI] 2 to 3; p <0.001), postprocedural TIM! 3 flow (p <0.001), the rate of complete ST-segment resolution (p <0.001), and the rate of myocardial blush grade 2 to 3 (p <0.001) and inversely associated with the occurrence of distal embolization (p <0.001). Follow-up data were collected at a median (twenty-fifth to seventy-fifth) of 360 (30 to 1,095) days. A total of 52 patients had died. Time to GpIIbIIIa had a significant impact on mortality (hazard ratio [95% confidence interval] 1.46 [1.11 to 1.92], p = 0.007) that was confirmed after correction for baseline confounding factors (adjusted hazard ratio [95% confidence interval] 1.41 [1.02 to 2.21], p = 0.042). In conclusion, this study showed that in patients who underwent primary angioplasty with upstream GpIIbIIIa, time from symptoms onset to GpIIbIIIa strongly impacts on preprocedural recanalization, distal embolization, myocardial perfusion, and long-term survival. (C) 2015 Elsevier Inc. All rights reserved.
C1 [De Luca, Giuseppe] Eastern Piedmont Univ, Maggiore della Carita Hosp, Div Cardiol, Novara, Italy.
[van't Hof, Arnoud W. J.] Hosp Weezenlanden, Div Cardiol, Zwolle, Netherlands.
[Gibson, C. Michael] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.
[Cutlip, Donald] Beth Israel Deaconess Med Ctr, Intervent Cardiol Sect, Boston, MA 02215 USA.
[Zeymer, Uwe] Herzzentrum Ludwigshafen, Div Cardiol, Ludwigshafen, Germany.
[Noc, Marko; Zorman, Simona] Univ Med Ctr, Ctr Intens Internal Med, Ljubljana, Slovenia.
[Maioli, Mauro; Bellandi, Francesco] Prato Hosp, Prato, Italy.
[Gabriel, H. Mesquita] Hosp Santa Maria, Div Cardiol, Lisbon, Portugal.
[Emre, Ayse] Siyami Ersek Thorac & Cardiovasc Surg Ctr, Istanbul, Turkey.
[Rakowski, Tomasz; Dudek, Dariusz] Jagiellonian Univ, Inst Cardiol, Dept Cardiol 2, Krakow, Poland.
[Gyongyosi, Maryann] Med Univ Vienna, Dept Cardiol, Vienna, Austria.
[Huber, Kurt] Wilhelminenspital Stadt Wien, Dept Med Cardiol & Emergency Med 3, Vienna, Austria.
RP De Luca, G (reprint author), Eastern Piedmont Univ, Maggiore della Carita Hosp, Div Cardiol, Novara, Italy.
EM giuseppe.deluca@maggioreosp.novara.it
NR 30
TC 4
Z9 4
U1 2
U2 4
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD MAR 15
PY 2015
VL 115
IS 6
BP 711
EP 715
DI 10.1016/j.amjcard.2014.12.030
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CE0GO
UT WOS:000351482700002
PM 25655867
ER
PT J
AU Gao, L
Park, SJ
Jang, Y
Lee, S
Tian, JW
Minami, Y
Jia, HB
Ong, D
Soeda, T
Vergallo, R
Lee, H
Yu, B
Uemura, S
Jang, IK
AF Gao, Lei
Park, Seung-Jung
Jang, Yangsoo
Lee, Stephen
Tian, Jinwei
Minami, Yoshiyasu
Jia, Haibo
Ong, Daniel
Soeda, Tsunenari
Vergallo, Rocco
Lee, Hang
Yu, Bo
Uemura, Shiro
Jang, Ik-Kyung
TI Optical Coherence Tomographic Evaluation of the Effect of Cigarette
Smoking on Vascular Healing After Sirolimus-Eluting Stent Implantation
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID ENDOTHELIAL PROGENITOR CELLS; ANGIOGENESIS; THROMBOSIS
AB Cigarette smoking is known to be deleterious to patients with coronary artery disease; however, the effect of smoking on vascular responses after coronary drug-eluting stent implantation is unknown. We sought to examine vascular response after sirolimus-eluting stent implantation in patients with ongoing smoking using optical coherence tomography, compared with former smokers and nonsmokers. We identified 181 sirolimus-eluting stents in 140 subjects who underwent follow-up optical coherence tomography imaging. Subjects were divided into 3 groups: current smokers (n = 28), former smokers (n = 35), and nonsmokers (n = 77). Stent strut coverage, neointimal characteristics, and strut malapposition were evaluated. The incidence of uncovered stent struts was significantly higher in nonsmokers compared with current smokers (13.3 +/- 13.3% vs 6.7 +/- 8.3%; p = 0.001). On qualitative evaluation of neointimal morphology, the prevalence of heterogeneous neointima was higher in current smokers (71.9%) than in former smokers (36.0%) or nonsmokers (10.1%) (p = 0.004 and p <0.001, respectively). There was no difference in the incidence of malapposition among the 3 groups. Multivariate modeling showed that current smoking was negatively associated with the presence of uncovered struts (odds ratio 0.33; 95% confidence interval 0.14 to 0.79; p = 0.013) and positively associated with the presence of heterogeneous neointima (odds ratio 9.47; 95% confidence interval 3.79 to 23.72; p <0.001). In conclusion, the incidence of strut coverage was higher in current smokers compared with nonsmokers. However, the pattern of neointima was more heterogeneous in current smokers. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Gao, Lei; Tian, Jinwei; Minami, Yoshiyasu; Jia, Haibo; Ong, Daniel; Soeda, Tsunenari; Vergallo, Rocco; Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02138 USA.
[Lee, Hang] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Biostat, Boston, MA USA.
[Park, Seung-Jung] Univ Ulsan, Coll Med, Asan Med Ctr, Div Cardiol, Seoul, South Korea.
[Jang, Yangsoo] Yonsei Univ, Coll Med, Severance Cardiovasc Hosp, Div Cardiol, Seoul, South Korea.
[Lee, Stephen] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.
[Tian, Jinwei; Jia, Haibo; Yu, Bo] Harbin Med Univ, Chinese Minist Educ, Key Lab Myocardial Ischemia, Dept Cardiol,Affiliated Hosp 2, Harbin, Peoples R China.
[Soeda, Tsunenari; Uemura, Shiro] Nara Med Univ, Dept Med 1, Nara, Japan.
[Jang, Ik-Kyung] Kyung Hee Univ, Div Cardiol, Seoul, South Korea.
RP Jang, IK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02138 USA.
EM ijang@mgh.harvard.edu
FU St. Jude Medical, Westford, MA, USA; Boston Scientific Corp.,
Marlborough, MA, USA; Dr. John Nam OCT fellowship grant; Michael A. Park
grant; National Natural Science Foundation of China, Beijing, P.R.China
[81300201, 81200076, 30871064]; China Postdoctoral Science Foundation,
Beijing, P.R.China [2013M531074]; Heilongjiang Postdoctoral Science
Foundation, Haerbin, Heilongjiang, P.R.China [LBH-Z12180]; Italian
Society of Cardiology Award
FX Dr. Jang reports receiving a research grant and honorarium from St. Jude
Medical, Westford, MA, USA and research grant from Boston Scientific
Corp., Marlborough, MA, USA. This study was supported by the Dr. John
Nam OCT fellowship grant and "Michael A. Park grant." Dr. Tian has
received a grant from the National Natural Science Foundation of China,
Beijing, P.R.China (81300201), a grant from China Postdoctoral Science
Foundation, Beijing, P.R.China (2013M531074), and a grant from
Heilongjiang Postdoctoral Science Foundation, Haerbin, Heilongjiang,
P.R.China (LBH-Z12180). Dr. Jia received a grant from the National
Natural Science Foundation of China, Beijing, P.R.China (81200076). Dr.
Vergallo was funded in part by the 2013 Italian Society of Cardiology
Award for Research Abroad. Dr. Yu received a grant from the National
Natural Science Foundation of China, Beijing, P.R.China (30871064).
NR 21
TC 1
Z9 1
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD MAR 15
PY 2015
VL 115
IS 6
BP 751
EP 757
DI 10.1016/j.amjcard.2014.12.038
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CE0GO
UT WOS:000351482700008
PM 25620038
ER
PT J
AU Khan, SS
Campia, U
Chioncel, O
Zannad, F
Rossignol, P
Maggioni, AP
Swedberg, K
Konstam, MA
Senni, M
Nodari, S
Vaduganathan, M
Subacius, H
Butler, J
Gheorghiade, M
AF Khan, Sadiya S.
Campia, Umberto
Chioncel, Ovidiu
Zannad, Faiez
Rossignol, Patrick
Maggioni, Aldo P.
Swedberg, Karl
Konstam, Marvin A.
Senni, Michele
Nodari, Savina
Vaduganathan, Muthiah
Subacius, Haris
Butler, Javed
Gheorghiade, Mihai
CA EVEREST Trial Investigators
TI Changes in Serum Potassium Levels During Hospitalization in Patients
With Worsening Heart Failure and Reduced Ejection Fraction (from the
EVEREST Trial)
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; RENAL-FUNCTION; DOUBLE-BLIND; HYPERKALEMIA;
TOLVAPTAN; MORTALITY; PLACEBO; MILD; ANTAGONIST; RATIONALE
AB Both hyperkalemia and hypokalemia may be related to heart failure (HF) therapy and are associated with adverse outcomes. Abnormalities in serum potassium levels in hospitalized patients with HF and reduced ejection fraction (EF) have not been previously investigated. A post hoc analysis was performed in 1,907 hospitalized patients with worsening HF and reduced EF in the placebo arm of the Efficacy of Vasopressin Antagonism in HF Outcome Study with Tolvaptan (EVEREST) trial. Serum potassium was measured at randomization and at discharge or day 7. The co-primary end points were all-cause mortality (ACM) and cardiovascular mortality or the first HF hospitalization (CVM + HFH). The association between inhospital change in potassium levels and time to outcomes was evaluated using multivariate Cox regression models. Study participants had a mean age of 65.6 +/- 12.0 years and were on optimal guideline-directed medical therapies, including beta blockers (77%), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (85%), and aldosterone antagonists (55%). Baseline potassium concentration was 4.3 +/- 0.6 mEq/l, and hyperkalemia or hypokalemia was seen in 6.5% of the participants. On average, serum potassium level increased by 0.21 +/- 0.66 mEq/l, p < 0.0001, during hospitalization. Inhospital potassium change was not associated with either the primary or the secondary end point over a median follow-up of 9.9 months. In conclusion, in patients with reduced EF hospitalized for worsening HF, serum potassium abnormalities are common at baseline (within 48 hours of admission) and potassium levels increase during hospitalization, despite aggressive diuretic therapy. However, they are not associated with all-cause or CVM or HFH. Inhospital changes in potassium may limit the implementation of evidence-based therapies such as mineralocorticoid receptor antagonists. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Khan, Sadiya S.; Subacius, Haris] Northwestern Univ, Dept Med, Div Cardiol, Feinberg Sch Med, Chicago, IL 60611 USA.
[Gheorghiade, Mihai] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA.
[Campia, Umberto] MedStar Heart Inst, Washington, DC USA.
[Campia, Umberto] MedStar Cardiovasc Res Network, Washington, DC USA.
[Chioncel, Ovidiu] Inst Boli Cardiovasc CC Iliescu, Cardiol 1, Bucharest, Romania.
[Zannad, Faiez; Rossignol, Patrick] Univ Lorraine, INSERM, Ctr Invest Clin, Nancy, France.
[Zannad, Faiez; Rossignol, Patrick] CHU Nancy, Nancy, France.
[Maggioni, Aldo P.] ANMCO Res Ctr, Florence, Italy.
[Swedberg, Karl] Univ Gothenburg, Sahlgrenska Acad, Dept Mol & Clin Med, Gothenburg, Sweden.
[Konstam, Marvin A.] Tufts Med Ctr, Ctr Cardiovasc, Boston, MA USA.
[Senni, Michele] Osped Papa Giovanni XXIII, Cardiovasc Dept, Bergamo, Italy.
[Nodari, Savina] Univ Brescia, Dept Cardiol, Brescia, Italy.
[Vaduganathan, Muthiah] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA.
[Butler, Javed] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA.
RP Gheorghiade, M (reprint author), Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA.
EM m-gheorghiade@northwestern.edu
OI chioncel, ovidiu/0000-0002-3197-3628; Maggioni, Aldo
Pietro/0000-0003-2764-6779
FU Otsuka Inc. (Rockville, Maryland)
FX Otsuka Inc. (Rockville, Maryland) provided financial and material
support for the EVEREST trial. Database management was performed by the
sponsor.
NR 21
TC 8
Z9 9
U1 0
U2 5
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD MAR 15
PY 2015
VL 115
IS 6
BP 790
EP 796
DI 10.1016/j.amjcard.2014.12.045
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CE0GO
UT WOS:000351482700014
PM 25728846
ER
PT J
AU Yancey, DM
Guichard, JL
Ahmed, MI
Zhou, LF
Murphy, MP
Johnson, MS
Benavides, GA
Collawn, J
Darley-Usmar, V
Dell'Italia, LJ
AF Yancey, Danielle M.
Guichard, Jason L.
Ahmed, Mustafa I.
Zhou, Lufang
Murphy, Michael P.
Johnson, Michelle S.
Benavides, Gloria A.
Collawn, James
Darley-Usmar, Victor
Dell'Italia, Louis J.
TI Cardiomyocyte mitochondrial oxidative stress and cytoskeletal breakdown
in the heart with a primary volume overload
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE heart failure; mitochondria; cardiomyocyte
ID ISOLATED MITRAL REGURGITATION; MICE LACKING DESMIN; HYPERTROPHIED
MYOCARDIUM; CONTRACTILE DYSFUNCTION; EXTRACELLULAR-MATRIX; CARDIAC
DYSFUNCTION; SKELETAL MYOPATHY; XANTHINE-OXIDASE; FAILURE; BIOENERGETICS
AB Left ventricular (LV) volume overload (VO) results in cardiomyocyte oxidative stress and mitochondrial dysfunction. Because mitochondria are both a source and target of ROS, we hypothesized that the mitochondrially targeted antioxidant mitoubiquinone (MitoQ) will improve cardiomyocyte damage and LV dysfunction in VO. Isolated cardiomyocytes from Sprague-Dawley rats were exposed to stretch in vitro and VO of aortocaval fistula (ACF) in vivo. ACF rats were treated with and without MitoQ. Isolated cardiomyocytes were analyzed after 3 h of cyclical stretch or 8 wk of ACF with MitoSox red or 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate to measure ROS and with tetramethylrhodamine to measure mitochondrial membrane potential. Transmission electron microscopy and immunohistochemistry were used for cardiomyocyte structural assessment. In vitro cyclical stretch and 8-wk ACF resulted in increased cardiomyocyte mitochondrial ROS production and decreased mitochondrial membrane potential, which were significantly improved by MitoQ. ACF had extensive loss of desmin and beta(2)-tubulin that was paralleled by mitochondrial disorganization, loss of cristae, swelling, and clustering identified by mitochondria complex IV staining and transmission electron microscopy. MitoQ improved mitochondrial structural damage and attenuated desmin loss/degradation evidenced by immunohistochemistry and protein expression. However, LV dilatation and fractional shortening were unaffected by MitoQ treatment in 8-wk ACF. In conclusion, although MitoQ did not affect LV dilatation or function in ACF, these experiments suggest a connection of cardiomyocyte mitochondria-derived ROS production with cytoskeletal disruption and mitochondrial damage in the VO of ACF.
C1 [Dell'Italia, Louis J.] Dept Vet Affairs Med Ctr, Birmingham, AL USA.
[Yancey, Danielle M.; Guichard, Jason L.; Ahmed, Mustafa I.; Zhou, Lufang; Dell'Italia, Louis J.] Univ Alabama Birmingham, UAB Comprehens Cardiovasc Ctr, Birmingham, AL USA.
[Yancey, Danielle M.; Guichard, Jason L.; Ahmed, Mustafa I.; Zhou, Lufang; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Johnson, Michelle S.; Benavides, Gloria A.; Darley-Usmar, Victor] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Johnson, Michelle S.; Benavides, Gloria A.; Darley-Usmar, Victor] Univ Alabama Birmingham, UAB Ctr Free Radical Biol, Birmingham, AL USA.
[Murphy, Michael P.] MRC, Mitochondrial Biol Unit, Cambridge, England.
[Collawn, James] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA.
RP Dell'Italia, LJ (reprint author), Birmingham Vet Affairs Med Ctr, 700 S 19th St, Birmingham, AL 35294 USA.
EM louis.dellitalia@va.gov
FU American Heart Association Predoctoral Fellowship [13PRE14560035];
National Heart, Lung, and Blood Institute Training Grant
[5-T32-HL-072757, R01-HL-54816]
FX This work was supported by American Heart Association Predoctoral
Fellowship 13PRE14560035 (to D. M. Yancey) and National Heart, Lung, and
Blood Institute Training Grant 5-T32-HL-072757 (to J. L. Guichard) and
Grant R01-HL-54816 (to L. J. Dell'Italia).
NR 47
TC 12
Z9 12
U1 0
U2 12
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
EI 1522-1539
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD MAR 15
PY 2015
VL 308
IS 6
BP H651
EP H663
DI 10.1152/ajpheart.00638.2014
PG 13
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Physiology
GA CD3OU
UT WOS:000350988900009
PM 25599572
ER
PT J
AU Branson, RD
Hess, DR
AF Branson, Richard D.
Hess, Dean R.
TI Lost in Translation: Failure of Tracheal Tube Modifications to Impact
Ventilator-associated Pneumonia
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Editorial Material
ID ENDOTRACHEAL-TUBE
C1 [Branson, Richard D.] Univ Cincinnati, Cincinnati, OH 45220 USA.
[Hess, Dean R.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA.
[Hess, Dean R.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA.
RP Branson, RD (reprint author), Univ Cincinnati, Cincinnati, OH 45220 USA.
NR 16
TC 4
Z9 4
U1 0
U2 1
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD MAR 15
PY 2015
VL 191
IS 6
BP 606
EP 608
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA CD7FW
UT WOS:000351257200002
PM 25767919
ER
PT J
AU Mylonakis, E
Clancy, CJ
Ostrosky-Zeichner, L
Garey, KW
Alangaden, GJ
Vazquez, JA
Groeger, JS
Judson, MA
Vinagre, YM
Heard, SO
Zervou, FN
Zacharioudakis, IM
Kontoyiannis, DP
Pappas, PG
AF Mylonakis, Eleftherios
Clancy, Cornelius J.
Ostrosky-Zeichner, Luis
Garey, Kevin W.
Alangaden, George J.
Vazquez, Jose A.
Groeger, Jeffrey S.
Judson, Marc A.
Vinagre, Yuka-Marie
Heard, Stephen O.
Zervou, Fainareti N.
Zacharioudakis, Ioannis M.
Kontoyiannis, Dimitrios P.
Pappas, Peter G.
TI T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in
Whole Blood: A Clinical Trial
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE T2 magnetic resonance; T2MR; Candida; fungal infections; clinical trial
ID INVASIVE CANDIDIASIS; ECHINOCANDIN RESISTANCE; OPPORTUNISTIC YEAST;
ANTIFUNGAL THERAPY; FUNGAL-INFECTIONS; RISK-FACTORS; CULTURE;
MANAGEMENT; TIME; FLUCONAZOLE
AB Background. Microbiologic cultures, the current gold standard diagnostic method for invasive Candida infections, have low specificity and take up to 2-5 days to grow. We present the results of the first extensive multicenter clinical trial of a new nanodiagnostic approach, T2 magnetic resonance (T2MR), for diagnosis of candidemia.
Methods. Blood specimens were collected from 1801 hospitalized patients who had a blood culture ordered for routine standard of care; 250 of them were manually supplemented with concentrations from <1 to 100 colonyforming units (CFUs)/mL for 5 different Candida species.
Results. T2MR demonstrated an overall specificity per assay of 99.4% (95% confidence interval [CI], 99.1%-99.6%) with a mean time to negative result of 4.2 +/- 0.9 hours. Subanalysis yielded a specificity of 98.9% (95% CI, 98.3%-99.4%) for Candida albicans/Candida tropicalis, 99.3% (95% CI, 98.7%-99.6%) for Candida parapsilosis, and 99.9% (95% CI, 99.7%-100.0%) for Candida krusei/Candida glabrata. The overall sensitivity was found to be 91.1% (95% CI, 86.9%-94.2%) with a mean time of 4.4 +/- 1.0 hours for detection and species identification. The subgroup analysis showed a sensitivity of 92.3% (95% CI, 85.4%-96.6%) for C. albicans/C. tropicalis, 94.2% (95% CI, 84.1%-98.8%) for C. parapsilosis, and 88.1% (95% CI, 80.2%-93.7%) for C. krusei/C. glabrata. The limit of detection was 1 CFU/mL for C. tropicalis and C. krusei, 2 CFU/mL for C. albicans and C. glabrata, and 3 CFU/mL for C. parapsilosis. The negative predictive value was estimated to range from 99.5% to 99.0% in a study population with 5% and 10% prevalence of candidemia, respectively.
Conclusions. T2MR is the first fully automated technology that directly analyzes whole blood specimens to identify species without the need for prior isolation of Candida species, and represents a breakthrough shift into a new era of molecular diagnostics.
C1 [Mylonakis, Eleftherios; Zervou, Fainareti N.; Zacharioudakis, Ioannis M.] Brown Univ, Rhode Isl Hosp, Div Infect Dis, Warren Alpert Med Sch, Providence, RI 02903 USA.
[Clancy, Cornelius J.] Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Div Infect Dis, Pittsburgh, PA 15260 USA.
[Ostrosky-Zeichner, Luis] Univ Texas Med Sch Houston, Div Infect Dis, Houston, TX USA.
[Ostrosky-Zeichner, Luis] Mem Hermann Texas Med Ctr, Houston, TX USA.
[Garey, Kevin W.] Univ Houston, Coll Pharm, Houston, TX 77004 USA.
[Alangaden, George J.] Henry Ford Hlth Syst, Div Infect Dis, Detroit, MI USA.
[Vazquez, Jose A.] Georgia Regents Univ, Med Coll Georgia, Dept Med, Augusta, GA USA.
[Groeger, Jeffrey S.] Mem Sloan Kettering Canc Ctr, Urgent Care Serv, New York, NY 10021 USA.
[Judson, Marc A.] Albany Med Coll, Div Pulm & Crit Care Med, New York, NY USA.
[Vinagre, Yuka-Marie] St Vincent Hosp, Dept Crit Care Med, Worcester, MA 01604 USA.
[Heard, Stephen O.] UMass Mem Med Ctr, Dept Anesthesiol, Worcester, MA USA.
[Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX 77030 USA.
[Pappas, Peter G.] Univ Alabama, Div Infect Dis, Birmingham, W Midlands, England.
RP Mylonakis, E (reprint author), Brown Univ, Rhode Isl Hosp, Div Infect Dis, Warren Alpert Med Sch, 593 Eddy St,3rd Floor,Ste 328-330, Providence, RI 02903 USA.
EM emylonakis@lifespan.org
OI Garey, Kevin/0000-0003-2063-7503
FU T2 Biosystems
FX This work was supported by T2 Biosystems.
NR 39
TC 60
Z9 60
U1 2
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAR 15
PY 2015
VL 60
IS 6
BP 892
EP 899
DI 10.1093/cid/ciu959
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CD4KP
UT WOS:000351051600012
PM 25586686
ER
PT J
AU Walensky, RP
Auerbach, JD
AF Walensky, Rochelle P.
Auerbach, Judith D.
CA Off AIDS Res Advisory Council
TI Focusing National Institutes of Health HIV/AIDS Research for Maximum
Population Impact
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
DE HIV; AIDS; research; National Institutes of Health (NIH)
ID HIV; CARE; PREVENTION; INFECTION
AB Progress in advancing research on the pathophysiology, prevention, treatment, and impact of human immunodeficiency virus (HIV) is threatened by the decaying purchasing power of National Institutes of Health (NIH) dollars. A working group of the NIH Office of AIDS Research Advisory Council was charged by the NIH Director with developing a focused and concise blueprint to guide the use of limited funding over the next few years. Science priorities outlined by the working group and reported here are intended to maximally address individuals, groups, and settings most affected by the epidemic, and to redress shortcomings in realizing population-level HIV prevention, treatment, and eradication goals. Optimizing these priorities requires that traditional silos-defined by topic focus and by scientific discipline-be dissolved and that structural issues affecting the pipeline of new investigators and the ability of the Office of AIDS Research to fulfill its role of steward of the NIH HIV/AIDS research program be directly addressed.
C1 [Walensky, Rochelle P.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
[Walensky, Rochelle P.] Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA.
[Walensky, Rochelle P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Dept Med, Boston, MA 02114 USA.
[Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Walensky, Rochelle P.] Harvard Univ, Sch Med, Ctr AIDS Res, Boston, MA USA.
[Auerbach, Judith D.] Univ Calif San Francisco, Sch Med, Div Med, Ctr AIDS Prevent Studies, San Francisco, CA USA.
RP Walensky, RP (reprint author), Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Div Infect Dis, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM rwalensky@partners.org
FU NIMH NIH HHS [P30 MH062246]
NR 15
TC 1
Z9 1
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAR 15
PY 2015
VL 60
IS 6
BP 937
EP 940
DI 10.1093/cid/ciu942
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CD4KP
UT WOS:000351051600020
PM 25422391
ER
PT J
AU Pandit, MM
Inscho, EW
Zhang, SL
Seki, T
Rohatgi, R
Gusella, L
Kishore, B
Kohan, DE
AF Pandit, Meghana M.
Inscho, Edward W.
Zhang, Shali
Seki, Tsugio
Rohatgi, Rajeev
Gusella, Luca
Kishore, Bellamkonda
Kohan, Donald E.
TI Flow regulation of endothelin-1 production in the inner medullary
collecting duct
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE collecting duct; endothelin; flow; purinergic
ID POLYCYSTIC KIDNEY-DISEASE; EPITHELIAL NA+ CHANNEL;
ESSENTIAL-HYPERTENSION; URINARY ENDOTHELIN-1; SODIUM RETENTION;
PRINCIPAL CELLS; TRPC3 CHANNELS; BLOOD-PRESSURE; PRIMARY CILIUM;
SHEAR-STRESS
AB Collecting duct-derived endothelin (ET)-1 is an autocrine inhibitor of Na+ and water reabsorption; its deficiency causes hypertension and water retention. Extracellular fluid volume expansion increases collecting duct ET-1, thereby promoting natriuresis and diuresis; however, how this coupling between volume expansion and collecting duct ET-1 occurs is incompletely understood. One possibility is that volume expansion increases tubular fluid flow. To investigate this, cultured IMCD3 cells were subjected to static or flow conditions. Exposure to a shear stress of 2 dyn/cm(2) for 2 h increased ET-1 mRNA content by similar to 2.3-fold. Absence of perfusate Ca2+, chelation of intracellular Ca2+, or inhibition of Ca2+ signaling (calmodulin, Ca2+/calmodulin-dependent kinase, calcineurin, PKC, or phospholipase C) prevented the flow response. Evaluation of possible flow-activated Ca2+ entry pathways revealed no role for transient receptor potential (TRP)C3, TRPC6, and TRPV4; however, cells with TRPP2 (polycystin-2) knockdown had no ET-1 flow response. Flow increased intracellular Ca2+ was blunted in TRPP2 knockdown cells. Nonspecific blockade of P2 receptors, as well as specific inhibition of P2X(7) and P2Y(2) receptors, prevented the ET-1 flow response. The ET-1 flow response was not affected by inhibition of either epithelial Na+ channels or the mitochondrial Na+/Ca2+ exchanger. Taken together, these findings provide evidence that in IMCD3 cells, flow, via polycystin-2 and P2 receptors, engages Ca2+ dependent signaling pathways that stimulate ET-1 synthesis.
C1 [Pandit, Meghana M.; Kishore, Bellamkonda; Kohan, Donald E.] Univ Utah, Hlth Sci Ctr, Div Nephrol, Salt Lake City, UT 84132 USA.
[Pandit, Meghana M.; Kohan, Donald E.] Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT USA.
[Inscho, Edward W.; Zhang, Shali] Univ Alabama Birmingham, Birmingham, AL USA.
[Seki, Tsugio] Calif Northstate Univ, Dept Med Educ, Elk Grove, CA USA.
[Rohatgi, Rajeev; Gusella, Luca] James J Peter Vet Affairs Med Ctr, Dept Med, Bronx, NY USA.
[Rohatgi, Rajeev; Gusella, Luca] Icahn Sch Med Mt Sinai, Dept Med & Pediat, New York, NY 10029 USA.
[Kishore, Bellamkonda; Kohan, Donald E.] Salt Lake Vet Affairs Med Ctr, Salt Lake City, UT USA.
RP Kohan, DE (reprint author), Univ Utah, Hlth Sci Ctr, Div Nephrol, 1900 E 30 N, Salt Lake City, UT 84132 USA.
EM donald.kohan@hsc.utah.edu
OI Kishore, Bellamkonda/0000-0001-8232-9827
FU National Institutes of Health (NIH) [P01-HL-095499]; Veterans Affairs
Merit Reviews; NIH [DK-044628, HL-098135]
FX This work was supported in part by National Institutes of Health (NIH)
Grants P01-HL-095499 (to D. E. Kohan and E. W. Inscho), Veterans Affairs
Merit Reviews (to R. Rohatgi and to B. Kishore), and NIH Grants
DK-044628 and HL-098135 (to E. W. Inscho).
NR 57
TC 7
Z9 7
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
EI 1522-1466
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD MAR 15
PY 2015
VL 308
IS 6
BP F541
EP F552
DI 10.1152/ajprenal.00456.2014
PG 12
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA CD4NT
UT WOS:000351060800004
PM 25587122
ER
PT J
AU Oreskovic, NM
Perrin, JM
Robinson, AI
Locascio, JJ
Blossom, J
Chen, ML
Winickoff, JP
Field, AE
Green, C
Goodman, E
AF Oreskovic, Nicolas M.
Perrin, James M.
Robinson, Alyssa I.
Locascio, Joseph J.
Blossom, Jeff
Chen, Minghua L.
Winickoff, Jonathan P.
Field, Alison E.
Green, Chloe
Goodman, Elizabeth
TI Adolescents' use of the built environment for physical activity
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Physical activity; Built environment; Accelerometer; Adolescents; Global
positioning system; Geographic information systems
ID AMERICAN-HEART-ASSOCIATION; ACCELEROMETER DATA; SPORTS-MEDICINE;
PUBLIC-HEALTH; PEACH PROJECT; CHILDREN; OBESITY; GPS; RECOMMENDATION;
OVERWEIGHT
AB Background: Physical activity is a health-enhancing behavior, but few adolescents achieve the recommended levels of moderate-to-vigorous physical activity. Understanding how adolescents use different built environment spaces for physical activity and activity varies by location could help in designing effective interventions to promote moderate-to-vigorous physical activity. The objective of this study was to describe the locations where adolescents engage in physical activity and compare traditional intensity-based measures with continuous activity when describing built environment use patterns among adolescents.
Methods: Eighty adolescents aged 11-14 years recruited from community health and recreation centers. Adolescents wore accelerometers (Actigraph GT3X) and global positioning system receivers (QStarz BT-Q1000XT) for two separate weeks to record their physical activity levels and locations. Accelerometer data provided a continuous measure of physical activity and intensity-based measures (sedentary time, moderate-to-vigorous physical activity). Physical activity was mapped by land-use classification (home, school, park, playground, streets & sidewalks, other) using geographic information systems and this location-based activity was assessed for both continuous and intensity-based physical activity derived from mixed-effects models which accounted for repeated measures and clustering effects within person, date, school, and town.
Results: Mean daily moderate-to-vigorous physical activity was 22 minutes, mean sedentary time was 134 minutes. Moderate-to-vigorous physical activity occurred in bouts lasting up to 15 minutes. Compared to being at home, being at school, on the streets and sidewalks, in parks, and playgrounds were all associated with greater odds of being in moderate-to-vigorous physical activity and achieving higher overall activity levels. Playground use was associated with the highest physical activity level (beta = 172 activity counts per minute, SE = 4, p < 0.0001) and greatest odds of being in moderate-to-vigorous physical activity (odds ratio 8.3, 95% confidence interval 4.8-14.2).
Conclusion: Adolescents were more likely to engage in physical activity, and achieved their highest physical activity levels, when using built environments located outdoors. Novel objective methods for determining physical activity can provide insight into adolescents' spatial physical activity patterns, which could help guide physical activity interventions. Promoting zoning and health policies that encourage the design and regular use of outdoor spaces may offer another promising opportunity for increasing adolescent physical activity.
C1 [Oreskovic, Nicolas M.; Perrin, James M.; Robinson, Alyssa I.; Locascio, Joseph J.; Chen, Minghua L.; Winickoff, Jonathan P.; Goodman, Elizabeth] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Oreskovic, Nicolas M.; Perrin, James M.; Locascio, Joseph J.; Chen, Minghua L.; Winickoff, Jonathan P.; Field, Alison E.; Goodman, Elizabeth] Harvard Univ, Sch Med, Boston, MA USA.
[Blossom, Jeff; Green, Chloe] Harvard Ctr Geog Anal, Boston, MA USA.
[Field, Alison E.] Boston Childrens Hosp, Boston, MA USA.
RP Oreskovic, NM (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM noreskovic@mgh.harvard.edu
FU National Institutes of Health [K23HL103841, P30DK46200]
FX The authors gratefully thank Daniel A. Rodriguez, PhD, of University of
North Carolina at Chapel Hill for his helpful input on study design and
insightful comments on the manuscript. Dr. Oreskovic had full access to
all of the data in the study and takes responsibility for the integrity
of the data and the accuracy of the data analysis. This study was funded
by National Institutes of Health grants K23HL103841 and P30DK46200.
NR 27
TC 10
Z9 10
U1 6
U2 32
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD MAR 15
PY 2015
VL 15
AR 251
DI 10.1186/s12889-015-1596-6
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CD7JK
UT WOS:000351266400001
PM 25880654
ER
PT J
AU Hamstra, DA
Bae, K
Hanks, G
Hu, C
Shipley, WU
Pan, CC
Roach, M
Lawton, CA
Sandler, HM
AF Hamstra, Daniel A.
Bae, Kyounghwa
Hanks, Gerald
Hu, Chen
Shipley, William U.
Pan, Charlie C.
Roach, Mack, III
Lawton, Colleen A.
Sandler, Howard M.
TI Impact of Biochemical Failure Classification on Clinical Outcome: A
Secondary Analysis of Radiation Therapy Oncology Group 9202 and 9413
SO CANCER
LA English
DT Article; Proceedings Paper
CT 1st Palliative Care in Oncology Symposium
CY OCT, 2014
CL Boston, MA
DE prostate-specific antigen; prostate-specific antigen failure;
radiotherapy
ID PROSTATE-SPECIFIC ANTIGEN; ADJUVANT ANDROGEN DEPRIVATION; EXTERNAL-BEAM
RADIOTHERAPY; CANCER-SPECIFIC MORTALITY; PHASE-III TRIAL; DOUBLING TIME;
COMPETING RISK; MEN; SURVIVAL; INTERVAL
AB BACKGROUNDBiochemical failure (BF) after radiation therapy is defined on the basis of a rising prostate-specific antigen (PSA) level (A1 failure) or any event that prompts the initiation of salvage androgen-deprivation therapy without PSA failure (A2). It was hypothesized that A2 failure may have a different prognosis.
METHODSData for 2799 eligible patients from Radiation Therapy Oncology Group (RTOG) 9202 and RTOG 9413 were analyzed. BF was defined according to the 1997 American Society for Therapeutic Radiology and Oncology consensus definition as A1 for PSA failure or as A2 for the start of salvage hormone therapy before 3 consecutive PSA rises.
RESULTSRates of all-cause mortality (hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.5-2.0; P<.0001) and distant metastasis (DM; HR, 1.6; 95% CI, 1.3-2.0; P<.0001) were greater with A2 failure. The 5-year overall survival (OS) rates were 88.2% and 74.6% for A1 and A2, respectively (P<.0001), and the DM rates were 15.7% and 29.0%, respectively (P<.0001). The DM rate was greater at 5 years for A2 patients with DM as the first sign of failure versus patients with other A2 failures (87.3% vs 11.7%, P<.001), and this also correlated with worse OS at 5 years: 81.1% for A2 failure without DM and 52.8% with DM (P<.001). After the removal of patients with DM, the difference between A1 and A2 BF persisted for OS (P=.002) but not for DM (P=.16)
CONCLUSIONSThese results suggest that patients with rising PSA levels alone have less risk than those with A2 failures; although DM was the largest contributor of adverse risk to A2 failure, it did not account for all excess risk in A2 failure. Cancer 2015;121:844-852. (c) 2014 American Cancer Society.
After radiation therapy, biochemical failure is defined on the basis of either rising prostate-specific antigen levels or the initiation of salvage androgen ablation for other reasons. Patients started on salvage androgen therapy without meeting the criteria for rising prostate-specific antigen levels may have worse clinical outcomes; as such, those with rising prostate-specific antigen levels only may actually represent a more favorable group of patients.
C1 [Hamstra, Daniel A.] Univ Michigan, Med Ctr, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.
[Bae, Kyounghwa; Hu, Chen] Ctr Stat, Radiat Therapy Oncol Grp, Philadelphia, PA USA.
[Hanks, Gerald] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Shipley, William U.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Pan, Charlie C.] Bellin Canc Ctr, Green Bay, WI USA.
[Roach, Mack, III] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Lawton, Colleen A.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Sandler, Howard M.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA.
EM dhamm@umich.edu
FU Radiation Therapy Oncology Group grant from the National Cancer
Institute [U10 CA21661]; Community Clinical Oncology Program grant from
the National Cancer Institute [U10 CA37422]; NRG grant from the National
Cancer Institute [U10 CA180822]; National Cancer Institute [U10 CA32115]
FX This project was supported by Radiation Therapy Oncology Group grant U10
CA21661, Community Clinical Oncology Program grant U10 CA37422, NRG
grant U10 CA180822, and statistical grant U10 CA32115 from the National
Cancer Institute.
NR 26
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAR 15
PY 2015
VL 121
IS 6
BP 844
EP 852
DI 10.1002/cncr.29146
PG 9
WC Oncology
SC Oncology
GA CD0HF
UT WOS:000350750700008
PM 25410885
ER
PT J
AU Jabbour, EJ
Garcia-Manero, G
Strati, P
Mishra, A
Al Ali, NH
Padron, E
Lancet, J
Kadia, T
Daver, N
O'Brien, S
Steensma, DP
Sekeres, MA
Gore, SD
Dezern, A
Roboz, GJ
List, AF
Kantarjian, HM
Komrokji, RS
AF Jabbour, Elias J.
Garcia-Manero, Guillermo
Strati, Paolo
Mishra, Asmita
Al Ali, Najla H.
Padron, Eric
Lancet, Jeffrey
Kadia, Tapan
Daver, Naval
O'Brien, Susan
Steensma, David P.
Sekeres, Mikkael A.
Gore, Steven D.
Dezern, Amy
Roboz, Gail J.
List, Alan F.
Kantarjian, Hagop M.
Komrokji, Rami S.
TI Outcome of Patients With Low-Risk and Intermediate-1-Risk
Myelodysplastic Syndrome After Hypomethylating Agent Failure
SO CANCER
LA English
DT Article; Proceedings Paper
CT 1st Palliative Care in Oncology Symposium
CY OCT, 2014
CL Boston, MA
DE myelodysplastic syndrome; low-risk; hypomethylating agent failure;
survival
ID AZACITIDINE TREATMENT FAILURE; PROGNOSTIC SCORING SYSTEM; PHASE-III;
DECITABINE; LEUKEMIA; PROPOSAL; THERAPY
AB BACKGROUNDThe hypomethylating agents (HMAs) azacitidine and decitabine are most commonly used to treat patients with higher-risk myelodysplastic syndromes (MDS). To the authors' knowledge, the prognosis of patients with low-risk and intermediate-1-risk MDS by the International Prognostic Scoring System (IPSS) after HMA failure has not been explored comprehensively.
METHODSThe clinical characteristics and treatment outcome of 438 patients with low-risk and intermediate-1-risk MDS who were treated with HMAs were retrospectively analyzed.
RESULTSUsing the International Working Group response criteria, the overall objective response to HMA was 35% with a median of 6 cycles of HMA administered, and the median response duration was 7 months. Only 7% of patients had disease that transformed into acute myeloid leukemia while receiving therapy. Of the 290 patients who were evaluable at the time of HMA failure, 77% remained in the lower-risk disease categories. On multivariate analysis, baseline neutropenia, intermediate-risk and poor-risk baseline karyotype, and lack of response to HMA were found to be independently associated with a higher risk of disease progression. With a median follow-up of 16 months, the median transformation-free survival and overall survival (OS) after HMA failure were 15 months and 17 months, respectively. On multivariate analysis, only The University of Texas MD Anderson Global Scoring System was found to be independently predictive of outcome, with patients with higher-risk categories having poor transformation-free survival (hazards ratio [HR], 1.5; P=.003) and OS (HR, 1.8; P=.002). The administration of salvage therapy was independently associated with better OS only (HR, 0.8; P=.01).
CONCLUSIONSOutcomes of patients with lower-risk MDS after HMA failure are poor and the treatment of these patients remains an unmet medical need. OS is a reasonable primary endpoint for clinical studies targeting this population. Cancer 2015;121:876-882. (c) 2014 American Cancer Society.
The outcomes of patients with lower-risk myelodysplastic syndromes after treatment failure with hypomethylating agents are poor, with a median survival of 17 months reported. Overall survival is a reasonable primary endpoint for clinical studies targeting this patient population.
C1 [Jabbour, Elias J.; Garcia-Manero, Guillermo; Strati, Paolo; Kadia, Tapan; Daver, Naval; O'Brien, Susan; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
[Mishra, Asmita; Padron, Eric; Lancet, Jeffrey; List, Alan F.; Komrokji, Rami S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Med Oncol, Tampa, FL 33612 USA.
[Al Ali, Najla H.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA.
[Steensma, David P.] Dana Farber Canc Inst, Dept Hematol Oncol, Boston, MA 02115 USA.
[Sekeres, Mikkael A.] Cleveland Clin, Dept Hematol & Oncol, Cleveland, OH 44106 USA.
[Gore, Steven D.] Yale Univ, Sch Med, Dept Hematol, New Haven, CT USA.
[Dezern, Amy] Johns Hopkins Univ, Dept Oncol, Baltimore, MD USA.
[Roboz, Gail J.] Cornell Univ, Dept Hematol, New York, NY 10021 USA.
EM ggarciam@mdanderson.org
FU MDS Clinical Research Consortium sponsored by the Aplastic Anemia and
MDS International Foundation; Edward P. Evans Foundation; University of
Texas MD Anderson Cancer Center [CA016672]; Fundacion Ramon Areces
(Madrid, Spain)
FX Supported in part by the following grants: the MDS Clinical Research
Consortium sponsored by the Aplastic Anemia and MDS International
Foundation (made possible by funding from the Edward P. Evans
Foundation); The University of Texas MD Anderson Cancer Center Support
Grant CA016672; the Fundacion Ramon Areces (Madrid, Spain); and generous
philanthropic contributions to The University of Texas MD Anderson
Cancer Center Moon Shots Program.
NR 21
TC 13
Z9 13
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAR 15
PY 2015
VL 121
IS 6
BP 876
EP 882
DI 10.1002/cncr.29145
PG 7
WC Oncology
SC Oncology
GA CD0HF
UT WOS:000350750700012
PM 25410759
ER
PT J
AU El-Jawahri, AR
Traeger, LN
Kuzmuk, K
Eusebio, JR
Vandusen, HB
Shin, JA
Keenan, T
Gallagher, ER
Greer, JA
Pirl, WF
Jackson, VA
Ballen, KK
Spitzer, TR
Graubert, TA
McAfee, SL
Dey, BR
Chen, YBA
Temel, JS
AF El-Jawahri, Areej R.
Traeger, Lara N.
Kuzmuk, Kailyn
Eusebio, Justin R.
Vandusen, Harry B.
Shin, Jennifer A.
Keenan, Tanya
Gallagher, Emily R.
Greer, Joseph A.
Pirl, William F.
Jackson, Vicki A.
Ballen, Karen K.
Spitzer, Thomas R.
Graubert, Timothy A.
McAfee, Steven L.
Dey, Bimalangshu R.
Chen, Yi-Bin A.
Temel, Jennifer S.
TI Quality of Life and Mood of Patients and Family Caregivers During
Hospitalization for Hematopoietic Stem Cell Transplantation
SO CANCER
LA English
DT Article; Proceedings Paper
CT 1st Palliative Care in Oncology Symposium
CY OCT, 2014
CL Boston, MA
DE quality of life (QOL); depression; mood; family caregivers; stem cell
transplantation
ID BONE-MARROW-TRANSPLANTATION; CANCER-PATIENTS; DEPRESSION; LEUKEMIA;
IMPACT; CARE; AGE
AB BACKGROUNDWe conducted a study to investigate the impact of hospitalization for hematopoietic stem cell transplantation (HCT) on the quality of life (QOL) and mood of patients and family caregivers (FC).
METHODSWe conducted a longitudinal study of patients who were hospitalized for HCT and their FC. We assessed QOL (using the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation) and mood (using the Hospital Anxiety and Depression Scale) at baseline (6 days before HCT), day +1, and day +8 of HCT. We administered the Medical Outcomes Study Health Survey Short Form-36 to examine FC QOL (Physical Component Scale and Mental Component Scale). To identify predictors of changes in QOL, we used multivariable linear mixed models.
RESULTSWe enrolled 97% of eligible patients undergoing autologous (30 patients), myeloablative (30 patients), or reduced intensity (30 patients) allogeneic HCT. Patients' QOL markedly declined (mean Functional Assessment of Cancer Therapy-Bone Marrow Transplantation score, 109.6 to 96.0; P<.0001) throughout hospitalization. The percentage of patients with depression (Hospital Anxiety and Depression Scale-Depression score of >7) more than doubled from baseline to day +8 (15.6% to 37.8%; P<.0001), whereas the percentage of patients with anxiety remained stable (22.2%; P=.8). These results remained consistent when data were stratified by HCT type. Baseline depression (, -2.24; F, 42.2 [P<.0001]) and anxiety (, -0.63; F, 4.4 [P =.03]) were found to independently predict worse QOL throughout hospitalization. FC QOL declined during the patient's hospitalization (physical component scale: 83.1 to 79.6 [P =.03] and mental component scale: 71.6 to 67.4 [P =.04]).
CONCLUSIONSPatients undergoing HCT reported a steep deterioration in QOL and substantially worsening depression during hospitalization. Baseline anxiety and depression predicted worse QOL during hospitalization, underscoring the importance of assessing pre-HCT psychiatric morbidity. Cancer 2015;121:951-959. (c) 2014 American Cancer Society.
Patients undergoing hematopoietic stem cell transplantation reported a steep deterioration in quality of life and substantially worsening depression during hospitalization. Baseline anxiety and depression were found to predict worse quality of life during hospitalization, underscoring the importance of assessing psychiatric morbidity prior to hematopoietic stem cell transplantation.
C1 [El-Jawahri, Areej R.; Shin, Jennifer A.; Keenan, Tanya; Gallagher, Emily R.; Ballen, Karen K.; Spitzer, Thomas R.; Graubert, Timothy A.; McAfee, Steven L.; Dey, Bimalangshu R.; Chen, Yi-Bin A.; Temel, Jennifer S.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA.
[Traeger, Lara N.; Kuzmuk, Kailyn; Eusebio, Justin R.; Vandusen, Harry B.; Greer, Joseph A.; Pirl, William F.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Jackson, Vicki A.] Massachusetts Gen Hosp, Div Palliat Care, Boston, MA 02114 USA.
EM ael-jawahri@partners.org
OI Graubert, Timothy/0000-0002-7710-1171
FU Massachusetts General Hospital Cancer Center; National Institutes of
Health [K24CA181253]
FX Supported by funds from the Massachusetts General Hospital Cancer Center
and National Institutes of Health grant K24CA181253 (to Dr. Temel).
NR 27
TC 15
Z9 15
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAR 15
PY 2015
VL 121
IS 6
BP 951
EP 959
DI 10.1002/cncr.29149
PG 9
WC Oncology
SC Oncology
GA CD0HF
UT WOS:000350750700021
PM 25469752
ER
PT J
AU Passeri, JJ
Elmariah, S
Xu, K
Inglessis, I
Baker, JN
Alu, M
Kodali, S
Leon, MB
Svensson, LG
Pibarot, P
Fearon, WF
Kirtane, AJ
Vlahakes, GJ
Palacios, IF
Douglas, PS
AF Passeri, Jonathan J.
Elmariah, Sammy
Xu, Ke
Inglessis, Ignacio
Baker, Joshua N.
Alu, Maria
Kodali, Susheel
Leon, Martin B.
Svensson, Lars G.
Pibarot, Philippe
Fearon, William F.
Kirtane, Ajay J.
Vlahakes, Gus J.
Palacios, Igor F.
Douglas, Pamela S.
CA PARTNER Investigators
TI Transcatheter aortic valve replacement and standard therapy in
inoperable patients with aortic stenosis and low EF
SO HEART
LA English
DT Article
ID LEFT-VENTRICULAR DYSFUNCTION; LOW EJECTION FRACTION; HIGH-RISK PATIENTS;
BALLOON VALVULOPLASTY; CARDIAC-SURGERY; ECHOCARDIOGRAPHY;
RECOMMENDATIONS; IMPLANTATION; MORTALITY; SURVIVAL
AB Objectives The aims of this study were to evaluate the effect of left ventricular (LV) dysfunction on clinical outcomes after transcatheter aortic valve replacement (TAVR) and standard therapy for severe aortic stenosis (AS) and to assess LV ejection fraction (LVEF) recovery and its impact on subsequent clinical outcomes.
Methods Cohort B of the Placement of AoRtic TraNscathetER Valves trial randomised 342 inoperable patients with severe AS to TAVR or standard therapy. We defined LV dysfunction as an LVEF < 50% and LVEF improvement as an absolute increase in LVEF >= 10% at 30 days.
Results Baseline LV dysfunction did not affect survival after TAVR but was associated with increased cardiac mortality at 1 year with standard therapy (59.3% vs 45.8% with normal LVEF; HR=1.71 (95% CI 1.08 to 2.71); p= 0.02). In those with LV dysfunction, LVEF improvement occurred in 48.7% and 30.4% of TAVR and standard therapy patients, respectively (p= 0.08), and was independently predicted by relative wall thickness and receipt of TAVR. LVEF improvement with standard therapy portended reduced all-cause mortality at 1 year (28.6% vs 65.6% without LVEF improvement; HR=0.32 (95% CI 0.11 to 0.93); p=0.03) but not at 2 years.
Conclusions In inoperable patients with severe AS, mild-to-moderate LV dysfunction is associated with higher cardiac mortality with standard therapy but not TAVR. A subset of patients undergoing standard therapy with LV dysfunction demonstrates LVEF improvement and favourable 1-year but not 2-year survival. TAVR improves survival and should be considered the standard of care for inoperable patients with AS and LVEF > 20%.
C1 [Passeri, Jonathan J.; Elmariah, Sammy; Inglessis, Ignacio; Palacios, Igor F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Cardiol Div, Boston, MA USA.
[Elmariah, Sammy] Harvard Univ, Clin Res Inst, Boston, MA 02115 USA.
[Xu, Ke; Alu, Maria; Kodali, Susheel; Leon, Martin B.; Kirtane, Ajay J.] Columbia Univ, Med Ctr, New York Presbyterian Hosp, Cardiovasc Res Fdn, New York, NY USA.
[Baker, Joshua N.; Vlahakes, Gus J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Cardiac Surg, Boston, MA USA.
[Svensson, Lars G.] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA.
[Pibarot, Philippe] Univ Laval, Quebec Heart & Lung Inst, Quebec City, PQ, Canada.
[Fearon, William F.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Douglas, Pamela S.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
RP Passeri, JJ (reprint author), Massachusetts Gen Hosp, 55 Fruit St,YAW 5700, Boston, MA 02114 USA.
EM jpasseri@mgh.harvard.edu; selmariah@mgh.harvard.edu
FU Edwards Lifesciences; American Heart Association [14 FTF20440012]
FX The PARTNER Trial was supported by Edwards Lifesciences, and the
protocol was designed collaboratively by the Steering Committee and
Sponsor. This work was, in part, supported by the American Heart
Association (14 FTF20440012 to SE).
NR 33
TC 8
Z9 8
U1 2
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1355-6037
EI 1468-201X
J9 HEART
JI Heart
PD MAR 15
PY 2015
VL 101
IS 6
BP 463
EP 471
DI 10.1136/heartjnl-2014-306737
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CC4UY
UT WOS:000350350800012
PM 25586156
ER
PT J
AU Sachs, GS
Greenberg, WM
Starace, A
Lu, K
Ruth, A
Laszlovszky, I
Nemeth, G
Durgam, S
AF Sachs, Gary S.
Greenberg, William M.
Starace, Anju
Lu, Kaifeng
Ruth, Adam
Laszlovszky, Istvan
Nemeth, Gyoergy
Durgam, Suresh
TI Cariprazine in the treatment of acute mania in bipolar trial I disorder:
A double-blind, placebo-controlled, Phase III
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Cariprazine; Bipolar disorder; Mania; Antipsychotic; Dopamine D-3
receptors; Remission
ID DOPAMINE D-3 RECEPTOR; ANTIPSYCHOTIC-DRUGS; RATING-SCALE; ANTIMANIC
TREATMENTS; AFFINITY; SCHIZOPHRENIA; METAANALYSIS; ANTAGONISTS;
DEPRESSION; VALIDITY
AB Background: This Phase III, randomized, double-blind, placebo-controlled study investigated the efficacy and tolerability of flexibly-dosed cariprazine in patients with acute manic or mixed episodes associated with bipolar I disorder.
Methods: Patients were randomized to 3 weeks of double-blind treatment with cariprazine 3-12 mg/day (n=158) or placebo (n=154). The primary efficacy parameter was change from baseline to Week 3 in Young Mania Rating Scale (YMRS) total score. The secondary efficacy parameter was change from baseline to Week 3 in Clinical Global Impressions-Severity (CGI-S) score.
Results: Mean change from baseline to Week 3 in YMRS total score was significantly greater for patients receiving cariprazine 3-12 mg/day versus placebo (P=0.0004). Significant differences between groups in YMRS total score mean change were observed by Day 4 (first postbaseline assessment) and maintained throughout double-blind treatment (all assessments, P < 0.01). Cariprazine also demonstrated statistically significant superiority over placebo on YMRS response (>= 50% improvement: cariprazine, 58.9%; placebo, 44.1%; P=0.0097) and remission (YMRS total score < 12: cariprazine, 51.9%; placebo, 34.9%; P=0.0025) and mean change in CGI-S (P=0.0027) score and Positive and Negative Syndrome Scale (PANSS) (P=0.0035) total score. The most common cariprazine-related (>= 10% and twice placebo) treatment emergent adverse events (TEAEs) were akathisia, extrapyramiclal disorder, tremor, dyspepsia, and vomiting. Mean change from baseline in metabolic parameters were generally small and similar between groups.
Limitations: Lack of active comparator arm; short duration of study.
Conclusion: In this study, cariprazine 3-12 mg/day was effective and generally well tolerated in the treatment of manic and mixed episodes associated with bipolar l disorder. (C)2014 The Authors. Published by Elsevier B.V.
C1 [Sachs, Gary S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Greenberg, William M.; Starace, Anju; Lu, Kaifeng] Forest Res Inst, Jersey City, NJ USA.
[Ruth, Adam] Prescott Med Commun Grp, Chicago, IL USA.
[Laszlovszky, Istvan; Nemeth, Gyoergy] Gedeon Richter Plc, Budapest, Hungary.
RP Sachs, GS (reprint author), Massachusetts Gen Hosp, 15 Parkman St, Boston, MA 02114 USA.
EM sachsg@aol.com
FU Forest Laboratories, Inc.; Actavis Plc (New York, New York); Gedeon
Richter Plc (Budapest, Hungary)
FX This study was supported by funding from Forest Laboratories, Inc., a
subsidiary of Actavis Plc (New York, New York), and Gedeon Richter Plc
(Budapest, Hungary). Forest Laboratories, Inc. and Gedeon Richter Plc
were involved in the study design, collection (via contracted clinical
investigator sites), analysis, and interpretation of data, and the
decision to present these results.
NR 37
TC 21
Z9 23
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
EI 1573-2517
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD MAR 15
PY 2015
VL 174
BP 296
EP 302
DI 10.1016/j.jad.2014.11.018
PG 7
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA CC0CY
UT WOS:000350003800041
PM 25532076
ER
PT J
AU Pietrzak, RH
Tsai, J
Armour, C
Mota, N
Harpaz-Rotem, I
Southwick, SM
AF Pietrzak, Robert H.
Tsai, Jack
Armour, Cherie
Mota, Natalie
Harpaz-Rotem, Ilan
Southwick, Steven M.
TI Functional significance of a novel 7-factor model of DSM-5 PTSD
symptoms: Results from the National Health and Resilience in Veterans
Study
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Posttraumatic stress disorder; Veterans; Trauma; Symptomatology;
Functioning
ID POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; DEPRESSION; ANXIETY
AB Background: While post:traumatic stress disorder (PTSD) symptoms in the recently published Diagnostic. and Statistical Manual of Mental Disorders, Filth Edition (DSM-5) are clustered into four factors, emerging confirmatory factor analytic studies suggest that this disorder is best characterized by seven symptom clusters, including re-experiencing, avoidance, negative affect, anhedonia, externalizing behaviors, and anxious and dysphoric arousal symptoms. To date, however, data are lacking regarding the relation between this novel model of DSM-5 PTSD symptoms and measures of clinical significance in this population (e.g., functioning).
Methods: Using data from the National Health and Resilience in Veterans Study (NHRVS), a contemporary, nationally representative sample of 1484 U.S. veterans, we evaluated clinical and functional Correlates of a novel 7-factor model of DSM-5 PTSD symptoms.
Results: Differential patterns of associations were observed between DSM-5 PTSD symptom clusters, and psychiatric comorbidities, suicidal ideation, hostility, and functioning and quality of life. Anhedonia symptoms, in particular, were strongly related to current depression, as well as reduced mental Functioning and quality of life. Externalizing behaviors were most strongly related to hostility, supporting the convergent validity of this construct.
Limitations: Cross-sectional design and employment of self-report measures.
Conclusions: These results suggest that a more refined 7-factor model of DSM-5 PTSD symptoms may provide greater specificity in understanding associations with comorbid psychopathology, suicidal ideation, and functioning and quality of life in US. veterans. They further suggest that prevention and treatment efforts that target distinct aspects of the PTSD phenotype may be more effective in mitigating key clinical and functional outcomes in this population. Published by Elsevier B.V.
C1 [Pietrzak, Robert H.; Harpaz-Rotem, Ilan; Southwick, Steven M.] US Dept Vet Affairs, Natl Ctr Posttraumut Stress Disorder, Clin Neurosci Div, VA Connecticut Healthcare Syst, West Haven, CT USA.
[Pietrzak, Robert H.; Tsai, Jack; Mota, Natalie; Harpaz-Rotem, Ilan; Southwick, Steven M.] Yale Univ, Dept Psychiat, West Haven, CT 06516 USA.
[Tsai, Jack] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA.
[Armour, Cherie] Univ Ulster, Psychol Res Inst, Coleraine BT52 1SA, Londonderry, North Ireland.
RP Pietrzak, RH (reprint author), Yale Univ, Dept Psychiat, 950 Campbell Ave 151E, West Haven, CT 06516 USA.
EM robert.pietrzak@yale.edu
OI Armour, Cherie/0000-0001-7649-3874
FU U.S. Department of Veterans Affairs National Center for Posttraumatic
Stress Disorder
FX The National Health and Resilience in Veterans Study (NHRVS) and
preparation of this report was supported by the U.S. Department of
Veterans Affairs National Center for Posttraumatic Stress Disorder and a
private donation.
NR 22
TC 19
Z9 19
U1 2
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
EI 1573-2517
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD MAR 15
PY 2015
VL 174
BP 522
EP 526
DI 10.1016/j.jad.2014.12.007
PG 5
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA CC0CY
UT WOS:000350003800071
PM 25556669
ER
PT J
AU Cadoni, S
Falt, P
Gallittu, P
Liggi, M
Mura, D
Smajstrla, V
Erriu, M
Leung, FW
AF Cadoni, S.
Falt, P.
Gallittu, P.
Liggi, M.
Mura, D.
Smajstrla, V.
Erriu, M.
Leung, F. W.
TI COMPARISON OF METHODS FOR LUMINAL DISTENTION FOR ON-DEMAND SEDATION
COLONOSCOPY: AIR INSUFFLATION, CARBON DIOXIDE AND WATER-AIDED
COLONOSCOPY: A 2-CENTER RANDOMIZED CONTROLLED TRIAL
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Meeting Abstract
C1 [Cadoni, S.; Gallittu, P.; Liggi, M.; Mura, D.] S Barbara Hosp, Digest Endoscopy Unit, Iglesias, CI, Italy.
[Falt, P.; Smajstrla, V.] Vitkovice Hosp, Ctr Digest Dis, Ostrava, Czech Republic.
[Erriu, M.] Univ Cagliari, Dept Surg Sci, Cagliari, Italy.
[Leung, F. W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1590-8658
EI 1878-3562
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD MAR 15
PY 2015
VL 47
SU 2
MA OC.02.2
BP E75
EP E76
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V46MS
UT WOS:000209888900018
ER
PT J
AU Shimada, YJ
Scirica, BM
AF Shimada, Yuichi J.
Scirica, Benjamin M.
TI Long-Term Management and Unmet Needs After an Acute Coronary Syndrome
Event
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; T-WAVE ALTERNANS; DUAL ANTIPLATELET
THERAPY; ASSOCIATION TASK-FORCE; HEART-RATE-VARIABILITY; SUDDEN CARDIAC
DEATH; DRUG-ELUTING STENT; CARDIOVERTER-DEFIBRILLATOR; BAROREFLEX
SENSITIVITY; PRACTICE GUIDELINES
C1 [Shimada, Yuichi J.; Scirica, Benjamin M.] Brigham & Womens Hosp, Cardiovasc Div, Boston, MA 02115 USA.
[Scirica, Benjamin M.] Brigham & Womens Hosp, TIMI Study Grp, Cardiovasc Div, Boston, MA 02115 USA.
RP Scirica, BM (reprint author), Brigham & Womens Hosp, TIMI Study Grp, Cardiovasc Div, 350 Longwood Ave, Boston, MA 02115 USA.
EM bscirica@partners.org
OI Shimada, Yuichi/0000-0002-3494-307X
FU AstraZeneca LP
FX Publication of this article was supported by funding from AstraZeneca
LP.
NR 33
TC 1
Z9 1
U1 0
U2 1
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD MAR 14
PY 2015
VL 115
IS 5
SU S
BP 37
EP 43
DI 10.1016/j.amjcard.2015.01.005
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CE0HY
UT WOS:000351486300005
PM 25728972
ER
PT J
AU Valenza, G
Garcia, RG
Citi, L
Scilingo, EP
Tomaz, CA
Barbieri, R
AF Valenza, Gaetano
Garcia, Ronald G.
Citi, Luca
Scilingo, Enzo P.
Tomaz, Carlos A.
Barbieri, Riccardo
TI Nonlinear digital signal processing in mental health: characterization
of major depression using instantaneous entropy measures of heartbeat
dynamics
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE nonlinear; heart rate variability; instantaneous entropy; point process;
Wiener-Volterra series; Laguerre expansion
ID RATE-VARIABILITY; DISORDERS; MECHANISMS; COMPLEXITY; ILLNESS; STATES;
SCALE
AB Nonlinear digital signal processing methods that address system complexity have provided useful computational tools for helping in the diagnosis and treatment of a wide range of pathologies. More specifically, nonlinear measures have been successful in characterizing patients with mental disorders such as Major Depression (MD). In this study, we propose the use of instantaneous measures of entropy, namely the inhomogeneous point-process approximate entropy (ipApEn) and the inhomogeneous point-process sample entropy (ipSampEn), to describe a novel characterization of MD patients undergoing affective elicitation. Because these measures are built within a nonlinear point-process model, they allow for the assessment of complexity in cardiovascular dynamics at each moment in time. Heartbeat dynamics were characterized from 48 healthy controls and 48 patients with MD while emotionally elicited through either neutral or arousing audiovisual stimuli. Experimental results coming from the arousing tasks show that ipApEn measures are able to instantaneously track heartbeat complexity as well as discern between healthy subjects and MD patients. Conversely, standard heart rate variability (HRV) analysis performed in both time and frequency domains did not show any statistical significance. We conclude that measures of entropy based on nonlinear point-process models might contribute to devising useful computational tools for care in mental health.
C1 [Valenza, Gaetano; Barbieri, Riccardo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
[Valenza, Gaetano] MIT, Cambridge, MA 02139 USA.
[Valenza, Gaetano; Scilingo, Enzo P.] Univ Pisa, Dept Informat Engn, Res Ctr E Piaggio, Pisa, Italy.
[Garcia, Ronald G.] Massachusetts Gen Hosp, Dept Radiol, Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Garcia, Ronald G.] Univ Santander, Masira Res Inst, Sch Med, Dept Psychiat, Bucaramanga, Colombia.
[Citi, Luca] Univ Essex, Sch Comp Sci & Elect Engn, Colchester CO4 3SQ, Essex, England.
[Tomaz, Carlos A.] Univ Brasilia, Lab Neurosci & Behav, Brasilia, DF, Brazil.
RP Barbieri, R (reprint author), Massachusetts Gen Hosp, Dept Anesthesia, Crit Care, 55 Fruit St,Jackson 4, Boston, MA 02114 USA.
EM barbieri@neurostat.mit.edu
OI Barbieri, Riccardo/0000-0001-9381-3833; Garcia, Ronald
Gerardo/0000-0002-8325-9944; Scilingo, Enzo
Pasquale/0000-0003-2588-4917; Valenza, Gaetano/0000-0001-6574-1879
FU Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts
General Hospital, Harvard Medical School, Boston, MA, USA; European
Union [601165]; Colombian Institute for the Development of Science and
Technology "Colciencias" [6566-408-20391]
FX This study received partial funding from the Department of Anesthesia,
Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard
Medical School, Boston, MA, USA, from the European Union Seventh
Framework Programme FP7/2007-2013 under Grant No. 601165 of the project
"WEARHAP," and from the Colombian Institute for the Development of
Science and Technology "Colciencias" (Project No. 6566-408-20391).
NR 36
TC 3
Z9 3
U1 2
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD MAR 13
PY 2015
VL 6
AR 74
DI 10.3389/fphys.2015.00074
PG 8
WC Physiology
SC Physiology
GA CG0DG
UT WOS:000352936200001
PM 25821435
ER
PT J
AU Choi, YE
Park, E
AF Choi, Young Eun
Park, Eunmi
TI Ferulic acid in combination with PARP inhibitor sensitizes breast cancer
cells as chemotherapeutic strategy
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Ferulic acid; ABT-888; Breast cancer cells; Homologous-recombination
repair
ID MAMMALIAN-CELLS; REPAIR; CISPLATIN; MICE
AB Homologous-recombination (HR)-dependent repair defective cells are hypersensitive to poly (ADPribose) polymerase (PARP) inhibitors. Combinations of defective HR pathway and PARP inhibitors have been an effective chemotherapeutic modality. We previously showed that knockdown of the WD40-repeat containing protein, Uafl, causes an HR repair defect in mouse embryo fibroblast cells and therefore, increases sensitivity to PARP inhibitor, ABT-888. Similarly, here, we show that ferulic acid reduces HR repair, inhibits RAD 51 foci formation, and accumulates gamma-H2AX in breast cancer cells. Moreover, ferulic acid, when combined with ABT-888, renders breast cancer cells become hypersensitive to ABT-888. Our study indicates that ferulic acid in combination with ABT-888 treatment may serve as an effective combination chemotherapeutic agent as a natural bioactive compound. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Choi, Young Eun] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Park, Eunmi] Hannam Univ, Sch Life Sci & Nanotechnol, Dept Food & Nutr, Taejon 305811, South Korea.
RP Park, E (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, 44 Binney St, Boston, MA 02115 USA.
EM eunmi_park@hnu.kr
NR 18
TC 7
Z9 8
U1 3
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 13
PY 2015
VL 458
IS 3
BP 520
EP 524
DI 10.1016/j.bbrc.2015.01.147
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA CE2QD
UT WOS:000351659200012
PM 25677620
ER
PT J
AU Cai, Y
Hirata, A
Nakayama, S
VanderLaan, PA
Levantini, E
Yamamoto, M
Hirai, H
Wong, KK
Costa, DB
Watanabe, H
Kobayashi, SS
AF Cai, Yi
Hirata, Ayako
Nakayama, Sohei
VanderLaan, Paul A.
Levantini, Elena
Yamamoto, Mihoko
Hirai, Hideyo
Wong, Kwok-Kin
Costa, Daniel B.
Watanabe, Hideo
Kobayashi, Susumu S.
TI CCAAT/Enhancer Binding Protein beta Is Dispensable for Development of
Lung Adenocarcinoma
SO PLOS ONE
LA English
DT Article
ID EPITHELIAL-CELL PROLIFERATION; C/EBP-BETA; TRANSCRIPTION FACTORS;
DIFFERENTIAL EXPRESSION; DOWN-REGULATION; CANCER-THERAPY; MAMMARY-GLAND;
IN-VIVO; ALPHA; FAMILY
AB Lung cancer is the leading cause of cancer death worldwide. Although disruption of normal proliferation and differentiation is a vital component of tumorigenesis, the mechanisms of this process in lung cancer are still unclear. A transcription factor, C/EBP beta is a critical regulator of proliferation and/or differentiation in multiple tissues. In lung, C/EBP beta is expressed in alveolar pneumocytes and bronchial epithelial cells; however, its roles on normal lung homeostasis and lung cancer development have not been well described. Here we investigated whether C/EBP beta is required for normal lung development and whether its aberrant expression and/or activity contribute to lung tumorigenesis. We showed that C/EBP beta was expressed in both human normal pneumocytes and lung adenocarcinoma cell lines. We found that overall lung architecture was maintained in Cebpb knockout mice. Neither overexpression of nuclear C/EBP beta nor suppression of CEBPB expression had significant effects on cell proliferation. C/EBP beta expression and activity remained unchanged upon EGF stimulation. Furthermore, deletion of Cebpb had no impact on lung tumor burden in a lung specific, conditional mutant EGFR lung cancer mouse model. Analyses of data from The Cancer Genome Atlas (TCGA) revealed that expression, promoter methylation, or copy number of CEBPB was not significantly altered in human lung adenocarcinoma. Taken together, our data suggest that C/EBP beta is dispensable for development of lung adenocarcinoma.
C1 [Cai, Yi; Hirata, Ayako; Nakayama, Sohei; Levantini, Elena; Yamamoto, Mihoko; Costa, Daniel B.; Kobayashi, Susumu S.] Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA USA.
[VanderLaan, Paul A.] Harvard Univ, Sch Med, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
[Levantini, Elena] CNR, Natl Res Council, Inst Biomed Technol, I-56100 Pisa, Italy.
[Hirata, Ayako; Hirai, Hideyo] Kyoto Univ Hosp, Dept Transfus Med & Cell Therapy, Kyoto 606, Japan.
[Wong, Kwok-Kin; Watanabe, Hideo] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Watanabe, Hideo] Broad Inst MIT & Harvard, Canc Program, Cambridge, MA USA.
[Kobayashi, Susumu S.] Harvard Stem Cell Inst, Cambridge, MA USA.
RP Watanabe, H (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM hideo_watanabe@dfci.harvard.edu; skobayas@bidmc.harvard.edu
OI Costa, Daniel/0000-0002-0689-395X
FU National Institution of Health [R00CA126026, R01CA169259]; Harvard Stem
Cell Institute [DP-0110-12-00]; Lung Cancer Foundation of
America-International Association; American Cancer Society [RSG-13-047,
RSG-11-186]; Bonnie J. Addario Lung Cancer Foundation
FX Funding: This work was supported by National Institution of Health
grants (R00CA126026 and R01CA169259 to S. S. K.); Harvard Stem Cell
Institute (DP-0110-12-00); an Lung Cancer Foundation of
America-International Association to Study Lung Cancer grant (D. B. C.);
an American Cancer Society grant (RSG-13-047 to S. S. K. and RSG-11-186
to D. B. C.); and Bonnie J. Addario Lung Cancer Foundation grant (S.
N.). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 45
TC 0
Z9 0
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 13
PY 2015
VL 10
IS 3
AR e0120647
DI 10.1371/journal.pone.0120647
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CD7NO
UT WOS:000351277500132
PM 25767874
ER
PT J
AU Weber, GF
Chousterman, BG
He, S
Fenn, AM
Nairz, M
Anzai, A
Brenner, T
Uhle, F
Iwamoto, Y
Robbins, CS
Noiret, L
Maier, SL
Zonnchen, T
Rahbari, NN
Scholch, S
Ameln, AKV
Chavakis, T
Weitz, J
Hofer, S
Weigand, MA
Nahrendorf, M
Weissleder, R
Swirski, FK
AF Weber, Georg F.
Chousterman, Benjamin G.
He, Shun
Fenn, Ashley M.
Nairz, Manfred
Anzai, Atsushi
Brenner, Thorsten
Uhle, Florian
Iwamoto, Yoshiko
Robbins, Clinton S.
Noiret, Lorette
Maier, Sarah L.
Zoennchen, Tina
Rahbari, Nuh N.
Schoelch, Sebastian
Ameln, Anne Klotzsche-von
Chavakis, Triantafyllos
Weitz, Juergen
Hofer, Stefan
Weigand, Markus A.
Nahrendorf, Matthias
Weissleder, Ralph
Swirski, Filip K.
TI Interleukin-3 amplifies acute inflammation and is a potential
therapeutic target in sepsis
SO SCIENCE
LA English
DT Article
ID B-CELLS PROTECT; UNITED-STATES; SEPTIC SHOCK; IN-VITRO;
IMMUNOSUPPRESSION; FAILURE; BIOLOGY; TRIAL; CSF
AB Sepsis is a frequently fatal condition characterized by an uncontrolled and harmful host reaction to microbial infection. Despite the prevalence and severity of sepsis, we lack a fundamental grasp of its pathophysiology. Here we report that the cytokine interleukin-3 (IL-3) potentiates inflammation in sepsis. Using a mouse model of abdominal sepsis, we showed that innate response activator B cells produce IL-3, which induces myelopoiesis of Ly-6C(high) monocytes and neutrophils and fuels a cytokine storm. IL-3 deficiency protects mice against sepsis. In humans with sepsis, high plasma IL-3 levels are associated with high mortality even after adjusting for prognostic indicators. This study deepens our understanding of immune activation, identifies IL-3 as an orchestrator of emergency myelopoiesis, and reveals a new therapeutic target for treating sepsis.
C1 [Weber, Georg F.; Chousterman, Benjamin G.; He, Shun; Fenn, Ashley M.; Nairz, Manfred; Anzai, Atsushi; Iwamoto, Yoshiko; Robbins, Clinton S.; Noiret, Lorette; Nahrendorf, Matthias; Weissleder, Ralph; Swirski, Filip K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02163 USA.
[Weber, Georg F.; Maier, Sarah L.; Zoennchen, Tina; Rahbari, Nuh N.; Schoelch, Sebastian; Weitz, Juergen] Tech Univ Dresden, Dept Visceral Thorac & Vasc Surg, D-01062 Dresden, Germany.
[Brenner, Thorsten; Uhle, Florian; Hofer, Stefan; Weigand, Markus A.] Heidelberg Univ, Dept Anesthesiol, Heidelberg, Germany.
[Ameln, Anne Klotzsche-von; Chavakis, Triantafyllos] Tech Univ Dresden, Dept Clin Pathobiochem, D-01062 Dresden, Germany.
[Ameln, Anne Klotzsche-von; Chavakis, Triantafyllos] Tech Univ Dresden, Inst Clin Chem & Lab Med, D-01062 Dresden, Germany.
[Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
RP Weber, GF (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02163 USA.
EM georg.weber@uniklinikum-dresden.de; fswirski@mgh.harvard.edu
RI He, Shun/K-7448-2014;
OI Scholch, Sebastian/0000-0003-0012-3177
FU NIH [5R01HL095612, R56-AI104695]; Massachusetts General Hospital Howard
M. Goodman Fellowship; German Research Foundation [WE4892/1-2,
WE4892/3-1]; Societe Francaise d'Anesthesie-Reanimation (SFAR); Institut
Servier; Fondation Groupe Pasteur Mutualite; Fulbright Scholarships
(Monahan Foundation); Fulbright Scholarships (Harvard French Scholarship
Fund); Erwin Schrodinger Fellowship of the Austrian Science Fund FWF
[J3486-B13]
FX We thank M. Greene for secretarial assistance, M. Waring and A. Chicoine
for sorting cells, and K. Joyes for editing the manuscript. The data
presented in this manuscript are tabulated in the main paper and in the
supplementary materials. The General Hospital Corporation has filed a
patent application (61/973,458) with the U.S. Patent and Trademark
Office entitled "Agents and Methods for Diagnosing and Treating Sepsis,"
which names F.K.S. and G.F.W. as inventors. Il3-/- mice are
available from Riken, Japan, under a materials transfer agreement. This
work was supported by NIH grants 5R01HL095612 and R56-AI104695 and the
Massachusetts General Hospital Howard M. Goodman Fellowship (F.K.S.).
G.F.W. was supported by the German Research Foundation (WE4892/1-2 and
3-1). B.G.C. was supported by the Societe Francaise
d'Anesthesie-Reanimation (SFAR), Institut Servier, Fondation Groupe
Pasteur Mutualite, and Fulbright Scholarships (Monahan Foundation and
Harvard French Scholarship Fund). M.N. was supported by an Erwin
Schrodinger Fellowship of the Austrian Science Fund FWF (J3486-B13). The
authors declare no conflicts of interest.
NR 32
TC 39
Z9 40
U1 10
U2 49
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAR 13
PY 2015
VL 347
IS 6227
BP 1260
EP 1265
DI 10.1126/science.aaa4268
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CD1GZ
UT WOS:000350824300041
PM 25766237
ER
PT J
AU Wigley, F
Friday, RP
Shepard, JAO
Nazarian, RM
AF Wigley, Fredrick
Friday, Robert P.
Shepard, Jo-Anne O.
Nazarian, Rosalynn M.
TI Case 8-2015: A 68-Year-Old Man with Multiple Myeloma, Skin Tightness,
Arthralgias, and Edema
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID NEPHROGENIC SYSTEMIC FIBROSIS; RENAL-FAILURE; SCLEROMYXEDEMA;
SCLERODERMA; SCLEROSIS; ANTIBODIES; DISORDERS; MUCINOSIS; PATIENT;
DISEASE
C1 [Wigley, Fredrick] Johns Hopkins Univ, Sch Med, Dept Med, Johns Hopkins Hosp, Baltimore, MD 21205 USA.
[Wigley, Fredrick] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Friday, Robert P.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Shepard, Jo-Anne O.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Nazarian, Rosalynn M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Friday, Robert P.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Shepard, Jo-Anne O.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Nazarian, Rosalynn M.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Wigley, F (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, Johns Hopkins Hosp, Baltimore, MD 21205 USA.
FU Eiger Biopharmaceuticals; Actelion Pharmaceuticals; MedImmune; Novartis;
United Therapeutics; CSL Behring; Sanofi Aventis; Hoffmann-La Roche
FX Dr. Wigley reports receiving consulting fees from Eiger
Bio-pharmaceuticals and grant support from Actelion Pharmaceuticals,
MedImmune, Novartis, United Therapeutics, CSL Behring, Sanofi Aventis,
and Hoffmann-La Roche; and Dr. Shepard, receiving consulting fees for
providing expert testimony in a legal case regarding thoracic imaging.
No other potential conflict of interest relevant to this article was
reported.
NR 27
TC 1
Z9 1
U1 1
U2 4
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAR 12
PY 2015
VL 372
IS 11
BP 1056
EP 1067
DI 10.1056/NEJMcpc1409840
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA CD0XK
UT WOS:000350797300012
PM 25760359
ER
PT J
AU Papavasileiou, E
Lobo, AM
AF Papavasileiou, Evangelia
Lobo, Ann-Marie
TI Birdshot chorioretinopathy in a male patient with facioscapulohumeral
muscular dystrophy
SO JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION
LA English
DT Article
DE Birdshot chorioretinopathy; Facioscapulohumeral muscular dystrophy
ID COATS-DISEASE; RETINOCHOROIDOPATHY; ASSOCIATION
AB Background: We report a case of birdshot chorioretinopathy (BSCR) in a patient with facioscapulohumeral muscular dystrophy (FSHD). A 40-year-old male with history of facioscapulohumeral muscular dystrophy with significant facial diplegia and lagophthalmos presents for an evaluation of bilateral choroiditis with vasculitis and optic disc edema. Clinical examination included fundus and autofluorescence photographs, fluorescein angiography, and optical coherence tomography. To our knowledge, this patient represents the first reported case of birdshot chorioretinopathy with facioscapulohumeral muscular dystrophy. Patients with FSHD can present with ocular findings and should be screened with dilated fundus examinations for retinal vascular changes and posterior uveitis.
C1 [Papavasileiou, Evangelia; Lobo, Ann-Marie] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02163 USA.
[Lobo, Ann-Marie] Massachusetts Eye & Ear Infirm, Ocular Immunol & Uveitis Serv, Boston, MA 02114 USA.
RP Lobo, AM (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02163 USA.
EM Ann-Marie_Lobo@meei.harvard.edu
NR 23
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1869-5760
J9 J OPHTHALMIC INFLAMM
JI J. Ophthalmic Inflamm. Infect.
PD MAR 12
PY 2015
VL 5
AR 7
DI 10.1186/s12348-014-0030-z
PG 4
WC Ophthalmology
SC Ophthalmology
GA CZ2JW
UT WOS:000366932400001
PM 25861398
ER
PT J
AU Sarantopoulos, S
Ritz, J
AF Sarantopoulos, Stefanie
Ritz, Jerome
TI Aberrant B-cell homeostasis in chronic GVHD
SO BLOOD
LA English
DT Article
ID VERSUS-HOST-DISEASE; CD4(+) T-CELLS; HISTOCOMPATIBILITY ANTIGEN DBY;
SYSTEMIC-LUPUS-ERYTHEMATOSUS; REGULATORY B10 CELLS; BRONCHIOLITIS
OBLITERANS; ACTIVATING FACTOR; TRANSPLANTATION; BAFF; MEMORY
AB Recent studies have compelled further interest in the potential pathological role of B cells in chronic graft-versus-host disease (cGVHD). In patients with cGVHD, B cells are activated and primed for survival viaB-cell activating factor and B-cell receptor-associated pathways. Understanding the signaling pathways that drive immune pathology in cGVHD will facilitate the development of new strategies to selectively target aberrantly activated B cells and restore normal B-cell homeostasis after allogeneic stem cell transplantation.
C1 [Sarantopoulos, Stefanie] Duke Univ, Dept Med, Duke Canc Inst, Div Cell Therapy & Hematol Malignancies, Durham, NC USA.
[Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA.
RP Sarantopoulos, S (reprint author), Duke Canc Inst, Div Cell Therapy & Hematol Malignancies, Box 3961 Jones Bldg,Room 152, Durham, NC 27710 USA.
EM stefanie.sarantopoulos@duke.edu; jerome_ritz@dfci.harvard.edu
OI Ritz, Jerome/0000-0001-5526-4669
FU National Institutes of Health, National Heart, Lung, and Blood Institute
[K08HL107756]; National Cancer Institute [P01CA142106]
FX This work was supported by grants from the National Institutes of
Health, National Heart, Lung, and Blood Institute (K08HL107756) and
National Cancer Institute (P01CA142106).
NR 67
TC 23
Z9 24
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAR 12
PY 2015
VL 125
IS 11
BP 1703
EP 1707
DI 10.1182/blood-2014-12-567834
PG 5
WC Hematology
SC Hematology
GA CI3BF
UT WOS:000354621700008
PM 25645355
ER
PT J
AU Chen, SD
Sanjana, NE
Zheng, KJ
Shalem, O
Lee, K
Shi, X
Scott, DA
Song, J
Pan, JQ
Weissleder, R
Lee, H
Zhang, F
Sharp, PA
AF Chen, Sidi
Sanjana, Neville E.
Zheng, Kaijie
Shalem, Ophir
Lee, Kyungheon
Shi, Xi
Scott, David A.
Song, Jun
Pan, Jen Q.
Weissleder, Ralph
Lee, Hakho
Zhang, Feng
Sharp, Phillip A.
TI Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and
Metastasis
SO CELL
LA English
DT Article
ID IN-VIVO; BREAST-CANCER; HUMAN-CELLS; DNA; IMMUNITY; RNA; PROVIDES;
SYSTEMS; COMPLEX; CAS9
AB Genetic screens are powerful tools for identifying genes responsible for diverse phenotypes. Here we describe a genome-wide CRISPR/Cas9-mediated loss-of-function screen in tumor growth and metastasis. We mutagenized a non-metastatic mouse cancer cell line using a genome-scale library with 67,405 single-guide RNAs (sgRNAs). The mutant cell pool rapidly generates metastases when transplanted into immunocompromised mice. Enriched sgRNAs in lung metastases and late-stage primary tumors were found to target a small set of genes, suggesting that specific loss-of-function mutations drive tumor growth and metastasis. Individual sgRNAs and a small pool of 624 sgRNAs targeting the top-scoring genes from the primary screen dramatically accelerate metastasis. In all of these experiments, the effect of mutations on primary tumor growth positively correlates with the development of metastases. Our study demonstrates Cas9-based screening as a robust method to systematically assay gene phenotypes in cancer evolution in vivo.
C1 [Chen, Sidi; Sharp, Phillip A.] David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Chen, Sidi; Sharp, Phillip A.] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Chen, Sidi; Sanjana, Neville E.; Zheng, Kaijie; Shalem, Ophir; Shi, Xi; Scott, David A.; Pan, Jen Q.; Zhang, Feng] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Sanjana, Neville E.; Zheng, Kaijie; Shalem, Ophir; Shi, Xi; Scott, David A.; Pan, Jen Q.; Zhang, Feng] Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA.
[Sanjana, Neville E.; Zhang, Feng] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA.
[Sanjana, Neville E.; Zhang, Feng] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Sanjana, Neville E.; Zhang, Feng] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
[Lee, Kyungheon; Song, Jun; Weissleder, Ralph; Lee, Hakho] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
RP Zhang, F (reprint author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
EM zhang@broadinstitute.org; sharppa@mit.edu
RI Lee, Kyungheon/E-3863-2013;
OI Sanjana, Neville/0000-0002-1504-0027
FU United States Public Health Service from the NIH [R01-CA133404];
MIT-Harvard Center for Cancer Nanotechnology Excellence from the
National Cancer Institute [U54 CA151884]; Skolkovo Foundation; Koch
Institute from the National Cancer Institute [P30-CA14051]; NIH through
NIMH [5DP1-MH100706]; NIDDK [5R01-DK097768]; National Science
Foundation; Keck foundation; New York Stem Cell foundation; Damon Runyon
foundation; Searle Scholars foundation; Merkin foundation; Vallee
foundation; Bob Metcalfe; Dale Frey Award for Breakthrough Scientists;
Simons Center for the Social Brain Postdoctoral Fellowship; NIH NHGRI
[K99-HG008171]; NIH [U54 CA151884]; NSF; Department of Defense [OCRP
W81XWH-14-1-0279]
FX We thank R. Weinberg and R. Kerbel for critically reading the
manuscript; the entire P.A.S. lab and F.Z. lab, L. Cong, T. Kelly, X.
Ni, M. Nobel, J. Boehm, A. Tsherniak, S. Levine, M. Cornwall-Brady, S.
Malstrom, M. Jennings, E. Vasile, C. Whittaker, K. Cormier, R. Bronson,
and colleagues at the Koch Institute, Broad Institute, McGovern
Institute, and Department of Biology for technical assistance and/or
discussion; the Swanson Biotechnology Center for technical support
(Genomics, Animal Imaging and Preclinical Testing, Bioinformatics and
Computing, Microscopy, Flow Cytometry, Microscopy, and Histology, in
particular). This work is supported by grants to P.A.S., including a
United States Public Health Service grant R01-CA133404 from the NIH, an
MIT-Harvard Center for Cancer Nanotechnology Excellence Grant U54
CA151884 from the National Cancer Institute, a generous gift from the
Marie D. and Pierre Casimir-Lambert Fund, an SkTech/MIT Initiative Grant
from the Skolkovo Foundation, and the Koch Institute Support (core)
grant P30-CA14051 from the National Cancer Institute. F.Z. is supported
by the NIH through NIMH grant 5DP1-MH100706) and NIDDK grant
5R01-DK097768; a Waterman Award from the National Science Foundation;
the Keck, New York Stem Cell, Damon Runyon, Searle Scholars, Merkin, and
Vallee foundations; and Bob Metcalfe. F.Z. is a New York Stem Cell
Foundation Robertson Investigator. S. C. is a Damon Runyon Cancer
Research Fellow (DRG-2117-12) and also supported by the Dale Frey Award
for Breakthrough Scientists. N.E.S. is supported by a Simons Center for
the Social Brain Postdoctoral Fellowship and NIH NHGRI award
K99-HG008171. O.S. is a fellow of the Klarman Cell Observatory. R.W. is
supported by NIH grant U54 CA151884. D. A. S. is supported by a NSF
Graduate Research Fellowship. H.L. is supported by Department of Defense
grant OCRP W81XWH-14-1-0279. CRISPR reagents (plasmids and libraries)
are available to the academic community through Addgene. F.Z. is a
co-founder of Editas Medicine and a scientific advisor for Editas
Medicine and Horizon Discovery.
NR 51
TC 107
Z9 122
U1 35
U2 168
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAR 12
PY 2015
VL 160
IS 6
BP 1246
EP 1260
DI 10.1016/j.cell.2015.02.038
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CE6MT
UT WOS:000351951800022
PM 25748654
ER
PT J
AU Nazha, B
Salloum, RH
Fahed, AC
Nabulsi, M
AF Nazha, Bassel
Salloum, Rony H.
Fahed, Akl C.
Nabulsi, Mona
TI Students' Perceptions of Peer-Organized Extra-Curricular Research Course
during Medical School: A Qualitative Study
SO PLOS ONE
LA English
DT Article
ID ASSOCIATION; EDUCATION
AB Early integration of research education into medical curricula is crucial for evidence-based practice. Yet, many medical students are graduating with no research experience due to the lack of such integration in their medical school programs. The purpose of this study was to explore the impact of a peer-organized, extra-curricular research methodology course on the attitudes of medical students towards research and future academic careers. Twenty one medical students who participated in a peer-organized research course were enrolled in three focus group discussions to explore their experiences, perceptions and attitudes towards research after the course. Discussions were conducted using a semi-structured interview guide, and were transcribed and thematically analyzed for major and minor themes identification. Our findings indicate that students' perceptions of research changed after the course from being difficult initially to becoming possible. Participants felt that their research skills and critical thinking were enhanced and that they would develop research proposals and abstracts successfully. Students praised the peer-assisted teaching approach as being successful in enhancing the learning environment and filling the curricular gap. In conclusion, peer-organized extra-curricular research courses may be a useful option to promote research interest and skills of medical students when gaps in research education in medical curricula exist.
C1 [Nazha, Bassel] NorthShore LIJ Staten Isl Univ Hosp, Dept Internal Med, Staten Isl, NY USA.
[Salloum, Rony H.] Cleveland Clin, Dept Neurosci, Lerner Res Inst, Cleveland, OH 44106 USA.
[Fahed, Akl C.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Nabulsi, Mona] Amer Univ Beirut, Dept Pediat & Adolescent Med, Fac Med, Beirut, Lebanon.
RP Nabulsi, M (reprint author), Amer Univ Beirut, Dept Pediat & Adolescent Med, Fac Med, Beirut, Lebanon.
EM bnazha@nshs.edu; mn04@aub.edu.lb
NR 16
TC 0
Z9 0
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 12
PY 2015
VL 10
IS 3
AR e0119375
DI 10.1371/journal.pone.0119375
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CD7ND
UT WOS:000351276300025
PM 25764441
ER
PT J
AU Ebina, W
Rossi, DJ
AF Ebina, Wataru
Rossi, Derrick J.
TI Transcription factor-mediated reprogramming toward hematopoietic stem
cells
SO EMBO JOURNAL
LA English
DT Review
DE cell fate conversion; hematopoietic stem cells; induced reprogramming;
transcription factors
ID ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ADULT-MOUSE
HEMATOPOIESIS; GROUND-STATE PLURIPOTENCY; REGULATES SELF-RENEWAL;
MODIFIED MESSENGER-RNA; HUMAN FIBROBLASTS; PROGENITOR CELLS; DEFINED
FACTORS; IN-VIVO
AB De novo generation of human hematopoietic stem cells (HSCs) from renewable cell types has been a long sought-after but elusive goal in regenerative medicine. Paralleling efforts to guide pluripotent stem cell differentiation by manipulating developmental cues, substantial progress has been made recently toward HSC generation via combinatorial transcription factor (TF)-mediated fate conversion, a paradigm established by Yamanaka's induction of pluripotency in somatic cells by mere four TFs. This review will integrate the recently reported strategies to directly convert a variety of starting cell types toward HSCs in the context of hematopoietic transcriptional regulation and discuss how these findings could be further developed toward the ultimate generation of therapeutic human HSCs.
C1 [Ebina, Wataru; Rossi, Derrick J.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Ebina, Wataru; Rossi, Derrick J.] Boston Childrens Hosp, Div Hematol Oncol, Program Cellular & Mol Med, Boston, MA USA.
[Rossi, Derrick J.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Rossi, Derrick J.] Harvard Stem Cell Inst, Cambridge, MA USA.
RP Rossi, DJ (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
EM Derrick.Rossi@childrens.harvard.edu
NR 215
TC 12
Z9 12
U1 5
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD MAR 12
PY 2015
VL 34
IS 6
BP 694
EP 709
DI 10.15252/embj.201490804
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CD2BE
UT WOS:000350877800003
PM 25712209
ER
PT J
AU Org, T
Duan, D
Ferrari, R
Montel-Hagen, A
Van Handel, B
Kerenyi, MA
Sasidharan, R
Rubbi, L
Fujiwara, Y
Pellegrini, M
Orkin, SH
Kurdistani, SK
Mikkola, HKA
AF Org, Tonis
Duan, Dan
Ferrari, Roberto
Montel-Hagen, Amelie
Van Handel, Ben
Kerenyi, Marc A.
Sasidharan, Rajkumar
Rubbi, Liudmilla
Fujiwara, Yuko
Pellegrini, Matteo
Orkin, Stuart H.
Kurdistani, Siavash K.
Mikkola, Hanna K. A.
TI Scl binds to primed enhancers in mesoderm to regulate hematopoietic and
cardiac fate divergence
SO EMBO JOURNAL
LA English
DT Article
DE cardiac specification; enhancer; hematopoiesis; mesoderm
diversification; transcriptional regulation
ID STEM-CELL DIFFERENTIATION; TRANSCRIPTION FACTORS; AORTIC ENDOTHELIUM;
GENE-EXPRESSION; MOUSE EMBRYO; HEMOGENIC ENDOTHELIUM; TAL1 FUNCTION;
YOLK-SAC; RNA-SEQ; GENOME
AB Scl/Tal1 confers hemogenic competence and prevents ectopic cardiomyogenesis in embryonic endothelium by unknown mechanisms. We discovered that Scl binds to hematopoietic and cardiac enhancers that become epigenetically primed in multipotent cardiovascular mesoderm, to regulate the divergence of hematopoietic and cardiac lineages. Scl does not act as a pioneer factor but rather exploits a pre-established epigenetic landscape. As the blood lineage emerges, Scl binding and active epigenetic modifications are sustained in hematopoietic enhancers, whereas cardiac enhancers are decommissioned by removal of active epigenetic marks. Our data suggest that, rather than recruiting corepressors to enhancers, Scl prevents ectopic cardiogenesis by occupying enhancers that cardiac factors, such as Gata4 and Hand1, use for gene activation. Although hematopoietic Gata factors bind with Scl to both activated and repressed genes, they are dispensable for cardiac repression, but necessary for activating genes that enable hematopoietic stem/progenitor cell development. These results suggest that a unique subset of enhancers in lineage-specific genes that are accessible for regulators of opposing fates during the time of the fate decision provide a platform where the divergence of mutually exclusive fates is orchestrated.
C1 [Org, Tonis; Duan, Dan; Montel-Hagen, Amelie; Van Handel, Ben; Sasidharan, Rajkumar; Rubbi, Liudmilla; Pellegrini, Matteo; Mikkola, Hanna K. A.] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.
[Ferrari, Roberto; Kurdistani, Siavash K.] Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90024 USA.
[Ferrari, Roberto; Kurdistani, Siavash K.; Mikkola, Hanna K. A.] Univ Calif Los Angeles, Eli & Edythe Broad Stem Cell Res Ctr, Los Angeles, CA USA.
[Kerenyi, Marc A.; Fujiwara, Yuko; Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Kerenyi, Marc A.; Fujiwara, Yuko; Orkin, Stuart H.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Div Hematol Oncol,Childrens Hosp Boston,Harvard S, Boston, MA 02115 USA.
RP Mikkola, HKA (reprint author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.
EM hmikkola@mcdb.ucla.edu
RI Org, Tonis/E-8596-2010;
OI Org, Tonis/0000-0003-3071-2183; Kurdistani, Siavash/0000-0003-3295-3511
FU California Institute for Regenerative Medicine (CIRM) New Faculty Award
[RN1-00557]; Eli and Edythe Broad Center of Regenerative Medicine and
Stem Cell Research at UCLA Research Award; American Heart Association
[14GRNT20480340]; Leukemia Lymphoma Society Scholar Award [20103778];
Leukemia Lymphoma Society postdoctoral fellowship [57537-13]; European
Union through the European Social Fund [MJD284]; government of P.R.C
through the State Scholarship Fund [2011624028]; HFSP; American Society
of Hematology; NIH/NHLBI [T32 HL69766]; [P30DK049216]
FX The authors thank the Broad Stem Cell Research Center (BSCRC) Flow
Cytometry Core for FACS sorting and BSCRC Sequencing core for
next-generation sequencing. This work was funded by the California
Institute for Regenerative Medicine (CIRM) New Faculty Award
(RN1-00557), the Eli and Edythe Broad Center of Regenerative Medicine
and Stem Cell Research at UCLA Research Award, American Heart
Association (#14GRNT20480340), and Leukemia Lymphoma Society Scholar
Award to HKAM (20103778). TO was supported by Leukemia Lymphoma Society
postdoctoral fellowship (57537-13) and by the European Union through the
European Social Fund (Mobilitas Grant No. MJD284). DD was supported by
the government of P.R.C through the State Scholarship Fund (File No.
2011624028). AMH was supported by a fellowship from HFSP and American
Society of Hematology. BVH was supported by the NIH/NHLBI T32 HL69766.
Contributions of YF and SHO were supported by P30DK049216.
NR 89
TC 15
Z9 15
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD MAR 12
PY 2015
VL 34
IS 6
BP 759
EP 777
DI 10.15252/embj.201490542
PG 19
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CD2BE
UT WOS:000350877800007
PM 25564442
ER
PT J
AU Genovese, G
Jaiswal, S
Ebert, BL
McCarroll, SA
AF Genovese, Giulio
Jaiswal, Siddhartha
Ebert, Benjamin L.
McCarroll, Steven A.
TI Clonal Hematopoiesis and Blood-Cancer Risk REPLY
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Genovese, Giulio] Broad Inst, Cambridge, MA 02142 USA.
[Jaiswal, Siddhartha] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ebert, Benjamin L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[McCarroll, Steven A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Genovese, G (reprint author), Broad Inst, Cambridge, MA 02142 USA.
EM mccarroll@genetics.med.harvard.edu
NR 4
TC 10
Z9 10
U1 2
U2 6
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAR 12
PY 2015
VL 372
IS 11
BP 1071
EP 1072
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA CD0XK
UT WOS:000350797300015
PM 25760361
ER
PT J
AU Nunez, JK
Lee, ASY
Engelman, A
Doudna, JA
AF Nunez, James K.
Lee, Amy S. Y.
Engelman, Alan
Doudna, Jennifer A.
TI Integrase-mediated spacer acquisition during CRISPR-Cas adaptive
immunity
SO NATURE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SHORT PALINDROMIC REPEATS; TOPOISOMERASE-I
MUTANTS; DNA STRAND TRANSFER; ESCHERICHIA-COLI; ACQUIRED-RESISTANCE;
BACTERIAL IMMUNITY; GYRASE GENES; SEQUENCE; SYSTEM
AB Bacteria and archaea insert spacer sequences acquired from foreign DNAs into CRISPR loci to generate immunological memory. The Escherichia coli Cas1-Cas2 complex mediates spacer acquisition in vivo, but the molecular mechanism of this process is unknown. Here we show that the purified Cas1-Cas2 complex integrates oligonucleotide DNA substrates into acceptor DNA to yield products similar to those generated by retroviral integrases and transposases. Cas1 is the catalytic subunit and Cas2 substantially increases integration activity. Protospacer DNA with free 3'-OH ends and supercoiled target DNA are required, and integration occurs preferentially at the ends of CRISPR repeats and at sequences adjacent to cruciform structures abutting AT-rich regions, similar to the CRISPR leader sequence. Our results demonstrate the Cas1-Cas2 complex to be the minimal machinery that catalyses spacer DNA acquisition and explain the significance of CRISPR repeats in providing sequence and structural specificity for Cas1-Cas2-mediated adaptive immunity.
C1 [Nunez, James K.; Lee, Amy S. Y.; Doudna, Jennifer A.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
[Lee, Amy S. Y.; Doudna, Jennifer A.] Univ Calif Berkeley, Ctr RNA Syst Biol, Berkeley, CA 94720 USA.
[Engelman, Alan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Engelman, Alan] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Doudna, Jennifer A.] Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.
[Doudna, Jennifer A.] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.
[Doudna, Jennifer A.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA.
RP Doudna, JA (reprint author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.
EM doudna@berkeley.edu
FU US National Science Foundation [1244557]; NIH [AI070042]; NIH S10
Instrumentation Grants [S10RR029668, S10RR027303]; US National Science
Foundation Graduate Research Fellowship; UC Berkeley Chancellor's
Graduate Fellowship; American Cancer Society [PF-14-108-01-RMC]
FX We are grateful to M. Chung, P. J. Kranzusch and A.V. Wright for
technical assistance and members of the Doudna laboratory and J. Cate
for discussions. This project was funded by US National Science
Foundation grant no. 1244557 to J.A.D. and by NIH grant AI070042 to A.E.
This work used the Vincent J. Coates Genomics Sequencing Laboratory at
UC Berkeley, supported by NIH S10 Instrumentation Grants S10RR029668 and
S10RR027303. J.K.N. is supported by a US National Science Foundation
Graduate Research Fellowship and a UC Berkeley Chancellor's Graduate
Fellowship. A.S.Y.L. is supported as an American Cancer Society
Postdoctoral Fellow (PF-14-108-01-RMC). J.A.D. is an Investigator of the
Howard Hughes Medical Institute and a member of the Center for RNA
Systems Biology.
NR 49
TC 66
Z9 69
U1 8
U2 68
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAR 12
PY 2015
VL 519
IS 7542
BP 193
EP +
DI 10.1038/nature14237
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CD0NH
UT WOS:000350770500030
PM 25707795
ER
PT J
AU Zhu, W
Dotson, AL
Libal, NL
Lapato, AS
Bodhankar, S
Offner, H
Alkayed, NJ
AF Zhu, W.
Dotson, A. L.
Libal, N. L.
Lapato, A. S.
Bodhankar, S.
Offner, H.
Alkayed, N. J.
TI RECOMBINANT T-CELL RECEPTOR LIGAND RTL1000 LIMITS INFLAMMATION AND
DECREASES INFARCT SIZE AFTER EXPERIMENTAL ISCHEMIC STROKE IN MIDDLE-AGED
MICE
SO NEUROSCIENCE
LA English
DT Article
DE ischemic stroke; immunotherapy; recombinant T-cell receptor ligand;
HLA-DR2 transgenic mice
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; RECOMMENDATIONS; LYMPHOCYTES
AB We have previously demonstrated that recombinant T-cell receptor ligand 1000 (RTL1000) reduces infarct size and improves long-term functional recovery after experimental stroke in young transgenic mice expressing human leukocyte antigen DR2 (DR2-Tg). In this study, we determined the effect of RTL1000 on infarct size in 12-month-old middle-aged DR2-Tg mice, and investigated its mechanism of action. Twelve-month-old male DR2-Tg mice underwent 60 min of intraluminal reversible middle cerebral artery occlusion (MCAO). Vehicle or RTL1000 was injected 4, 24, 48 and 72 h after MCAO. Cortical, striatal and total hemispheric infarcts were measured 96 h after stroke. Spleen and brain tissues were collected 96 h after stroke for immunological analysis. Our data showed that RTL1000 significantly reduced infarct size 96 h after MCAO in middle-aged male DR2-Tg mice. RTL1000 decreased the number of activated monocytes/microglia cells (CD11b(+)CD45(hi)) and CD3(+) T cells in the ischemic hemisphere. RTL1000 also reduced the percentage of total T cells and inflammatory neutrophils in the spleen. These findings suggest that RTL1000 protects against ischemic stroke in middle-aged male mice by limiting post-ischemic inflammation. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Zhu, W.; Libal, N. L.; Offner, H.; Alkayed, N. J.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA.
[Alkayed, N. J.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA.
[Dotson, A. L.; Lapato, A. S.; Bodhankar, S.; Offner, H.; Alkayed, N. J.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Dotson, A. L.; Lapato, A. S.; Bodhankar, S.; Offner, H.] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Alkayed, NJ (reprint author), Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA.
EM alkayedn@ohsu.edu
OI Lapato, Andrew/0000-0002-4931-7370
FU NIH [NS076013 (STTR)]; Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Biomedical
Laboratory Research and Development
FX This work was supported by NIH Grants #NS076013 (STTR) and by the
Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Biomedical Laboratory Research and
Development.
NR 30
TC 2
Z9 2
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD MAR 12
PY 2015
VL 288
BP 112
EP 119
DI 10.1016/j.neuroscience.2014.12.037
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA CA2TD
UT WOS:000348759600011
PM 25556831
ER
PT J
AU Slama, MCC
Delgutte, B
AF Slama, Michael C. C.
Delgutte, Bertrand
TI Neural Coding of Sound Envelope in Reverberant Environments
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE amplitude modulation; envelope; inferior colliculus; reverberation;
single-unit; unanesthetized rabbit
ID AMPLITUDE-MODULATED TONES; VENTRAL COCHLEAR NUCLEUS; SUPERIOR OLIVARY
COMPLEX; AUDITORY-NERVE FIBERS; SMALL-ROOM ACOUSTICS; INFERIOR
COLLICULUS; SPEECH-INTELLIGIBILITY; INTERAURAL CORRELATION;
UNANESTHETIZED RABBIT; LATERAL LEMNISCUS
AB Speech reception depends critically on temporal modulations in the amplitude envelope of the speech signal. Reverberation encountered in everyday environments can substantially attenuate these modulations. To assess the effect of reverberation on the neural coding of amplitude envelope, we recorded from single units in the inferior colliculus (IC) of unanesthetized rabbit using sinusoidally amplitude modulated (AM) broadband noise stimuli presented in simulated anechoic and reverberant environments. Although reverberation degraded both rate and temporal coding of AM in IC neurons, in most neurons, the degradation in temporal coding was smaller than the AM attenuation in the stimulus. This compensation could largely be accounted for by the compressive shape of the modulation input-output function (MIOF), which describes the nonlinear transformation of modulation depth from acoustic stimuli into neural responses. Additionally, in a subset of neurons, the temporal coding of AM was better for reverberant stimuli than for anechoic stimuli having the same modulation depth at the ear. Using hybrid anechoic stimuli that selectively possess certain properties of reverberant sounds, we show that this reverberant advantage is not caused by envelope distortion, static interaural decorrelation, or spectral coloration. Overall, our results suggest that the auditory system may possess dual mechanisms that make the coding of amplitude envelope relatively robust in reverberation: one general mechanism operating for all stimuli with small modulation depths, and another mechanism dependent on very specific properties of reverberant stimuli, possibly the periodic fluctuations in interaural correlation at the modulation frequency.
C1 [Slama, Michael C. C.; Delgutte, Bertrand] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
[Delgutte, Bertrand] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA.
[Slama, Michael C. C.; Delgutte, Bertrand] MIT, Speech & Hearing Biosci & Technol Program, Cambridge, MA 02139 USA.
RP Delgutte, B (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, 243 Charles St, Boston, MA 02114 USA.
EM Bertrand_Delgutte@meei.harvard.edu
OI , /0000-0003-1349-9608
FU National Institutes of Health [R01 DC002258, P30 DC0005209]; Paul and
Daisy Soros Fellowship for New Americans
FX This work was supported by National Institutes of Health Grants R01
DC002258 and P30 DC0005209, and the Paul and Daisy Soros Fellowship for
New Americans. We thank Sasha Devore, Ken Hancock, Melissa McKinnon,
Chris Scarpino, Ishmael Stefanov-Wagner, Shig Kuwada, and Rachel Slama
for technical assistance, and Barbara Shinn-Cunningham, Michale Fee, and
Luke Shaheen for valuable comments on the manuscript.
NR 71
TC 4
Z9 4
U1 1
U2 8
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAR 11
PY 2015
VL 35
IS 10
BP 4452
EP 4468
DI 10.1523/JNEUROSCI.3615-14.2015
PG 17
WC Neurosciences
SC Neurosciences & Neurology
GA CE9YP
UT WOS:000352199900029
PM 25762687
ER
PT J
AU Howie, LJ
Peppercorn, JM
AF Howie, Lynn J.
Peppercorn, Jeffrey M.
TI Polls and Policy: Signals or Substance
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID CANCER CARE; UNITED-STATES; MEDICARE; COST; EXPERIENCE; ATTITUDES; VIEWS
C1 [Howie, Lynn J.] Duke Univ, Med Ctr, Durham, NC 27710 USA.
[Peppercorn, Jeffrey M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Howie, LJ (reprint author), Duke Univ, Med Ctr, Durham, NC 27710 USA.
NR 17
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 10
PY 2015
VL 33
IS 8
BP 819
EP +
DI 10.1200/JCO.2014.59.8524
PG 4
WC Oncology
SC Oncology
GA CK2QI
UT WOS:000356055600005
PM 25624434
ER
PT J
AU Overmoyer, B
AF Overmoyer, Beth
TI Treatment With Adjuvant Endocrine Therapy for Early-Stage Breast Cancer:
Is It Forever?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; ESTROGEN-RECEPTOR; DISTANT RECURRENCE;
GENE-EXPRESSION; POSTMENOPAUSAL WOMEN; TAMOXIFEN THERAPY; LYMPH-NODES;
PAM50 RISK; FOLLOW-UP; LETROZOLE
AB A 64-year-old healthy postmenopausal woman with an intact uterus had been diagnosed with mammo-graphically detected invasive ductal carcinoma of the right breast at the age of 59 years. She underwent breast-conservation surgery, with an excisional biopsy and sentinel lymph node sampling revealing a 1.2-cm Bloom-Richardson grade 2 invasive ductal carcinoma with negative surgical margins and one negative sentinel lymph node. Immunohistochemical testing showed that the tumor was estrogen receptor positive (strong intensity, > 95%) and progesterone receptor positive (strong intensity, 90%) but negative for human epidermal growth factor receptor 2 overexpression. The Oncotype DX(Genomic Health, Redwood City, CA) recurrence score was 13, associated with a 10-year risk of distant recurrence equaling 8% with 5 years of tamoxifen adjuvant treatment. On the basis of this result, she declined chemotherapy and received hypofractionated whole-breast irradiation in 16 fractions without a boost, receiving 42.5 Gy of radiation to the breast. At the time of her diagnosis, baseline bone density demonstrated osteopenia, with a T-score average of -1.5 for the lumbar spine and a T-score average of -1.9 for the left hip. The patient was concerned about the risk of osteoporosis associated with aromatase inhibitors and therefore chose to receive tamoxifen alone as adjuvant endocrine therapy. Serial bone-mineral density evaluation over the subsequent years has shown stable T scores (lumbar spine, -1.3; hip, -1.7). She has tolerated tamoxifen well for 5 years, without experiencing menopausal symptoms or vaginal bleeding. She is requesting an opinion on whether she should receive extended endocrine therapy for an additional 5 years.
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Overmoyer, B (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
FU Genentech
FX Research Funding: Genentech
NR 38
TC 3
Z9 3
U1 0
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 10
PY 2015
VL 33
IS 8
BP 823
EP +
DI 10.1200/JCO.2014.58.2361
PG 7
WC Oncology
SC Oncology
GA CK2QI
UT WOS:000356055600007
PM 25624431
ER
PT J
AU Ezoe, Y
Anada, T
Yamazaki, H
Handa, T
Kobayashi, K
Takahashi, T
Suzuki, O
AF Ezoe, Yushi
Anada, Takahisa
Yamazaki, Hajime
Handa, Takuto
Kobayashi, Kazuhito
Takahashi, Tetsu
Suzuki, Osamu
TI Characterization of partially hydrolyzed OCP crystals deposited in a
gelatin matrix as a scaffold for bone tissue engineering
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Octacalcium phosphate; Gelatin; Hydrolysis; Hydroxyapatite; Osteoblasts;
Tissue engineering; Nano-biochemistry
ID OCTACALCIUM PHOSPHATE; CALCIUM PHOSPHATES; HYDROXYAPATITE; REGENERATION;
AMELOGENINS; ADSORPTION; COMPOSITE; CHEMISTRY; SIZE
AB The present study was designed to investigate how hydrolysis of octacalcium phosphate (OCP) into hydroxyapatite is affected by the presence of gelatin (Gel) molecules and how osteoblastic cells respond to the resultant OCP hydrolyzate/Gel composites as the hydrolysis advances. OCP was prepared from a solution containing calcium and phosphate ions and Gel molecules, having a composition to produce a 40 wt% OCP as a final co-precipitate as the OCP/Gel. The precipitate was further incubated up to 40 h to advance the hydrolysis of OCP. These precipitates were processed to mold OCP/Gel sponges through lyophilization and dehydrothermal treatment. Chemical analysis, X-ray diffraction, Fourier transform infrared spectroscopy, transmission electron microscopy, and selected area electron diffraction revealed that the hydrolysis of OCP/Gel composite in hot water advanced in a time-dependent manner and faster than hydrolysis of OCP alone. The effect of Gel on the OCP hydrolysis was further examined in the presence of distinct concentrations of Gel molecules in hot water, showing that the Gel enhanced the hydrolysis as the concentration increased. Proliferation and differentiation of mouse bone marrow stromal ST-2 cells on the hydrolyzed OCP/Gel composites were compatible with Gel sponge alone after 21 days of culture, suggesting that these composites could be a candidate as a scaffold in bone tissue engineering.
C1 [Ezoe, Yushi; Handa, Takuto; Kobayashi, Kazuhito; Takahashi, Tetsu] Tohoku Univ, Grad Sch Dent, Div Oral & Maxillofacial Surg, Aoba Ku, Sendai, Miyagi 9808575, Japan.
[Ezoe, Yushi; Anada, Takahisa; Handa, Takuto; Kobayashi, Kazuhito; Suzuki, Osamu] Tohoku Univ, Grad Sch Dent, Div Craniofacial Funct Engn, Aoba Ku, Sendai, Miyagi 9808575, Japan.
[Yamazaki, Hajime] Forsyth Inst, Dept Appl Oral Sci, Ctr Biomineralizat, Cambridge, MA 02142 USA.
[Handa, Takuto] Yokushukai Dent Clin, Yachichuo, Yamagata 9993512, Japan.
RP Suzuki, O (reprint author), Tohoku Univ, Grad Sch Dent, Div Craniofacial Funct Engn, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM suzuki-o@m.tohoku.ac.jp
FU Ministry of Education, Science, Sports, and Culture of Japan [23106010,
25670829, 26670846, 26282133, 26293417]
FX This study was supported in part by Grants-in-aid (23106010, 25670829,
26670846, 26282133 and 26293417) from the Ministry of Education,
Science, Sports, and Culture of Japan.
NR 33
TC 2
Z9 2
U1 2
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
EI 1572-896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD MAR 10
PY 2015
VL 17
IS 3
AR 127
DI 10.1007/s11051-015-2864-1
PG 10
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA CI8IU
UT WOS:000355016800003
ER
PT J
AU Du, ZM
Abedalthagafi, M
Aizer, AA
McHenry, AR
Sun, HH
Bray, MA
Viramontes, O
Machaidze, R
Brastianos, PK
Reardon, DA
Dunn, IF
Freeman, GJ
Ligon, KL
Carpenter, AE
Alexander, BM
Agar, NY
Rodig, SJ
Bradshaw, EM
Santagata, S
AF Du, Ziming
Abedalthagafi, Malak
Aizer, Ayal A.
McHenry, Allison R.
Sun, Heather H.
Bray, Mark-Anthony
Viramontes, Omar
Machaidze, Revaz
Brastianos, Priscilla K.
Reardon, David A.
Dunn, Ian F.
Freeman, Gordon J.
Ligon, Keith L.
Carpenter, Anne E.
Alexander, Brian M.
Agar, Nathalie Y.
Rodig, Scott J.
Bradshaw, Elizabeth M.
Santagata, Sandro
TI Increased expression of the immune modulatory molecule PD-L1 (CD274) in
anaplastic meningioma
SO ONCOTARGET
LA English
DT Article
DE meningioma; PD-L1; RNAscope; immunotherapy
ID MALIGNANT MENINGIOMAS; SPORADIC MENINGIOMAS; CANCER-IMMUNOTHERAPY;
BRAIN-TUMORS; NF2 GENE; MUTATIONS; BLOCKADE; MELANOMA; SAFETY;
PROGRESSION
AB There are no effective medical treatments for WHO grade III (anaplastic) meningioma. Patients with this high-grade malignancy have a median survival of less than two years. Therapeutics that modulate the mechanisms that inhibit local immune responses in the tumor microenvironment are showing significant and durable clinical responses in patients with treatment refractory high-grade tumors. We examined the immune infiltrate of 291 meningiomas including WHO grade I-III meningiomas using immunohistochemistry and we examined the expression of PD-L1 mRNA by RNAscope in situ hybridization and PD-L1 protein by immunohistochemistry. In meningioma, the tumor infiltrating lymphocytes are predominantly T cells. In anaplastic meningioma, there is a sharp decrease in the number of T cells, including the numbers of CD4+ and CD8+ T cells and cells expressing PD-1 and there is also an increase in the number of FOXP3 expressing immunoregulatory (Treg) cells. PD-L1 expression is increased in anaplastic meningioma - both mRNA and protein. Using patient derived meningioma cell, we confirm that PD-L1 is expressed in meningioma cells themselves, and not solely in infiltrating immune cells. This work indicates that high-grade meningioma harbor an immunosuppressive tumor microenviroment and that increased Treg cells and elevated PD-L1 may contribute to the aggressive phenotype of these tumors.
C1 [Du, Ziming; Abedalthagafi, Malak; Sun, Heather H.; Machaidze, Revaz; Ligon, Keith L.; Rodig, Scott J.; Santagata, Sandro] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Du, Ziming; Abedalthagafi, Malak; Aizer, Ayal A.; McHenry, Allison R.; Sun, Heather H.; Viramontes, Omar; Machaidze, Revaz; Brastianos, Priscilla K.; Reardon, David A.; Dunn, Ian F.; Freeman, Gordon J.; Ligon, Keith L.; Alexander, Brian M.; Agar, Nathalie Y.; Rodig, Scott J.; Bradshaw, Elizabeth M.; Santagata, Sandro] Harvard Univ, Sch Med, Boston, MA USA.
[Aizer, Ayal A.; Alexander, Brian M.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.
[McHenry, Allison R.; Bradshaw, Elizabeth M.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Bray, Mark-Anthony; Carpenter, Anne E.] Broad Inst MIT & Harvard, Imaging Platform, Cambridge, MA USA.
[Viramontes, Omar; Machaidze, Revaz; Dunn, Ian F.; Agar, Nathalie Y.] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
[Brastianos, Priscilla K.; Reardon, David A.; Freeman, Gordon J.; Ligon, Keith L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Brastianos, Priscilla K.] Massachusetts Gen Hosp, Dept Neurooncol, Boston, MA 02114 USA.
[Santagata, Sandro] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
RP Santagata, S (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
EM ssantagata@partners.org
FU National Institutes of Health [RO1 GM089652]; Center for Immune Oncology
at the Dana Farber Cancer Institute; Brain Science Foundation; Jared
Branfman Sunflowers for Life Fund for Pediatric Brain and Spinal Cancer
Research; V Foundation; King Abdulaziz City for Science and Technology
(KACST), Saudi Arabia
FX The authors would like to thank members of the Santagata, Bradshaw and
Agar labs for helpful discussions. The authors would like to thank
Chungdak Namgyal for TMA construction and Terri Woo, Teri Bowman and the
BWH/DFCI Specialized Histopathology Core for assistance with some of the
immunohistochemistry staining. We thank Yuko G. Miki for guidance with
cell culturing. We thank Dr. Mariano Viapiano and the Cooperative Human
Tissue Network for tissue distributions for generating certain cell
lines. We thank William G. Richards, Kristen K. Gill and the BWH tissue
bank for access to frozen tissue samples as well as the BWH Division of
Neuropathology under the leadership of Dr. Rebecca Folkerth for sample
procurement. M.A.B. and A.E.C. were funded by National Institutes of
Health RO1 GM089652 and H.H.S. and S.J.R. were supported by the Center
for Immune Oncology at the Dana Farber Cancer Institute. This study was
supported by Brain Science Foundation (S.S), the Jared Branfman
Sunflowers for Life Fund for Pediatric Brain and Spinal Cancer Research
(S.S), the V Foundation (S.S), King Abdulaziz City for Science and
Technology (KACST), Saudi Arabia (M.A.) and National Institutes of
Health RO1 GM089652 (A,E,C).
NR 48
TC 19
Z9 20
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 10
PY 2015
VL 6
IS 7
BP 4704
EP 4716
PG 13
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA CF8FR
UT WOS:000352792000013
PM 25609200
ER
PT J
AU Golestanirad, L
Das, S
Schweizer, TA
Graham, SJ
AF Golestanirad, Laleh
Das, Sunit
Schweizer, Tom A.
Graham, Simon J.
TI A preliminary fMRI study of a novel self-paced written fluency task:
observation of left-hemispheric activation, and increased frontal
activation in late vs. early task phases
SO FRONTIERS IN HUMAN NEUROSCIENCE
LA English
DT Article
DE fMRI; language; verbal fluency; phonemic fluency; tablet; writing
ID OVERT VERBAL FLUENCY; EVENT-RELATED FMRI; SEMANTIC FLUENCY; FUNCTIONAL
MRI; LANGUAGE DOMINANCE; LESION LOCALIZATION; BRAIN ACTIVATION;
PRECENTRAL GYRUS; WORD GENERATION; NORMATIVE DATA
AB Neuropsychological tests of verbal fluency are very widely used to characterize impaired cognitive function. For clinical neuroscience studies and potential medical applications, measuring the brain activity that underlies such tests with functional magnetic resonance imaging (fMRI) is of significant interest-but a challenging proposition because overt speech can cause signal artifacts, which tend to worsen as the duration of speech tasks becomes longer. In a novel approach, we present the group brain activity of 12 subjects who performed a self-paced written version of phonemic fluency using fM RI-compatible tablet technology that recorded responses and provided task-related feedback on a projection screen display, over long-duration task blocks (60s). As predicted, we observed robust activation in the left anterior inferior and medial frontal gyri, consistent with previously reported results of verbal fluency tasks which established the role of these areas in strategic word retrieval. In addition, the number of words produced in the late phase (last 30s) of written phonemic fluency was significantly less (p < 0.05) than the number produced in the early phase (first 30s). Activation during the late phase vs. the early phase was also assessed from the first 20s and last 20s of task performance, which eliminated the possibility that the sluggish hemodynamic response from the early phase would affect the activation estimates of the late phase. The last 20s produced greater activation maps covering extended areas in bilateral precuneus, cuneus, middle temporal gyrus, insula, middle frontal gyrus and cingulate gyrus. Among these areas, greater activation was observed in the bilateral middle frontal gyrus (Brodmann area BA 9) and cingulate gyrus (BA 24, 32) likely as part of the initiation, maintenance, and shifting of attentional resources. Consistent with previous pertinent fMRI literature involving overt and covert verbal responses, these findings highlight the promise and practicality of fMRI of written phonemic fluency.
C1 [Golestanirad, Laleh] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02129 USA.
[Das, Sunit; Schweizer, Tom A.] St Michaels Hosp, Keenan Res Inst, Toronto, ON M5B 1W8, Canada.
[Graham, Simon J.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada.
RP Golestanirad, L (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Biomed Imaging, Bldg 75,Room 2-109,13th St,Third Av, Boston, MA 02129 USA.
EM lgolestanirad@mgh.harvard.edu
FU Canadian Cancer Society [701770]
FX The authors would like to thank Mr. Fred Tam for his assistance in
experiment setup and data collection. This research was made possible by
a grant awarded by the Canadian Cancer Society, Grant #701770.
NR 81
TC 3
Z9 4
U1 4
U2 8
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5161
J9 FRONT HUM NEUROSCI
JI Front. Hum. Neurosci.
PD MAR 10
PY 2015
VL 9
AR UNSP 113
DI 10.3389/fnhum.2015.00113
PG 14
WC Neurosciences; Psychology
SC Neurosciences & Neurology; Psychology
GA CF3WK
UT WOS:000352479500002
PM 25805984
ER
PT J
AU Barrett, TW
Shanmugam, NR
Selvam, AP
Kazmierczak, SC
Prasad, S
AF Barrett, Thomas W.
Shanmugam, Nandhinee Radha
Selvam, Anjan Panneer
Kazmierczak, Steven C.
Prasad, Shalini
TI Novel Nanomonitor ultra-sensitive detection of troponin T
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Point-of-care; Nanotechnology; Troponin T; Functional sensitivity
ID CARDIAC TROPONIN; MYOCARDIAL-INFARCTION; ASSAYS; DIAGNOSTICS;
POPULATION; PREDICTION; DISEASE
AB Background: Troponin is the preferred biomarker for diagnosing myocardial infarction. Point of care devices have not matched the sensitivity of laboratory-based methods for measuring troponin. The Nanomonitor is a novel point-of-care device that uses the change in electrical impedance that occurs when a biomarker binds to its antibody, which is then correlated to the concentration of the target biomarker.
Methods: Performance characteristics of the Nanomonitor were evaluated and compared to a standard laboratory-based method.
Results: The limit of detection of the Nanomonior for troponin T was 0.0088 ng/l. Total imprecission was 238% and 0.85% at troponin T concentrations of 73 ng/l and 1800 ng/l. The functional sensitivity (10% coeffecient of variation) was 0329 ng/l. The linear regression had a slope of 0.996 (95% confidence interval, 0.991, 1.002), r = 1.00, and an intercept of 15.88 ng/l (95% confidence interval, -68.39 ng/l, 100.15 ng/l). The mean difference between the assays was -7.54 ng/l, determined by Bland-Altman analysis.
Conclusion: The Nanomonitor preliminary results have favorable performance characteristics for detecting troponin Tin patient blood, provide results in 15 min, and are portable. More research is needed. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Barrett, Thomas W.] Portland VA Med Ctr, Portland, OR USA.
[Shanmugam, Nandhinee Radha; Selvam, Anjan Panneer; Prasad, Shalini] Oregon Hlth & Sci Univ, Div Hosp Med, Portland, OR 97201 USA.
[Kazmierczak, Steven C.] Univ Texas Dallas, Dept Bioengn, Richardson, TX 75080 USA.
Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA.
RP Prasad, S (reprint author), Univ Texas Dallas, Dept Bioengn, 800 W Campbell Rd,EC 39, Richardson, TX 75080 USA.
EM Shalini.Prasad@utdallas.edu
RI Radha Shanmugam, Nandhinee/D-1896-2017
OI Radha Shanmugam, Nandhinee/0000-0002-8572-7801
FU National Center for Research Resources (NCRR) [UL1 RR024140]
FX This work was presented, in part, in poster form at the Materials
Research Society Conference, April 24, 2014, San Francisco, California,
"Rapid and Sensitive Detection of Nano-fluidically Trapped Protein
Biomarkers". Oregon Nanoscience and Microtechnologies Institute, and
Oregon Clinical and Translational Research Institute (OCTRI), grant
number UL1 RR024140 from the National Center for Research Resources
(NCRR) and the National Center for Advancing Translational Sciences
(NCATS) of the National Institutes of Health (NIH), and the Cecil and
Ida Green Endowment in Systems Biology at University of Texas at Dallas.
NR 25
TC 5
Z9 5
U1 2
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD MAR 10
PY 2015
VL 442
BP 96
EP 101
DI 10.1016/j.cca.2015.01.013
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA CE7TY
UT WOS:000352045900019
PM 25619774
ER
PT J
AU Nowacki, M
Nazarewski, L
Pokrywczynska, M
Kloskowski, T
Tyloch, D
Pietkun, K
Jundzill, A
Rasmus, M
Warda, K
Gagat, M
Grzanka, A
Bodnar, M
Marszalek, A
Krawczyk, M
Habib, SL
Drewa, T
AF Nowacki, Maciej
Nazarewski, Lukasz
Pokrywczynska, Marta
Kloskowski, Tomasz
Tyloch, Dominik
Pietkun, Katarzyna
Jundzill, Arkadiusz
Rasmus, Marta
Warda, Karolina
Gagat, Maciej
Grzanka, Alina
Bodnar, Magdalena
Marszalek, Andrzej
Krawczyk, Marek
Habib, Samy L.
Drewa, Tomasz
TI Long-Term Influence of Bone Marrow-Derived Mesenchymal Stem Cells on
Liver Ischemia-Reperfusion Injury in a Rat Model
SO ANNALS OF TRANSPLANTATION
LA English
DT Article
DE Mesenchymal Stromal Cells; Reperfusion Injury; Tissue Engineering
ID HEPATIC ISCHEMIA/REPERFUSION INJURY; WARM ISCHEMIA; ANIMAL-MODELS;
MURINE MODEL; TRANSPLANTATION; APOPTOSIS; PROTECTS; THERAPY; SURGERY;
INNATE
AB Background: The aim of this study was to evaluate the long-term usefulness of intraportal injection of the bone marrow-derived mesenchymal stem cells (BM-MSCs) in limitation of experimentally induced ischemia-reperfusion injury (IRI) in a rat model.
Material/Methods: Twenty Wistar rats were divided into 3 groups: donor group (n=5), study group (n=10), and control group (n=5). IRI was performed using a modified hanging-weight system after left portal triad occlusion in study group animals. Isolated autologous BM-MSCs were labeled with fluorochrome PKH-26 then intraportally injected into the rats in the study group. Control group animals were intraportally injected with 1 ml of PBS. Follow-up was 3 months, after which animals were sacrificed for histopathological examination. Migration of BM-MSCs into different organs was examined.
Results: H&E staining of liver tissue sections from "time zero" biopsies did not show many irregularities in structural or histological construction compared to liver sections from the control group. However, a small amount of centrilobular hepatocyte necrosis and coagulative necrosis with neutrophil infiltration areas was observed in liver sections of the study group. The migration assay of BM-MSCs labeled with PKH-26 showed the highest positive BM-MSCs staining (6%) in the spleen, while few positively stained cells were found (2%) in liver sections. No BM-MSCs were detected in brain, kidney, or lung tissues.
Conclusions: These results suggest that intraportal bone marrow-derived mesenchymal stem cell injection is safe and cells do not migrate chaotically to other organs after targeted implementation.
C1 [Nowacki, Maciej; Pokrywczynska, Marta; Kloskowski, Tomasz; Tyloch, Dominik; Pietkun, Katarzyna; Jundzill, Arkadiusz; Rasmus, Marta; Warda, Karolina; Drewa, Tomasz] Nicolaus Copernicus Univ Torun, Coll Med Bydgoszcz, Dept Tissue Engn, Chair Regenerat Med, Bydgoszcz, Poland.
[Nazarewski, Lukasz; Krawczyk, Marek] Med Univ Warsaw, Dept Gen Transplant & Liver Surg, Warsaw, Poland.
[Gagat, Maciej; Grzanka, Alina] Nicolaus Copernicus Univ Torun, Coll Med Bydgoszcz, Dept Histol & Embryol, Bydgoszcz, Poland.
[Bodnar, Magdalena; Marszalek, Andrzej] Nicolaus Copernicus Univ Torun, Coll Med Bydgoszcz, Dept Clin Pathomorphol, Bydgoszcz, Poland.
[Marszalek, Andrzej] Poznan Univ Med Sci, Dept Oncol Pathol, Poznan, Poland.
[Marszalek, Andrzej] Greater Poland Oncol Ctr, Poznan, Poland.
[Habib, Samy L.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Drewa, Tomasz] Nicolaus Copernicus Hosp, Dept Gen & Oncol Urol, Torun, Poland.
RP Kloskowski, T (reprint author), Nicolaus Copernicus Univ Torun, Coll Med Bydgoszcz, Dept Tissue Engn, Chair Regenerat Med, Bydgoszcz, Poland.
EM tomaszkloskowski@op.pl
RI Kloskowski, Tomasz/D-4353-2014; Bodnar, Magdalena/D-6131-2014; Gagat,
Maciej/D-5356-2014; Grzanka, Alina/D-9941-2014; Pietkun ,
Katarzyna/Q-6718-2016
OI Kloskowski, Tomasz/0000-0001-5599-9315; Bodnar,
Magdalena/0000-0003-3748-1058; Gagat, Maciej/0000-0002-5445-8821;
FU Nicolaus Copernicus University [112, 266]
FX This work was supported by research task within framework of the
statutory activities no. 112 and 266 from Nicolaus Copernicus University
NR 47
TC 3
Z9 3
U1 1
U2 5
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1425-9524
J9 ANN TRANSPL
JI Ann. Transpl.
PD MAR 10
PY 2015
VL 20
BP 132
EP 140
DI 10.12659/AOT.892364
PG 9
WC Surgery; Transplantation
SC Surgery; Transplantation
GA CE0DV
UT WOS:000351475600001
PM 25754665
ER
PT J
AU Rabinstein, AA
Anderson, CD
AF Rabinstein, Alejandro A.
Anderson, Christopher D.
TI Time is brain also counts for ICH
SO NEUROLOGY
LA English
DT Editorial Material
ID ACUTE INTRACEREBRAL HEMORRHAGE; HEMATOMA GROWTH; DETERMINANT; OUTCOMES
C1 [Rabinstein, Alejandro A.] Mayo Clin, Dept Neurol, Rochester, MN 55902 USA.
[Anderson, Christopher D.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Rabinstein, AA (reprint author), Mayo Clin, Dept Neurol, Rochester, MN 55902 USA.
EM rabinstein.alejandro@mayo.edu
OI Anderson, Christopher/0000-0002-0053-2002
FU NINDS NIH HHS [K23 NS086873-01]
NR 11
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAR 10
PY 2015
VL 84
IS 10
BP 970
EP 971
DI 10.1212/WNL.0000000000001349
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA CD9YR
UT WOS:000351458100007
PM 25663224
ER
PT J
AU Beecham, GW
Dickson, DW
Scott, WK
Martin, ER
Schellenberg, G
Nuytemans, K
Larson, EB
Buxbaum, JD
Trojanowski, JQ
Van Deerlin, VM
Hurtig, HI
Mash, DC
Beach, TG
Troncoso, JC
Pletnikova, O
Frosch, MP
Ghetti, B
Foroud, TM
Honig, LS
Marder, K
Vonsattel, JP
Goldman, SM
Vinters, HV
Ross, OA
Wszolek, ZK
Wang, LY
Dykxhoorn, DM
Pericak-Vance, MA
Montine, TJ
Leverenz, JB
Dawson, TM
Vance, JM
AF Beecham, Gary W.
Dickson, Dennis W.
Scott, William K.
Martin, Eden R.
Schellenberg, Gerard
Nuytemans, Karen
Larson, Eric B.
Buxbaum, Joseph D.
Trojanowski, John Q.
Van Deerlin, Vivianna M.
Hurtig, Howard I.
Mash, Deborah C.
Beach, Thomas G.
Troncoso, Juan C.
Pletnikova, Olga
Frosch, Matthew P.
Ghetti, Bernardino
Foroud, Tatiana M.
Honig, Lawrence S.
Marder, Karen
Vonsattel, Jean Paul
Goldman, Samuel M.
Vinters, Harry V.
Ross, Owen A.
Wszolek, Zbigniew K.
Wang, Liyong
Dykxhoorn, Derek M.
Pericak-Vance, Margaret A.
Montine, Thomas J.
Leverenz, James B.
Dawson, Ted M.
Vance, Jeffery M.
TI PARK10 is a major locus for sporadic neuropathologically confirmed
Parkinson disease
SO NEUROLOGY
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; CLINICAL-DIAGNOSIS; GENETIC-VARIATION; ONSET;
IDENTIFICATION; METAANALYSIS; ACCURACY; RISK; PREDICTION; IMPUTATION
AB Objective: To minimize pathologic heterogeneity in genetic studies of Parkinson disease (PD), the Autopsy-Confirmed Parkinson Disease Genetics Consortium conducted a genome-wide association study using both patients with neuropathologically confirmed PD and controls.
Methods: Four hundred eighty-four cases and 1,145 controls met neuropathologic diagnostic criteria, were genotyped, and then imputed to 3,922,209 variants for genome-wide association study analysis.
Results: A small region on chromosome 1 was strongly associated with PD (rs10788972; p = 6.23 x 10(-8)). The association peak lies within and very close to the maximum linkage peaks of 2 prior positive linkage studies defining the PARK10 locus. We demonstrate that rs10788972 is in strong linkage disequilibrium with rs914722, the single nucleotide polymorphism defining the PARK10 haplotype previously shown to be significantly associated with age at onset in PD. The region containing the PARK10 locus was significantly reduced from 10.6 megabases to 100 kilobases and contains 4 known genes: TCEANC2, TMEM59, miR-4781, and LDLRAD1.
Conclusions: We confirm the association of a PARK10 haplotype with the risk of developing idiopathic PD. Furthermore, we significantly reduce the size of the PARK10 region. None of the candidate genes in the new PARK10 region have been previously implicated in the biology of PD, suggesting new areas of potential research. This study strongly suggests that reducing pathologic heterogeneity may enhance the application of genetic association studies to PD.
C1 [Beecham, Gary W.; Scott, William K.; Martin, Eden R.; Nuytemans, Karen; Wang, Liyong; Dykxhoorn, Derek M.; Pericak-Vance, Margaret A.; Vance, Jeffery M.] Miami Univ, Miller Sch Med, John P Hussman Inst Human Genom, Oxford, OH 45056 USA.
[Mash, Deborah C.] Miami Univ, Miller Sch Med, Univ Miami Brain Endowment Bank, Oxford, OH 45056 USA.
[Dickson, Dennis W.; Ross, Owen A.] Mayo Clin Florida, Dept Neurosci, Jacksonville, FL USA.
[Wszolek, Zbigniew K.] Mayo Clin Florida, Dept Neurol, Jacksonville, FL USA.
[Schellenberg, Gerard; Trojanowski, John Q.; Van Deerlin, Vivianna M.; Hurtig, Howard I.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA USA.
[Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA.
[Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA.
[Beach, Thomas G.] Arizona Alzheimers Consortium, Phoenix, AZ USA.
[Beach, Thomas G.] Sun Hlth Res Inst, Sun City, AZ USA.
[Troncoso, Juan C.; Pletnikova, Olga] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA.
[Dawson, Ted M.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
[Dawson, Ted M.] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD 21205 USA.
[Frosch, Matthew P.] Massachusetts Gen Hosp, Kubik Lab Neuropathol, Charlestown, MA USA.
Harvard Univ, Sch Med, Charlestown, MA USA.
[Ghetti, Bernardino] Indiana Univ Sch Med, Indiana Alzheimer Dis Ctr, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA.
[Foroud, Tatiana M.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
[Honig, Lawrence S.; Marder, Karen] Columbia Univ, Gertrude H Sergievsky Ctr, Dept Neurol, New York, NY 10027 USA.
[Marder, Karen] Columbia Univ, Gertrude H Sergievsky Ctr, Dept Psychiat, New York, NY 10027 USA.
Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA.
[Vonsattel, Jean Paul] Taub Inst Res Alzheimers Dis & Aging Brain, Dept Pathol & Cell Biol, New York, NY USA.
[Goldman, Samuel M.] Parkinsons Inst, Sunnyvale, CA USA.
[Vinters, Harry V.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med Neuropathol, Los Angeles, CA 90024 USA.
[Vinters, Harry V.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA.
[Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.
Univ Washington, Sch Med, Seattle, WA USA.
[Leverenz, James B.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Vance, JM (reprint author), Miami Univ, Miller Sch Med, John P Hussman Inst Human Genom, Oxford, OH 45056 USA.
EM jvance@med.miami.edu
OI Buxbaum, Joseph/0000-0001-8898-8313
FU NIH; JPB Foundation; NIH, National Institute on Aging (NIH-NIA) [ADGC
U01 AG032984, RC2 AG036528, NACC U01 AG016976, NCRAD U24 AG021886, NIA
LOAD U24 AG026395, U24 AG026390]; Banner Sun Health Research Institute
[P30 AG019610]; Boston University [P30 AG013846, U01 AG10483, R01
CA129769, R01 MH080295, R01 AG017173, R01 AG025259, R01AG33193];
Columbia University [P01 AG007232, P50 AG008702, R37 AG015473]; Duke
University [P30 AG028377, AG05128]; Emory University [AG025688]; Group
Health Research Institute [UO1 AG06781, UO1 HG004610]; Indiana
University [P30 AG10133]; Johns Hopkins University [P50 AG005146, R01
AG020688]; Massachusetts General Hospital [P50 AG005134]; Mayo Clinic
[P50 AG016574]; Mount Sinai School of Medicine [P50 AG005138, P01
AG002219]; New York University [P30 AG08051, MO1RR00096, UL1 RR029893,
5R01AG012101, 5R01AG022374, 5R01AG013616, 1RC2AG036502, 1R01AG035137];
Northwestern University [P30 AG013854]; Oregon Health & Science
University [P30 AG008017, R01 AG026916]; Rush University [P30 AG010161,
R01 AG019085, R01 AG15819, R01 AG17917, R01 AG30146]; TGen [R01
NS059873]; University of Alabama at Birmingham [P50 AG016582,
UL1RR02777]; University of Arizona [R01 AG031581]; University of
California, Davis [P30 AG010129]; University of California, Irvine [P50
AG016573, P50 AG016575, P50 AG016576, P50 AG016577]; University of
California, Los Angeles [P50 AG016570]; University of California, San
Diego [P50 AG005131]; University of California, San Francisco [P50
AG023501, P01 AG019724]; University of Kentucky [P30 AG028383, AG05144];
University of Michigan [P50 AG008671]; University of Pennsylvania [P30
AG010124]; University of Pittsburgh [P50 AG005133, AG030653]; University
of Southern California [P50 AG005142]; University of Texas Southwestern
[P30 AG012300]; University of Miami [R01 AG027944, AG010491, AG027944,
AG021547, AG019757]; University of Washington [P50 AG005136]; Vanderbilt
University [R01 AG019085]; Washington University [P50 AG005681, P01
AG03991]; National Institute of Neurological Disorders and Stroke
[NS39764]; NIMH [MH60451]; GlaxoSmithKline; Kronos Science; NIA
[AG034504]; Banner Alzheimer's Foundation; Alzheimer's Institute;
Medical Research Council; state of Arizona; Medical Research Council,
NHS trusts; Newcastle University; Higher Education Funding Council for
England [HEFCE]; Alzheimer's Research Trust [ART]; BRACE; North Bristol
NHS Trust Research and Innovation Department; DeNDRoN; Stichting MS
Research; Brain Net Europe; Hersenstichting Nederland Breinbrekend Werk;
International Parkinson Fonds; Internationale Stiching Alzheimer
Onderzoek; Institut de Neuropatologia; Servei Anatomia Patologica;
Universitat de Barcelona; Abbott; AstraZeneca AB; Bayer Schering Pharma
AG; Bristol-Myers Squibb; Eisai Global Clinical Development; Elan
Corporation; Genentech; GE Healthcare; Innogenetics; Johnson Johnson;
Eli Lilly and Co.; Medpace, Inc.; Merck and Co., Inc.; Novartis AG;
Pfizer Inc.; F. Hoffmann-La Roche; Schering-Plough; Synarc, Inc.;
Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Dana
Foundation; National Institute of Biomedical Imaging and Bioengineering;
NIA grants [U01 AG024904, RC2 AG036535, K01 AG030514]; Alzheimer's
Association [IIRG-08-89720, IIRG-0514147]; US Department of Veterans
Affairs Administration, Office of Research and Development, Biomedical
Laboratory Research Program; Wellcome Trust; Howard Hughes Medical
Institute; Canadian Institute of Health Research; [P50 NS072187]; [P50
NS053488]; [U24 NS072026]; [NS38377]; [AG06781]; [AG005136];
[NS062684]; [P50 AG16570]; [R01NS37167]; [P30AG10133];
[U24AG021886]; [P50 NS038372]; [NS039764]; [NS071674]
FX Primary funding was by the NIH. A complete description of the Alzheimer
Disease Genetics Consortium funding is below. This project was supported
by the following: P50 NS072187, P50 AG016574 (D.W.D., O.A.R., Z.K.W.);
P50 NS053488 (J.Q.T., V.M.V., H.I.H.); U24 NS072026 (T.G.B.); NS38377
and the JPB Foundation (T.M.D., J.C.T., O.P.); AG06781, AG005136, and
NS062684 (T.J.M.); P50 AG16570 (H.V.V.); P01 AG007232 (L.S.H.); AG005136
and NS062684 (J.B.L.); R01NS37167, P30AG10133, and U24AG021886 (T.F.,
B.G.); P50 AG005134 and P50 NS038372 (M.P.F.); NS039764 and NS071674
(G.W.B., W.K.S., E.R.M., L.W., K.N., D.M.D., J.M.V.). The Alzheimer
Disease Genetics Consortium was supported by the NIH, National Institute
on Aging (NIH-NIA), which supported this work through the following
grants: ADGC, U01 AG032984, RC2 AG036528; NACC, U01 AG016976; NCRAD, U24
AG021886; NIA LOAD, U24 AG026395, U24 AG026390; Banner Sun Health
Research Institute, P30 AG019610; Boston University, P30 AG013846, U01
AG10483, R01 CA129769, R01 MH080295, R01 AG017173, R01 AG025259,
R01AG33193; Columbia University, P50 AG008702, R37 AG015473, P01
AG007232; Duke University, P30 AG028377, AG05128; Emory University,
AG025688; Group Health Research Institute, UO1 AG06781, UO1 HG004610;
Indiana University, P30 AG10133; Johns Hopkins University, P50 AG005146,
R01 AG020688; Massachusetts General Hospital, P50 AG005134; Mayo Clinic,
P50 AG016574; Mount Sinai School of Medicine, P50 AG005138, P01
AG002219; New York University, P30 AG08051, MO1RR00096, UL1 RR029893,
5R01AG012101, 5R01AG022374, 5R01AG013616, 1RC2AG036502, 1R01AG035137;
Northwestern University, P30 AG013854; Oregon Health & Science
University, P30 AG008017, R01 AG026916; Rush University, P30 AG010161,
R01 AG019085, R01 AG15819, R01 AG17917, R01 AG30146; TGen, R01 NS059873;
University of Alabama at Birmingham, P50 AG016582, UL1RR02777;
University of Arizona, R01 AG031581; University of California, Davis,
P30 AG010129; University of California, Irvine, P50 AG016573, P50, P50
AG016575, P50 AG016576, P50 AG016577; University of California, Los
Angeles, P50 AG016570; University of California, San Diego, P50
AG005131; University of California, San Francisco, P50 AG023501, P01
AG019724; University of Kentucky, P30 AG028383, AG05144; University of
Michigan, P50 AG008671; University of Pennsylvania, P30 AG010124;
University of Pittsburgh, P50 AG005133, AG030653; University of Southern
California, P50 AG005142; University of Texas Southwestern, P30
AG012300; University of Miami, R01 AG027944, AG010491, AG027944,
AG021547, AG019757; University of Washington, P50 AG005136; Vanderbilt
University, R01 AG019085; and Washington University, P50 AG005681, P01
AG03991. The Kathleen Price Bryan Brain Bank at Duke University Medical
Center is funded by National Institute of Neurological Disorders and
Stroke grant NS39764, NIMH MH60451 and by GlaxoSmithKline. Genotyping of
the TGEN2 cohort was supported by Kronos Science. The TGen series was
also funded by NIA grant AG034504 to A.J.M., The Banner Alzheimer's
Foundation, The Johnnie B. Byrd, Sr.; , Alzheimer's Institute, the
Medical Research Council, and the state of Arizona and also includes
samples from the following sites: Newcastle Brain Tissue Resource
(funding via the Medical Research Council, local NHS trusts, and
Newcastle University), MRC London Brain Bank for Neurodegenerative
Diseases (funding via the Medical Research Council), South West Dementia
Brain Bank (funding via numerous sources including the Higher Education
Funding Council for England [HEFCE], Alzheimer's Research Trust [ART],
BRACE, as well as North Bristol NHS Trust Research and Innovation
Department and DeNDRoN), The Netherlands Brain Bank (funding via
numerous sources including Stichting MS Research, Brain Net Europe,
Hersenstichting Nederland Breinbrekend Werk, International Parkinson
Fonds, Internationale Stiching Alzheimer Onderzoek), Institut de
Neuropatologia, Servei Anatomia Patologica, Universitat de Barcelona.
ADNI funding for ADNI is through the Northern California Institute for
Research and Education by grants from Abbott, AstraZeneca AB, Bayer
Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical
Development, Elan Corporation, Genentech, GE Healthcare,
GlaxoSmithKline, Innogenetics, Johnson & Johnson, Eli Lilly and Co.,
Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc., F.
Hoffmann-La Roche, Schering-Plough, Synarc, Inc., Alzheimer's
Association, Alzheimer's Drug Discovery Foundation, the Dana Foundation,
and by the National Institute of Biomedical Imaging and Bioengineering
and NIA grants U01 AG024904, RC2 AG036535, and K01 AG030514. The authors
thank Drs. D. Stephen Snyder and Marilyn Miller from NIA who are ex
officio ADGC members. Support was also from the Alzheimer's Association
(LAF, IIRG-08-89720; MP-V, IIRG-0514147) and the US Department of
Veterans Affairs Administration, Office of Research and Development,
Biomedical Laboratory Research Program. P.S.G.-H. is supported by
Wellcome Trust, Howard Hughes Medical Institute, and the Canadian
Institute of Health Research.
NR 27
TC 13
Z9 13
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAR 10
PY 2015
VL 84
IS 10
BP 972
EP 980
DI 10.1212/WNL.0000000000001332
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA CD9YR
UT WOS:000351458100008
PM 25663231
ER
PT J
AU Ciaranello, AL
Myer, L
Kelly, K
Christensen, S
Daskilewicz, K
Doherty, K
Bekker, LG
Hou, T
Wood, R
Francke, JA
Wools-Kaloustian, K
Freedberg, KA
Walensky, RP
AF Ciaranello, Andrea L.
Myer, Landon
Kelly, Kathleen
Christensen, Sarah
Daskilewicz, Kristen
Doherty, Katie
Bekker, Linda-Gail
Hou, Taige
Wood, Robin
Francke, Jordan A.
Wools-Kaloustian, Kara
Freedberg, Kenneth A.
Walensky, Rochelle P.
TI Point-of-Care CD4 Testing to Inform Selection of Antiretroviral
Medications in South African Antenatal Clinics: A Cost-Effectiveness
Analysis
SO PLOS ONE
LA English
DT Article
ID TO-CHILD TRANSMISSION; RESOURCE-LIMITED SETTINGS; SINGLE-DOSE
NEVIRAPINE; HIV-INFECTED CHILDREN; CAPE-TOWN; RANDOMIZED-TRIAL;
PREGNANT-WOMEN; PILOT PROGRAM; COTE-DIVOIRE; THERAPY
AB Background
Many prevention of mother-to-child HIV transmission (PMTCT) programs currently prioritize antiretroviral therapy (ART) for women with advanced HIV. Point-of-care (POC) CD4 assays may expedite the selection of three-drug ART instead of zidovudine, but are costlier than traditional laboratory assays.
Methods
We used validated models of HIV infection to simulate pregnant, HIV-infected women (mean age 26 years, gestational age 26 weeks) in a general antenatal clinic in South Africa, and their infants. We examined two strategies for CD4 testing after HIV diagnosis: laboratory (test rate: 96%, result-return rate: 87%, cost: $14) and POC (test rate: 99%, result-return rate: 95%, cost: $26). We modeled South African PMTCT guidelines during the study period (WHO "Option A"): antenatal zidovudine (CD4 <= 350/mu L) or ART (CD4 > 350/mu L). Outcomes included MTCT risk at weaning (age 6 months), maternal and pediatric life expectancy (LE), maternal and pediatric lifetime healthcare costs (2013 USD), and cost-effectiveness ($/life-year saved).
Results
In the base case, laboratory led to projected MTCT risks of 5.7%, undiscounted pediatric LE of 53.2 years, and undiscounted PMTCT plus pediatric lifetime costs of $1,070/infant. POC led to lower modeled MTCT risk (5.3%), greater pediatric LE (53.4 years) and lower PMTCT plus pediatric lifetime costs ($1,040/infant). Maternal outcomes following laboratory were similar to POC (LE: 21.2 years; lifetime costs: $23,860/person). Compared to laboratory, POC improved clinical outcomes and reduced healthcare costs.
Conclusions
In antenatal clinics implementing Option A, the higher initial cost of a one-time POC CD4 assay will be offset by cost-savings from prevention of pediatric HIV infection.
C1 [Ciaranello, Andrea L.; Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
[Kelly, Kathleen; Christensen, Sarah; Doherty, Katie; Hou, Taige; Francke, Jordan A.; Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Dept Med, Gen Med, Boston, MA 02114 USA.
[Ciaranello, Andrea L.; Hou, Taige; Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Dept Med, Med Practice Evaluat Ctr, Boston, MA 02114 USA.
[Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Myer, Landon; Daskilewicz, Kristen] Univ Cape Town, Sch Publ Hlth & Family Med, Div Epidemiol & Biostat, ZA-7925 Cape Town, South Africa.
[Bekker, Linda-Gail; Wood, Robin] Univ Cape Town, Inst Infect Dis & Mol Med, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa.
[Wools-Kaloustian, Kara] Indiana Univ Sch Med, Dept Med, Div Infect Dis, Indianapolis, IN 46202 USA.
[Freedberg, Kenneth A.; Walensky, Rochelle P.] Harvard Univ, Ctr AIDS Res, Boston, MA 02115 USA.
[Freedberg, Kenneth A.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
RP Ciaranello, AL (reprint author), Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
EM aciaranello@partners.org; rwalensky@partners.org
FU March of Dimes Foundation; National Institutes of Health (NIAID) [K01
AI078754, R01 AI058736, R01 AI093269]; East African IeDEA Consortium
[U01 AI069911]; IMPAACT network [U01 AI068632]; Massachusetts General
Hospital Executive Committee on Research; Elizabeth Glaser Pediatric
AIDS Foundation; National Institute of Allergy and Infectious Diseases
(NIAID); Eunice Kennedy Shriver National Institute of Child Health and
Human Development (NICHD) [N01-DK-9-001/HHSN267200800001C]; National
Cancer Institute; National Institute of Allergy and Infectious Diseases
(NIAID) of the National Institutes of Health (NIH) [UM1AI068632,
UM1AI068616]; National Institute of Mental Health (NIMH)
FX This work was supported by the March of Dimes Foundation (ALC, LM, KK,
SC, K. Daskilewicz, K. Doherty, LGB, TH), National Institutes of Health
(NIAID) (K01 AI078754 (ALC), R01 AI058736 ((KK, K. Doherty, TH, KAF,
RPW), R01 AI093269 (KAF, RPW), East African IeDEA Consortium U01
AI069911, starand IMPAACT network U01 AI068632star
star (KK, SC, K. Doherty, TH, KAF, RW)), the Massachusetts General
Hospital Executive Committee on Research (ALC), and the Elizabeth Glaser
Pediatric AIDS Foundation (ALC, LM). Point-of-care CD4 measurement
devices for use in the pilot evaluation were donated by Alere
Healthcare. The funders and the suppliers of CD4 measurement devices had
no role in study design, interpretation of results, or decision to
publish. starOverall support for the IeDEA network is
provided by the National Institute of Allergy and Infectious Diseases
(NIAID), the Eunice Kennedy Shriver National Institute of Child Health
and Human Development (NICHD), and the National Cancer Institute.
star starOverall support for the International Maternal
Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided
by the National Institute of Allergy and Infectious Diseases (NIAID) of
the National Institutes of Health (NIH) under Award Numbers UM1AI068632
(IMPAACT LOC), UM1AI068616 (IMPAACT SDMC), with co-funding from the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD) and the National Institute of Mental Health (NIMH).
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the NIH. Support of the
sites was provided by the National Institute of Allergy and Infectious
Diseases (NIAID) and the NICHD International and Domestic Pediatric and
Maternal HIV Clinical Trials Network funded by NICHD (contract number
N01-DK-9-001/HHSN267200800001C). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 83
TC 7
Z9 7
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 10
PY 2015
VL 10
IS 3
AR UNSP e0117751
DI 10.1371/journal.pone.0117751
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CD7MX
UT WOS:000351275700017
PM 25756498
ER
PT J
AU Sim, K
Sum, MY
Navedo, D
AF Sim, Kang
Sum, Min Yi
Navedo, Deborah
TI Use of narratives to enhance learning of research ethics in residents
and researchers
SO BMC MEDICAL EDUCATION
LA English
DT Article
DE Narratives; Research ethics; Engagement; Motivation; Reflective learning
ID MEDICINE; MODEL
AB Background: Past didactic pedagogy on biomedical research ethics and informed consent in our program had resulted in passive memorization of information and disengaged learning within psychiatry residents and clinical researchers. The question is how do we better motivate and engage learners within the session. Thus, we incorporated narratives into the learning environment and hypothesised that the use of narratives in the teaching of biomedical research ethics and informed consent would be associated with greater engagement, motivation, understanding, reflective learning and effectiveness of the teaching session.
Methods: The narratives were chosen from the history of research ethics and the humanities literature related to human subject research. Learners were asked to provide post-session feedback through an anonymised questionnaire on their learning session. An outcomes logic model was used for assessment with focus on immediate outcomes such as engagement, motivation, understanding and reflective learning.
Results: Overall, 70.5% (N = 273) of the learners responded to the questionnaire. Amongst the respondents, 92.6% (N = 253) of the participants ranked use of narratives as most helpful in appreciating the historical context of research ethics and informed consent in research. The majority felt engaged (89.8%, N = 245), more motivated to learn (77.5%, N = 212) and better equipped (86.4%, N = 236) about the subject matter. Better appreciation of the learning topic, engagement, motivation to learn, equipping were strongly correlated with the promotion of reflective learning, effectiveness of teaching, promotion of critical thinking and overall positive rating of the teaching session on research ethics (all p < 0.001). Multivariate analyses found that the use of narratives was associated with higher overall rating of the teaching session (p = 0.003) and promotion of critical thinking (p = 0.02).
Conclusion: Results revealed that the use of narratives could enhance engagement, appreciation of biomedical research ethics and informed consent, and address underlying motivational factors behind learning and understanding of research ethics.
C1 [Sim, Kang] Inst Mental Hlth, Dept Gen Psychiat, Singapore 539747, Singapore.
[Sim, Kang; Sum, Min Yi] Inst Mental Hlth, Div Res, Singapore 539747, Singapore.
[Navedo, Deborah] Massachusetts Gen Hosp, Inst Hlth Profess, Charlestown Navy Yard, Hlth Profess Educ Program,Ctr Interprofess Studie, Boston, MA 02129 USA.
RP Sim, K (reprint author), Inst Mental Hlth, Dept Gen Psychiat, 10 Buangkok View, Singapore 539747, Singapore.
EM kang_sim@imh.com.sg
NR 22
TC 0
Z9 0
U1 2
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6920
J9 BMC MED EDUC
JI BMC Med. Educ.
PD MAR 10
PY 2015
VL 15
AR 41
DI 10.1186/s12909-015-0329-y
PG 7
WC Education & Educational Research; Education, Scientific Disciplines
SC Education & Educational Research
GA CD4EB
UT WOS:000351034300003
PM 25890045
ER
PT J
AU Platzer, B
Elpek, KG
Cremasco, V
Baker, K
Stout, MM
Schultz, C
Dehlink, E
Shade, KTC
Anthony, RM
Blumberg, RS
Turley, SJ
Fiebiger, E
AF Platzer, Barbara
Elpek, Kutlu G.
Cremasco, Viviana
Baker, Kristi
Stout, Madeleine M.
Schultz, Cornelia
Dehlink, Eleonora
Shade, Kai-Ting C.
Anthony, Robert M.
Blumberg, Richard S.
Turley, Shannon J.
Fiebiger, Edda
TI IgE/Fc epsilon RI-Mediated Antigen Cross-Presentation by Dendritic Cells
Enhances Anti-Tumor Immune Responses
SO CELL REPORTS
LA English
DT Article
ID NEONATAL FC-RECEPTOR; IN-VIVO; PROTECTIVE IMMUNITY; IMMUNOGLOBULIN-E;
CANCER; IMMUNOTHERAPY; CD8(+); TUMORS; INTERNALIZATION; EXPRESSION
AB Epidemiologic studies discovered an inverse association between immunoglobulin E (IgE)-mediated allergies and cancer, implying tumor-protective properties of IgE. However, the underlying immunologic mechanisms remain poorly understood. Antigen cross-presentation by dendritic cells (DCs) is of key importance for anti-tumor immunity because it induces the generation of cytotoxic CD8(+) T lymphocytes (CTLs) with specificity for tumor antigens. We demonstrate that DCs use IgE and Fc epsilon RI, the high-affinity IgE receptor, for cross-presentation and priming of CTLs in response to free soluble antigen at low doses. Importantly, IgE/Fc epsilon RI-mediated cross-presentation is a distinct receptor-mediated pathway because it does not require MyD88 signals or IL-12 induction in DCs. Using passive immunization with tumor antigen-specific IgE and DC-based vaccination experiments, we demonstrate that IgE-mediated cross-presentation significantly improves anti-tumor immunity and induces memory responses in vivo. Our findings suggest a cellular mechanism for the tumor-protective features of IgE and expand the known physiological functions of this immunoglobulin.
C1 [Platzer, Barbara; Stout, Madeleine M.; Schultz, Cornelia; Dehlink, Eleonora; Fiebiger, Edda] Harvard Univ, Sch Med, Div Gastroenterol & Nutr, Boston Childrens Hosp, Boston, MA 02115 USA.
[Platzer, Barbara; Stout, Madeleine M.; Schultz, Cornelia; Dehlink, Eleonora; Fiebiger, Edda] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Elpek, Kutlu G.; Cremasco, Viviana; Turley, Shannon J.] Dana Farber Canc Inst, Dept Canc Immunol, Boston, MA 02115 USA.
[Elpek, Kutlu G.; Cremasco, Viviana; Turley, Shannon J.] Dana Farber Canc Inst, AIDS, Boston, MA 02115 USA.
[Baker, Kristi; Blumberg, Richard S.] Harvard Univ, Sch Med, Div Gastroenterol, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Baker, Kristi; Blumberg, Richard S.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Shade, Kai-Ting C.; Anthony, Robert M.] Harvard Univ, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Massachusetts Gen Hosp,Med Sch, Boston, MA 02129 USA.
RP Fiebiger, E (reprint author), Harvard Univ, Sch Med, Div Gastroenterol & Nutr, Boston Childrens Hosp, Boston, MA 02115 USA.
EM edda.fiebiger@childrens.harvard.edu
FU NIH [K01DK093597, DK53056, 5R01 DK074500-08, 2P01AI045757-15, R21
CA182598-01, T32 CA 070083-15, AI075037]; Claudia Adams Barr Award for
Innovative Cancer Research; Canadian Institutes of Health Research;
Cancer Research Institute fellowship; APART Fellowship of the Austrian
Academy of Sciences; Austrian Marshall Plan Foundation;
Industriellenvereinigung Kaernten; HDDC [P30DK034854]
FX We thank Dr. R. Massol, Dr. N. Anandasabapathy, B. Nelms, and S.
Schopoff for suggestions and technical assistance. We also thank the
Leusen laboratory for reagents. This work was supported by the NIH
(K01DK093597 to B.P.; DK53056 to R.S.B.; 5R01 DK074500-08,
2P01AI045757-15, and R21 CA182598-01 to S.J.T.; T32 CA 070083-15 to
V.C.; and AI075037 to E.F.). Further support was provided by the Claudia
Adams Barr Award for Innovative Cancer Research (to S.J.T.) and the
Canadian Institutes of Health Research (to K.B.). V.C. was supported by
a Cancer Research Institute fellowship, E.D. was supported by an APART
Fellowship of the Austrian Academy of Sciences, and C.S. was supported
by the Austrian Marshall Plan Foundation and the
Industriellenvereinigung Kaernten. This work was also supported by HDDC
grant P30DK034854 and by an unrestricted gift from the Mead Johnson
Nutrition Company to the Division of Gastroenterology and Nutrition,
Boston Children's Hospital (to E.F.).
NR 37
TC 7
Z9 7
U1 1
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD MAR 10
PY 2015
VL 10
IS 9
BP 1487
EP 1495
DI 10.1016/j.celrep.2015.02.015
PG 9
WC Cell Biology
SC Cell Biology
GA CD0DJ
UT WOS:000350740300007
ER
PT J
AU Medeiros, K
O'Connor, M
Baicu, CF
Fitzgibbons, T
Shaw, P
Tighe, DA
Zile, MR
Aurigemma, GP
AF Medeiros, Keith
O'Connor, Mark
Baicu, Catalin F.
Fitzgibbons, Timothy
Shaw, Peter
Tighe, Dennis A.
Zile, Michael R.
Aurigemma, Gerard P.
TI Response to Letters Regarding Article, "Systolic and Diastolic Mechanics
in Stress Cardiomyopathy"
SO CIRCULATION
LA English
DT Letter
C1 [Medeiros, Keith; O'Connor, Mark; Fitzgibbons, Timothy; Tighe, Dennis A.; Aurigemma, Gerard P.] Univ Massachusetts, Sch Med, Dept Med, Div Cardiovasc Med, Worcester, MA 01655 USA.
[Baicu, Catalin F.; Zile, Michael R.] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA.
[Baicu, Catalin F.; Zile, Michael R.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA.
[Shaw, Peter] Univ Virginia, Sch Med, Dept Med, Div Cardiovasc Med, Charlottesville, VA 22908 USA.
RP Medeiros, K (reprint author), Univ Massachusetts, Sch Med, Dept Med, Div Cardiovasc Med, Worcester, MA 01655 USA.
OI Fitzgibbons, Timothy/0000-0003-0229-034X
NR 3
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD MAR 10
PY 2015
VL 131
IS 10
BP E372
EP E372
DI 10.1161/CIRCULATIONAHA.114.012819
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA CD0NR
UT WOS:000350771700005
PM 25753351
ER
PT J
AU Addisu, F
Wondafrash, M
Chemali, Z
Dejene, T
Tesfaye, M
AF Addisu, Fikir
Wondafrash, Mekitie
Chemali, Zeina
Dejene, Tariku
Tesfaye, Markos
TI Length of stay of psychiatric admissions in a general hospital in
Ethiopia: a retrospective study
SO INTERNATIONAL JOURNAL OF MENTAL HEALTH SYSTEMS
LA English
DT Article
DE Psychiatric admission; Mental illness; Psychiatric care; Length of
hospital stay; Sub-Saharan Africa; Ethiopia
ID GLOBAL MENTAL-HEALTH; CARE; PATTERNS; COHORT; COMMUNITY; CONSEQUENCES;
COMORBIDITY; DISORDER; BALANCE; SERVICE
AB Background: In sub-Saharan Africa, the number of psychiatric beds per population is disproportionately low. Moreover, there is a lack of data regarding the patterns of psychiatric admissions and the factors leading to long psychiatric hospitalization in this region. This study aimed to investigate the average length of stay (LOS) and the factors associated with prolonged hospitalizations.
Methods: A ten-year retrospective chart review of patients admitted to the psychiatric facility of Jimma University Specialized Hospital in southwest Ethiopia was conducted. The medical charts of 846 admissions spanning the period from January 2001 to December 2010 were reviewed. LOS greater than 21 days was considered as a cut-off point for lengthier stay. Bivariate and multivariable logistic regression analyses were conducted to identify factors independently associated with LOS.
Results: The most common discharge diagnoses were schizophrenia and other psychotic disorders (27.6%), and bipolar disorder (23.4%). A global clinical rating taken on discharge showed 90.3% improved outcome. The median (25th, 75th percentiles) LOS was 22 (15, 36) days. Patients with major depressive disorder [aOR = 0.51 (0.32 - 0.81)] and brief psychotic disorder [aOR = 0.52 (0.33 - 0.84)] were less likely than patients with schizophrenia and other psychotic disorders to have long hospital stays. Presence of extrapyramidal side-effects and out of pocket expenditures predicted LOS.
Conclusions: Patients with psychoses and bipolar disorder have lengthier hospital stays burdening the cost of care of psychiatric treatment in a general hospital setting. Our findings call for identifying those cases quickly, attending to their needs with evidence-based efficient treatment and for improving and developing an aftercare system such that the utilization of acute inpatient beds, already a scarce resource, could achieve higher efficiency.
C1 [Addisu, Fikir; Tesfaye, Markos] Jimma Univ, Dept Psychiat, Jimma, Ethiopia.
[Wondafrash, Mekitie] Jimma Univ, Dept Populat & Family Hlth, Jimma, Ethiopia.
[Chemali, Zeina] Massachusetts Gen Hosp, Dept Psychiat & Neurol, Boston, MA 02114 USA.
[Dejene, Tariku] Jimma Univ, Dept Epidemiol, Jimma, Ethiopia.
[Tesfaye, Markos] Univ Munich, Ctr Int Hlth, Munich, Germany.
RP Tesfaye, M (reprint author), Jimma Univ, Dept Psychiat, Jimma, Ethiopia.
EM tesmarkos@yahoo.com
OI Tesfaye, Markos/0000-0002-3351-701X
FU Jimma University
FX The study was funded by Jimma University. The authors would like to
thank the staff of Jimma University Specialized Hospital for their
support during data collection. We are grateful to Mr. Yohannes Dibaba
for additional support in the statistical analysis of our data.
NR 36
TC 1
Z9 1
U1 2
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1752-4458
J9 INT J MENT HEALTH SY
JI Int. J. Ment. Health Syst.
PD MAR 10
PY 2015
VL 9
AR 13
DI 10.1186/s13033-015-0006-x
PG 9
WC Psychiatry
SC Psychiatry
GA CD3DF
UT WOS:000350957300002
PM 25780386
ER
PT J
AU Ganda, OP
AF Ganda, Om P.
TI Deciphering Cholesterol Treatment Guidelines A Clinician's Perspective
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
C1 Harvard Univ, Med Sch, Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Ganda, OP (reprint author), Harvard Univ, Med Sch, Joslin Diabet Ctr, 1 Joslin Pl,Ste 242, Boston, MA 02215 USA.
EM om.ganda@joslin.harvard.edu
FU NIDDK NIH HHS [P30 DK036836, DK036836]
NR 6
TC 5
Z9 5
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAR 10
PY 2015
VL 313
IS 10
BP 1009
EP 1010
DI 10.1001/jama.2015.216
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA CC8UE
UT WOS:000350643100011
PM 25756432
ER
PT J
AU Holmes, DR
Brennan, JM
Rumsfeld, JS
Dai, D
O'Brien, SM
Vemulapalli, S
Edwards, FH
Carroll, J
Shahian, D
Grover, F
Tuzcu, EM
Peterson, ED
Brindis, RG
Mack, MJ
AF Holmes, David R., Jr.
Brennan, J. Matthew
Rumsfeld, John S.
Dai, David
O'Brien, Sean M.
Vemulapalli, Sreekanth
Edwards, Fred H.
Carroll, John
Shahian, David
Grover, Fred
Tuzcu, E. Murat
Peterson, Eric D.
Brindis, Ralph G.
Mack, Michael J.
CA STS ACC TVT Registry
TI Clinical Outcomes at 1 Year Following Transcatheter Aortic Valve
Replacement
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID HIGH-RISK PATIENTS; ACADEMIC RESEARCH CONSORTIUM; END-POINT DEFINITIONS;
EDWARDS SAPIEN; CONSENSUS DOCUMENT; PREDICT OUTCOMES; COMPETING RISK;
EUROSCORE II; IMPLANTATION; REGISTRY
AB IMPORTANCE Introducing new medical devices into routine practice raises concerns because patients and outcomesmay differ from those in randomized trials.
OBJECTIVE To update the previous report of 30-day outcomes and present 1-year outcomes following transcatheter aortic valve replacement (TAVR) in the United States.
DESIGN, SETTING, AND PARTICIPANTS Data from the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) Transcatheter Valve Therapies Registry were linked with patient-specific Centers for Medicare & Medicaid Services (CMS) administrative claims data. At 299 US hospitals, 12 182 patients linked with CMS data underwent TAVR procedures performed from November 2011 through June 30, 2013, and the end of the follow-up period was June 30, 2014.
EXPOSURE Transcatheter aortic valve replacement.
MAIN OUTCOMES AND MEASURES One-year outcomes including mortality, stroke, and rehospitalization were evaluated using multivariate modeling.
RESULTS The median age of patients was 84 years and 52% were women, with a median STS Predicted Risk of Operative Mortality (STS PROM) score of 7.1%. Following the TAVR procedure, 59.8% were discharged to home and the 30-day mortality was 7.0% (95% CI, 6.5%-7.4%) (n = 847 deaths). In the first year after TAVR, patients were alive and out of the hospital for a median of 353 days (interquartile range, 312-359 days); 24.4%(n = 2074) of survivors were rehospitalized once and 12.5%(n = 1525) were rehospitalized twice. By 1 year, the overall mortality rate was 23.7%(95% CI, 22.8%-24.5%) (n = 2450 deaths), the stroke rate was 4.1%(95% CI, 3.7%-4.5%) (n = 455 stroke events), and the rate of the composite outcome of mortality and stroke was 26.0%(25.1%-26.8%) (n = 2719 events). Characteristics significantly associated with 1-year mortality included advanced age (hazard ratio [HR] for >= 95 vs <75 years, 1.61 [95% CI, 1.24-2.09]; HR for 85-94 years vs <75 years, 1.35 [95% CI, 1.18-1.55]; and HR for 75-84 years vs < 75 years, 1.23 [95% CI, 1.08-1.41]), male sex (HR, 1.21; 95% CI, 1.12-1.31), end-stage renal disease (HR, 1.66; 95% CI, 1.41-1.95), severe chronic obstructive pulmonary disease (HR, 1.39; 95% CI, 1.25-1.55), nontransfemoral access (HR, 1.37; 95% CI, 1.27-1.48), STS PROM score greater than 15% vs less than 8%(HR, 1.82; 95% CI, 1.60-2.06), and preoperative atrial fibrillation/flutter (HR, 1.37; 95% CI, 1.27-1.48). Compared with men, women had a higher risk of stroke (HR, 1.40; 95% CI, 1.15-1.71).
CONCLUSIONS AND RELEVANCE Among patients undergoing TAVR in US clinical practice, at 1-year follow-up, overall mortality was 23.7%, the stroke rate was 4.1%, and the rate of the composite outcome of death and stroke was 26.0%. These findings should be helpful in discussions with patients undergoing TAVR.
C1 [Holmes, David R., Jr.] Mayo Clin, Rochester, MN 55905 USA.
[Brennan, J. Matthew; Dai, David; O'Brien, Sean M.; Vemulapalli, Sreekanth] Duke Clin Res Inst, Durham, NC USA.
[Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
[Edwards, Fred H.] Univ Florida, Jacksonville, FL USA.
[Carroll, John; Grover, Fred] Univ Colorado, Denver, CO 80202 USA.
[Shahian, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Tuzcu, E. Murat] Cleveland Clin, Cleveland, OH 44106 USA.
[Peterson, Eric D.] Duke Univ, Med Ctr, Durham, NC USA.
[Brindis, Ralph G.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Mack, Michael J.] Baylor Scott & White Hlth, Plano, TX USA.
RP Holmes, DR (reprint author), Mayo Clin, 200 First St SW, Rochester, MN 55905 USA.
EM holmes.david@mayo.edu
FU American College of Cardiology Foundation's National Cardiovascular Data
Registry; Society of Thoracic Surgeons
FX The STS/ACC TVT Registry is an initiative of the Society of Thoracic
Surgeons and the American College of Cardiology Foundation. This
research was supported by the American College of Cardiology
Foundation's National Cardiovascular Data Registry and the Society of
Thoracic Surgeons.
NR 33
TC 88
Z9 88
U1 1
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAR 10
PY 2015
VL 313
IS 10
BP 1019
EP 1028
DI 10.1001/jama.2015.1474
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA CC8UE
UT WOS:000350643100017
PM 25756438
ER
PT J
AU Patel, MR
Conte, MS
Cutlip, DE
Dib, N
Geraghty, P
Gray, W
Hiatt, WR
Ho, M
Ikeda, K
Ikeno, F
Jaff, MR
Jones, WS
Kawahara, M
Lookstein, RA
Mehran, R
Misra, S
Norgren, L
Olin, JW
Povsic, TJ
Rosenfield, K
Rundback, J
Shamoun, F
Tcheng, J
Tsai, TT
Suzuki, Y
Vranckx, P
Wiechmann, BN
White, CJ
Yokoi, H
Krucoff, MW
AF Patel, Manesh R.
Conte, Michael S.
Cutlip, Donald E.
Dib, Nabil
Geraghty, Patrick
Gray, William
Hiatt, William R.
Ho, Mami
Ikeda, Koji
Ikeno, Fumiaki
Jaff, Michael R.
Jones, W. Schuyler
Kawahara, Masayuki
Lookstein, Robert A.
Mehran, Roxana
Misra, Sanjay
Norgren, Lars
Olin, Jeffrey W.
Povsic, Thomas J.
Rosenfield, Kenneth
Rundback, John
Shamoun, Fadi
Tcheng, James
Tsai, Thomas T.
Suzuki, Yuka
Vranckx, Pascal
Wiechmann, Bret N.
White, Christopher J.
Yokoi, Hiroyoshi
Krucoff, Mitchell W.
TI Evaluation and Treatment of Patients With Lower Extremity Peripheral
Artery Disease Consensus Definitions From Peripheral Academic Research
Consortium (PARC)
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Review
DE amputation; foot; intermittent claudication; leg; myocardial infarction;
stroke
ID PERCUTANEOUS CORONARY INTERVENTION; AORTIC-VALVE IMPLANTATION;
INTER-SOCIETY CONSENSUS; END-POINT DEFINITIONS; STENT THROMBOSIS;
STANDARDIZED DEFINITIONS; CLINICAL-OUTCOMES; HEART-ASSOCIATION; LIMB
ISCHEMIA; TASK-FORCE
AB The lack of consistent definitions and nomenclature across clinical trials of novel devices, drugs, or biologics poses a significant barrier to accrual of knowledge in and across peripheral artery disease therapies and technologies. Recognizing this problem, the Peripheral Academic Research Consortium, together with the U.S. Food and Drug Administration and the Japanese Pharmaceuticals and Medical Devices Agency, has developed a series of pragmatic consensus definitions for patients being treated for peripheral artery disease affecting the lower extremities. These consensus definitions include the clinical presentation, anatomic depiction, interventional outcomes, surrogate imaging and physiological follow-up, and clinical outcomes of patients with lower-extremity peripheral artery disease. Consistent application of these definitions in clinical trials evaluating novel revascularization technologies should result in more efficient regulatory evaluation and best practice guidelines to inform clinical decisions in patients with lower extremity peripheral artery disease. (C) 2015 by the American College of Cardiology Foundation.
C1 [Patel, Manesh R.; Povsic, Thomas J.; Tcheng, James; Krucoff, Mitchell W.] Duke Univ, Duke Clin Res Inst, Durham, NC 27710 USA.
[Conte, Michael S.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Cutlip, Donald E.] Harvard Clin Res Inst, Boston, MA USA.
[Cutlip, Donald E.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Dib, Nabil] Univ Calif San Diego, San Diego, CA 92103 USA.
[Geraghty, Patrick] Washington Univ, Sch Med, St Louis, MO USA.
[Gray, William] Cardiovasc Res Fdn, New York, NY USA.
[Gray, William] Columbia Univ, Med Ctr, New York, NY USA.
[Hiatt, William R.] Univ Colorado, Sch Med, Aurora, CO USA.
[Hiatt, William R.] CPC Clin Res, Aurora, CO USA.
[Ho, Mami; Kawahara, Masayuki] Pharmaceut & Med Devices Agcy, Office Med Devices 1, Tokyo, Japan.
[Ikeda, Koji] Tohoku Univ Hosp, Sendai, Miyagi, Japan.
[Ikeno, Fumiaki] Stanford Univ, Palo Alto, CA 94304 USA.
[Jaff, Michael R.] Massachusetts Gen Hosp, VasCore, Boston, MA 02114 USA.
[Lookstein, Robert A.; Mehran, Roxana; Olin, Jeffrey W.] Mt Sinai Med Ctr, New York, NY 10029 USA.
[Misra, Sanjay] Mayo Clin, Rochester, MN USA.
[Norgren, Lars] Univ Hosp, Orebro, Sweden.
[Rosenfield, Kenneth] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rundback, John] Holy Name Med Ctr, Teaneck, NJ USA.
[Shamoun, Fadi] Mayo Clin Arizona, Phoenix, AZ USA.
[Tsai, Thomas T.] Univ Colorado, Kaiser Permanente Colorado Inst Hlth Res, Denver, CO 80202 USA.
[Suzuki, Yuka] Pharmaceut & Med Devices Agcy, Off Med Devices 2, Tokyo, Japan.
[Vranckx, Pascal] Cardialysis, Rotterdam, Netherlands.
[Wiechmann, Bret N.] Vasc & Intervent Phys, Gainesville, FL USA.
[White, Christopher J.] Ochsner Med Ctr, New Orleans, LA USA.
[Yokoi, Hiroyoshi] Kokura Mem Hosp, Kitakyuku, Japan.
RP Patel, MR (reprint author), Duke Univ, Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27710 USA.
EM manesh.patel@duke.edu
RI White, Christopher/J-6686-2012
OI White, Christopher/0000-0001-8618-7539
FU Johnson & Johnson Pharmaceutical Research and Development; AstraZeneca;
National Heart, Lung, and Blood Institute; Agency for Healthcare
Research and Quality; Maquet; Medtronic; Boston Scientific; Abbott
Vascular; STENTYS; Celonova; Cordis; Abbott; WL Gore; Mercator;
Medicines Company; Cardiovascular Systems Incorporated; CPC Clinical
Research; Bayer Healthcare; National Institutes of Health; CSI; DNAVEC;
GlaxoSmithKline; Kyushu University; Pluristem; ReNeuron; American Heart
Association; Bristol-Myers Squibb; Bristol-Myers Squibb/Sanofi;
Lilly/Daiichi Sankyo; Regado Biosciences; Baxter Healthcare; Food and
Drug Administration; Cordis Corporation; Bard Peripheral Vascular
FX Grants were provided from the industry sponsors and representative
listed to the International Society for Cardiovascular Translational
Research and the Duke Clinical Research Institute to cover the costs of
travel, lodging, and the meeting expenses for academic attendees to the
meetings in Silver Spring, Maryland. Dr. Patel has received research
grants from Johnson & Johnson Pharmaceutical Research and Development,
AstraZeneca, the National Heart, Lung, and Blood Institute, Agency for
Healthcare Research and Quality, and Maquet; and has served on the
advisory board and/or as a consultant to Bayer Healthcare, Janssen, and
Genzyme. Dr. Conte has served as a member of the steering committee for
AstraZeneca; and has served as a consultant/advisory board member for
Cook Medical and Medtronic. Dr. Dib is the Medical Director of CSI. Dr.
Cutlip has received research grants or contracts from Medtronic, Boston
Scientific, Abbott Vascular, STENTYS, and Celonova. Dr. Geraghty has
served as a consultant and trial principal investigator for
Bard/Lutonix; has served as an advisory board member for Bard/Lutonix
and Boston Scientific; was on the trial steering committee for Covidien;
and has served as a speaker and trial principal investigator for Cook
Medical. Dr. Gray has received consultant fees from Cordis, Medtronic,
Abbott, Boston Scientific, and WL Gore; and research support from
Cordis, Medtronic, Abbott, WL Gore, Mercator, The Medicines Company, and
Cardiovascular Systems Incorporated. Dr. Hiatt has received grant
support from CPC Clinical Research (a nonprofit affiliate of the
University of Colorado), AstraZeneca, Bayer Healthcare, the National
Institutes of Health, CSI, DNAVEC, GlaxoSmithKline, Kyushu University,
Pluristem, ReNeuron, and Rigel. Dr. Jaff was a noncompensated advisor to
Abbott Vascular, Boston Scientific, Cordis Corporation, Covidien
Vascular, and Medtronic Vascular; has served as a board member for VIVA
Physicians, a 501(c) 3 not-for-profit education and research
organization; and has equity investment in Embolitech, Hotspur, Icon
Interventional, PQ Bypass, and Vascular Therapies. Dr. Jones has
received research grants from the American Heart Association,
AstraZeneca, Boston Scientific, and Bristol-Myers Squibb; and has served
as an advisory board member for AstraZeneca. Dr. Lookstein has served as
a consultant to Boston Scientific, Bayer Healthcare, and Cordis
Corporation. Dr. Mehran has received institutional research grant
support from The Medicines Company, Bristol-Myers Squibb/Sanofi,
Lilly/Daiichi Sankyo, Regado Biosciences, and STENTYS; has served as a
consultant to Abbott Vascular, AstraZeneca, Boston Scientific, Covidien,
CSL Behring, Janssen (Johnson & Johnson), Maya Medical, and Merck; has
served on the advisory board of Covidien, Janssen Pharmaceuticals,
Merck, Sanofi, and Endothelix, Inc.; and has equity/is a shareholder in
Endothelix, Inc. Dr. Misra was the Chair for the Data Safety and
Monitoring Board for the FLEXSTENT study sponsored by CORDIS (modest
grant); and received research grants from the National Institute of
Health. Dr. Norgren was a steering committee member/consultant for
Otsuka Pharma, AnGes, AstraZeneca, and Novartis. Dr.; Olin was on the
member steering committee clinical trial on placental stem cells for
claudication and medical advisory board for PAD related studies for
Pluristem; was on the international steering committee for EUCLID trial
and was the site investigator for EUCLID trial for AztraZeneca; was on
the steering committee TRA2P trial for Vorapaxar and the medical
advisory board for Vorapaxor clinical trials for PAD for Merck; and was
on the medical advisory and safety board for Tyrosine Kinase Inhibitors
and Cardiovascular Risk for Novartis. Dr. Rundback has served on the
clinical events committee for Biotronik and St. Jude; has served as a
principal investigator for Covidien and Symbionix; has served as a
course director for CSI; and has served as a consultant for Covidien,
CSI, Sil Vascular, and Intact Vascular. Dr. Povsic was supported by
research grants and received advisory fees from Baxter Healthcare; and
has served on the data safety monitoring board of Pluristem, Inc. Dr.
Tcheng has served on the advisory board of Philips Medical Systems and
Cardiovascular Systems, Inc.; and has received research grants from the
Food and Drug Administration. Dr. White has served on the
research/advisory board of St. Jude and Neovasc; and has served as the
steering committee chair for NCDR CathPVI, as the executive committee
co-chair for the BEST trial, and as a member of the steering committee
for EUCLID (AstraZeneca). Dr. Wiechmann has served on the advisory
boards of Boston Scientific and Bard Peripheral Vascular; has received
research funding from The Medicines Company; has served as a consultant
to Cordis Corporation, Terumo Medical, and Bard Peripheral Vascular; has
received clinical trial support from Cordis Corporation, and Bard
Peripheral Vascular; and has an equity interest in PQ Bypass. Dr.
Krucoff has received modest consulting fees from Medtronic, CSI,
Covidien, Abbott Vascular, and Boston Scientific; and has received
significant grant funding from Medtronic, CSI, and Abbott Vascular. All
other authors have reported that they have no relationships relevant to
the contents of this paper to disclose. Dr. Michael H. Criqui, MD, MPH,
has served as Guest Editor for this paper.
NR 33
TC 27
Z9 28
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAR 10
PY 2015
VL 65
IS 9
BP 931
EP 941
DI 10.1016/j.jacc.2014.12.036
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CC3AO
UT WOS:000350216700011
PM 25744011
ER
PT J
AU Webb, AR
Heller, HT
Benson, CB
Lahav, A
AF Webb, Alexandra R.
Heller, Howard T.
Benson, Carol B.
Lahav, Amir
TI Mother's voice and heartbeat sounds elicit auditory plasticity in the
human brain before full gestation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE auditory; brain; mother's voice; heartbeat; preterm newborns
ID NEONATAL INTENSIVE-CARE; LOW-BIRTH-WEIGHT; BIOLOGICAL MATERNAL SOUNDS;
CORPUS-CALLOSUM SIZE; PRETERM INFANTS; PREMATURE-INFANTS; SENSORY
DEPRIVATION; SPEECH-PERCEPTION; CRITICAL PERIOD; NEWBORN BRAIN
AB Brain development is largely shaped by early sensory experience. However, it is currently unknown whether, how early, and to what extent the newborn's brain is shaped by exposure to maternal sounds when the brain is most sensitive to early life programming. The present study examined this question in 40 infants born extremely prematurely (between 25- and 32-wk gestation) in the first month of life. Newborns were randomized to receive auditory enrichment in the form of audio recordings of maternal sounds (including their mother's voice and heartbeat) or routine exposure to hospital environmental noise. The groups were otherwise medically and demographically comparable. Cranial ultrasonography measurements were obtained at 30 +/- 3 d of life. Results show that newborns exposed to maternal sounds had a significantly larger auditory cortex (AC) bilaterally compared with control newborns receiving standard care. The magnitude of the right and left AC thickness was significantly correlated with gestational age but not with the duration of sound exposure. Measurements of head circumference and the widths of the frontal horn (FH) and the corpus callosum (CC) were not significantly different between the two groups. This study provides evidence for experience-dependent plasticity in the primary AC before the brain has reached full-term maturation. Our results demonstrate that despite the immaturity of the auditory pathways, the AC is more adaptive to maternal sounds than environmental noise. Further studies are needed to better understand the neural processes underlying this early brain plasticity and its functional implications for future hearing and language development.
C1 [Webb, Alexandra R.; Lahav, Amir] Brigham & Womens Hosp, Dept Pediat Newborn Med, Boston, MA 02115 USA.
[Heller, Howard T.; Benson, Carol B.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Lahav, Amir] Harvard Univ, Sch Med, Dept Pediat, MassGen Hosp Children, Boston, MA 02115 USA.
RP Lahav, A (reprint author), Brigham & Womens Hosp, Dept Pediat Newborn Med, 75 Francis St, Boston, MA 02115 USA.
EM amir@hms.harvard.edu
FU Charles H. Hood Foundation; Peter and Elizabeth C. Tower Foundation;
Little Giraffe Foundation; Gerber Foundation; Hailey's Hope Foundation
FX We thank the families and babies who participated in this study; Anna
Alkozei and Katie Rand for their kind assistance in early stages of this
work; and Peter Forbes for statistical consultation. This study was
supported in part by grants made to A.L. from the Charles H. Hood
Foundation, the Peter and Elizabeth C. Tower Foundation, Little Giraffe
Foundation, Gerber Foundation, and Hailey's Hope Foundation.
NR 103
TC 9
Z9 10
U1 4
U2 24
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 10
PY 2015
VL 112
IS 10
BP 3152
EP 3157
DI 10.1073/pnas.1414924112
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC8VK
UT WOS:000350646500063
PM 25713382
ER
PT J
AU Lin, CW
Chang, LC
Tseng, GC
Kirkwood, CM
Sibille, EL
Sweet, RA
AF Lin, Chien-Wei
Chang, Lun-Ching
Tseng, George C.
Kirkwood, Caitlin M.
Sibille, Etienne L.
Sweet, Robert A.
TI VSNL1 co-expression networks in aging include calcium signaling,
synaptic plasticity, and Alzheimer's disease pathways
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE visinin-like 1; visinin-like protein 1; Alzheimer disease; co-expression
networks; calcium signaling; synaptic plasticity
ID VISININ-LIKE PROTEINS; AMYLOID-BETA-PEPTIDE; COGNITIVE DECLINE;
GENE-EXPRESSION; HUMAN BRAIN; SENSOR; CORTEX; TRANSCRIPTOME; DISORDERS;
DISCOVERY
AB The visinin-like 1 (VSNL1) gene encodes visinin-like protein 1, a peripheral biomarker for Alzheimer disease (AD). Little is known, however, about normal VSNL1 expression in brain and the biologic networks in which it participates. Frontal cortex gray matter obtained from 209 subjects without neurodegenerative or psychiatric illness, ranging in age from 16 to 91, was processed on Affymetrix GeneChip 1.1 ST and Human SNP Array 6.0. VSNL1 expression was unaffected by age and sex, and not significantly associated with SNPs in cis or trans. VSNL1 was significantly co-expressed with genes in pathways for calcium signaling, AD, long-term potentiation, long-term depression, and trafficking of AMPA receptors. The association with AD was driven, in part, by correlation with amyloid precursor protein (APP) expression. These findings provide an unbiased link between VSNL1 and molecular mechanisms of AD, including pathways implicated in synaptic pathology in AD. Whether APP may drive increased VSNL1 expression, VSNL1 drives increased APP expression, or both are downstream of common pathogenic regulators will need to be evaluated in model systems.
C1 [Lin, Chien-Wei; Chang, Lun-Ching; Tseng, George C.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15213 USA.
[Kirkwood, Caitlin M.; Sibille, Etienne L.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Sibille, Etienne L.] Univ Toronto, Dept Psychiat, Campbell Family Mental Hlth Res Inst, CAMH, Toronto, ON, Canada.
[Sibille, Etienne L.] Univ Toronto, Dept Pharmacol &Toxicol, Campbell Family Mental Hlth Res Inst, CAMH, Toronto, ON, Canada.
[Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA.
RP Sweet, RA (reprint author), Univ Pittsburgh, Dept Psychiat, Biomed Sci Tower,Room W-1645,3811 OHara St, Pittsburgh, PA 15213 USA.
EM sweetra@upmc.edu
FU BLRD VA [I01 BX000452]; NIA NIH HHS [F31 AG044070, P50 AG005133, R01
AG027224]; NIMH NIH HHS [K02 MH084060, R01 MH071533, R01 MH093723, R21
MH094862]
NR 50
TC 3
Z9 4
U1 2
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD MAR 9
PY 2015
VL 6
AR 30
DI 10.3389/fpsyt.2015.00030
PG 9
WC Psychiatry
SC Psychiatry
GA CV4BA
UT WOS:000364209200001
PM 25806004
ER
PT J
AU Dirkmann, D
Groeben, H
Farhan, H
Stahl, DL
Eikermann, M
AF Dirkmann, Daniel
Groeben, Harald
Farhan, Hassan
Stahl, David L.
Eikermann, Matthias
TI Effects of parecoxib on analgesia benefit and blood loss following open
prostatectomy: a multicentre randomized trial
SO BMC ANESTHESIOLOGY
LA English
DT Article
DE Analgesics non-opioids; Parecoxib; Analgesics opioids; Morphine; Pain;
Postoperative pain
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; POSTOPERATIVE PAIN MANAGEMENT;
ADVERSE EVENTS; INHIBITORS PARECOXIB; DOUBLE-BLIND; SURGERY; VALDECOXIB;
MORPHINE; SODIUM; ACETAMINOPHEN
AB Background: This multi-centre, prospective, randomized, double-blind, placebo-controlled study was designed to test the hypotheses that parecoxib improves patients' postoperative analgesia without increasing surgical blood loss following radical open prostatectomy.
Methods: 105 patients (64 +/- 7 years old) were randomized to receive either parecoxib or placebo with concurrent morphine patient controlled analgesia. Cumulative opioid consumption (primary objective) and the overall benefit of analgesia score (OBAS), the modified brief pain inventory short form (m-BPI-sf), the opioid-related symptom distress scale (OR-SDS), and perioperative blood loss (secondary objectives) were assessed.
Results: In each group 48 patients received the study medication for 48 hours postoperatively. Parecoxib significantly reduced cumulative opioid consumption by 24% (43 +/- 24.1 mg versus 57 +/- 28 mg, mean +/- SD, p=0.02), translating into improved benefit of analgesia (OBAS: 2(0/4) versus 3(1/5.25), p=0.01), pain severity (m-BPI-sf: 1(1/2) versus 2(2/3), p < 0.01) and pain interference (m-BPI-sf: 1(0/1) versus 1(1/3), p=0.001), as well as reduced opioid-related side effects (OR-SDS score: 0.3(0.075/0.51) versus 0.4(0.2/0.83), p=0.03). Blood loss was significantly higher at 24 hours following surgery in the parecoxib group (4.3 g.dL(-1) (3.6/4.9) versus (3.2 g.dL(-1) (2.4/4.95), p=0.02).
Conclusions: Following major abdominal surgery, parecoxib significantly improves patients' perceived analgesia. Parecoxib may however increase perioperative blood loss. Further trials are needed to evaluate the effects of selective cyclooxygenase-2 inhibitors on blood loss.
C1 [Dirkmann, Daniel; Eikermann, Matthias] Univ Duisburg Essen, Univ Klinikum Essen, Klin Anesthesiol & Intensivmed, D-45144 Essen, Germany.
[Groeben, Harald] Kliniken Essen Mitte, Klin Anesthesiol Intensivmed & Schmerztherapie, D-45136 Essen, Germany.
[Farhan, Hassan; Stahl, David L.; Eikermann, Matthias] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Dirkmann, D (reprint author), Univ Duisburg Essen, Univ Klinikum Essen, Klin Anesthesiol & Intensivmed, Hufelandstr 55, D-45144 Essen, Germany.
EM Daniel.Dirkmann@uk-essen.de
RI Stahl, David/E-8015-2015
FU Pfizer, Germany
FX The study was funded by Pfizer, Germany.
NR 42
TC 8
Z9 8
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2253
J9 BMC ANESTHESIOL
JI BMC Anesthesiol.
PD MAR 9
PY 2015
VL 15
AR 31
DI 10.1186/s12871-015-0015-y
PG 9
WC Anesthesiology
SC Anesthesiology
GA CD3EF
UT WOS:000350960000001
PM 25767411
ER
PT J
AU Sharpe, HJ
Pau, G
Dijkgraaf, GJ
Basset-Seguin, N
Modrusan, Z
Januario, T
Tsui, V
Durham, AB
Dlugosz, AA
Haverty, PM
Bourgon, R
Tang, JY
Sarin, KY
Dirix, L
Fisher, DC
Rudin, CM
Sofen, H
Migden, MR
Yauch, RL
de Sauvage, FJ
AF Sharpe, Hayley J.
Pau, Gregoire
Dijkgraaf, Gerrit J.
Basset-Seguin, Nicole
Modrusan, Zora
Januario, Thomas
Tsui, Vickie
Durham, Alison B.
Dlugosz, Andrzej A.
Haverty, Peter M.
Bourgon, Richard
Tang, Jean Y.
Sarin, Kavita Y.
Dirix, Luc
Fisher, David C.
Rudin, Charles M.
Sofen, Howard
Migden, Michael R.
Yauch, Robert L.
de Sauvage, Frederic J.
TI Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell
Carcinoma
SO CANCER CELL
LA English
DT Article
ID HEDGEHOG PATHWAY INHIBITOR; PROTEIN-COUPLED RECEPTOR; MUTATIONAL
LANDSCAPE; ACQUIRED-RESISTANCE; SONIC HEDGEHOG; HUMAN HOMOLOG; CANCER;
MEDULLOBLASTOMA; VISMODEGIB; ACTIVATION
AB Smoothened (SMO) inhibitors are under clinical investigation for the treatment of several cancers. Vismodegib is approved for the treatment of locally advanced and metastatic basal cell carcinoma (BCC). Most BCC patients experience significant clinical benefit on vismodegib, but some develop resistance. Genomic analysis of tumor biopsies revealed that vismodegib resistance is associated with Hedgehog (Hh) pathway reactivation, predominantly through mutation of the drug target SMO and to a lesser extent through concurrent copy number changes in SUFU and GLI2. SMO mutations either directly impaired drug binding or activated SMO to varying levels. Furthermore, we found evidence for intra-tumor heterogeneity, suggesting that a combination of therapies targeting components at multiple levels of the Hh pathway is required to overcome resistance.
C1 [Sharpe, Hayley J.; Dijkgraaf, Gerrit J.; Januario, Thomas; Yauch, Robert L.; de Sauvage, Frederic J.] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.
[Pau, Gregoire; Haverty, Peter M.; Bourgon, Richard] Genentech Inc, Dept Bioinformat & Computat Biol, San Francisco, CA 94080 USA.
[Modrusan, Zora] Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA.
[Tsui, Vickie] Genentech Inc, Dept Discovery Chem, San Francisco, CA 94080 USA.
[Basset-Seguin, Nicole] Paris 7 Hop St Louis, F-75010 Paris, France.
[Durham, Alison B.; Dlugosz, Andrzej A.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA.
[Tang, Jean Y.; Sarin, Kavita Y.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Dirix, Luc] Univ Antwerp, Univ Antwerp Hosp, Sint Augustinus Canc Ctr, B-2610 Antwerp, Belgium.
[Fisher, David C.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Rudin, Charles M.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
[Sofen, Howard] Univ Calif Los Angeles, Sch Med, Dept Med Dermatol, Los Angeles, CA 90095 USA.
[Migden, Michael R.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
RP de Sauvage, FJ (reprint author), Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.
EM sauvage@gene.com
OI Rudin, Charles/0000-0001-5204-3465
FU NCI NIH HHS [P30 CA046592, R01 CA087837]
NR 49
TC 47
Z9 49
U1 2
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD MAR 9
PY 2015
VL 27
IS 3
BP 327
EP 341
DI 10.1016/j.ccell.2015.02.001
PG 15
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA CD3KL
UT WOS:000350977200006
PM 25759019
ER
PT J
AU Wilson, FH
Johannessen, CM
Piccioni, F
Tamayo, P
Kim, JW
Van Allen, EM
Corsello, SM
Capelletti, M
Calles, A
Butaney, M
Sharifnia, T
Gabriel, SB
Mesirov, JP
Hahn, WC
Engelman, JA
Meyerson, M
Root, DE
Janne, PA
Garraway, LA
AF Wilson, Frederick H.
Johannessen, Cory M.
Piccioni, Federica
Tamayo, Pablo
Kim, Jong Wook
Van Allen, Eliezer M.
Corsello, Steven M.
Capelletti, Marzia
Calles, Antonio
Butaney, Mohit
Sharifnia, Tanaz
Gabriel, Stacey B.
Mesirov, Jill P.
Hahn, William C.
Engelman, Jeffrey A.
Meyerson, Matthew
Root, David E.
Jaenne, Pasi A.
Garraway, Levi A.
TI A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
SO CANCER CELL
LA English
DT Article
ID HUMAN BREAST-CANCER; EGF RECEPTOR; CRIZOTINIB RESISTANCE;
ACQUIRED-RESISTANCE; KINASE INHIBITORS; TARGETED THERAPY; ACTIVATION;
CELLS; EML4-ALK; EXPRESSION
AB We conducted a large-scale functional genetic study to characterize mechanisms of resistance to ALK inhibition in ALK-dependent lung cancer cells. We identify members of known resistance pathways and additional putative resistance drivers. Among the latter were members of the P2Y purinergic receptor family of G-protein-coupled receptors (P2Y1, P2Y2, and P2Y6). P2Y receptors mediated resistance in part through a protein-kinase-C (PKC)-dependent mechanism. Moreover, PKC activation alone was sufficient to confer resistance to ALK inhibitors, whereas combined ALK and PKC inhibition restored sensitivity. We observed enrichment of gene signatures associated with several resistance drivers (including P2Y receptors) in crizotinib-resistant ALK-rearranged lung tumors compared to treatment-naive controls, supporting a role for these identified mechanisms in clinical ALK inhibitor resistance.
C1 [Wilson, Frederick H.; Kim, Jong Wook; Van Allen, Eliezer M.; Corsello, Steven M.; Capelletti, Marzia; Calles, Antonio; Butaney, Mohit; Sharifnia, Tanaz; Hahn, William C.; Meyerson, Matthew; Jaenne, Pasi A.; Garraway, Levi A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Wilson, Frederick H.; Johannessen, Cory M.; Piccioni, Federica; Tamayo, Pablo; Kim, Jong Wook; Van Allen, Eliezer M.; Corsello, Steven M.; Sharifnia, Tanaz; Gabriel, Stacey B.; Mesirov, Jill P.; Hahn, William C.; Meyerson, Matthew; Root, David E.; Garraway, Levi A.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.
[Meyerson, Matthew] Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA.
[Jaenne, Pasi A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02215 USA.
RP Garraway, LA (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
EM levi_garraway@dfci.harvard.edu
OI Calles, Antonio/0000-0002-2547-1947
FU Starr Cancer Consortium [I5-A560]; NIH [DP2 0D002750, 5R33CA155554-03,
R01 CA136851, T32 CA009172, R01 CA154480, GM074024]; Huber-Foster
fellowship; Conquer Cancer Foundation of ASCO Young Investigator Award;
AACR-Bristol-Myers Squibb Oncology Fellowship in Clinical Cancer
Research [14-40-15-WILS]; Novartis Institute for BioMedical Research;
National Human Genome Research Institute (NHGRI) [5U54HG003067-11];
National Cancer Institute (NCI) [U54 CA112962, U01 CA176058]; Melanoma
Research Foundation; LINCS program [U54 HG006093]; Novartis; Bayer
FX We thank the patients for their participation in this study. We thank
Daniel Lam, Mukta Bagul, and Thomas Nieland for technical assistance. We
thank Chandra Pedamallu and Akinyemi Ojesina for assistance with
processing RNA-seq data, as well as Deborah Farlow and Samira Bahl for
assistance in data management. We thank Ami Bhatt, David Barbie, David
Takeda, Andrew Aguirre, Yaara Zwang, Rajiv Narayan, and members of the
L.A.G. laboratory for helpful discussions. This work was supported by
the Starr Cancer Consortium (I5-A560; L.A.G.), the NIH Director's New
Innovator Award (DP2 0D002750; L.A.G.), NIH 5R33CA155554-03 (L.A.G.),
NIH R01 CA136851 (P.A.J.), NIH grant T32 CA009172 (F.H.W., S.M.C.), the
Huber-Foster fellowship (F.H.W.), the Conquer Cancer Foundation of ASCO
Young Investigator Award (F.H.W., S.M.C.), the 2014 AACR-Bristol-Myers
Squibb Oncology Fellowship in Clinical Cancer Research (grant
14-40-15-WILS; F.H.W.), a grant from the Novartis Institute for
BioMedical Research (L.A.G., W.C.H.), the National Human Genome Research
Institute (NHGRI; #5U54HG003067-11; S.B.G., L.A.G.), grants from the
National Cancer Institute (NCI; U54 CA112962 and U01 CA176058; W.C.H.),
a Career Development Award from the Melanoma Research Foundation
(C.M.J.), the LINCS program (U54 HG006093), and NIH R01 CA154480 and
GM074024 (J.P.M., P.T.).; L.A.G. is a consultant and equity holder in
Foundation Medicine. L.A.G. is a consultant to Novartis,
Millenium/Takeda, and Boehringer Ingelheim and a recipient of a grant
from Novartis. P.A.J. is a consultant/advisory board member for Abbott
Laboratories, AstraZeneca, Boehringer Ingelheim, Chugai, Clovis,
Genentech, Pfizer, and Sanofi. W.C.H. is a consultant for Novartis and
recipient of a grant from Novartis. M.M. receives research support from
Bayer and is a consultant and equity holder in Foundation Medicine.
J.A.E. is a consultant/advisory board member of Novartis, GSK,
Genentech, and AstraZeneca and a recipient of a grant from Novartis.
NR 51
TC 39
Z9 40
U1 7
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD MAR 9
PY 2015
VL 27
IS 3
BP 397
EP 408
DI 10.1016/j.ccell.2015.02.005
PG 12
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA CD3KL
UT WOS:000350977200011
PM 25759024
ER
PT J
AU Chen, HX
Guan, RN
Lei, YP
Chen, JY
Ge, Q
Zhang, XS
Dou, RX
Chen, HY
Liu, H
Qi, XL
Zhou, XD
Chen, CY
AF Chen, Hongxia
Guan, Runnian
Lei, Yupeng
Chen, Jianyong
Ge, Qi
Zhang, Xiaoshen
Dou, Ruoxu
Chen, Hongyuan
Liu, Hao
Qi, Xiaolong
Zhou, Xiaodong
Chen, Changyan
TI Lymphangiogenesis in Gastric Cancer regulated through
Akt/mTOR-VEGF-C/VEGF-D axis
SO BMC CANCER
LA English
DT Article
DE Lymphangiogenesis; Gastric cancer; Akt/mTOR; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; LYMPH-NODE METASTASIS; FACTOR-C;
PHOSPHORYLATED AKT; MAMMALIAN TARGET; DOWN-REGULATION; FACTOR (VEGF)-C;
VESSEL DENSITY; KINASE-B; EXPRESSION
AB Background: Lymphangiogenesis plays a significant role in metastasis and recurrence of gastric cancer. There is no report yet focusing on the modulation of VEGF pathway and lymphangiogenesis of gastric cancer by targeting Akt/mTOR pathway. This study aims to demonstrate the relationship between Akt/mTOR pathway and VEGF-C/-D in gastric cancer.
Methods: We collected surgically resected gastric adenocarcinoma specimens from 55 consented patients. Immunohistochemistry staining of p-Akt, p-mTOR, VEGF-C, VEGF-D were performed and scored by two independent pathologists. The results were presented as staining intensity and positive staining cell rate. We also measured lymphatic vessel density (LVD) by D2-40 staining. Different dosages of p-Akt inhibitor LY294002 (12.5 mu M, 25 mu M, 50 mu M) and p-mTOR inhibitor Rapamycin (25 nM, 50 nM, 100 nM) were given to gastric cancer cell line SGC-7901 in vitro. The inhibition rate of cell growth was tested by MTT at 24 h, 48 h and 72 h, respectively and protein expressions of Akt, p-Akt, mTOR, p-mTOR, VEGF-C and VEGF-D were examined by Western blot.
Results: The positive staining rates of p-Akt, p-mTOR, VEGF-C and VEGF-D in 55 gastric cancer clinical specimens were 74.54%, 85.45%, 72.73% and 58.18%. p-Akt and p-mTOR were positively correlated with VEGF-C and VEGF-D (p < 0.01). The LVD increased with incremental tendency of staining intensity of p-Akt, p-mTOR, VEGF-C and VEGF-D. LY294002 or Rapamycin significantly suppressed SGC-7901 cell growth and the inhibition rate was dose and time dependent (p < 0.001). In addition, the protein expression of p-Akt and p-mTOR were positively correlated with that of VEGF-C and VEGF-D (p < 0.05).
Conclusions: The level of LVD in gastric cancer specimens was significant higher than that of normal gastric tissue and was positively correlated with p-Akt, p-mTOR, VEGF-C and VEGF-D. Inhibition of p-Akt and p-mTOR, in vitro, decreased tumor cell VEGF-C and VEGF-D significantly. Therefore, we concluded that lymphangiogenesis of gastric cancer might be related to Akt/mTOR-VEGF-C/VEGF-D axis.
C1 [Chen, Hongxia; Lei, Yupeng; Ge, Qi; Qi, Xiaolong; Zhou, Xiaodong; Chen, Changyan] Nanchang Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanchang 330006, Peoples R China.
[Guan, Runnian] Kaiping Cent Hosp, Dept Gastroenterol, Kaiping 529300, Peoples R China.
[Chen, Jianyong] Jiangxi Prov Peoples Hosp, Dept Gastroenterol, Nanchang 330006, Peoples R China.
[Zhang, Xiaoshen; Dou, Ruoxu; Liu, Hao; Qi, Xiaolong] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Zhang, Xiaoshen; Dou, Ruoxu; Liu, Hao; Qi, Xiaolong] Harvard Univ, Sch Med, Boston, MA USA.
[Chen, Hongyuan] Guangdong Pharmaceut Univ, Sch Basic Course, Dept Pathogen Biol & Immunol, Guangzhou 510060, Guangdong, Peoples R China.
[Chen, Changyan] Northeastern Univ, Ctr Drug Discovery, Boston, MA 02115 USA.
RP Qi, XL (reprint author), Nanchang Univ, Affiliated Hosp 1, Dept Gastroenterol, 17 Yongwaizheng St, Nanchang 330006, Peoples R China.
EM qixiaolongmd@gmail.com; yfyzxd@163.com
FU National Science Foundation Grants of China [81160307]; Jiangxi Science
& Technology Pillar Program; Science Foundation for Young Scholars of
Jiangxi Province [2007GQY1167]; Voyage Project of Jiangxi Province
Science and Technology Association
FX The study was supported by funding from National Science Foundation
Grants of China (No. 81160307); Jiangxi Science & Technology Pillar
Program and the Science Foundation for Young Scholars of Jiangxi
Province (No. 2007GQY1167); Voyage Project of Jiangxi Province Science
and Technology Association.
NR 29
TC 8
Z9 10
U1 3
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAR 7
PY 2015
VL 15
AR 103
DI 10.1186/s12885-015-1109-0
PG 7
WC Oncology
SC Oncology
GA CD1WJ
UT WOS:000350864900001
PM 25884175
ER
PT J
AU Doolan, PJ
Testa, M
Sharp, G
Bentefour, EH
Royle, G
Lu, HM
AF Doolan, P. J.
Testa, M.
Sharp, G.
Bentefour, E. H.
Royle, G.
Lu, H-M
TI Patient-specific stopping power calibration for proton therapy planning
based on single-detector proton radiography
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE proton radiography; proton therapy; treatment planning; stoichiometric;
calibration
ID MONTE-CARLO SIMULATIONS; VIVO RANGE VERIFICATION; CT-HOUNSFIELD UNITS;
HEAVY-ION CT; COMPUTED-TOMOGRAPHY; TISSUE; SYSTEM; PATH; UNCERTAINTIES;
PRINCIPLE
AB A simple robust optimizer has been developed that can produce patient-specific calibration curves to convert x-ray computed tomography (CT) numbers to relative stopping powers (HU-RSPs) for proton therapy treatment planning. The difference between a digitally reconstructed radiograph water-equivalent path length (DRRWEPL) map through the x-ray CT dataset and a proton radiograph (set as the ground truth) is minimized by optimizing the HU-RSP calibration curve. The function of the optimizer is validated with synthetic datasets that contain no noise and its robustness is shown against CT noise. Application of the procedure is then demonstrated on a plastic and a real tissue phantom, with proton radiographs produced using a single detector. The mean errors using generic/optimized calibration curves between the DRRWEPL map and the proton radiograph were 1.8/0.4% for a plastic phantom and -2.1/-0.2% for a real tissue phantom. It was then demonstrated that these optimized calibration curves offer a better prediction of the water equivalent path length at a therapeutic depth. We believe that these promising results are suggestive that a single proton radiograph could be used to generate a patient-specific calibration curve as part of the current proton treatment planning workflow.
C1 [Doolan, P. J.; Royle, G.] UCL, Dept Med Phys & Bioengn, London, England.
[Testa, M.; Sharp, G.; Lu, H-M] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Bentefour, E. H.] IBA, B-1348 Louvain, Belgium.
RP Doolan, PJ (reprint author), UCL, Dept Med Phys & Bioengn, London, England.
EM paul.doolan.09@ucl.ac.uk
FU Engineering and Physical Sciences Research Council (UK); Ion Beam
Applications (Louvain-La-Neuve, Belgium); NIH/NCI [PO1 CA21239]
FX PD was funded by the Engineering and Physical Sciences Research Council
(UK) and Ion Beam Applications (Louvain-La-Neuve, Belgium). MT was
funded by grant number NIH/NCI PO1 CA21239. We would also like to
acknowledge the operators at Massachusetts General Hospital and
Savenor's Butchers, who helped in the construction of the real tissue
phantom.
NR 35
TC 10
Z9 10
U1 1
U2 7
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD MAR 7
PY 2015
VL 60
IS 5
BP 1901
EP 1917
DI 10.1088/0031-9155/60/5/1901
PG 17
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA CB3LZ
UT WOS:000349530700012
PM 25668437
ER
PT J
AU Wulker, C
Sitek, A
Prevrhal, S
AF Wuelker, Christian
Sitek, Arkadiusz
Prevrhal, Sven
TI Time-of-flight PET image reconstruction using origin ensembles
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE positron emission tomography; reconstruction algorithms; Bayesian
reconstruction; Markov chain Monte Carlo methods
ID SINGLE SCATTER SIMULATION; EMISSION-TOMOGRAPHY; VOLUME ELEMENTS; EM
ALGORITHM; LIKELIHOOD; CHAINS; MCMC
AB The origin ensemble (OE) algorithm is a novel statistical method for minimummean- square-error (MMSE) reconstruction of emission tomography data. This method allows one to perform reconstruction entirely in the image domain, i.e. without the use of forward and backprojection operations. We have investigated the OE algorithm in the context of list-mode (LM) time-of-flight (TOF) PET reconstruction. In this paper, we provide a general introduction to MMSE reconstruction, and a statistically rigorous derivation of the OE algorithm. We show how to efficiently incorporate TOF information into the reconstruction process, and how to correct for random coincidences and scattered events. To examine the feasibility of LM-TOF MMSE reconstruction with the OE algorithm, we applied MMSE-OE and standard maximum-likelihood expectation-maximization (ML-EM) reconstruction to LM-TOF phantom data with a count number typically registered in clinical PET examinations. We analyzed the convergence behavior of the OE algorithm, and compared reconstruction time and image quality to that of the EM algorithm. In summary, during the reconstruction process, MMSE-OE contrast recovery (CRV) remained approximately the same, while background variability (BV) gradually decreased with an increasing number of OE iterations. The final MMSE-OE images exhibited lower BV and a slightly lower CRV than the corresponding ML-EM images. The reconstruction time of the OE algorithm was approximately 1.3 times longer. At the same time, the OE algorithm can inherently provide a comprehensive statistical characterization of the acquired data. This characterization can be utilized for further data processing, e. g. in kinetic analysis and image registration, making the OE algorithm a promising approach in a variety of applications.
C1 [Wuelker, Christian] Heidelberg Univ, Med Fac Mannheim, D-68167 Mannheim, Germany.
[Sitek, Arkadiusz] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Prevrhal, Sven] Philips Res Labs Hamburg, Dept Digital Imaging, D-22335 Hamburg, Germany.
RP Wulker, C (reprint author), Heidelberg Univ, Med Fac Mannheim, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM christian.wuelker@gmx.de; sarkadiu@gmail.com; sven.prevrhal@philips.com
OI Sitek, Arkadiusz/0000-0002-0677-4002
FU NHLBI NIH HHS [R21 HL106474]
NR 34
TC 2
Z9 2
U1 0
U2 8
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD MAR 7
PY 2015
VL 60
IS 5
BP 1919
EP 1944
DI 10.1088/0031-9155/60/5/1919
PG 26
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA CB3LZ
UT WOS:000349530700013
PM 25668558
ER
PT J
AU Jovanovic, M
Rooney, MS
Mertins, P
Przybylski, D
Chevrier, N
Satija, R
Rodriguez, EH
Fields, AP
Schwartz, S
Raychowdhury, R
Mumbach, MR
Eisenhaure, T
Rabani, M
Gennert, D
Lu, DN
Delorey, T
Weissman, JS
Carr, SA
Hacohen, N
Regev, A
AF Jovanovic, Marko
Rooney, Michael S.
Mertins, Philipp
Przybylski, Dariusz
Chevrier, Nicolas
Satija, Rahul
Rodriguez, Edwin H.
Fields, Alexander P.
Schwartz, Schraga
Raychowdhury, Raktima
Mumbach, Maxwell R.
Eisenhaure, Thomas
Rabani, Michal
Gennert, Dave
Lu, Diana
Delorey, Toni
Weissman, Jonathan S.
Carr, Steven A.
Hacohen, Nir
Regev, Aviv
TI Dynamic profiling of the protein life cycle in response to pathogens
SO SCIENCE
LA English
DT Article
ID DENDRITIC CELL ACTIVATION; MESSENGER-RNA; TEMPORAL DYNAMICS; REVEALS;
EXPRESSION; TRANSLATION; YEAST; PRINCIPLES; PROTEOMES; ABUNDANCE
AB Protein expression is regulated by the production and degradation of messenger RNAs (mRNAs) and proteins, but their specific relationships remain unknown. We combine measurements of protein production and degradation and mRNA dynamics so as to build a quantitative genomic model of the differential regulation of gene expression in lipopolysaccharide-stimulated mouse dendritic cells. Changes in mRNA abundance play a dominant role in determining most dynamic fold changes in protein levels. Conversely, the preexisting proteome of proteins performing basic cellular functions is remodeled primarily through changes in protein production or degradation, accounting for more than half of the absolute change in protein molecules in the cell. Thus, the proteome is regulated by transcriptional induction for newly activated cellular functions and by protein life-cycle changes for remodeling of preexisting functions.
C1 [Jovanovic, Marko; Rooney, Michael S.; Mertins, Philipp; Przybylski, Dariusz; Chevrier, Nicolas; Satija, Rahul; Schwartz, Schraga; Raychowdhury, Raktima; Mumbach, Maxwell R.; Eisenhaure, Thomas; Rabani, Michal; Gennert, Dave; Lu, Diana; Delorey, Toni; Carr, Steven A.; Hacohen, Nir; Regev, Aviv] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Rooney, Michael S.] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Chevrier, Nicolas] Harvard Univ, Harvard Fac Arts & Sci, Ctr Syst Biol, Cambridge, MA 02138 USA.
[Rodriguez, Edwin H.; Fields, Alexander P.; Weissman, Jonathan S.] Univ Calif San Francisco, Calif Inst Quantitat Biomed Res, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA.
[Eisenhaure, Thomas; Hacohen, Nir] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
[Weissman, Jonathan S.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA.
[Hacohen, Nir] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Regev, Aviv] MIT, Dept Biol, Cambridge, MA 02140 USA.
[Regev, Aviv] MIT, Dept Biol, HHMI, Cambridge, MA 02140 USA.
RP Regev, A (reprint author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
EM nhacohen@mgh.harvard.edu; aregev@broad.mit.edu
FU National Human Genome Research Institute Centers of Excellence in
Genomics Science [P50 HG006193]; Broad Institute Funds; NIH Pioneer
Award; Klarman Cell Observatory; HHMI; Swiss National Science Foundation
(SNF); Marie Sklodowska-Curie International Outgoing Fellowships; NIH
Training Program in Bioinformatics and Integrative Genomics training
grant; Rothschild Fellowship; European Molecular Biology Organization
fellowship; Human Frontier Science Program fellowships; Howard Hughes
Medical Institute Gilliam Fellowship for Advanced Study
FX We thank members of the Regev, Hacohen, and Carr groups, as well as G.
Brar, N. Slavov, and E. Airoldi for constant input and discussions. We
thank L. Gaffney for help with the figures and K. Lage and A. Kashani
for help with some of the analyses. This work was supported by National
Human Genome Research Institute Centers of Excellence in Genomics
Science P50 HG006193 (A.R, N.H., S.A.C.) and Broad Institute Funds. A.R.
was supported by an NIH Pioneer Award, the Klarman Cell Observatory, and
HHMI. M.J. was supported by fellowships of the Swiss National Science
Foundation for advanced researchers (SNF) and the Marie Sklodowska-Curie
International Outgoing Fellowships. M.S.R. was supported by the NIH
Training Program in Bioinformatics and Integrative Genomics training
grant. S.S. was supported by a Rothschild Fellowship, a European
Molecular Biology Organization fellowship, and Human Frontier Science
Program fellowships. E.H.R. was supported by the Howard Hughes Medical
Institute Gilliam Fellowship for Advanced Study. Data have been
deposited in the Gene Expression Omnibus under accession number
GSE59793. The original mass spectra, may be downloaded from MassIVE
(http://massive.ucsd.edu) using the identifier MSV000078994. The data
are accessible at ftp://MSV000078994:a@massive.ucsd.edu. DogmaQuant is
distributed under open source (BSD) license.
NR 56
TC 58
Z9 58
U1 4
U2 16
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAR 6
PY 2015
VL 347
IS 6226
AR 1259038
DI 10.1126/science.1259038
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC4WB
UT WOS:000350354200045
PM 25745177
ER
PT J
AU Sharma, RK
Baehr, W
Makino, CL
Duda, T
AF Sharma, Rameshwar K.
Baehr, Wolfgang
Makino, Clint L.
Duda, Teresa
TI Ca2+ and Ca2+-interlocked membrane guanylate cyclase signal modulation
of neuronal and cardiovascular signal transduction
SO Frontiers in Molecular Neuroscience
LA English
DT Editorial Material
DE cyclic GMP; Ca2+; membrane guanylate cyclase; multiple transduction
modes; signal transduction
ID GENE-THERAPY; INSIGHTS; ACTIVATION; MUTATIONS; MODELS; GCAP1; SHAPE
C1 [Sharma, Rameshwar K.; Duda, Teresa] Salus Univ, Unit Regulatory & Mol Biol, Res Div Biochem & Mol Biol, Elkins Pk, PA 19027 USA.
[Baehr, Wolfgang] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
[Makino, Clint L.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Makino, Clint L.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Sharma, RK (reprint author), Salus Univ, Unit Regulatory & Mol Biol, Res Div Biochem & Mol Biol, Elkins Pk, PA 19027 USA.
EM rsharma@salus.edu
OI Makino, Clint/0000-0002-6005-9069
NR 16
TC 2
Z9 2
U1 0
U2 2
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5099
J9 FRONT MOL NEUROSCI
JI Front. Molec. Neurosci.
PD MAR 6
PY 2015
VL 8
AR 7
DI 10.3389/fnmol.2015.00007
PG 2
WC Neurosciences
SC Neurosciences & Neurology
GA CG6HW
UT WOS:000353401400001
PM 25798085
ER
PT J
AU Jacobo, SMP
Kazlauskas, A
AF Jacobo, Sarah Melissa P.
Kazlauskas, Andrius
TI Insulin-like Growth Factor 1 (IGF-1) Stabilizes Nascent Blood Vessels
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID FACTOR-I RECEPTOR; LYSOPHOSPHATIDIC ACID; ENDOTHELIAL-CELLS; RETINAL
NEOVASCULARIZATION; VASCULAR MORPHOGENESIS; DIABETIC-RETINOPATHY;
ANGIOGENESIS; ACTIVATION; REGRESSION; MIGRATION
AB Here we report that VEGF-A and IGF-1 differ in their ability to stabilize newly formed blood vessels and endothelial cell tubes. Although VEGF-A failed to support an enduring vascular response, IGF-1 stabilized neovessels generated from primary endothelial cells derived from various vascular beds and mouse retinal explants. In these experimental systems, destabilization/regression was driven by lysophosphatidic acid (LPA). Because previous studies have established that Erk antagonizes LPA-mediated regression, we considered whether Erk was an essential component of IGF-dependent stabilization. Indeed, IGF-1 lost its ability to stabilize neovessels when the Erk pathway was inhibited pharmacologically. Furthermore, stabilization was associated with prolonged Erk activity. In the presence of IGF-1, Erk activity persisted longer than in the presence of VEGF or LPA alone. These studies reveal that VEGF and IGF-1 can have distinct inputs in the angiogenic process. In contrast to VEGF, IGF-1 stabilizes neovessels, which is dependent on Erk activity and associated with prolonged activation.
C1 [Kazlauskas, Andrius] Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA 02115 USA.
Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
RP Kazlauskas, A (reprint author), Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA 02115 USA.
EM andrius_kazlauskas@meei.harvard.edu
OI Jacobo, Sarah Melissa/0000-0002-1341-7222
FU Knights Templar Eye Foundation Early Career Award
FX This work was supported by a Knights Templar Eye Foundation Early Career
Award (to S. M. P. J.).
NR 53
TC 8
Z9 9
U1 1
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 6
PY 2015
VL 290
IS 10
BP 6349
EP 6360
DI 10.1074/jbc.M114.634154
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CD0AO
UT WOS:000350732500040
PM 25564613
ER
PT J
AU Abou Hassan, OK
Fahed, AC
Batrawi, M
Arabi, M
Refaat, MM
DePalma, SR
Seidman, JG
Seidman, CE
Bitar, FF
Nemer, GM
AF Abou Hassan, Ossama K.
Fahed, Akl C.
Batrawi, Manal
Arabi, Mariam
Refaat, Marwan M.
DePalma, Steven R.
Seidman, J. G.
Seidman, Christine E.
Bitar, Fadi F.
Nemer, Georges M.
TI NKX2-5 Mutations in an Inbred Consanguineous Population: Genetic and
Phenotypic Diversity
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CONGENITAL HEART-DISEASE; CARDIAC CONDUCTION SYSTEM;
ATRIAL-FIBRILLATION; TRANSCRIPTION FACTORS; PRESSURE-OVERLOAD;
HOMEODOMAIN; ASSOCIATION; DEFECTS; NETWORK; BLOCK
AB NKX2-5 mutations are associated with different forms of congenital heart disease. Despite the knowledge gained from molecular and animal studies, genotype-phenotype correlations in humans are limited by the lack of large cohorts and the incomplete assessment of family members. We hypothesized that studying the role of NKX2-5 in inbred populations with homogeneous genetic backgrounds and high consanguinity rates such as Lebanon could help closing this gap. We sequenced NKX2-5 in 188 index CHD cases (25 with ASD). Five variants (three segregated in families) were detected in eleven families including the previously documented p.R25C variant, which was found in seven patients from different families, and in one healthy individual. In 3/5 familial dominant ASD cases, we identified an NKX2-5 mutation. In addition to the heterogeneity of NKX2-5 mutations, a diversity of phenotypes occurred within the families with predominant ASD and AV block. We did in fact identify a large prevalence of Sudden Cardiac Death (SCD) in families with truncating mutations, and two patients with coronary sinus disease. NKX2-5 is thus responsible for dominant familial ASD even in consanguineous populations, and a wide genetic and phenotypic diversity is characteristic of NKX2-5 mutations in the Lebanese population.
C1 [Abou Hassan, Ossama K.; Batrawi, Manal; Refaat, Marwan M.; Bitar, Fadi F.; Nemer, Georges M.] Amer Univ Beirut, Dept Biochem & Mol Genet, Beirut, Lebanon.
[Fahed, Akl C.; DePalma, Steven R.; Seidman, J. G.; Seidman, Christine E.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Fahed, Akl C.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Arabi, Mariam; Bitar, Fadi F.] Amer Univ Beirut, Dept Pediat & Adolescent Med, Beirut, Lebanon.
[Refaat, Marwan M.] Amer Univ Beirut, Dept Internal Med, Beirut, Lebanon.
[Seidman, J. G.] Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Seidman, J. G.] Brigham & Womens Hosp, Div Cardiol, Boston, MA 02115 USA.
RP Bitar, FF (reprint author), Amer Univ Beirut, Dept Biochem & Mol Genet, Beirut, Lebanon.
EM fadi.bitar@aub.edu.lb; georges.nemer@aub.edu.lb
OI Nemer, Georges/0000-0003-2157-5279
FU Dubai Harvard Foundation for Medical Research (DHFMR)
FX We thank the families for their contribution to this research. We also
thank members of the Congenital Heart Disease Genetic Program (CHDGP)
especially Ms. Jane Bou Diab, and Ms. Inaam El-Rassy from the Molecular
Core Facility at AUB for their technical assistance. This work is
supported by a grant from the Dubai Harvard Foundation for Medical
Research (DHFMR). We are also grateful for Dr. Alexander G. Bick for his
help with CNV analysis.
NR 52
TC 4
Z9 4
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 6
PY 2015
VL 5
AR 8848
DI 10.1038/srep08848
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC6LM
UT WOS:000350476400001
PM 25742962
ER
PT J
AU Schram, AM
Campigotto, F
Mullally, A
Fogerty, A
Massarotti, E
Neuberg, D
Berliner, N
AF Schram, Alison M.
Campigotto, Federico
Mullally, Ann
Fogerty, Annemarie
Massarotti, Elena
Neuberg, Donna
Berliner, Nancy
TI Marked hyperferritinemia does not predict for HLH in the adult
population
SO BLOOD
LA English
DT Article
ID SERUM FERRITIN LEVELS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS;
IRON-DEFICIENCY; ANTIPHOSPHOLIPID SYNDROME; CELLULAR-REGULATION;
STILLS-DISEASE; DIAGNOSIS; GUIDELINES; OVERLOAD
AB Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome of uncontrolled immune activation that has gained increasing attention during the last decade. The diagnosis of HLH is based on a constellation of clinical and laboratory abnormalities, including elevated serum ferritin levels. In the pediatric population, marked hyperferritinemia is specific for HLH. To determine what conditions are associated with profoundly elevated ferritin in the adult population, we performed a retrospective analysis in a large academic health care system. We identified 113 patients with serum ferritin levels higher than 50 000 mu g/L. The most frequently observed conditions included renal failure, hepatocellular injury, infections, and hematologic malignancies. Our results suggest that marked hyperferritinemia can be seen in a variety of conditions and is not specific for HLH in adults.
C1 [Schram, Alison M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[Campigotto, Federico; Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Mullally, Ann; Berliner, Nancy] Harvard Univ, Brigham & Womens Hosp, Div Hematol, Dept Med,Med Sch, Boston, MA 02115 USA.
[Fogerty, Annemarie] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Hematol,Dept Med, Boston, MA USA.
[Massarotti, Elena] Harvard Univ, Brigham & Womens Hosp, Dept Med, Div Rheumatol,Med Sch, Boston, MA 02115 USA.
RP Berliner, N (reprint author), Brigham & Womens Hosp, Div Hematol, 75 Francis St,Midcampus 3, Boston, MA 02115 USA.
EM nberliner@partners.org
OI Schram, Alison/0000-0002-6070-2413
NR 30
TC 25
Z9 26
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAR 5
PY 2015
VL 125
IS 10
BP 1548
EP 1552
DI 10.1182/blood-2014-10-602607
PG 5
WC Hematology
SC Hematology
GA CI3AM
UT WOS:000354619800012
PM 25573993
ER
PT J
AU Dahlem, MA
Schmidt, B
Bojak, I
Boie, S
Kneer, F
Hadjikhani, N
Kurths, J
AF Dahlem, Markus A.
Schmidt, Bernd
Bojak, Ingo
Boie, Sebastian
Kneer, Frederike
Hadjikhani, Nouchine
Kurths, Juergen
TI Cortical hot spots and labyrinths: why cortical neuromodulation for
episodic migraine with aura should be personalized
SO FRONTIERS IN COMPUTATIONAL NEUROSCIENCE
LA English
DT Article
DE migraine; reaction-diffusion; spreading depression; gyrification;
neuromodulation
ID REACTION-DIFFUSION SYSTEMS; SURFACE-BASED ANALYSIS; PRIMARY
VISUAL-CORTEX; SPREADING DEPRESSION; CURVED SURFACES; CEREBRAL-CORTEX;
INTERSUBJECT VARIABILITY; COORDINATE SYSTEM; EXCITATION WAVES;
AUDITORY-CORTEX
AB Stimulation protocols for medical devices should be rationally designed. For episodic migraine with aura we outline model-based design strategies toward preventive and acute therapies using stereotactic cortical neuromodulation. To this end, we regard a localized spreading depression (SD) wave segment as a central element in migraine pathophysiology. To describe nucleation and propagation features of the SD wave segment, we define the new concepts of cortical hot spots and labyrinths, respectively. In particular, we firstly focus exclusively on curvature-induced dynamical properties by studying a generic reaction-diffusion model of SD on the folded cortical surface. This surface is described with increasing level of details, including finally personalized simulations using patient's magnetic resonance imaging (MRI) scanner readings. At this stage, the only relevant factor that can modulate nucleation and propagation paths is the Gaussian curvature, which has the advantage of being rather readily accessible by MRI. We conclude with discussing further anatomical factors, such as areal, laminar, and cellular heterogeneity, that in addition to and in relation to Gaussian curvature determine the generalized concept of cortical hot spots and labyrinths as target structures for neuromodulation. Our numerical simulations suggest that these target structures are like fingerprints, they are individual features of each migraine sufferer. The goal in the future will be to provide individualized neural tissue simulations. These simulations should predict the clinical data and therefore can also serve as a test bed for exploring stereotactic cortical neuromodulation.
C1 [Dahlem, Markus A.; Schmidt, Bernd; Kurths, Juergen] Humboldt Univ, Dept Phys, D-10115 Berlin, Germany.
[Dahlem, Markus A.] Max Planck Inst Phys Komplexer Syst, Dept Biol Phys, Dresden, Germany.
[Bojak, Ingo] Univ Reading, Sch Syst Engn, Cybernet Res Grp, Reading, Berks, England.
[Boie, Sebastian] Univ Auckland, Dept Math, Auckland 1, New Zealand.
[Kneer, Frederike] Tech Univ Berlin, Dept Software Engn & Theoret Comp Sci, Berlin, Germany.
[Hadjikhani, Nouchine] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Kurths, Juergen] Potsdam Inst Climate Impact Res, Potsdam, Germany.
[Kurths, Juergen] Univ Aberdeen, Inst Complex Syst & Math Biol, Aberdeen, Scotland.
RP Dahlem, MA (reprint author), Humboldt Univ, AG NLD Cardiovasc Phys, Robert Koch Pl 4, D-10115 Berlin, Germany.
EM dahlem@physik.hu-berlin.de
RI Bojak, Ingo/E-9759-2010;
OI Bojak, Ingo/0000-0003-1765-3502; Hadjikhani,
Nouchine/0000-0003-4075-3106; Boie, Sebastian/0000-0001-7993-7901
FU Bun desministerium fur Bildung und Forschung [BMBF 01GQ1109, BMBF
01GQ1001A]
FX This work was supported by the Bun desministerium fur Bildung und
Forschung (BMBF 01GQ1109 and BMBF 01GQ1001A).
NR 84
TC 2
Z9 2
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1662-5188
J9 FRONT COMPUT NEUROSC
JI Front. Comput. Neurosci.
PD MAR 5
PY 2015
VL 9
AR UNSP 29
DI 10.3389/fncom.2015.00029
PG 13
WC Mathematical & Computational Biology; Neurosciences
SC Mathematical & Computational Biology; Neurosciences & Neurology
GA CF3QA
UT WOS:000352462400001
PM 25798103
ER
PT J
AU Barclay, LA
Wales, TE
Garner, TP
Wachter, F
Lee, S
Guerra, RM
Stewart, ML
Braun, CR
Bird, GH
Gavathiotis, E
Engen, JR
Walensky, LD
AF Barclay, Lauren A.
Wales, Thomas E.
Garner, Thomas P.
Wachter, Franziska
Lee, Susan
Guerra, Rachel M.
Stewart, Michelle L.
Braun, Craig R.
Bird, Gregory H.
Gavathiotis, Evripidis
Engen, John R.
Walensky, Loren D.
TI Inhibition of Pro-Apoptotic BAX by a Noncanonical Interaction Mechanism
SO MOLECULAR CELL
LA English
DT Article
ID BCL-2 FAMILY; BIOPHYSICAL CHARACTERIZATION; PROTEIN INTERACTIONS;
HYDROGEN-EXCHANGE; MASS-SPECTROMETRY; PROAPOPTOTIC BAX; BH4 DOMAIN;
IN-VIVO; ACTIVATION; PEPTIDES
AB BCL-2 is a negative regulator of apoptosis implicated in homeostatic and pathologic cell survival. The canonical anti-apoptotic mechanism involves entrapment of activated BAX by a groove on BCL-2, preventing BAX homo-oligomerization and mitochondrial membrane poration. The BCL-2 BH4 domain also confers anti-apoptotic functionality, but the mechanism is unknown. We find that a synthetic a-helical BH4 domain binds to BAX with nanomolar affinity and independently inhibits the conformational activation of BAX. Hydrogen-deuterium exchange mass spectrometry demonstrated that the N-terminal conformational changes in BAX induced by a triggering BIM BH3 helix were suppressed by the BCL-2 BH4 helix. Structural analyses localized the BH4 interaction site to a groove formed by residues of alpha 1, alpha 1-alpha 2 loop, and alpha 2-alpha 3 and alpha 5-alpha 6 hairpins on the BAX surface. These data reveal a previously unappreciated binding site for targeted inhibition of BAX and suggest that the BCL-2 BH4 domain may participate in apoptosis blockade by a noncanonical interaction mechanism.
C1 [Barclay, Lauren A.; Wachter, Franziska; Lee, Susan; Guerra, Rachel M.; Stewart, Michelle L.; Braun, Craig R.; Bird, Gregory H.; Walensky, Loren D.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
[Barclay, Lauren A.; Wachter, Franziska; Lee, Susan; Guerra, Rachel M.; Stewart, Michelle L.; Braun, Craig R.; Bird, Gregory H.; Walensky, Loren D.] Dana Farber Canc Inst, Linde Program Canc Chem Biol, Boston, MA 02215 USA.
[Wales, Thomas E.; Engen, John R.] Northeastern Univ, Barnett Inst Chem & Biol Anal, Dept Chem & Chem Biol, Boston, MA 02115 USA.
[Garner, Thomas P.; Gavathiotis, Evripidis] Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA.
RP Walensky, LD (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
EM loren_walensky@dfci.harvard.edu
FU NIH [5R01CA050239, 5R01GM090299, R01GM086507, R01GM101135, R00HL095929];
NSF; Kimmel Scholar Award; Sinsheimer Scholar Award; NYSTAR;
[T32GM007306]
FX We thank E. Smith for editorial and graphics assistance, and S. Cahill
for NMR technical support (Albert Einstein College of Medicine
Structural NMR Resource). This work was supported by NIH grants
5R01CA050239 and 5R01GM090299 to L.D.W., NIH grants R01GM086507 and
R01GM101135 to J.R.E., an NSF Graduate Research Fellowship to L.A.B.,
additional support to L.A.B. from T32GM007306, and NIH grant
R00HL095929, a Kimmel Scholar Award, and a Sinsheimer Scholar Award to
E.G. Additionally, E.G is a member of the New York Structural Biology
Center (NYSBC), and the data collected at NYSBC was made possible by a
grant from NYSTAR. L.D.W. is a scientific advisory board member and
consultant for Aileron Therapeutics. J.R.E. is a consultant for the
Waters Corporation.
NR 36
TC 22
Z9 23
U1 0
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD MAR 5
PY 2015
VL 57
IS 5
BP 873
EP 886
DI 10.1016/j.molcel.2015.01.014
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CE3GO
UT WOS:000351714900012
PM 25684204
ER
PT J
AU McMillan, BJ
Schnute, B
Ohlenhard, N
Zimmerman, B
Miles, L
Beglova, N
Klein, T
Blacklow, SC
AF McMillan, Brian J.
Schnute, Bjoern
Ohlenhard, Nadja
Zimmerman, Brandon
Miles, Laura
Beglova, Natalia
Klein, Thomas
Blacklow, Stephen C.
TI A Tail of Two Sites: A Bipartite Mechanism for Recognition of Notch
Ligands by Mind Bomb E3 Ligases
SO MOLECULAR CELL
LA English
DT Article
ID UBIQUITIN LIGASE; INTRACELLULAR MOTIFS; DROSOPHILA; DELTA; SERRATE;
ENDOCYTOSIS; PROTEIN; SYSTEM; DIFFERENTIATION; MORPHOGENESIS
AB Mind bomb (Mib) proteins are large, multi-domain E3 ligases that promote ubiquitination of the cytoplasmic tails of Notch ligands. This ubiquitination step marks the ligand proteins for epsin-dependent endocytosis, which is critical for in vivo Notch receptor activation. We present here crystal structures of the substrate recognition domains of Mib1, both in isolation and in complex with peptides derived from Notch ligands. The structures, in combination with biochemical, cellular, and in vivo assays, show that Mib1 contains two independent substrate recognition domains that engage two distinct epitopes from the cytoplasmic tail of the ligand Jagged1, one in the intracellular membrane proximal region and the other near the C terminus. Together, these studies provide insights into the mechanism of ubiquitin transfer by Mind bomb E3 ligases, illuminate a key event in ligand-induced activation of Notch receptors, and identify a potential target for therapeutic modulation of Notch signal transduction in disease.
C1 [McMillan, Brian J.; Zimmerman, Brandon; Miles, Laura; Beglova, Natalia; Blacklow, Stephen C.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Schnute, Bjoern; Ohlenhard, Nadja; Klein, Thomas] Univ Dusseldorf, D-40225 Dusseldorf, Germany.
[Zimmerman, Brandon; Miles, Laura; Blacklow, Stephen C.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Beglova, Natalia] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Blacklow, SC (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.
EM Stephen_Blacklow@hms.harvard.edu
FU NIH [P01 CA119070, R01 CA092433]; American Cancer Society fellowship
[120246-PF-11-044-01-DMC]; Deutsche Forschungsgemeinschaft (DFG) [KL
1028/3-1]; U.S. DOE [DE-AC02-06CH11357]
FX This work was supported in part by NIH grants P01 CA119070 (Subproject 3
to S.C.B.) and R01 CA092433 (to S.C.B.) and by American Cancer Society
fellowship 120246-PF-11-044-01-DMC (to B.J.M). The work of T.K., B.S.,
and N.O. was supported by the Deutsche Forschungsgemeinschaft (DFG)
through Sachbeihilfe KL 1028/3-1. X-ray crystallography was performed at
the Advanced Photon Source, an Office of Science User Facility supported
by the U.S. DOE under Contract No. DE-AC02-06CH11357. SAXS was conducted
at the Advanced Light Source (ALS), a national user facility supported
by the DOE. We thank Kelly Arnett for helpful discussions and critical
review of the manuscript.
NR 43
TC 5
Z9 5
U1 0
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD MAR 5
PY 2015
VL 57
IS 5
BP 912
EP 924
DI 10.1016/j.molcel.2015.01.019
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CE3GO
UT WOS:000351714900015
PM 25747658
ER
PT J
AU Orkin, SH
AF Orkin, Stuart H.
TI 2014 William Allan Award: A Hematologist's Pursuit of Hemoglobin
Genetics
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Editorial Material
ID BETA-GLOBIN GENE; SICKLE-CELL-DISEASE; FETAL-HEMOGLOBIN; DNA; BCL11A;
ASSOCIATION; THALASSEMIA; EXPRESSION; MUTATION; LINEAGE
C1 [Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp,Canc & Blood Disorders Ctr, Boston, MA 02215 USA.
[Orkin, Stuart H.] Howard Hughes Med Inst, Boston, MA 02215 USA.
RP Orkin, SH (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp,Canc & Blood Disorders Ctr, Boston, MA 02215 USA.
EM stuart_orkin@dfci.harvard.edu
NR 20
TC 0
Z9 0
U1 0
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD MAR 5
PY 2015
VL 96
IS 3
BP 354
EP 360
DI 10.1016/j.ajhg.2014.12.007
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA CD0GD
UT WOS:000350747800003
PM 25748351
ER
PT J
AU Palotie, A
AF Palotie, Aarno
TI 2014 Curt Stern Award Introduction: Mark Daly
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Editorial Material
C1 [Palotie, Aarno] Univ Helsinki, Inst Mol Med Finland, FIN-00014 Helsinki, Finland.
[Palotie, Aarno] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Palotie, Aarno] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Palotie, Aarno] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Palotie, Aarno] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA.
[Palotie, Aarno] Massachusetts Gen Hosp, Dept Psychiat, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
[Palotie, Aarno] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Palotie, A (reprint author), Univ Helsinki, Inst Mol Med Finland, FIN-00014 Helsinki, Finland.
EM aarno.palotie@helsinki.fi
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD MAR 5
PY 2015
VL 96
IS 3
BP 367
EP 368
DI 10.1016/j.ajhg.2014.12.018
PG 2
WC Genetics & Heredity
SC Genetics & Heredity
GA CD0GD
UT WOS:000350747800006
PM 25748354
ER
PT J
AU Daly, MJ
AF Daly, Mark J.
TI 2014 Curt Stern Award: A Tryst with Genetics
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Editorial Material
C1 [Daly, Mark J.] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Daly, Mark J.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Daly, Mark J.] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA.
[Daly, Mark J.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Daly, Mark J.] Univ Helsinki, Inst Mol Med Finland, FIN-00014 Helsinki, Finland.
RP Daly, MJ (reprint author), Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
EM mjdaly@atgu.mgh.harvard.edu
NR 0
TC 1
Z9 1
U1 0
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD MAR 5
PY 2015
VL 96
IS 3
BP 369
EP 371
DI 10.1016/j.ajhg.2014.12.028
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA CD0GD
UT WOS:000350747800007
PM 25748355
ER
PT J
AU Machiela, MJ
Zhou, WY
Sampson, JN
Dean, MC
Jacobs, KB
Black, A
Brinton, LA
Chang, IS
Chen, C
Chen, C
Chen, KX
Cook, LS
Bou, MC
De Vivo, I
Doherty, J
Friedenreich, CM
Gaudet, MM
Haiman, CA
Hankinson, SE
Hartge, P
Henderson, BE
Hong, YC
Hosgood, HD
Hsiung, CA
Hu, W
Hunter, DJ
Jessop, L
Kim, HN
Kim, YH
Kim, YT
Klein, R
Kraft, P
Lan, Q
Lin, DX
Liu, JJ
Le Marchand, L
Liang, XL
Lissowska, J
Lu, LG
Magliocco, AM
Matsuo, K
Olson, SH
Orlow, I
Park, JY
Pooler, L
Prescott, J
Rastogi, R
Risch, HA
Schumacher, F
Seow, A
Setiawan, VW
Shen, HB
Sheng, X
Shin, MH
Shu, XO
VanDen Berg, D
Wang, JC
Wentzensen, N
Wong, MP
Wu, C
Wu, TC
Wu, YL
Xia, L
Yang, HP
Yang, PC
Zheng, W
Zhou, BS
Abnet, CC
Albanes, D
Aldrich, MC
Amos, C
Amundadottir, LT
Berndt, SI
Blot, WJ
Bock, CH
Bracci, PM
Burdett, L
Buring, JE
Butler, MA
Carreon, T
Chatterjee, N
Chung, CC
Cook, MB
Cullen, M
Davis, FG
Ding, T
Duell, EJ
Epstein, CG
Fan, JH
Figueroa, JD
Fraumeni, JF
Freedman, ND
Fuchs, CS
Gao, YT
Gapstur, SM
Patino-Garcia, A
Garcia-Closas, M
Gaziano, JM
Giles, GG
Gillanders, EM
Giovannucci, EL
Goldin, L
Goldstein, AM
Greene, MH
Hallmans, G
Harris, CC
Henriksson, R
Holly, EA
Hoover, RN
Hu, N
Hutchinson, A
Jenab, M
Johansen, C
Khaw, KT
Koh, WP
Kolonel, LN
Kooperberg, C
Krogh, V
Kurtz, RC
LaCroix, A
Landgren, A
Landi, MT
Li, DH
Liao, LM
Malats, N
McGlynn, KA
McNeill, LH
McWilliams, RR
Melin, BS
Mirabello, L
Peplonska, B
Peters, U
Petersen, GM
Prokunina-Olsson, L
Purdue, M
Qiao, YL
Rabe, KG
Rajaraman, P
Real, FX
Riboli, E
Rodriguez-Santiago, B
Rothman, N
Ruder, AM
Savage, SA
Schwartz, AG
Schwartz, KL
Sesso, HD
Severi, G
Silverman, DT
Spitz, MR
Stevens, VL
Stolzenberg-Solomon, R
Stram, D
Tang, ZZ
Taylor, PR
Teras, LR
Tobias, GS
Viswanathan, K
Wacholder, S
Wang, ZM
Weinstein, SJ
Wheeler, W
White, E
Wiencke, JK
Wolpin, BM
Wu, XF
Wunder, JS
Yu, K
Zanetti, KA
Zeleniuch-Jacquotte, A
Ziegler, RG
De Andrade, M
Barnes, KC
Beaty, TH
Bierut, LJ
Desch, KC
Doheny, KF
Feenstra, B
Ginsburg, D
Heit, JA
Kang, JH
Laurie, CA
Li, JZ
Lowe, WL
Marazita, ML
Melbye, M
Mirel, DB
Murray, JC
Nelson, SC
Pasquale, LR
Rice, K
Wiggs, JL
Wise, A
Tucker, M
Perez-Jurado, LA
Laurie, CC
Caporaso, NE
Yeager, M
Chanock, SJ
AF Machiela, Mitchell J.
Zhou, Weiyin
Sampson, Joshua N.
Dean, Michael C.
Jacobs, Kevin B.
Black, Amanda
Brinton, Louise A.
Chang, I-Shou
Chen, Chu
Chen, Constance
Chen, Kexin
Cook, Linda S.
Bou, Marta Crous
De Vivo, Immaculata
Doherty, Jennifer
Friedenreich, Christine M.
Gaudet, Mia M.
Haiman, Christopher A.
Hankinson, Susan E.
Hartge, Patricia
Henderson, Brian E.
Hong, Yun-Chul
Hosgood, H. Dean, III
Hsiung, Chao A.
Hu, Wei
Hunter, David J.
Jessop, Lea
Kim, Hee Nam
Kim, Yeul Hong
Kim, Young Tae
Klein, Robert
Kraft, Peter
Lan, Qing
Lin, Dongxin
Liu, Jianjun
Le Marchand, Loic
Liang, Xiaolin
Lissowska, Jolanta
Lu, Lingeng
Magliocco, Anthony M.
Matsuo, Keitaro
Olson, Sara H.
Orlow, Irene
Park, Jae Yong
Pooler, Loreall
Prescott, Jennifer
Rastogi, Radhai
Risch, Harvey A.
Schumacher, Fredrick
Seow, Adeline
Setiawan, Veronica Wendy
Shen, Hongbing
Sheng, Xin
Shin, Min-Ho
Shu, Xiao-Ou
VanDen Berg, David
Wang, Jiu-Cun
Wentzensen, Nicolas
Wong, Maria Pik
Wu, Chen
Wu, Tangchun
Wu, Yi-Long
Xia, Lucy
Yang, Hannah P.
Yang, Pan-Chyr
Zheng, Wei
Zhou, Baosen
Abnet, Christian C.
Albanes, Demetrius
Aldrich, Melinda C.
Amos, Christopher
Amundadottir, Laufey T.
Berndt, Sonja I.
Blot, William J.
Bock, Cathryn H.
Bracci, Paige M.
Burdett, Laurie
Buring, Julie E.
Butler, Mary A.
Carreon, Tania
Chatterjee, Nilanjan
Chung, Charles C.
Cook, Michael B.
Cullen, Michael
Davis, Faith G.
Ding, Ti
Duell, Eric J.
Epstein, Caroline G.
Fan, Jin-Hu
Figueroa, Jonine D.
Fraumeni, Joseph F., Jr.
Freedman, Neal D.
Fuchs, Charles S.
Gao, Yu-Tang
Gapstur, Susan M.
Patino-Garcia, Ana
Garcia-Closas, Montserrat
Gaziano, J. Michael
Giles, Graham G.
Gillanders, Elizabeth M.
Giovannucci, Edward L.
Goldin, Lynn
Goldstein, Alisa M.
Greene, Mark H.
Hallmans, Goran
Harris, Curtis C.
Henriksson, Roger
Holly, Elizabeth A.
Hoover, Robert N.
Hu, Nan
Hutchinson, Amy
Jenab, Mazda
Johansen, Christoffer
Khaw, Kay-Tee
Koh, Woon-Puay
Kolonel, Laurence N.
Kooperberg, Charles
Krogh, Vittorio
Kurtz, Robert C.
LaCroix, Andrea
Landgren, Annelie
Landi, Maria Teresa
Li, Donghui
Liao, Linda M.
Malats, Nuria
McGlynn, Katherine A.
McNeill, Lorna H.
McWilliams, Robert R.
Melin, Beatrice S.
Mirabello, Lisa
Peplonska, Beata
Peters, Ulrike
Petersen, Gloria M.
Prokunina-Olsson, Ludmila
Purdue, Mark
Qiao, You-Lin
Rabe, Kari G.
Rajaraman, Preetha
Real, Francisco X.
Riboli, Elio
Rodriguez-Santiago, Benjamin
Rothman, Nathaniel
Ruder, Avima M.
Savage, Sharon A.
Schwartz, Ann G.
Schwartz, Kendra L.
Sesso, Howard D.
Severi, Gianluca
Silverman, Debra T.
Spitz, Margaret R.
Stevens, Victoria L.
Stolzenberg-Solomon, Rachael
Stram, Daniel
Tang, Ze-Zhong
Taylor, Philip R.
Teras, Lauren R.
Tobias, Geoffrey S.
Viswanathan, Kala
Wacholder, Sholom
Wang, Zhaoming
Weinstein, Stephanie J.
Wheeler, William
White, Emily
Wiencke, John K.
Wolpin, Brian M.
Wu, Xifeng
Wunder, Jay S.
Yu, Kai
Zanetti, Krista A.
Zeleniuch-Jacquotte, Anne
Ziegler, Regina G.
De Andrade, Mariza
Barnes, Kathleen C.
Beaty, Terri H.
Bierut, Laura J.
Desch, Karl C.
Doheny, Kimberly F.
Feenstra, Bjarke
Ginsburg, David
Heit, John A.
Kang, Jae H.
Laurie, Cecilia A.
Li, Jun Z.
Lowe, William L.
Marazita, Mary L.
Melbye, Mads
Mirel, Daniel B.
Murray, Jeffrey C.
Nelson, Sarah C.
Pasquale, Louis R.
Rice, Kenneth
Wiggs, Janey L.
Wise, Anastasia
Tucker, Margaret
Perez-Jurado, Luis A.
Laurie, Cathy C.
Caporaso, Neil E.
Yeager, Meredith
Chanock, Stephen J.
TI Characterization of Large Structural Genetic Mosaicism in Human
Autosomes
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID DETECTABLE CLONAL MOSAICISM; COPY-NUMBER-VARIATION; SOMATIC MOSAICISM;
MAFFUCCI SYNDROME; OLLIER DISEASE; HUMAN GENOME; MUTATIONS; CANCER;
CELLS; IDENTIFICATION
AB Analyses of genome-wide association study (GWAS) data have revealed that detectable genetic mosaicism involving large (>2 Mb) structural autosomal alterations occurs in a fraction of individuals. We present results for a set of 24,849 genotyped individuals (total GWAS set II [TGSII]) in whom 341 large autosomal abnormalities were observed in 168 (0.68%) individuals. Merging data from the new TGSII set with data from two prior reports (the Gene-Environment Association Studies and the total GWAS set I) generated a large dataset of 127,179 individuals; we then conducted a meta-analysis to investigate the patterns of detectable autosomal mosaicism (n = 1,315 events in 925 [0.73%] individuals). Restricting to events >2 Mb in size, we observed an increase in event frequency as event size decreased. The combined results underscore that the rate of detectable mosaicism increases with age (p value = 5.5 x 3 10(-31)) and is higher in men (p value = 0.002) but lower in participants of African ancestry (p value = 0.003). In a subset of 47 individuals from whom serial samples were collected up to 6 years apart, complex changes were noted over time and showed an overall increase in the proportion of mosaic cells as age increased. Our large combined sample allowed for a unique ability to characterize detectable genetic mosaicism involving large structural events and strengthens the emerging evidence of non-random erosion of the genome in the aging population.
C1 [Machiela, Mitchell J.; Zhou, Weiyin; Sampson, Joshua N.; Black, Amanda; Brinton, Louise A.; Hartge, Patricia; Hosgood, H. Dean, III; Hu, Wei; Jessop, Lea; Lan, Qing; Wentzensen, Nicolas; Yang, Hannah P.; Abnet, Christian C.; Albanes, Demetrius; Amundadottir, Laufey T.; Berndt, Sonja I.; Burdett, Laurie; Chatterjee, Nilanjan; Chung, Charles C.; Cook, Michael B.; Cullen, Michael; Epstein, Caroline G.; Figueroa, Jonine D.; Fraumeni, Joseph F., Jr.; Freedman, Neal D.; Goldin, Lynn; Goldstein, Alisa M.; Greene, Mark H.; Hoover, Robert N.; Hu, Nan; Hutchinson, Amy; Landgren, Annelie; Landi, Maria Teresa; Liao, Linda M.; McGlynn, Katherine A.; Mirabello, Lisa; Prokunina-Olsson, Ludmila; Purdue, Mark; Rajaraman, Preetha; Rothman, Nathaniel; Savage, Sharon A.; Silverman, Debra T.; Stolzenberg-Solomon, Rachael; Taylor, Philip R.; Tobias, Geoffrey S.; Wacholder, Sholom; Wang, Zhaoming; Weinstein, Stephanie J.; Yu, Kai; Ziegler, Regina G.; Tucker, Margaret; Caporaso, Neil E.; Yeager, Meredith; Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Zhou, Weiyin; Jacobs, Kevin B.; Burdett, Laurie; Chung, Charles C.; Cullen, Michael; Hutchinson, Amy; Wang, Zhaoming; Yeager, Meredith] NCI, Canc Genom Res Lab, Div Canc Epidemiol & Genet, NIH,Leidos Biomed Res Inc, Bethesda, MD 20892 USA.
[Dean, Michael C.] NCI, Expt Immunol Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA.
[Jacobs, Kevin B.] BioInformed LLC, Gaithersburg, MD 20877 USA.
[Chang, I-Shou] Natl Inst Canc Res, Natl Hlth Res Inst, Zhunan 35053, Taiwan.
[Chen, Chu; Kooperberg, Charles; LaCroix, Andrea; Peters, Ulrike; White, Emily] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
[Chen, Constance; Bou, Marta Crous; De Vivo, Immaculata; Hunter, David J.; Kraft, Peter; Prescott, Jennifer] Harvard Univ, Sch Publ Hlth, Program Genet Epidemiol & Stat Genet, Boston, MA 02115 USA.
[Chen, Kexin] Tianjin Med Univ, Canc Inst & Hosp, Dept Epidemiol & Biostat, Tianjin 300040, Peoples R China.
[Cook, Linda S.] Univ New Mexico, Albuquerque, NM 87131 USA.
[Bou, Marta Crous; De Vivo, Immaculata; Hankinson, Susan E.; Hunter, David J.; Prescott, Jennifer; Fuchs, Charles S.; Giovannucci, Edward L.; Wolpin, Brian M.; Kang, Jae H.; Pasquale, Louis R.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Bou, Marta Crous; De Vivo, Immaculata; Hankinson, Susan E.; Hunter, David J.; Prescott, Jennifer; Fuchs, Charles S.; Gaziano, J. Michael; Giovannucci, Edward L.; Wolpin, Brian M.; Kang, Jae H.; Pasquale, Louis R.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Doherty, Jennifer] Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA.
[Friedenreich, Christine M.] Alberta Hlth Serv, CancerControl Alberta, Dept Populat Hlth Res, Calgary, AB T2N 2T9, Canada.
[Gaudet, Mia M.; Gapstur, Susan M.; Stevens, Victoria L.; Teras, Lauren R.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30303 USA.
[Haiman, Christopher A.; Henderson, Brian E.; Schumacher, Fredrick; Setiawan, Veronica Wendy; VanDen Berg, David; Stram, Daniel] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Hankinson, Susan E.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Div Biostat & Epidemiol, Amherst, MA 01003 USA.
[Hong, Yun-Chul] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul 151742, South Korea.
[Hosgood, H. Dean, III] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA.
[Hsiung, Chao A.] Inst Populat Hlth Sci, Natl Hlth Res Inst, Zhunan 35053, Taiwan.
[Hunter, David J.; Mirel, Daniel B.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Kim, Hee Nam] Chonnam Natl Univ, Ctr Creat Biomed Scientists, Kwangju 500757, South Korea.
[Kim, Yeul Hong] Korea Univ, Anam Hosp, Coll Med, Div Oncol Hematol,Dept Internal Med, Seoul 151742, South Korea.
[Kim, Young Tae] Seoul Natl Univ, Coll Med, Dept Thorac & Cardiovasc Surg, Canc Res Inst, Seoul 151742, South Korea.
[Klein, Robert] Mem Sloan Kettering Canc Ctr, Program Canc Biol & Genet, New York, NY 10065 USA.
[Lin, Dongxin; Wu, Chen] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Etiol & Carcinogenesis, Beijing 100730, Peoples R China.
[Lin, Dongxin; Wu, Chen] Peking Union Med Coll, Beijing 100730, Peoples R China.
[Lin, Dongxin; Wu, Chen] Chinese Acad Med Sci, Canc Inst & Hosp, State Key Lab Mol Oncol, Beijing 100730, Peoples R China.
[Liu, Jianjun] Genome Inst Singapore, Dept Human Genet, Singapore 138672, Singapore.
[Liu, Jianjun] Anhui Med Univ, Sch Life Sci, Hefei 230032, Peoples R China.
[Le Marchand, Loic; Kolonel, Laurence N.] Univ Hawaii, Ctr Canc, Program Epidemiol, Honolulu, HI 96813 USA.
[Liang, Xiaolin; Olson, Sara H.; Orlow, Irene; Rastogi, Radhai] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA.
[Lissowska, Jolanta] Maria Sklodowska Curie Canc Ctr, Dept Canc Epidemiol & Prevent, PL-02781 Warsaw, Poland.
[Lissowska, Jolanta] Inst Oncol, PL-02781 Warsaw, Poland.
[Lu, Lingeng; Risch, Harvey A.] Yale Univ, Sch Publ Hlth, New Haven, CT 06510 USA.
[Magliocco, Anthony M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Matsuo, Keitaro] Kyushu Univ, Fac Med Sci, Dept Prevent Med, Fukuoka 8190395, Japan.
[Park, Jae Yong] Kyungpook Natl Univ, Med Ctr, Lung Canc Ctr, Daegu 101, South Korea.
[Pooler, Loreall; Sheng, Xin; Xia, Lucy] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90007 USA.
[Seow, Adeline; Koh, Woon-Puay] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 119077, Singapore.
[Shen, Hongbing] Nanjing Med Univ, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 210029, Jiangsu, Peoples R China.
[Shen, Hongbing] Nanjing Med Univ, Minist Educ, Key Lab Modern Toxicol, Nanjing 210029, Jiangsu, Peoples R China.
[Shin, Min-Ho] Chonnam Natl Univ, Sch Med, Dept Prevent Med, Gwanju 501746, South Korea.
[Shu, Xiao-Ou] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Med,Vanderbilt Epidemiol Ctr, Nashville, TN 37232 USA.
[Wang, Jiu-Cun] Fudan Univ, Sch Life Sci, Key Lab Contemporary Anthropol, Minist Educ, Shanghai 200433, Peoples R China.
[Wang, Jiu-Cun] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
[Wong, Maria Pik] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
[Wu, Tangchun] Huazhong Univ Sci & Technol, Sch Publ Hlth, Inst Occupat Med, Wuhan 430400, Peoples R China.
[Wu, Tangchun] Huazhong Univ Sci & Technol, Sch Publ Hlth, Minist Educ, Key Lab Environm & Hlth, Wuhan 430400, Peoples R China.
[Wu, Yi-Long] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou 515200, Guangdong, Peoples R China.
[Wu, Yi-Long] Guangdong Acad Med Sci, Guangzhou 515200, Guangdong, Peoples R China.
[Yang, Pan-Chyr] Natl Taiwan Univ, Dept Internal Med, Coll Med, Taipei 10617, Taiwan.
[Zheng, Wei; Aldrich, Melinda C.; Blot, William J.] Vanderbilt Univ, Med Ctr, Vanderbilt Epidemiol Ctr, Div Epidemiol,Dept Med, Nashville, TN 37232 USA.
[Zhou, Baosen] China Med Univ, Sch Publ Hlth, Dept Epidemiol, Shenyang 110001, Peoples R China.
[Aldrich, Melinda C.] Vanderbilt Univ, Sch Med, Dept Thorac Surg, Nashville, TN 37232 USA.
[Amos, Christopher] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Div Canc Prevent & Populat Sci, Houston, TX 77030 USA.
[Blot, William J.] Int Epidemiol Inst, Rockville, MD 20850 USA.
[Bock, Cathryn H.; Schwartz, Ann G.] Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI 48201 USA.
[Bock, Cathryn H.; Schwartz, Ann G.] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48201 USA.
[Bracci, Paige M.; Holly, Elizabeth A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Buring, Julie E.; Sesso, Howard D.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
[Butler, Mary A.; Carreon, Tania; Ruder, Avima M.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA.
[Davis, Faith G.] Univ Alberta, Sch Publ Hlth, Dept Publ Hlth Sci, Edmonton, AB T6G 2R3, Canada.
[Ding, Ti; Tang, Ze-Zhong] Shanxi Canc Hosp, Taiyuan 030013, Shanxi, Peoples R China.
[Duell, Eric J.] Catalan Inst Oncol, Bellvitge Biomed Res Inst, Canc Epidemiol Res Program, Unit Nutr Environm & Canc, Barcelona 08908, Spain.
[Fan, Jin-Hu] Shanghai Canc Inst, Shanghai 200032, Peoples R China.
[Fuchs, Charles S.; Wolpin, Brian M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Gao, Yu-Tang] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Epidemiol,Shanghai Canc Inst, Shanghai 200032, Peoples R China.
[Patino-Garcia, Ana] Univ Navarra, Univ Navarra Clin, Dept Pediat, E-31080 Pamplona, Spain.
[Garcia-Closas, Montserrat] Inst Canc Res, Div Genet & Epidemiol, London SM2 5NG, Surrey, England.
[Garcia-Closas, Montserrat] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SM2 5NG, Surrey, England.
[Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
[Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA.
[Gaziano, J. Michael] Vet Affairs Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA 02130 USA.
[Gaziano, J. Michael] Vet Affairs Boston Healthcare Syst, Cooperat Studies Programs, Boston, MA 02130 USA.
[Giles, Graham G.; Severi, Gianluca] Univ Melbourne, Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic 3010, Australia.
[Giles, Graham G.; Severi, Gianluca] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic 3010, Australia.
[Gillanders, Elizabeth M.; Zanetti, Krista A.] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA.
[Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Hallmans, Goran] Umea Univ, Dept Publ Hlth & Clin Med, Nutr Res Unit, S-90187 Umea, Sweden.
[Harris, Curtis C.] NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Henriksson, Roger; Melin, Beatrice S.] Umea Univ, Dept Radiat Sci, Dept Oncol, S-90187 Umea, Sweden.
[Jenab, Mazda] Int Agcy Res Canc, F-69372 Lyon, France.
[Johansen, Christoffer] Rigshosp, Finsen Ctr, Dept Oncol, DK-2100 Copenhagen, Denmark.
[Johansen, Christoffer] Danish Canc Soc, Res Ctr, Unit Survivorship Res, DK-2100 Copenhagen, Denmark.
[Khaw, Kay-Tee] Univ Cambridge, Sch Clin Med, Cambridge CB2 1TN, England.
[Koh, Woon-Puay] Duke NUS Grad Med Sch, Singapore 169857, Singapore.
[Krogh, Vittorio] Fdn IRCCS Ist Nazl Tumori, I-20133 Milan, Italy.
[Kurtz, Robert C.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.
[Li, Donghui] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
[Malats, Nuria; Real, Francisco X.] Spanish Natl Canc Res Ctr, Madrid 28029, Spain.
[McNeill, Lorna H.] Univ Texas MD Anderson Canc Ctr, Dept Hlth Dispar Res, Div OVP Canc Prevent & Populat Sci, Houston, TX 77030 USA.
[McNeill, Lorna H.] Univ Texas MD Anderson Canc Ctr, Ctr Community Engaged Translat Res, Duncan Family Inst, Houston, TX 77030 USA.
[McWilliams, Robert R.] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA.
[Peplonska, Beata] Nofer Inst Occupat Med, PL-91348 Lodz, Poland.
[Petersen, Gloria M.; Rabe, Kari G.; De Andrade, Mariza] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA.
[Qiao, You-Lin] Chinese Acad Med Sci, Inst Canc, Dept Epidemiol, Beijing 100730, Peoples R China.
[Real, Francisco X.; Rodriguez-Santiago, Benjamin; Perez-Jurado, Luis A.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona 08003, Spain.
[Riboli, Elio] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Div Epidemiol & Biostat, London SW7 2AZ, England.
[Rodriguez-Santiago, Benjamin; Perez-Jurado, Luis A.] Ctr Invest Biomed Red Enfermedades Raras, Barcelona 08003, Spain.
[Rodriguez-Santiago, Benjamin] QGenomics, Quantitat Genom Med Lab, Barcelona 08003, Spain.
[Schwartz, Kendra L.] Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI 48201 USA.
[Schwartz, Kendra L.] Wayne State Univ, Sch Med, Dept Family Med & Publ Hlth Sci, Detroit, MI 48201 USA.
[Severi, Gianluca] Human Genet Fdn, I-10126 Turin, Italy.
[Spitz, Margaret R.] Baylor Coll Med, Houston, TX 77030 USA.
[Viswanathan, Kala; Beaty, Terri H.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA.
[Wheeler, William] Informat Management Serv Inc, Calverton, MD 20904 USA.
[Wiencke, John K.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Wu, Xifeng] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
[Wunder, Jay S.] Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA.
[Zeleniuch-Jacquotte, Anne] NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA.
[Zeleniuch-Jacquotte, Anne] NYU, Perlmutter Canc Inst, New York, NY 10016 USA.
[Barnes, Kathleen C.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
[Bierut, Laura J.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
[Desch, Karl C.] Univ Michigan, Dept Pediat & Communicable Dis, CS Mott Childrens Hosp, Ann Arbor, MI 48109 USA.
[Doheny, Kimberly F.] Johns Hopkins Univ, Inst Med Genet, Sch Med, Ctr Inherited Dis Res, Baltimore, MD 21218 USA.
[Feenstra, Bjarke; Melbye, Mads] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark.
[Ginsburg, David] Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.
[Ginsburg, David] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Heit, John A.] Mayo Clin, Dept Internal Med, Rochester, MN 55905 USA.
[Laurie, Cecilia A.; Nelson, Sarah C.; Rice, Kenneth; Laurie, Cathy C.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Li, Jun Z.] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.
[Lowe, William L.] Northwestern Univ, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Evanston, IL 60208 USA.
[Marazita, Mary L.] Univ Pittsburgh, Sch Dent Med, Dept Oral Biol, Ctr Craniofacial & Dent Genet, Pittsburgh, PA 15260 USA.
[Marazita, Mary L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15260 USA.
[Melbye, Mads] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.
[Murray, Jeffrey C.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.
[Pasquale, Louis R.; Wiggs, Janey L.] Harvard Univ, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Wise, Anastasia] NHGRI, Off Populat Genom, NIH, Bethesda, MD 20892 USA.
[Perez-Jurado, Luis A.] Hosp del Mar, Res Inst, Barcelona 08003, Spain.
RP Chanock, SJ (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
EM chanocks@mail.nih.gov
RI Hsiung, Chao Agnes/E-3994-2010; Garcia-Closas, Montserrat /F-3871-2015;
Chang, I-Shou/D-2084-2010; Brinton, Louise/G-7486-2015; Freedman,
Neal/B-9741-2015; Abnet, Christian/C-4111-2015; Malats,
Nuria/H-7041-2015; Patino-Garcia, Ana/I-4299-2012; Perez Jurado, Luis
Alberto/M-7706-2015; Real Arribas, Francisco/H-5275-2015; Cook,
Michael/A-5641-2009; U-ID, Kyushu/C-5291-2016; Savage,
Sharon/B-9747-2015; Krogh, Vittorio/K-2628-2016; Tobias,
Geoffrey/M-4135-2016; Qiao, You-Lin/B-4139-2012;
OI Garcia-Closas, Montserrat /0000-0003-1033-2650; Brinton,
Louise/0000-0003-3853-8562; Freedman, Neal/0000-0003-0074-1098; Abnet,
Christian/0000-0002-3008-7843; Malats, Nuria/0000-0003-2538-3784; Real
Arribas, Francisco/0000-0001-9501-498X; Cook,
Michael/0000-0002-0533-7302; Savage, Sharon/0000-0001-6006-0740; Krogh,
Vittorio/0000-0003-0122-8624; Tobias, Geoffrey/0000-0002-2878-8253;
Qiao, You-Lin/0000-0001-6380-0871; Nelson, Sarah/0000-0002-2109-6465;
Rodriguez-Santiago, Benjamin/0000-0003-1167-3852; YANG,
PAN-CHYR/0000-0001-6330-6048; Prokunina-Olsson,
Ludmila/0000-0002-9622-2091; Liao, Linda/0000-0002-1923-5294; Machiela,
Mitchell/0000-0001-6538-9705; Orlow, Irene/0000-0001-6234-6961; Giles,
Graham/0000-0003-4946-9099; Zeleniuch-Jacquotte,
Anne/0000-0001-9350-1303; Matsuo, Keitaro/0000-0003-1761-6314
FU Medical Research Council [G0401527, G1000143]; NCI NIH HHS [R25
CA174664, K05 CA154337, K07 CA172294, P01 CA087969, P30 CA008748, P30
CA016672, P30 CA023108, R01 CA092447, R01 CA124908, UM1 CA182934]; NEI
NIH HHS [P30 EY014104, R01 EY015473, R01 EY022305]; NHLBI NIH HHS [R01
HL039693, R01 HL112642]; NIDCR NIH HHS [R01 DE014899, R01 DE016148]
NR 35
TC 14
Z9 14
U1 2
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD MAR 5
PY 2015
VL 96
IS 3
BP 487
EP 497
DI 10.1016/j.ajhg.2015.01.011
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA CD0GD
UT WOS:000350747800022
PM 25748358
ER
PT J
AU Kfoury, Y
Scadden, DT
AF Kfoury, Youmna
Scadden, David T.
TI Mesenchymal Cell Contributions to the Stem Cell Niche
SO CELL STEM CELL
LA English
DT Review
ID HUMAN-BONE-MARROW; GROWTH-FACTOR RECEPTOR; HEMATOPOIETIC
MICRO-ENVIRONMENT; THERAPY POSITION STATEMENT; COLONY-FORMING CELLS;
LONG-TERM CULTURE; STROMAL CELLS; PROGENITOR CELLS; IN-VIVO; RADIATION
SENSITIVITY
AB Mesenchymal stromal cells (MSCs) are heterogeneous and primitive cells discovered first in the bone marrow (BM). They have putative roles in maintaining tissue homeostasis and are increasingly recognized as components of stem cell niches, which are best defined in the blood. The absence of in vivo MSC markers has limited our ability to track their behavior in vivo and draw comparisons with in vitro observations. Here we review the historical background of BM-MSCs, advances made in their prospective isolation, their developmental origin and contribution to maintaining subsets of hematopoietic cells, and how mesenchymal cells contribute to other stem cell niches.
C1 [Kfoury, Youmna; Scadden, David T.] Harvard Univ, Ctr Regenerat Med, Boston, MA 02114 USA.
[Kfoury, Youmna; Scadden, David T.] Harvard Univ, MGH Canc Ctr, Massachusetts Gen Hosp, Dept Stem Cell & Regenerat Biol, Boston, MA 02114 USA.
[Kfoury, Youmna; Scadden, David T.] Harvard Univ, Harvard Stem Cell Inst, Boston, MA 02114 USA.
RP Scadden, DT (reprint author), Harvard Univ, Ctr Regenerat Med, Boston, MA 02114 USA.
EM david_scadden@harvard.edu
FU National Institutes of Health [U01H100402, R01EB014703, R01HL044851];
Aplastic Anemia and MDS International foundation; Dubai Harvard
foundation
FX D.T.S. is Gerald and Darlene Jordan Professor of Medicine and was
supported by the National Institutes of Health (U01H100402, R01EB014703,
and R01HL044851). Y.K. is a recipient of the Aplastic Anemia and MDS
International foundation research grant and a former recipient of the
Dubai Harvard foundation for medical research post-doctoral fellowship.
NR 140
TC 56
Z9 59
U1 10
U2 55
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD MAR 5
PY 2015
VL 16
IS 3
BP 239
EP 253
DI 10.1016/j.stem.2015.02.019
PG 15
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA CD0GC
UT WOS:000350747700007
PM 25748931
ER
PT J
AU Hallett, PJ
Deleidi, M
Astradsson, A
Smith, GA
Cooper, O
Osborn, TM
Sundberg, M
Moore, MA
Perez-Torres, E
Brownell, AL
Schumacher, JM
Spealman, RD
Isacson, O
AF Hallett, Penelope J.
Deleidi, Michela
Astradsson, Arnar
Smith, Gaynor A.
Cooper, Oliver
Osborn, Teresia M.
Sundberg, Maria
Moore, Michele A.
Perez-Torres, Eduardo
Brownell, Anna-Liisa
Schumacher, James M.
Spealman, Roger D.
Isacson, Ole
TI Successful Function of Autologous iPSC-Derived Dopamine Neurons
following Transplantation in a Non-Human Primate Model of Parkinson's
Disease
SO CELL STEM CELL
LA English
DT Article
ID PLURIPOTENT STEM-CELLS; RAT MODEL; VENTRAL MESENCEPHALON; NEURAL CELLS;
C-11 CFT; IN-VIVO; BRAIN; DIFFERENTIATION; DEFICIENT; SYMPTOMS
AB Autologous transplantation of patient-specific induced pluripotent stem cell (iPSC)-derived neurons is a potential clinical approach for treatment of neurological disease. Preclinical demonstration of long-term efficacy, feasibility, and safety of iPSC-derived dopamine neurons in non-human primate models will be an important step in clinical development of cell therapy. Here, we analyzed cynomolgus monkey (CM) iPSC-derived midbrain dopamine neurons for up to 2 years following autologous transplantation in a Parkinson's disease (PD) model. In one animal, with the most successful protocol, we found that unilateral engraftment of CM-iPSCs could provide a gradual onset of functional motor improvement contralateral to the side of dopamine neuron transplantation, and increased motor activity, without a need for immunosuppression. Postmortem analyses demonstrated robust survival of midbrain-like dopaminergic neurons and extensive outgrowth into the transplanted putamen. Our proof of concept findings support further development of autologous iPSC-derived cell transplantation for treatment of PD.
C1 [Hallett, Penelope J.; Deleidi, Michela; Astradsson, Arnar; Smith, Gaynor A.; Cooper, Oliver; Osborn, Teresia M.; Sundberg, Maria; Moore, Michele A.; Perez-Torres, Eduardo; Brownell, Anna-Liisa; Schumacher, James M.; Spealman, Roger D.; Isacson, Ole] McLean Hosp, Neuroregenerat Res Inst, Belmont, MA 02478 USA.
[Hallett, Penelope J.; Deleidi, Michela; Astradsson, Arnar; Smith, Gaynor A.; Cooper, Oliver; Osborn, Teresia M.; Sundberg, Maria; Moore, Michele A.; Perez-Torres, Eduardo; Brownell, Anna-Liisa; Schumacher, James M.; Spealman, Roger D.; Isacson, Ole] Harvard Univ, Sch Med, Belmont, MA 02478 USA.
[Moore, Michele A.; Spealman, Roger D.] Harvard Univ, Sch Med, New England Primate Res Ctr, Southborough, MA 01772 USA.
[Brownell, Anna-Liisa] Massachusetts Gen Hosp, MGH HST Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Brownell, Anna-Liisa] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Isacson, Ole] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
RP Isacson, O (reprint author), McLean Hosp, Neuroregenerat Res Inst, Belmont, MA 02478 USA.
EM isacson@hms.harvard.edu
OI Cooper, Oliver/0000-0001-6567-7491; Hallett,
Penelope/0000-0002-8858-9096
FU Harvard Stem Cell Institute Miller Consortium; Udall Parkinson's Disease
Center of Excellence [P50 NS39793]; Department of Defense
[WX81XWH-11-1-0069]; Orchard Foundation; Poul Hansen Family;
Consolidated Anti-Aging Foundation; Harold and Ronna Cooper Family;
National Center for Research Resources [RR00168]; Office of Research
Infrastructure Programs [OD011103]
FX We thank the veterinary and research staff, including Dr. Leah Makaron,
Dr. Angela Carville, Dr. Andrew Miller, Matthew Beck, Jack McDowell,
Melissa Hayes, Jonathan Beagan, Zachary Schneider-Lynch, Sayantan Deb,
and Alex Casler, at the New England Primate Research Center and the
Neuroregeneration Research Institute for excellent veterinary and
technical assistance. This study was supported by the Harvard Stem Cell
Institute Miller Consortium for the Development of Nervous System
Therapies and the Udall Parkinson's Disease Center of Excellence grant
P50 NS39793, Department of Defense WX81XWH-11-1-0069, Orchard
Foundation, Poul Hansen Family, Consolidated Anti-Aging Foundation and
Harold and Ronna Cooper Family (to O.I.), National Center for Research
Resources RR00168, and the Office of Research Infrastructure Programs
OD011103 (to R.D.S.).
NR 28
TC 45
Z9 48
U1 4
U2 43
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD MAR 5
PY 2015
VL 16
IS 3
BP 269
EP 274
DI 10.1016/j.stem.2015.01.018
PG 6
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA CD0GC
UT WOS:000350747700009
PM 25732245
ER
PT J
AU Ewald, CY
Landis, JN
Abate, JP
Murphy, CT
Blackwell, TK
AF Ewald, Collin Y.
Landis, Jess N.
Abate, Jess Porter
Murphy, Coleen T.
Blackwell, T. Keith
TI Dauer-independent insulin/IGF-1-signalling implicates collagen
remodelling in longevity
SO NATURE
LA English
DT Article
ID ELEGANS LIFE-SPAN; NEMATODE CAENORHABDITIS-ELEGANS; LARGE GENE LISTS;
C-ELEGANS; STRESS-RESPONSE; REGULATES LONGEVITY; PROLINE CATABOLISM;
MESSENGER-RNA; EXPRESSION; DAF-2
AB Interventions that delay ageing mobilize mechanisms that protect and repair cellular components(1-3), but it is unknown how these interventions might slow the functional decline of extracellular matrices(4,5), which are also damaged during ageing(6,7). Reduced insulin/I GF-1 signalling (HIS) extends lifespan across the evolutionary spectrum, and in juvenile Caenorhabditis elegans also allows the transcription factor DAF-16/FOX0 to induce development into dauer, a diapause that withstands harsh conditions(1,2). It has been suggested that rIIS delays C. elegans ageing through activation of dauer-related processes during adulthood(2,8,9), but some HIS conditions confer robust lifespan extension unaccompanied by any dauer-like traits(1,10,11). Here we show that HIS can promote C. elegans longevity through a program that is genetically distinct from the dauer pathway, and requires the Nrf (NF-E2-related factor) orthologue SKN-1 acting in parallel to DAF-16. SKN-1 is inhibited by IIS and has been broadly implicated in longevity(12-14), but is rendered dispensable for HIS lifespan extension by even mild activity of dauer-related processes. When IIS is decreased under conditions that do not induce dauer traits, SKN-1 most prominently increases expression of collagens and other extracellular matrix genes. Diverse genetic, nutritional, and pharmacological pro-longevity interventions delay an age-related decline in collagen expression. These collagens mediate adulthood extracellular matrix remodelling, and are needed for ageing to be delayed by interventions that do not involve dauer traits. By genetically delineating a dauer-independent HIS ageing pathway, our results show that IIS controls a broad set of protective mechanisms during C. elegans adulthood, and may facilitate elucidation of processes of general importance for longevity. The importance of collagen production in diverse anti-ageing interventions implies that extracellular matrix remodelling is a generally essential signature of longevity assurance, and that agents promoting extracellular matrix youthfulness may have systemic benefit.
C1 [Ewald, Collin Y.; Abate, Jess Porter; Blackwell, T. Keith] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Ewald, Collin Y.; Abate, Jess Porter; Blackwell, T. Keith] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Ewald, Collin Y.; Abate, Jess Porter; Blackwell, T. Keith] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02215 USA.
[Landis, Jess N.; Murphy, Coleen T.] Princeton Univ, Dept Mol Biol, Lewis Sigler Inst Integrat Genom, Carl Icahn Lab 148, Princeton, NJ 08544 USA.
RP Blackwell, TK (reprint author), Joslin Diabet Ctr, One Joslin Pl, Boston, MA 02215 USA.
EM ctmurphy@princeton.edu; keith.blackwell@joslin.harvard.edu
RI Ewald, Collin/K-6303-2015
OI Ewald, Collin/0000-0003-1166-4171
FU National Institutes of Health Office of Research Infrastructure Programs
[P40 OD010440]; National Institutes of Health [GM062891, 5T32DK007260];
Diabetes Research Center award [P30DK036836]; National Science
Foundation; Swiss National Science Foundation [PBSKP3_140135]
FX We thank C. Kenyon,S. Mitani, and J. Shim for strains, P. Sengupta
fordauer pheromone, C. Obieglo, L. Moronetti, M. Bland,and K. Patel for
assistance,and J. Apfeld, E. Greer, C. Kenyon, W. Mair, and Blackwell
laboratory members for discussions or comments on the manuscript. Some
strains were provided by the Caenorhabditis Genetics Center, which is
funded by the National Institutes of Health Office of Research
Infrastructure Programs (P40 OD010440). The work was supported by
funding from the National Institutes of Health to T.K.B. (GM062891),
C.T.M. (New Innovator), and J.P.A. (5T32DK007260), a Diabetes Research
Center award to the Joslin Diabetes Center (P30DK036836), and
fellowships from the National Science Foundation to J.N.L., and the
Swiss National Science Foundation (PBSKP3_140135) to C.Y.E.
NR 93
TC 37
Z9 37
U1 4
U2 55
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAR 5
PY 2015
VL 519
IS 7541
BP 97
EP U212
DI 10.1038/nature14021
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC4EQ
UT WOS:000350304000043
PM 25517099
ER
PT J
AU Moore, HCF
Unger, JM
Phillips, KA
Boyle, F
Hitre, E
Porter, D
Francis, PA
Goldstein, LJ
Gomez, HL
Vallejos, CS
Partridge, AH
Dakhil, SR
Garcia, AA
Gralow, J
Lombard, JM
Forbes, JF
Martino, S
Barlow, WE
Fabian, CJ
Minasian, L
Meyskens, FL
Gelber, RD
Hortobagyi, GN
Albain, KS
AF Moore, Halle C. F.
Unger, Joseph M.
Phillips, Kelly-Anne
Boyle, Frances
Hitre, Erika
Porter, David
Francis, Prudence A.
Goldstein, Lori J.
Gomez, Henry L.
Vallejos, Carlos S.
Partridge, Ann H.
Dakhil, Shaker R.
Garcia, Agustin A.
Gralow, Julie
Lombard, Janine M.
Forbes, John F.
Martino, Silvana
Barlow, William E.
Fabian, Carol J.
Minasian, Lori
Meyskens, Frank L., Jr.
Gelber, Richard D.
Hortobagyi, Gabriel N.
Albain, Kathy S.
CA POEMS S0230 Investigators
TI Goserelin for Ovarian Protection during Breast-Cancer Adjuvant
Chemotherapy
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID RANDOMIZED-CONTROLLED-TRIAL; FERTILITY PRESERVATION; HORMONE AGONISTS;
SUPPRESSION; AMENORRHEA; WOMEN; TRIPTORELIN; PREVENTION
AB BACKGROUND
Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack data on pregnancy outcomes.
METHODS
We randomly assigned 257 premenopausal women with operable hormone-receptor-negative breast cancer to receive standard chemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy without goserelin (chemotherapy-alone group). The primary study end point was the rate of ovarian failure at 2 years, with ovarian failure defined as the absence of menses in the preceding 6 months and levels of follicle-stimulating hormone (FSH) in the postmenopausal range. Rates were compared with the use of conditional logistic regression. Secondary end points included pregnancy outcomes and disease-free and overall survival.
RESULTS
At baseline, 218 patients were eligible and could be evaluated. Among 135 with complete primary end-point data, the ovarian failure rate was 8% in the goserelin group and 22% in the chemotherapy-alone group (odds ratio, 0.30; 95% confidence interval, 0.09 to 0.97; two-sided P = 0.04). Owing to missing primary end-point data, sensitivity analyses were performed, and the results were consistent with the main findings. Missing data did not differ according to treatment group or according to the stratification factors of age and planned chemotherapy regimen. Among the 218 patients who could be evaluated, pregnancy occurred in more women in the goserelin group than in the chemotherapy-alone group (21% vs. 11%, P = 0.03); women in the goserelin group also had improved disease-free survival (P = 0.04) and overall survival (P = 0.05).
CONCLUSIONS Although missing data weaken interpretation of the findings, administration of goserelin with chemotherapy appeared to protect against ovarian failure, reducing the risk of early menopause and improving prospects for fertility. (Funded by the National Cancer Institute and others; POEMS/S0230 ClinicalTrials.gov number, NCT00068601.)
C1 [Moore, Halle C. F.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Unger, Joseph M.; Barlow, William E.] Fred Hutchinson Canc Res Ctr, SWOG Canc Res Grp Stat Ctr, Seattle, WA 98104 USA.
[Gralow, Julie] Seattle Canc Care Alliance, Seattle, WA USA.
[Gralow, Julie] Univ Washington, Seattle, WA 98195 USA.
[Phillips, Kelly-Anne; Francis, Prudence A.] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Phillips, Kelly-Anne; Francis, Prudence A.; Forbes, John F.] New Zealand Breast Canc Trials Grp ANZBCTG, Newcastle, NSW, Australia.
[Boyle, Frances; Lombard, Janine M.; Forbes, John F.] Calvary Mater Hosp, Newcastle, NSW, Australia.
[Boyle, Frances] Univ Sydney, Sydney, NSW 2006, Australia.
[Phillips, Kelly-Anne; Francis, Prudence A.] IBCSG, Bern, Switzerland.
[Hitre, Erika] Natl Inst Oncol, Budapest, Hungary.
[Porter, David] Auckland Reg Canc & Blood Serv, Auckland, New Zealand.
[Goldstein, Lori J.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Gomez, Henry L.] Inst Enfermedades Neoplas, Lima, Peru.
[Vallejos, Carlos S.] Oncosalud SAC, Lima, Peru.
[Partridge, Ann H.; Gelber, Richard D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gelber, Richard D.] IBCSG Stat Ctr, Boston, MA USA.
[Dakhil, Shaker R.] Wichita Community Clin Oncol Program, Wichita, KS USA.
[Fabian, Carol J.] Univ Kansas, Westwood, KS USA.
[Garcia, Agustin A.] Univ So Calif, Norris Canc Ctr, Los Angeles, CA USA.
[Martino, Silvana] Angeles Clin, Santa Monica, CA USA.
[Martino, Silvana] Res Inst, Santa Monica, CA USA.
[Meyskens, Frank L., Jr.] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA.
[Minasian, Lori] NCI, Canc Prevent Div, Bethesda, MD 20892 USA.
[Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Albain, Kathy S.] Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA.
RP Moore, HCF (reprint author), Cleveland Clin Fdn, Taussig Canc Inst, R35,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM mooreh1@ccf.org
OI Gomez, Henry/0000-0003-2660-1843; Phillips,
Kelly-Anne/0000-0002-0475-1771
FU National Cancer Institute
FX Funded by the National Cancer Institute and others; POEMS/S0230
ClinicalTrials.gov number, NCT00068601.
NR 23
TC 102
Z9 108
U1 3
U2 30
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAR 5
PY 2015
VL 372
IS 10
BP 923
EP 932
DI 10.1056/NEJMoa1413204
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA CC4EU
UT WOS:000350304500008
PM 25738668
ER
PT J
AU Simmons, LH
Iyasere, CA
Hamilton, KL
AF Simmons, Leigh H.
Iyasere, Christiana A.
Hamilton, Kathleen L.
TI Case 38-2014: A Man with Sore Throat, Hoarseness, Fatigue, and Dyspnea
REPLY
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Simmons, Leigh H.; Iyasere, Christiana A.; Hamilton, Kathleen L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Simmons, LH (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 1
TC 0
Z9 0
U1 0
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAR 5
PY 2015
VL 372
IS 10
BP 982
EP 982
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA CC4EU
UT WOS:000350304500025
PM 25738684
ER
PT J
AU Lyons, KD
Hull, JG
Kaufman, PA
Li, ZZ
Seville, JL
Ahles, TA
Kornblith, AB
Hegel, MT
AF Lyons, Kathleen D.
Hull, Jay G.
Kaufman, Peter A.
Li, Zhongze
Seville, Janette L.
Ahles, Tim A.
Kornblith, Alice B.
Hegel, Mark T.
TI Development and Initial Evaluation of a Telephone-Delivered, Behavioral
Activation, and Problem-Solving Treatment Program to Address Functional
Goals of Breast Cancer Survivors
SO JOURNAL OF PSYCHOSOCIAL ONCOLOGY
LA English
DT Article
DE survivorship; occupational therapy; rehabilitation
ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; PARTICIPATION
RESTRICTIONS; PHYSICAL PERFORMANCE; RADIATION-THERAPY; DEPRESSION;
SCALE; INTERVENTION; METAANALYSIS; RELIABILITY
AB The purpose of this research was to develop and pilot test an intervention to optimize functional recovery for breast cancer survivors. Over two studies, 31 women enrolled in a goal-setting program via telephone. All eligible women enrolled (37% of those screened) and 66% completed all study activities. Completers were highly satisfied with the intervention, using it to address, on average, four different challenging activities. The longitudinal analysis showed a main effect of time for overall quality of life (F(5, 43.1) = 5.1, p = 0.001) and improvements in active coping (F (3, 31.7) = 4.9, p = 0.007), planning (F (3, 36.0) = 4.1, p = 0.01), reframing (F (3, 29.3) = 8.5, p < 0.001), and decreases in self-blame (F (3,31.6) = 4.3, p = 0.01). The intervention is feasible and warrants further study to determine its efficacy in fostering recovery and maximizing activity engagement after cancer treatment.
C1 [Lyons, Kathleen D.; Kaufman, Peter A.; Seville, Janette L.; Hegel, Mark T.] Dartmouth Coll, Geisel Sch Med Dartmouth, Hanover, NH 03755 USA.
[Lyons, Kathleen D.; Hegel, Mark T.] Norris Cotton Canc Ctr, Canc Control Program, Lebanon, NH USA.
[Hull, Jay G.] Dartmouth Coll, Dartmouth Grad Studies, Hanover, NH 03755 USA.
[Kaufman, Peter A.] Norris Cotton Canc Ctr, Mol Therapeut Program, Lebanon, NH USA.
[Li, Zhongze] Norris Cotton Canc Ctr, Biostat Shared Resource, Lebanon, NH USA.
[Ahles, Tim A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Kornblith, Alice B.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Lyons, KD (reprint author), Dartmouth Hitchcock Med Ctr, Psychiat Dept 7750, 1 Med Ctr Dr, Lebanon, NH 03756 USA.
EM kathleen.d.lyons@dartmouth.edu
FU Alliance for Clinical Trials in Oncology Foundation [70804]; National
Cancer Institute [R21 CA140849-01]; Mentored Research Scholar Grant in
Applied and Clinical Research from the American Cancer Society
[MRSG-12-113-01-CPPB]
FX These studies were funded by grants to Dr. Hegel from the Cancer and
Leukemia Group B Foundation (now the Alliance for Clinical Trials in
Oncology Foundation; #70804; Study 1) and the National Cancer Institute
(1 R21 CA140849-01; Study 2). The first author was supported by a
Mentored Research Scholar Grant in Applied and Clinical Research,
MRSG-12-113-01-CPPB from the American Cancer Society.
NR 29
TC 2
Z9 2
U1 0
U2 2
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0734-7332
EI 1540-7586
J9 J PSYCHOSOC ONCOL
JI J. Psychosoc. Oncol.
PD MAR 4
PY 2015
VL 33
IS 2
BP 199
EP 218
DI 10.1080/07347332.2014.1002659
PG 20
WC Psychology, Social
SC Psychology
GA CG6NC
UT WOS:000353417400006
PM 25668509
ER
PT J
AU Yao, YW
Cui, XT
Al-Ramahi, I
Sun, XL
Li, B
Hou, JP
Difiglia, M
Palacino, J
Wu, ZY
Ma, LX
Botas, J
Lu, BX
AF Yao, Yuwei
Cui, Xiaotian
Al-Ramahi, Ismael
Sun, Xiaoli
Li, Bo
Hou, Jiapeng
Difiglia, Marian
Palacino, James
Wu, Zhi-Ying
Ma, Lixiang
Botas, Juan
Lu, Boxun
TI A striatal-enriched intronic GPCR modulates huntingtin levels and
toxicity
SO ELIFE
LA English
DT Article
ID DEPENDENT PROTEIN-KINASE; LONG NONCODING RNAS; MUTANT-HUNTINGTIN;
CYCLIC-AMP; HUMAN BRAIN; DISEASE; CAMP; NEURONS; EPAC; MICE
AB Huntington's disease (HD) represents an important model for neurodegenerative disorders and proteinopathies. It is mainly caused by cytotoxicity of the mutant huntingtin protein (Htt) with an expanded polyQ stretch. While Htt is ubiquitously expressed, HD is characterized by selective neurodegeneration of the striatum. Here we report a striatal-enriched orphan G proteincoupled receptor(GPCR) Gpr52 as a stabilizer of Htt in vitro and in vivo. Gpr52 modulates Htt via cAMP-dependent but PKA independent mechanisms. Gpr52 is located within an intron of Rabgap1l, which exhibits epistatic effects on Gpr52-mediated modulation of Htt levels by inhibiting its substrate Rab39B, which co-localizes with Htt and translocates Htt to the endoplasmic reticulum. Finally, reducing Gpr52 suppresses HD phenotypes in both patient iPS-derived neurons and in vivo Drosophila HD models. Thus, our discovery reveals modulation of Htt levels by a striatal-enriched GPCR via its GPCR function, providing insights into the selective neurodegeneration and potential treatment strategies.
C1 [Yao, Yuwei; Cui, Xiaotian; Sun, Xiaoli; Li, Bo; Hou, Jiapeng; Lu, Boxun] Fudan Univ, Sch Life Sci, Dept Biophys, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
[Yao, Yuwei; Cui, Xiaotian; Sun, Xiaoli; Lu, Boxun] Collaborat Innovat Ctr Brain Sci, Shanghai, Peoples R China.
[Al-Ramahi, Ismael; Botas, Juan] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
[Difiglia, Marian] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Boston, MA 02114 USA.
[Palacino, James] Novartis Inst Biomed Res, Dev Mol Pathways, Cambridge, MA USA.
[Wu, Zhi-Ying] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurol, Hangzhou 310003, Zhejiang, Peoples R China.
[Wu, Zhi-Ying] Zhejiang Univ, Affiliated Hosp 2, Res Ctr Neurol, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China.
[Ma, Lixiang] Fudan Univ, Shanghai Med Coll, Dept Anat Histol & Embryol, Shanghai 200433, Peoples R China.
RP Wu, ZY (reprint author), Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurol, Hangzhou 310003, Zhejiang, Peoples R China.
EM zhiyingwu@zju.edu.cn; lxma@fudan.edu.cn; jbotas@bcm.edu;
luboxun@fudan.edu.cn
RI Al-Ramahi, Ismael/B-4000-2017
OI Al-Ramahi, Ismael/0000-0002-1275-1114
FU National Natural Science Foundation of China (NSFC) [31371421, 31422024,
81271259, 12ZR1403100]; Ministry of Science and Technology of the
People's Republic of China [2014AA02502]; Science and Technology
Commission of Shanghai Municipality [13PJ1400600]; National Institutes
of Health (NIH) [NS42179]
FX National Natural Science Foundation of China (NSFC) 31371421 Yuwei Yao,
Xiaotian Cui, Xiaoli Sun, Bo Li, Jiapeng Hou, Boxun Lu; National Natural
Science Foundation of China (NSFC) 31422024 Yuwei Yao, Xiaotian Cui,
Xiaoli Sun, Bo Li, Jiapeng Hou, Boxun Lu; Ministry of Science and
Technology of the People's Republic of China 2014AA02502 Yuwei Yao,
Xiaotian Cui, Xiaoli Sun, Boxun Lu; Science and Technology Commission of
Shanghai Municipality 13PJ1400600 Boxun Lu; National Natural Science
Foundation of China (NSFC) 81271259 Lixiang Ma; National Natural Science
Foundation of China (NSFC) 12ZR1403100 Lixiang Ma; National Institutes
of Health (NIH) NS42179 Ismael Al-Ramahi, Juan Botas
NR 46
TC 5
Z9 5
U1 7
U2 16
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD MAR 4
PY 2015
VL 4
AR e05449
DI 10.7554/eLife.05449
PG 19
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA CE5IC
UT WOS:000351863800001
ER
PT J
AU Menkes-Caspi, N
Yamin, HG
Kellner, V
Spires-Jones, TL
Cohen, D
Stern, EA
AF Menkes-Caspi, Noa
Yamin, Hagar G.
Kellner, Vered
Spires-Jones, Tara L.
Cohen, Dana
Stern, Edward A.
TI Pathological Tau Disrupts Ongoing Network Activity
SO NEURON
LA English
DT Article
ID RTG4510 MOUSE MODEL; NEURONS IN-VIVO; PYRAMIDAL CELLS; TAUOPATHY;
INHIBITION; CORTEX; NEURODEGENERATION; OSCILLATION; VARIABILITY;
INTEGRATION
AB Pathological tau leads to dementia and neurodegeneration in tauopathies, including Alzheimer's disease. It has been shown to disrupt cellular and synaptic functions, yet its effects on the function of the intact neocortical network remain unknown. Using in vivo intracellular and extracellular recordings, we measured ongoing activity of neocortical pyramidal cells during various arousal states in the rTg4510 mouse model of tauopathy, prior to significant cell death, when only a fraction of the neurons show pathological tau. In transgenic mice, membrane potential oscillations are slower during slow-wave sleep and under anesthesia. Intracellular recordings revealed that these changes are due to longer Down states and state transitions of membrane potentials. Firing rates of transgenic neurons are reduced, and firing patterns within Up states are altered, with longer latencies and inter-spike intervals. By changing the activity patterns of a subpopulation of affected neurons, pathological tau reduces the activity of the neocortical network.
C1 [Menkes-Caspi, Noa; Yamin, Hagar G.; Kellner, Vered; Cohen, Dana; Stern, Edward A.] Bar Ilan Univ, Gonda Brain Res Ctr, IL-52900 Ramat Gan, Israel.
[Spires-Jones, Tara L.] Univ Edinburgh, Ctr Cognit & Neural Syst, Edinburgh EH8 9XD, Midlothian, Scotland.
[Spires-Jones, Tara L.] Univ Edinburgh, Euan MacDonald Ctr Motorneurone Dis Res, Edinburgh EH8 9XD, Midlothian, Scotland.
[Stern, Edward A.] Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA.
RP Stern, EA (reprint author), Bar Ilan Univ, Gonda Brain Res Ctr, IL-52900 Ramat Gan, Israel.
EM sterned@mail.biu.ac.il
FU Alzheimer's Research UK
FX We are grateful to Dr. Jada Lewis for granting permission to use the
rTg4510 mice; and to Professor George Carlson and Ms. Rose Pitstick for
kindly providing them. We thank Dr. Peter Davies for kindly providing
PHF1 and Alz50 antibodies, and Dr. Shih-Chieh Lin for kindly providing
the MATLAB code for construction of a two-dimensional state space. We
thank Professors Bradley T. Hyman and Israel Nelken for critical reading
of the manuscript. Funding for this work was provided by Alzheimer's
Research UK (T.S.-J.).
NR 29
TC 14
Z9 14
U1 3
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD MAR 4
PY 2015
VL 85
IS 5
BP 959
EP 966
DI 10.1016/j.neuron.2015.01.025
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA CD8AZ
UT WOS:000351318900010
PM 25704951
ER
PT J
AU Xia, D
Watanabe, H
Wu, B
Lee, SH
Li, Y
Tsvetkov, E
Bolshakov, VY
Shen, J
Kelleher, RJ
AF Xia, Dan
Watanabe, Hirotaka
Wu, Bei
Lee, Sang Hun
Li, Yan
Tsvetkov, Evgeny
Bolshakov, Vadim Y.
Shen, Jie
Kelleher, Raymond J., III
TI Presenilin-1 Knockin Mice Reveal Loss-of-Function Mechanism for Familial
Alzheimer's Disease
SO NEURON
LA English
DT Article
ID AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE ACTIVITY; TRANSGENIC MICE;
SYNAPTIC PLASTICITY; HIPPOCAMPAL-NEURONS; MEMORY IMPAIRMENTS; MISSENSE
MUTATIONS; SPATIAL MEMORY; IN-VIVO; ONSET
AB Presenilins play essential roles in memory formation, synaptic function, and neuronal survival. Mutations in the Presenilin-1 (PSEN1) gene are the major cause of familial Alzheimer's disease (FAD). How PSEN1 mutations cause FAD is unclear, and pathogenic mechanisms based on gain or loss of function have been proposed. Here, we generated Psen1 knockin (KI) mice carrying the FAD mutation L435F or C410Y. Remarkably, KI mice homozygous for either mutation recapitulate the phenotypes of Psen1(-/-) mice. Neither mutation altered Psen1 mRNA expression, but both abolished g-secretase activity. Heterozygosity for the KI mutation decreased production of A beta 40 and A beta 42, increased the A beta 42/A beta 40 ratio, and exacerbated A beta deposition. Furthermore, the L435F mutation impairs hippocampal synaptic plasticity and memory and causes age-dependent neurodegeneration in the aging cerebral cortex. Collectively, our findings reveal that FAD mutations can cause complete loss of Presenilin-1 function in vivo, suggesting that clinical PSEN mutations produce FAD through a loss-of-function mechanism.
C1 [Xia, Dan; Watanabe, Hirotaka; Wu, Bei; Lee, Sang Hun; Shen, Jie; Kelleher, Raymond J., III] Harvard Univ, Brigham & Womens Hosp, Ctr Neurol Dis, Sch Med,Dept Neurol, Boston, MA 02115 USA.
[Xia, Dan; Kelleher, Raymond J., III] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Human Genet Res,Dept Neurol, Boston, MA 02114 USA.
[Li, Yan; Tsvetkov, Evgeny; Bolshakov, Vadim Y.] Harvard Univ, Sch Med, McLean Hosp, Dept Psychiat, Belmont, MA 02478 USA.
[Bolshakov, Vadim Y.; Shen, Jie; Kelleher, Raymond J., III] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA.
RP Shen, J (reprint author), Harvard Univ, Brigham & Womens Hosp, Ctr Neurol Dis, Sch Med,Dept Neurol, Boston, MA 02115 USA.
EM jshen@rics.bwh.harvard.edu; kelleher@helix.mgh.harvard.edu
RI Lee, Sang Hun/C-1198-2015; Tsvetkov, Evgeny/B-6573-2016
OI Lee, Sang Hun/0000-0002-0020-4631; Tsvetkov, Evgeny/0000-0002-6784-0907
FU NIH [R01NS041783, R01NS042818, R01NS075346]; Alzheimer's Association;
Pew Scholars Program in the Biomedical Sciences
FX We would like to thank T. Sudhof for critical reading of the manuscript,
L. Mucke for APP transgenic mice, T. Iwatsubo and T. Tomita for the
pTrcHis2A-C100-FmH and pTrcHis2A-N102-FmH plasmids, E. Heilig, T. Ding,
and H. Zhao for assistance, and other lab members for helpful
discussions. This work was supported by grants from the NIH (R01NS041783
and R01NS042818 to J.S., R01NS075346 to R.J.K.) and the Alzheimer's
Association. R.J.K. was supported by the Pew Scholars Program in the
Biomedical Sciences.
NR 55
TC 48
Z9 48
U1 8
U2 46
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD MAR 4
PY 2015
VL 85
IS 5
BP 967
EP 981
DI 10.1016/j.neuron.2015.02.010
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA CD8AZ
UT WOS:000351318900011
PM 25741723
ER
PT J
AU von Bornstadt, D
Houben, T
Seidel, JL
Zheng, Y
Dilekoz, E
Qin, T
Sandow, N
Kura, S
Eikermann-Haerter, K
Endres, M
Boas, DA
Moskowitz, MA
Lo, EH
Dreier, JP
Woitzik, J
Sakadzic, S
Ayata, C
AF von Bornstaedt, Daniel
Houben, Thijs
Seidel, Jessica L.
Zheng, Yi
Dilekoz, Ergin
Qin, Tao
Sandow, Nora
Kura, Sreekanth
Eikermann-Haerter, Katharina
Endres, Matthias
Boas, David A.
Moskowitz, Michael A.
Lo, Eng H.
Dreier, Jens P.
Woitzik, Johannes
Sakadzic, Sava
Ayata, Cenk
TI Supply-Demand Mismatch Transients in Susceptible Peri-infarct Hot Zones
Explain the Origins of Spreading Injury Depolarizations
SO NEURON
LA English
DT Article
ID FOCAL CEREBRAL-ISCHEMIA; LASER SPECKLE FLOWMETRY; BLOOD-FLOW;
BRAIN-INJURY; FUNCTIONAL ACTIVATION; OXYGEN-METABOLISM; MALIGNANT
STROKE; CORTEX; DEPRESSION; HEMORRHAGE
AB Peri-infarct depolarizations (PIDs) are seemingly spontaneous spreading depression-like waves that negatively impact tissue outcome in both experimental and human stroke. Factors triggering PIDs are unknown. Here, we show that somatosensory activation of peri-infarct cortex triggers PIDs when the activated cortex is within a critical range of ischemia. We show that the mechanism involves increased oxygen utilization within the activated cortex, worsening the supply-demand mismatch. We support the concept by clinical data showing that mismatch predisposes stroke patients to PIDs as well. Conversely, transient worsening of mismatch by episodic hypoxemia or hypotension also reproducibly triggers PIDs. Therefore, PIDs are triggered upon supply-demand mismatch transients in metastable peri-infarct hot zones due to increased demand or reduced supply. Based on the data, we propose that minimizing sensory stimulation and hypoxic or hypotensive transients in stroke and brain injury would reduce PID incidence and their adverse impact on outcome.
C1 [von Bornstaedt, Daniel; Houben, Thijs; Seidel, Jessica L.; Zheng, Yi; Dilekoz, Ergin; Qin, Tao; Eikermann-Haerter, Katharina; Moskowitz, Michael A.; Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurovasc Res Lab,Dept Radiol, Charlestown, MA 02129 USA.
[von Bornstaedt, Daniel; Endres, Matthias; Dreier, Jens P.] Charite, Dept Neurol, D-10117 Berlin, Germany.
[Houben, Thijs] Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RC Leiden, Netherlands.
[Dilekoz, Ergin] Gazi Univ, Dept Pharmacol, Fac Med, TR-06560 Ankara, Turkey.
[Sandow, Nora; Woitzik, Johannes] Charite, Dept Neurosurg, D-13353 Berlin, Germany.
[von Bornstaedt, Daniel; Sandow, Nora; Endres, Matthias; Dreier, Jens P.; Woitzik, Johannes] Charite, Ctr Stroke Res, D-10117 Berlin, Germany.
[Kura, Sreekanth; Boas, David A.; Sakadzic, Sava] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Dept Radiol, Opt Div,MHG MIT HMS Athinoula A Martinos Ctr Biom, Charlestown, MA 02129 USA.
[Endres, Matthias] Charite, German Ctr Neurodegenerat Dis DZNE, D-10117 Berlin, Germany.
[Endres, Matthias] Charite, German Ctr Cardiovasc Res DZHK, D-10117 Berlin, Germany.
[Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Radiol, Charlestown, MA 02129 USA.
[Dreier, Jens P.] Charite, Dept Expt Neurol, D-10117 Berlin, Germany.
[Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Stroke Serv & Neurosci Intens Care Unit,Dept Neur, Boston, MA 02114 USA.
RP Ayata, C (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurovasc Res Lab,Dept Radiol, 149 13th St,6408, Charlestown, MA 02129 USA.
EM cayata@partners.org
OI Dreier, Jens/0000-0001-7459-2828
FU NIH [NS055104, NS061505]; AHA [11SDG7600037]; Fondation Leducq; Heitman
Foundation; Ellison Foundation; Konrad-Adenauer-Foundation; Deutsche
Forschungsgemeinschaft [DFG-WO 1704/1-1, DFG DR 323/5-1, SFB TR 43, KFO
247, KFO 213]; EU (European Stroke Network, WakeUp, Counterstroke);
Corona Foundation and Bundesministerium fur Bildung und Forschung
(Center for Stroke Research Berlin) [01 EO 0801]
FX Supported by grants from the NIH (NS055104, NS061505), the AHA
(11SDG7600037), the Fondation Leducq, the Heitman Foundation, the
Ellison Foundation, the Konrad-Adenauer-Foundation, the Deutsche
Forschungsgemeinschaft (DFG-WO 1704/1-1, DFG DR 323/5-1, Excellence
cluster Neuro-Cure; SFB TR 43, KFO 247, KFO 213), EU (European Stroke
Network, WakeUp, Counterstroke), Corona Foundation and Bundesministerium
fur Bildung und Forschung (Center for Stroke Research Berlin, 01 EO
0801).
NR 34
TC 20
Z9 20
U1 2
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD MAR 4
PY 2015
VL 85
IS 5
BP 1117
EP 1131
DI 10.1016/j.neuron.2015.02.007
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA CD8AZ
UT WOS:000351318900021
PM 25741731
ER
PT J
AU Claycomb, MA
Wang, L
Sharp, C
Ractliffe, KC
Elhai, JD
AF Claycomb, Meredith A.
Wang, Li
Sharp, Carla
Ractliffe, Kendra C.
Elhai, Jon D.
TI Assessing Relations between PTSD's Dysphoria and Reexperiencing Factors
and Dimensions of Rumination
SO PLOS ONE
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; CONFIRMATORY FACTOR-ANALYSIS; DEPRESSED
MOOD; SYMPTOMS; MEMORIES; DURATION; EPISODES; MODEL
AB The purpose of the present study was to investigate the relations between posttraumatic stress disorder's (PTSD) dysphoria and reexperiencing factors and underlying dimensions of rumination. 304 trauma-exposed primary care patients were administered the Stressful Life Events Screening Questionnaire, PTSD Symptom Scale based on their worst traumatic event, and Ruminative Thought Style Questionnaire (RTSQ). Confirmatory factor analyses (CFAs) were conducted to determine the dysphoria and reexperiencing factors' relationships with the four factors of rumination. Results revealed that both the dysphoria and reexperiencing factors related more to problem-focused thinking and anticipatory thoughts than counterfactual thinking. Additionally, the reexperiencing factor related more to anticipatory thinking than repetitive thinking. Clinical and theoretical implications are discussed.
C1 [Claycomb, Meredith A.; Elhai, Jon D.] Univ Toledo, Dept Psychol, Toledo, OH 43606 USA.
[Wang, Li] Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing 100101, Peoples R China.
[Sharp, Carla] Univ Houston, Dept Psychol, Baylor Coll Med, Menninger Clin, Houston, TX USA.
[Ractliffe, Kendra C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Elhai, Jon D.] Univ Toledo, Dept Psychiat, Toledo, OH 43606 USA.
RP Elhai, JD (reprint author), Univ Toledo, Dept Psychol, Toledo, OH 43606 USA.
EM contact@jon-elhai.com
OI 王, 力/0000-0002-1459-3412
NR 35
TC 5
Z9 5
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 4
PY 2015
VL 10
IS 3
AR e0118435
DI 10.1371/journal.pone.0118435
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC9JM
UT WOS:000350685900034
PM 25738868
ER
PT J
AU Grove, O
Berglund, AE
Schabath, MB
Aerts, HJWL
Dekker, A
Wang, H
Velazquez, ER
Lambin, P
Gu, YH
Balagurunathan, Y
Eikman, E
Gatenby, RA
Eschrich, S
Gillies, RJ
AF Grove, Olya
Berglund, Anders E.
Schabath, Matthew B.
Aerts, Hugo J. W. L.
Dekker, Andre
Wang, Hua
Velazquez, Emmanuel Rios
Lambin, Philippe
Gu, Yuhua
Balagurunathan, Yoganand
Eikman, Edward
Gatenby, Robert A.
Eschrich, Steven
Gillies, Robert J.
TI Quantitative Computed Tomographic Descriptors Associate Tumor Shape
Complexity and Intratumor Heterogeneity with Prognosis in Lung
Adenocarcinoma
SO PLOS ONE
LA English
DT Article
ID TEXTURE ANALYSIS; CT IMAGES; POTENTIAL MARKER; CANCER; SURVIVAL;
REPRODUCIBILITY; MUTATIONS
AB Two CT features were developed to quantitatively describe lung adenocarcinomas by scoring tumor shape complexity (feature 1: convexity) and intratumor density variation (feature 2: entropy ratio) in routinely obtained diagnostic CT scans. The developed quantitative features were analyzed in two independent cohorts (cohort 1: n = 61; cohort 2: n = 47) of patients diagnosed with primary lung adenocarcinoma, retrospectively curated to include imaging and clinical data. Preoperative chest CTs were segmented semi-automatically. Segmented tumor regions were further subdivided into core and boundary sub-regions, to quantify intensity variations across the tumor. Reproducibility of the features was evaluated in an independent test-retest dataset of 32 patients. The proposed metrics showed high degree of reproducibility in a repeated experiment (concordance, CCC >= 0.897; dynamic range, DR >= 0.92). Association with overall survival was evaluated by Cox proportional hazard regression, Kaplan-Meier survival curves, and the log-rank test. Both features were associated with overall survival (convexity: p = 0.008; entropy ratio: p = 0.04) in Cohort 1 but not in Cohort 2 (convexity: p = 0.7; entropy ratio: p = 0.8). In both cohorts, these features were found to be descriptive and demonstrated the link between imaging characteristics and patient survival in lung adenocarcinoma.
C1 [Grove, Olya; Wang, Hua; Gu, Yuhua; Balagurunathan, Yoganand; Gatenby, Robert A.; Gillies, Robert J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Imaging & Metab, Tampa, FL 33612 USA.
[Berglund, Anders E.; Eschrich, Steven] H Lee Moffitt Canc Ctr & Res Inst, Dept Biomed Informat, Tampa, FL USA.
[Schabath, Matthew B.] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA.
[Eikman, Edward; Gatenby, Robert A.; Gillies, Robert J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiol, Tampa, FL USA.
[Dekker, Andre; Lambin, Philippe] Maastricht Univ, Res Inst GROW, MAASTRO Clin, Dept Radiat Oncol, NL-6229 ET Maastricht, Netherlands.
[Wang, Hua] Tianjin Med Univ, Key Lab Canc Prevent & Therapy, Canc Inst & Hosp, Dept Radiol,Natl Clin Res Ctr Canc, Tianjin, Peoples R China.
[Aerts, Hugo J. W. L.; Velazquez, Emmanuel Rios] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiat Oncol,Dana Farber Canc Inst, Boston, MA USA.
[Aerts, Hugo J. W. L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol, Boston, MA USA.
RP Gillies, RJ (reprint author), H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Imaging & Metab, Tampa, FL 33612 USA.
EM Robert.Gillies@Moffitt.org
RI Aerts, Hugo/P-6350-2015; Schabath, Matthew/J-3763-2016;
OI Aerts, Hugo/0000-0002-2122-2003; Schabath, Matthew/0000-0003-3241-3216;
Dekker, Andre/0000-0002-0422-7996
FU National Cancer Institute; NIH/NCI, Radiomics of NSCLC [U01CA143062];
NIH/NCI, Radiomics of Lung Cancer Screening [P50CA119997]; Florida
Biomedical Research Programs: King Team Science Grant [2KT01]
FX Funding provided by National Cancer Institute: http://www.cancer.gov/,
1.NIH/NCI U01CA143062, Radiomics of NSCLC; 2. NIH/NCI P50CA119997,
Radiomics of Lung Cancer Screening. Florida Biomedical Research
Programs:
http://researchtest.magnet.fsu.edu/newsletters/2013/July/documents/2013-
2014%20SUMMER%20CALL%20King%20Program.pdf, King Team Science Grant
2KT01. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 28
TC 20
Z9 20
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 4
PY 2015
VL 10
IS 3
AR e0118261
DI 10.1371/journal.pone.0118261
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC9JM
UT WOS:000350685900026
PM 25739030
ER
PT J
AU Reategui, E
Aceto, N
Lim, EJ
Sullivan, JP
Jensen, AE
Zeinali, M
Martel, JM
Aranyosi, AJ
Li, W
Castleberry, S
Bardia, A
Sequist, LV
Haber, DA
Maheswaran, S
Hammond, PT
Toner, M
Stott, SL
AF Reategui, Eduardo
Aceto, Nicola
Lim, Eugene J.
Sullivan, James P.
Jensen, Anne E.
Zeinali, Mahnaz
Martel, Joseph M.
Aranyosi, Alexander J.
Li, Wei
Castleberry, Steven
Bardia, Aditya
Sequist, Lecia V.
Haber, Daniel A.
Maheswaran, Shyamala
Hammond, Paula T.
Toner, Mehmet
Stott, Shannon L.
TI Tunable Nanostructured Coating for the Capture and Selective Release of
Viable Circulating Tumor Cells
SO ADVANCED MATERIALS
LA English
DT Article
ID BREAST-CANCER; EFFICIENT CAPTURE; MELANOMA-CELLS; WHOLE-BLOOD;
NANOMATERIALS; METASTASIS; MUTATIONS; EGFR
AB A layer-by-layer gelatin nanocoating is presented for use as a tunable, dual response biomaterial for the capture and release of circulating tumor cells (CTCs) from cancer patient blood. The entire nanocoating can be dissolved from the surface of microfluidic devices through biologically compatible temperature shifts. Alternatively, individual CTCs can be released through locally applied mechanical stress.
C1 [Reategui, Eduardo; Lim, Eugene J.; Jensen, Anne E.; Zeinali, Mahnaz; Martel, Joseph M.; Aranyosi, Alexander J.; Toner, Mehmet; Stott, Shannon L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med, Charlestown, MA 02129 USA.
[Reategui, Eduardo; Martel, Joseph M.; Toner, Mehmet; Stott, Shannon L.] Harvard Univ, Sch Med, Shriners Hosp Children, Boston, MA 02114 USA.
[Reategui, Eduardo; Martel, Joseph M.; Toner, Mehmet] Harvard Univ, Med Sch 55, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Aceto, Nicola; Sullivan, James P.; Bardia, Aditya; Sequist, Lecia V.; Haber, Daniel A.; Maheswaran, Shyamala] Harvard Univ, Med Sch Boston, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Lim, Eugene J.] MIT, Dept Elect Engn, Cambridge, MA 02139 USA.
[Li, Wei; Castleberry, Steven; Hammond, Paula T.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Haber, Daniel A.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
[Stott, Shannon L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RP Stott, SL (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med, Bldg 114,16th St, Charlestown, MA 02129 USA.
EM sstott@mgh.harvard.edu
RI Li, Wei/P-3546-2016;
OI Li, Wei/0000-0002-4738-1475; Aranyosi, Alexander/0000-0002-8133-5026
FU Stand Up to Cancer; Howard Hughes Medical Institute; NIH [CA129933, P41
EB002503-11]; National Institute for Biomedical Imaging and
Bioengineering (NIBIB) [EB008047]
FX The authors acknowledge all our patients who participated in this study
and the healthy volunteers who kindly donated their blood. Blood
specimens for CTC isolation were obtained after informed patient consent
according to institutional review board (IRB) protocol (05-300), at the
Massachusetts General Hospital. This work was supported by grants from
Stand Up to Cancer (D.A.H., M.T., S.M.), Howard Hughes Medical Institute
(D.A.H.), NIH CA129933 (D.A.H.), National Institute for Biomedical
Imaging and Bioengineering (NIBIB) EB008047 (M.T., D.A.H.), NIH P41
EB002503-11 (M.T.). Thanks to Laura Libby and Octavio Hurtado for expert
technical support. Thanks to Bavand Keshavarz for helping with microtip
design, Matthew Phillips for the CTC enumeration scans, Thomas Carey for
the atomic force microscopy analysis, and Charles P. Lai for the
nanoparticle size characterization.
NR 33
TC 33
Z9 33
U1 40
U2 180
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD MAR 4
PY 2015
VL 27
IS 9
BP 1593
EP +
DI 10.1002/adma.201404677
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
Physics
GA CC7IO
UT WOS:000350541100015
PM 25640006
ER
PT J
AU Blount, JW
Redan, BW
Ferruzzi, MG
Reuhs, BL
Cooper, BR
Harwood, JS
Shulaev, V
Pasinetti, G
Dixon, RA
AF Blount, Jack W.
Redan, Benjamin W.
Ferruzzi, Mario G.
Reuhs, Bradley L.
Cooper, Bruce R.
Harwood, John S.
Shulaev, Vladimir
Pasinetti, Giulio
Dixon, Richard A.
TI Synthesis and Quantitative Analysis of Plasma-Targeted Metabolites of
Catechin and Epicatechin
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE catechin; glucuronosylation; O-methylation; phase II metabolites;
semisynthesis; structure determination; two-site validation
ID (-)-EPICATECHIN METABOLITES; GASTROINTESTINAL-TRACT; ALZHEIMERS-DISEASE;
ORAL INGESTION; RAT PLASMA; IN-VIVO; MATRIX; BIOAVAILABILITY;
PROCYANIDINS; FLAVAN-3-OLS
AB Grape seed polyphenolic extract (GSPE) rich in the flavan-3-ols (+)-catechin and (-)-epicatechin beneficially modulates Alzheimer's Disease phenotypes in animal models. The parent molecules in the extract are converted to a series of methylated and glucuronidated derivatives. To fully characterize these metabolites and establish a robust quantitative assay of their levels in biological fluids, we have implemented a partial synthetic approach utilizing chemical methylation followed by enzymatic glucuronidation. Liquid chromatography/time-of-flight mass spectrometry (LC-TOF-MS) and nuclear magnetic resonance (NMR) spectroscopy were used to assign unequivocal structures to the compounds. An analytical method using solid-phase extraction and LC-MS/MS in selective reaction monitoring mode (SRM) was validated for their quantitation in plasma. These studies provide a basis for improvements in future work on the bioavailability, metabolism, and mechanism of action of metabolites derived from dietary flavan-3-ols in a range of interventions.
C1 [Blount, Jack W.; Shulaev, Vladimir; Dixon, Richard A.] Univ N Texas, Dept Biol Sci, Denton, TX 76203 USA.
[Redan, Benjamin W.; Ferruzzi, Mario G.; Reuhs, Bradley L.] Purdue Univ, Dept Nutr Sci, W Lafayette, IN 47907 USA.
[Ferruzzi, Mario G.] Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA.
[Pasinetti, Giulio] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Pasinetti, Giulio] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Cooper, Bruce R.] Purdue Univ, Bindley Biosci Ctr Metabolite Profiling Facil, W Lafayette, IN 47907 USA.
[Harwood, John S.] Purdue Univ, Purdue Interdept NMR Facil, W Lafayette, IN 47907 USA.
[Harwood, John S.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
RP Dixon, RA (reprint author), Univ N Texas, Dept Biol Sci, 1155 Union Circle 305220, Denton, TX 76203 USA.
EM Richard.Dixon@unt.edu
FU National Institutes of Health [5 PO1 AT004511-05]; University of North
Texas; Purdue University; Career Scientist Award in the Research and
Development unit; National Science Foundation [DGE-1333468]
FX This work was supported by National Institutes of Health grant 5 PO1
AT004511-05 Administrative Supplement to G.P. and by the University of
North Texas and Purdue University. This material is also the result of
work supported in part with resources and the use of facilities at the
James J. Peters Veterans Affairs Medical Center, Bronx, NY. In addition,
GMP holds a Career Scientist Award in the Research and Development unit
and is the Director of the Basic and Biomedical Research and Training
Program, GRECC, James J. Peters Veterans Affairs Medical Center. We
acknowledge that the contents of this manuscript do not represent the
views of the U.S. Department of Veterans Affairs or the United States
Government. B.W.R. is supported by National Science Foundation grant
DGE-1333468.
NR 27
TC 4
Z9 4
U1 7
U2 50
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD MAR 4
PY 2015
VL 63
IS 8
BP 2233
EP 2240
PG 8
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
Technology
SC Agriculture; Chemistry; Food Science & Technology
GA CC8JR
UT WOS:000350615000014
PM 25671729
ER
PT J
AU Akamatsu, Y
Nishijima, Y
Lee, CC
Yang, SY
Shi, L
An, L
Wang, RK
Tominaga, TJ
Liu, JL
AF Akamatsu, Yosuke
Nishijima, Yasuo
Lee, Chih Cheng
Yang, Shih Yen
Shi, Lei
An, Lin
Wang, Ruikang K.
Tominaga, Teiji
Liu, Jialing
TI Impaired Leptomeningeal Collateral Flow Contributes to the Poor Outcome
following Experimental Stroke in the Type 2 Diabetic Mice
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE anastomosis; arteriogenesis; Doppler OCT; MCAO; metabolic syndrome;
vascular remodeling
ID ACUTE ISCHEMIC-STROKE; FOCAL CEREBRAL-ISCHEMIA; PLASMINOGEN-ACTIVATOR
INHIBITOR-1; MARKED NEUROPROTECTIVE EFFICACY; ALBUMIN THERAPY;
BLOOD-FLOW; IN-VIVO; MICROVASCULAR RESPONSES; SERUM-ALBUMIN;
HYPERGLYCEMIA
AB Collateral status is an independent predictor of stroke outcome. However, the spatiotemporal manner in which collateral flow maintains cerebral perfusion during cerebral ischemia is poorly understood. Diabetes exacerbates ischemic brain damage, although the impact of diabetes on collateral dynamics remains to be established. Using Doppler optical coherent tomography, a robust recruitment of leptomeningeal collateral flow was detected immediately after middle cerebral artery ( MCA) occlusion in C57BL/6 mice, and it continued to grow over the course of 1 week. In contrast, an impairment of collateral recruitment was evident in the Type 2 diabetic db/db mice, which coincided with a worse stroke outcome compared with their normoglycemic counterpart db/+, despite their equally well-collateralized leptomeningeal anastomoses. Similar to the wild-type mice, both db/+ and db/db mice underwent collateral growth 7 d after MCA stroke, although db/db mice still exhibited significantly reduced retrograde flow into the MCA territory chronically. Acutely induced hyperglycemia in the db/+ mice did not impair collateral flow after stroke, suggesting that the state of hyperglycemia alone was not sufficient to impact collateral flow. Human albumin was efficacious in improving collateral flow and outcome after stroke in the db/db mice, enabling perfusion to proximal MCA territory that was usually not reached by retrograde flow from anterior cerebral artery without treatment. Our results suggest that the impaired collateral status contributes to the exacerbated ischemic injury in mice with Type 2 diabetes, and modulation of collateral flow has beneficial effects on stroke outcome among these subjects.
C1 [Akamatsu, Yosuke; Nishijima, Yasuo; Lee, Chih Cheng; Yang, Shih Yen; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94121 USA.
[Akamatsu, Yosuke; Nishijima, Yasuo; Lee, Chih Cheng; Yang, Shih Yen; Liu, Jialing] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Akamatsu, Yosuke; Nishijima, Yasuo; Tominaga, Teiji] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi 9808574, Japan.
[Shi, Lei; An, Lin; Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
[Shi, Lei; An, Lin; Wang, Ruikang K.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
RP Liu, JL (reprint author), Univ Calif San Francisco, Dept Neurol Surg 112C, 1700 Owens St, San Francisco, CA 94158 USA.
EM jialing.liu@ucsf.edu
RI Liu, Jialing/A-8627-2012
OI Liu, Jialing/0000-0003-4420-4382
FU National Institutes of Health [R01 NS071050]; Veterans Administration
Merit Award [I01RX000655]; American Heart Hospital Association [EIA
0940065N]; NIH [R01HL093140]
FX This work was supported by National Institutes of Health Grant R01
NS071050 to J.L., Veterans Administration Merit Award I01RX000655 to J.
L., American Heart Hospital Association EIA 0940065N to J.L., and NIH
R01HL093140 to R.K.W. We thank Dr. Philip Weinstein (University of
California at San Francisco) for helpful discussion and Ilona Garner
(University of California at San Francisco) for editorial assistance.
NR 55
TC 13
Z9 13
U1 1
U2 5
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAR 4
PY 2015
VL 35
IS 9
BP 3851
EP 3864
DI 10.1523/JNEUROSCI.3838-14.2015
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA CD0DP
UT WOS:000350740900013
PM 25740515
ER
PT J
AU Thomson, D
Turner, A
Lauder, S
Gigler, ME
Berk, L
Singh, AB
Pasco, JA
Berk, M
Sylvia, L
AF Thomson, Daniel
Turner, Alyna
Lauder, Sue
Gigler, Margaret E.
Berk, Lesley
Singh, Ajeet B.
Pasco, Julie A.
Berk, Michael
Sylvia, Louisa
TI A brief review of exercise, bipolar disorder, and mechanistic pathways
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Review
DE bipolar disorder; exercise; mechanistic pathways; depression; hypomania;
neurogenesis
ID APPROACH SYSTEM BAS; PHYSICAL-ACTIVITY; PSYCHIATRIC-DISORDERS; SPECTRUM
DISORDERS; RANDOMIZED-TRIALS; MENTAL-ILLNESS; BLOOD-PRESSURE;
DEPRESSION; SYMPTOMS; STRESS
AB Despite evidence that exercise has been found to be effective in the treatment of depression, it is unclear whether these data can be extrapolated to bipolar disorder. Available evidence for bipolar disorder is scant, with no existing randomized controlled trials having tested the impact of exercise on depressive, manic or hypomanic symptomatology. Although exercise is often recommended in bipolar disorder, this is based on extrapolation from the unipolar literature, theory and clinical expertise and not empirical evidence. In addition, there are currently no available empirical data on program variables, with practical implications on frequency, intensity and type of exercise derived from unipolar depression studies. The aim of the current paper is to explore the relationship between exercise and bipolar disorder and potential mechanistic pathways. Given the high rate of medical co-morbidities experienced by people with bipolar disorder, it is possible that exercise is a potentially useful and important intervention with regard to general health benefits; however, further research is required to elucidate the impact of exercise on mood symptomology.
C1 [Thomson, Daniel] RMIT Univ, Dept Appl Sci, Bundoora, Vic, Australia.
[Turner, Alyna; Berk, Lesley; Singh, Ajeet B.; Pasco, Julie A.; Berk, Michael] Deakin Univ, Innovat Mental & Phys Hlth & Clin Treatment Strat, Sch Med, Geelong, Vic 3220, Australia.
[Turner, Alyna; Lauder, Sue; Berk, Michael] Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia.
[Turner, Alyna] Univ Newcastle, Sch Med & Publ Hlth, Ctr Translat Neurosci & Mental Hlth, Callaghan, NSW 2308, Australia.
[Lauder, Sue] Federat Univ Australia, Ballarat, NC, Australia.
[Gigler, Margaret E.; Sylvia, Louisa] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Berk, Lesley] Deakin Univ, Sch Psychol, Mental Hlth & Wellbeing Strateg Res Ctr, Greelong, Vic, Australia.
[Pasco, Julie A.] Univ Melbourne, North West Acad Ctr, Dept Med, St Albans, Vic, Australia.
[Berk, Michael] Furey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia.
[Berk, Michael] Natl Ctr Excellence Youth Mental Hlth, Orygen, Parkville, Vic, Australia.
[Sylvia, Louisa] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA.
RP Turner, A (reprint author), Deakin Univ, Innovat Mental & Phys Hlth & Clin Treatment Strat, Sch Med, Kitchener House,POB 281, Geelong, Vic 3220, Australia.
EM alyna.turner@barwonhealth.org.au
OI Berk, Lesley/0000-0002-3677-7503
FU NHMRC; Perpetual; Amgen (Europe) GmBH; BUPA Foundation; Amgen; Sanofi
Aventis; NHMRC Senior Principal Research Fellowship [1059660]; NTH;
Cooperative Research Centre; Simons Autism Foundation; Cancer Council of
Victoria; Stanley Medical Research Foundation; MBF; Beyond Blue; Rotary
Health; Geelong Medical Research Foundation; Bristol Myers Squibb; Eli
Lilly; Glaxo SmithKline; Meat and Livestock Board; Organon; Novartis;
Mayne Pharma; Servier; Woolworths
FX No funding has been received to support this study, Ajeet B. Singh is a
casual speaker for Servier Australia, Pfizer Australia, and Lundbeck
Australia. Julie A. Pasco has received grant/research support from the
NHMRC, Perpetual, Amgen (Europe) GmBH, and BUPA Foundation and has
received speaker fees from Amgen and Sanofi Aventis. Michael Berk is
supported by a NHMRC Senior Principal Research Fellowship 1059660 and
has received Grant/Research Support from the NTH, Cooperative Research
Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley
Medical Research Foundation, MBF, NHMRC, Beyond Blue, Rotary Health,
Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly,
Glaxo SmithKline, Meat and Livestock Board, Organon, Novartis, Mayne
Pharma, Servier and Woolworths, has been a speaker for Astra Zeneca,
Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag,
Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth,
and served as a consultant to Astra Zeneca, Bioadvaraex, Bristol Myers
Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck Merck and
Servier. Louisa Sylvia was a shareholder in Concordant Rater Systems and
serves as a consultant for United Biosource Corporation, Clinical Trials
Network and Institute, Clintara. She receives royalties from New
Harbinger.
NR 77
TC 9
Z9 9
U1 6
U2 27
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD MAR 4
PY 2015
VL 6
AR 147
DI 10.3389/fpsyg.2015.00147
PG 10
WC Psychology, Multidisciplinary
SC Psychology
GA CC3WP
UT WOS:000350282000001
PM 25788889
ER
PT J
AU Hatfield, SM
Kjaergaard, J
Lukashev, D
Schreiber, TH
Belikoff, B
Abbott, R
Sethumadhavan, S
Philbrook, P
Ko, K
Cannici, R
Thayer, M
Rodig, S
Kutok, JL
Jackson, EK
Karger, B
Podack, ER
Ohta, A
Sitkovsky, MV
AF Hatfield, Stephen M.
Kjaergaard, Jorgen
Lukashev, Dmitriy
Schreiber, Taylor H.
Belikoff, Bryan
Abbott, Robert
Sethumadhavan, Shalini
Philbrook, Phaethon
Ko, Kami
Cannici, Ryan
Thayer, Molly
Rodig, Scott
Kutok, Jeffrey L.
Jackson, Edwin K.
Karger, Barry
Podack, Eckhard R.
Ohta, Akio
Sitkovsky, Michail V.
TI Immunological mechanisms of the antitumor effects of supplemental
oxygenation
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID NEGATIVE BREAST-CANCER; T REGULATORY CELLS; LUNG INJURY; ADOPTIVE
IMMUNOTHERAPY; THERAPEUTIC-EFFICACY; TUMOR INFILTRATION; ADENOSINE
RELEASE; DOWN-REGULATION; HYPOXIA; RECEPTOR
AB Antitumor T cells either avoid or are inhibited in hypoxic and extracellular adenosine-rich tumor microenvironments (TMEs) by A2A adenosine receptors. This may limit further advances in cancer immunotherapy. There is a need for readily available and safe treatments that weaken the hypoxia-A2-adenosinergic immunosuppression in the TME. Recently, we reported that respiratory hyperoxia decreases intratumoral hypoxia and concentrations of extracellular adenosine. We show that it also reverses the hypoxia-adenosinergic immunosuppression in the TME. This, in turn, stimulates (i) enhanced intratumoral infiltration and reduced inhibition of endogenously developed or adoptively transfered tumor-reactive CD8 T cells, (ii) increased proinflammatory cytokines and decreased immunosuppressive molecules, such as transforming growth factor-beta (TGF-beta), (iii) weakened immunosuppression by regulatory T cells, and (iv) improved lung tumor regression and long-term survival in mice. Respiratory hyperoxia also promoted the regression of spontaneous metastasis from orthotopically grown breast tumors. These effects are entirely T cell- and natural killer cell- dependent, thereby justifying the testing of supplemental oxygen as an immunological coadjuvant to combine with existing immunotherapies for cancer.
C1 [Hatfield, Stephen M.; Kjaergaard, Jorgen; Lukashev, Dmitriy; Belikoff, Bryan; Abbott, Robert; Sethumadhavan, Shalini; Philbrook, Phaethon; Ko, Kami; Cannici, Ryan; Thayer, Molly; Ohta, Akio; Sitkovsky, Michail V.] Northeastern Univ, New England Inflammat & Tissue Protect Inst, Boston, MA 02115 USA.
[Schreiber, Taylor H.; Podack, Eckhard R.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
[Rodig, Scott; Kutok, Jeffrey L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Jackson, Edwin K.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15219 USA.
[Karger, Barry] Northeastern Univ, Barnett Inst Chem & Biol Anal, Boston, MA 02115 USA.
[Sitkovsky, Michail V.] Harvard Inst Med, Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
RP Sitkovsky, MV (reprint author), Northeastern Univ, New England Inflammat & Tissue Protect Inst, 360 Huntington Ave, Boston, MA 02115 USA.
EM m.sitkovsky@neu.edu
FU Northeastern University; NIH [R01 CA 112561, R01 CA 111985, R21 AT
002788, U19 AI 091693]; National Cancer Institute [5PO1CA109094-03];
National Institute of Allergy and Infectious Diseases 1P01 grant
[AI096396-01 3, HL109002, DK091190, DK068575, DK079307, CA168628];
Bankhead-Coley Postdoctoral Fellowship; NIH (Dana-Farber Cancer
Institute); NIH (Harvard Medical School-Northeastern University Joint
Program in Cancer Drug Development)
FX This work was supported by funding from Northeastern University and NIH
grants to M.V.S. (R01 CA 112561, R01 CA 111985, R21 AT 002788, U19 AI
091693, Dana-Farber Cancer Institute, and Harvard Medical
School-Northeastern University Joint Program in Cancer Drug Development)
as well as by National Cancer Institute grant 5PO1CA109094-03 and
National Institute of Allergy and Infectious Diseases 1P01 grant
AI096396-01 3 to E.R.P.; HL109002, DK091190, DK068575, DK079307, and
CA168628 to E.K.J.; and a Bankhead-Coley Postdoctoral Fellowship to
T.H.S.
NR 49
TC 35
Z9 36
U1 2
U2 20
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAR 4
PY 2015
VL 7
IS 277
AR 277ra30
DI 10.1126/scitranslmed.aaa1260
PG 12
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA CC4YE
UT WOS:000350361800006
PM 25739764
ER
PT J
AU Kim, HI
Kim, JA
Choi, EJ
Harris, JB
Jeong, SY
Son, SJ
Kim, Y
Shin, OS
AF Kim, Hyung-Ip
Kim, Ji-Ae
Choi, Eun-Jin
Harris, Jason B.
Jeong, Seong-Yeop
Son, Seok-Jun
Kim, Younghoon
Shin, Ok Sarah
TI In vitro and in vivo antimicrobial efficacy of natural plant-derived
compounds against Vibrio cholerae of O1 El Tor Inaba serotype
SO BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE magnolol; honokiol; V. cholerae; C. elegans; antibacterial effect
ID KAPPA-B ACTIVATION; CAENORHABDITIS-ELEGANS; STAPHYLOCOCCUS-AUREUS;
BACTERICIDAL ACTIVITY; BIOFILMS ENHANCE; HONOKIOL; MAGNOLOL; CELLS;
INHIBITION; EMERGENCE
AB In this study, we investigated antibacterial activities of 20 plant-derived natural compounds against Gram-negative enteric pathogens. We found that both flavonoids and non-flavonoids, including honokiol and magnolol, possess specific antibacterial activities against V. cholerae, but not against other species of Gram-negative bacterium which we tested. Using various antibacterial assays, we determined that there was a dose-dependent bactericidal and biofilm inhibitory activity of honokiol and magnolol against Vibrio cholerae. In addition to antibacterial activities, these molecules also induced an attenuating effect on reactive oxygen species (ROS) production and pro-inflammatory responses generated by macrophages in response to lipopolysaccharides (LPS). Additionally, Caenorhabditis elegans lethality assay revealed that honokiol and magnolol have an ability to extend a lifespan of V. cholerae-infected worms, contributing to prolonged survival of worms after lethal infection. Altogether, our data show for the first time that honokiol and magnolol may be considered as attractive protective or preventive food adjuncts for cholera.
C1 [Kim, Hyung-Ip; Kim, Ji-Ae; Shin, Ok Sarah] Korea Univ, Coll Med, Dept Biomed Sci, Seoul 136705, South Korea.
[Choi, Eun-Jin] Korea Univ, Coll Med, Asian Pacific Influenza Inst, Seoul 136705, South Korea.
[Harris, Jason B.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Harris, Jason B.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Jeong, Seong-Yeop] MIFI, Sunchang Gun, South Korea.
[Son, Seok-Jun; Kim, Younghoon] Chonbuk Natl Univ, Dept Anim Sci, Plus Grad Program BK21, Jeonju 561756, South Korea.
[Son, Seok-Jun; Kim, Younghoon] Chonbuk Natl Univ, Inst Agr Sci & Technol, Jeonju 561756, South Korea.
[Shin, Ok Sarah] Korea Univ, Coll Med, Dept Microbiol, Seoul 136705, South Korea.
RP Kim, Y (reprint author), Chonbuk Natl Univ, Dept Anim Sci, Plus Grad Program BK21, Jeonju 561756, South Korea.
EM ykeys2584@jbnu.ac.kr
FU Ministry for Health & Welfare, Republic of Korea [R1306922]; Rural
Development Administration, Republic of Korea [PJ009990032014]
FX Korean Health Technology R&D Projects (R1306922), Ministry for Health &
Welfare, Republic of Korea (O.S.S), and by the Cooperative Research
Program for Agriculture Science & Technology Development
(PJ009990032014), Rural Development Administration, Republic of Korea
(S.Y.J.).
NR 38
TC 4
Z9 5
U1 1
U2 15
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0916-8451
EI 1347-6947
J9 BIOSCI BIOTECH BIOCH
JI Biosci. Biotechnol. Biochem.
PD MAR 4
PY 2015
VL 79
IS 3
BP 475
EP 483
DI 10.1080/09168451.2014.991685
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Chemistry, Applied; Food Science & Technology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Chemistry; Food Science & Technology
GA CC6JE
UT WOS:000350470400017
PM 25516242
ER
PT J
AU Sinclair, SJ
Smith, M
Chung, WJ
Liebman, R
Stein, MB
Antonius, D
Siefert, CJ
Haggerty, G
Blais, MA
AF Sinclair, Samuel Justin
Smith, Michaela
Chung, Wei-Jean
Liebman, Rachel
Stein, Michelle B.
Antonius, Daniel
Siefert, Caleb J.
Haggerty, Greg
Blais, Mark A.
TI Extending the Validity of the Personality Assessment Inventory's (PAI)
Level of Care Index (LOCI) in Multiple Psychiatric Settings
SO JOURNAL OF PERSONALITY ASSESSMENT
LA English
DT Article
ID SERVICE UTILIZATION; HOSPITALIZATION; SCHIZOPHRENIA; SAMPLE
AB The purpose of this study was to extend the validity and clinical application of the Level of Care Index (LOCI) from the Personality Assessment Inventory (PAI) in 2 independent psychiatric samples. In Study 1 (N = 201), the LOCI effectively differentiated level of care (inpatients from outpatients), and was also meaningfully associated with risk factors for psychiatric admission (e.g., suicidal ideation, self-harming behavior, previous psychiatric admission, etc.), even after controlling for other demographic variables (range of Cohen's ds = 0.57-1.00). Likewise, the LOCI also incremented other risk indicators (suicide and violence history) and relevant PAI indexes (i.e., Mean Clinical Elevation, and Suicide and Violence Potential) in predicting level of care, and explained an additional 6% to 12% of variance in the target variable. Diagnostic efficiency analyses indicated LOCI scores in the range of 15 to 18 optimize positive and negative predictive power, and classification rate. In Study 2 (N = 96), the LOCI was found to be significantly higher in those with a recent psychiatric admission within the past 6 months (d = 0.64), as compared to those without an admission. Similarly, those who were admitted for suicide risk had significantly higher mean LOCI scores as compared to those who did not (d = 0.70). The clinical implications of these findings and potential application of the LOCI are discussed.
C1 [Sinclair, Samuel Justin; Smith, Michaela; Chung, Wei-Jean; Liebman, Rachel; Stein, Michelle B.; Blais, Mark A.] Massachusetts Gen Hosp, Psychol Evaluat & Res Lab PEaRL, Boston, MA 02114 USA.
[Sinclair, Samuel Justin; Smith, Michaela; Chung, Wei-Jean; Liebman, Rachel; Stein, Michelle B.; Blais, Mark A.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Antonius, Daniel] SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14260 USA.
[Antonius, Daniel] NYU, Dept Psychiat, Sch Med, New York, NY 10003 USA.
[Siefert, Caleb J.] Univ Michigan Dearborn, Dept Behav Sci, Dearborn, MI USA.
[Haggerty, Greg] Nassau Univ, Von Tauber Inst Global Psychiat, Med Ctr, E Meadow, NY USA.
RP Sinclair, SJ (reprint author), Massachusetts Gen Hosp, Psychol Evaluat & Res Lab PEaRL, One Bowdoin Sq,7th Floor, Boston, MA 02114 USA.
EM SJSinclair@MGH.Harvard.Edu
NR 26
TC 0
Z9 0
U1 0
U2 7
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0022-3891
EI 1532-7752
J9 J PERS ASSESS
JI J. Pers. Assess.
PD MAR 4
PY 2015
VL 97
IS 2
BP 145
EP 152
DI 10.1080/00223891.2014.941441
PG 8
WC Psychology, Clinical; Psychology, Social
SC Psychology
GA CB2JZ
UT WOS:000349454700005
PM 25101817
ER
PT J
AU Ruben, MA
Hall, JA
Mast, MS
AF Ruben, Mollie A.
Hall, Judith A.
Mast, Marianne Schmid
TI Smiling in a Job Interview: When Less Is More
SO JOURNAL OF SOCIAL PSYCHOLOGY
LA English
DT Article
DE smiling; interview context; nonverbal behavior; hiring decisions;
impression management
ID NONVERBAL BEHAVIOR; EMPLOYMENT INTERVIEWS; SELECTION INTERVIEW;
METAANALYSIS; FEMALE; COMMUNICATION; JUDGMENTS; PERFORMANCE; APPLICANTS;
TACTICS
AB Two studies examined the effect of applicants' smiling on hireability. In a pre-test study, participants were asked to rate the expected behavior for four types of applicants. Newspaper reporter applicants were expected to be more serious than applicants for other jobs. In Study 1, participants were randomly assigned to be an applicant or interviewer for a newspaper reporting job. Smiling was negatively related to hiring, and smiling mediated the relation between applicants' motivation to make a good impression and hiring. Hiring was maximized when applicants smiled less in the middle of the interview relative to the start and end. In Study 2, participants watched Study 1 clips and were randomly assigned to believe the applicants were applying to one of four jobs. Participants rated more suitability when applicants smiled less, especially for jobs associated with a serious demeanor. This research shows that job type is an important moderator of the impact of smiling on hiring.
C1 [Ruben, Mollie A.] US Dept Vet Affairs, Ctr Healthcare Org & Implementat Res, Boston, MA 02130 USA.
[Hall, Judith A.] Northeastern Univ, Dept Psychol, Boston, MA USA.
[Mast, Marianne Schmid] Univ Lausanne, Dept Org Behav, CH-1015 Lausanne, Switzerland.
RP Ruben, MA (reprint author), US Dept Vet Affairs, Ctr Healthcare Org & Implementat Res, 150 S Huntington Ave,Bldg 9, Boston, MA 02130 USA.
EM mollie.ruben@va.gov
OI Ruben, Mollie/0000-0001-8918-8932
NR 33
TC 2
Z9 2
U1 2
U2 28
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0022-4545
EI 1940-1183
J9 J SOC PSYCHOL
JI J. Soc. Psychol.
PD MAR 4
PY 2015
VL 155
IS 2
BP 107
EP 126
DI 10.1080/00224545.2014.972312
PG 20
WC Psychology, Social
SC Psychology
GA CB0PG
UT WOS:000349328100003
PM 25309976
ER
PT J
AU Olds, PK
Kiwanuka, JP
Nansera, D
Huang, Y
Bacchetti, P
Jin, CS
Gandhi, M
Haberer, JE
AF Olds, Peter K.
Kiwanuka, Julius P.
Nansera, Denis
Huang, Yong
Bacchetti, Peter
Jin, Chengshi
Gandhi, Monica
Haberer, Jessica E.
TI Assessment of HIV antiretroviral therapy adherence by measuring drug
concentrations in hair among children in rural Uganda
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
DE human immunodeficiency virus; Uganda; adherence; children;
antiretroviral therapy
ID SELF-REPORT MEASURES; TANDEM MASS-SPECTROMETRY; INFECTED CHILDREN;
HIV-1-INFECTED PATIENTS; VIROLOGICAL RESPONSE; VIRAL LOAD; RESISTANCE;
INDINAVIR; ASSOCIATION; EFAVIRENZ
AB Current tools for measuring medication adherence have significant limitations, especially among pediatric populations. We conducted a prospective observational study to assess the use of antiretroviral (ARV) drug levels in hair for evaluating antiretroviral therapy (ART) adherence among HIV-infected children in rural Uganda. Three-day caregiver recall, 30-day visual analog scale (VAS), Medication Event Monitoring System (MEMS), and unannounced pill counts and liquid formulation weights (UPC) were collected monthly over a one-year period. Hair samples were collected quarterly and analyzed for nevirapine (NVP) levels, and plasma HIV RNA levels were collected every six months. Among children with at least one hair sample collected, we used univariable random intercept linear regression models to compare log transformed NVP concentrations with each adherence measure, and the child's age, sex, and CD4 count percentage (CD4%). One hundred and twenty-one children aged 2-10 years were enrolled in the study; 74 (61%) provided at least one hair sample, and the mean number of hair samples collected per child was 1.9 (standard deviation [SD] 1.0). Three-day caregiver recall, VAS, and MEMS were found to be positively associated with increasing NVP concentration in hair, although associations were not statistically significant. UPC was found to have a nonsignificant negative association with increasing hair NVP concentration. In conclusion, NVP drug concentrations in hair were found to have nonsignificant, although generally positive, associations with other adherence measures in a cohort of HIV-infected children in Uganda. Hair collection in this population proved challenging, suggesting the need for community education and buy-in with the introduction of novel methodologies.
C1 [Olds, Peter K.; Haberer, Jessica E.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02163 USA.
[Kiwanuka, Julius P.; Nansera, Denis] Mbarara Univ Sci & Technol, Dept Paediat, Mbarara, Uganda.
[Huang, Yong; Bacchetti, Peter; Jin, Chengshi; Gandhi, Monica] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Haberer, Jessica E.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Haberer, Jessica E.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
RP Haberer, JE (reprint author), Harvard Univ, Sch Med, Dept Med, Boston, MA 02163 USA.
EM JHABERER@partners.org
FU NIAID NIH HHS [R01 AI065233, 3R01AI065233-05S2, R01AI098472, U01
AI034989, R01 AI098472]; NIMH NIH HHS [R21 MH083306, K23MH087228,
R21MH083306, K23 MH087228]
NR 47
TC 4
Z9 4
U1 4
U2 15
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0954-0121
EI 1360-0451
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PD MAR 4
PY 2015
VL 27
IS 3
BP 327
EP 332
DI 10.1080/09540121.2014.983452
PG 6
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychology, Multidisciplinary; Respiratory System; Social Sciences,
Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychology; Respiratory System; Biomedical Social Sciences
GA CA1HI
UT WOS:000348663000009
PM 25483955
ER
PT J
AU Barocas, JA
Erlandson, KM
Belzer, BK
Hess, T
Sosman, J
AF Barocas, Joshua A.
Erlandson, Kristine M.
Belzer, Blythe K.
Hess, Timothy
Sosman, James
TI Advance directives among people living with HIV: room for improvement
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
DE patient care; outpatient clinic; HIV/AIDS; advance care planning;
advance directives
ID OF-LIFE CARE; CANCER-PATIENTS; HEART-FAILURE; ATTITUDES; COMPLETION;
BARRIERS; DISEASE; COMMUNICATION; ADULTS; INTERVENTION
AB While HIV has become a largely chronic disease, age-associated comorbidities are prevalent in people living with HIV (PLWH). Therefore, PLWH are appropriate for advance care planning (ACP) and advance directives (ADs) completion. We sought to characterize AD completion among outpatient PLWH. We conducted a retrospective chart review of PLWH who receive their routine care at the University of Wisconsin HIV clinic. Data were extracted from the electronic health record. Variables were entered into a stepwise multivariate logistic regression model to assess which factors were independently associated with AD completion. Five hundred and eighty eight charts were reviewed. Eighty-one percent of subjects were male and 72% were white; mean age was 46.8 years. ADs were completed by 134 subjects and 6.7% of those were completed at the HIV clinic. In the final multivariate model, those who had completed an AD were more likely to be older than age 45; ever been diagnosed with AIDS; have cardiovascular disease, neurologic disorder, chronic kidney disease, or malignancy. In this study, a small percentage of patients had documented ADs, with only a small proportion completed in the HIV clinic. The HIV clinic is an underutilized resource to offer ACP. Interventions are needed to provide the necessary ACP resources for PLWH.
C1 [Barocas, Joshua A.; Belzer, Blythe K.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53718 USA.
[Barocas, Joshua A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Erlandson, Kristine M.] Univ Colorado, Dept Med, Div Infect Dis, Aurora, CO USA.
[Hess, Timothy; Sosman, James] Univ Wisconsin, Sch Med & Publ Hlth, Div Infect Dis, Madison, WI USA.
RP Barocas, JA (reprint author), Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53718 USA.
EM jbarocas@medicine.wisc.edu
NR 48
TC 1
Z9 1
U1 2
U2 4
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0954-0121
EI 1360-0451
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PD MAR 4
PY 2015
VL 27
IS 3
BP 370
EP 377
DI 10.1080/09540121.2014.963019
PG 8
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychology, Multidisciplinary; Respiratory System; Social Sciences,
Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychology; Respiratory System; Biomedical Social Sciences
GA CA1HI
UT WOS:000348663000016
PM 25307722
ER
PT J
AU Park, CL
Wachen, JS
Kaiser, AP
Stellman, JM
AF Park, Crystal L.
Wachen, Jennifer Schuster
Kaiser, Anica Pless
Stellman, Jeanne Mager
TI Cumulative trauma and midlife well-being in American women who served in
Vietnam: effects of combat exposure and postdeployment social support
SO ANXIETY STRESS AND COPING
LA English
DT Article
DE combat exposure; trauma; PTSD; women; perceived social support
ID POSTTRAUMATIC-STRESS-DISORDER; ADVERSE CHILDHOOD EXPERIENCES;
RISK-FACTORS; NATIONAL SAMPLE; MEDIATING ROLE; VETERANS; ABUSE;
SYMPTOMS; WAR; LEGIONNAIRES
AB Background and Objectives: Research increasingly demonstrates that trauma exposure can have cumulative effects, yet much remains to be learned about effects of cumulative trauma, particularly regarding longer term adjustment. One such trauma, combat exposure, is insufficiently understood, especially for women, who are increasingly engaged in professional combat activities. Design: The study comprised a cross-sectional survey assessing multiple aspects of current well-being in women approximately 25 years after their service in Vietnam during the Vietnam War. Methods: Participants were 1374 women (78% military and 22% nonmilitary; mean age = 59.7). This study investigated the relations between three separate categories of trauma exposure (childhood, adulthood, and combat) and well-being and examined whether perceived social support at return from Vietnam moderated the association between combat exposure and well-being. Results: While both childhood and adulthood trauma exposure related to midlife well-being, combat exposure still uniquely predicted outcomes. Further, postdeployment perceived social support moderated the association of combat and well-being: recollected higher perceived social support at homecoming buffered participants from the links between combat exposure and well-being. Conclusions: These results may have important implications for interventions to reduce the impact of traumatic experiences, particularly in light of the increasing exposure of women to direct combat events.
C1 [Park, Crystal L.] Univ Connecticut, Dept Psychol, Storrs, CT 06269 USA.
[Wachen, Jennifer Schuster] VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr PTSD, Boston, MA USA.
[Wachen, Jennifer Schuster; Kaiser, Anica Pless] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Kaiser, Anica Pless] VA Boston Healthcare Syst, Behav Sci Div, Natl Ctr PTSD, Boston, MA USA.
[Stellman, Jeanne Mager] Columbia Univ, Dept Hlth Policy & Management, Mailman Sch Publ Hlth, New York, NY USA.
RP Park, CL (reprint author), Univ Connecticut, Dept Psychol, Storrs, CT 06269 USA.
EM crystal.park@uconn.edu
NR 40
TC 0
Z9 0
U1 1
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1061-5806
EI 1477-2205
J9 ANXIETY STRESS COPIN
JI Anxiety Stress Coping
PD MAR 4
PY 2015
VL 28
IS 2
BP 144
EP 161
DI 10.1080/10615806.2014.944905
PG 18
WC Neurosciences; Psychiatry; Psychology, Multidisciplinary
SC Neurosciences & Neurology; Psychiatry; Psychology
GA AY6MX
UT WOS:000347681400002
PM 25115369
ER
PT J
AU Lovejoy, J
Riffe, D
Lovejoy, TI
AF Lovejoy, Jennette
Riffe, Daniel
Lovejoy, Travis I.
TI An Examination of Direct and Indirect Effects of Exposure and Attention
to Health Media on Intentions to Avoid Unprotected Sun Exposure
SO HEALTH COMMUNICATION
LA English
DT Article
ID COGNITIVE VARIABLES RELEVANT; PARENT-BASED INTERVENTION; SKIN-CANCER
PREVENTION; UNITED-STATES; PLANNED BEHAVIOR; SUNSCREEN USE; NEWS
COVERAGE; PROTECTION; ATTITUDES; ADULTS
AB Skin cancer is the most commonly diagnosed cancer in the United States, accounting for more than 2 million diagnoses and more than 9,000 deaths annually. A regional online survey of students enrolled at institutions of higher education (N = 1,251) examined (a) associations between health media use and intentions to avoid unprotected sun exposure and (b) theoretically derived health behavior constructs that may mediate the relationship between media use and individuals' decisions to avoid unprotected sun exposure. Individuals with greater exposure and attention to health information in television, magazines, and newspapers had higher intentions to avoid unprotected sun exposure. Multiple mediation models indicated that health behavior constructs collectively mediated the relationship between television use and sun-protective behavioral intentions. Both cumulative and specific indirect mediating effects were observed for the relationship between magazine use and sun-protective behavioral intentions. However, the direction of effects was opposite to the hypothesized direction, due primarily to the association of magazine use with less favorable attitudes about sun protection and reduced behavioral control to avoid unprotected sun exposure. This study provides preliminary evidence for the interrelationships among media use, internal psychological states and cognitions, and health behavior decision making. Future studies should further explicate the mediating processes that account for the relationships between media and health behavior.
C1 [Lovejoy, Jennette] Univ Portland, Dept Commun Studies, Portland, OR 97203 USA.
[Riffe, Daniel] Univ N Carolina, Sch Journalism & Mass Commun, Chapel Hill, NC USA.
[Lovejoy, Travis I.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland Vet Affairs Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97201 USA.
RP Lovejoy, J (reprint author), Univ Portland, Dept Commun Studies, Buckley Ctr 233, 5000 N Willamette Blvd, Portland, OR 97203 USA.
EM lovejoy@up.edu
NR 59
TC 2
Z9 2
U1 3
U2 31
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1041-0236
EI 1532-7027
J9 HEALTH COMMUN
JI Health Commun.
PD MAR 4
PY 2015
VL 30
IS 3
BP 261
EP 270
DI 10.1080/10410236.2013.842526
PG 10
WC Communication; Health Policy & Services
SC Communication; Health Care Sciences & Services
GA AW9NZ
UT WOS:000346585600006
PM 24597527
ER
PT J
AU Cao, Y
Keum, NN
Chan, AT
Fuchs, CS
Wu, K
Giovannucci, EL
AF Cao, Y.
Keum, N. N.
Chan, A. T.
Fuchs, C. S.
Wu, K.
Giovannucci, E. L.
TI Television watching and risk of colorectal adenoma
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE colorectal adenoma; sedentary behaviour; television watching
ID TYPE-2 DIABETES-MELLITUS; INTENSITY PHYSICAL-ACTIVITY; ALL-CAUSE
MORTALITY; BODY-MASS INDEX; COLON-CANCER; CARDIOVASCULAR-DISEASE;
SEDENTARY BEHAVIOR; METABOLIC SYNDROME; RECTAL-CANCER; MICROSATELLITE
INSTABILITY
AB Background: Prolonged TV watching, a major sedentary behaviour, is associated with increased risk of obesity and diabetes and may involve in colorectal carcinogenesis.
Methods: We conducted a cross-sectional analysis among 31 065 men with >= 1 endoscopy in the Health Professionals Follow-up Study (1988-2008) to evaluate sitting while watching TV and its joint influence with leisure-time physical activity on risk of colorectal adenoma. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs).
Results: Prolonged sitting while watching TV was significantly associated with increased risk of colorectal adenoma (n = 4280), and adjusting for physical activity or a potential mediator body mass index did not change the estimates. The ORs (95% CIs) across categories of TV watching (0-6, 7-13, 14-20, and 21 + h per week) were 1.00 (referent), 1.09 (1.01-1.17), 1.16 (1.06-1.27), and 1.10 (0.97-1.25) (OR per 14-h per week increment = 1.11; 95% CI: 1.04-1.18; P-trend = 0.001). Compared with the least sedentary (0-6 h per week of TV) and most physically active (highest quintile) men, the most sedentary (14 + h per week) and least active (lowest quintile) men had a significant increased risk of adenoma (OR = 1.25; 95% CI: 1.05-1.49), particularly for high-risk adenoma.
Conclusions: Prolonged TV viewing is associated with modest increased risk of colorectal adenoma independent of leisure-time physical activity and minimally mediated by obesity.
C1 [Cao, Y.; Keum, N. N.; Wu, K.; Giovannucci, E. L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Chan, A. T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Chan, A. T.; Fuchs, C. S.; Giovannucci, E. L.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Chan, A. T.; Fuchs, C. S.; Giovannucci, E. L.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Fuchs, C. S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Giovannucci, E. L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Giovannucci, EL (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
EM egiovann@hsph.harvard.edu
FU NIH [P01 CA87969, P01 CA55075, 1UM1 CA167552, R01 CA137178, K24
DK098311]; Entertainment Industry Foundation through the National
Colorectal Cancer Research Alliance
FX We thank the participants and staff of the Health Professionals
Follow-Up Study for their valuable contributions as well as the
following state cancer registries for their help: AL, AZ, AR, CA, CO,
CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY,
NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. This work was
supported by grants from the NIH (P01 CA87969 to Dr Meir Stampfer; P01
CA55075 and 1UM1 CA167552 to Dr Walter Willett; R01 CA137178 and K24
DK098311 to Dr Andrew Chan) and the Entertainment Industry Foundation
through the National Colorectal Cancer Research Alliance. Dr Chan is a
Damon Runyon Clinical Investigator.
NR 57
TC 1
Z9 1
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAR 3
PY 2015
VL 112
IS 5
BP 934
EP 942
DI 10.1038/bjc.2014.655
PG 9
WC Oncology
SC Oncology
GA CD8ZH
UT WOS:000351384800020
PM 25590667
ER
PT J
AU Shyh-Chang, N
Daley, GQ
AF Shyh-Chang, Ng
Daley, George Q.
TI Metabolic Switches Linked to Pluripotency and Embryonic Stem Cell
Differentiation
SO CELL METABOLISM
LA English
DT Editorial Material
AB Embryonic stem cells (ESCs) manifest a unique metabolism that is intimately linked to their pluripotent state. In this issue, Moussaieff et al. (2015) find that ESCs utilize glycolysis to fuel high rates of cytosolic acetyl-CoA synthesis to maintain the histone acetylation required for pluripotency.
C1 [Shyh-Chang, Ng] Genome Inst Singapore, Agcy Sci Technol & Res, Singapore 138672, Singapore.
[Daley, George Q.] Boston Childrens Hosp, Stem Cell Transplantat Program, Div Pediat Hematol Oncol, Boston, MA 02115 USA.
[Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Daley, George Q.] Harvard Stem Cell Inst, Boston, MA 02115 USA.
[Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Daley, George Q.] Manton Ctr Orphan Dis Res, Boston, MA 02115 USA.
[Daley, George Q.] Howard Hughes Med Inst, Boston, MA 02115 USA.
RP Daley, GQ (reprint author), Boston Childrens Hosp, Stem Cell Transplantat Program, Div Pediat Hematol Oncol, Boston, MA 02115 USA.
EM george.daley@childrens.harvard.edu
OI Shyh-Chang, Ng/0000-0003-3138-9525
FU Howard Hughes Medical Institute
NR 9
TC 9
Z9 10
U1 1
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD MAR 3
PY 2015
VL 21
IS 3
BP 349
EP 350
DI 10.1016/j.cmet.2015.02.011
PG 2
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA CD1ZI
UT WOS:000350872800001
PM 25738450
ER
PT J
AU Rannikmae, K
Davies, G
Thomson, PA
Bevan, S
Devan, WJ
Falcone, GJ
Traylor, M
Anderson, CD
Battey, TWK
Radmanesh, F
Deka, R
Woo, JG
Martin, LJ
Jimenez-Conde, J
Selim, M
Brown, DL
Silliman, SL
Kidwell, CS
Montaner, J
Langefeld, CD
Slowik, A
Hansen, BM
Lindgren, AG
Meschia, JF
Fornage, M
Bis, JC
Debette, S
Ikram, MA
Longstreth, WT
Schmidt, R
Zhang, CR
Yang, Q
Sharma, P
Kittner, SJ
Mitchell, BD
Holliday, EG
Levi, CR
Attia, J
Rothwell, PM
Poole, DL
Boncoraglio, GB
Psaty, BM
Malik, R
Rost, N
Worrall, BB
Dichgans, M
Van Agtmael, T
Woo, D
Markus, HS
Seshadri, S
Rosand, J
Sudlow, CLM
AF Rannikmaee, Kristiina
Davies, Gail
Thomson, Pippa A.
Bevan, Steve
Devan, William J.
Falcone, Guido J.
Traylor, Matthew
Anderson, Christopher D.
Battey, Thomas W. K.
Radmanesh, Farid
Deka, Ranjan
Woo, Jessica G.
Martin, Lisa J.
Jimenez-Conde, Jordi
Selim, Magdy
Brown, Devin L.
Silliman, Scott L.
Kidwell, Chelsea S.
Montaner, Joan
Langefeld, Carl D.
Slowik, Agnieszka
Hansen, Bjoern M.
Lindgren, Arne G.
Meschia, James F.
Fornage, Myriam
Bis, Joshua C.
Debette, Stephanie
Ikram, Mohammad A.
Longstreth, Will T.
Schmidt, Reinhold
Zhang, Cathy R.
Yang, Qiong
Sharma, Pankaj
Kittner, Steven J.
Mitchell, Braxton D.
Holliday, Elizabeth G.
Levi, Christopher R.
Attia, John
Rothwell, Peter M.
Poole, Deborah L.
Boncoraglio, Giorgio B.
Psaty, Bruce M.
Malik, Rainer
Rost, Natalia
Worrall, Bradford B.
Dichgans, Martin
Van Agtmael, Tom
Woo, Daniel
Markus, Hugh S.
Seshadri, Sudha
Rosand, Jonathan
Sudlow, Cathie L. M.
CA METASTROKE Consortium
CHARGE WMH Grp
ISGC ICH GWAS Study Collaborat
WMH Ischemic Stroke GWAS Study
Int Stroke Genetics Consortium
TI Common variation in COL4A1/COL4A2 is associated with sporadic cerebral
small vessel disease
SO NEUROLOGY
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; MATTER HYPERINTENSITY VOLUME; MULTIPLE TESTING
CORRECTION; INTRACEREBRAL HEMORRHAGE; ISCHEMIC-STROKE; NYHOLTS
PROCEDURE; COL4A1 MUTATIONS; RISK-FACTORS; COLLAGEN-IV; METAANALYSIS
AB Objectives:We hypothesized that common variants in the collagen genes COL4A1/COL4A2 are associated with sporadic forms of cerebral small vessel disease.Methods:We conducted meta-analyses of existing genotype data among individuals of European ancestry to determine associations of 1,070 common single nucleotide polymorphisms (SNPs) in the COL4A1/COL4A2 genomic region with the following: intracerebral hemorrhage and its subtypes (deep, lobar) (1,545 cases, 1,485 controls); ischemic stroke and its subtypes (cardioembolic, large vessel disease, lacunar) (12,389 cases, 62,004 controls); and white matter hyperintensities (2,733 individuals with ischemic stroke and 9,361 from population-based cohorts with brain MRI data). We calculated a statistical significance threshold that accounted for multiple testing and linkage disequilibrium between SNPs (p < 0.000084).Results:Three intronic SNPs in COL4A2 were significantly associated with deep intracerebral hemorrhage (lead SNP odds ratio [OR] 1.29, 95% confidence interval [CI] 1.14-1.46, p = 0.00003; r(2) > 0.9 between SNPs). Although SNPs associated with deep intracerebral hemorrhage did not reach our significance threshold for association with lacunar ischemic stroke (lead SNP OR 1.10, 95% CI 1.03-1.18, p = 0.0073), and with white matter hyperintensity volume in symptomatic ischemic stroke patients (lead SNP OR 1.07, 95% CI 1.01-1.13, p = 0.016), the direction of association was the same. There was no convincing evidence of association with white matter hyperintensities in population-based studies or with non-small vessel disease cerebrovascular phenotypes.Conclusions:Our results indicate an association between common variation in the COL4A2 gene and symptomatic small vessel disease, particularly deep intracerebral hemorrhage. These findings merit replication studies, including in ethnic groups of non-European ancestry.
C1 [Rannikmaee, Kristiina; Sudlow, Cathie L. M.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH8 9YL, Midlothian, Scotland.
[Davies, Gail] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh EH8 9YL, Midlothian, Scotland.
[Davies, Gail] Univ Edinburgh, Dept Psychol, Edinburgh EH8 9YL, Midlothian, Scotland.
[Thomson, Pippa A.; Sudlow, Cathie L. M.] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh EH8 9YL, Midlothian, Scotland.
[Bevan, Steve; Traylor, Matthew; Markus, Hugh S.] Univ Cambridge, Clin Neurosci, Cambridge CB2 1TN, England.
[Devan, William J.; Falcone, Guido J.; Anderson, Christopher D.; Battey, Thomas W. K.; Radmanesh, Farid; Zhang, Cathy R.; Rost, Natalia; Rosand, Jonathan] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Falcone, Guido J.; Anderson, Christopher D.; Rosand, Jonathan] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Falcone, Guido J.; Anderson, Christopher D.; Battey, Thomas W. K.; Radmanesh, Farid; Rosand, Jonathan] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Deka, Ranjan] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45221 USA.
[Woo, Jessica G.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA.
[Martin, Lisa J.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA.
[Jimenez-Conde, Jordi] Univ Autonoma Barcelona, Dept Neurol, Neurovascular Res Unit, E-08193 Barcelona, Spain.
[Jimenez-Conde, Jordi] Univ Autonoma Barcelona, IMIM Inst Hosp Mar Invest Med, Cardiovasc Epidemiol & Genet Res Grp, E-08193 Barcelona, Spain.
[Selim, Magdy] Beth Israel Deaconess Med Ctr, Dept Neurol, Stroke Div, Boston, MA 02215 USA.
[Brown, Devin L.] Univ Michigan Hlth Syst, Dept Neurol, Stroke Program, Ann Arbor, MI USA.
[Silliman, Scott L.] Univ Florida, Coll Med, Dept Neurol, Jacksonville, FL USA.
[Kidwell, Chelsea S.] Univ Arizona, Dept Neurol, Tucson, AZ USA.
[Montaner, Joan] Univ Autonoma Barcelona, Hosp Vall dHebron, Inst Recerca, Neurovasc Res Lab, E-08193 Barcelona, Spain.
[Montaner, Joan] Univ Autonoma Barcelona, Hosp Vall dHebron, Inst Recerca, Neurovasc Unit, E-08193 Barcelona, Spain.
[Langefeld, Carl D.] Wake Forest Univ, Ctr Publ Hlth Genom, Winston Salem, NC 27109 USA.
[Langefeld, Carl D.] Wake Forest Univ, Dept Biostat Sci, Winston Salem, NC 27109 USA.
[Slowik, Agnieszka] Jagiellonian Univ, Coll Med, Dept Neurol, Krakow, Poland.
[Hansen, Bjoern M.; Lindgren, Arne G.] Lund Univ, Dept Clin Sci Lund, Neurol, Lund, Sweden.
[Hansen, Bjoern M.; Lindgren, Arne G.] Skane Univ Hosp, Dept Neurol, Lund, Sweden.
[Meschia, James F.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
[Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Houston, TX 77030 USA.
[Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Div Epidemiol, Ctr Human Genet, Houston, TX 77030 USA.
[Bis, Joshua C.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Bis, Joshua C.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Longstreth, Will T.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Longstreth, Will T.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Debette, Stephanie; Yang, Qiong; Seshadri, Sudha] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA.
[Debette, Stephanie] Univ Paris 07, Lariboisiere Hosp, Dept Neurol, F-75221 Paris 05, France.
[Debette, Stephanie] Bordeaux Univ, INSERM, UMR897, Bordeaux, France.
[Ikram, Mohammad A.] Erasmus MC Univ Med Ctr, Dept Epidemiol, Rotterdam, Netherlands.
[Ikram, Mohammad A.] Erasmus MC Univ Med Ctr, Dept Radiol, Rotterdam, Netherlands.
[Ikram, Mohammad A.] Erasmus MC Univ Med Ctr, Dept Neurol, Rotterdam, Netherlands.
[Ikram, Mohammad A.] Netherlands Consortium Hlth Aging, Amsterdam, Netherlands.
[Schmidt, Reinhold] Med Univ Graz, Dept Neurol, Graz, Austria.
[Sharma, Pankaj] Univ London ICR2UL, Inst Cardiovasc Res, London, England.
[Sharma, Pankaj] Ashford & St Peters Hosp, London, England.
[Kittner, Steven J.] Vet Affairs Med Ctr, Dept Neurol, Baltimore, MD USA.
[Kittner, Steven J.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA.
[Mitchell, Braxton D.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.
[Holliday, Elizabeth G.; Attia, John] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Callaghan, NSW 2308, Australia.
[Levi, Christopher R.] Univ Newcastle, Ctr Translat Neurosci & Mental Hlth Res, Callaghan, NSW 2308, Australia.
[Levi, Christopher R.] Hunter Med Res Inst, New Lambton, Australia.
[Rothwell, Peter M.; Poole, Deborah L.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Stroke Prevent Res Unit, Oxford OX3 9DU, England.
[Boncoraglio, Giorgio B.] Fdn IRCCS Ist Neurol Carlo Besta, Dept Cerebrovasc Dis, Milan, Italy.
[Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Epidemiol, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, Seattle, WA 98195 USA.
Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
Grp Hlth, Res Inst, Seattle, WA USA.
[Malik, Rainer; Dichgans, Martin] Univ Munich, Klinikum Univ Munchen, Inst Stroke & Dementia Res, Munich, Germany.
[Worrall, Bradford B.] Univ Virginia, Dept Neurol, Charlottesville, VA USA.
[Worrall, Bradford B.] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA USA.
[Dichgans, Martin] Munich Cluster Syst Neurol SyNergy, Munich, Germany.
[Van Agtmael, Tom] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow G12 8QQ, Lanark, Scotland.
[Woo, Daniel] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH 45221 USA.
RP Sudlow, CLM (reprint author), Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH8 9YL, Midlothian, Scotland.
EM cathie.sudlow@e.ac.uk
RI Boncoraglio, Giorgio/B-8647-2011; Martin, Lisa/E-2425-2016;
JIMENEZ-CONDE, JORDI/C-1941-2012; IBIS, NEUROVASCULAR/O-1855-2015;
Falcone, Guido/L-2287-2016; Montaner, Joan/D-3063-2015;
OI Mitchell, Braxton/0000-0003-4920-4744; Martin, Lisa/0000-0001-8702-9946;
Falcone, Guido/0000-0002-6407-0302; Ikram, Mohammad
Arfan/0000-0003-0372-8585; Traylor, Matthew/0000-0001-6624-8621; Bevan,
Steve/0000-0003-0490-6830; Anderson, Christopher/0000-0002-0053-2002;
Van Agtmael, Tom/0000-0003-4282-449X; Hansen, Bjorn/0000-0001-8661-9063;
Seshadri, Sudha/0000-0001-6135-2622
FU Edinburgh and Lothians Health Foundation REMIND Fund; Stroke Research
and Amenities Endowments Fund; Scottish Funding Council; University of
Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part
of the cross council Lifelong Health and Wellbeing Initiative
[MR/K026992/1]; BBSRC; Medical Research Council (MSRC); Kidney Research
UK [RP19/2012]; Fondation Leducq (Transatlantic Network of Excellence on
the Pathogenesis of Small Vessel Disease of the Brain); NIH/National
Institute of Neurological Disorders and Stroke (NINDS) [P50NS061343];
American Brain Foundation Clinical Research Training Fellowship;
NIH/NINDS [K23NS086873, R01NS059727]; Massachusetts General Hospital
Institute for Heart, Vascular, and Stroke Care SPARK award
FX Kristiina Rannikmae is supported by the Edinburgh and Lothians Health
Foundation REMIND Fund and Stroke Research and Amenities Endowments
Fund. Cathie Sudlow is supported by the Scottish Funding Council. Gail
Davies is supported by The University of Edinburgh Centre for Cognitive
Ageing and Cognitive Epidemiology, part of the cross council Lifelong
Health and Wellbeing Initiative (MR/K026992/1), BBSRC, and Medical
Research Council (MSRC). Tom Van Agtmael is supported by the Kidney
Research UK project grant RP19/2012. Details of funding for the studies
contributing to the ICH GWAS can be found in reference 4. Details of
funding for the studies contributing to the ischaemic stroke GWAS can be
found in reference 2. Details of funding for the studies contributing to
the WMH in ischaemic stroke GWAS can be found in reference 11. Details
of funding for the studies contributing to the WMH in population GWAS
can be found in reference 3. Martin Dichgans is supported by the
Fondation Leducq (Transatlantic Network of Excellence on the
Pathogenesis of Small Vessel Disease of the Brain). Guido J. Falcone is
supported by the NIH/National Institute of Neurological Disorders and
Stroke (NINDS) grant P50NS061343. Chistopher D. Anderson is supported by
the American Brain Foundation Clinical Research Training Fellowship,
NIH/NINDS K23NS086873, and Massachusetts General Hospital Institute for
Heart, Vascular, and Stroke Care SPARK award. Jonathan Rosand is
supported by the NIH/NINDS grant R01NS059727.
NR 36
TC 13
Z9 14
U1 1
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAR 3
PY 2015
VL 84
IS 9
BP 918
EP 926
DI 10.1212/WNL.0000000000001309
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA CC7VO
UT WOS:000350576700015
PM 25653287
ER
PT J
AU Utheim, O
Islam, R
Lyberg, T
Roald, B
Eidet, JR
de la Paz, MF
Dartt, DA
Raeder, S
Utheim, TP
AF Utheim, Oeygunn
Islam, Rakibul
Lyberg, Torstein
Roald, Borghild
Eidet, Jon Roger
Fideliz de la Paz, Maria
Dartt, Darlene A.
Raeder, Sten
Utheim, Tor Paaske
TI Serum-Free and Xenobiotic-Free Preservation of Cultured Human Limbal
Epithelial Cells
SO PLOS ONE
LA English
DT Article
ID DENUDED AMNIOTIC MEMBRANE; EX-VIVO EXPANSION; FETAL CALF SERUM;
STEM-CELLS; CORNEAL EPITHELIUM; SUSPENSION CULTURE; FEEDER LAYER;
TRANSPLANTATION; EXPRESSION; PHENOTYPE
AB Aim/Purpose of the Study
To develop a one-week storage method, without serum and xenobiotics, that would maintain cell viability, morphology, and phenotype of cultured human limbal epithelial sheets.
Materials and Methods
Human limbal explants were cultured on intact human amniotic membranes for two weeks. The sheets were stored in a hermetically sealed container at 23 degrees C in either a serum-free medium with selected animal serum-derived compounds (Quantum 286) or a xenobioticfree medium (Minimal Essential Medium) for 4 and 7 days. Stored and non-stored cultures were analyzed for cell viability, amniotic membrane and epithelial sheet thickness, and a panel of immunohistochemical markers for immature cells (Delta Np63 alpha, p63, Bmi-1, C/EBP partial derivative, ABCG2 and K19), differentiated cells (K3 and Cx43), proliferation (PCNA), and apoptosis (Caspase-3).
Results
The cell viability of the cultures was 98 +/- 1% and remained high after storage. Mean central thickness of non-stored limbal epithelial sheets was 23 +/- 3 mu m, and no substantial loss of cells was observed after storage. The non-stored epithelial sheets expressed a predominantly immature phenotype with Delta Np63a positivity of more than 3% in 9 of 13 cultures. After storage, the expression of ABCG2 and C/EBP partial derivative was reduced for the 7 day Quantum 286-storage group; (P = 0.04), and Bmi1 was reduced after 4 day Quantum 286-storage; (P = 0.02). No other markers varied significantly. The expression of differentiation markers was unrelated to the thickness of the epithelia and amnioticmembrane, apart from ABCG2, which correlated negatively with thickness of limbal epithelia (R = -0.69, P = 0.01) and Delta Np63 alpha, which correlated negatively with amniotic membrane thickness (R = -0.59, P = 0.03).
Conclusion
Limbal epithelial cells cultured from explants on amniotic membrane can be stored at 23 degrees C in both serum-free and xenobiotic-free media, with sustained cell viability, ultrastructure, and Delta Np63 alpha-positivity after both 4 and 7 days.
C1 [Utheim, Oeygunn; Islam, Rakibul; Lyberg, Torstein; Eidet, Jon Roger; Utheim, Tor Paaske] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway.
[Utheim, Oeygunn; Utheim, Tor Paaske] Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway.
[Islam, Rakibul; Utheim, Tor Paaske] Univ Oslo, Fac Dent, Dept Oral Biol, Oslo, Norway.
[Roald, Borghild] Oslo Univ Hosp, Dept Pathol, Oslo, Norway.
[Fideliz de la Paz, Maria] Univ Autonoma Barcelona, Inst Univ Barraquer, E-08193 Barcelona, Spain.
[Dartt, Darlene A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA USA.
[Raeder, Sten] Norwegian Dry Eye Clin, Oslo, Norway.
RP Utheim, O (reprint author), Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway.
EM utheim2@gmail.com
FU South-Eastern Norway Regional Health Authority [2010092]
FX The research was funded by the South-Eastern Norway Regional Health
Authority, grant number 2010092, project name "Treating blindness using
novel tissue storage technology", url
http://forskningsprosjekter.ihelse.net/visningprosjektrapport.aspx?repor
tId=7593 and http://www.helse-sorost.no/omoss_/english. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 58
TC 0
Z9 0
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 3
PY 2015
VL 10
IS 3
AR e0118517
DI 10.1371/journal.pone.0118517
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC4HV
UT WOS:000350314700036
PM 25734654
ER
PT J
AU Levy, O
Mortensen, LJ
Boquet, G
Tong, ZX
Perrault, C
Benhamou, B
Zhang, JD
Stratton, T
Han, E
Safaee, H
Musabeyezu, J
Yang, ZJ
Multon, MC
Rothblatt, J
Deleuze, JF
Lin, CP
Karp, JM
AF Levy, Oren
Mortensen, Luke J.
Boquet, Gerald
Tong, Zhixiang
Perrault, Christelle
Benhamou, Brigitte
Zhang, Jidong
Stratton, Tara
Han, Edward
Safaee, Helia
Musabeyezu, Juliet
Yang, Zijiang
Multon, Marie-Christine
Rothblatt, Jonathan
Deleuze, Jean-Francois
Lin, Charles P.
Karp, Jeffrey M.
TI A Small-Molecule Screen for Enhanced Homing of Systemically Infused
Cells
SO CELL REPORTS
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; ENDOTHELIAL-CELLS; KINASE; EXPRESSION; ADHESION;
BONE; RUBOXISTAURIN; INFLAMMATION; ACTIVATION; INHIBITOR
AB Poor homing of systemically infused cells to disease sites may limit the success of exogenous cell-based therapy. In this study, we screened 9,000 signal-transduction modulators to identify hits that increase mesenchymal stromal cell (MSC) surface expression of homing ligands that bind to intercellular adhesion molecule 1 (ICAM-1), such as CD11a. Pretreatment of MSCs with Ro-31-8425, an identified hit from this screen, increased MSC firm adhesion to an ICAM-1-coated substrate in vitro and enabled targeted delivery of systemically administered MSCs to inflamed sites in vivo in a CD11a- (and other ICAM-1-binding domains)-dependent manner. This resulted in a heightened anti-inflammatory response. This represents a new strategy for engineering cell homing to enhance therapeutic efficacy and validates CD11a and ICAM-1 as potential targets. Altogether, this multi-step screening process may significantly improve clinical outcomes of cell-based therapies.
C1 [Levy, Oren; Tong, Zhixiang; Han, Edward; Safaee, Helia; Musabeyezu, Juliet; Yang, Zijiang; Karp, Jeffrey M.] Harvard Univ, Brigham & Womens Hosp, Ctr Regenerat Therapeut, Div Biomed Engn,Dept Med,Med Sch, Cambridge, MA 02139 USA.
[Levy, Oren; Mortensen, Luke J.; Tong, Zhixiang; Stratton, Tara; Han, Edward; Safaee, Helia; Musabeyezu, Juliet; Yang, Zijiang; Lin, Charles P.; Karp, Jeffrey M.] Harvard Stem Cell Inst, Cambridge, MA 02139 USA.
[Levy, Oren; Tong, Zhixiang; Han, Edward; Safaee, Helia; Musabeyezu, Juliet; Yang, Zijiang; Karp, Jeffrey M.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Mortensen, Luke J.; Stratton, Tara; Lin, Charles P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Mortensen, Luke J.; Stratton, Tara; Lin, Charles P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02114 USA.
[Boquet, Gerald; Perrault, Christelle; Benhamou, Brigitte; Zhang, Jidong; Multon, Marie-Christine; Deleuze, Jean-Francois] Sanofi R&D, Ctr Rech Vitry Alfortville, F-94403 Vitry Sur Seine, France.
[Rothblatt, Jonathan] Sanofi R&D, Cambridge, MA 02139 USA.
RP Lin, CP (reprint author), Harvard Stem Cell Inst, Cambridge, MA 02139 USA.
EM lin@helix.mgh.harvard.edu; jeffkarp.bwh@gmail.com
RI Tong, Zhixiang/G-5685-2016;
OI Mortensen, Luke/0000-0002-4331-4099
FU Sanofi-Aventis U.S.; National Institutes of Health [HL095722, P41
EB015903-02S1]
FX The authors wish to thank Sophie Fontaine and Celine Chansac from Sanofi
for their technical support. This work was supported by a research grant
from Sanofi-Aventis U.S. to J.M.K. and C.P.L. and by National Institutes
of Health grants HL095722 (to J.M.K.) and P41 EB015903-02S1 (to C.P.L.).
G.B., C.P., B.B., J.Z., M.C., and J.R. are employed by Sanofi. J.M.K.
consults in the field of cell therapy for Stempeutics, Sanofi, and
Mesoblast.
NR 26
TC 9
Z9 9
U1 0
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD MAR 3
PY 2015
VL 10
IS 8
BP 1261
EP 1268
DI 10.1016/j.celrep.2015.01.057
PG 8
WC Cell Biology
SC Cell Biology
GA CC7QW
UT WOS:000350564200004
PM 25732817
ER
PT J
AU Wurtz, P
Havulinna, AS
Soininen, P
Tynkkynen, T
Prieto-Merino, D
Tillin, T
Ghorbani, A
Artati, A
Wang, Q
Tiainen, M
Kangas, AJ
Kettunen, J
Kaikkonen, J
Mikkila, V
Jula, A
Kahonen, M
Lehtimaki, T
Lawlor, DA
Gaunt, TR
Hughes, AD
Sattar, N
Illig, T
Adamski, J
Wang, TJ
Perola, M
Ripatti, S
Vasan, RS
Raitakari, OT
Gerszten, RE
Casas, JP
Chaturvedi, N
Ala-Korpela, M
Salomaa, V
AF Wurtz, Peter
Havulinna, Aki S.
Soininen, Pasi
Tynkkynen, Tuulia
Prieto-Merino, David
Tillin, Therese
Ghorbani, Anahita
Artati, Anna
Wang, Qin
Tiainen, Mika
Kangas, Antti J.
Kettunen, Johannes
Kaikkonen, Jari
Mikkila, Vera
Jula, Antti
Kahonen, Mika
Lehtimaki, Terho
Lawlor, Debbie A.
Gaunt, Tom R.
Hughes, Alun D.
Sattar, Naveed
Illig, Thomas
Adamski, Jerzy
Wang, Thomas J.
Perola, Markus
Ripatti, Samuli
Vasan, Ramachandran S.
Raitakari, Olli T.
Gerszten, Robert E.
Casas, Juan-Pablo
Chaturvedi, Nish
Ala-Korpela, Mika
Salomaa, Veikko
TI Metabolite Profiling and Cardiovascular Event Risk A Prospective Study
of 3 Population-Based Cohorts
SO CIRCULATION
LA English
DT Article
DE amino acids; biological markers; fatty acids; metabolomics; risk factors
ID MONOUNSATURATED FATTY-ACIDS; HOSPITAL DISCHARGE REGISTER;
CORONARY-HEART-DISEASE; YOUNG FINNS; SUBCLINICAL ATHEROSCLEROSIS;
ASSOCIATION; BIOMARKERS; EPIDEMIOLOGY; METABOLOMICS; PREDICTION
AB Background-High-throughput profiling of circulating metabolites may improve cardiovascular risk prediction over established risk factors.
Methods and Results-We applied quantitative nuclear magnetic resonance metabolomics to identify the biomarkers for incident cardiovascular disease during long-term follow-up. Biomarker discovery was conducted in the National Finnish FINRISK study (n = 7256; 800 events). Replication and incremental risk prediction was assessed in the Southall and Brent Revisited (SABRE) study (n = 2622; 573 events) and British Women's Health and Heart Study (n = 3563; 368 events). In targeted analyses of 68 lipids and metabolites, 33 measures were associated with incident cardiovascular events at P < 0.0007 after adjusting for age, sex, blood pressure, smoking, diabetes mellitus, and medication. When further adjusting for routine lipids, 4 metabolites were associated with future cardiovascular events in meta-analyses: higher serum phenylalanine (hazard ratio per standard deviation, 1.18; 95% confidence interval, 1.12-1.24; P = 4x10(-10)) and monounsaturated fatty acid levels (1.17; 1.11-1.24; P = 1x10(-8)) were associated with increased cardiovascular risk, while higher omega-6 fatty acids (0.89; 0.84-0.94; P = 6x10(-5)) and docosahexaenoic acid levels (0.90; 0.86-0.95; P = 5x10(-5)) were associated with lower risk. A risk score incorporating these 4 biomarkers was derived in FINRISK. Risk prediction estimates were more accurate in the 2 validation cohorts (relative integrated discrimination improvement, 8.8% and 4.3%), albeit discrimination was not enhanced. Risk classification was particularly improved for persons in the 5% to 10% risk range (net reclassification, 27.1% and 15.5%). Biomarker associations were further corroborated with mass spectrometry in FINRISK (n = 671) and the Framingham Offspring Study (n = 2289).
Conclusions-Metabolite profiling in large prospective cohorts identified phenylalanine, monounsaturated fatty acids, and polyunsaturated fatty acids as biomarkers for cardiovascular risk. This study substantiates the value of high-throughput metabolomics for biomarker discovery and improved risk assessment.
C1 [Wurtz, Peter; Soininen, Pasi; Tynkkynen, Tuulia; Wang, Qin; Tiainen, Mika; Kangas, Antti J.; Kettunen, Johannes; Ala-Korpela, Mika] Univ Oulu, Inst Hlth Sci, Oulu 90014, Finland.
[Wurtz, Peter; Havulinna, Aki S.; Kettunen, Johannes; Jula, Antti; Perola, Markus; Salomaa, Veikko] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Oulu, Finland.
[Wurtz, Peter; Havulinna, Aki S.; Perola, Markus; Ripatti, Samuli] Univ Helsinki, Inst Mol Med Finland, FIN-00014 Helsinki, Finland.
[Wurtz, Peter; Tynkkynen, Tuulia; Wang, Qin; Tiainen, Mika; Ala-Korpela, Mika] Univ Eastern Finland, Sch Pharm, NMR Metab Lab, Kuopio, Finland.
[Prieto-Merino, David; Casas, Juan-Pablo] Univ London London Sch Hyg & Trop Med, Fac Epidemiol & Publ Hlth, London WC1E 7HT, England.
[Tillin, Therese; Hughes, Alun D.; Casas, Juan-Pablo; Chaturvedi, Nish] UCL, Inst Cardiovasc Sci, London WC1E 6BT, England.
[Ghorbani, Anahita; Vasan, Ramachandran S.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Ghorbani, Anahita; Vasan, Ramachandran S.] Boston Univ, Sch Med, Framingham, MA USA.
[Artati, Anna; Adamski, Jerzy] Helmholtz Zentrum Munchen, Inst Expt Genet, Genome Anal Ctr, Neuherberg, Germany.
[Kaikkonen, Jari; Mikkila, Vera; Raitakari, Olli T.] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, SF-20500 Turku, Finland.
[Mikkila, Vera] Univ Helsinki, Dept Food & Environm Sci, FIN-00014 Helsinki, Finland.
[Kahonen, Mika] Univ Tampere, Dept Clin Physiol, FIN-33101 Tampere, Finland.
[Kahonen, Mika] Tampere Univ Hosp, Tampere, Finland.
[Lehtimaki, Terho] Univ Tampere, Fimlab Labs, Dept Clin Chem, FIN-33101 Tampere, Finland.
[Lehtimaki, Terho] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland.
[Lawlor, Debbie A.; Gaunt, Tom R.; Ala-Korpela, Mika] Univ Bristol, MRC, Integrat Epidemiol Unit, Bristol BS8 1TH, Avon, England.
[Lawlor, Debbie A.; Gaunt, Tom R.; Ala-Korpela, Mika] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England.
[Sattar, Naveed] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow G12 8QQ, Lanark, Scotland.
[Illig, Thomas] Hannover Med Sch, Hannover Unified Biobank, Hannover, Germany.
[Illig, Thomas] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Res Unit Mol Epidemiol, Neuherberg, Germany.
[Adamski, Jerzy] German Ctr Diabet Res, Neuherberg, Germany.
[Adamski, Jerzy] Tech Univ Munich, Freising Weihenstephan, Germany.
[Wang, Thomas J.; Gerszten, Robert E.] Harvard Univ, Sch Med, Cardiovasc Res Ctr, Boston, MA USA.
[Wang, Thomas J.; Gerszten, Robert E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Wang, Thomas J.] Vanderbilt Univ, Div Cardiol, Nashville, TN 37232 USA.
[Ripatti, Samuli] Univ Helsinki, Hjelt Inst, FIN-00014 Helsinki, Finland.
[Ripatti, Samuli] Wellcome Trust Sanger Inst, Hinxton, England.
[Vasan, Ramachandran S.] Boston Univ, Sect Prevent Med & Epidemiol, Boston, MA 02215 USA.
[Vasan, Ramachandran S.] Boston Univ, Cardiol Sect, Dept Med, Boston, MA 02215 USA.
[Raitakari, Olli T.] Turku Univ Hosp, Dept Clin Physiol & Nucl Med, Turku, Finland.
[Gerszten, Robert E.] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Ala-Korpela, Mika] Oulu Univ Hosp, Oulu, Finland.
RP Wurtz, P (reprint author), Univ Oulu, Inst Hlth Sci, Aapistie 5A,POB 5000, Oulu 90014, Finland.
EM peter.wurtz@computationalmedicine.fi
RI Ripatti, Samuli/H-9446-2014;
OI Ripatti, Samuli/0000-0002-0504-1202; Tynkkynen,
Tuulia/0000-0002-8586-7345; Wurtz, Peter/0000-0002-5832-0221;
Ramachandran, Vasan/0000-0001-7357-5970; Lawlor, Debbie
A/0000-0002-6793-2262; Prieto-Merino, David/0000-0001-5001-0061; Gaunt,
Tom/0000-0003-0924-3247
FU Academy of Finland [139635, 137870, 250422, 251217, 266199]; European
Commission Seventh Framework Programme [BioSHaRE 261433]; Sigrid
Juselius Foundation; Yrjo Jahnsson Foundation; Emil Aaltonen Foundation;
Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research;
Medical Research Fund of Tampere; UK Medical Research Council via the
University of Bristol Integrative Epidemiology Unit (IEU)
[MC_UU_12013/5]; University of Oulu, Finland; Wellcome Trust
[WT082464AIA]; British Heart Foundation [SP/07/001/23603]; Diabetes UK
[13/0004774]; UK Department of Health Policy Research Programme - UK
Medical Research Council [G1000427]; US National Institutes of Health
[R01 DK 081572, R01 HL98280]; NHLBI [N01-HC-25195]
FX This study was supported by the Academy of Finland (139635, 137870,
250422, 251217, 266199), the European Commission Seventh Framework
Programme (BioSHaRE 261433), the Sigrid Juselius Foundation, the Yrjo
Jahnsson Foundation, the Emil Aaltonen Foundation, the Paavo Nurmi
Foundation, the Finnish Foundation for Cardiovascular Research, the
Medical Research Fund of Tampere, the UK Medical Research Council via
the University of Bristol Integrative Epidemiology Unit (IEU;
MC_UU_12013/5), and Strategic Research Funding from the University of
Oulu, Finland. The Wellcome Trust (WT082464AIA), British Heart
Foundation (SP/07/001/23603) and Diabetes UK (13/0004774) support the
SABRE Study. The British Women's Heart and Health Study was funded by
the British Heart Foundation and UK Department of Health Policy Research
Programme with metabolomics data funded by the UK Medical Research
Council (G1000427). Metabolomics in the Framingham offspring study was
supported by the US National Institutes of Health grants R01 DK 081572
and R01 HL98280. Surveillance of CVD in the Framingham Heart Study is
supported by N01-HC-25195 (from the NHLBI).
NR 57
TC 58
Z9 59
U1 5
U2 28
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD MAR 3
PY 2015
VL 131
IS 9
BP 774
EP U52
DI 10.1161/CIRCULATIONAHA.114.013116
PG 37
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA CC4FY
UT WOS:000350308400004
PM 25573147
ER
PT J
AU Yeh, RW
Mauri, L
Kereiakes, DJ
AF Yeh, Robert W.
Mauri, Laura
Kereiakes, Dean J.
TI Dual Antiplatelet Therapy Duration Following Coronary Stenting
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Editorial Material
DE drug-eluting stent(s); percutaneous coronary angioplasty
ID DRUG-ELUTING STENTS; IMPLANTATION; TRIAL; MULTICENTER; THROMBOSIS; LONG
C1 [Yeh, Robert W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Mauri, Laura] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med, Boston, MA 02115 USA.
[Kereiakes, Dean J.] Christ Hosp, Lindner Res Ctr, Heart & Vasc Ctr, Cincinnati, OH 45219 USA.
RP Kereiakes, DJ (reprint author), Christ Hosp, Lindner Res Ctr, Heart & Vasc Ctr, 2123 Auburn Ave,Suite 424, Cincinnati, OH 45219 USA.
EM lindner@thechristhospital.com
FU NHLBI NIH HHS [K23 HL118138]
NR 13
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAR 3
PY 2015
VL 65
IS 8
BP 787
EP 790
DI 10.1016/j.jacc.2015.01.004
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CC3AG
UT WOS:000350215800004
PM 25720621
ER
PT J
AU Wang, GH
Shi, YJ
Jiang, XY
Leak, RK
Hu, XM
Wu, Y
Pu, HJ
Li, WW
Tang, B
Wang, Y
Gao, YQ
Zheng, P
Bennett, MVL
Chen, J
AF Wang, Guohua
Shi, Yejie
Jiang, Xiaoyan
Leak, Rehana K.
Hu, Xiaoming
Wu, Yun
Pu, Hongjian
Li, Wei-Wei
Tang, Bo
Wang, Yun
Gao, Yanqin
Zheng, Ping
Bennett, Michael V. L.
Chen, Jun
TI HDAC inhibition prevents white matter injury by modulating
microglia/macrophage polarization through the GSK3 beta/PTEN/Akt axis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE traumatic brain injury; oligodendrocyte; microglial polarization;
myelination; inflammation
ID TRAUMATIC BRAIN-INJURY; MICROGLIA; ACTIVATION; NEUROPROTECTION;
DEGENERATION; INFLAMMATION; CHALLENGES; ISCHEMIA; DYNAMICS; DAMAGE
AB Severe traumatic brain injury (TBI) elicits destruction of both gray and white matter, which is exacerbated by secondary proinflammatory responses. Although white matter injury (WMI) is strongly correlated with poor neurological status, the maintenance of white matter integrity is poorly understood, and no current therapies protect both gray and white matter. One candidate approach that may fulfill this role is inhibition of class I/II histone deacetylases (HDACs). Here we demonstrate that the HDAC inhibitor Scriptaid protects white matter up to 35 d after TBI, as shown by reductions in abnormally dephosphorylated neurofilament protein, increases in myelin basic protein, anatomic preservation of myelinated axons, and improved nerve conduction. Furthermore, Scriptaid shifted microglia/macrophage polarization toward the protective M2 phenotype and mitigated inflammation. In primary cocultures of microglia and oligodendrocytes, Scriptaid increased expression of microglial glycogen synthase kinase 3 beta (GSK3 beta), which phosphorylated and inactivated phosphatase and tensin homologue (PTEN), thereby enhancing phosphatidylinositide 3-kinases (PI3K)/Akt signaling and polarizing microglia toward M2. The increase in GSK3 beta in microglia and their phenotypic switch to M2 was associated with increased preservation of neighboring oligodendrocytes. These findings are consistent with recent findings that microglial phenotypic switching modulates white matter repair and axonal remyelination and highlight a previously unexplored role for HDAC activity in this process. Furthermore, the functions of GSK3 beta may be more subtle than previously thought, in that GSK3 beta can modulate microglial functions via the PTEN/PI3K/Akt signaling pathway and preserve white matter homeostasis. Thus, inhibition of HDACs in microglia is a potential future therapy in TBI and other neurological conditions with white matter destruction.
C1 [Wang, Guohua; Jiang, Xiaoyan; Pu, Hongjian; Li, Wei-Wei; Tang, Bo; Wang, Yun; Gao, Yanqin; Zheng, Ping; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.
[Wang, Guohua; Jiang, Xiaoyan; Pu, Hongjian; Li, Wei-Wei; Tang, Bo; Wang, Yun; Gao, Yanqin; Zheng, Ping; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China.
[Wang, Guohua; Shi, Yejie; Hu, Xiaoming; Wu, Yun; Pu, Hongjian; Gao, Yanqin; Chen, Jun] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA.
[Shi, Yejie; Hu, Xiaoming; Wu, Yun; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA.
[Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA.
[Bennett, Michael V. L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA.
RP Bennett, MVL (reprint author), Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA.
EM michael.bennett@einstein.yu.edu; chenj2@upmc.edu
RI Gao, Yanqin/I-6790-2016;
OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417
FU National Institutes of Health [NS36736, NS43802, NS45048, NS45287]; US
Department of Veterans Affairs Research Career Scientist Award; Chinese
Natural Science Foundation [81020108021, 81171149, 81371306, 81000497,
81471257, 81228008]; PhD Training Grant [20120071110042]; Ministry of
Education of the People's Republic of China Talent Training Fellowship
Grant [J1210041]; State Administration of Foreign Experts Affairs
High-End Distinguished Professorship Grant [GDW20133100069]; Hillman
Foundation Award
FX This research was supported by National Institutes of Health Grants
NS36736, NS43802, and NS45048 (to J.C.) and NS45287 (to M.V.L.B.); US
Department of Veterans Affairs Research Career Scientist Award (to
J.C.); Chinese Natural Science Foundation Grants 81020108021, 81171149,
and 81371306 (to Y.G.), 81000497 and 81471257 (to G.W.), and 81228008
(to J.C. and P.Z.), and PhD Training Grant 20120071110042 (to J.C.);
Ministry of Education of the People's Republic of China Talent Training
Fellowship Grant J1210041 (to B.T.); and State Administration of Foreign
Experts Affairs High-End Distinguished Professorship Grant
GDW20133100069 (to M.V.L.B.). R.K.L. is supported by a Hillman
Foundation Award.
NR 33
TC 44
Z9 48
U1 5
U2 31
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 3
PY 2015
VL 112
IS 9
BP 2853
EP 2858
DI 10.1073/pnas.1501441112
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC3DK
UT WOS:000350224900065
PM 25691750
ER
PT J
AU Han, HS
Niemeyer, E
Huang, YH
Kamoun, WS
Martin, JD
Bhaumik, J
Chen, YC
Roberge, S
Cui, J
Martin, MR
Fukumura, D
Jain, RK
Bawendi, MG
Duda, DG
AF Han, Hee-Sun
Niemeyer, Elisabeth
Huang, Yuhui
Kamoun, Walid S.
Martin, John D.
Bhaumik, Jayeeta
Chen, Yunching
Roberge, Sylvie
Cui, Jian
Martin, Margaret R.
Fukumura, Dai
Jain, Rakesh K.
Bawendi, Moungi G.
Duda, Dan G.
TI APPLIED BIOLOGICAL SCIENCES, CHEMISTRY (vol 112, pg 1350, 2015)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Correction
C1 [Han, Hee-Sun; Cui, Jian; Bawendi, Moungi G.] MIT, Dept Chem, Cambridge, MA 02139 USA.
[Martin, John D.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Niemeyer, Elisabeth; Huang, Yuhui; Kamoun, Walid S.; Martin, John D.; Bhaumik, Jayeeta; Chen, Yunching; Roberge, Sylvie; Martin, Margaret R.; Fukumura, Dai; Jain, Rakesh K.; Duda, Dan G.] Massachusetts Gen Hosp, Edwin L Steele Lab, Boston, MA 02114 USA.
[Niemeyer, Elisabeth; Huang, Yuhui; Kamoun, Walid S.; Martin, John D.; Bhaumik, Jayeeta; Chen, Yunching; Roberge, Sylvie; Martin, Margaret R.; Fukumura, Dai; Jain, Rakesh K.; Duda, Dan G.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Han, HS (reprint author), MIT, Dept Chem, Cambridge, MA 02139 USA.
NR 1
TC 0
Z9 0
U1 1
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 3
PY 2015
VL 112
IS 9
BP E1048
EP E1048
DI 10.1073/pnas.1501954112
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC3DK
UT WOS:000350224900019
ER
PT J
AU Pangrsic, T
Gabrielaitis, M
Michanski, S
Schwaller, B
Wolf, F
Strenzke, N
Moser, T
AF Pangrsic, Tina
Gabrielaitis, Mantas
Michanski, Susann
Schwaller, Beat
Wolf, Fred
Strenzke, Nicola
Moser, Tobias
TI EF-hand protein Ca2+ buffers regulate Ca2+ influx and exocytosis in
sensory hair cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE calcium buffers; exocytosis; calcium current; synapse; hair cell
ID AUDITORY-NERVE FIBERS; FAST-TWITCH MUSCLES; RIBBON SYNAPSE;
CALCIUM-CHANNELS; CALBINDIN D-28K; TRANSMITTER RELEASE; AFFERENT
SYNAPSE; CA2+-DEPENDENT INACTIVATION; PRESYNAPTIC ACTIVITY; LACKING
PARVALBUMIN
AB EF-hand Ca2+-binding proteins are thought to shape the spatio-temporal properties of cellular Ca2+ signaling and are prominently expressed in sensory hair cells in the ear. Here, we combined genetic disruption of parvalbumin-a, calbindin-D28k, and calretinin in mice with patch-clamp recording, in vivo physiology, and mathematical modeling to study their role in Ca2+ signaling, exocytosis, and sound encoding at the synapses of inner hair cells (IHCs). IHCs lacking all three proteins showed excessive exocytosis during prolonged depolarizations, despite enhanced Ca2+-dependent inactivation of their Ca2+ current. Exocytosis of readily releasable vesicles remained unchanged, in accordance with the estimated tight spatial coupling of Ca2+ channels and release sites (effective "coupling distance" of 17 nm). Substitution experiments with synthetic Ca2+ chelators indicated the presence of endogenous Ca2+ buffers equivalent to 1 mM synthetic Ca2+- binding sites, approximately half of them with kinetics as fast as 1,2-Bis(2-aminophenoxy) ethane N, N, N', N'-tetraacetic acid (BAPTA). Synaptic sound encoding was largely unaltered, suggesting that excess exocytosis occurs extrasynaptically. We conclude that EF-hand Ca2+ buffers regulate presynaptic IHC function for metabolically efficient sound coding.
C1 [Pangrsic, Tina; Gabrielaitis, Mantas; Michanski, Susann; Moser, Tobias] Univ Med Ctr Gottingen, Inst Auditory Neurosci & InnerEarLab, D-37099 Gottingen, Germany.
[Pangrsic, Tina; Michanski, Susann; Wolf, Fred; Strenzke, Nicola; Moser, Tobias] Univ Gottingen, Collaborat Res Ctr 889, D-37099 Gottingen, Germany.
[Gabrielaitis, Mantas; Wolf, Fred] Max Planck Inst Dynam & Self Org, Theoret Neurophys Grp, D-37077 Gottingen, Germany.
[Gabrielaitis, Mantas; Wolf, Fred; Moser, Tobias] Univ Gottingen, Bernstein Ctr Computat Neurosci, D-37077 Gottingen, Germany.
[Schwaller, Beat] Univ Fribourg, Dept Med, Unit Anat, CH-1700 Fribourg, Switzerland.
[Strenzke, Nicola] Univ Med Ctr Gottingen, Dept Otolaryngol, Auditory Syst Physiol Grp, InnerEarLab, D-37099 Gottingen, Germany.
[Strenzke, Nicola] Harvard Univ, Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
RP Pangrsic, T (reprint author), Univ Med Ctr Gottingen, Inst Auditory Neurosci, Synapt Physiol Mammalian Vestibular Hair Cells Jr, D-37099 Gottingen, Germany.
EM tpangrs@gwdg.de; nstrenzke@med.uni-goettingen.de; tmoser@gwdg.de
RI Moser, Tobias/L-5068-2014
OI Moser, Tobias/0000-0001-7145-0533
FU Humboldt fellowship; Deutsche Forschungsgemeinschaft (DFG);
Collaborative Research Center 889 Projects; German Federal Ministry for
Education and Research through the Bernstein Center for Computational
Neuroscience [01GQ0811, 01GQ1005A]
FX We thank M. Charles Liberman for providing guidance and the facilities
for the single auditory nerve fiber recordings, Gerhard Hoch for
providing image analysis MATLAB routines, Carolin Wichmann for providing
the EM micrograph, Erwin Neher, Aaron B. Wong, and members of the
InnerEarLab for discussion and comments on the manuscript, and Margitta
Koppler, Sonja Blume, Christian Rudiger, Sandra Gerke, and Christiane
Senger-Freitag (Institute for Auditory Neuroscience, University Medical
Center Gottingen,) and Simone Eichenberger and Valerie Salicio (Unit of
Anatomy, University of Fribourg) for excellent technical assistance.
This work was supported by a Humboldt fellowship (to T.P.), grants of
the Deutsche Forschungsgemeinschaft (DFG) through a fellowship (to N.S.)
and the Collaborative Research Center 889 Projects A2, A6, and C6 (to
T.M., N.S., and F.W.), and German Federal Ministry for Education and
Research Grants 01GQ0811 (to F.W.) and 01GQ1005A (to T.M.) through the
Bernstein Center for Computational Neuroscience.
NR 73
TC 15
Z9 15
U1 1
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 3
PY 2015
VL 112
IS 9
BP E1028
EP E1037
DI 10.1073/pnas.1416424112
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC3DK
UT WOS:000350224900017
PM 25691754
ER
PT J
AU Haffajee, RL
Jena, AB
Weiner, SG
AF Haffajee, Rebecca L.
Jena, Anupam B.
Weiner, Scott G.
TI Mandatory Use of Prescription Drug Monitoring Programs
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
C1 [Haffajee, Rebecca L.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02215 USA.
[Haffajee, Rebecca L.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Jena, Anupam B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Jena, Anupam B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Jena, Anupam B.] Natl Bur Econ Res, Cambridge, MA 02138 USA.
[Weiner, Scott G.] Brigham & Womens Hosp, Div Hlth Policy Res Translat, Dept Emergency Med, Boston, MA 02115 USA.
RP Haffajee, RL (reprint author), Harvard Univ, Sch Med, Dept Populat Med, 133 Brookline Ave,Sixth Floor, Boston, MA 02215 USA.
EM haffajee@fas.harvard.edu
FU NIH HHS [1DP5OD017897-01, DP5 OD017897]
NR 10
TC 22
Z9 23
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAR 3
PY 2015
VL 313
IS 9
BP 891
EP 892
DI 10.1001/jama.2014.18514
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA CC3FN
UT WOS:000350231800007
PM 25622279
ER
PT J
AU Darrow, KN
Slama, MCC
Kozie, ED
Owoc, M
Hancock, K
Kempfle, J
Edge, A
Lacour, S
Boyden, E
Polley, D
Brown, MC
Lee, DJ
AF Darrow, Keith N.
Slama, Michael C. C.
Kozie, Elliott D.
Owoc, Maryanna
Hancock, Kenneth
Kempfle, Judith
Edge, Albert
Lacour, Stephanie
Boyden, Edward
Polley, Daniel
Brown, M. Christian
Lee, Daniel J.
TI Optogenetic stimulation of the cochlear nucleus using channelrhodopsin-2
evokes activity in the central auditory pathways
SO BRAIN RESEARCH
LA English
DT Article
DE ChR2; Inferior colliculus; Auditory cortex; Synchronization index;
Neural prosthesis
ID BRAIN-STEM IMPLANT; INFERIOR COLLICULUS; TRANSGENIC MICE; OPTICAL
CONTROL; NEUROFIBROMATOSIS TYPE-2; MILLISECOND-TIMESCALE; PHONEME
RECOGNITION; SPEECH-PERCEPTION; NEURAL ACTIVITY; SUPERIOR OLIVE
AB Optogenetics has become an important research tool and is being considered as the basis for several neural prostheses. However, few studies have applied optogenetics to the auditory brainstem. This study explored whether optical activation of the cochlear nucleus (CN) elicited responses in neurons in higher centers of the auditory pathway and whether it elicited an evoked response. Viral-mediated gene transfer was used to express channelrhodopsin-2 (ChR2) in the mouse CN. Blue light was delivered via an optical fiber placed near the surface of the infected CN and recordings were made in higher-level centers. Optical stimulation evoked excitatory multiunit spiking activity throughout the tonotopic axis of the central nucleus of the inferior colliculus (IC) and the auditory cortex (Actx). The pattern and magnitude of IC activity elicited by optical stimulation was comparable to that obtained with a 50 dB SPL acoustic click. This broad pattern of activity was consistent with histological confirmation of green fluorescent protein (GFP) label of cell bodies and axons throughout the CN. Increasing pulse rates up to 320 Hz did not significantly affect threshold or bandwidth of the IC responses, but rates higher than 50 Hz resulted in desynchronized activity. Optical stimulation also evoked an auditory brainstem response, which had a simpler waveform than the response to acoustic stimulation. Control cases showed no responses to optical stimulation. These data suggest that optogenetic control of central auditory neurons is feasible, but opsins with faster channel kinetics may be necessary to convey information at rates typical of many auditory signals. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Darrow, Keith N.; Owoc, Maryanna] Worcester State Univ, Dept Commun Sci & Disorders, Worcester, MA USA.
[Darrow, Keith N.; Slama, Michael C. C.; Kempfle, Judith; Polley, Daniel; Brown, M. Christian] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Slama, Michael C. C.; Kozie, Elliott D.; Hancock, Kenneth; Kempfle, Judith; Edge, Albert; Polley, Daniel; Brown, M. Christian; Lee, Daniel J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Kozie, Elliott D.; Lee, Daniel J.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA.
[Lacour, Stephanie] Ecole Polytech Fed Lausanne, IMT IBI, Ctr Neuroprosthet, Lab Soft Bioelect Interfaces, Lausanne, Switzerland.
[Boyden, Edward] MIT, Media Lab, Dept Brain & Cognit Sci & Biol Engn, Cambridge, MA 02139 USA.
[Boyden, Edward] MIT, McGovern Inst, Cambridge, MA 02139 USA.
RP Lee, DJ (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM Daniel_Lee@meei.harvard.edu
RI Lacour, Stephanie/E-6375-2010; Kozin, Elliott/J-1225-2014;
OI Kozin, Elliott/0000-0002-0305-0682; Polley, Daniel/0000-0002-5120-2409
FU Fondation Bertarelli grant; MED-EL grant; National Institutes of Health
[DC01089, DC012894]
FX Preliminary results of this study were presented at the Association for
Research in Otolaryngology Midwinter Meeting, February 2013. This work
was supported by a Fondation Bertarelli grant (D.J.L and S.L), a MED-EL
grant (D.J.L), and a National Institutes of Health Grants DC01089
(M.C.B.) and DC012894 (D.P.).
NR 58
TC 5
Z9 6
U1 3
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD MAR 2
PY 2015
VL 1599
BP 44
EP 56
DI 10.1016/j.brainres.2014.11.044
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA CD7CH
UT WOS:000351247900005
PM 25481416
ER
PT J
AU Shen, Q
Huang, SL
Duong, TQ
AF Shen, Qiang
Huang, Shiliang
Duong, Timothy Q.
TI Ultra-high spatial resolution basal and evoked cerebral blood flow MRI
of the rat brain
SO BRAIN RESEARCH
LA English
DT Article
DE High resolution imaging; Columnar resolution; Layer specificity;
Arterial spin labeling
ID FUNCTIONAL MRI; OXYGEN-CONSUMPTION; QUANTITATIVE PERFUSION;
SOMATOSENSORY CORTEX; BOLD RESPONSES; STROKE MODEL; CMRO2 FMRI;
SPIN-ECHO; CBF; DIFFUSION
AB Cerebral blood flow (CBF) is tightly coupled to metabolism and neural activity under normal physiological conditions, and is often perturbed in disease states. The goals of this study were to implement a high-resolution (up to 50 x 38 mu m(2)) CBF MRI protocol of the rat brain, create a digital CBF atlas, report CBF values for 30+ brain structures based on the atlas, and explore applications of high-resolution CBF fMRI of forepaw stimulation. Excellent blood-flow contrasts were observed among different cortical and subcortical structures. CBF MRI showed column-like alternating bright and dark bands in the neocortices, reflecting the layout of descending arterioles and ascending venules, respectively. CBF MRI also showed lamina-like alternating bright and dark layers across the cortical thicknesses, consistent with the underlying vascular density. CBF profiles across the cortical thickness showed two peaks in layers IV and VI and a shallow trough in layer V. Whole-brain CBF was about 0.89 ml/g/min, with the highest CBF values found amongst the neocortical structures (1 ml/g/min, range: 0.89-1.16 ml/g/min) and the lowest CBF values in the corpus callosum (0.32 ml/g/min), yielding a gray:white matter CBF ratio of 3.1. CBF fMRI responses peaked across layers IV V, whereas the BOLD fMRI responses showed a peak in the superficial layers High-resolution basal CBF MRI, evoked CBF fMRI, and CBF brain atlas can be used to study neurological disorders (such as ischemic stroke). (C) 2014 Elsevier B.V. All rights reserved.
C1 [Shen, Qiang; Huang, Shiliang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Shen, Qiang/B-8784-2008
OI Shen, Qiang/0000-0002-4287-3403
FU NIH [R01NS45879]; NIH/CTSA Pilot Grant [UL1TR001120]; American Heart
Association [EIA0940104N, BGIA9300047]
FX This work was supported in part by NIH (R01NS45879), a NIH/CTSA Pilot
Grant (via UL1TR001120), and American Heart Association (EIA0940104N,
BGIA9300047).
NR 50
TC 2
Z9 2
U1 2
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD MAR 2
PY 2015
VL 1599
BP 126
EP 136
DI 10.1016/j.brainres.2014.12.049
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA CD7CH
UT WOS:000351247900012
PM 25557404
ER
PT J
AU Boros, E
Caravan, P
AF Boros, Eszter
Caravan, Peter
TI Probing the Structure-Relaxivity Relationship of Bis-hydrated Gd(DOTAla)
Derivatives
SO INORGANIC CHEMISTRY
LA English
DT Article
ID MRI CONTRAST AGENTS; FAST WATER EXCHANGE; ACID GD-COMPLEX;
LANTHANIDE(III) COMPLEXES; GADOLINIUM(III) COMPLEXES; EUROPIUM
COMPLEXES; ALBUMIN-BINDING; O-17 NMR; LIGAND; LUMINESCENCE
AB Two structural isomers of the heptadentate chelator DO3Ala were synthesized, with carboxymethyl groups at either the 1,4- or 1,7-positions of the cyclen macrocycle. To interrogate the relaxivity under different rotatational dynamics regimes, the pendant primary amine was coupled to ibuprofen to enable binding to serum albumin. These chelators 6a and 6b form bis(aqua) ternary complexes with Gd(III) or Tb(III) as estimated from relaxivity measurements or luminescence lifetime measurements in water. The relaxivity of [Gd(6a)(H2O)(2)] and [Gd(6b)(H2O)(2)] was measured in the presence and absence of coordinating anions prevalent in vivo such as phosphate, lactate, and bicarbonate and compared with data attained for the q = 2 complex [Gd(DO(3)A)(H2O)(2)]. We found that relaxivity was reduced through formation of ternary complexes with lactate and bicarbonate, albeit to a lesser degree then the relaxivity of Gd(DO(3)A). In the presence of 100-fold excess phosphate, relaxivity was slightly increased and typical for q = 2 complexes of this size (8.3 mM(-1) s1 and 9.5 mM(-1) s(-1), respectively, at 37 degrees C, 60 MHz). Relaxivity for the complexes in the presence of HSA corresponded well to relaxivity obtained for complexes with reduced access for inner-sphere water (13.5 and 12.7 mM(-1) s(-1) at 37 degrees C, 60 MHz). Mean water residency time at 37 degrees C was determined using temperature-dependent O-17-T2 measurements at 11.7 T and calculated to be (310)(tau M) = 23 +/- 1 ns for both structural isomers. Kinetic inertness under forcing conditions (pH 3, competing DTPA ligand) was found to be comparable to [Gd(DO(3)A)(H2O)]. Overall, we found that the replacement of one of the acetate arms of DO(3)A with an amino-propionate arm does not significantly alter the relaxometric and kinetic inertness properties of the corresponding Gd complexes; however, it does provide access to easily functionalizable q = 2 derivatives.
C1 [Boros, Eszter; Caravan, Peter] Harvard Univ, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol,Med Sch, Charlestown, MA 02129 USA.
RP Caravan, P (reprint author), Harvard Univ, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol,Med Sch, 149 Thirteenth St,Suite 2301, Charlestown, MA 02129 USA.
EM caravan@nmr.mgh.harvard.edu
FU National Institute for Biomedical Imaging and Bioengineering (NIBIB)
[R01EB009062]; National Center for Research Resources [S10OD010650,
S10RR023385, P41RR14075]; Swiss National Science Foundation
FX P.C. acknowledges the National Institute for Biomedical Imaging and
Bioengineering for funding for this project (NIBIB, Award No.
R01EB009062), and the National Center for Research Resources for
instrumentation grants (Nos. S10OD010650, S10RR023385, P41RR14075). E.B.
thanks the Swiss National Science Foundation (Advanced Postdoc Mobility
Fellowship) for support.
NR 45
TC 1
Z9 1
U1 2
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0020-1669
EI 1520-510X
J9 INORG CHEM
JI Inorg. Chem.
PD MAR 2
PY 2015
VL 54
IS 5
BP 2403
EP 2410
DI 10.1021/ic503035f
PG 8
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA CC5IF
UT WOS:000350391600039
PM 25693053
ER
PT J
AU Flores, EN
Duggan, A
Madathany, T
Hogan, AK
Marquez, FG
Kumar, G
Seal, RP
Edwards, RH
Liberman, MC
Garcia-Anoveros, J
AF Flores, Emma N.
Duggan, Anne
Madathany, Thomas
Hogan, Ann K.
Marquez, Freddie G.
Kumar, Gagan
Seal, Rebecca P.
Edwards, Robert H.
Liberman, M. Charles
Garcia-Anoveros, Jaime
TI A Non-canonical Pathway from Cochlea to Brain Signals Tissue-Damaging
Noise
SO CURRENT BIOLOGY
LA English
DT Article
ID OUTER HAIR-CELLS; VESICULAR GLUTAMATE TRANSPORTER-3; AUDITORY-NERVE
FIBERS; SPIRAL GANGLION-CELLS; GUINEA-PIG; CENTRAL TRAJECTORIES;
RECIPROCAL SYNAPSES; AFFERENT-FIBERS; MOUSE; MICE
AB Intense noise damages the cochlear organ of Corti, particularly the outer hair cells (OHCs) [1]; however, this epithelium is not innervated by nociceptors of somatosensory ganglia, which detect damage elsewhere in the body. The only sensory neurons innervating the organ of Corti originate from the spiral ganglion, roughly 95% of which innervate exclusively inner hair cells (IHCs) [2-4]. Upon sound stimulation, IHCs release glutamate to activate AMPA-type receptors on these myelinated type-I neurons, which carry the neuronal signals to the cochlear nucleus. The remaining spiral ganglion cells (type IIs) are unmyelinated and contact OHCs [2-4]. Their function is unknown. Using immunoreactivity to cFos, we documented neuronal activation in the brainstem of Vglut3(-/-) mice, in which the canonical auditory pathway (activation of type-I afferents by glutamate released from inner hair cells) is silenced [5, 6]. In these deaf mice, we found responses to noxious noise, which damages hair cells, but not to innocuous noise, in neurons of the cochlear nucleus, but not in the vestibular or trigeminal nuclei. This response originates in the cochlea and not in other areas also stimulated by intense noise (middle ear and vestibule) as it was absent in CD1 mice with selective cochlear degeneration but normal vestibular and somatosensory function. These data imply the existence of an alternative neuronal pathway from cochlea to brainstem that is activated by tissue-damaging noise and does not require glutamate release from IHCs. This detection of noise-induced tissue damage, possibly by type-II cochlear afferents, represents a novel form of sensation that we term auditory nociception.
C1 [Flores, Emma N.; Duggan, Anne; Madathany, Thomas; Hogan, Ann K.; Marquez, Freddie G.; Kumar, Gagan; Garcia-Anoveros, Jaime] Northwestern Univ, Dept Anesthesiol, Feinberg Sch Med, Chicago, IL 60611 USA.
[Garcia-Anoveros, Jaime] Northwestern Univ, Dept Neurol, Feinberg Sch Med, Chicago, IL 60611 USA.
[Garcia-Anoveros, Jaime] Northwestern Univ, Dept Physiol, Feinberg Sch Med, Chicago, IL 60611 USA.
[Garcia-Anoveros, Jaime] Northwestern Univ, Hugh Knowles Ctr Clin & Basic Sci Hearing & Its D, Feinberg Sch Med, Chicago, IL 60611 USA.
[Seal, Rebecca P.; Edwards, Robert H.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA.
[Seal, Rebecca P.; Edwards, Robert H.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA.
[Liberman, M. Charles] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Liberman, M. Charles] Harvard Univ, Dept Otol & Laryngol, Sch Med, Boston, MA 02114 USA.
RP Garcia-Anoveros, J (reprint author), Northwestern Univ, Dept Anesthesiol, Feinberg Sch Med, Chicago, IL 60611 USA.
EM anoveros@northwestern.edu
FU Office of Naval Research [F31DC012013, R01DC00188, R01NS044363, R21
DC006089, N00014-14-1-0709]
FX We thank Claus-Peter Richter for auditory testing facilities and
supervision and Jody Ciolino (Robert H. Lurie Biostatistics Facility)
for statistics. This work was funded by F31DC012013 (E.N.F.), R01DC00188
(M.C.L.), and R01NS044363, R21 DC006089, and N00014-14-1-0709 from the
Office of Naval Research (J.G.-A.).
NR 40
TC 14
Z9 14
U1 1
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD MAR 2
PY 2015
VL 25
IS 5
BP 606
EP 612
DI 10.1016/j.cub.2015.01.009
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CC9RP
UT WOS:000350708800023
PM 25639244
ER
PT J
AU Choi, M
Lee, WM
Yun, SH
AF Choi, Myunghwan
Lee, Woei Ming
Yun, Seok Hyun
TI Intravital Microscopic Interrogation of Peripheral Taste Sensation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SWEET TASTE; RAT TONGUE; RECEPTORS; CELLS; BUDS; BRAIN; MICE
AB Intravital microscopy is a powerful tool in neuroscience but has not been adapted to the taste sensory organ due to anatomical constraint. Here we developed an imaging window to facilitate microscopic access to the murine tongue in vivo. Real-time two-photon microscopy allowed the visualization of three-dimensional microanatomy of the intact tongue mucosa and functional activity of taste cells in response to topically administered tastants in live mice. Video microscopy also showed the calcium activity of taste cells elicited by small-sized tastants in the blood circulation. Molecular kinetic analysis suggested that intravascular taste sensation takes place at the microvilli on the apical side of taste cells after diffusion of the molecules through the pericellular capillaries and tight junctions in the taste bud. Our results demonstrate the capabilities and utilities of the new tool for taste research in vivo.
C1 [Choi, Myunghwan; Lee, Woei Ming; Yun, Seok Hyun] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02139 USA.
[Choi, Myunghwan; Lee, Woei Ming; Yun, Seok Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA 02139 USA.
[Choi, Myunghwan] Sungkyunkwan Univ, Global Biomed Engn, Suwon, South Korea.
[Lee, Woei Ming] Australian Natl Univ, Res Sch Engn, Canberra, ACT 0200, Australia.
RP Yun, SH (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 65 Landsdowne St,UP-5, Cambridge, MA 02139 USA.
EM syun@mgh.harvard.edu
OI Lee, W M Steve/0000-0002-3912-6095; Choi, Myunghwan/0000-0002-4235-7003
FU U.S. National Institutes of Health [P41EB015903, U54CA143837]; National
Research Foundation of Korea [NRF-2013R1A6A3A03060958]
FX We thank K.B. Lee, H. Koo, and S.J.J. Kwok in the Wellman Center for
Photomedicine for helpful discussions and J. M. Bekker in Australian
National University for comments. This work was in part funded by the
U.S. National Institutes of Health (P41EB015903, U54CA143837) and a
Postdoctoral Fellowship from the National Research Foundation of Korea
(NRF-2013R1A6A3A03060958).
NR 33
TC 1
Z9 1
U1 2
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 2
PY 2015
VL 5
AR 8661
DI 10.1038/srep08661
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC4DF
UT WOS:000350300300006
PM 25726964
ER
PT J
AU Kales, HC
Gitlin, LN
Lyketsos, CG
AF Kales, Helen C.
Gitlin, Laura N.
Lyketsos, Constantine G.
TI Assessment and management of behavioral and psychological symptoms of
dementia
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Review
ID ALZHEIMERS-DISEASE PATIENTS; ATYPICAL ANTIPSYCHOTIC MEDICATIONS;
SEROTONIN REUPTAKE INHIBITORS; RANDOMIZED CONTROLLED-TRIAL;
PLACEBO-CONTROLLED TRIALS; HOME-BASED INTERVENTION; TO-MODERATE
DEMENTIA; NEUROPSYCHIATRIC-SYMPTOMS; DOUBLE-BLIND; NURSING-HOME
AB Behavioral and psychological symptoms of dementia include agitation, depression, apathy, repetitive questioning, psychosis, aggression, sleep problems, wandering, and a variety of inappropriate behaviors. One or more of these symptoms will affect nearly all people with dementia over the course of their illness. These symptoms are among the most complex, stressful, and costly aspects of care, and they lead to a myriad of poor patient health outcomes, healthcare problems, and income loss for family care givers. The causes include neurobiologically related disease factors; unmet needs; care giver factors; environmental triggers; and interactions of individual, care giver, and environmental factors. The complexity of these symptoms means that there is no "one size fits all solution," and approaches tailored to the patient and the care giver are needed. Non-pharmacologic approaches should be used first line, although several exceptions are discussed. Non-pharmacologic approaches with the strongest evidence base involve family care giver interventions. Regarding pharmacologic treatments, antipsychotics have the strongest evidence base, although the risk to benefit ratio is a concern. An approach to integrating non-pharmacologic and pharmacologic treatments is described. Finally, the paradigm shift needed to fully institute tailored treatments for people and families dealing with these symptoms in the community is discussed.
C1 [Kales, Helen C.] Univ Michigan, Dept Psychiat, Sect Geriatr Psychiat, Ann Arbor, MI 48109 USA.
[Kales, Helen C.] US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI USA.
[Kales, Helen C.] VA Ann Arbor Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI USA.
[Gitlin, Laura N.] Johns Hopkins Univ, Sch Nursing, Dept Community Publ Hlth, Baltimore, MD USA.
[Gitlin, Laura N.] Johns Hopkins Univ, Sch Med, Div Geriatr & Gerontol, Baltimore, MD USA.
[Gitlin, Laura N.] Johns Hopkins Univ, Ctr Innovat Care Aging, Baltimore, MD USA.
[Lyketsos, Constantine G.] Johns Hopkins Bayview, Dept Psychiat & Behav Sci, Baltimore, MD USA.
[Lyketsos, Constantine G.] Johns Hopkins Univ, Baltimore, MD USA.
RP Kales, HC (reprint author), Univ Michigan, Dept Psychiat, Sect Geriatr Psychiat, Ann Arbor, MI 48109 USA.
EM kales@umich.edu
FU Johns Hopkins Alzheimer's Disease Research Center [P50AG005146];
[R01NR014200]
FX HCK and LNG were supported in part by R01NR014200. CGL was supported in
part by the Johns Hopkins Alzheimer's Disease Research Center
(P50AG005146).
NR 172
TC 37
Z9 38
U1 14
U2 57
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD MAR 2
PY 2015
VL 350
AR h369
DI 10.1136/bmj.h369
PG 16
WC Medicine, General & Internal
SC General & Internal Medicine
GA CC4BV
UT WOS:000350296600007
PM 25731881
ER
PT J
AU Hoguet, A
Parrish, RK
AF Hoguet, Ambika
Parrish, Richard K., II
TI Unexpected Hypotony After Glaucoma Drainage Implant Surgery Associated
With Anti-Vascular Endothelial Growth Factor Treatment
SO JAMA OPHTHALMOLOGY
LA English
DT Letter
ID BEVACIZUMAB; SUBCONJUNCTIVAL; TRABECULECTOMY
C1 [Hoguet, Ambika] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
[Parrish, Richard K., II] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
RP Hoguet, A (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM ambika.sud@gmail.com
FU NEI NIH HHS [P0EY01480]
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2015
VL 133
IS 3
BP 349
EP 350
DI 10.1001/jamaophthalmol.2014.5058
PG 2
WC Ophthalmology
SC Ophthalmology
GA CD6UE
UT WOS:000351224200020
PM 25474585
ER
PT J
AU Nogiec, C
Burkart, A
Dreyfuss, JM
Lerin, C
Kasif, S
Patti, ME
AF Nogiec, Christopher
Burkart, Alison
Dreyfuss, Jonathan M.
Lerin, Carles
Kasif, Simon
Patti, Mary-Elizabeth
TI Metabolic modeling of muscle metabolism identifies key reactions linked
to insulin resistance phenotypes
SO MOLECULAR METABOLISM
LA English
DT Article
DE Muscle insulin resistance; Muscle metabolism; Flux balance analysis;
Computational modeling
ID HUMAN SKELETAL-MUSCLE; PYRUVATE-DEHYDROGENASE; DIABETES-MELLITUS; GLOBAL
RECONSTRUCTION; HEART-MITOCHONDRIA; ATP SYNTHESIS; OXIDATION; NETWORK;
GLUCOSE; EXERCISE
AB Objective: Dysregulated muscle metabolism is a cardinal feature of human insulin resistance (IR) and associated diseases, including type 2 diabetes (T2D). However, specific reactions contributing to abnormal energetics and metabolic inflexibility in IR are unknown.
Methods: We utilize flux balance computational modeling to develop the first systems-level analysis of IR metabolism in fasted and fed states, and varying nutrient conditions. We systematically perturb the metabolic network to identify reactions that reproduce key features of IR-linked metabolism.
Results: While reduced glucose uptake is a major hallmark of IR, model-based reductions in either extracellular glucose availability or uptake do not alter metabolic flexibility, and thus are not sufficient to fully recapitulate IR-linked metabolism. Moreover, experimentally-reduced flux through single reactions does not reproduce key features of IR-linked metabolism. However, dual knockdowns of pyruvate dehydrogenase (PDH), in combination with reduced lipid uptake or lipid/amino acid oxidation (ETFDH), does reduce ATP synthesis, TCA cycle flux, and metabolic flexibility. Experimental validation demonstrates robust impact of dual knockdowns in PDH/ETFDH on cellular energetics and TCA cycle flux in cultured myocytes. Parallel analysis of transcriptomic and metabolomics data in humans with IR and T2D demonstrates downregulation of PDH subunits and upregulation of its inhibitory kinase PDK4, both of which would be predicted to decrease PDH flux, concordant with the model.
Conclusions: Our results indicate that complex interactions between multiple biochemical reactions contribute to metabolic perturbations observed in human IR, and that the PDH complex plays a key role in these metabolic phenotypes. (C) 2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Nogiec, Christopher] Boston Univ, Grad Program Bioinformat, Boston, MA 02215 USA.
[Burkart, Alison; Dreyfuss, Jonathan M.; Lerin, Carles; Kasif, Simon; Patti, Mary-Elizabeth] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA.
[Burkart, Alison; Patti, Mary-Elizabeth] Harvard Univ, Sch Med, Boston, MA USA.
[Dreyfuss, Jonathan M.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
[Kasif, Simon] Boston Univ, Biomed Engn, Boston, MA 02215 USA.
[Kasif, Simon] Harvard Mit Div Hlth Sci & Technol, Childrens Hosp Informat Program, Boston, MA USA.
RP Patti, ME (reprint author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.
EM Nogiec@bu.edu; Alison.burkart@joslin.harvard.edu; clerin@fsjd.edu;
Kasif@bu.edu; mary.elizabeth.patti@joslin.harvard.edu
OI Dreyfuss, Jonathan/0000-0001-7242-3991
FU NIDDK NIH HHS [P30 DK036836, T32 DK007260]; NLM NIH HHS [U54 LM008748]
NR 71
TC 7
Z9 8
U1 2
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2212-8778
J9 MOL METAB
JI Mol. Metab.
PD MAR
PY 2015
VL 4
IS 3
BP 151
EP 163
DI 10.1016/j.molmet.2014.12.012
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CZ9RH
UT WOS:000367434200001
PM 25737951
ER
PT J
AU Hobbs, GS
Perales, MA
AF Hobbs, Gabriela Soriano
Perales, Miguel-Angel
TI Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell
Transplantation Outcomes in AML Patients
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE AML; CD34+ selection; T-cell depletion; graft-versus-host disease;
hematopoietic stem cell transplantation
ID VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; ACUTE MYELOGENOUS
LEUKEMIA; ACUTE MYELOID-LEUKEMIA; 1ST COMPLETE REMISSION;
MONOCLONAL-ANTIBODY OKT3; RED-BLOOD-CELLS; UNRELATED-DONOR; HEMATOLOGIC
MALIGNANCIES; ANTITHYMOCYTE GLOBULIN
AB Graft versus host disease (GVHD) remains one of the leading causes of morbidity and mortality associated with conventional allogeneic hematopoietic stem cell transplantation (HCT). The use of T-cell depletion significantly reduces this complication. Recent prospective and retrospective data suggest that, in patients with AML in first complete remission, CD34+ selected grafts afford overall and relapse-free survival comparable to those observed in recipients of conventional grafts, while significantly decreasing GVHD. In addition, CD34+ selected grafts allow older patients, and those with medical comorbidities or with only HLA-mismatched donors to successfully undergo transplantation. Prospective data are needed to further define which groups of patients with AML are most likely to benefit from CD34+ selected grafts. Here we review the history of T-cell depletion in AML, and techniques used. We then summarize the contemporary literature using CD34+ selection in recipients of matched or partially mismatched donors (7/8 or 8/8 HLA-matched), and provide a summary of the risks and benefits of using T-cell depletion.
C1 [Hobbs, Gabriela Soriano] Massachusetts Gen Hosp, Adult Leukemia Serv, Boston, MA 02114 USA.
[Hobbs, Gabriela Soriano] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, Adult Bone Marrow Transplantat Serv, New York, NY 10065 USA.
[Perales, Miguel-Angel] Weill Cornell Med Coll, New York, NY 10065 USA.
RP Perales, MA (reprint author), Mem Sloan Kettering Canc Ctr, Adult Bone Marrow Transplantat Serv, New York, NY 10065 USA.
EM ghobbs@partners.org; peralesm@mskcc.org
OI Hobbs, Gabriela/0000-0002-0199-9333
FU NCI NIH HHS [P01 CA023766]
NR 79
TC 1
Z9 1
U1 0
U2 0
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2015
VL 4
IS 3
BP 488
EP 503
DI 10.3390/jcm4030488
PG 16
WC Medicine, General & Internal
SC General & Internal Medicine
GA CT9KT
UT WOS:000363136600009
PM 26239251
ER
PT J
AU Lee, CT
Chuang, SK
Stoupel, J
AF Lee, Chun-Teh
Chuang, Sung-Kiang
Stoupel, Janet
TI Survival Analysis and Other Clinical Outcomes of Immediate Implant
Placement in Sites with Periapical Lesions: Systematic Review
SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS
LA English
DT Article
DE dental implants; evidence-based dentistry; oral pathology
ID OF-THE-LITERATURE; DENTAL IMPLANTS; INFECTED SITES; EXTRACTION SOCKETS;
RETROSPECTIVE ANALYSIS; ENDODONTIC SURGERY; CONSENSUS CONFERENCE; BONE
REGENERATION; FOLLOW-UP; TEETH
AB Purpose: Immediate implantation has become one of the therapeutic options for replacement of a hopeless tooth. In the case of a tooth with a periapical lesion, this approach remains controversial. The aims of this article were to systematically review the evidence on immediate implants in sites with periapical lesions with reference to: (1) survival rates, (2) changes in crestal bone levels and marginal tissues, (3) complication rates, and (4) comparison of clinical outcomes with other implant treatments. Materials and Methods: An electronic search was conducted in MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), and EMBASE for articles published between January 1990 and August 2013. Publications were screened, and data extraction and quality assessment were performed. Implant survival rates were calculated using predicted Ka survival analysis. Crestal bone level changes, soft tissue outcomes, complications, and procedure characteristics were analyzed descriptively. Results: Initially, 301 articles were identified. Three prospective controlled trials of immediate implant placement in sites with periapical lesions with a follow-up period of at least 1 year were selected for the survival analysis. The predicted cumulative 5-year survival rate of immediate implants in sites with periapical lesions was 96.23%. Bone and gingival level changes were comparable to those of implants placed in sites without periapical pathology. The complication rates, reported in only one study, were 15.4% (2/13) in sites with periapical lesions and 6.7% (1/15) in healthy sites. Conclusion: Limited evidence suggests that immediate implant placement in sites with periapical lesions leads to clinical outcomes comparable to those of immediate implants in healthy sites. Additional prospective controlled trials with large sample sizes and long-term follow-up are needed to further investigate these results.
C1 [Lee, Chun-Teh] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Div Periodontol, Boston, MA 02115 USA.
[Chuang, Sung-Kiang] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
[Chuang, Sung-Kiang] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA.
[Stoupel, Janet] Columbia Univ, Coll Dent Med, Div Periodont, Sect Oral & Diagnost Sci, New York, NY USA.
RP Lee, CT (reprint author), Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, 188 Longwood Ave, Boston, MA 02115 USA.
EM chun-teh_lee@hsdm.harvard.edu
NR 82
TC 3
Z9 3
U1 4
U2 4
PU QUINTESSENCE PUBLISHING CO INC
PI HANOVER PARK
PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA
SN 0882-2786
EI 1942-4434
J9 INT J ORAL MAX IMPL
JI Int. J. Oral Maxillofac. Implants
PD MAR-APR
PY 2015
VL 30
IS 2
BP 268
EP 278
PG 11
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA CZ6XB
UT WOS:000367243200003
PM 25830386
ER
PT J
AU Zafar, SY
McNeil, RB
Thomas, CM
Lathan, CS
Ayanian, JZ
Provenzale, D
AF Zafar, S. Yousuf
McNeil, Rebecca B.
Thomas, Catherine M.
Lathan, Christopher S.
Ayanian, John Z.
Provenzale, Dawn
TI Population-Based Assessment of Cancer Survivors' Financial Burden and
Quality of Life: A Prospective Cohort Study
SO JOURNAL OF ONCOLOGY PRACTICE
LA English
DT Article
ID CARE OUTCOMES RESEARCH; PATIENTS EXPERIENCE; BREAST-CANCER; TOXICITY;
ADULTS; COSTS; WOMEN; RISK
AB Purpose: The impact of financial burden among patients with cancer has not yet been measured in a way that accounts for inter-relationships between quality of life, perceived quality of care, disease status, and sociodemographic characteristics.
Patients and Methods: In a national, prospective, observational, population-and health care systems-based cohort study, patients with colorectal or lung cancer were enrolled from 2003 to 2006 within 3 months of diagnosis. For this analysis, surviving patients who were either disease free or had advanced disease were resurveyed a median 7.3 years from diagnosis. Structural equation modeling was used to investigate relationships between financial burden, quality of life, perceived quality of care, and sociodemographic characteristics.
Results: Among 1,000 participants enrolled from five geographic regions, five integrated health care systems, or 15 Veterans Administration Hospitals, 89% (n = 889) were cancer free, and 11% (n = 111) had advanced cancer. Overall, 48% (n = 482) reported difficulties living on their household income, and 41% (n = 396) believed their health care to be "excellent." High financial burden was associated with lower household income (adjusted odds ratio [OR] = 0.61 per $20k per year, P < .001) and younger age (adjusted OR = 0.63 per 10 years; P < .001). High financial burden was also associated with poorer quality of life (adjusted beta = -0.06 per burden category; P < .001). Better quality of life was associated with fewer perceptions of poorer quality of care (adjusted OR = 0.85 per 0.10 EuroQol units; P < .001).
Conclusion: Financial burden is prevalent among cancer survivors and is related to patients' health-related quality of life. Future studies should consider interventions to improve patient education and engagement with regard to financial burden.
C1 Duke Canc Inst, Durham, NC USA.
Duke Clin Res Inst, Ctr Learning Hlth Care, Durham, NC USA.
[Zafar, S. Yousuf] Duke Univ, Med Ctr, Durham, NC 27705 USA.
Durham Vet Affairs Med Ctr Durham, Epidemiol Ctr Durham, Cooperat Studies Program, Durham, NC USA.
Med Univ S Carolina, Charleston, SC 29425 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Zafar, SY (reprint author), Duke Univ, Med Ctr, DUMC 3850,2400 Pratt St,Rm 8039, Durham, NC 27705 USA.
EM yousuf.zafar@duke.edu
FU NCI NIH HHS [1-KM1-CA-156687-01, KM1 CA156687, U01 CA093324, U01
CA093326, U01 CA093329, U01 CA093332, U01 CA093339, U01 CA093344, U01
CA093348]
NR 33
TC 18
Z9 18
U1 3
U2 8
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 1554-7477
EI 1935-469X
J9 J ONCOL PRACT
JI J. Oncol. Pract.
PD MAR
PY 2015
VL 11
IS 2
BP 145
EP U472
DI 10.1200/JOP.2014.001542
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CY1PA
UT WOS:000366178400032
PM 25515717
ER
PT J
AU Margalit, DN
Losi, SM
Tishler, RB
Schoenfeld, JD
Fugazzotto, JA
Stephens, J
Cebulski, AL
Hammerstrand, EL
Ma, L
Lopes, HM
Haddad, RI
Treister, NS
Frustino, JL
AF Margalit, Danielle N.
Losi, Stephanie M.
Tishler, Roy B.
Schoenfeld, Jonathan D.
Fugazzotto, Jo Ann
Stephens, Josie
Cebulski, Amy L.
Hammerstrand, Elizabeth L.
Ma, Laura
Lopes, Holly M.
Haddad, Robert I.
Treister, Nathaniel S.
Frustino, Jennifer L.
TI Ensuring Head and Neck Oncology Patients Receive Recommended
Pretreatment Dental Evaluations
SO JOURNAL OF ONCOLOGY PRACTICE
LA English
DT Article
ID CARE
AB Purpose: Head and neck (H&N) cancer therapy can have a detrimental effect on oral health by increasing the risk of dry mouth, dental caries, dental infection, and osteonecrosis of the jaw. Pretreatment dental evaluations are recommended for patients with H&N cancer before radiation therapy to minimize the risk of acute and long-term adverse effects. In an earlier effort to educate patients and community dentists about the importance of pretreatment dental evaluations, we created a dental instructional guide (DIG) that outlines the necessary components of the preradiation dental evaluation. Yet our program did not have a system for documenting which patients received the DIG. The aim of this project was to create a reliable system to ensure that patients are given the DIG before radiation therapy and that such patients are readily identifiable, allowing us to confirm that their dental evaluations are complete before starting treatment.
Methods: We implemented a tracking template within the H&N oncology program at the Dana-Farber Cancer Institute that documents the date, patient, and clinician who gave the DIG. We used the Model for Improvement methodology and performed plan-do-study-act (PDSA) cycles to test and monitor the results of the template implementation.
Results: We showed a significant improvement in the rate of DIG documentation from a baseline of 0% (range, 0% to 0%) to a mean of 53% (range, 0% to 100%) over 3 months (P < .01).
Conclusion: This intervention was the first step in creating a sustainable system for ensuring timely preradiation dental evaluation, thereby decreasing the risk of dental complications from H&N cancer therapy.
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Ctr Clin Excellence, Boston, MA 02115 USA.
Erie Cty Med Ctr & Labs, Ctr Oncol Care, Buffalo, NY USA.
RP Margalit, DN (reprint author), Dept Radiat Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM dmargalit@lroc.harvard.edu
NR 6
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 1554-7477
EI 1935-469X
J9 J ONCOL PRACT
JI J. Oncol. Pract.
PD MAR
PY 2015
VL 11
IS 2
BP 151
EP U504
DI 10.1200/JOP.2014.000414
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CY1PA
UT WOS:000366178400033
PM 25628388
ER
PT J
AU Kehl, KL
Gray, SW
Kim, B
Kahn, KL
Haggstrom, D
Roudier, M
Keating, NL
AF Kehl, Kenneth L.
Gray, Stacy W.
Kim, Benjamin
Kahn, Katherine L.
Haggstrom, David
Roudier, Maryse
Keating, Nancy L.
TI Oncologists' Experiences With Drug Shortages
SO JOURNAL OF ONCOLOGY PRACTICE
LA English
DT Article
ID ADVANCED COLORECTAL-CANCER; RACEMIC LEUCOVORIN; UNITED-STATES; L-ISOMER;
CARE; IMPACT; LEVOLEUCOVORIN
AB Purpose: There have been numerous reports of shortages of injectable drugs for cancer in the last decade. Weassessed physician experiences with drug shortages in a population-based cohort of medical oncologists caring for patients with lung or colorectal cancer.
Methods: We surveyed medical oncologists caring for patients with lung or colorectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium from 2012 to 2013 (participation rate, 53%). Oncologists reported experiences with shortages of leucovorin, fluorouracil, dexamethasone, cyanocobalamin, paclitaxel, cisplatin, and etoposide in the prior year and whether they had used a less-effective alternative because of a shortage. We used multivariable logistic regression to assess for associations between physician or practice characteristics and encountering shortages.
Results: Among 330 respondents, 74% reported experiences with a shortage of at least one drug in our survey, and 28% reported using a less-effective alternative because of a shortage. Although physician demographic characteristics did not predict reports of drug shortages, practice characteristics did. Veterans Affairs (VA) oncologists were less likely to report experiencing any shortage than oncologists in single-specialty group practice (odds ratio [OR], 0.4; 95% CI, 0.2 to 0.9). The reported use of a less effective alternative to any drug was also less common among VA oncologists (OR, 0.3; 95% CI, 0.1 to 0.9) and oncologists affiliated with health maintenance organizations (OR, 0.4; 95% CI, 0.2 to 0.9) compared with physicians in single-specialty groups.
Conclusion: Most oncologists encountered drug shortages in the year before our survey, but experiences with shortages varied with practice structure. Further research is needed to quantitatively assess the impact of drug shortages on patients and evaluate various strategies for managing them.
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Frontier Sci & Technol Res Fdn Inc, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
RAND Corp, Santa Monica, CA USA.
Vet Affairs VA Hlth Serv Res & Dev, Roudebush, VA USA.
Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
RP Keating, NL (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.
EM keating@hcp.med.harvard.edu
FU NCI NIH HHS [K24 CA181510]
NR 30
TC 5
Z9 5
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 1554-7477
EI 1935-469X
J9 J ONCOL PRACT
JI J. Oncol. Pract.
PD MAR
PY 2015
VL 11
IS 2
BP E154
EP E162
DI 10.1200/JOP.2014.000380
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CY1PA
UT WOS:000366178400006
PM 25549653
ER
PT J
AU Palmer, SC
Stricker, CT
Panzer, SL
Arvey, SA
Baker, KS
Casillas, J
Ganz, PA
McCabe, MS
Nekhlyudov, L
Overholser, L
Partridge, AH
Risendal, B
Rosenstein, DL
Syrjala, KL
Jacobs, LA
AF Palmer, Steven C.
Stricker, Carrie Tompkins
Panzer, SarahLena L.
Arvey, Sarah A.
Baker, K. Scott
Casillas, Jackie
Ganz, Patricia A.
McCabe, Mary S.
Nekhlyudov, Larissa
Overholser, Linda
Partridge, Ann H.
Risendal, Betsy
Rosenstein, Donald L.
Syrjala, Karen L.
Jacobs, Linda A.
TI Outcomes and Satisfaction After Delivery of a Breast Cancer Survivorship
Care Plan: Results of a Multicenter Trial
SO JOURNAL OF ONCOLOGY PRACTICE
LA English
DT Article
ID COLORECTAL-CANCER; FOLLOW-UP; PATIENT SATISFACTION; HEALTH-CARE;
PREFERENCES; ADULT; INFORMATION; PERSPECTIVE; DIAGNOSIS; SERVICES
AB Purpose: Survivorship care plans (SCPs) have been suggested to reduce fragmentation of care experienced by cancer survivors. Acceptance of SCPs is high, but trials in the United States are few. This pilot study used a quasiexperimental design to examine the outcomes achieved by breast cancer survivors receiving a standardized SCP visit at one of seven comprehensive cancer centers.
Materials and Methods: Outcomes were assessed before and again 3 months after delivery of an SCP and included survivors' use of and satisfaction with SCPs, perceived knowledge about survivorship, and assessment of the quality and coordination of survivorship care.
Results: One hundred thirty-nine survivors of breast cancer completed baseline and follow-up measures and received a standardized SCP visit. Participants most commonly used SCP materials to make decisions about exercise (64%), which tests to receive and when (62%), and dietary changes (62%). Only 21% shared the SCP with their primary care provider during that time. Satisfaction with the SCP was high, with 90% of participants reporting being at least satisfied with the SCP. Perceived knowledge about survivorship improved after SCP delivery, as did perceived care coordination and the provider's knowledge of the effects of cancer on survivors (all P < .001). Individuals closer to the time of diagnosis reported greater satisfaction with and use of SCPs.
Conclusion: This study demonstrates improvements in perceived knowledge and quality of survivorship care after receipt of a comprehensive SCP. Survivors were satisfied with their SCP, and those closer to diagnosis reported greater satisfaction with and use of the materials.
C1 Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
LIVESTRONG, Austin, TX USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Colorado, Ctr Canc, Denver, CO 80262 USA.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
RP Palmer, SC (reprint author), 3400 Civ Ctr Blvd,3 WEST, Philadelphia, PA 19104 USA.
EM Stpalmer@mail.med.upenn.edu
FU NCI NIH HHS [R01 CA160684]
NR 45
TC 8
Z9 8
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 1554-7477
EI 1935-469X
J9 J ONCOL PRACT
JI J. Oncol. Pract.
PD MAR
PY 2015
VL 11
IS 2
BP E222
EP E229
DI 10.1200/JOP.2014.001404
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CY1PA
UT WOS:000366178400016
PM 25784579
ER
PT J
AU Zerillo, JA
Pham, TH
Kadlubek, P
Severson, JA
Mackler, E
Jacobson, JO
Blayney, DW
AF Zerillo, Jessica A.
Pham, Trang H.
Kadlubek, Pamela
Severson, Jane Alcyne
Mackler, Emily
Jacobson, Joseph O.
Blayney, Douglas W.
TI Administration of Oral Chemotherapy: Results From Three Rounds of the
Quality Oncology Practice Initiative
SO JOURNAL OF ONCOLOGY PRACTICE
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; PEDIATRIC-PATIENTS; COLORECTAL-CANCER;
ADHERENCE; CARE; SAFETY; AGENTS
AB Purpose: Although use of oral chemotherapy is becoming more prevalent, little is known about the quality of care that patients receive when these agents are prescribed. Moreover, few practice-level systems are in place to ensure safe management of oral chemotherapy in the vulnerable population of patients with cancer.
Methods: We analyzed results from 155 practices that were voluntarily participating in the American Society of Clinical Oncology Quality Oncology Practice Initiative (QOPI) program on 17 test measures of oral chemotherapy administration and management in at least one of three collection periods: spring or fall of 2012, or spring of 2013. The 17 test measures cover three domains: treatment plan documentation, patient education, and adherence/toxicity monitoring. We defined composite scores for each of the three domains. We analyzed the composite scores by secular trend and tested the difference in composite scores for the three domains. Additionally, we tested change in scores over time among practices that participated at least twice.
Results: The majority of data was provided by QOPI-certified practices. Overall, mean practice composite scores ranged from 66% to 68% for treatment plan documentation, 51% to 57% for patient education, and 75% to 81% for adherence/toxicity monitoring. Composite scores for practices that participated more than once did not improve significantly.
Conclusion: The collection of oral chemotherapy test measure data is feasible. Composite scores for treatment plan documentation and patient education were not only lower, but had greater variability compared with adherence/toxicity monitoring. Improvement opportunities exist for patients who are prescribed oral chemotherapy.
C1 [Zerillo, Jessica A.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Amer Soc Clin Oncol, Alexandria, VA USA.
Michigan Oncol Qual Consortium, Ann Arbor, MI USA.
Stanford Canc Inst, Stanford, CA USA.
RP Zerillo, JA (reprint author), Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Shapiro 913, Boston, MA 02215 USA.
EM jzerillo@bidmc.harvard.edu
NR 37
TC 2
Z9 2
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 1554-7477
EI 1935-469X
J9 J ONCOL PRACT
JI J. Oncol. Pract.
PD MAR
PY 2015
VL 11
IS 2
BP E255
EP E262
DI 10.1200/JOP.2014.001842
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CY1PA
UT WOS:000366178400020
PM 25784581
ER
PT J
AU Felker, GM
Butler, J
Collins, SP
Cotter, G
Davison, BA
Ezekowitz, JA
Filippatos, G
Levy, PD
Metra, M
Ponikowski, P
Soergel, DG
Teerlink, JR
Violin, JD
Voors, AA
Pang, PS
AF Felker, G. Michael
Butler, Javed
Collins, Sean P.
Cotter, Gad
Davison, Beth A.
Ezekowitz, Justin A.
Filippatos, Gerasimos
Levy, Phillip D.
Metra, Marco
Ponikowski, Piotr
Soergel, David G.
Teerlink, John R.
Violin, Jonathan D.
Voors, Adriaan A.
Pang, Peter S.
TI Heart Failure Therapeutics on the Basis of a Biased Ligand of the
Angiotensin-2 Type 1 Receptor Rationale and Design of the BLAST-AHF
Study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart
Failure)
SO JACC-HEART FAILURE
LA English
DT Article
DE BLAST-AHF; NT-proBNP; TRV027
ID LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; MULTIPLE
END-POINTS; CLINICAL-TRIALS; INTRAVENOUS ENALAPRILAT; CARDIAC MYOCYTES;
BETA-ARRESTINS; I RECEPTOR; PHASE-II; ASSOCIATION
AB The BLAST-AHF (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure) study is designed to test the efficacy and safety of TRV027, a novel biased ligand of the angiotensin-2 type 1 receptor, in patients with acute heart failure (AHF). AHF remains a major public health problem, and no currently-available therapies have been shown to favorably affect outcomes. TRV027 is a novel biased ligand of the angiotensin-2 type 1 receptor that antagonizes angiotensin-stimulated G-protein activation while stimulating beta-arrestin. In animal models, these effects reduce afterload while increasing cardiac performance and maintaining stroke volume. In initial human studies, TRV027 appears to be hemodynamically active primarily in patients with activation of the renin-angiotensin-aldosterone system, a potentially attractive profile for an AHF therapeutic. BLAST-AHF is an international prospective, randomized, phase IIb, dose-ranging study that will randomize up to 500 AHF patients with systolic blood pressure >= 120 mm Hg and <= 200 mm Hg within 24 h of initial presentation to 1 of 3 doses of intravenous TRV027 (1, 5, or 25 mg/h) or matching placebo (1: 1: 1: 1) for at least 48 h and up to 96 h. The primary endpoint is a composite of 5 clinical endpoints (dyspnea, worsening heart failure, length of hospital stay, 30-day rehospitalization, and 30-day mortality) combined using an average z-score. Secondary endpoints will include the assessment of dyspnea and change in amino-terminal pro-B-type natriuretic peptide. The BLAST-AHF study will assess the efficacy and safety of a novel biased ligand of the angiotensin-2 type 1 receptor in AHF. (C) 2015 by the American College of Cardiology Foundation.
C1 [Felker, G. Michael] Duke Univ, Sch Med, Div Cardiol, Durham, NC USA.
[Butler, Javed] SUNY Stony Brook, Div Cardiol, Stony Brook, NY 11794 USA.
[Collins, Sean P.] Vanderbilt Univ, Dept Emergency Med, Nashville, TN 37235 USA.
[Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA.
[Ezekowitz, Justin A.] Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB, Canada.
[Filippatos, Gerasimos] Athens Univ Hosp Attikon, Dept Cardiol, Athens, Greece.
[Levy, Phillip D.] Wayne State Sch Med, Dept Emergency Med, Detroit, MI USA.
[Levy, Phillip D.] Wayne State Sch Med, Cardiovasc Res Inst, Detroit, MI USA.
[Metra, Marco] Univ Brescia, Dept Med & Surg Specialties, Cardiol, Radiol Sci & Publ Hlth, Brescia, Italy.
[Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Dept Cardiol, Wroclaw, Poland.
[Soergel, David G.; Violin, Jonathan D.] Trevena Inc, King Of Prussia, PA USA.
[Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA USA.
[Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.
[Pang, Peter S.] Indiana Univ Sch Med, Dept Emergency Med, Indianapolis, IN 46202 USA.
RP Felker, GM (reprint author), Duke Clin Res Inst, 2400 Pratt St,Room 0311 Terrace Level, Durham, NC 27710 USA.
EM Michael.felker@duke.edu
RI Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064
FU Trevena, Inc.; National Heart, Lung, and Blood Institute; Novartis;
Roche Diagnostics; Otsuka; Amgen; National Institutes of Health (NIH);
European Union; Health Resources Service Administration; NIH/National
Heart, Lung, and Blood Institute; Cardiorentis; Abbott Point-of-Care;
Medicines Company; Astellas; Intersection Medical; Radiometer;
Medtronic; Trevena; Bayer; Cardio3Bioscience; Cytokinetics; Department
of Veterans Affairs; Duke Clinical Research Institute; Janssen; Mast
Therapeutics; Sorbent; St. Jude Medical
FX The BLAST-AHF study is funded by Trevena, Inc. Dr. Felker has received
grant support from the National Heart, Lung, and Blood Institute,
Novartis, Roche Diagnostics, Otsuka, and Amgen; and has served as a
consultant to Trevena, Amgen, Novartis, Celladon, Sorbent, Bristol-Myers
Squibb, Singulex, St. Jude Medical, and Medtronic. Dr. Butler has
received research support from the National Institutes of Health (NIH),
European Union, and Health Resources Service Administration; and is a
consultant to Amgen, Bayer, BG Medicine, Cardiocell, Celladon, GE
Healthcare, Medtronic, Novartis, Ono Pharma, Otsuka, Takeda, Trevena,
and Zensun. Dr. Collins has received research support from the
NIH/National Heart, Lung, and Blood Institute, Cardiorentis, Abbott
Point-of-Care, Novartis, The Medicines Company, Astellas, Intersection
Medical, Radiometer, and Medtronic; and has served as a consultant to
Trevena, Novartis, Cardiorentis, Otsuka, Radiometer, The Medicines
Company, Medtronic, Intersection Medical, Cardioxyl, and Abbott
Point-of-Care. Drs. Cotter and Davison are employees of Momentum
Research, Inc., which has received compensation for coordinating
research activities or participated in the design of research programs
for Merck, Corthera Inc., Novartis Inc., Nile Therapeutics Inc.,
Amgen/Cytokinetics Inc., Travena Inc., Cardio3 Inc., Sorbent Inc., Chan
Rx Inc.; and has received grants from not-for-profit nongovernmental
organizations and the NIH. Dr. Davison has received honoraria from
Novartis. Dr. Ezekowitz is codirector of the Canadian VIGOUR Centre,
which is involved in site-management for the BLAST-AHF study. Dr.
Filippatos has served on the executive committee of acute heart failure
studies sponsored by Trevena, Novartis, Bayer, and Cardiorentis. Dr.
Levy has served as a consultant for Trevena, Novartis, and Cardiorentis.
Dr. Metra has served as a consultant for Bayer, Novartis, Servier, and
Trevena. Drs. Ponikowski and Voors have served as a consultant for
Trevena. Drs. Soergel and Violin are employees of Trevena. Dr. Teerlink
has received research grants and/or consultant fees from Amgen,
Cardio3Bioscience, Cytokinetics, Department of Veterans Affairs, Duke
Clinical Research Institute, Janssen, Medtronic, Mast Therapeutics,
Novartis, Sorbent, St. Jude Medical, and Trevena. All other authors have
reported that they have no relationships relevant to the contents of
this paper to disclose.
NR 39
TC 27
Z9 27
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-1779
EI 2213-1787
J9 JACC-HEART FAIL
JI JACC-Heart Fail.
PD MAR
PY 2015
VL 3
IS 3
BP 193
EP 201
DI 10.1016/j.jchf.2014.09.008
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CX4EC
UT WOS:000365650600001
PM 25650371
ER
PT J
AU Cerda, R
Perez, F
Domingues, RMSM
Luz, PM
Grinsztejn, B
Veloso, VG
Caffe, S
Francke, JA
Freedberg, KA
Ciaranello, AL
AF Cerda, Rodrigo
Perez, Freddy
Domingues, Rosa Maria S. M.
Luz, Paula M.
Grinsztejn, Beatriz
Veloso, Valdilea G.
Caffe, Sonja
Francke, Jordan A.
Freedberg, Kenneth A.
Ciaranello, Andrea L.
TI Prenatal Transmission of Syphilis and Human Immunodeficiency Virus in
Brazil: Achieving Regional Targets for Elimination
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE congenital syphilis; disease elimination; human immunodeficiency virus;
infectious disease transmission; mathematical models; vertical
transmission
ID MOTHER-TO-CHILD; HIV TRANSMISSION; CONGENITAL-SYPHILIS; ANTIRETROVIRAL
THERAPY; COST-EFFECTIVENESS; RANDOMIZED-TRIAL; PREGNANT-WOMEN;
SOUTH-AFRICA; SAO-PAULO; PREVENTION
AB Background. The Pan-American Health Organization has called for reducing (1) human immunodeficiency virus (HIV) mother-to-child transmission (MTCT) to <= 0.30 infections/1000 live births (LB), (2) HIV MTCT risk to <= 2.0%, and (3) congenital syphilis (CS) incidence to <= 0.50/1000 LB in the Americas by 2015.
Methods. Using published Brazilian data in amathematical model, we simulated a cohort of pregnant women from antenatal care (ANC) through birth. We investigated 2 scenarios: "current access" (89.1% receive one ANC syphilis test and 41.1% receive 2; 81.7% receive one ANC HIV test and 18.9% receive birth testing; if diagnosed, 81.0% are treated for syphilis and 87.5% are treated for HIV) and "ideal access" (95% of women undergo 2 HIV and syphilis screenings; 95% receive appropriate treatment). We conducted univariate and multivariate sensitivity analyses on key inputs.
Results. With current access, we projected 2.95 CS cases/1000 LB, 0.29 HIV infections/1000 LB, 7.1% HIV MTCT risk, and 11.11 intrauterine fetal demises (IUFD)/1000 pregnancies, with significant regional variation. With ideal access, we projected improved outcomes: 1.00 CS cases/1000 LB, 0.10 HIV infections/1000 LB, HIV MTCT risk of 2.4%, and 10.65 IUFD/1000 pregnancies. Increased testing drove the greatest improvements. Even with ideal access, only HIV infections/1000 LB met elimination goals. Achieving all targets required testing and treatment >95% and reductions in prevalence and incidence of HIV and syphilis.
Conclusions. Increasing access to care and HIV and syphilis antenatal testing will substantially reduce HIV and syphilis MTCT in Brazil. In addition, regionally tailored interventions reducing syphilis incidence and prevalence and supporting HIV treatment adherence are necessary to completely meet elimination goals.
C1 [Cerda, Rodrigo; Francke, Jordan A.; Freedberg, Kenneth A.] Pan Amer Hlth Org, Div Gen Med, Washington, DC USA.
[Perez, Freddy; Caffe, Sonja] Pan Amer Hlth Org, Communicable Dis & Hlth Anal Dept, HIV Hepatitis TB & Sexually Transmitted Infect Un, Washington, DC USA.
[Domingues, Rosa Maria S. M.; Luz, Paula M.; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
[Francke, Jordan A.; Freedberg, Kenneth A.; Ciaranello, Andrea L.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Dept Med, Boston, MA 02114 USA.
[Freedberg, Kenneth A.; Ciaranello, Andrea L.] Harvard Univ, Sch Publ Hlth, Div Infect Dis, Boston, MA 02115 USA.
[Freedberg, Kenneth A.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
RP Ciaranello, AL (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 50 Staniford St,Room 936, Boston, MA 02114 USA.
EM aciaranello@partners.org
NR 61
TC 1
Z9 1
U1 1
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD SPR
PY 2015
VL 2
IS 2
DI 10.1093/ofid/ofv073
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA CX6BM
UT WOS:000365786200005
ER
PT J
AU Naggie, S
Patel, K
Yang, LY
Chow, SC
Johnson, V
Guyton, JR
Muir, AJ
Sulkowski, M
Hicks, C
AF Naggie, Susanna
Patel, Keyur
Yang, Lan-Yan
Chow, Shein-Chung
Johnson, Victoria
Guyton, John R.
Muir, Andrew J.
Sulkowski, Mark
Hicks, Charles
TI Antiretroviral Effects on Host Lipoproteins Are Associated With Changes
in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency
Virus/HCV Coinfected Individuals
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE apolipoprotein CIII; apolipoproteins; HCV; HCV RNA; HIV; lipoproteins
ID HIV; INFECTION; THERAPY
AB We evaluated the impact of antiretroviral-induced dyslipidemia on hepatitis C virus (HCV) biogenesis in human immunodeficiency virus (HIV)/HCV coinfected patients. This study used serum samples from antiretroviral-naive HIV/HCV patients initiating their first regimen as part of AIDS Clinical Trials Group study protocols (A5142, A5202). Initiation of antiretrovirals increased most lipoproteins and apolipoproteins. In the multivariable model, changes in apolipoproteins were associated with changes in log(10) HCV RNA from baseline to week-24 of therapy. Off-target lipogenic changes need to be considered in the context of liver and other metabolic disease in HIV/HCV patients.
C1 [Naggie, Susanna; Patel, Keyur; Muir, Andrew J.] Duke Clin Res Inst, Durham, NC USA.
[Naggie, Susanna; Patel, Keyur; Guyton, John R.; Muir, Andrew J.] Duke Univ, Med Ctr, Durham, NC USA.
[Yang, Lan-Yan; Chow, Shein-Chung] Duke Dept Biostat & Bioinformat, Durham, NC USA.
[Yang, Lan-Yan] Chang Gung Mem Hosp, Clin Trial Ctr, Taoyuan, Taiwan.
[Johnson, Victoria] Birmingham VA Med Ctr, Birmingham, AL USA.
[Johnson, Victoria] Univ Alabama, Tuscaloosa, AL 35487 USA.
[Sulkowski, Mark] Johns Hopkins Univ, Baltimore, MD USA.
[Hicks, Charles] Univ Calif San Diego, La Jolla, CA 92093 USA.
RP Naggie, S (reprint author), 2400 Pratt St,Rm 0311,Terrace Level, Durham, NC 27705 USA.
EM susanna.naggie@duke.edu
NR 14
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD SPR
PY 2015
VL 2
IS 2
DI 10.1093/ofid/ofv066
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA CX6BM
UT WOS:000365786200035
ER
PT J
AU Ouyang, ZY
Buzon, MJ
Zheng, L
Sun, H
Yu, XG
Bosch, RJ
Mellors, JW
Eron, JJ
Gandhi, RT
Lichterfeld, M
AF Ouyang, Zhengyu
Buzon, Maria J.
Zheng, Lu
Sun, Hong
Yu, Xu G.
Bosch, Ronald J.
Mellors, John W.
Eron, Joseph J.
Gandhi, Rajesh T.
Lichterfeld, Mathias
TI Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy
Intensified With Raltegravir
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE antiretroviral therapy; CD8 T cells; gene expression profiling; HIV-1;
raltegravir
ID SET ENRICHMENT ANALYSIS; HIV-INFECTED PATIENTS; CONTROLLED-TRIAL;
ACTIVATION; VIREMIA; REPLICATION; IDENTIFICATION; SUPPRESSION; LOADS
AB Background. Intensification of antiretroviral therapy with raltegravir does not affect levels of residual human immunodeficiency virus (HIV)-1 viremia, but it has led to increased levels of episomal HIV-1 DNA in some patients, suggesting antiviral activity against otherwise unresponsive components of the viral reservoir. Effects of raltegravir on host cells remain less well understood.
Methods. We used comprehensive and unbiased microarray-based transcriptional profiling to analyze gene expression changes in CD8(+) T cells from participants in a randomized clinical trial (AIDS Clinical Trials Group [ACTG] A5244) comparing raltegravir-intensified to nonintensified antiretroviral therapy.
Results. Although raltegravir intensification failed to induce statistically significant changes in HIV-1 DNA or residual plasma viremia, we observed significant increases in the expression intensity of 121 host gene transcripts. In functional annotations of these transcripts, we found that they were mainly involved in glucose and carbohydrate metabolism, immune regulation, control of cell proliferation, and tumor suppression. Two of the raltegravir-responsive gene transcripts were statistically correlated with levels of residual HIV-1 RNA, but none of the remaining 119 transcripts were associated with immunologic or virologic characteristics of the study patients.
Conclusions. Together, these findings demonstrate that raltegravir intensification can induce previously unrecognized, statistically significant gene expression changes in host CD8(+) T lymphocytes.
C1 [Ouyang, Zhengyu; Buzon, Maria J.; Sun, Hong; Yu, Xu G.; Gandhi, Rajesh T.] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA.
[Buzon, Maria J.; Gandhi, Rajesh T.; Lichterfeld, Mathias] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Zheng, Lu; Bosch, Ronald J.] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
[Mellors, John W.] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA 15260 USA.
[Eron, Joseph J.] Univ N Carolina, Div Infect Dis, Chapel Hill, NC USA.
RP Lichterfeld, M (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA.
EM mlichterfeld@partners.org
OI Buzon, Maria Jose/0000-0003-4427-9413
NR 37
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD SPR
PY 2015
VL 2
IS 2
DI 10.1093/ofid/ofv045
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA CX6BM
UT WOS:000365786200039
ER
PT J
AU Siedner, MJ
Campbell, JI
Kanters, S
Bennett, JE
Thorlund, K
Tsai, AC
Mills, EJ
AF Siedner, Mark J.
Campbell, Jeffrey I.
Kanters, Steve
Bennett, John E.
Thorlund, Kristian
Tsai, Alexander C.
Mills, Edward J.
TI Combination Therapy for Human Immunodeficiency Virus-Associated
Cryptococcal Meningitis: Whom, When, and Where?
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Letter
ID ANTIFUNGAL
C1 [Siedner, Mark J.; Campbell, Jeffrey I.; Tsai, Alexander C.] Harvard Univ, Sch Med, Boston, MA USA.
[Siedner, Mark J.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
[Siedner, Mark J.; Tsai, Alexander C.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Kanters, Steve; Mills, Edward J.] Univ Ottawa, Fac Hlth Sci, Ottawa, ON K1N 6N5, Canada.
[Kanters, Steve] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada.
[Bennett, John E.] NIH, Lab Clin Infect Dis, Bethesda, MD 20892 USA.
[Thorlund, Kristian] McMaster Univ, Fac Hlth Sci, Hamilton, ON, Canada.
[Tsai, Alexander C.] Massachusetts Gen Hosp, Div Global Psychiat, Boston, MA 02114 USA.
[Tsai, Alexander C.] Mbarara Univ Sci & Technol, Mbarara, Uganda.
[Mills, Edward J.] Stanford Univ, Stanford Prevent Res Ctr, Stanford, CA 94305 USA.
RP Siedner, MJ (reprint author), 55 Fruit St,GRJ5, Boston, MA 02114 USA.
EM msiedner@partners.org
NR 7
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD SPR
PY 2015
VL 2
IS 2
DI 10.1093/ofid/ofv071
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CX6BM
UT WOS:000365786200045
ER
PT J
AU Lee, W
Yagel, S
Cohen, SM
Benacerraf, BR
Cuckle, H
Kagan, KO
Van den Veyver, I
Wapner, R
AF Lee, Wesley
Yagel, Simcha
Cohen, Sarah M.
Benacerraf, Beryl R.
Cuckle, Howard
Kagan, Karl O.
Van den Veyver, Ignatia
Wapner, Ron
TI Noninvasive Prenatal Testing and Fetal Sonographic Screening Roundtable
Discussion
SO JOURNAL OF ULTRASOUND IN MEDICINE
LA English
DT Editorial Material
ID MATERNAL PLASMA; DNA; DIAGNOSIS; ANEUPLOIDY; COST; AMNIOCENTESIS; RISK;
CARE
C1 [Lee, Wesley] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA.
[Yagel, Simcha; Cohen, Sarah M.] Hadassah Hebrew Univ Med Ctr, Dept Obstet & Gynecol, IL-91240 Jerusalem, Israel.
[Benacerraf, Beryl R.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Benacerraf, Beryl R.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA.
[Benacerraf, Beryl R.] Harvard Univ, Massachusetts Gen Hosp, Dept Obstet & Gynecol, Sch Med, Boston, MA USA.
[Cuckle, Howard] Univ Leeds, Dept Reprod Epidemiol, Leeds, W Yorkshire, England.
[Kagan, Karl O.] Univ Tubingen, Dept Obstet & Gynecol, Tubingen, Germany.
[Van den Veyver, Ignatia] Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA.
[Van den Veyver, Ignatia] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
[Wapner, Ron] Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA.
RP Yagel, S (reprint author), Hadassah Hebrew Univ Med Ctr, Dept Obstet & Gynecol, POB 24035, IL-91240 Jerusalem, Israel.
EM simcha.yagel@gmail.com
NR 35
TC 1
Z9 1
U1 0
U2 0
PU AMER INST ULTRASOUND MEDICINE
PI LAUREL
PA SUBSCRIPTION DEPT, 14750 SWEITZER LANE, STE 100, LAUREL, MD 20707-5906
USA
SN 0278-4297
EI 1550-9613
J9 J ULTRAS MED
JI J. Ultrasound Med.
PD MAR 1
PY 2015
VL 34
IS 3
BP 363
EP 369
DI 10.7863/ultra.34.3.363
PG 7
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA CS1PS
UT WOS:000361840100001
ER
PT J
AU Benacerraf, BR
Groszmann, Y
Hornstein, MD
Bromley, B
AF Benacerraf, Beryl R.
Groszmann, Yvette
Hornstein, Mark D.
Bromley, Bryann
TI Deep Infiltrating Endometriosis of the Bowel Wall The Comet Sign
SO JOURNAL OF ULTRASOUND IN MEDICINE
LA English
DT Article
DE bowel; cul-de-sac; endometriosis; gynecologic ultrasound; pelvic pain;
sonography
ID GUIDED TRANSVAGINAL ULTRASONOGRAPHY; PELVIC ENDOMETRIOSIS;
DIAGNOSTIC-ACCURACY; SLIDING SIGN; SONOGRAPHY; ULTRASOUND; OBLITERATION;
PREDICTION; LOCATION; RECTUM
AB The purpose of this study was to evaluate the appearance of deep infiltrating endometriosis of the bowel wall in the cul-de-sac and determine the characteristic appearance of these lesions. We searched our database between January 1, 2011, and December 31, 2013, for all patients who had sonographic findings of suspected deep infiltrating endometriosis of the bowel with obliteration of the cul-de-sac. The medical record of each patient was examined retrospectively for evidence of surgical confirmation of disease. The sonographic appearance, shape, and size of the bowel wall lesions were evaluated to develop criteria for deep infiltrating endometriosis of the rectosigmoid and cul-de-sac. The search of our database revealed 35 patients with sonographic findings of pelvic bowel wall endometriosis associated with obliteration of the cul-de-sac. Ten of these patients had surgical confirmation of bowel wall endometriosis after the scan, and another 4 patients had surgical evidence of endometriosis from prior surgery. All of the patients who underwent surgery subsequent to sonography had confirmation of their bowel wall infiltrative endometriosis. Sonographically, the bowel lesions were solid, focal, and tubular with slightly irregular margins and in most cases a thinner section or a "tail" at one end, resembling a comet. This study confirms that bowel wall implants have a very characteristic appearance, and extending the transvaginal examination to include an evaluation of the rectosigmoid seeking these bowel lesions is valuable, especially in any patient presenting with a history of pelvic pain.
C1 [Benacerraf, Beryl R.; Groszmann, Yvette; Bromley, Bryann] Diagnost Ultrasound Associates PC, Boston, MA USA.
[Benacerraf, Beryl R.; Bromley, Bryann] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Benacerraf, Beryl R.; Groszmann, Yvette; Hornstein, Mark D.; Bromley, Bryann] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA.
[Benacerraf, Beryl R.; Bromley, Bryann] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA USA.
RP Benacerraf, BR (reprint author), Diagnost Ultrasound Associates PC, 1 Brookline Pl, Brookline, MA 02445 USA.
EM bbsono@aol.com
NR 19
TC 7
Z9 7
U1 0
U2 1
PU AMER INST ULTRASOUND MEDICINE
PI LAUREL
PA SUBSCRIPTION DEPT, 14750 SWEITZER LANE, STE 100, LAUREL, MD 20707-5906
USA
SN 0278-4297
EI 1550-9613
J9 J ULTRAS MED
JI J. Ultrasound Med.
PD MAR 1
PY 2015
VL 34
IS 3
BP 537
EP 542
DI 10.7863/ultra.34.3.537
PG 6
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA CS1PS
UT WOS:000361840100020
PM 25715375
ER
PT J
AU Byne, W
AF Byne, William
TI LGBT Health: Going Strong as We Begin Our Second Year
SO LGBT HEALTH
LA English
DT Editorial Material
DE cancer; Department of Health and Human Services (HHS); disorders of sex
development (DSD); Institute of Medicine (IOM); intersex; LGBT health;
LGBT rights; National Institutes of Health (NIH); pre-exposure
prophylaxis (PrEP)
C1 [Byne, William] Icahn Sch Med, Dept Psychiat, Bronx, NY USA.
[Byne, William] James J Peters VAMC, Bronx, NY 10467 USA.
RP Byne, W (reprint author), James J Peters VAMC, Dept Psychiat, Res Bldg,Room 2F39,130 West Kingsbridge Rd, Bronx, NY 10467 USA.
EM william.byne@mssm.edu
NR 2
TC 0
Z9 0
U1 3
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2325-8292
EI 2325-8306
J9 LGBT HEALTH
JI LGBT Health
PD MAR
PY 2015
VL 2
IS 1
BP 1
EP 2
DI 10.1089/lgbt.2015.0010
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CR9QU
UT WOS:000361692500001
PM 26790010
ER
PT J
AU Byne, W
Reiner, W
AF Byne, William
Reiner, William
TI Interview with William Reiner, MD, Urologist and Child Psychiatrist, on
Approaches to Care for Individuals with Disorders of Sex Development and
Somatic Intersex Conditions
SO LGBT HEALTH
LA English
DT Editorial Material
DE assigned gender; disorders of sex development (DSD); intersex; optimal
gender policy
C1 [Byne, William] Icahn Sch Med, Dept Psychiat, Bronx, NY USA.
[Byne, William] James J Peters VA Med Ctr, Bronx, NY 10467 USA.
[Reiner, William] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat Urol, Pediat Urol, Oklahoma City, OK USA.
RP Byne, W (reprint author), James J Peters VAMC, Dept Psychiat, Res Bldg,Room 2F39,130 West Kingsbridge Rd, Bronx, NY 10467 USA.
EM william.byne@mssm.edu
NR 0
TC 0
Z9 0
U1 1
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2325-8292
EI 2325-8306
J9 LGBT HEALTH
JI LGBT Health
PD MAR
PY 2015
VL 2
IS 1
BP 3
EP 10
DI 10.1089/lgbt.2015.0008
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CR9QU
UT WOS:000361692500002
ER
PT J
AU Mifflin, J
AF Mifflin, Jeffrey
TI RETURN TO THE LAND OF THE HEAD HUNTERS: Edward S. Curtis, the
Kwakwuka'wakw, and the Making of Modern Cinema
SO JOURNAL OF THE WEST
LA English
DT Book Review
C1 [Mifflin, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Mifflin, Jeffrey] McLean Hosp, Belmont, MA USA.
[Mifflin, Jeffrey] MIT, Cambridge, MA 02139 USA.
[Mifflin, Jeffrey] Harvard Univ, Sch Business, Cambridge, MA 02138 USA.
[Mifflin, Jeffrey] Massachusetts Med Soc, Waltham, MA USA.
RP Mifflin, J (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ABC-CLIO
PI SANTA BARBARA
PA 130 CREMONA DR, SANTA BARBARA, CA 93117 USA
SN 0022-5169
EI 1930-0115
J9 J WEST
JI J. West
PD SPR
PY 2015
VL 54
IS 2
BP 68
EP 70
PG 3
WC History
SC History
GA CP4UI
UT WOS:000359877700007
ER
PT J
AU Thurmond, P
Yang, JH
Li, YD
Lerner, LB
Azadzoi, KM
AF Thurmond, Portia
Yang, Jing-Hua
Li, Yedan
Lerner, Lori B.
Azadzoi, Kazem M.
TI Structural modifications of the prostate in hypoxia, oxidative stress,
and chronic ischemia
SO KOREAN JOURNAL OF UROLOGY
LA English
DT Article
DE Fibrosis; Ischemia; Oxidative stress; Prostate
ID LOWER URINARY-TRACT; NATURAL-HISTORY; PELVIC ISCHEMIA; HYPERPLASIA;
SYMPTOMS; BLADDER; MEN; ASSOCIATION; VOLUME; RISK
AB Purpose: Clinical studies have reported a correlation between pelvic ischemia and voiding dysfunction in elderly men. The aim of this study was to identify and compare prostate structural modifications in cultured cells and in a rabbit model after exposure to hypoxia, oxidative stress, and chronic ischemia.
Materials and Methods: Cultured human prostate smooth muscle cells (SMCs), epithelial cells (ECs), and stromal cells (SCs) were incubated under normoxia, hypoxia, and oxidative stress conditions by use of a computerized oxycycler system. We developed a rabbit model of chronic prostate ischemia by creating aorto-iliac arterial atherosclerosis. Markers of oxidative stress were examined by using fluorometric analysis and enzyme immunoassay. Prostate structure was examined by using Masson's trichrome staining and transmission electron microscopy (TEM).
Results: Lipid peroxidation was found in SMCs exposed to hypoxia and in all cell types exposed to oxidative stress. We identified protein oxidation in ECs exposed to hypoxia and in all cell types exposed to oxidative stress. Markers indicating oxidative damage were present in chronically ischemic rabbit prostate tissue. These reactions were associated with DNA damage. Prostate ischemia resulted in epithelial atrophy, loss of smooth muscle, and diffuse fibrosis. TEM showed swollen mitochondria with degraded cristae, loss of membrane, loss of Golgi bodies, degenerated nerves, and disrupted cell-to-cell junctions.
Conclusions: Human prostate cells exhibited differential reactions to hypoxia and oxidative stress with widespread DNA damage. Structural modifications in ischemic prostate tissue were similar to those in cells exposed to oxidative stress. Structural changes due to ischemia and oxidative stress may contribute to prostatic noncompliance in aging men.
C1 [Thurmond, Portia; Yang, Jing-Hua; Li, Yedan; Lerner, Lori B.; Azadzoi, Kazem M.] VA Boston Healthcare Syst, Dept Urol, Boston, MA 02130 USA.
[Thurmond, Portia; Yang, Jing-Hua; Li, Yedan; Lerner, Lori B.; Azadzoi, Kazem M.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Azadzoi, Kazem M.] VA Boston Healthcare Syst, Dept Pathol, Boston, MA 02130 USA.
RP Azadzoi, KM (reprint author), VA Boston Healthcare Syst, Dept Urol, 150 South Huntington Ave,Bldg 1A,Room 315 151, Boston, MA 02130 USA.
EM kazadzoi@bu.edu
FU BLRD VA [I01 BX001428]
NR 30
TC 2
Z9 4
U1 1
U2 3
PU KOREAN UROLOGICAL ASSOC
PI SEOUL
PA RM 103-1102, PARK TOWER OFFICETEL 5-19, YONGSAN-DONG, YONGSAN-GU, SEOUL,
140-904, SOUTH KOREA
SN 2005-6737
EI 2005-6745
J9 KOREAN J UROL
JI Korean J. Urol.
PD MAR
PY 2015
VL 56
IS 3
BP 187
EP 196
DI 10.4111/kju.2015.56.3.187
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA CN4ZO
UT WOS:000358439300004
PM 25763122
ER
PT J
AU Kopacz, MS
Connery, AL
AF Kopacz, Marek S.
Connery, April L.
TI The Veteran Spiritual Struggle
SO SPIRITUALITY IN CLINICAL PRACTICE
LA English
DT Article
DE service members; spirituality; suicide; veterans
ID POSTTRAUMATIC-STRESS-DISORDER; MILITARY VETERANS; SUICIDAL IDEATION;
VIETNAM VETERANS; COMBAT VETERANS; WAR VETERANS; DEPRESSION; GUILT;
RISK; PTSD
AB Although a considerable body of literature has been devoted to examining the physical, psychological, and social needs of veterans after their return from deployment, relatively little is known about the spiritual struggles some veterans face. In this article, we review what we know about this spiritual struggle, highlight the relevance of spirituality in clinical practice, and show examples of how a veteran's spiritual struggle may simultaneously present alongside different suicide risk factors. Suggestions for handling this spiritual struggle are then made.
C1 [Kopacz, Marek S.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA.
[Connery, April L.] US Dept Vet Affairs, Canandaigua VA Med Ctr, Canandaigua, NY 14424 USA.
RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA.
EM marek.kopacz@va.gov
NR 75
TC 4
Z9 4
U1 0
U2 1
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 2326-4500
EI 2326-4519
J9 SPIRITUAL CLIN PRACT
JI Spiritual. Clin. Pract.
PD MAR
PY 2015
VL 2
IS 1
BP 61
EP 67
DI 10.1037/scp0000059
PG 7
WC Psychology, Clinical
SC Psychology
GA CL5BJ
UT WOS:000356974500010
ER
PT J
AU Kopacz, MS
AF Kopacz, Marek S.
TI Spirituality and Suicide Prevention: Charting a Course for Research and
Clinical Practice
SO SPIRITUALITY IN CLINICAL PRACTICE
LA English
DT Editorial Material
DE service members; spirituality; suicide prevention; veterans
ID MEDICINE
AB In their commentary, Bryan, Graham, and Roberge (2015) examine how spirituality can be conceptualized as a protective factor against suicide. The commentary submitted by Currier, Kuhlman, and Smith (2015) offers a review of the extant literature examining the relationship between spirituality and suicidal behavior as well as several ethical considerations related to applying spirituality in clinical practice. The present article looks to add to these discussions by providing further insight into understandings of spirituality as well as suggest additional steps which could be useful in developing the applicability of spirituality to suicide prevention efforts targeting current and former military personnel.
C1 US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA.
RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA.
EM marek.kopacz@va.gov
NR 7
TC 0
Z9 0
U1 1
U2 1
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 2326-4500
EI 2326-4519
J9 SPIRITUAL CLIN PRACT
JI Spiritual. Clin. Pract.
PD MAR
PY 2015
VL 2
IS 1
BP 79
EP 81
DI 10.1037/scp0000062
PG 3
WC Psychology, Clinical
SC Psychology
GA CL5BJ
UT WOS:000356974500013
ER
PT J
AU Yoon, J
Liu, CF
Lo, J
Schectman, G
Stark, R
Rubenstein, LV
Yano, EM
AF Yoon, Jean
Liu, Chuan-Fen
Lo, Jeanie
Schectman, Gordon
Stark, Richard
Rubenstein, Lisa V.
Yano, Elizabeth M.
TI Early Changes in VA Medical Home Components and Utilization
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID CLINICS
AB Objectives: In 2010, the Veterans Health Administration (VA) began national implementation of its patient-centered medical home (PCMH) model, called Patient Aligned Care Teams (PACTs), to improve access, coordination, and patient-centered care. We evaluated changes in reported implementation of PCMH components in all VA primary care clinics, and patients' utilization of acute and non-acute care and total costs after 2 years.
Study Design: Longitudinal study of 2,607,902 patients from 796 VA primary care clinics.
Methods: Clinics were surveyed for their implementation of PCMH components. Patient outcomes were measured by outpatient visits for primary care, specialty care, telephone care, and emergency department (ED) care; hospitalizations for an ambulatory care-sensitive condition (ACSC); and costs of VA care in fiscal years (FYs) 2009 and 2011. Multi-level, multivariable models predicted changes in utilization and costs, adjusting for patients' health status, clinic PCMH component scores, and a patient fixed effect.
Results: Clinics reported large improvements in adoption of all PCMH components from FY 2009 to FY 2011. Higher organization of practice scores was associated with fewer primary care visits (P =.012). Greater care coordination/transitions was modestly associated with more specialty care visits (P =.010) and fewer ED visits (P =.018), but quality/performance improvement was associated with more ED visits (P =.032). None of the PCMH components were significantly related to telephone visits, ACSC hospitalizations, or total healthcare costs.
Conclusions: Improvements under organization of practice and care coordination/transitions appear to have impacted outpatient care, but reductions in acute care were largely absent.
C1 [Yoon, Jean; Lo, Jeanie] VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA USA.
[Yoon, Jean] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA USA.
[Liu, Chuan-Fen] VA Puget Sound, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA.
[Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Schectman, Gordon; Stark, Richard] Vet Hlth Adm, Patient Care Serv, Washington, DC USA.
[Rubenstein, Lisa V.; Yano, Elizabeth M.] VA Greater Los Angeles, Ctr Innovat Study Healthcare Innovat Implementat, Sepulveda, CA USA.
[Rubenstein, Lisa V.] RAND Corp, Santa Monica, CA USA.
[Rubenstein, Lisa V.; Yano, Elizabeth M.] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA.
[Rubenstein, Lisa V.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
RP Yoon, J (reprint author), 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA.
EM jean.yoon@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Patient
Care Services [XVA 65-018]; VA HSRD [RCS 05-195]
FX This work was supported by the Department of Veterans Affairs, Veterans
Health Administration, Patient Care Services (XVA 65-018). Dr Yano's
effort was covered by a VA HSR&D Senior Research Career Scientist Award
(Project #RCS 05-195). The views expressed in this article are those of
the authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or the United States federal government.
NR 14
TC 1
Z9 1
U1 1
U2 2
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD MAR
PY 2015
VL 21
IS 3
BP 197
EP U142
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA CN7YF
UT WOS:000358651300011
PM 25880624
ER
PT J
AU Prentice, JC
Conlin, PR
Gellad, WF
Edelman, D
Lee, TA
Pizer, SD
AF Prentice, Julia C.
Conlin, Paul R.
Gellad, Walid F.
Edelman, David
Lee, Todd A.
Pizer, Steven D.
TI Long-Term Outcomes of Analogue Insulin Compared With NPH for Patients
With Type 2 Diabetes Mellitus
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID INSTRUMENTAL VARIABLES; COST-EFFECTIVENESS; VETERANS AFFAIRS;
HEALTH-CARE; RISK; COMPLICATIONS; HYPOGLYCEMIA; MANAGEMENT; MORTALITY;
MEDICARE
AB Background: Long-acting insulin analogues (eg, insulin glargine and insulin detemir) are an alternative to neutral protamine Hagedorn (NPH) insulin for maintaining glycemic control in patients with diabetes. Clinical trials comparing analogue insulin and NPH have neither been adequately powered nor had sufficient follow-up to examine long-term health outcomes.
Objectives: To compare the effects of NPH and long-acting insulin analogues on long-term outcomes.
Study Design: This retrospective observational study relied on administrative data from the Veterans Health Administration and Medicare from 2000 to 2010. Local variations in analogue insulin prescribing rates were used in instrumental variable models to control for confounding. Outcomes were assessed using survival models.
Methods: The study population included US veterans dually enrolled in Medicare who received at least 1 prescription for oral diabetes medication and then initiated long-acting insulin between 2001 and 2009. Outcomes included ambulatory care-sensitive condition (ACSC) hospitalizations and mortality.
Results: There was no significant relationship between type of insulin and ACSC hospitalization or mortality. The hazard ratio for mortality of individuals starting a long-acting analogue insulin was 0.97 (95% CI, 0.85-1.11), and was 1.05 (95% CI, 0.95-1.16) for ACSC hospitalization. Differences in risk remained insignificant when predicting diabetes-specific ACSC hospitalizations, but starting on long-acting analogue insulin significantly increased the risk of a cardiovascular-specific ACSC hospitalization.
Conclusions: We found no consistent difference in long-term health outcomes when comparing use of long-acting insulin analogues and NPH insulin. The higher cost of analogue insulin without demonstrable clinical benefit raises questions of its cost-effectiveness in the treatment of patients with diabetes.
C1 [Prentice, Julia C.; Conlin, Paul R.; Pizer, Steven D.] VA Boston Healthcare Syst, Boston, MA 02130 USA.
[Prentice, Julia C.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Conlin, Paul R.] Harvard Univ, Sch Med, Boston, MA USA.
[Gellad, Walid F.] VA Pittsburgh Med Ctr, Pittsburgh, PA USA.
[Gellad, Walid F.] Univ Pittsburgh, Pittsburgh, PA USA.
[Edelman, David] VA Durham Med Ctr, Durham, NC USA.
[Edelman, David] Duke Univ, Sch Med, Durham, NC USA.
[Lee, Todd A.] Univ Illinois, Chicago, IL USA.
[Pizer, Steven D.] Northeastern Univ, Boston, MA 02115 USA.
RP Prentice, JC (reprint author), VA Boston Healthcare Syst, Hlth Care Financing & Econ, 150 So Huntington Ave 152H, Boston, MA 02130 USA.
EM jprentic@bu.edu
FU Health Services Research and Development Service of the US Department of
Veterans Affairs [IIR 10-136]; AHRQ [R01 HS019708]; NIH [K24 DK63214]
FX Health Services Research and Development Service of the US Department of
Veterans Affairs (Grant No. IIR 10-136), AHRQ R01 HS019708, and NIH K24
DK63214.
NR 39
TC 1
Z9 1
U1 0
U2 0
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD MAR
PY 2015
VL 21
IS 3
BP E235
EP U78
PG 24
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA CN7YF
UT WOS:000358651300007
PM 26014311
ER
PT J
AU Trippa, L
Waldron, L
Huttenhower, C
Parmigiani, G
AF Trippa, Lorenzo
Waldron, Levi
Huttenhower, Curtis
Parmigiani, Giovanni
TI BAYESIAN NONPARAMETRIC CROSS-STUDY VALIDATION OF PREDICTION METHODS
SO ANNALS OF APPLIED STATISTICS
LA English
DT Article
DE Reproducibility; validation analysis; meta-analysis; random partitions;
Bayesian nonparametrics; cancer signatures
ID RANDOM-EFFECTS METAANALYSIS; GENE-EXPRESSION PROFILE; OVARIAN-CANCER;
SURVIVAL; CHEMOTHERAPY; SIGNATURE; OUTCOMES; CLASSIFIERS; BOOTSTRAP;
MODELS
AB We consider comparisons of statistical learning algorithms using multiple data sets, via leave-one-in cross-study validation: each of the algorithms is trained on one data set; the resulting model is then validated on each remaining data set. This poses two statistical challenges that need to be addressed simultaneously. The first is the assessment of study heterogeneity, with the aim of identifying a subset of studies within which algorithm comparisons can be reliably carried out. The second is the comparison of algorithms using the ensemble of data sets. We address both problems by integrating clustering and model comparison. We formulate a Bayesian model for the array of cross-study validation statistics, which defines clusters of studies with similar properties and provides the basis for meaningful algorithm comparison in the presence of study heterogeneity. We illustrate our approach through simulations involving studies with varying severity of systematic errors, and in the context of medical prognosis for patients diagnosed with cancer, using high-throughput measurements of the transcriptional activity of the tumor's genes.
C1 [Trippa, Lorenzo; Parmigiani, Giovanni] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA.
[Waldron, Levi] CUNY Hunter Coll, Sch Urban Publ Hlth, New York, NY 10035 USA.
[Huttenhower, Curtis] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
RP Trippa, L (reprint author), Dana Farber Canc Inst, Biostat & Computat Biol, 450 Brookline Ave, Boston, MA 02115 USA.
EM ltrippa@jimmy.harvard.edu; levi.waldron@hunter.cuny.edu;
chuttenh@hsph.harvard.edu; gp@jimmy.harvard.edu
OI Waldron, Levi/0000-0003-2725-0694
NR 45
TC 0
Z9 0
U1 4
U2 10
PU INST MATHEMATICAL STATISTICS
PI CLEVELAND
PA 3163 SOMERSET DR, CLEVELAND, OH 44122 USA
SN 1932-6157
J9 ANN APPL STAT
JI Ann. Appl. Stat.
PD MAR
PY 2015
VL 9
IS 1
BP 402
EP 428
DI 10.1214/14-AOAS798
PG 27
WC Statistics & Probability
SC Mathematics
GA CN3UX
UT WOS:000358354400017
ER
PT J
AU Brewer, C
Abernethy, A
Currow, D
Fearon, K
Friend, J
Temel, J
AF Brewer, Cheryl
Abernethy, Amy
Currow, David
Fearon, Kenneth
Friend, John
Temel, Jennifer
TI EVALUATION OF ANOREXIA-CACHEXIA SYMPTOMS/CONCERNS FROM ROMANA 2, A PHASE
III TRIAL OF ANAMORELIN IN NON-SMALL CELL LUNG CANCER PATIENTS WITH
CACHEXIA.
SO ONCOLOGY NURSING FORUM
LA English
DT Meeting Abstract
C1 [Brewer, Cheryl; Abernethy, Amy] Duke Univ, Med Ctr, Durham, NC USA.
[Currow, David] Flinders Univ S Australia, Adelaide, SA 5001, Australia.
[Fearon, Kenneth] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland.
[Friend, John] Helsinn Therapeut Inc, Bridgewater, NJ USA.
[Temel, Jennifer] Massachusets Gen Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 0190-535X
EI 1538-0688
J9 ONCOL NURS FORUM
JI Oncol. Nurs. Forum
PD MAR
PY 2015
VL 42
IS 2
MA 71
BP E229
EP E229
PG 1
WC Oncology; Nursing
SC Oncology; Nursing
GA CM7UF
UT WOS:000357901300317
ER
PT J
AU Brock, J
Barron, AM
AF Brock, Jennifer
Barron, Anne-Marie
TI EXPLORATORY STUDY TO UNDERSTAND AUTO LOGOUS HEMATOPEOIETIC STEM CELL
TRANSPLANT PATIENTS' EXPERIENCES OF HATHA YOGA.
SO ONCOLOGY NURSING FORUM
LA English
DT Meeting Abstract
C1 [Brock, Jennifer; Barron, Anne-Marie] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Barron, Anne-Marie] Simmons Coll, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 0190-535X
EI 1538-0688
J9 ONCOL NURS FORUM
JI Oncol. Nurs. Forum
PD MAR
PY 2015
VL 42
IS 2
MA 38
BP E215
EP E215
PG 1
WC Oncology; Nursing
SC Oncology; Nursing
GA CM7UF
UT WOS:000357901300284
ER
PT J
AU Cashavelly, B
Blakeney, B
Bursn-Britton, B
Gorynski, K
AF Cashavelly, Barbara
Blakeney, Barbara
Bursn-Britton, BettyAnn
Gorynski, Kristen
TI ENHANCING INPATIENT ONCOLOGY CARE BY REDUCING WAIT TIMES-NURSES DECREASE
DOOR-TO-CHEMO TIMES.
SO ONCOLOGY NURSING FORUM
LA English
DT Meeting Abstract
C1 [Cashavelly, Barbara; Blakeney, Barbara; Bursn-Britton, BettyAnn; Gorynski, Kristen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 0190-535X
EI 1538-0688
J9 ONCOL NURS FORUM
JI Oncol. Nurs. Forum
PD MAR
PY 2015
VL 42
IS 2
BP E119
EP E120
PG 2
WC Oncology; Nursing
SC Oncology; Nursing
GA CM7UF
UT WOS:000357901300045
ER
PT J
AU Cronin, J
Searle, F
AF Cronin, Julie
Searle, Frances
TI INVESTIGATING THE IMPACT OF AN EDUCATIONAL PROGRAM ON NURSE'S ATTITUDES
TOWARDS SEXUAL HEALTH CARE.
SO ONCOLOGY NURSING FORUM
LA English
DT Meeting Abstract
C1 [Cronin, Julie; Searle, Frances] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 0190-535X
EI 1538-0688
J9 ONCOL NURS FORUM
JI Oncol. Nurs. Forum
PD MAR
PY 2015
VL 42
IS 2
MA 6
BP E202
EP E202
PG 1
WC Oncology; Nursing
SC Oncology; Nursing
GA CM7UF
UT WOS:000357901300252
ER
PT J
AU Gribbin, N
Bowes, C
AF Gribbin, Nicola
Bowes, Cynthia
TI RE-CHALLENGE AFTER PACLITAXEL-RELATED INFUSION REACTIONS IN AN ONCOLOGY
INFUSION UNIT.
SO ONCOLOGY NURSING FORUM
LA English
DT Meeting Abstract
C1 [Gribbin, Nicola; Bowes, Cynthia] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 0190-535X
EI 1538-0688
J9 ONCOL NURS FORUM
JI Oncol. Nurs. Forum
PD MAR
PY 2015
VL 42
IS 2
MA 46
BP E218
EP E219
PG 2
WC Oncology; Nursing
SC Oncology; Nursing
GA CM7UF
UT WOS:000357901300292
ER
PT J
AU Sipples, R
Andan, C
Eaby-Sandy, B
AF Sipples, Rebecca
Andan, Christine
Eaby-Sandy, Beth
TI PRACTICAL MANAGEMENT OF ADVERSE EVENTS ASSOCIATED WITH AFATINIB.
SO ONCOLOGY NURSING FORUM
LA English
DT Meeting Abstract
C1 [Sipples, Rebecca] Univ Alabama Birmingham, Birmingham, AL USA.
[Andan, Christine] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Eaby-Sandy, Beth] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 0190-535X
EI 1538-0688
J9 ONCOL NURS FORUM
JI Oncol. Nurs. Forum
PD MAR
PY 2015
VL 42
IS 2
MA 51
BP E220
EP E221
PG 2
WC Oncology; Nursing
SC Oncology; Nursing
GA CM7UF
UT WOS:000357901300297
ER
PT J
AU Albiges, L
Fay, AP
Xie, WL
McDermott, DF
Heng, DYC
Dariane, C
De Velasco, G
Lester, RE
Escudier, B
Choueiri, TK
AF Albiges, Laurence
Fay, Andre Poisl
Xie, Wanling
McDermott, David F.
Heng, Daniel Yick Chin
Dariane, Charles
De Velasco, Guillermo
Lester, Renee Elizabeth
Escudier, Bernard
Choueiri, Toni K.
TI Efficacy of targeted therapies after PD1/PD-L1 inhibitors in metastatic
clear cell renal cell carcinoma (mRCC): A multi-institution
retrospective cohort
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Univ Paris 11, Inst Gustave Roussy, Villejuif, France.
HSL PUCRS, Oncol Serv, Porto Alegre, RS, Brazil.
HSL PUCRS, Oncol Res Unit, Porto Alegre, RS, Brazil.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
Inst Gustave Roussy, Villejuif, France.
Hosp Univ 12 Octubre, Med Oncol Serv, Madrid, Spain.
Tom Baker Canc Clin, Calgary, AB, Canada.
Inst Gustave Roussy, Villejuif, France.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 456
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700453
ER
PT J
AU Albiges, L
Hakimi, AA
Lin, X
Simantov, R
Zabor, EC
Jacobsen, A
Furberg, H
Fay, AP
Heng, DYC
Signoretti, S
McKay, RR
Choueiri, TK
AF Albiges, Laurence
Hakimi, A. Ari
Lin, Xun
Simantov, Ronit
Zabor, Emily C.
Jacobsen, Anders
Furberg, Helena
Fay, Andre Poisl
Heng, Daniel Yick Chin
Signoretti, Sabina
McKay, Rana R.
Choueiri, Toni K.
TI The impact of BMI on outcomes of patients with metastatic renal cell
carcinoma treated with targeted therapy: An external validation data set
and analysis of underlying biology from The Cancer Genome Atlas.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USA.
Pfizer Oncol, La Jolla, CA USA.
Pfizer Oncol, New York, NY USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Pontificia Univ Catolica Rio Grande do Sul, HSL, Oncol Serv, Porto Alegre, RS, Brazil.
Pontificia Univ Catolica Rio Grande do Sul, HSL, Oncol Res Unit, Porto Alegre, RS, Brazil.
Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 405
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700402
ER
PT J
AU Alimohamed, NS
Templeton, AJ
Knox, JJ
Lin, X
Simantov, R
Xie, WL
Lawrence, NJ
Broom, RJ
Fay, AP
Rini, BI
Bjarnason, GA
Smoragiewicz, M
Kollmannsberger, CK
Kanesvaran, R
Wells, C
Amir, E
Choueiri, TK
Heng, DYC
AF Alimohamed, Nimira S.
Templeton, Arnoud J.
Knox, Jennifer J.
Lin, Xun
Simantov, Ronit
Xie, Wanling
Lawrence, Nicola Jane
Broom, Reuben James
Fay, Andre Poisl
Rini, Brian I.
Bjarnason, Georg A.
Smoragiewicz, Martin
Kollmannsberger, Christian K.
Kanesvaran, Ravindran
Wells, Connor
Amir, Eitan
Choueiri, Toni K.
Heng, Daniel Yick Chin
TI Change in neutrophil to lymphocyte ratio as a prognostic and predictive
marker in response to targeted therapy for metastatic renal cell
carcinoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Tom Baker Canc Clin, Calgary, AB, Canada.
Kantonsspital, St Gallen, Switzerland.
Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada.
Pfizer Oncol, La Jolla, CA USA.
Pfizer Oncol, New York, NY USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Auckland City Hosp, Auckland, New Zealand.
Pontificia Univ Catolica Rio Grande do Sul, HSL, Oncol Serv, Porto Alegre, RS, Brazil.
Pontificia Univ Catolica Rio Grande do Sul, HSL, Oncol Res Unit, Porto Alegre, RS, Brazil.
Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
BC Canc Agcy, Vancouver, BC, Canada.
BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada.
Natl Canc Ctr Singapore, Singapore, Singapore.
Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
Univ Toronto, Dept Med, Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
OI Alimohamed, Nimira/0000-0002-2930-4206
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 404
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700401
ER
PT J
AU Bellmunt, J
Guo, GW
Mullane, SA
Orsola, A
Werner, L
Van Hummelen, P
Thorner, A
Loda, M
Choueiri, TK
Barletta, JA
Kwiatkowski, DJ
Meyerson, M
Van Allen, EM
AF Bellmunt, Joaquim
Guo, Guangwu
Mullane, Stephanie A.
Orsola, Anna
Werner, Lillian
Van Hummelen, Paul
Thorner, Aaron
Loda, Massimo
Choueiri, Toni K.
Barletta, Justine A.
Kwiatkowski, David J.
Meyerson, Matthew
Van Allen, Eliezer Mendel
TI Genomic landscape of high-grade T1 micropapillary bladder tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Univ Hosp Mar, IMIM, Barcelona, Spain.
Broad Inst, Cambridge, MA USA.
Dana Farber Canc Inst, Bladder Canc Ctr, Brigham & Womens Canc Ctr, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Massachusetts Gen Hosp,MIT, Dana Farber Canc Inst,Sch Med,Broad Inst Harvard, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 299
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700299
ER
PT J
AU Choueiri, TK
Michaelson, MD
Posadas, EM
Sonpavde, G
McDermott, DF
Walsh, MK
Wall, KC
Seon, BK
Jivani, MA
Adams, BJ
Theuer, CP
AF Choueiri, Toni K.
Michaelson, M. Dror
Posadas, Edwin M.
Sonpavde, Guru
McDermott, David F.
Walsh, Meghara K.
Wall, Kevin C.
Seon, Ben K.
Jivani, Manoj A.
Adams, Bonne J.
Theuer, Charles P.
TI A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in
combination with axitinib in patients with metastatic renal cell
carcinoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA.
Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
TRACON Pharmaceut Inc, San Diego, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 426
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700423
ER
PT J
AU Curreri, SA
Markt, SC
Miller, R
O'Donnell, E
Bernard, BD
Kamran, SC
Albiges, L
Wright, AA
Sweeney, C
Beard, C
AF Curreri, Stephanie A.
Markt, Sarah C.
Miller, Rowan
O'Donnell, Elizabeth
Bernard, Brandon David
Kamran, Sophia C.
Albiges, Laurence
Wright, Alexi A.
Sweeney, Christopher
Beard, Clair
TI Bilateral testicular germ cell tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Inst Canc Res, London SW3 6JB, England.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Radiat Oncol Program, Boston, MA USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 392
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700389
ER
PT J
AU De Bono, JS
Smith, MR
Saad, F
Rathkopf, DE
Mulders, PFA
Small, EJ
Shore, ND
Fizazi, K
De Porre, P
San Kheoh, T
Li, JH
Todd, MB
Griffin, TW
Ryan, CJ
AF De Bono, Johann Sebastian
Smith, Matthew Raymond
Saad, Fred
Rathkopf, Dana E.
Mulders, Peter F. A.
Small, Eric Jay
Shore, Neal D.
Fizazi, Karim
De Porre, Peter
San Kheoh, Thian
Li, Jinhui
Todd, Mary Beth
Griffin, Thomas W.
Ryan, Charles J.
TI Response to taxane chemotherapy as first subsequent therapy after
abiraterone acetate (AA) in patients (pts) with metastatic
castration-resistant prostate cancer (mCRPC): Post-hoc analysis of
COU-AA-302.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Montreal, Montreal, PQ, Canada.
Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, New York, NY 10021 USA.
Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
Carolina Urol Res Ctr, Myrtle Beach, SC USA.
Univ Paris 11, Inst Gustave Roussy, Paris, France.
Janssen Res & Dev, Beerse, Belgium.
Janssen Res & Dev, Los Angeles, CA USA.
Johnson & Johnson Med China, Shanghai, Peoples R China.
Janssen Global Serv, Raritan, NJ USA.
RI Mulders, Peter/H-8076-2014
NR 0
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 184
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700186
ER
PT J
AU Efstathiou, JA
Lin, CC
Gray, PJ
Jemal, A
AF Efstathiou, Jason Alexander
Lin, Chun Chieh
Gray, Phillip John
Jemal, Ahmedin
TI Androgen deprivation with or without radiation therapy for clinically
node-positive prostate cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
Amer Canc Soc, Atlanta, GA 30329 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 198
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700199
ER
PT J
AU Fung, C
Feldman, DR
Hamilton, RJ
Case-Eads, S
Vaughn, DJ
Beard, C
Moore, MJ
Sahasrabudhe, DM
Brames, MJ
Fossa, SD
Sesso, HD
Einhorn, LH
The, LBTF
AF Fung, Chunkit
Feldman, Darren Richard
Hamilton, Robert James
Case-Eads, Somer
Vaughn, David J.
Beard, Clair
Moore, Malcolm J.
Sahasrabudhe, Deepak M.
Brames, Mary J.
Fossa, Sophie D.
Sesso, Howard D.
Einhorn, Lawrence H.
The, Lois B. Travis For
CA Platinum Study Grp
TI Cardiovascular disease (CVD) risk factors among cisplatin-treated
testicular cancer survivors (TCS): A multicenter clinical study of US
and Canadian patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Toronto, Princess Margaret Hosp, Div Surg Oncol, Toronto, ON, Canada.
Indiana Univ, Indianapolis, IN 46204 USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
Univ Rochester, Wilmot Canc Ctr, Rochester, NY USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Oslo Univ Hosp, Dept Oncol, N-0450 Oslo, Norway.
Univ Oslo, Oslo, Norway.
Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
Univ Rochester, Sch Med & Dent, Rochester, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 391
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700388
ER
PT J
AU Gan, HK
Lickliter, J
Millward, M
Gu, Y
Su, WG
Qi, C
Mu, H
Frigault, M
Morgan, S
Gardner, HA
Albiges, L
Pal, SK
Burris, HA
Choueiri, TK
AF Gan, Hui Kong
Lickliter, Jason
Millward, Michael
Gu, Yi
Su Weiguo
Qi, Chuan
Mu, Hua
Frigault, Melanie
Morgan, Shethah
Gardner, Humphrey Athelstan
Albiges, Laurence
Pal, Sumanta Kumar
Burris, Howard A.
Choueiri, Toni K.
TI cMet: Results in papillary renal cell carcinoma of a phase I study of
AZD6094/volitinib leading to a phase 2 clinical trial with
AZD6094/volitinib in patients with advanced papillary renal cell cancer
(PRCC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Austin Hlth, Heidelberg, Germany.
Nucleus Network Ltd, Melbourne, Vic, Australia.
Univ Western Australia, Perth, WA 6009, Australia.
Hutchison MediPharma, Shanghai, Peoples R China.
AstraZeneca, Boston, MA USA.
AstraZeneca, Macclesfield, Cheshire, England.
AstraZeneca, Waltham, MA USA.
Univ Paris Sud, Inst Gustave Roussy, Villejuif, France.
City Hope Natl Med Ctr, Duarte, CA USA.
PLLC, Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 487
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700484
ER
PT J
AU Gerke, T
Tyekucheva, S
Penney, K
Sweeney, C
Lis, R
Sesso, HD
Nuttall, E
Loda, M
Stampfer, MJ
Parmigiani, G
Mucci, LA
AF Gerke, Travis
Tyekucheva, Svitlana
Penney, Kathryn
Sweeney, Christopher
Lis, Rosina
Sesso, Howard D.
Nuttall, Elizabeth
Loda, Massimo
Stampfer, Meir J.
Parmigiani, Giovanni
Mucci, Lorelei A.
TI Discovery and validation of a 30-gene expression signature to identify
prostate cancer patients who are candidates for active surveillance
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Univ Florida, Gainesville, FL USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA USA.
Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 10
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700011
ER
PT J
AU Giannatempo, P
Pond, GR
Sonpavde, G
Albany, C
Loriot, Y
Sweeney, C
Cary, KC
Salvioni, R
Colecchia, M
Nicolai, N
Raggi, D
El Mouallem, NR
Feldman, H
Fizazi, K
Einhorn, LH
Necchi, A
AF Giannatempo, Patrizia
Pond, Gregory Russell
Sonpavde, Guru
Albany, Costantine
Loriot, Yohann
Sweeney, Christopher
Cary, Kelly Clint
Salvioni, Roberto
Colecchia, Maurizio
Nicolai, Nicola
Raggi, Daniele
El Mouallem, Nemer Robert
Feldman, Hope
Fizazi, Karim
Einhorn, Lawrence H.
Necchi, Andrea
TI Treatment and clinical outcomes of patients with teratoma with
somatic-type malignant transformation (TMT): An international
collaboration.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
McMaster Univ, Hamilton, ON, Canada.
Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Gustave Roussy, Villejuif, France.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Indiana Univ Sch Med, Dept Urol, Indianapolis, IN 46202 USA.
Univ Paris Sud, Inst Gustave Roussy, Villejuif, France.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 375
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700099
ER
PT J
AU Graff, JN
Baciarello, G
Armstrong, AJ
Higano, CS
Iversen, P
Forer, D
Mansbach, HH
Phung, D
Tombal, BF
Beer, TM
Sternberg, CN
AF Graff, Julie Nicole
Baciarello, Giulia
Armstrong, Andrew J.
Higano, Celestia S.
Iversen, Peter
Forer, David
Mansbach, Harry H.
Phung, De
Tombal, Bertrand F.
Beer, Tomasz M.
Sternberg, Cora N.
TI Clinical outcomes and safety in men >= 75 and < 75 years with metastatic
castration-resistant prostate cancer (mCRPC) treated with enzalutamide
in the phase 3 PREVAIL trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Portland VA Med Ctr, OHSU Knight Canc Inst, Portland, OR USA.
Grand Paris, Dept Canc Med, Gustave Roussy, Villejuif, France.
Duke Univ, Durham, NC USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark.
Medivation Inc, San Francisco, CA USA.
Astellas Pharma Global Dev Inc, Leiderdorp, Netherlands.
Clin Univ St Luc, Div Urol, B-1200 Brussels, Belgium.
Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Portland, OR 97201 USA.
Hosp San Camillo Forlanini, Rome, Italy.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 200
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700201
ER
PT J
AU Gray, PJ
Lin, CC
Jemal, A
Efstathiou, JA
AF Gray, Phillip John
Lin, Chun Chieh
Jemal, Ahmedin
Efstathiou, Jason Alexander
TI Temporal trends in the management of localized prostate cancer: From
2004 to 2011.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Amer Canc Soc, Atlanta, GA 30329 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 42
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700044
ER
PT J
AU Haas, NB
Manola, J
Uzzo, RG
Atkins, MB
Wilding, G
Pins, M
Jewett, MAS
Kane, CJ
Cella, D
Wagner, LI
Coomes, B
Wood, CG
Dutcher, JP
Flaherty, K
DiPaola, RS
AF Haas, Naomi B.
Manola, Judith
Uzzo, Robert G.
Atkins, Michael B.
Wilding, George
Pins, Michael
Jewett, Michael A. S.
Kane, Christopher J.
Cella, David
Wagner, Lynne I.
Coomes, Bob
Wood, Christopher G.
Dutcher, Janice P.
Flaherty, Keith
DiPaola, Robert S.
TI Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for
unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Lombardi Comprehens Canc Ctr, Washington, DC USA.
Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
Univ Illinois, Coll Med, Chicago, IL USA.
Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada.
Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Our Lady Mercy Canc Ctr, Bronx, NY USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Rutgers Biomed & Hlth Sci, New Brunswick, NJ USA.
NR 0
TC 12
Z9 13
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 403
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700400
ER
PT J
AU Heng, DYC
Wells, C
Donskov, F
Rini, BI
Lee, JL
Bjarnason, GA
Beuselinck, B
Smoragiewicz, M
Alva, AS
Srinivas, S
Wood, L
Yamamoto, H
Ernst, DS
Pal, SK
Yuasa, T
Broom, RJ
Kanesvaran, R
Bamias, A
Knox, JJ
Choueiri, TK
AF Heng, Daniel Yick Chin
Wells, Connor
Donskov, Frede
Rini, Brian I.
Lee, Jae-Lyun
Bjarnason, Georg A.
Beuselinck, Benoit
Smoragiewicz, Martin
Alva, Ajjai Shivaram
Srinivas, Sandy
Wood, Lori
Yamamoto, Haru
Ernst, D. Scott
Pal, Sumanta Kumar
Yuasa, Takeshi
Broom, Reuben James
Kanesvaran, Ravindran
Bamias, Aristotelis
Knox, Jennifer J.
Choueiri, Toni K.
TI Third-line therapy in metastatic renal cell carcinoma: Results from the
International mRCC Database Consortium.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark.
Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea.
Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium.
BC Canc Agcy, Vancouver, BC, Canada.
Univ Michigan, Ann Arbor, MI 48109 USA.
Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
London Reg Canc Ctr, London, ON N6A 4L6, Canada.
City Hope Natl Med Ctr, Duarte, CA USA.
Japanese Fdn Canc Res, Dept Urol, Canc Inst Hosp, Tokyo, Japan.
Auckland City Hosp, Auckland, New Zealand.
Natl Canc Ctr Singapore, Singapore, Singapore.
Univ Athens, Alexandra Gen Hosp Athens, Dept Oncol, Dept Clin Therapeut, Athens, Greece.
Univ Toronto, Dept Med Oncol, Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 430
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700427
ER
PT J
AU Kaffenberger, SD
Ciriello, G
Winer, AG
Voss, MH
Maranchie, JK
Tamboli, P
Rathmell, K
Choueiri, TK
Motzer, RJ
Coleman, JA
Russo, P
Hsieh, J
Hakimi, AA
AF Kaffenberger, Samuel D.
Ciriello, Giovanni
Winer, Andrew G.
Voss, Martin Henner
Maranchie, Jodi Kathleen
Tamboli, Pheroze
Rathmell, Kimryn
Choueiri, Toni K.
Motzer, Robert J.
Coleman, Jonathan A.
Russo, Paul
Hsieh, James
Hakimi, A. Ari
TI Proteomic stratification of clear cell renal cell carcinoma utilizing
The Cancer Genome Atlas (TCGA) with external validation.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ N Carolina, Chapel Hill, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 406
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700403
ER
PT J
AU Kaymakcalan, MD
Xie, WL
Albiges, L
North, SA
Kollmannsberger, CK
Smoragiewicz, M
Kroeger, N
Wells, C
Rha, SY
Lee, JL
Fay, AP
Heng, DYC
Choueiri, TK
AF Kaymakcalan, Marina Dusevic
Xie, Wanling
Albiges, Laurence
North, Scott A.
Kollmannsberger, Christian K.
Smoragiewicz, Martin
Kroeger, Nils
Wells, Connor
Rha, Sun Young
Lee, Jae-Lyun
Fay, Andre Poisl
Heng, Daniel Yick Chin
Choueiri, Toni K.
TI Risk factors and a model to predict toxicity-related treatment
discontinuation in patients with metastatic renal cell carcinoma treated
with VEGF-targeted therapy: Results from the International Metastatic
RCC Database Consortium
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Univ Paris 11, Inst Gustave Roussy, Villejuif, France.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada.
BC Canc Agcy, Vancouver, BC, Canada.
Univ Med Greifswald, Dept Urol, Greifswald, Germany.
Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
Yonsei Univ, Coll Med, Seoul, South Korea.
Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea.
HSL PUCRS, Oncol Serv, Porto Alegre, RS, Brazil.
HSL PUCRS, Oncol Res Unit, Porto Alegre, RS, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 464
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700461
ER
PT J
AU Kennedy, MW
Carter, J
Wright, S
Contreras, M
Winkfield, KM
AF Kennedy, Mark Wendell
Carter, Jacques
Wright, Stephen
Contreras, Magnolia
Winkfield, Karen Marie
TI A community-based approach to educating black men in underserved
communities about the risks and benefits of prostate cancer screening.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Massachusetts Prostate Canc Coalit Inc, Boston, MA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Mattapan Community Hlth Ctr, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 99
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700102
ER
PT J
AU Mahal, BAV
Aizer, AA
Efstathiou, JA
Nguyen, PL
AF Mahal, Brandon Arvin Virgil
Aizer, Ayal Aaron
Efstathiou, Jason Alexander
Nguyen, Paul Linh
TI The association of very low PSA with increased cancer-specific death in
men with high-grade prostate cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Harvard Univ, Sch Med, Boston, MA USA.
Massachusetts Gen Hosp, Brigham & Womens Hosp, Boston, MA 02114 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 62
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700063
ER
PT J
AU Mak, KS
Smith, A
Eidelman, A
Clayman, RH
Cheng, JS
Matthews, J
Niemierko, A
Nielsen, ME
Feldman, AS
Lee, RJ
Zietman, AL
Shipley, WU
Chen, RC
Milowsky, MI
Efstathiou, JA
AF Mak, Kimberley S.
Smith, Angela
Eidelman, Alec
Clayman, Rebecca Helen
Cheng, Jed-Sian
Matthews, Jonathan
Niemierko, Andrzej
Nielsen, Matthew Edward
Feldman, Adam S.
Lee, Richard J.
Zietman, Anthony L.
Shipley, William U.
Chen, Ronald C.
Milowsky, Matthew I.
Efstathiou, Jason Alexander
TI Quality of life in long-term survivors of muscle-invasive bladder
cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Harvard Radiat Oncol Program, Boston, MA USA.
Univ N Carolina, Chapel Hill, NC USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 319
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700319
ER
PT J
AU Markt, SC
Miller, R
O'Donnell, E
Albiges, L
Bernard, BD
Lago-Hernandez, C
Curreri, SA
Wright, AA
Beard, C
Sweeney, C
AF Markt, Sarah C.
Miller, Rowan
O'Donnell, Elizabeth
Albiges, Laurence
Bernard, Brandon David
Lago-Hernandez, Carlos
Curreri, Stephanie A.
Wright, Alexi A.
Beard, Clair
Sweeney, Christopher
TI BMI at diagnosis and adverse outcomes among men with malignant
testicular germ cell tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
Inst Canc Res, London SW3 6JB, England.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Paris Sud, Inst Gustave Roussy, Villejuif, France.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 400
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700397
ER
PT J
AU McGinley, KF
Sun, XZ
Howard, LE
Aronson, WJ
Terris, MK
Kane, CJ
Amling, CL
Cooperberg, MR
Freedland, SJ
AF McGinley, Kathleen F.
Sun, Xizi
Howard, Lauren E.
Aronson, William J.
Terris, Martha K.
Kane, Christopher J.
Amling, Christopher L.
Cooperberg, Matthew R.
Freedland, Stephen J.
TI Utilization and impact of surgical technique on the performance of
pelvic lymph node dissection at radical prostatectomy: Results from the
SEARCH database.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Duke Univ, Med Ctr, Durham, NC USA.
Duke Univ, Durham VA Med Ctr, Durham, NC USA.
Duke Univ, Durham VA Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA.
Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
Georgia Regents Univ, Med Coll Georgia, Charles Norwood VA Med Ctr, Augusta, GA USA.
Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 73
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700074
ER
PT J
AU McGinley, KF
Sun, XZ
Howard, LE
Aronson, WJ
Terris, MK
Kane, CJ
Amling, CL
Cooperberg, MR
Freedland, SJ
AF McGinley, Kathleen F.
Sun, Xizi
Howard, Lauren E.
Aronson, William J.
Terris, Martha K.
Kane, Christopher J.
Amling, Christopher L.
Cooperberg, Matthew R.
Freedland, Stephen J.
TI Can Gleason 7 prostate cancer ever be low-risk? Results from the Shared
Equal Access Regional Cancer Hospital (SEARCH) database.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Duke Univ, Med Ctr, Durham, NC USA.
Duke Univ, Durham VA Med Ctr, Durham, NC USA.
Duke Univ, Durham VA Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA.
Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
Georgia Regents Univ, Charles Norwood VA Med Ctr, Med Coll Georgia, Augusta, GA USA.
Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 57
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700058
ER
PT J
AU McKay, RR
Lin, X
Albiges, LK
Fay, AP
Kaymakcalan, MD
Mickey, SS
Ghoroghchian, PP
Bhatt, RS
Simantov, R
Choueiri, TK
Heng, DYC
AF McKay, Rana R.
Lin, Xun
Albiges, Laurence K.
Fay, Andre Poisl
Kaymakcalan, Marina Dusevic
Mickey, Suzanne S.
Ghoroghchian, Paiman Peter
Bhatt, Rupal Satish
Simantov, Ronit
Choueiri, Toni K.
Heng, Daniel Yick Chin
TI Impact of statins and survival outcomes in patients with metastatic
renal cell carcinoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Pfizer Oncol, La Jolla, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
HSL PUCRS, Oncol Serv, Porto Alegre, RS, Brazil.
HSL PUCRS, Oncol Res Unit, Porto Alegre, RS, Brazil.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Pfizer Oncol, New York, NY USA.
Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 435
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700432
ER
PT J
AU McKay, RR
Choueiri, TK
Werner, L
Atkins, MB
Olivier, KM
Song, JX
Signoretti, S
McDermott, DF
Michaelson, MD
AF McKay, Rana R.
Choueiri, Toni K.
Werner, Lillian
Atkins, Michael B.
Olivier, Kara M.
Song, Jiaxi
Signoretti, Sabina
McDermott, David F.
Michaelson, M. Dror
TI A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or
poor-risk patients with metastatic renal cell carcinoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Lombardi Comprehens Canc Ctr, Washington, DC USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 408
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700405
ER
PT J
AU Morris, MJ
Higano, CS
Scher, HI
Sweeney, C
Antonarakis, ES
Shevrin, DH
Ryan, CJ
Lorlot, Y
Fizazi, K
Pandit-Taskar, N
Garcia-Vargas, JE
Lyseng, K
Bloma, M
Aksnes, AK
Carrasquillo, JA
AF Morris, Michael J.
Higano, Celestia S.
Scher, Howard I.
Sweeney, Christopher
Antonarakis, Emmanuel S.
Shevrin, Daniel H.
Ryan, Charles J.
Lorlot, Yohann
Fizazi, Karim
Pandit-Taskar, Neeta
Garcia-Vargas, Jose E.
Lyseng, Kari
Bloma, Marianne
Aksnes, Anne-Kirsti
Carrasquillo, Jorge A.
TI Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on
prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in
patients (pts) with castration-resistant prostate cancer (CRPC) and bone
metastases (mets): A phase 1/2a clinical trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
NorthShore Univ HealthSyst, Evanston, IL USA.
UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
Univ Paris 11, Inst Gustave Roussy, Villejuif, France.
Bayer HealthCare, Whippany, NJ USA.
Bayer Oslo, As, Norway.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 202
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700203
ER
PT J
AU O'Donnell, PH
Plimack, ER
Bellmunt, J
Berger, R
Montgomery, RB
Heath, K
Dolled-Filhart, M
Pathiraja, K
Gause, CK
Cheng, JD
Perini, RF
Gupta, S
AF O'Donnell, Peter H.
Plimack, Elizabeth R.
Bellmunt, Joaquim
Berger, Raanan
Montgomery, Robert B.
Heath, Karl
Dolled-Filhart, Marisa
Pathiraja, Kumudu
Gause, Christine K.
Cheng, Jonathan D.
Perini, Rodolfo F.
Gupta, Shilpa
TI Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results
of a phase IB study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Univ Chicago, Chicago, IL 60637 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel.
Univ Washington, Seattle, WA 98195 USA.
Merck & Co Inc, Whitehouse Stn, NJ USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 296
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700296
ER
PT J
AU Paly, JJ
Gray, PJ
Lin, CC
Sineshaw, H
Jemal, A
Efstathiou, JA
AF Paly, Jonathan J.
Gray, Phillip John
Lin, Chun Chieh
Sineshaw, Helmneh
Jemal, Ahmedin
Efstathiou, Jason Alexander
TI Management and outcomes of clinical stage II a/b seminoma: Results from
the National Cancer Database
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Amer Canc Soc, Atlanta, GA 30329 USA.
Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 4
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 378
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700376
ER
PT J
AU Ramos, J
Casey, MF
Crabb, SJ
Bamias, A
Harshman, LC
Wong, YN
Bellmunt, J
De Giorgi, U
Ladoire, S
Powles, T
Pal, SK
Niegisch, G
Sternberg, CN
Alva, AS
Agarwal, N
Necchi, A
Vaishampayan, UN
Rosenberg, JE
Galsky, MD
Yu, EY
AF Ramos, Jorge
Casey, Martin Francis
Crabb, Simon J.
Bamias, Aristotelis
Harshman, Lauren Christine
Wong, Yu-Ning
Bellmunt, Joaquim
De Giorgi, Ugo
Ladoire, Sylvain
Powles, Thomas
Pal, Sumanta Kumar
Niegisch, Guenter
Sternberg, Cora N.
Alva, Ajjai Shivaram
Agarwal, Neeraj
Necchi, Andrea
Vaishampayan, Ulka N.
Rosenberg, Jonathan E.
Galsky, Matt D.
Yu, Evan Y.
CA RISC Investigators
TI Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and
prognostic implications in patients with metastatic urinary tract tumors
(UTT).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Univ Washington, Sch Med, Seattle, WA USA.
Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
Univ Southampton, Southampton, Hants, England.
Univ Athens, Alexandra Gen Hosp Athens, Dept Oncol, Dept Clin Therapeut, Athens, Greece.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA.
IMIM, Univ Hosp del Mar, Barcelona, Spain.
IRCCS, Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy.
Georges Francois Leclerc Canc Ctr, Dijon, France.
Barts Hlth & Royal Free NHS Trust, Barts Canc Inst, London, England.
City Hope Natl Med Ctr, Duarte, CA USA.
Univ Dusseldorf, Dept Urol, Dusseldorf, Germany.
Hosp San Camillo Forlanini, Rome, Italy.
Univ Michigan, Ann Arbor, MI 48109 USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 318
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700318
ER
PT J
AU Ryan, CJ
Smith, MR
Fizazi, K
Saad, F
Sternberg, CN
Logothetis, C
Small, EJ
Carles, J
Flaig, TW
Taplin, ME
Higano, CS
De Souza, PL
De Bono, JS
Griffin, TW
De Porre, P
Park, YC
Li, JH
Kheoh, TS
Molina, A
Rathkopf, DE
AF Ryan, Charles J.
Smith, Matthew Raymond
Fizazi, Karim
Saad, Fred
Sternberg, Cora N.
Logothetis, Christopher
Small, Eric Jay
Carles, Joan
Flaig, Thomas W.
Taplin, Mary-Ellen
Higano, Celestia S.
De Souza, Paul L.
De Bono, Johann Sebastian
Griffin, Thomas W.
De Porre, Peter
Park, Youn Choi
Li, Jinhui
Kheoh, Thian San
Molina, Arturo
Rathkopf, Dana E.
TI Impact of crossover and baseline prognostic factors on overall survival
(OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Paris 11, Inst Gustave Roussy, Paris, France.
Univ Montreal, Montreal, PQ, Canada.
San Camillo & Forlanini Hosp, Rome, Italy.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Hosp Vall dHebron, Vall dHebron Inst Oncol, Barcelona, Spain.
Univ Colorado, Sch Med, Ctr Canc, Aurora, CO USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Univ Western Sydney, Sch Med, Liverpool, Australia.
Ingham Inst, Liverpool, Australia.
Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England.
Janssen Res & Dev, Los Angeles, CA USA.
Janssen Res & Dev, Beerse, Belgium.
Janssen Res & Dev, Raritan, NJ USA.
Johnson & Johnson Med China, Shanghai, Peoples R China.
Janssen Res & Dev, Menlo Pk, CA USA.
Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 142
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700144
ER
PT J
AU Sartor, AO
Fernandez, DC
Morris, MJ
Iagaru, A
Brown, A
Almeida, F
Sweeney, C
Smith, MR
Dicker, A
Wong, YN
Shore, ND
Gratt, J
Petrenciuc, O
Vogelzang, NJ
AF Sartor, A. Oliver
Fernandez, Daniel Celestino
Morris, Michael J.
Iagaru, Andrei
Brown, Alan
Almeida, Fabio
Sweeney, Christopher
Smith, Matthew Raymond
Dicker, Adam
Wong, Yu-Ning
Shore, Neal D.
Gratt, Jeremy
Petrenciuc, Oana
Vogelzang, Nicholas J.
TI Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in
an expanded access setting.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Tulane Canc Ctr, New Orleans, LA USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Stanford Univ, Stanford, CA 94305 USA.
21st Century Oncol, Ft Myers, FL USA.
Arizona Mol Imaging Ctr, Phoenix, AZ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA.
Carolina Urol Res Ctr, Myrtle Beach, SC USA.
Bayer HealthCare, Whippany, NJ USA.
Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 253
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700254
ER
PT J
AU Smith, MR
Brown, JE
Fizazi, K
Klotz, L
Marx, GM
Wang, H
Warner, D
Lipton, A
AF Smith, Matthew Raymond
Brown, Janet Elizabeth
Fizazi, Karim
Klotz, Laurence
Marx, Gavin M.
Wang, Huei
Warner, Douglas
Lipton, Allan
TI Bone metabolism biomarkers in men with advanced prostate cancer (PC) and
bone metastases treated with denosumab versus zoledronic acid (ZA).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Canc Res UK Clin Ctr, Leeds, W Yorkshire, England.
Univ Paris Sud, Inst Gustave Roussy, Villejuif, France.
Univ Toronto, Toronto, ON, Canada.
Northern Haematol & Oncol Grp, Sydney, NSW, Australia.
Amgen Inc, Thousand Oaks, CA 91320 USA.
Amgen Inc, Dept Clin Dev, Thousand Oaks, CA 91320 USA.
Penn State Milton S Hershey Med Ctr, Hershey, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 267
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700268
ER
PT J
AU Smith, MR
De Bono, JS
Sternberg, CN
Le Moulec, S
Oudard, S
De Giorgi, U
Krainer, M
Bergman, AM
Hoelzer, W
De Wit, R
Boegemann, M
Saad, F
Cruciani, G
Thiery-Vuillemin, A
Feyerabend, S
Miller, K
Ramies, DA
Hessel, C
Weitzman, A
Fizazi, K
AF Smith, Matthew Raymond
De Bono, Johann Sebastian
Sternberg, Cora N.
Le Moulec, Sylvestre
Oudard, Stephane
De Giorgi, Ugo
Krainer, Michael
Bergman, Andre M.
Hoelzer, Wolfgang
De Wit, Ronald
Boegemann, Martin
Saad, Fred
Cruciani, Giorgio
Thiery-Vuillemin, Antoine
Feyerabend, Susan
Miller, Kurt
Ramies, David Albert
Hessel, Colin
Weitzman, Aaron
Fizazi, Karim
TI Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred)
in metastatic castration-resistant prostate cancer (mCRPC) patients
(pts) previously treated with docetaxel (D) and abiraterone (A) and/or
enzalutamide (E).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Royal Marsden Hosp NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England.
Hosp San Camillo Forlanini, Rome, Italy.
Val de Grace Hosp, Paris, France.
Hop Europeen Georges Pompidou, Dept Med Oncol, Paris, France.
IRCS Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy.
Med Univ Vienna, Vienna, Austria.
Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands.
Erasmus Univ, Med Ctr, Rotterdam, Netherlands.
Univ Hosp Munster, Dept Urol, Munster, Germany.
Univ Montreal, Ctr Hosp, CRCHUM, Montreal, PQ, Canada.
Azienda USL, Med Oncol Dept, Ravenna, Italy.
CHU Minjoz, Med Oncol Unit, Besancon, France.
Charite, D-13353 Berlin, Germany.
Exelixis Inc, San Francisco, CA USA.
Univ Paris 11, Inst Gustave Roussy, Villejuif, France.
NR 0
TC 16
Z9 16
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 139
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700141
ER
PT J
AU Sonpavde, G
Pond, GR
Rosenberg, JE
Bajorin, DF
Regazzi, AM
Choueiri, TK
Mullane, SA
Niegisch, G
Albers, P
Necchi, A
di Lorenzo, G
Fougeray, R
Galsky, MD
Sridhar, SS
Ko, YJ
Milowsky, MI
Bellmunt, J
AF Sonpavde, Guru
Pond, Gregory Russell
Rosenberg, Jonathan E.
Bajorin, Dean F.
Regazzi, Ashley Marie
Choueiri, Toni K.
Mullane, Stephanie A.
Niegisch, Guenter
Albers, Peter
Necchi, Andrea
di Lorenzo, Giuseppe
Fougeray, Ronan
Galsky, Matt D.
Sridhar, Srikala S.
Ko, Yoo-Joung
Milowsky, Matthew I.
Bellmunt, Joaquim
TI Improved prognostic classification of patients receiving salvage
systemic therapy for advanced urothelial carcinoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA.
McMaster Univ, Hamilton, ON, Canada.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA USA.
Univ Dusseldorf, Dept Urol, Dusseldorf, Germany.
Univ Dusseldorf, Dusseldorf, Germany.
Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
Univ Naples Federico II, Dept Clin Med, Med Oncol Unit, Naples, Italy.
Inst Rech Pierre Fabre, Boulogne, France.
Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
Univ Toronto, Dept Med, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 311
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700311
ER
PT J
AU Vogelzang, NJ
Fernandez, DC
Morris, MJ
Iagaru, A
Brown, A
Almeida, F
Sweeney, C
Smith, MR
Dicker, A
Wong, YN
Shore, ND
Bangerter, K
Petrenciuc, O
Sartor, AO
AF Vogelzang, Nicholas J.
Fernandez, Daniel Celestino
Morris, Michael J.
Iagaru, Andrei
Brown, Alan
Almeida, Fabio
Sweeney, Christopher
Smith, Matthew Raymond
Dicker, Adam
Wong, Yu-Ning
Shore, Neal D.
Bangerter, Keith
Petrenciuc, Oana
Sartor, A. Oliver
TI Radium-223 dichloride (Ra-223) in US expanded access program (EAP).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Stanford Univ, Stanford, CA 94305 USA.
21st Century Oncol, Ft Myers, FL USA.
Arizona Mol Imaging Ctr, Phoenix, AZ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA.
Carolina Urol Res Ctr, Myrtle Beach, SC USA.
Bayer HealthCare, Whippany, NJ USA.
Tulane Canc Ctr, New Orleans, LA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 247
PG 2
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700248
ER
PT J
AU Wilson, KM
Cheng, JS
Sanchez, A
Graff, R
Rodriguez, D
Feldman, AS
Barrisford, G
Bechis, S
Blute, M
Stampfer, MJ
Chang, SL
Giovannucci, EL
Albiges, LK
Choueiri, TK
Cho, EY
Preston, MA
AF Wilson, Kathryn M.
Cheng, Jed-Sian
Sanchez, Alejandro
Graff, Rebecca
Rodriguez, Dayron
Feldman, Adam S.
Barrisford, Glenn
Bechis, Seth
Blute, Michael
Stampfer, Meir J.
Chang, Steven L.
Giovannucci, Edward L.
Albiges, Laurence K.
Choueiri, Toni K.
Cho, Eunyoung
Preston, Mark A.
TI The association between obesity and incidence of total and fatal renal
cell carcinoma in two prospective cohorts.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium
CY FEB 26-28, 2015
CL Orlando, FL
C1 Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Harvard Univ, Brigham & Womens Hosp, TH Chan Sch Publ Hlth, Sch Med, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Dept Surg, Div Urol,Med Sch, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Channing Div Nework Med, Sch Med, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
SU S
MA 414
PG 1
WC Oncology
SC Oncology
GA CL3XX
UT WOS:000356886700411
ER
PT J
AU Callen, J
Giardina, TD
Singh, H
Li, L
Paoloni, R
Georgiou, A
Runciman, WB
Westbrook, JI
AF Callen, Joanne
Giardina, Traber Davis
Singh, Hardeep
Li, Ling
Paoloni, Richard
Georgiou, Andrew
Runciman, William B.
Westbrook, Johanna I.
TI Emergency Physicians' Views of Direct Notification of Laboratory and
Radiology Results to Patients Using the Internet: A Multisite Survey
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE Internet; patient safety; electronic health records; patient
empowerment; diagnostic tests; emergency care; radiology
ID RANDOMIZED CONTROLLED-TRIAL; CLOSED MALPRACTICE CLAIMS; ELECTRONIC
MEDICAL-RECORD; E-MAIL; DELAYED DIAGNOSES; INVITING PATIENTS; ENHANCE
PATIENT; CANCER-PATIENTS; YOUNG-PATIENTS; DOCTORS NOTES
AB Background: Patients are increasingly using the Internet to communicate with health care providers and access general and personal health information. Missed test results have been identified as a critical safety issue with studies showing up to 75% of tests for emergency department (ED) patients not being followed-up. One strategy that could reduce the likelihood of important results being missed is for ED patients to have direct access to their test results. This could be achieved electronically using a patient portal tied to the hospital's electronic medical record or accessed from the relevant laboratory information system. Patients have expressed interest in accessing test results directly, but there have been no reported studies on emergency physicians' opinions.
Objective: The aim was to explore emergency physicians' current practices of test result notification and attitudes to direct patient notification of clinically significant abnormal and normal test results.
Methods: A cross-sectional survey was self-administered by senior emergency physicians (site A: n=50; site B: n=39) at 2 large public metropolitan teaching hospitals in Australia. Outcome measures included current practices for notification of results (timing, methods, and responsibilities) and concerns with direct notification.
Results: The response rate was 69% (61/89). More than half of the emergency physicians (54%, 33/61) were uncomfortable with patients receiving direct notification of abnormal test results. A similar proportion (57%, 35/61) was comfortable with direct notification of normal test results. Physicians were more likely to agree with direct notification of normal test results if they believed it would reduce their workload (OR 5.72, 95% CI 1.14-39.76). Main concerns were that patients could be anxious (85%, 52/61), confused (92%, 56/61), and lacking in the necessary expertise to interpret their results (90%, 55/61).
Conclusions: Although patients' direct access to test results could serve as a safety net reducing the likelihood of abnormal results being missed, emergency physicians' concerns need further exploration: which results are suitable and the timing and method of direct release to patients. Methods of access, including secure Web-based patient portals with drill-down facilities providing test descriptions and result interpretations, or laboratories sending results directly to patients, need evaluation to ensure patient safety is not compromised and the processes fit with ED clinician and laboratory work practices and patient needs.
C1 [Callen, Joanne; Li, Ling; Georgiou, Andrew; Westbrook, Johanna I.] Macquarie Univ, Australian Inst Hlth Innovat, Ctr Hlth Syst & Safety Res, Sydney, NSW 2109, Australia.
[Giardina, Traber Davis; Singh, Hardeep] Baylor Coll Med, Houston VA HSR&D Ctr Innovat Qual Effectiveness &, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA.
[Paoloni, Richard] Concord Repatriat & Gen Hosp, Emergency Dept, Sydney, NSW, Australia.
[Runciman, William B.] Univ Adelaide, Dept Anaesthesia & Intens Care, Joanna Briggs Inst, Adelaide, SA, Australia.
RP Callen, J (reprint author), Macquarie Univ, Australian Inst Hlth Innovat, Ctr Hlth Syst & Safety Res, Level 6,75 Talavera Rd, Sydney, NSW 2109, Australia.
EM joanne.callen@mq.edu.au
OI Runciman, William (Bill)/0000-0001-8489-0693
FU Australian Research Council [DP120100297]; VA Health Services through
the VA Office of Academic Affiliations; VA Health Services Research and
Development Service [CRE 12-033]; VA National Center for Patient Safety;
Agency for Health Care Research and Quality [R01HS022087]; Houston VA
HSR&D Center for Innovations in Quality, Effectiveness and Safety [CIN
13-413, 14-274]
FX We would like to acknowledge the contributions of Louise Robertson,
Michael Stewart, Julie Li, George Touli, and Elia Vecellio. This study
is part of an Australian Research Council Discovery Project Grant
(DP120100297) to investigate whether technology can make communication
in complex systems safer and more efficient.; Dr Giardina is supported
by the VA Health Services Research postdoctoral fellowship through the
VA Office of Academic Affiliations. Dr Singh is supported by the VA
Health Services Research and Development Service (CRE 12-033;
Presidential Early Career Award for Scientists and Engineers USA
14-274), the VA National Center for Patient Safety and the Agency for
Health Care Research and Quality (R01HS022087). This work is also
supported in part by the Houston VA HSR&D Center for Innovations in
Quality, Effectiveness and Safety (CIN 13-413).
NR 67
TC 2
Z9 2
U1 3
U2 10
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD MAR
PY 2015
VL 17
IS 3
AR e60
DI 10.2196/jmir.3721
PG 13
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA CL2NJ
UT WOS:000356780900003
PM 25739322
ER
PT J
AU Agboola, SO
Ju, W
Elfiky, A
Kvedar, JC
Jethwani, K
AF Agboola, Stephen O.
Ju, Woong
Elfiky, Aymen
Kvedar, Joseph C.
Jethwani, Kamal
TI The Effect of Technology-Based Interventions on Pain, Depression, and
Quality of Life in Patients With Cancer: A Systematic Review of
Randomized Controlled Trials
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Review
DE telehealth; connected health; cancer; telephone; pain; depression;
quality of life; systematic review; randomized controlled trials
ID STAGE BREAST-CANCER; TELEPHONE INTERVENTION; CARE INTERVENTION;
COLORECTAL-CANCER; SUPPORTIVE CARE; CLINICAL-TRIAL; OUTCOMES; SURVIVORS;
PROGRAM; MANAGEMENT
AB Background: The burden of cancer is increasing; projections over the next 2 decades suggest that the annual cases of cancer will rise from 14 million in 2012 to 22 million. However, cancer patients in the 21st century are living longer due to the availability of novel therapeutic regimens, which has prompted a growing focus on maintaining patients' health-related quality of life. Telehealth is increasingly being used to connect with patients outside of traditional clinical settings, and early work has shown its importance in improving quality of life and other clinical outcomes in cancer care.
Objective: The aim of this study was to systematically assess the literature for the effect of supportive telehealth interventions on pain, depression, and quality of life in cancer patients via a systematic review of clinical trials.
Methods: We searched PubMed, EMBASE, Google Scholar, CINAHL, and PsycINFO in July 2013 and updated the literature search again in January 2015 for prospective randomized trials evaluating the effect of telehealth interventions in cancer care with pain, depression, and quality of life as main outcomes. Two of the authors independently reviewed and extracted data from eligible randomized controlled trials, based on pre-determined selection criteria. Methodological quality of studies was assessed by the Cochrane Collaboration risk of bias tool.
Results: Of the 4929 articles retrieved from databases and relevant bibliographies, a total of 20 RCTs were included in the final review. The studies were largely heterogeneous in the type and duration of the intervention as well as in outcome assessments. A majority of the studies were telephone-based interventions that remotely connected patients with their health care provider or health coach. The intervention times ranged from 1 week to 12 months. In general, most of the studies had low risk of bias across the domains of the Cochrane Collaboration risk of bias tool, but most of the studies had insufficient information about the allocation concealment domain. Two of the three studies focused on pain control reported significant effects of the intervention; four of the nine studies focus on depression reported significant effects, while only the studies that were focused on quality of life reported significant effects.
Conclusions: This systematic review demonstrates the potential of telehealth interventions in improving outcomes in cancer care. However, more high-quality large-sized trials are needed to demonstrate cogent evidence of its effectiveness.
C1 [Agboola, Stephen O.; Kvedar, Joseph C.; Jethwani, Kamal] Partners Healthcare Ctr Connected Hlth, Boston, MA 02114 USA.
[Agboola, Stephen O.; Kvedar, Joseph C.; Jethwani, Kamal] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Agboola, Stephen O.; Elfiky, Aymen; Kvedar, Joseph C.; Jethwani, Kamal] Harvard Univ, Sch Med, Boston, MA USA.
[Ju, Woong] Ewha Womans Univ, Dept Obstet & Gynecol, Coll Med, Med Res Inst, Seoul, South Korea.
[Elfiky, Aymen] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Agboola, SO (reprint author), Partners Healthcare Ctr Connected Hlth, 25 New Chardon St,Suite 300, Boston, MA 02114 USA.
EM sagboola@partners.org
NR 41
TC 11
Z9 11
U1 4
U2 13
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD MAR
PY 2015
VL 17
IS 3
AR e65
DI 10.2196/jmir.4009
PG 14
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA CL2NJ
UT WOS:000356780900007
PM 25793945
ER
PT J
AU Bossarte, R
AF Bossarte, Robert
TI Enhancing Surveillance of Suicide Ideation and Suicide Attempt Through
Integration of Data from Multiple Systems
SO PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES
LA English
DT Article
ID PREVENTION; RISK
C1 [Bossarte, Robert] US Dept Vet Affairs, Off Publ Hlth, Rochester, NY USA.
RP Bossarte, R (reprint author), Univ Rochester, Off Publ Hlth, US Dept Vet Affairs, Dept Psychiat,Sch Med & Dent, Rochester, NY 14642 USA.
EM Robert.Bossarte@va.gov
NR 9
TC 0
Z9 0
U1 3
U2 4
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA
SN 0033-2747
J9 PSYCHIATRY
JI Psychiatry-Interpers. Biol. Process.
PD SPR
PY 2015
VL 78
IS 1
BP 22
EP 24
DI 10.1080/00332747.2015.1021657
PG 3
WC Psychiatry
SC Psychiatry
GA CK6DN
UT WOS:000356318800002
PM 26168023
ER
PT J
AU Fisher, LB
Overholser, JC
Ridley, J
Braden, A
Rosoff, C
AF Fisher, Lauren B.
Overholser, James C.
Ridley, Josephine
Braden, Abby
Rosoff, Cari
TI From the Outside Looking In: Sense of Belonging, Depression, and Suicide
Risk
SO PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES
LA English
DT Article
ID INTERPERSONAL-PSYCHOLOGICAL THEORY; PERCEIVED SOCIAL SUPPORT;
PSYCHIATRIC OUTPATIENTS; PSYCHOMETRIC PROPERTIES; MULTIDIMENSIONAL
SCALE; HOPELESSNESS SCALE; CONSTRUCT-VALIDITY; MALE VETERANS;
INVENTORY-II; LIFE STRESS
AB Sense of belonging has demonstrated significant relationships with depression and suicidal thoughts, highlighting its potential utility in refining assessment of suicide risk. Method: Structured clinical interviews and self-report measures were used to assess depression, suicidal behaviors, hopelessness, life stress, social support, and sense of belonging in a sample of 116 depressed psychiatric patients. Results: Lower sense of belonging was significantly associated with greater severity of depression, hopelessness, suicidal ideation, and history of prior suicide attempt(s). However, sense of belonging did not predict suicidal ideation and history of prior suicide attempt(s) beyond the association between suicidal behaviors and established risk factors. Sense of belonging displayed a significant relationship with depression and hopelessness and is likely to play a critical role in both the development of and recovery from depression. Conclusions: Sense of belonging is directly related to depression and hopelessness, while indirecdy related to suicidal ideation. Low sense of belonging provides an important target for assessment and intervention in the treatment of depression. Cognitive, behavioral, and interpersonal interventions may help improve an individual's sense of belonging and decrease symptoms of depression and hopelessness.
C1 [Fisher, Lauren B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Overholser, James C.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Ridley, Josephine] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA.
[Braden, Abby] Univ Calif San Diego, San Diego, CA 92103 USA.
[Rosoff, Cari] Virginia Polytech Inst & State Univ, Roanoke, VA USA.
RP Fisher, LB (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, One Bowdoin Sq,6th Floor, Boston, MA 02114 USA.
EM lbfisher@mgh.harvard.edu
NR 58
TC 4
Z9 4
U1 3
U2 8
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA
SN 0033-2747
J9 PSYCHIATRY
JI Psychiatry-Interpers. Biol. Process.
PD SPR
PY 2015
VL 78
IS 1
BP 29
EP 41
DI 10.1080/00332747.2015.1015867
PG 13
WC Psychiatry
SC Psychiatry
GA CK6DN
UT WOS:000356318800004
PM 26168025
ER
PT J
AU Johnson, RS
Stolar, AG
Wu, E
Coonan, LA
Graham, DP
AF Johnson, R. Scott
Stolar, Andrea G.
Wu, Emily
Coonan, Loretta A.
Graham, David P.
TI An analysis of successful outcomes and associated contributing factors
in veterans' court
SO BULLETIN OF THE MENNINGER CLINIC
LA English
DT Article
ID DRUG
AB This study aims to examine the extent to which a veteran's propensity for arrest following separation from veterans' court is associated with that veteran's length of stay within the program, type of discharge, or number of judicial sanctions issued. This is a retrospective chart review that focuses on the first 100 participants in the Harris County Veterans' Court Program. After controlling for a number of demographic factors, both arrests during enrollment in the veterans' court program (p = .031) and Factor Score 1 (unsuccessful discharge, fewer months in the veterans' court program, and more months of follow up) (p = .042) were predictive of arrest following separation from the veterans' court program. In addition, a prior diagnosis of opiate misuse was also predictive of arrest following separation (p < .001). Given these findings, veterans' court judges and program administrators might examine ways of continuing enrollment for veterans at highest risk for recidivism.
C1 [Johnson, R. Scott] Michael E DeBakey Vet Affairs VA Med Ctr, Mental Hlth Care Line, Houston, TX USA.
[Johnson, R. Scott] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Stolar, Andrea G.; Graham, David P.] Baylor Coll Med, Psychiat, Houston, TX 77030 USA.
[Wu, Emily] Baylor Coll Med, Houston, TX 77030 USA.
[Coonan, Loretta A.] Michael E DeBakey Med Ctr, Houston, TX USA.
[Graham, David P.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Graham, David P.] Michael E DeBakey VA Med Ctr, Neurorehabil Neurons Networks Traumat Brain Injur, Houston, TX USA.
RP Johnson, RS (reprint author), 1977 Butler Blvd,Suite E4-400, Houston, TX 77030 USA.
EM rscottjohnson3@gmail.com
NR 5
TC 2
Z9 2
U1 0
U2 1
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA
SN 0025-9284
EI 1943-2828
J9 B MENNINGER CLIN
JI Bull. Menninger Clin.
PD SPR
PY 2015
VL 79
IS 2
BP 166
EP 173
PG 8
WC Psychiatry; Psychology, Psychoanalysis
SC Psychiatry; Psychology
GA CJ7RD
UT WOS:000355695000004
PM 26035089
ER
PT J
AU Schlett, CL
Hoffmann, U
Geisler, T
Nikolaou, K
Bamberg, F
AF Schlett, Christopher L.
Hoffmann, Udo
Geisler, Tobias
Nikolaou, Konstantin
Bamberg, Fabian
TI Cardiac Computed Tomography for the Evaluation of the Acute Chest Pain
Syndrome: State of the Art
SO RADIOLOGIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Acute chest pain syndrome; Acute coronary syndrome; Cardiac Computed
tomography; CCTA
ID ACUTE CORONARY SYNDROME; NAPKIN-RING SIGN; LEFT-VENTRICULAR FUNCTION;
EMERGENCY-DEPARTMENT; CT ANGIOGRAPHY; ATHEROSCLEROTIC PLAQUE;
COST-EFFECTIVENESS; ROMICAT TRIAL; MYOCARDIAL-PERFUSION; PROGNOSTIC
VALUE
AB Coronary computed tomography angiography (CCTA) is recommended for the triage of acute chest pain in patients with a low-to-intermediate likelihood for acute coronary syndrome. Absence of coronary artery disease (CAD) confirmed by CCTA allows rapid emergency department discharge. This article shows that CCTA-based triage is as safe as traditional triage, reduces the hospital length of stay, and may provide cost-effective or even cost-saving care.
C1 [Schlett, Christopher L.] Univ Heidelberg Hosp, Dept Diagnost & Intervent Radiol, D-69120 Heidelberg, Germany.
[Schlett, Christopher L.; Hoffmann, Udo; Bamberg, Fabian] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA.
[Geisler, Tobias] Univ Tubingen Hosp, Dept Cardiol & Cardiovasc Med, D-72076 Tubingen, Germany.
[Nikolaou, Konstantin; Bamberg, Fabian] Univ Tubingen Hosp, Dept Diagnost & Intervent Radiol, D-72076 Tubingen, Germany.
RP Bamberg, F (reprint author), Univ Tubingen Hosp, Dept Diagnost & Intervent Radiol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.
EM fabian.bamberg@med.uni-tuebingen.de
FU Bayer Healthcare; Siemens Healthcare
FX Financial Disclosures and Conflicts of Interest: Dr F. Bamberg received
unrestricted research grants from Bayer Healthcare and Siemens
Healthcare. He serves on the speakers' bureau of Bayer Healthcare and
Siemens Healthcare. Dr K. Nikolaou has served on a scientific advisory
board for Bayer Schering Pharma and on speakers' bureaus for and has
received speaker honoraria from Bayer Schering Pharma, Bracco, and
Siemens Medical Solutions.
NR 47
TC 5
Z9 5
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0033-8389
EI 1557-8275
J9 RADIOL CLIN N AM
JI Radiol. Clin. N. Am.
PD MAR
PY 2015
VL 53
IS 2
BP 297
EP +
DI 10.1016/j.rcl.2014.11.007
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CJ3NA
UT WOS:000355389900005
PM 25726995
ER
PT J
AU van Tellingen, O
Yetkin-Arik, B
de Gooijer, MC
Wesseling, P
Wurdinger, T
de Vries, HE
AF van Tellingen, O.
Yetkin-Arik, B.
de Gooijer, M. C.
Wesseling, P.
Wurdinger, T.
de Vries, H. E.
TI Overcoming the blood-brain tumor barrier for effective glioblastoma
treatment
SO DRUG RESISTANCE UPDATES
LA English
DT Review
DE Glioma; Blood-brain barrier; Drug delivery
ID CONVECTION-ENHANCED DELIVERY; CANCER RESISTANCE PROTEIN; RECURRENT
MALIGNANT GLIOMA; PEGYLATED LIPOSOMAL DOXORUBICIN; P-GLYCOPROTEIN ABCB1;
CAPILLARY ENDOTHELIAL-CELLS; CENTRAL-NERVOUS-SYSTEM; HIGH-GRADE GLIOMA;
PHASE-II TRIAL; MULTIDRUG-RESISTANCE
AB Gliomas are the most common primary brain tumors. Particularly in adult patients, the vast majority of gliomas belongs to the heterogeneous group of diffuse gliomas, i.e. glial tumors characterized by diffuse infiltrative growth in the preexistent brain tissue. Unfortunately, glioblastoma, the most aggressive (WHO grade IV) diffuse glioma is also by far the most frequent one. After standard treatment, the 2-year overall survival of glioblastoma patients is approximately only 25%. Advanced knowledge in the molecular pathology underlying malignant transformation has offered new handles and better treatments for several cancer types. Unfortunately, glioblastoma multiforme (GBM) patients have not yet profited as although numerous experimental drugs have been tested in clinical trials, all failed miserably. This grim prognosis for GBM is at least partly due to the lack of successful drug delivery across the blood brain tumor barrier (BBTB). The human brain comprises over 100 billion capillaries with a total length of 400 miles, a total surface area of 20 m(2) and a median inter-capillary distance of about 50 pm, making it the best perfused organ in the body. The BBTB encompasses existing and newly formed blood vessels that contribute to the delivery of nutrients and oxygen to the tumor and facilitate glioma cell migration to other parts of the brain. The high metabolic demands of high-grade glioma create hypoxic areas that trigger increased expression of VEGF and angiogenesis, leading to the formation of abnormal vessels and a dysfunctional BBTB. Even though the BBTB is considered 'leaky' in the core part of glioblastomas, in large parts of glioblastomas and, even more so, in lower grade diffuse gliomas the BBTB more closely resembles the intact blood brain barrier (BBB) and prevents efficient passage of cancer therapeutics, including small molecules and antibodies. Thus, many drugs can still be blocked from reaching the many infiltrative glioblastoma cells that demonstrate 'within-organ-metastasis' away from the core part to brain areas displaying a more organized and less leaky BBTB. Hence, drug delivery in glioblastoma deserves explicit attention as otherwise new experimental therapies will continue to fail. In the current review we highlight different aspects of the BBTB in glioma patients and preclinical models and discuss the advantages and drawbacks of drug delivery approaches for the treatment of glioma patients. We provide an overview on methods to overcome the BBTB, including osmotic blood brain barrier disruption (BBBD), bradykinin receptor-mediated BBTB opening, inhibition of multidrug efflux transporters, receptor-mediated transport systems and physiological circumvention of the BBTB. While our knowledge about the molecular biology of glioma cells is rapidly expanding and is, to some extent, already assisting us in the design of tumor-tailored therapeutics, we are still struggling to develop modalities to expose the entire tumor to such-therapeutics at pharmacologically meaningful quantities. Therefore, we must expand our knowledge about the fundamentals of the BBTB as a step toward the design of practical and safe devices and approaches for enhanced drug delivery into the diseased brain area. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Wurdinger, T.] Vrije Univ Amsterdam Med Ctr, Neurooncol Res Grp, Dept Neurosurg, Canc Ctr Amsterdam, NL-1081 BT Amsterdam, Netherlands.
[Wurdinger, T.] Harvard Univ, Sch Med, Dept Neurol, Mol Neurogenet Unit,Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Yetkin-Arik, B.; de Vries, H. E.] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, NL-1081 BT Amsterdam, Netherlands.
[van Tellingen, O.; de Gooijer, M. C.] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Clin Chem Preclin Pharmacol, Amsterdam, Netherlands.
[Wesseling, P.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, NL-1081 BT Amsterdam, Netherlands.
[Wesseling, P.] Radboud Univ Nijmegen Med Ctr, Dept Pathol, Nijmegen, Netherlands.
RP de Vries, HE (reprint author), Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.
EM o.v.tellingen@nki.nl; he.devries@vumc.nl
RI Wesseling, P./H-8114-2014
OI Wesseling, P./0000-0001-5453-5201
FU VIDI fellowship from Dutch Organization of Scientific Research (NWO)
[91711366]; European Research Council Starting Researchers Grant
[336540]; Stichting Stophersentumoren.n1
FX This work was supported by the VIDI fellowship 91711366 (T.W.) from the
Dutch Organization of Scientific Research (NWO), European Research
Council Starting Researchers Grant 336540 (T.W), and Stichting
Stophersentumoren.n1 (T.W., O.v.T.).
NR 159
TC 51
Z9 52
U1 34
U2 95
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1368-7646
EI 1532-2084
J9 DRUG RESIST UPDATE
JI Drug Resist. Update
PD MAR
PY 2015
VL 19
BP 1
EP 12
DI 10.1016/j.drup.2015.02.002
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CI8ME
UT WOS:000355025600001
PM 25791797
ER
PT J
AU Shapero, K
Wylie-Sears, J
Levine, RA
Mayer, JE
Bischoff, J
AF Shapero, Kayle
Wylie-Sears, Jill
Levine, Robert A.
Mayer, John E., Jr.
Bischoff, Joyce
TI Reciprocal interactions between mitral valve endothelial and
interstitial cells reduce endothelial-to-mesenchymal transition and
myofibroblastic activation
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article
DE Mitral valve; Endothelial cells; Endothelial-to-mesenchymal transition;
Valve interstitial cells
ID GROWTH-FACTOR-BETA; PROGENITOR CELLS; TGF-BETA; EXTRACELLULAR-MATRIX;
DEPENDENT REGULATION; SUBSTRATE STIFFNESS; CARDIAC VALVES;
HEART-FAILURE; DISEASE; MECHANISMS
AB Thickening of mitral leaflets, endothelial-to-mesenchymal transition (EndMT), and activated myofibroblast-like interstitial cells have been observed in ischemic mitral valve regurgitation. We set out to determine if interactions between mitral valve endothelial cells (VECs) and interstitial cells (VICs) might affect these alterations. We used in vitro co-culture in Transwell (TM) inserts to test the hypothesis that VICs secrete factors that inhibit EndMT and conversely, that VECs secrete factors that mitigate the activation of VICs to a myofibroblast-like, activated phenotype. Primary cultures and clonal populations of ovine mitral VICs and VECs were used. Western blot, quantitative reverse transcriptase PCR (qPCR) and functional assays were used to assess changes in cell phenotype and behavior. VICs or conditioned media from VICs inhibited transforming growth factor beta (TGF beta)-induced EndMT in VECs, as indicated by reduced expression of EndMT markers alpha-smooth muscle actin (alpha-SMA), Slug, Snail and MMP-2 and maintained the ability of VECs to mediate leukocyte adhesion, an important endothelial function. VECs or conditioned media from VECs reversed the spontaneous cell culture-induced change in VICs to an activated phenotype, as indicated by reduced expression of alpha-SMA and type I collagen, increased expression chondromodulin-1 (Chm1), and reduced contractile activity. These results demonstrate that mitral VECs and VICs secrete soluble factors that can reduce VIC activation and inhibit TCF beta-driven EndMT, respectively. These findings suggest that the endothelium of the mitral valve is critical for the maintenance of a quiescent VIC phenotype and that, in turn, VICs prevent EndMT. We speculate that the disturbance of the ongoing reciprocal interactions between VECs and VICs in vivo may contribute to the thickened and fibrotic leaflets observed in ischemic mitral regurgitation, and in other types of valve disease. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Shapero, Kayle; Wylie-Sears, Jill; Bischoff, Joyce] Harvard Univ, Sch Med, Boston Childrens Hosp, Vasc Biol Program,Dept Surg, Boston, MA 02115 USA.
[Shapero, Kayle] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
[Shapero, Kayle; Mayer, John E., Jr.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Cardiothorac Surg, Cambridge, MA 02138 USA.
[Levine, Robert A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
RP Bischoff, J (reprint author), Boston Childrens Hosp, Vasc Biol Program, Karp Family Res Bldg 12 212, Boston, MA 02115 USA.
EM joyce.bischoff@childrens.harvard.edu
OI Bischoff, Joyce/0000-0002-6367-1974
FU NHLBI of the National Institutes of Health [R01HL109506-01A1]; Fondation
Leducq Transatlantic Network; Tommy Kaplan Discretionary Fund
FX Research reported in this manuscript was supported by the NHLBI of the
National Institutes of Health under award number R01HL109506-01A1, to
R.A.L and J.B. The content is solely the responsibility of the authors
and does not necessarily represent the official views of the National
Institutes of Health. The study was also supported by the Fondation
Leducq Transatlantic Network (R.A.L and J.B.) and the Tommy Kaplan
Discretionary Fund (J.E.M.)
NR 57
TC 10
Z9 11
U1 1
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2828
EI 1095-8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD MAR
PY 2015
VL 80
BP 175
EP 185
DI 10.1016/j.yjmcc.2015.01.006
PG 11
WC Cardiac & Cardiovascular Systems; Cell Biology
SC Cardiovascular System & Cardiology; Cell Biology
GA CJ3MZ
UT WOS:000355389800020
PM 25633835
ER
PT J
AU Ducharme, S
Dickerson, BC
Larvie, M
Price, BH
AF Ducharme, Simon
Dickerson, Bradford C.
Larvie, Mykol
Price, Bruce H.
TI Differentiating Frontotemporal Dementia From Catatonia: A Complex
Neuropsychiatric Challenge
SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Letter
ID AKINETIC CATATONIA; CORTICAL DYSFUNCTION
C1 [Ducharme, Simon; Price, Bruce H.] McLean Hosp, Dept Neurol, Behav Neurol & Neuropsychiat Clin, Belmont, MA 02178 USA.
[Ducharme, Simon] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Ducharme, Simon; Dickerson, Bradford C.; Price, Bruce H.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Larvie, Mykol] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Ducharme, Simon] McGill Univ, Dept Psychiat, Ctr Hlth, Montreal, PQ, Canada.
[Ducharme, Simon] McGill Univ, Montreal Neurol Inst, McConnell Brain Imaging Ctr, Montreal, PQ, Canada.
RP Ducharme, S (reprint author), McLean Hosp, Dept Neurol, Behav Neurol & Neuropsychiat Clin, Belmont, MA 02178 USA.
EM simon.ducharme@mcgill.ca
NR 10
TC 2
Z9 2
U1 0
U2 1
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0895-0172
EI 1545-7222
J9 J NEUROPSYCH CLIN N
JI J. Neuropsychiatr. Clin. Neurosci.
PD SPR
PY 2015
VL 27
IS 2
BP E174
EP E176
DI 10.1176/appi.neuropsych.14070157
PG 3
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA CJ1NM
UT WOS:000355250300027
PM 25923875
ER
PT J
AU Ducharme, S
Dickerson, BC
Price, BH
AF Ducharme, Simon
Dickerson, Bradford C.
Price, Bruce H.
TI Improvement in Athletic Performance as an Early Symptom of Behavioral
Variant Frontotemporal Dementia
SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Letter
ID EXPERIENCE; SAMPLE; CORTEX; FLOW
C1 [Ducharme, Simon; Price, Bruce H.] McLean Hosp, Dept Neurol, Behav Neurol & Neuropsychiat Clin, Belmont, MA 02178 USA.
[Ducharme, Simon] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Ducharme, Simon; Dickerson, Bradford C.; Price, Bruce H.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Ducharme, Simon] McGill Univ, Dept Psychiat, Ctr Hlth, Montreal, PQ, Canada.
[Ducharme, Simon] McGill Univ, Montreal Neurol Inst, McConnell Brain Imaging Ctr, Montreal, PQ, Canada.
RP Ducharme, S (reprint author), McLean Hosp, Dept Neurol, Behav Neurol & Neuropsychiat Clin, Belmont, MA 02178 USA.
EM simon.ducharme@mcgill.ca
NR 10
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0895-0172
EI 1545-7222
J9 J NEUROPSYCH CLIN N
JI J. Neuropsychiatr. Clin. Neurosci.
PD SPR
PY 2015
VL 27
IS 2
BP E163
EP E164
DI 10.1176/appi.neuropsych.14060136
PG 2
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA CJ1NM
UT WOS:000355250300022
PM 25923870
ER
PT J
AU Garza-Mayers, AC
Miller, KA
Russo, BC
Nagda, DV
Goldberg, MB
AF Garza-Mayers, Anna Cristina
Miller, Kelly A.
Russo, Brian C.
Nagda, Dipal V.
Goldberg, Marcia B.
TI Shigella flexneri Regulation of ARF6 Activation during Bacterial Entry
via an IpgD-Mediated Positive Feedback Loop
SO MBIO
LA English
DT Article
ID NUCLEOTIDE EXCHANGE FACTOR; RIBOSYLATION FACTOR 6; PLECKSTRIN HOMOLOGY
DOMAINS; III SECRETION; DOWNSTREAM ACTIVATION; EPITHELIAL-CELLS;
PLASMA-MEMBRANE; PH DOMAIN; T-CELL; INVASION
AB Entry into cells is critical for virulence of the human bacterial pathogens Shigella spp. Shigella spp. induce membrane ruffle formation and macropinocytic uptake, but the events instigating this process are incompletely understood. The host small GTPase ADP-ribosylation factor 6 (ARF6) functions in membrane trafficking at the plasma membrane and activates membrane ruffle formation. We demonstrate that ARF6 is required for efficient Shigella flexneri entry, is activated by S. flexneri dependent on the phosphatase activity of the type III secreted effector IpgD, and depends on cytohesin guanine nucleotide exchange factors (GEFs) for recruitment to entry sites. The cytohesin GEF ARF nucleotide binding site opener (ARNO) is recruited to these sites, also dependent on IpgD phosphatase activity. ARNO recruitment is independent of ARF6, indicating that, in addition to the described recruitment of ARNO by ARF6, ARNO is recruited upstream of ARF6. Our data provide evidence that ARF6, IpgD, phosphoinositide species, and ARNO constitute a previously undescribed positive feedback loop that amplifies ARF6 activation at bacterial entry sites, thereby promoting efficient S. flexneri uptake.
IMPORTANCE Shigella spp. cause diarrhea and dysentery by infection of epithelial cells in the human colon. Critical to disease is the ability of Shigella to enter into cells, yet the mechanisms involved in entry are incompletely understood. We demonstrate that the small GTPase ADP-ribosylation factor 6 (ARF6) is required for efficient cellular entry of Shigella flexneri and that activation of ARF6 depends on the phosphatase activity of the Shigella protein IpgD, which is introduced into cells via the bacterial type III secretion system. We further show that IpgD phosphatase activity is required for recruitment of the ARF6 guanine nucleotide exchange factor (GEF) ARF nucleotide binding site opener (ARNO) to bacterial entry sites and that ARNO lies upstream of ARF6 activation. These relationships define a positive feedback loop that contributes to activation of ARF6 at S. flexneri entry sites and leads to local amplification of signals that promote bacterial entry.
C1 [Garza-Mayers, Anna Cristina; Goldberg, Marcia B.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
[Miller, Kelly A.; Russo, Brian C.; Nagda, Dipal V.; Goldberg, Marcia B.] Massachusetts Gen Hosp, Div Infect Dis, Dept Med, Cambridge, MA USA.
RP Goldberg, MB (reprint author), Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
EM marcia.goldberg@mgh.harvard.edu
FU Public Health Service grant from the National Institutes of Health
[R01AI081724, T32GM007753, T32AI007061]
FX This work was supported by Public Health Service grant R01AI081724 (to
M.B.G.), trainee support on T32GM007753 (to A.C.G.-M.), and T32AI007061
(to K.A.M. and B.C.R.) from the National Institutes of Health.
NR 72
TC 5
Z9 5
U1 1
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD MAR-APR
PY 2015
VL 6
IS 2
AR e02584-14
DI 10.1128/mBio.02584-14
PG 12
WC Microbiology
SC Microbiology
GA CJ2KE
UT WOS:000355312400029
PM 25736891
ER
PT J
AU Mitchell, AM
Stone, AEL
Cheng, LL
Ballinger, K
Edwards, MG
Stoddard, M
Li, H
Golden-Mason, L
Shaw, GM
Khetani, S
Rosen, HR
AF Mitchell, Angela M.
Stone, Amy E. L.
Cheng, Linling
Ballinger, Kimberly
Edwards, Michael G.
Stoddard, Mark
Li, Hui
Golden-Mason, Lucy
Shaw, George M.
Khetani, Salman
Rosen, Hugo R.
TI Transmitted/Founder Hepatitis C Viruses Induce Cell-Type- and
Genotype-Specific Differences in Innate Signaling within the Liver
SO MBIO
LA English
DT Article
ID PLASMACYTOID DENDRITIC CELLS; INFECTION; INTERFERON; CANCER; HCV;
IDENTIFICATION; REPLICATION; STEATOSIS; CLEARANCE; FIBROSIS
AB Hepatitis C virus (HCV) infection leads to persistence in the majority of cases despite triggering complex innate immune responses within the liver. Although hepatocytes are the preferred site for HCV replication, nonparenchymal cells (NPCs) can also contribute to antiviral immunity. Recent innovations involving single-genome amplification (SGA), direct amplicon sequencing, and phylogenetic inference have identified full-length transmitted/founder (T/F) viruses. Here, we tested the effect of HCV T/F viral RNA (vRNA) on innate immune signaling within hepatocytes and NPCs, including the HepG2 and Huh 7.5.1 cell lines, a human liver endothelial cell line (TMNK-1), a plasmacytoid dendritic cell line (GEN2.2), and a monocytic cell line (THP-1). Transfection with hepatitis C T/F vRNA induced robust transcriptional upregulation of type I and III interferons (IFNs) within HepG2 and TMNK-1 cells. Both the THP-1 and GEN2.2 lines demonstrated higher type I and III IFN transcription with genotype 3a compared to genotype 1a or 1b. Supernatants from HCV T/F vRNA-transfected TMNK-1 cells demonstrated superior viral control. Primary human hepatocytes (PHH) transfected with genotype 3a induced canonical pathways that included chemokine and IFN genes, as well as overrepresentation of RIG-I (DDX58), STAT1, and a Toll-like receptor 3 (TLR3) network. Full-length molecular clones of HCV induce broad IFN responses within hepatocytes and NPCs, highlighting that signals imparted by the various cell types within the liver may lead to divergent outcomes of infection. In particular, the finding that HCV genotypes differentially induce antiviral responses in NPCs and PHH might account for relevant clinical-epidemiological observations (higher clearance but greater necroinflammation in persistence with genotype 3).
IMPORTANCE Hepatitis C virus (HCV) has become a major worldwide problem, and it is now the most common viral infection for which there is no vaccine. HCV infection often leads to persistence of the virus and is a leading cause of chronic hepatitis, liver cancer, and cirrhosis. There are multiple genotypes of the virus, and patients infected with different viral genotypes respond to traditional therapy differently. However, the immune response to the virus within the liver has not been fully elucidated. Here, we determined the responses to different genotypes of HCV in cell types of the liver. We found that the immune response varied according to both cell type and HCV genotype, leading to a more pronounced induction of inflammatory pathways after exposure to certain genotypes. Therefore, inflammatory pathways that are being robustly activated by certain HCV genotypes could lead to more severe damage to the liver, inducing diverse outcomes and responses to therapy.
C1 [Mitchell, Angela M.; Stone, Amy E. L.; Golden-Mason, Lucy; Rosen, Hugo R.] Univ Colorado Denver, Integrated Dept Immunol, Denver, CO 80204 USA.
[Mitchell, Angela M.; Stone, Amy E. L.; Golden-Mason, Lucy; Rosen, Hugo R.] Natl Jewish Hlth, Denver, CO USA.
[Mitchell, Angela M.; Stone, Amy E. L.; Cheng, Linling; Golden-Mason, Lucy; Rosen, Hugo R.] Univ Colorado Denver, Div Gastroenterol & Hepatol, Hepatitis Ctr C, Dept Med, Denver, CO USA.
[Ballinger, Kimberly; Khetani, Salman] Colorado State Univ, Mech & Biomed Engn, Ft Collins, CO 80523 USA.
[Edwards, Michael G.] Univ Colorado Denver, Dept Med, Div Pulm Sci & Crit Care Med, Aurora, CO USA.
[Stoddard, Mark; Li, Hui; Shaw, George M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Rosen, Hugo R.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Rosen, HR (reprint author), Univ Colorado Denver, Integrated Dept Immunol, Denver, CO 80204 USA.
EM hugo.rosen@ucdenver.edu
FU National Institutes of Health [R21 AI 103361, R21-AI 106000]; HCV Center
[U19 AI 1066328]; VA Merit Review grant (Department of Veteran's
Affairs)
FX This work was supported by R21 AI 103361 (National Institutes of
Health), U19 AI 1066328 (HCV Center grant), and a VA Merit Review grant
(Department of Veteran's Affairs) to H.R.R. and R21-AI 106000 (National
Institutes of Health) to G.M.S.
NR 46
TC 3
Z9 3
U1 2
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD MAR-APR
PY 2015
VL 6
IS 2
AR e02510-14
DI 10.1128/mBio.02510-14
PG 11
WC Microbiology
SC Microbiology
GA CJ2KE
UT WOS:000355312400065
PM 25714713
ER
PT J
AU de Moya, MA
Sideris, AC
Choy, G
Chang, YC
Landman, WB
Cropano, CM
Cohn, SM
AF de Moya, Marc A.
Sideris, Antonios C.
Choy, Garry
Chang, Yuchiao
Landman, Wendy B.
Cropano, Catrina M.
Cohn, Stephen M.
TI Appendectomy and Pregnancy: Gestational Age Does Not Affect the Position
of the Incision
SO AMERICAN SURGEON
LA English
DT Article; Proceedings Paper
CT 7th Annual Academic Surgical Congress of the
Association-for-Academic-Surgery
CY FEB 14-16, 2012
CL Las Vegas, NV
SP Assoc Acad Surg
ID LOWER-QUADRANT PAIN; SUSPECTED APPENDICITIS; PELVIC PAIN; MRI; PATIENT;
WOMEN; LOCATION; RISK
AB The position of the base of the appendix during advancing gestational age is based on inadequate data. Therefore, the proper location for an appendectomy incision during pregnancy is highly unclear. This study investigated the location of the appendix during pregnancy to determine the optimal location for an incision in pregnant patients with appendicitis relative to McBurney's point. Magnetic resonance images (MRIs) were reviewed independently by two fellowship-trained abdominal MRI radiologists blinded to the imaging report. The distance of the appendix from anatomic landmarks was measured in a total of 114 pregnant women with an abdominal or pelvic MRI who were admitted between 2001 and 2011 at a Level I trauma center. Patients with a history of appendectomy were excluded. The distance from the base of the appendix to McBurney's point changed over the course of the gestation by only 1.2 cm and which did not amount to a clinically or statistically significant change in position. Our data provide evidence that there is minimal upward or lateral displacement of the appendix during pregnancy, and therefore its distance from the McBurney's point remains essentially unchanged. These findings justify the use of the McBurney's incision for appendectomy during pregnancy regardless of the trimester.
C1 [de Moya, Marc A.; Sideris, Antonios C.; Cropano, Catrina M.] Massachusetts Gen Hosp, Dept Surg, Div Trauma, Boston, MA 02114 USA.
[Choy, Garry] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Chang, Yuchiao] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Landman, Wendy B.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Cohn, Stephen M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA.
RP de Moya, MA (reprint author), Massachusetts Gen Hosp, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.
EM mdemoya@partners.org
NR 29
TC 1
Z9 1
U1 1
U2 1
PU SOUTHEASTERN SURGICAL CONGRESS
PI CUMMING
PA 115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA
SN 0003-1348
EI 1555-9823
J9 AM SURGEON
JI Am. Surg.
PD MAR
PY 2015
VL 81
IS 3
BP 282
EP 288
PG 7
WC Surgery
SC Surgery
GA CI6TN
UT WOS:000354895100031
PM 25760205
ER
PT J
AU Bardia, A
AF Bardia, A.
TI TARGETING THE ESTROGEN RECEPTOR: OLD RECEPTOR, NEW DRUG(S)
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 13th International Congress on Targeted Anticancer Therapies (TAT)
CY MAR 02-04, 2015
CL Paris, FRANCE
ID BREAST-CANCER; MUTATIONS
C1 [Bardia, A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 4
TC 1
Z9 1
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD MAR
PY 2015
VL 26
SU 2
MA O3.1
BP 3
EP 3
DI 10.1093/annonc/mdv081.1
PG 1
WC Oncology
SC Oncology
GA CI4OC
UT WOS:000354729300004
ER
PT J
AU Gainor, J
AF Gainor, J.
TI Next generation ALK inhibitors and mechanisms of resistance to therapy
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 13th International Congress on Targeted Anticancer Therapies (TAT)
CY MAR 02-04, 2015
CL Paris, FRANCE
C1 [Gainor, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD MAR
PY 2015
VL 26
SU 2
MA O10.1
BP 14
EP 14
DI 10.1093/annonc/mdv088.1
PG 1
WC Oncology
SC Oncology
GA CI4OC
UT WOS:000354729300012
ER
PT J
AU Sher, L
AF Sher, Leo
TI Suicide in Men
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Editorial Material
ID OF-THE-LITERATURE; TESTOSTERONE LEVELS; BIPOLAR DISORDER; BEHAVIOR;
LITHIUM; GENDER; IMPULSIVITY
C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY 10468 USA.
[Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 West Kingsbridge Rd, New York, NY 10468 USA.
EM Leo.Sher@mssm.edu
NR 21
TC 3
Z9 3
U1 2
U2 11
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD MAR
PY 2015
VL 76
IS 3
BP E371
EP E372
DI 10.4088/JCP.14com09554
PG 2
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA CI7PD
UT WOS:000354955400008
PM 25830461
ER
PT J
AU Brennan, MB
Barocas, JA
Crnich, CJ
Hess, TM
Kolehmainen, CJ
Sosman, JM
Sethi, AK
AF Brennan, Meghan B.
Barocas, Joshua A.
Crnich, Christopher J.
Hess, Timothy M.
Kolehmainen, Christine J.
Sosman, James M.
Sethi, Ajay K.
TI "Oops! I forgot HIV": Resident physician self-audits and universal HIV
screening
SO JOURNAL OF INFECTION AND PUBLIC HEALTH
LA English
DT Article
DE HIV screening; Self-audit feedback; Chart review; Medical resident
education; Qualitative
ID HEALTH-CARE SETTINGS; UNITED-STATES; ANTIRETROVIRAL THERAPY;
RECOMMENDATIONS; PREVENTION; RISK; PREVALENCE; BEHAVIORS; VETERANS;
ADULTS
AB Background: Innovations are needed to increase universal HIV screening by primary care providers. One potential intervention is self-audit feedback, which describes the process of a clinician reviewing their own patient charts and reflecting on their performance.
Methods: The effectiveness of self-audit feedback was investigated using a mixed methods approach. A total of 2111 patient charts were analyzed in a quantitative pre-post intervention study design, where the intervention was providing self-audit feedback to all internal medicine residents at one institution through an annual chart review. Qualitative data generated from the subsequent resident focus group discussions explored the motivation and mechanism for change using a knowledge attitude behavior framework.
Results: The proportion of primary care patients screened for HIV increased from 17.9% (190/1060) to 40.3% (423/1051). The adjusted odds ratio of a patient being screened following resident self-audited feedback was 3.17 (95% Cl 2.11, 4.76, p < 0.001). Focus group participants attributed the improved performance to the self-audit feedback.
Conclusions: Self-audit feedback is a potentially effective intervention for increasing universal HIV screening in primary care. This strategy may be most useful in settings where (1) baseline performance is low, (2) behavioral change is provider-driven, and (3) resident trainees are targeted. Published by Elsevier Limited on behalf of King Saud Bin Abdulaziz University for Health Sciences.
C1 [Brennan, Meghan B.; Barocas, Joshua A.; Crnich, Christopher J.; Hess, Timothy M.; Kolehmainen, Christine J.; Sosman, James M.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA.
[Brennan, Meghan B.; Crnich, Christopher J.; Sethi, Ajay K.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53726 USA.
[Brennan, Meghan B.; Crnich, Christopher J.; Hess, Timothy M.; Kolehmainen, Christine J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
RP Brennan, MB (reprint author), UWMF Centennial Bldg,5th Floor,1685 Highland Ave, Madison, WI 53705 USA.
EM mbbrennan@medicine.wisc.edu; jbarocas@medicine.wisc.edu;
cjc@medicine.wisc.edu; tmhess@medicine.wisc.edu;
Christine.Kolehmainen@va.gov; jms@medicine.wisc.edu; aksethi@wisc.edu
OI Crnich, Christopher/0000-0002-9320-9262
FU University of Wisconsin Department of Medicine; University of Wisconsin
Department of Population Health Sciences; VA Advanced Women's Health
Research Fellowship
FX This study received no specific grant from any funding agency in the
public, commercial, or not-for-profit sectors. However, the authors did
receive general support from the University of Wisconsin Departments of
Medicine and Population Health Sciences and the VA Advanced Women's
Health Research Fellowship. These sources did not have a role in study
design; collection, analysis and interpretation of data; writing; or the
decision to submit the article for publication. This is GRECC manuscript
2014-022.
NR 34
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1876-0341
EI 1876-035X
J9 J INFECT PUBLIC HEAL
JI J. Infect. Public Health
PD MAR-APR
PY 2015
VL 8
IS 2
BP 161
EP 169
DI 10.1016/j.jiph.2014.08.010
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA CI7SK
UT WOS:000354964700007
PM 25277258
ER
PT J
AU Nau, P
Molina, G
Shima, A
Hani, A
Meireles, O
AF Nau, Peter
Molina, George
Shima, Aran
Hani, Abujudeh
Meireles, Ozanan
TI Roux-en-Y gastric bypass is associated with an increased exposure to
ionizing radiation
SO SURGERY FOR OBESITY AND RELATED DISEASES
LA English
DT Article
DE Roux-en-Y gastric bypass; Ionizing radiation; Weight loss surgery;
Radiation exposure
ID LAPAROSCOPIC BARIATRIC SURGERY; SWEDISH OBESE SUBJECTS; INTERNAL
HERNIAS; COMPUTED-TOMOGRAPHY; BODY-MASS; RISK; MORTALITY; WEIGHT;
CANCER; CT
AB Background: Bariatric surgery provides for a reliable and sustainable solution to the obesity epidemic. The gold standard bariatric surgical procedure is the Roux-en-Y gastric bypass (RYGB). Assessment of this population preoperatively and work-up of postoperative complications often includes radiographic evaluation. Repeated exposure to radiation is not without complication.
Objective: Assess the association between the RYGB and exposure to ionizing radiation.
Setting: Academic medical center.
Methods: Patients were identified by their ICD-9 code as having had a RYGB at the Massachusetts General Hospital (MGH) from 2002 to 2012. The number of abdominal and pelvis (A/P) computed tomography (CT) scans performed was determined and converted into an effective dose (ED) and expressed as milliSeiverts (mSv) to illustrate the biologic effects of radiation.
Results: From 2002 to 2012, 1789 primary laparoscopic RYGBs were completed. Fifty-five revisional operations were completed on 51 patients. Of these, 38 had both their index and second operation at the MGH. A total of 1065 A/P CTs were completed in the laparoscopic RYGB population (mean = .6), and 106 A/P CTs were done in the revisional surgery cohort (mean = 2.8). The mean ED of radiation was 56.1 mSv and 19.5 mSv for the index and revisional populations, respectively.
Conclusions: This study demonstrated the significant cumulative radiation exposure attributable to A/P CTs. This exposes the patient to a potential increased risk of malignancy as well as imposing a financial burden on the healthcare system. The findings of this study raise the awareness of an increased risk of radiation exposure for this population and the necessity of creation of a dedicated algorithm for the mindful utilization of CT imaging. (C) 2015 American Society for Metabolic and Bariatric Surgery. All rights reserved.
C1 [Nau, Peter] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.
[Molina, George; Shima, Aran; Hani, Abujudeh; Meireles, Ozanan] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Nau, P (reprint author), 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM peter-nau@uiowa.edu
NR 37
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1550-7289
EI 1878-7533
J9 SURG OBES RELAT DIS
JI Surg. Obes. Relat. Dis.
PD MAR-APR
PY 2015
VL 11
IS 2
BP 308
EP 312
DI 10.1016/j.soard.2014.07.022
PG 5
WC Surgery
SC Surgery
GA CI0HU
UT WOS:000354418500011
PM 25820075
ER
PT J
AU Hurtado, DA
Nelson, CC
Hashimoto, D
Sorensen, G
AF Hurtado, David A.
Nelson, Candace C.
Hashimoto, Dean
Sorensen, Glorian
TI Supervisors' Support for Nurses' Meal Breaks and Mental Health
SO WORKPLACE HEALTH & SAFETY
LA English
DT Article
DE supervisor support; meal breaks; mental health; hospital nurses
ID WORK-FAMILY CONFLICT; PATIENT-CARE WORKERS; REST BREAKS; MUSCULOSKELETAL
DISORDERS; STRESS; IMPACT; RISK; PERSPECTIVE; SCHEDULES
AB Meal breaks promote occupational health and safety; however, less is known about supervisors' support for nurses' meal breaks. In this study, the researchers tested whether the frequency of meal breaks was positively related to supervisors' support of nurses' meal breaks, and whether more frequent meal breaks were associated with less psychological distress. This study is based on a cross-sectional survey of 1,595 hospital nurses working on 85 units supervised by nursing directors. Specific meal-break support was measured at the nursing director level; frequency of meal breaks and psychological distress were measured at the individual nurse level. Multilevel adjusted models showed a positive association between supervisors' support for meal breaks and the frequency of nurses' meal breaks ( = .16, p < .001). Moreover, nurses who took meal breaks more frequently reported lower psychological distress ( = -.09, p < .05). Meal breaks might be daily opportunities to promote mental health and fatigue recovery and provide downtime.
C1 [Hurtado, David A.] Harvard Univ, TH Chan Sch Publ Hlth, Ctr Work Hlth & Well Being, Boston, MA 02115 USA.
[Nelson, Candace C.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Sorensen, Glorian] Harvard Univ, TH Chan Sch Publ Hlth, Social & Behav Sci, Boston, MA 02115 USA.
[Hashimoto, Dean] Partners HealthCare Syst, Occupat Hlth Serv, Occupat & Environm Med, Boston, MA USA.
[Sorensen, Glorian] Dana Farber Canc Inst, Fac Dev, Boston, MA USA.
RP Hurtado, DA (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, 677 Huntington Ave,Kresge Bldg 7th Floor, Boston, MA 02115 USA.
EM dhurtado@mail.harvard.edu
FU National Institute for Occupational Safety and Health [U19 OH008861]
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This work
was supported by a grant from the National Institute for Occupational
Safety and Health (U19 OH008861) for the Harvard School of Public Health
Center for Work, Health, and Well-Being.
NR 34
TC 3
Z9 3
U1 0
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2165-0799
EI 2165-0969
J9 WORKPLACE HEALTH SAF
JI Workplace Health Saf.
PD MAR
PY 2015
VL 63
IS 3
BP 107
EP 115
DI 10.1177/2165079915571354
PG 9
WC Nursing
SC Nursing
GA CI8AT
UT WOS:000354990500003
PM 25994975
ER
PT J
AU Chambers, KJ
Lehmann, AE
Remenschneider, A
Dedmon, M
Meier, J
Gray, ST
Lin, DT
AF Chambers, Kyle J.
Lehmann, Ashton E.
Remenschneider, Aaron
Dedmon, Matthew
Meier, Josh
Gray, Stacey T.
Lin, Derrick T.
TI Incidence and Survival Patterns of Sinonasal Undifferentiated Carcinoma
in the United States
SO JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE
LA English
DT Article
DE sinonasal undifferentiated carcinoma; SNUC; survival; multimodal
treatment; neuroendocrine tumors
ID OLFACTORY NEUROBLASTOMA; AGGRESSIVE NEOPLASM; EXPERIENCE;
DIFFERENTIATION; MALIGNANCIES; FAILURE; NECK; HEAD
AB Objective To determine trends in sinonasal undifferentiated carcinoma (SNUC) survival patterns in the United States.
Design Retrospective review of national database.
Participants All cases of SNUC in the National Cancer Institute's Surveillance Epidemiology and End Results program from 1973 to 2010 were examined.
Main Outcome Measures Age-adjusted incidence and survival rates were calculated and stratified by demographic information and treatment modality. Cohort analysis was performed to analyze survival patterns over time.
Results A total of 318 SNUC cases were identified. Age-adjusted incidence rate (IR) was 0.02 per 100,000. Incidence was greater in males (IR: 0.03) than females (IR: 0.01; p = 0.03). Overall 5- and 10-year relative survival rate was 34.9% and 31.3%, respectively. Overall median survival was 22.1 months. Median survival following surgery combined with radiation was 41.9 months. Five-year relative survival rate following surgery, radiation, or surgery combined with radiation was 38.7%, 36.0%, and 39.1%, respectively. Median survival from 1973-1986 and 1987-2010 was 14.5 and 23.5 months, respectively.
Conclusions This study provides new data regarding survival patterns of SNUC in the United States, confirming survival benefit with surgery and radiation as well as identifying a trend toward improved survival in recent decades.
C1 [Chambers, Kyle J.; Remenschneider, Aaron; Dedmon, Matthew; Meier, Josh; Gray, Stacey T.; Lin, Derrick T.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA.
[Chambers, Kyle J.; Lehmann, Ashton E.; Remenschneider, Aaron; Dedmon, Matthew; Meier, Josh; Gray, Stacey T.; Lin, Derrick T.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
RP Chambers, KJ (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM kyle_chambers@meei.harvard.edu
NR 27
TC 10
Z9 10
U1 0
U2 0
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 2193-6331
EI 2193-634X
J9 J NEUROL SURG PART B
JI Journal of Neurol. Surg. Part B
PD MAR
PY 2015
VL 76
IS 2
BP 94
EP 100
DI 10.1055/s-0034-1390016
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA CI2XY
UT WOS:000354612700003
PM 25844294
ER
PT J
AU Pietrzak, RH
Lim, YY
Ames, D
Harrington, K
Restrepo, C
Martins, RN
Rembach, A
Laws, SM
Masters, CL
Villemagne, VL
Rowe, CC
Maruff, P
AF Pietrzak, Robert H.
Lim, Yen Ying
Ames, David
Harrington, Karra
Restrepo, Carolina
Martins, Ralph N.
Rembach, Alan
Laws, Simon M.
Masters, Colin L.
Villemagne, Victor L.
Rowe, Christopher C.
Maruff, Paul
CA Australian Imaging Biomarkers Life
TI Trajectories of memory decline in preclinical Alzheimer's disease:
results from the Australian Imaging, Biomarkers and Lifestyle Flagship
Study of Ageing
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Alzheimer's disease; Memory; Trajectories; A beta; APOE
ID HEALTHY OLDER-ADULTS; MILD COGNITIVE IMPAIRMENT; AMYLOID-BETA;
PROSPECTIVE COHORT; EPISODIC MEMORY; DEMENTIA; ASSOCIATION; AGE;
DEPOSITION; ANXIETY
AB Memory changes in preclinical Alzheimer's disease (AD) are often characterized by heterogenous trajectories. However, data regarding the nature and determinants of predominant trajectories of memory changes in preclinical AD are lacking. We analyzed data from 333 cognitively healthy older adults who participated in a multicenter prospective cohort study with baseline and 18-, 36-, and 54-month follow-up assessments. Latent growth mixture modeling revealed 3 predominant trajectories of memory change: a below average, subtly declining memory trajectory (30.9%); a below average, rapidly declining memory trajectory (3.6%); and an above average, stable memory trajectory (65.5%). Compared with the stable memory trajectory, high A beta (relative risk ratio [RRR] = 2.1), and lower Mini-Mental State Examination (RRR = 0.6) and full-scale IQ (RRR =0.9) scores were independently associated with the subtly declining memory trajectory; and high Ab (RRR = 8 .3), APOE epsilon 4 carriage (RRR = 6.1), and greater subjective memory impairment (RRR - 1.2) were independently associated with the rapidly declining memory trajectory. Compared with the subtly declining memory trajectory group, APOE epsilon 4 carriage (RRR = 8.4), and subjective memory complaints (RRR = 1.2) were associated with a rapidly declining memory trajectory. These results suggest that the preclinical phase of AD may be characterized by 2 predominant trajectories of memory decline that have common (e.g., high A beta) and unique (e.g., APOE epsilon 4 genotype) determinants. Published by Elsevier Inc.
C1 [Pietrzak, Robert H.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, VA Connecticut Healthcare Syst, West Haven, CT 06516 USA.
[Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Lim, Yen Ying; Harrington, Karra; Restrepo, Carolina; Rembach, Alan; Masters, Colin L.; Villemagne, Victor L.; Maruff, Paul] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia.
[Lim, Yen Ying] Brown Univ, Warren Alpert Sch Med, Dept Neurol, Providence, RI 02912 USA.
[Ames, David] Univ Melbourne, Dept Psychiat, St Vincents Hlth, Acad Unit Psychiat Old Age, Kew, Vic, Australia.
[Ames, David] Natl Ageing Res Inst, Parkville, Vic, Australia.
[Martins, Ralph N.; Laws, Simon M.] Edith Cowan Univ, Sch Exercise Biomed & Hlth Sci, Ctr Excellence Alzheimers Dis Res & Care, Perth, WA, Australia.
[Martins, Ralph N.; Laws, Simon M.] Hollywood Private Hosp, Sir James McCusker Alzheimers Dis Res Unit, Nedlands, WA, Australia.
[Villemagne, Victor L.; Rowe, Christopher C.] Austin Hlth, Dept Nucl Med, Heidelberg, Vic, Australia.
[Villemagne, Victor L.; Rowe, Christopher C.] Austin Hlth, Ctr PET, Heidelberg, Vic, Australia.
[Villemagne, Victor L.; Rowe, Christopher C.] Univ Melbourne, Austin Hlth, Dept Med, Heidelberg, Vic, Australia.
[Maruff, Paul] Cogstate Ltd, Melbourne, Vic, Australia.
RP Pietrzak, RH (reprint author), US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, VA Connecticut Healthcare Syst, 950 Campbell Ave 161E, West Haven, CT 06516 USA.
EM robert.pietrzak@yale.edu
RI Laws, Simon/C-2858-2014;
OI Laws, Simon/0000-0002-4355-7082; Maruff, Paul/0000-0002-6947-9537
FU Commonwealth Scientific Industrial Research Organization (CSIRO); Edith
Cowan University (ECU); Mental Health Research Institute (MHRI);
National Ageing Research Institute (NARI); Austin Health; CogState Ltd.;
National Health and Medical Research Council (NHMRC); Dementia
Collaborative Research Centres program (DCRC2); Science and Industry
Endowment Fund (SIEF); Cooperative Research Centre for Mental Health
(CRCMH)
FX Funding for the study was provided in part by the study partners
[Commonwealth Scientific Industrial Research Organization (CSIRO), Edith
Cowan University (ECU), Mental Health Research Institute (MHRI),
National Ageing Research Institute (NARI), Austin Health, and CogState
Ltd]. The study also received support from the National Health and
Medical Research Council (NHMRC) and the Dementia Collaborative Research
Centres program (DCRC2), as well as funding from the Science and
Industry Endowment Fund (SIEF) and the Cooperative Research Centre for
Mental Health (CRCMH). Robert H. Pietrzak, Yen Ying Lim, and Paul Maruff
conceptualized the study design, reviewed the literature, and wrote the
first draft of the article, and conducted data analyses; David Ames,
Ralph N. Martins, Colin L. Masters, Paul Maruff, Victor L. Villemagne,
Alan Rembach, Christopher C. Rowe are senior investigators of the AIBL
study and responsible for the design of the AIBL study and selection of
study endpoints. Victor L. Villemagne and Christopher C. Rowe conducted
and oversaw neuroimaging for all participants. Yen Ying Lim and Karra
Harrington conducted neuropsychological assessments. Simon M. Laws
undertook genetic analyses for all participants. David Ames, Karra
Harrington, Carolina Restrepo, Ralph N. Martins, Alan Rembach, Simon M.
Laws, Colin L. Masters, Victor L. Villemagne, and Christopher C. Rowe
provided critical revision of article drafts.
NR 33
TC 16
Z9 16
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD MAR
PY 2015
VL 36
IS 3
BP 1231
EP 1238
DI 10.1016/j.neurobiolaging.2014.12.015
PG 8
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA CI1XJ
UT WOS:000354538100001
PM 25585532
ER
PT J
AU Quinzanos, I
Luong, PT
Bobba, S
Richards, JS
Majithia, V
Davis, LA
Caplan, L
AF Quinzanos, I.
Luong, P. T.
Bobba, S.
Richards, J. Steuart
Majithia, V.
Davis, L. A.
Caplan, L.
TI Validation of disease activity and functional status questionnaires in
spondyloarthritis
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Article
DE ankylosing spondylitis; questionnaires; health impact assessment
ID BATH ANKYLOSING-SPONDYLITIS; ACTIVITY INDEX; RELIABILITY; CRITERIA
AB Objective
Patients naive to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and to the Ankylosing Spondylitis Disease Activity Score (ASDAS) have voiced confusion in our clinics over the use of the term "AS" in these instruments. It is unknown whether these tools may be applied to other related forms of spondyloarthritis (SpA). The Bath Ankylosing Spondylitis Functional Index (BASFI) questionnaire also requires more definitive validation. We I) validated the BASFI against a standard definition of disability; and 2) validated slightly modified versions of the BASDAI and ASDAS questionnaires that replace references to "AS" with the term "inflammatory arthritis" for use in non-AS SpA.
Methods
Adult patients with SpA enrolled in the Veterans Affairs Program to Understand the Longterm outcomes in Spondylo-ARthritis (PULSAR) completed the BASFI, BASDAL ASDAS and altered versions of the BASDAI (PULSAR-modified Bath Disease Activity Index [PuBaDAI]) and ASDAS (PULSAR-modified Ankylosing Spondylitis Disease Activity Score [PuASDAS]). Spearman correlations and logistic regression were used to analyse the scores.
Results
The correlation between BASDAI and PuBaDAI and between ASDAS and PuASDAS scores was high (Spearman rho=0.92, p<0.001 and Spearman's rho=0.85, p<0.001, respectively). The test-retest correlation of BASFI was also high (Spearman's rho=0.92, p<0.001). The BASFI (OR 1.67, 95% C.I. 1.12-2.47), ASDAS (OR 1.34, 95% C.I. 1.02-1.76) and PuASDAS (OR 1.62, 95% C.I. 1.07-2.49) predicted federally-determined disability.
Conclusion
Preliminary data suggest that BASDAI and ASDAS scores correlate well with modified forms of these questionnaires and that the ASDAS, PuASDAS and BASFI are associated with disability.
C1 [Quinzanos, I.; Luong, P. T.; Bobba, S.; Davis, L. A.; Caplan, L.] Dept Vet Affairs, Denver, CO USA.
[Quinzanos, I.; Davis, L. A.; Caplan, L.] Univ Colorado, Sch Med, Aurora, CO USA.
[Richards, J. Steuart] Dept Vet Affairs, Washington, DC USA.
[Majithia, V.] Montgomery VAMC, Jackson, MS USA.
[Davis, L. A.] Denver Hlth, Denver, CO USA.
RP Caplan, L (reprint author), Univ Colorado, Sch Med, Denver Vet Affairs Med Ctr, 1775 Aurora Ct,POB 6511,B115, Denver, CO 80045 USA.
EM liron.caplan@ucdenver.edu
FU VA HSR&D Career Development Award [07-221]; NIH/NIAMS [T32 AR007534-24];
VA GME Enhancement Award
FX L. Caplan is supported by VA HSR&D Career Development Award (07-221);
L.A. Davis was supported by NIH/NIAMS T32 AR007534-24 and a VA GME
Enhancement Award during the time this research was conducted.
NR 18
TC 3
Z9 3
U1 0
U2 0
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392-856X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PD MAR-APR
PY 2015
VL 33
IS 2
BP 146
EP 152
PG 7
WC Rheumatology
SC Rheumatology
GA CG6TX
UT WOS:000353436400003
PM 25664820
ER
PT J
AU Riedl, MA
Banerji, A
Gower, R
AF Riedl, Marc A.
Banerji, Aleena
Gower, Richard
TI Current Medical Management of Hereditary Angioedema: Follow-up Survey of
US Physicians
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Article
DE Hereditary angioedema; C1-INH; ecallantide; Icatibant; Danazol;
Antifibrinolytics; On-demand therapy; Long-term prophylaxis; Short-term
prophylaxis; Self-administration; Home treatment
ID QUALITY-OF-LIFE; C1 INHIBITOR DEFICIENCY; INTERNATIONAL CONSENSUS;
C1-INHIBITOR DEFICIENCY; ACQUIRED ANGIOEDEMA; THERAPY; RECOMMENDATIONS;
DEPRESSION; ATTACKS; PLASMA
AB BACKGROUND: A physician survey conducted in the United States between October 2009 and February 2010 revealed wide variability in hereditary angioedema (HAE) management.
OBJECTIVE: A follow-up survey was conducted to assess the impact of newly available treatment options and investigate changes in HAE care patterns.
METHODS: Between March and June 2013, 6570 physicians were contacted, of whom, 245 HAE-treating physicians responded. Participants completed a 46-question online survey thatwas closely patterned after the initial survey. Although most data were analyzed descriptively, selected questions underwent statistical analysis to evaluate differences in treatment patterns between the 2 surveys.
RESULTS: Compared with the prior survey, this follow-up survey found that the proportion of physicians who reported danazol as the preferred long-term prophylaxis agent declined from 56% to 23% (P < .00005); conversely, C1-esterase inhibitor increased in this category (20% to 57%; P < .00005). The percentage of attacks self-treated at home increased from 8% to 27% (P < .00005). Decreases were observed in emergency department visits (61% to 54%; P = not significant) and hospitalizations (13% to 3%; P = .0001) for HAE attacks. The percentage of patients perceived by physicians to be very satisfied with HAE treatment increased from 13% to 40% (P < .00005). In 2013, convenience was reported more frequently as an important patient factor that drove long-term prophylaxis choice (27% vs 10%; P < .00005), whereas adverse effects were cited less frequently (16% vs 42%; P < .00005); in both surveys, cost and/or insurance coverage was the greatest driver in this category (43% and 46%).
CONCLUSION: Analysis of these findings suggests that the change in HAE treatment has increased self-treatment at home, decreased emergency department visits and/or hospitalizations, and provided greater patient satisfaction. (C) 2014 American Academy of Allergy, Asthma & Immunology
C1 [Riedl, Marc A.] Univ Calif San Diego, Dept Med, Div Allergy Immunol & Rheumatol, La Jolla, CA 92039 USA.
[Banerji, Aleena] Massachusetts Gen Hosp, Dept Med, Allergy & Immunol, Boston, MA 02114 USA.
[Gower, Richard] Marycliff Allergy Specialists, Spokane, WA USA.
RP Riedl, MA (reprint author), Univ Calif San Diego, Stein Clin Res Bldg,9500 Gilman Dr,Mail Code 0732, La Jolla, CA 92039 USA.
EM mriedl@ucsd.edu
FU CSL Behring
FX Frank Rodino, MHS, PA, and Sandra Westra, PharmD, of Churchill
Communications (Maplewood, NJ) assisted with the conduct of the survey
and manuscript preparation, funded by CSL Behring. Statistical analysis
was conducted by Thomas R. Sexton, PhD (Stony Brook University, Stony
Brook, NY), also funded by CSL Behring. The authors retained full
control over data interpretation and manuscript content.
NR 35
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD MAR-APR
PY 2015
VL 3
IS 2
BP 220
EP 227
DI 10.1016/j.jaip.2014.08.017
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA CH7JI
UT WOS:000354211800010
PM 25609328
ER
PT J
AU Blumenthal, KG
Wickner, PG
Lau, JJ
Zhou, L
AF Blumenthal, Kimberly G.
Wickner, Paige G.
Lau, Jason J.
Zhou, Li
TI Stevens-Johnson syndrome and toxic epidermal necrolysis: A
cross-sectional analysis of patients in an integrated allergy repository
of a large health care system
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Letter
ID DRUGS; MULTIFORME
C1 [Blumenthal, Kimberly G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Div Rheumatol Allergy & Immunol, Boston, MA USA.
[Wickner, Paige G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA.
[Lau, Jason J.; Zhou, Li] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA.
[Zhou, Li] Partners Healthcare Syst, Partners eCare, Clin Informat, Boston, MA USA.
RP Blumenthal, KG (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Cox 201 Allergy Associates, Boston, MA 02114 USA.
EM kblumenthal1@partners.org
OI Blumenthal, Kimberly/0000-0003-4773-9817
FU AHRQ HHS [R01 HS022728, 1R01HS022728-01]; NHLBI NIH HHS [T32 HL116275]
NR 12
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD MAR-APR
PY 2015
VL 3
IS 2
BP 277
EP +
DI 10.1016/j.jaip.2014.10.002
PG 5
WC Allergy; Immunology
SC Allergy; Immunology
GA CH7JI
UT WOS:000354211800020
PM 25609329
ER
PT J
AU Bortfeld, T
Torresin, A
Fiorino, C
Andreo, P
Gagliardi, G
Jeraj, R
Muren, LP
Paiusco, M
Thwaites, D
Knoos, T
AF Bortfeld, Thomas
Torresin, Alberto
Fiorino, Claudio
Andreo, Pedro
Gagliardi, Giovanna
Jeraj, Robert
Muren, Ludvig P.
Paiusco, Marta
Thwaites, David
Knoos, Tommy
TI The research versus clinical service role of medical physics
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Editorial Material
ID FUTURE
C1 [Bortfeld, Thomas] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Bortfeld, Thomas] Harvard Univ, Sch Med, Boston, MA USA.
[Torresin, Alberto] Osped Niguarda CaGranda Hosp, Dept Med Phys, Milan, Italy.
[Fiorino, Claudio] Ist Sci San Raffaele, Dept Med Phys, I-20132 Milan, Italy.
[Andreo, Pedro] Stockholm Univ, Karolinska Univ Hosp, Med Radiat Phys, Stockholm, Sweden.
[Gagliardi, Giovanna] Karolinska Univ Hosp, Dept Med Phys, Sect Radiotherapy Phys & Engn, Karolinska, Sweden.
[Jeraj, Robert] Univ Wisconsin, Dept Med Phys, Madison, WI 53706 USA.
[Muren, Ludvig P.] Aarhus Univ, Aarhus Univ Hosp, Dept Med Phys, Aarhus, Denmark.
[Paiusco, Marta] IOV, Dept Med Phys, Padua, Italy.
[Thwaites, David] Univ Sydney, Inst Med Phys, Sydney, NSW 2006, Australia.
[Knoos, Tommy] Skane Univ Hosp, Radiat Phys, Malmo, Sweden.
[Knoos, Tommy] Lund Univ, Dept Med Radiat Phys, Clin Sci, S-22100 Lund, Sweden.
RP Fiorino, C (reprint author), Ist Sci San Raffaele, Dept Med Phys, I-20132 Milan, Italy.
NR 11
TC 3
Z9 3
U1 0
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-8140
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD MAR
PY 2015
VL 114
IS 3
BP 285
EP 288
DI 10.1016/j.radonc.2015.02.003
PG 4
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CH0UL
UT WOS:000353737800001
PM 25727681
ER
PT J
AU Coroller, TP
Grossmann, P
Hou, Y
Velazquez, ER
Leijenaar, RTH
Hermann, G
Lambin, P
Haibe-Kains, B
Mak, RH
Aerts, HJWL
AF Coroller, Thibaud P.
Grossmann, Patrick
Hou, Ying
Velazquez, Emmanuel Rios
Leijenaar, Ralph T. H.
Hermann, Gretchen
Lambin, Philippe
Haibe-Kains, Benjamin
Mak, Raymond H.
Aerts, Hugo J. W. L.
TI CT-based radiomic signature predicts distant metastasis in lung
adenocarcinoma
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Article
DE Radiomics; Lung adenocarcinoma; NSCLC; Quantitative imaging; Biomarkers;
Distant metastasis
ID PHASE-III TRIAL; TEXTURE ANALYSIS; TUMOR VOLUME; FDG-PET;
PROGNOSTIC-FACTOR; ONCOLOGY-GROUP; CANCER; RADIOTHERAPY; STAGE; SURVIVAL
AB Background and purpose: Radiomics provides opportunities to quantify the tumor phenotype non-invasively by applying a large number of quantitative imaging features. This study evaluates computed-tomography (CT) radiomic features for their capability to predict distant metastasis (DM) for lung adenocarcinoma patients.
Material and methods: We included two datasets: 98 patients for discovery and 84 for validation. The phenotype of the primary tumor was quantified on pre-treatment CT-scans using 635 radiomic features. Univariate and multivariate analysis was performed to evaluate radiomics performance using the concordance index (CI).
Results: Thirty-five radiomic features were found to be prognostic (CI > 0.60, FDR < 5%) for DM and twelve for survival. It is noteworthy that tumor volume was only moderately prognostic for DM (CI = 0.55, p-value = 2.77 x 10(-5)) in the discovery cohort. A radiomic-signature had strong power for predicting DM in the independent validation dataset (CI = 0.61, p-value = 1.79 x 10(-17)). Adding this radiomic-signature to a clinical model resulted in a significant improvement of predicting DM in the validation dataset (p-value = 1.56 x 10(-11)).
Conclusions: Although only basic metrics are routinely quantified, this study shows that radiomic features capturing detailed information of the tumor phenotype can be used as a prognostic biomarker for clinically-relevant factors such as DM. Moreover, the radiomic-signature provided additional information to clinical data. (c) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Coroller, Thibaud P.; Grossmann, Patrick; Hou, Ying; Velazquez, Emmanuel Rios; Hermann, Gretchen; Mak, Raymond H.; Aerts, Hugo J. W. L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Brigham & Womens Hosp, Boston, MA 02115 USA.
[Aerts, Hugo J. W. L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiol,Brigham & Womens Hosp, Boston, MA 02115 USA.
[Coroller, Thibaud P.; Grossmann, Patrick; Leijenaar, Ralph T. H.; Lambin, Philippe; Aerts, Hugo J. W. L.] Maastricht Univ, Dept Radiat Oncol MAASTRO, GROW Res Inst, NL-6200 MD Maastricht, Netherlands.
[Haibe-Kains, Benjamin] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Haibe-Kains, Benjamin] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
RP Coroller, TP (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp, 450 Brookline Ave,JF518, Boston, MA 02115 USA.
EM tcoroller@lroc.harvard.edu; Hugo_Aerts@dfci.harvard.edu
RI Haibe-Kains, Benjamin/D-3702-2011; Aerts, Hugo/P-6350-2015;
OI Haibe-Kains, Benjamin/0000-0002-7684-0079; Aerts,
Hugo/0000-0002-2122-2003; , Patrick/0000-0003-4918-6902; Coroller,
Thibaud/0000-0001-7662-8724
FU National Institute of Health [NIH-USA U01CA190234]; QuIC-ConCePT project
- EFPI A companies; Innovative Medicine Initiative Joint Undertaking
(IMI JU) [115151]; Dutch technology Foundation STW [10696 DuCAT];
Technology Programme of the Ministry of Economic Affairs; EU 7th
framework program (EURECA, ARTFORCE); NGI Pre-Seed Grant [93612005];
Kankeronderzoekfonds Limburg from the Health Foundation Limburg; Dutch
Cancer Society [KWF UM 2011-5020, KWF UM 2009-4454, KWF MAC 2013-6089]
FX Authors acknowledge financial support from the National Institute of
Health (NIH-USA U01CA190234). Authors acknowledge financial support from
the QuIC-ConCePT project, which is partly funded by EFPI A companies and
the Innovative Medicine Initiative Joint Undertaking (IMI JU) under
Grant Agreement No. 115151. This research is also supported by the Dutch
technology Foundation STW (Grant No. 10696 DuCAT), which is the applied
science division of NWO, and the Technology Programme of the Ministry of
Economic Affairs. Authors also acknowledge financial support from EU 7th
framework program (EURECA, ARTFORCE), NGI Pre-Seed Grant (No. 93612005),
Kankeronderzoekfonds Limburg from the Health Foundation Limburg and the
Dutch Cancer Society (KWF UM 2011-5020, KWF UM 2009-4454, KWF MAC
2013-6089).
NR 39
TC 43
Z9 46
U1 9
U2 43
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-8140
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD MAR
PY 2015
VL 114
IS 3
BP 345
EP 350
DI 10.1016/j.radonc.2015.02.015
PG 6
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CH0UL
UT WOS:000353737800011
PM 25746350
ER
PT J
AU Bergen, SE
Howrigan, D
Sebat, J
Neale, B
Kendler, K
AF Bergen, Sarah E.
Howrigan, Daniel
Sebat, Jonathan
Neale, Benjamin
Kendler, Kenneth
TI CNVS AND POLYGENIC SCORES INTERACT TO CONTRIBUTE TO SCHIZOPHRENIA RISK
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Bergen, Sarah E.] Karolinska Inst, Med Epidemiol & Biostat, Stockholm, Sweden.
[Kendler, Kenneth] Virginia Commonwealth Univ, Virginia Inst Psychiat Genet, Richmond, VA USA.
[Sebat, Jonathan] Univ Calif San Diego, Psychiat & Cellular & Mol Med, San Diego, CA 92103 USA.
[Howrigan, Daniel; Neale, Benjamin] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Bergen, Sarah E.; Neale, Benjamin] Broad Inst, Stanley Ctr Psychiat Res, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2118820
BP S198
EP S198
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200523
ER
PT J
AU Blokland, GAM
Petryshen, TL
AF Blokland, Gabriella Antonina Maria
Petryshen, Tracey Lynn
TI BIG SCIENCE: HARMONIZING NEUROPSYCHOLOGICAL MEASURES FROM MULTIPLE
SAMPLES FOR GENETIC ASSOCIATION ANALYSIS IN THE GENUS CONSORTIUM
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Blokland, Gabriella Antonina Maria; Petryshen, Tracey Lynn] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Ctr Human Genet Res, Psychiat & Neurodev Genet Unit,Dept Psychiat, Boston, MA USA.
[Blokland, Gabriella Antonina Maria; Petryshen, Tracey Lynn] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA 02139 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2118755
BP S69
EP S69
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200185
ER
PT J
AU Cai, HL
Li, HD
Yao, JK
AF Cai, HuaLin
Li, HuanDe
Yao, Jeffrey K.
TI A POTENTIAL MECHANISM UNDERLYING ATYPICAL ANTIPSYCHOTIC INDUCED LIPID
DISTURBANCES
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Cai, HuaLin; Li, HuanDe] Cent S Univ, Xiangya Hosp 2, Changsha, Hunan, Peoples R China.
[Cai, HuaLin; Yao, Jeffrey K.] Cent S Univ, Inst Clin Pharm, Changsha, Hunan, Peoples R China.
[Cai, HuaLin; Yao, Jeffrey K.] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA USA.
[Cai, HuaLin; Yao, Jeffrey K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2095377
BP S124
EP S125
PG 2
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200330
ER
PT J
AU Carrion, RE
John, M
Addington, J
Bearden, CE
Cadenhead, K
Mathalon, D
McGlashan, T
Perkins, D
Seidman, LJ
Tsuang, M
Walker, E
Woods, S
Cannon, T
Cornblatt, B
AF Carrion, Ricardo E.
John, Majnu
Addington, Jean
Bearden, Carrie E.
Cadenhead, Kristin
Mathalon, Daniel
McGlashan, Thomas
Perkins, Diana
Seidman, Larry J.
Tsuang, Ming
Walker, Elaine
Woods, Scott
Cannon, Tyrone
Cornblatt, Barbara
TI THE DEVELOPMENTAL COURSE OF SOCIAL AND ROLE FUNCTIONING IN THE PRODROMAL
STAGES OF PSYCHOSIS
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Carrion, Ricardo E.; John, Majnu; Cornblatt, Barbara] Zucker Hillside Hosp, Psychiat Res, Glen Oaks, NE USA.
[Carrion, Ricardo E.; Cornblatt, Barbara] Hofstra North Shore LIJ Sch Med, Psychiat, Hempstead, NY USA.
[John, Majnu] Feinstein Inst Med Res, Ctr Psychiat Neurosci, Manhasset, NY USA.
[Addington, Jean] Univ Calgary, Psychiat, Calgary, AB T2N 1N4, Canada.
[Bearden, Carrie E.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
[Cadenhead, Kristin] Univ Calif San Diego, Psychiat, San Diego, CA 92103 USA.
[McGlashan, Thomas; Woods, Scott; Cannon, Tyrone] Yale Univ, Psychol, New Haven, CT USA.
[McGlashan, Thomas; Woods, Scott; Cannon, Tyrone] Yale Univ, Psychiat, New Haven, CT USA.
[Mathalon, Daniel] Univ Calif San Francisco, Psychiat, San Francisco, CA 94143 USA.
[Perkins, Diana] Univ N Carolina, Psychiat, Chapel Hill, NC USA.
[Seidman, Larry J.; Tsuang, Ming] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Psychiat, Boston, MA 02215 USA.
[Seidman, Larry J.; Tsuang, Ming] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Walker, Elaine] Emory Univ, Psychol, Atlanta, GA 30322 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2118187
BP S164
EP S164
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200431
ER
PT J
AU Chen, Y
Maher, S
Ekstrom, T
Holt, D
Ongur, D
AF Chen, Yue
Maher, Stephen
Ekstrom, Tor
Holt, Daphne
Ongur, Dost
TI THE FACE PROCESSING SYSTEM IN SCHIZOPHRENIA DOES NOT POSSESS A CORE
FUNCTIONAL PROPERTY: FACE-SELECTIVITY
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Chen, Yue; Maher, Stephen; Ekstrom, Tor; Ongur, Dost] Harvard Univ, McLean Hosp, Sch Med, Belmont, MA USA.
[Holt, Daphne] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2083578
BP S71
EP S71
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200189
ER
PT J
AU Chung, Y
Jacobson, A
He, G
van Erp, T
McEwen, S
Addington, J
Bearden, C
Cadenhead, K
Cornblatt, B
Mathalon, D
McGlashan, T
Perkins, D
Seidman, LJ
Tsuang, M
Walker, E
Woods, S
Heinssen, R
Cannon, T
AF Chung, Yoonho
Jacobson, Aims
He, George
van Erp, T.
McEwen, Sarah
Addington, Jean
Bearden, Carrie
Cadenhead, Kristin
Cornblatt, Barbara
Mathalon, Daniel
McGlashan, Thomas
Perkins, Diana
Seidman, Larry J.
Tsuang, Ming
Walker, Elaine
Woods, Scott
Heinssen, Robert
Cannon, Tyrone
TI PRODROMAL SYMPTOM SEVERITY PREDICTS ACCELERATED GRAY MATTER REDUCTION
AND THIRD VENTRICLE EXPANSION AMONG CLINICALLY HIGH RISK YOUTH
DEVELOPING PSYCHOTIC DISORDERS
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Chung, Yoonho; Jacobson, Aims; He, George; Cannon, Tyrone] Yale Univ, Psychol, New Haven, CT USA.
[van Erp, T.] UC Irvine, Psychiat & Human Behav, Irvine, CA USA.
[McEwen, Sarah; Bearden, Carrie] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
[McEwen, Sarah; Bearden, Carrie] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
[Addington, Jean] Univ Calgary, Psychiat, Calgary, AB, Canada.
[Cadenhead, Kristin; Tsuang, Ming] UCSD San Diego, Psychiat, La Jolla, CA USA.
[Cornblatt, Barbara] Zucker Hillside, Psychiat, Glen Oaks, NY USA.
[Mathalon, Daniel] UCSF, Psychiany, San Francisco, CA USA.
[McGlashan, Thomas; Woods, Scott] Yale Univ, Psychiat, New Haven, CT USA.
[Perkins, Diana] Univ N Carolina, Psychiat, Chapel Hill, NC USA.
[Perkins, Diana] Univ N Carolina, Renaissance Comp Inst, Chapel Hill, NC USA.
[Seidman, Larry J.] Beth Israel Deaconess Med Ctr, Psychiat, Cambridge, MA USA.
[Seidman, Larry J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Seidman, Larry J.] Massachusetts Gen Hosp, Psychiat, Cambridge, MA USA.
[Walker, Elaine] Emory Univ, Psychol, Atlanta, GA 30322 USA.
[Heinssen, Robert] NIMH, Div Treatment & Prevent Res, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
BP S249
EP S249
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200658
ER
PT J
AU Cortes-Briones, JA
Cahill, JD
Skosnik, PD
Mathalon, DH
Williams, A
Sewell, RA
Roach, BJ
Ford, JM
Ranganathan, M
D'Souza, DC
AF Cortes-Briones, Jose A.
Cahill, John Daniel
Skosnik, Patrick David
Mathalon, Daniel H.
Williams, Ashley
Sewell, Richard Andrew
Roach, Brian J.
Ford, Judith M.
Ranganathan, Mohini
D'Souza, Deepak Cyril
TI INCREASED NEURAL NOISE IS RELATED TO THE PSYCHOSIS-LIKE EFFECTS OF THC
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Cortes-Briones, Jose A.; Cahill, John Daniel; Skosnik, Patrick David; Williams, Ashley; Sewell, Richard Andrew; Ranganathan, Mohini; D'Souza, Deepak Cyril] VA Connecticut Healthcare Syst, Psychiat Serv, West Haven, CT USA.
[Cortes-Briones, Jose A.; Cahill, John Daniel; Skosnik, Patrick David; Williams, Ashley; Sewell, Richard Andrew; Ranganathan, Mohini; D'Souza, Deepak Cyril] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA.
[Mathalon, Daniel H.; Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Mathalon, Daniel H.; Roach, Brian J.; Ford, Judith M.] San Francisco VA Med Ctr, Mental Hlth Serv Line, San Francisco, CA USA.
RI Skosnik, Patrick/D-6466-2016
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2119314
BP S16
EP S16
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200041
ER
PT J
AU Curcio, N
Mervis, JE
Bisoglio, J
Fiszdon, JM
Reddy, F
Choi, J
AF Curcio, Nicholas
Mervis, Joshua E.
Bisoglio, Joseph
Fiszdon, Joanna M.
Reddy, Felice
Choi, Jimmy
TI ANTICIPATORY PLEASURE AND ITS IMPLICATIONS ON LEARNING IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Curcio, Nicholas; Mervis, Joshua E.; Bisoglio, Joseph; Choi, Jimmy] Columbia Univ, Neurocognit Rehabil Res Lab, Med Ctr, New York, NY USA.
[Fiszdon, Joanna M.] Yale Univ, Sch Med, VA Connecticut Healthcare Syst, New Haven, CT USA.
[Reddy, Felice] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Reddy, Felice] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2118001
BP S166
EP S167
PG 2
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200438
ER
PT J
AU Davis, MC
Wynn, JK
Weiner, K
Hellemann, GS
Green, MF
Marder, SR
AF Davis, Michael C.
Wynn, J. K.
Weiner, Katherine
Hellemann, Gerhard S.
Green, Michael F.
Marder, Stephen R.
TI RANDOMIZED CONTROLLED TRIAL OF N-ACETYLCYSTEINE FOR COGNITION AND EEG
CORRELATES IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Davis, Michael C.] Baylor Coll Med, Psychiat & Behav Sci, Houston, TX 77030 USA.
[Wynn, J. K.; Weiner, Katherine; Hellemann, Gerhard S.; Green, Michael F.; Marder, Stephen R.] UCLA Semel Inst, Psychiat & Biobehav Sci, Los Angeles, CA USA.
[Wynn, J. K.; Weiner, Katherine; Green, Michael F.; Marder, Stephen R.] VA Greater Los Angeles, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA.
[Davis, Michael C.] Michael E DeBakey VA Med Ctr, Mental Hlth Care Line, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2086799
BP S308
EP S309
PG 2
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200812
ER
PT J
AU del Re, EC
Gao, Y
Eckbo, R
Petryshen, TL
Blokland, GAM
Seidman, LJ
Mesholam-Gately, RI
Goldstein, J
Kubicki, M
McCarley, RW
Shenton, ME
Bouix, S
AF del Re, Elisabetta C.
Gao, Yi
Eckbo, Ryan
Petryshen, Tracey L.
Blokland, Gabriella A. M.
Seidman, Larry J.
Mesholam-Gately, Raquelle I.
Goldstein, Jill
Kubicki, Marek
McCarley, Robert W.
Shenton, Martha E.
Bouix, Sylvain
TI MULTI-ATLAS BRAIN MASKING FOR MRI ANALYSIS IN CONTROLS AND
SCHIZOPHRENIA: COMPARISON WITH OTHER MASKING TECHNIQUES AND MANUAL
MASKING
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [del Re, Elisabetta C.; McCarley, Robert W.; Shenton, Martha E.; Bouix, Sylvain] VA Boston Healthcare Syst, Psychiat, Brockton, MA USA.
[del Re, Elisabetta C.; McCarley, Robert W.; Shenton, Martha E.; Bouix, Sylvain] Harvard Univ, Sch Med, Brockton, MA 02401 USA.
[del Re, Elisabetta C.; Gao, Yi; Eckbo, Ryan; Kubicki, Marek; Shenton, Martha E.; Bouix, Sylvain] Harvard Univ, Brigham & Womens Hosp, Sch Med, Psychiat, Boston, MA 02115 USA.
[Gao, Yi; Seidman, Larry J.; Mesholam-Gately, Raquelle I.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Massachusetts Mental Hlth Ctr,Publ Psychiat Div, Boston, MA 02215 USA.
[Petryshen, Tracey L.; Blokland, Gabriella A. M.] Massachusetts Gen Hosp, Dept Psychiat, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
[Petryshen, Tracey L.; Blokland, Gabriella A. M.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Goldstein, Jill] Harvard Univ, Brigham & Womens Hosp, Sch Med, Psychiat & Med, Boston, MA 02115 USA.
[Petryshen, Tracey L.; Blokland, Gabriella A. M.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA.
[Seidman, Larry J.; Goldstein, Jill] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Psychiat, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2117752
BP S252
EP S253
PG 2
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200668
ER
PT J
AU DeLisi, LE
AF DeLisi, Lynn Eleanor
TI LANGUAGE PATHWAYS IN THE BRAIN AND THEIR BASIS FOR THE SYMPTOMS OF
SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [DeLisi, Lynn Eleanor] Va Boston Healthcare, Psychiat, Boston, MA USA.
[DeLisi, Lynn Eleanor] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2147964
BP S222
EP S222
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200587
ER
PT J
AU Demyanovich, H
Feldman, S
Jackson, J
Eaton, W
Cascella, NG
Fasano, A
Santora, D
Sullivan, KM
Raley, H
McMahon, R
Carpenter, WT
Kelly, D
AF Demyanovich, Haley
Feldman, Stephanie
Jackson, Jessica
Eaton, William
Cascella, Nicola G.
Fasano, Alessio
Santora, Debby
Sullivan, Kelli Marie
Raley, Heather
McMahon, Robert
Carpenter, William T.
Kelly, Deanna
TI THE RELATIONSHIP BETWEEN GLUTEN SENSITIVITY AND PSYCHIATRIC SYMPTOMS IN
PEOPLE WITH SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Demyanovich, Haley; Feldman, Stephanie; Sullivan, Kelli Marie; McMahon, Robert; Carpenter, William T.; Kelly, Deanna] Univ Maryland, Maryland Psychiat Res Ctr, Baltimore, MD 21201 USA.
[Jackson, Jessica] Temple Univ, Sch Med, Philadelphia, PA 19122 USA.
[Eaton, William] Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA.
[Cascella, Nicola G.] Sheppard Pratt Hosp, Neuropsychiat, Baltimore, MD USA.
[Fasano, Alessio] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Santora, Debby] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Raley, Heather] NIDA, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2092944
BP S17
EP S17
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200043
ER
PT J
AU Glynn, SM
Gingerich, S
Mueser, KT
Cather, C
Penn, D
AF Glynn, Shirley M.
Gingerich, Susan
Mueser, Kim T.
Cather, Cori
Penn, David
TI THE ROLE OF FAMILY INTERVENTION IN COORDINATED SPECIALTY CARE FOR FIRST
EPISODE PSYCHOSIS
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Glynn, Shirley M.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
[Penn, David] UNC, Psychol, Chapel Hill, NC USA.
[Cather, Cori] Massachusetts Gen Hosp, Psychiat, Boston, MA 02114 USA.
[Cather, Cori] Harvard Univ, Med Schoo, Boston, MA 02115 USA.
[Mueser, Kim T.] Boston Univ, Ctr Psychiat Rehabil, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2141449
BP S173
EP S173
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200455
ER
PT J
AU Greenwood, TA
Lazzeroni, LC
Calkins, ME
Freedman, R
Green, MF
Gur, RE
Gur, RC
Light, GA
Nuechterlein, KH
Olincy, A
Radant, AD
Seidman, LJ
Siever, LJ
Silverman, JM
Stone, WS
Sugar, CA
Swerdlow, NR
Tsuang, DW
Tsuang, MT
Turetsky, BI
Braff, DL
AF Greenwood, Tiffany A.
Lazzeroni, Laura C.
Calkins, Monica E.
Freedman, Robert
Green, Michael F.
Gur, Raquel E.
Gur, Ruben C.
Light, Gregory A.
Nuechterlein, Keith H.
Olincy, Ann
Radant, Allen D.
Seidman, Larry J.
Siever, Larry J.
Silverman, Jeremy M.
Stone, William S.
Sugar, Catherine A.
Swerdlow, Neal R.
Tsuang, Debby W.
Tsuang, Ming T.
Turetsky, Bruce I.
Braff, David L.
TI GENETIC ASSESSMENT OF CANDIDATE ENDOPHENOTYPES FROM THE CONSORTIUM ON
THE GENETICS OF SCHIZOPHRENIA FAMILY STUDY
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Greenwood, Tiffany A.; Light, Gregory A.; Swerdlow, Neal R.; Tsuang, Ming T.; Braff, David L.] Univ Calif San Diego, Psychiat, La Jolla, CA 92093 USA.
[Lazzeroni, Laura C.] Stanford Univ, Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Calkins, Monica E.; Gur, Raquel E.; Gur, Ruben C.; Turetsky, Bruce I.] Univ Penn, Psychiat, Philadelphia, PA 19104 USA.
[Freedman, Robert; Olincy, Ann] Univ Colorado, Hlth Sci Ctr, Psychiat, Denver, CO USA.
[Green, Michael F.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Psychiat & Biobehav Sci, Los Angeles, CA USA.
[Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Light, Gregory A.] VA San Diego Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 22, San Diego, CA USA.
[Radant, Allen D.; Tsuang, Debby W.] Univ Washington, Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Radant, Allen D.; Tsuang, Debby W.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Seidman, Larry J.; Stone, William S.] Harvard Univ, Sch Med, Psychiat, Boston, MA USA.
[Seidman, Larry J.; Stone, William S.] Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Publ Psychiat Div, Boston, MA 02215 USA.
[Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, Psychiat, New York, NY USA.
[Siever, Larry J.; Silverman, Jeremy M.] James J Peters VA Med Ctr, New York, NY USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Biostat, Los Angeles, CA 90024 USA.
[Tsuang, Ming T.] Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2117107
BP S203
EP S203
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200538
ER
PT J
AU Haas, GL
Honsaker, SM
Horton, LE
Luther, JF
Flounders, MW
AF Haas, Gretchen L.
Honsaker, Sarah M.
Horton, Leslie E.
Luther, James F.
Flounders, Matthew W.
TI DOES GENDER EXERT A MODERATING INFLUENCE ON SOCIAL PERSPECTIVE-TAKING IN
SCHIZOPHRENIA?
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Haas, Gretchen L.] Univ Pittsburgh, Psychiat & Psychol, Pittsburgh, PA USA.
[Horton, Leslie E.; Flounders, Matthew W.] Univ Pittsburgh, Psychiat, Pittsburgh, PA USA.
[Haas, Gretchen L.; Honsaker, Sarah M.; Horton, Leslie E.; Luther, James F.; Flounders, Matthew W.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA.
[Luther, James F.] Univ Pittsburgh, Epidemiol, Pittsburgh, PA USA.
[Honsaker, Sarah M.] Univ Pittsburgh, Psychol, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2117931
BP S77
EP S77
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200206
ER
PT J
AU Haut, KM
Addington, J
Bearden, CE
Cadenhead, K
Cornblatt, B
Mathalon, D
McGlashan, TH
Perkins, DO
Seidman, LJ
Tsuang, M
Walker, E
Woods, S
Heinssen, R
Cannon, T
AF Haut, Kristen M.
Addington, Jean
Bearden, Carrie E.
Cadenhead, Kristin
Cornblatt, Barbara
Mathalon, Daniel
McGlashan, Thomas H.
Perkins, Diana O.
Seidman, Larry J.
Tsuang, Ming
Walker, Elaine
Woods, Scott
Heinssen, Robert
Cannon, Tyrone
TI REDUCED WHITE MATTER INTEGRITY IN A MULTISITE LONGITUDINAL STUDY OF
YOUTH AT RISK FOR PSYCHOSIS
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Haut, Kristen M.; Cannon, Tyrone] Yale Univ, Psychol, New Haven, CT USA.
[Addington, Jean] Univ Calgary, Hotchkiss Brain Inst, Psychiat, Calgary, AB T2N 1N4, Canada.
[Bearden, Carrie E.] Univ Calif Los Angeles, Psychiat & Biobehav Sci & Psychol, Los Angeles, CA USA.
[Cadenhead, Kristin] Univ Calif San Diego, Psychiat, San Diego, CA 92103 USA.
[McGlashan, Thomas H.; Woods, Scott; Cannon, Tyrone] Yale Univ, Psychiat, New Haven, CT USA.
[Cornblatt, Barbara] Zucker Hillside Hosp, Psychiat, Long Isl City, NY USA.
[Mathalon, Daniel] Univ Calif San Francisco, Psychiat, San Francisco, CA 94143 USA.
[Perkins, Diana O.] Univ N Carolina, Psychiat, Chapel Hill, NC USA.
[Seidman, Larry J.] Beth Israel Deaconess Med Ctr, Harvard Med Sch, Psychiat, Boston, MA 02215 USA.
[Seidman, Larry J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Tsuang, Ming] Univ Calif San Diego, Ctr Behav Genom, Inst Genom Med, Psychiat, La Jolla, CA 92093 USA.
[Walker, Elaine] Emory Univ, Psychol & Psychiat, Atlanta, GA 30322 USA.
[Heinssen, Robert] NIMH, Div Adulta Translat Res & Treatment Dev, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2083088
BP S257
EP S257
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200679
ER
PT J
AU Hirano, Y
Oribe, N
Onitsuka, T
Kanba, S
Mesholam-Gately, R
Seidman, LJ
Niznikiewicz, MA
McCarley, RW
Spencer, KM
AF Hirano, Yoji
Oribe, Naoya
Onitsuka, Toshiaki
Kanba, Shigenobu
Mesholam-Gately, Raquelle
Seidman, Larry J.
Niznikiewicz, Margaret A.
McCarley, Robert W.
Spencer, Kevin M.
TI PROGRESSIVE AUDITORY GAMMA OSCILLATION DEFICIT IN CLINICAL HIGH-RISK
SUBJECTS AND FIRST-EPISODE SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Hirano, Yoji; Oribe, Naoya; Spencer, Kevin M.] VA Boston Healthcare Syst, Neural Dynam Lab, Psychiat, Boston, MA USA.
[Hirano, Yoji; Oribe, Naoya; Mesholam-Gately, Raquelle; Seidman, Larry J.; Spencer, Kevin M.] Harvard Univ, Sch Med, Boston, MA USA.
[Hirano, Yoji; Oribe, Naoya; Onitsuka, Toshiaki; Kanba, Shigenobu] Kyushu Univ, Grad Sch Med Sci, Neuropsychiat, Fukuoka 812, Japan.
[Mesholam-Gately, Raquelle; Seidman, Larry J.] Beth Israel Deaconess Med Ctr, Psychiat, Boston, MA 02215 USA.
[Seidman, Larry J.] Massachusetts Gen Hosp, Psychiat, Boston, MA 02114 USA.
[Niznikiewicz, Margaret A.; McCarley, Robert W.] VA Boston Healthcare Syst, Lab Neurosci, Psychiat, Brockton, MA USA.
[Niznikiewicz, Margaret A.; McCarley, Robert W.] Harvard Univ, Sch Med, Brockton, MA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2087079
BP S19
EP S20
PG 2
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200051
ER
PT J
AU Holt, D
Boeke, E
Coombs, G
DeCross, S
Rauch, S
Tootell, R
AF Holt, Daphne
Boeke, Emily
Coombs, Garth
DeCross, Stephanie
Rauch, Scott
Tootell, Roger
TI A SENSORY-MOTOR SYSTEM MEDIATING LOWER AND HIGHER-LEVEL SOCIAL DISTANCE
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Holt, Daphne; DeCross, Stephanie] Massachusetts Gen Hosp, Psychiat, Boston, MA 02114 USA.
[Holt, Daphne; Rauch, Scott; Tootell, Roger] Harvard Univ, Sch Med, Boston, MA USA.
[Boeke, Emily] NYU, Psychol, New York, NY USA.
[Coombs, Garth] Harvard Univ, Psychol, Cambridge, MA 02138 USA.
[Rauch, Scott] McLean Hosp, Belmont, MA 02178 USA.
[Tootell, Roger] Massachusetts Gen Hosp, Radiol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2117720
BP S78
EP S78
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200209
ER
PT J
AU Horan, WP
Marder, SR
Green, M
AF Horan, William Powers
Marder, Stephen R.
Green, Michael
TI FURTHER VALIDATION OF A "SECOND GENERATION" CLINICAL ASSESSMENT MEASURE
OF NEGATIVE SYMPTOMS
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Horan, William Powers; Marder, Stephen R.; Green, Michael] VA Greater Los Angeles Healthcare Syst, Psychiat, Los Angeles, CA USA.
[Horan, William Powers; Marder, Stephen R.; Green, Michael] Univ Calif Los Angeles, Psychiat & Biobehav Sci, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2096158
BP S108
EP S109
PG 2
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200291
ER
PT J
AU Horton, LE
Michael, VC
Haas, GL
AF Horton, Leslie E.
Michael, V. C.
Haas, Gretchen L.
TI EMOTION-BASED DECISION-MAKING IN THOSE AT HIGH RISK FOR SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Horton, Leslie E.; Michael, V. C.; Haas, Gretchen L.] Univ Pittsburgh, Sch Med, Psychiat, Pittsburgh, PA USA.
[Haas, Gretchen L.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2081626
BP S49
EP S49
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200132
ER
PT J
AU Jimenez, AM
Lee, J
Wynn, JK
Horan, WP
Green, MF
AF Jimenez, Amy M.
Lee, Junghee
Wynn, J. K.
Horan, William Powers
Green, Michael F.
TI SELF-REFERENTIAL MEMORY IN SCHIZOPHRENIA: AN FMRI STUDY
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Jimenez, Amy M.; Lee, Junghee; Wynn, J. K.; Horan, William Powers; Green, Michael F.] Vet Affairs Greater Los Angeles Healthcare Syst, Desert Pacific MIRECC, Los Angeles, CA USA.
[Jimenez, Amy M.; Lee, Junghee; Wynn, J. K.; Horan, William Powers; Green, Michael F.] Univ Calif Los Angeles, Psychiat & Biobehav Sci, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2115433
BP S81
EP S81
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200216
ER
PT J
AU Kern, RS
Zarate, R
Glynn, SM
Smith, KM
Reddy, F
Mitchell, SS
Turner, LR
Iglesias, J
Maes, L
McNair, A
Liberman, RP
Kopelowicz, A
Green, MF
AF Kern, Robert S.
Zarate, R.
Glynn, Shirley M.
Smith, K. M.
Reddy, Felice
Mitchell, S. S.
Turner, Luana R.
Iglesias, J.
Maes, L.
McNair, A.
Liberman, R. P.
Kopelowicz, A.
Green, Michael F.
TI THE EFFECTS OF ERRORLESS LEARNING ON WORK OUTCOME IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Kern, Robert S.; Zarate, R.; Glynn, Shirley M.; Smith, K. M.; Mitchell, S. S.; Turner, Luana R.; Iglesias, J.; Maes, L.; McNair, A.; Liberman, R. P.; Kopelowicz, A.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Kern, Robert S.; Glynn, Shirley M.; Reddy, Felice; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Dept Vet Affairs VISN MIRECC 22, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2083573
BP S178
EP S178
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200469
ER
PT J
AU Kikinis, Z
Fitzsimmons, J
Dunn, C
Vu, MA
Makris, N
Bouix, S
Goldstein, J
Mesholam-Gately, RI
Petryshen, T
del Re, EC
Wojcik, J
Seidman, LJ
McCarley, RW
Shenton, ME
Kubicki, M
AF Kikinis, Zora
Fitzsimmons, Jennifer
Dunn, Chandler
Mai-Anh Vu
Makris, Nikos
Bouix, Sylvain
Goldstein, Jill
Mesholam-Gately, Raquelle I.
Petryshen, Tracey
del Re, Elisabetta C.
Wojcik, Joanne
Seidman, Larry J.
McCarley, Robert W.
Shenton, Martha E.
Kubicki, Marek
TI ANTERIOR COMMISSURAL WHITE MATTER FIBER ABNORMALITIES IN FIRST-EPISODE
PSYCHOSIS: A TRACTOGRAPHY STUDY
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Kikinis, Zora; Fitzsimmons, Jennifer; Dunn, Chandler; Mai-Anh Vu; Makris, Nikos; Bouix, Sylvain; Goldstein, Jill; Shenton, Martha E.; Kubicki, Marek] Brigham & Womens Hosp, Psychiat, Boston, MA 02115 USA.
[Makris, Nikos; Petryshen, Tracey; Seidman, Larry J.] Massachusetts Gen Hosp, Psychiat, Charlestown, MA USA.
[Goldstein, Jill] Brigham & Womens Hosp, Med, Boston, MA 02115 USA.
[Mesholam-Gately, Raquelle I.; Wojcik, Joanne; Seidman, Larry J.] Beth Israel Deaconess Med Ctr, Publ Psychiat Div, Boston, MA 02215 USA.
[Petryshen, Tracey] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA.
[del Re, Elisabetta C.; McCarley, Robert W.; Shenton, Martha E.] VA Boston Healthcare Syst, Psychiat, Brockton, MA USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2118903
BP S260
EP S261
PG 2
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200687
ER
PT J
AU Levitt, JJ
Rathi, Y
Raviv, TR
Nestor, PG
Levin, L
McCarley, RW
Shenton, ME
AF Levitt, James J.
Rathi, Yogesh
Raviv, Tammy R.
Nestor, Paul G.
Levin, Laura
McCarley, Robert W.
Shenton, Martha E.
TI FRONTOSTRIATAL DYSCONNECTIVITY IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Levitt, James J.; Nestor, Paul G.; McCarley, Robert W.; Shenton, Martha E.] Harvard Univ, VA Boston Healthcare Syst, Psychiat, Sch Med, Brockton, MA 02401 USA.
[Levitt, James J.; Rathi, Yogesh; Raviv, Tammy R.; Levin, Laura; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Psychiat,Med Sch, Boston, MA 02115 USA.
RI Riklin Raviv, Tammy/A-3462-2013
NR 0
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2086698
BP S263
EP S263
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200694
ER
PT J
AU Lyall, AE
Savadjiev, P
del Re, E
O'Donnell, L
Seidman, LJ
Goldstein, J
Mesholam-Gately, R
Petryshen, T
Wojcik, J
McCarley, RW
Shenton, ME
Kubicki, M
AF Lyall, Amanda E.
Savadjiev, Peter
del Re, Elisabetta
O'Donnell, Lauren
Seidman, Larry J.
Goldstein, Jill
Mesholam-Gately, Raquelle
Petryshen, Tracey
Wojcik, Joanne
McCarley, Robert W.
Shenton, Martha E.
Kubicki, Marek
TI EXPLORING THE RELATIONSHIP OF GRAY AND WHITE MATTER STRUCTURAL PATHOLOGY
IN FIRST-EPISODE SCHIZOPHRENIA THROUGH MUTUAL INFORMATION
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
ID BRAIN-DEVELOPMENT
C1 [Lyall, Amanda E.; Savadjiev, Peter; del Re, Elisabetta; Shenton, Martha E.; Kubicki, Marek] Harvard Univ, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Sch Med, Boston, MA 02115 USA.
[Lyall, Amanda E.] Harvard Univ, Sch Med, Judge Bakers Children Ctr, Boston, MA USA.
[Savadjiev, Peter; O'Donnell, Lauren] Harvard Univ, Sch Med, Lab Math Imaging, Boston, MA USA.
[Seidman, Larry J.; Goldstein, Jill; Mesholam-Gately, Raquelle; Wojcik, Joanne] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Boston, MA USA.
[Seidman, Larry J.; Petryshen, Tracey] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Boston, MA 02114 USA.
[del Re, Elisabetta; Goldstein, Jill] Harvard Univ, Sch Med, Dept Psychiat, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Petryshen, Tracey] VA Boston Healthcare Syst, Res & Dev, Boston, MA USA.
[McCarley, Robert W.; Shenton, Martha E.] VA Boston Healthcare Syst, Brockton, MA USA.
NR 5
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2116580
BP S264
EP S264
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200696
ER
PT J
AU McCleery, A
Lee, J
Wynn, JK
Subotnik, KL
Ventura, J
Ghermezi, L
Hayata, JN
Pascual, GN
Green, MF
Nuechterlein, KH
AF McCleery, Amanda
Lee, Junghee
Wynn, Jonathan K.
Subotnik, Kenneth L.
Ventura, Joseph
Ghermezi, Livon
Hayata, Jacqueline N.
Pascual, Gabrielle N.
Green, Michael F.
Nuechterlein, Keith H.
TI SOCIAL COGNITION ACROSS PHASE OF ILLNESS IN SCHIZOPHRENIA: AN
EXAMINATION OF LOW-LEVEL AND HIGH-LEVEL PROCESSES
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [McCleery, Amanda; Lee, Junghee; Wynn, Jonathan K.; Subotnik, Kenneth L.; Ventura, Joseph; Ghermezi, Livon; Hayata, Jacqueline N.; Pascual, Gabrielle N.; Green, Michael F.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA.
[Wynn, Jonathan K.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, MIRECC, Los Angeles, CA USA.
[Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
BP S55
EP S56
PG 2
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200149
ER
PT J
AU Michaels, TM
Horan, WP
Ginger, EJ
Martinovich, Z
Pinkham, A
Smith, MJ
AF Michaels, Tania Marie
Horan, William Powers
Ginger, E. J.
Martinovich, Z.
Pinkham, Amy
Smith, Matthew James
TI COGNITIVE EMPATHY CONTRIBUTES TO POOR SOCIAL FUNCTIONING IN
SCHIZOPHRENIA: EVIDENCE FROM A NEW SELF-REPORT MEASURE OF COGNITIVE AND
AFFECTIVE EMPATHY
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Michaels, Tania Marie; Ginger, E. J.; Martinovich, Z.; Smith, Matthew James] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, Chicago, IL 60611 USA.
[Horan, William Powers] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Horan, William Powers] VA Greater Los Angeles Healthcare Syst, MIRECC VISN22, Los Angeles, CA USA.
[Pinkham, Amy] Univ Texas Dallas, Sch Behav & Brain Sci, Richardson, TX 75083 USA.
[Smith, Matthew James] Northwestern Univ, Warren Wright Adolescent Ctr, Feinberg Sch Med, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
BP S56
EP S56
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200150
ER
PT J
AU Pasternak, O
Durgun, I
Zuo, J
Mesholam-Gately, RI
Goldstein, JM
Seidman, LJ
McCarley, RW
Kubicki, M
Shenton, ME
AF Pasternak, Ofer
Durgun, Irem
Zuo, Jessica
Mesholam-Gately, Raquelle I.
Goldstein, Jill M.
Seidman, Larry J.
McCarley, Robert W.
Kubicki, Marek
Shenton, Martha E.
TI POSITIVE SYMPTOMS IN FIRST EPISODE SCHIZOPHRENIA PATIENTS CORRELATE WITH
EXCESSIVE EXTRACELLULAR SPACE
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Pasternak, Ofer; Kubicki, Marek; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Psychiat & Radiol, Sch Med, Boston, MA 02115 USA.
[Durgun, Irem; Zuo, Jessica] Harvard Univ, Brigham & Womens Hosp, Psychiat, Sch Med, Boston, MA 02115 USA.
[Mesholam-Gately, Raquelle I.; Seidman, Larry J.] Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Publ Psychiat Div, Boston, MA 02215 USA.
[Mesholam-Gately, Raquelle I.; Seidman, Larry J.; McCarley, Robert W.] Harvard Univ, Sch Med, Psychiat, Boston, MA USA.
[Goldstein, Jill M.] Harvard Univ, Brigham & Womens Hosp, Connors Ctr Womens Hlth & Gender Biol, Med Sch, Boston, MA 02115 USA.
[Goldstein, Jill M.] Harvard Univ, Sch Med, Psychiat & Med, Boston, MA USA.
[McCarley, Robert W.; Shenton, Martha E.] VA Boston Healthcare Syst, Brockton, MA USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2085277
BP S269
EP S269
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200709
ER
PT J
AU Reddy, F
Kern, RS
Smith, KM
Mitchell, S
Glynn, SM
Turner, LR
Zarate, R
Kopelowicz, A
Green, MF
AF Reddy, Felice
Kern, Robert S.
Smith, K. M.
Mitchell, Sharon
Glynn, Shirley M.
Turner, Luana R.
Zarate, Roberto
Kopelowicz, Alex
Green, Michael F.
TI PREDICTORS OF EMPLOYMENT IN ADULTS WITH SCHIZOPHRENIA: THE IMPORTANCE OF
BOTH INTRINSIC AND EXTRINSIC MOTIVATION
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Reddy, Felice; Kern, Robert S.; Glynn, Shirley M.; Green, Michael F.] Greater Los Angeles VA Healthcare Syst, MIRECC, Los Angeles, CA USA.
[Reddy, Felice; Kern, Robert S.; Smith, K. M.; Mitchell, Sharon; Glynn, Shirley M.; Turner, Luana R.; Zarate, Roberto; Kopelowicz, Alex; Green, Michael F.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA.
[Kopelowicz, Alex] San Fernando Valley Mental Hlth Ctr, Van Nuys, CA USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2119199
BP S187
EP S187
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200495
ER
PT J
AU Schlosser, D
Kim, D
Campellone, T
Ward, C
Vinogradov, S
AF Schlosser, Danielle
Kim, Daniel
Campellone, Tim
Ward, Charlie
Vinogradov, Sophia
TI PRIME: A NEUROSCIENCE-INFORMED MOBILE APP INTERVENTION TO TREAT REWARD
PROCESSING IMPAIRMENTS AND IMPROVE QUALITY OF LIFE IN RECENT ONSET
SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Schlosser, Danielle; Kim, Daniel; Campellone, Tim; Ward, Charlie; Vinogradov, Sophia] Univ Calif San Francisco, Psychiat, San Francisco, CA 94143 USA.
[Vinogradov, Sophia] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA.
[Campellone, Tim] Univ Calif Berkeley, Clin Sci, Berkeley, CA 94720 USA.
NR 0
TC 1
Z9 1
U1 1
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2119338
BP S332
EP S332
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200877
ER
PT J
AU Seidman, LJ
Brent, BK
Thermenos, HW
Keshavan, MS
Cannon, T
AF Seidman, Larry J.
Brent, Benjamin K.
Thermenos, Heidi W.
Keshavan, Matcheri S.
Cannon, Tyrone
TI FUNCTIONAL AND STRUCTURAL MRI STUDIES IN INDIVIDUALS WITH GENETIC OR
CLINICAL HIGH RISK FOR SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Seidman, Larry J.; Brent, Benjamin K.; Thermenos, Heidi W.; Keshavan, Matcheri S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Psychiat, Boston, MA 02215 USA.
[Seidman, Larry J.; Brent, Benjamin K.; Thermenos, Heidi W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Psychiat, Boston, MA USA.
[Cannon, Tyrone] Yale Univ, Psychol & Psychiat, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2115562
BP S273
EP S273
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200719
ER
PT J
AU Seidman, LJ
Shapiro, D
Stone, WS
Hooker, C
Woodberry, KS
Keshavan, MS
AF Seidman, Larry J.
Shapiro, Daniel
Stone, William S.
Hooker, Christine
Woodberry, Kristen S.
Keshavan, Matcheri S.
TI NEUROCOGNITIVE FUNCTIONING IN CLINICAL HIGH RISK STUDIES AND
IMPLICATIONS FOR COGNITIVE ENHANCEMENT IN THE PSYCHOSIS PRODROME
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Seidman, Larry J.; Stone, William S.; Woodberry, Kristen S.; Keshavan, Matcheri S.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Psychiat, Boston, MA USA.
[Seidman, Larry J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Psychiat, Boston, MA USA.
[Shapiro, Daniel] Univ Penn, Psychiat, Philadelphia, PA 19104 USA.
[Hooker, Christine] Harvard Univ, Psychol, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
BP S62
EP S62
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200167
ER
PT J
AU Seidman, LJ
Nuechterlein, KH
Gur, RC
Green, MF
Calkins, ME
Stone, WS
Lee, J
Swerdlow, NR
Gur, RE
Braff, DL
AF Seidman, Larry J.
Nuechterlein, Keith H.
Gur, Ruben C.
Green, Michael F.
Calkins, Monica E.
Stone, William S.
Lee, Junghee
Swerdlow, Neal R.
Gur, Raquel E.
Braff, David L.
TI NEUROCOGNITIVE ENDOPHENOTYPES IN THE COGS-2 STUDY
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Seidman, Larry J.; Stone, William S.] Harvard Univ, Sch Med, Psychiat, Beth Israel Deaconess Med Ctr, Boston, MA USA.
[Seidman, Larry J.] Harvard Univ, Sch Med, Psychiat, Massachusetts Gen Hosp, Boston, MA USA.
[Nuechterlein, Keith H.; Green, Michael F.; Lee, Junghee] Univ Calif Los Angeles, Geffen Sch Med, Psychiat & Biobehav Sci, Los Angeles, CA USA.
[Gur, Ruben C.; Calkins, Monica E.; Gur, Raquel E.] Univ Penn, Psychiat, Philadelphia, PA 19104 USA.
[Green, Michael F.; Lee, Junghee] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Swerdlow, Neal R.; Braff, David L.] Univ Calif San Diego, Psychiat, La Jolla, CA 92093 USA.
[Braff, David L.] MIRECC, VISN22, VA, San Diego, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
BP S61
EP S62
PG 2
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200166
ER
PT J
AU Seidman, LJ
Meyer, EC
Carrion, RE
Cornblatt, BA
Addington, J
Cadenhead, KS
Cannon, T
McGlashan, TH
Perkins, DO
Tsuang, MT
Walker, EF
Woods, SW
Heinssen, R
AF Seidman, Larry J.
Meyer, Eric C.
Carrion, Ricardo E.
Cornblatt, Barbara A.
Addington, Jean
Cadenhead, Kristin S.
Cannon, Tyrone
McGlashan, Thomas H.
Perkins, Diana O.
Tsuang, Ming T.
Walker, Elaine F.
Woods, Scott W.
Heinssen, Robert
TI THE RELATIONSHIP OF NEUROCOGNITION AND NEGATIVE SYMPTOMS TO SOCIAL AND
ROLE FUNCTIONING OVER TIME IN INDIVIDUALS AT CLINICAL HIGH RISK
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Meyer, Eric C.] VA VISN 17 Ctr Excellence Res Returning War Vet, Waco, TX USA.
[Meyer, Eric C.] Texas A&M Hlth Sci Ctr, Psychiat & Behav Sci, Coll Med, College Stn, TX USA.
[Carrion, Ricardo E.; Cornblatt, Barbara A.] NS LIJHS, Zucker Hillside Hosp, Div Psychiat Res, Glen Oaks, NY USA.
[Addington, Jean] Univ Calgary, Psychiat, Calgary, AB, Canada.
[Cadenhead, Kristin S.; Tsuang, Ming T.] Univ Calif San Diego, Psychiat, San Diego, CA USA.
[Cannon, Tyrone] Univ Calif Los Angeles, Psychol & Psychiat & Biobehav Sci, Los Angeles, CA USA.
[Cannon, Tyrone; McGlashan, Thomas H.; Woods, Scott W.] Yale Univ, Psychiat, New Haven, CT USA.
[Perkins, Diana O.] Univ N Carolina, Psychiat, Chapel Hill, NC USA.
[Tsuang, Ming T.] UCSD, Ctr Behav Genom, La Jolla, CA USA.
[Tsuang, Ming T.] UCSD, Inst Genom Med, La Jolla, CA USA.
[Walker, Elaine F.] Emory Univ, Psychol & Psychiat, Atlanta, GA 30322 USA.
[Heinssen, Robert] NIMH, Schizophrenia Spectrum Res Program, Div Adult Translat Res, Bethesda, MD 20892 USA.
[Seidman, Larry J.] Harvard Univ, Sch Med, Psychiat, Boston, MA USA.
[Seidman, Larry J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Seidman, Larry J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
BP S61
EP S61
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200165
ER
PT J
AU Siever, LJ
AF Siever, Larry J.
TI SOCIAL COGNITION IN THE SCHIZOPHRENIA SPECTRUM
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Siever, Larry J.] Icahn Sch Med Mt Sinai, Psychiat, New York, NY 10029 USA.
[Siever, Larry J.] James J Peters VAMC, VISN MIRECC 3, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2112833
BP S190
EP S190
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200502
ER
PT J
AU Spencer, KM
AF Spencer, Kevin M.
TI EVOKED AND SPONTANEOUS GAMMA ABNORMALITIES IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Spencer, Kevin M.] VA Boston Healthcare Syst, Res Serv, Boston, MA USA.
[Spencer, Kevin M.] Harvard Univ, Sch Med, Psychiat, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2118703
BP S26
EP S26
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200069
ER
PT J
AU Tabak, NT
Horan, WP
Bender, A
Dolinsky, M
Green, MF
AF Tabak, Naomi Tuchman
Horan, William Powers
Bender, A.
Dolinsky, M.
Green, Michael F.
TI MINDFULNESS, EMOTION REGULATION, AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Tabak, Naomi Tuchman] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
[Tabak, Naomi Tuchman; Horan, William Powers; Bender, A.; Dolinsky, M.; Green, Michael F.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Horan, William Powers; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2081514
BP S192
EP S193
PG 2
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200509
ER
PT J
AU Walsh-Messinger, J
Keller, A
Cieslak, K
Rotondo, E
Goetz, R
Gonen, O
Malaspina, D
AF Walsh-Messinger, Julie
Keller, Andreas
Cieslak, Kristina
Rotondo, Elena
Goetz, Raymond
Gonen, Oded
Malaspina, Dolores
TI INFLAMMATION IN THE ANTERIOR CINGULATE CORTEX (ACC) AND ASSOCIATIONS
WITH OLFACTORY HEDONICS AND ANHEDONIA IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Walsh-Messinger, Julie] Icahn Sch Med Mt Sinai, Psychiat, New York, NY 10029 USA.
[Walsh-Messinger, Julie] James J Peters VA Med Ctr, Mental Illness Educ Res & Clin Ctr, Bronx, NY USA.
[Keller, Andreas; Cieslak, Kristina; Rotondo, Elena; Goetz, Raymond; Malaspina, Dolores] NYU, Sch Med, Inst Social & Psychiat Initiat InSPIRES, Psychiat, New York, NY USA.
[Keller, Andreas] Rockefeller Univ, New York, NY 10021 USA.
[Goetz, Raymond] Columbia Univ, Psychiat, New York, NY USA.
[Gonen, Oded] NYU, Sch Med, Radiol, New York, NY USA.
[Malaspina, Dolores] NY State Off Mental Hlth, Creedmor Psychiat Ctr, Queens, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2083528
BP S278
EP S279
PG 2
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200733
ER
PT J
AU Wu, WL
Adams, CE
Stevens, K
Chow, K
Patterson, PH
AF Wu, Wei-Li
Adams, C. E.
Stevens, Karen
Chow, K.
Patterson, P. H.
TI NICOTINIC CHOLINERGIC MODULATION OF THE FETAL BRAIN RESPONSE TO MATERNAL
IMMUNE ACTIVATION
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Wu, Wei-Li; Chow, K.; Patterson, P. H.] CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA.
[Adams, C. E.] Denver VA Med Ctr, Denver, CO USA.
[Adams, C. E.; Stevens, Karen] Univ Colorado Denver, Dept Psychiat, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2077235
BP S216
EP S216
PG 1
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200573
ER
PT J
AU Yao, JK
Leonard, S
Reddy, R
AF Yao, Jeffrey K.
Leonard, Sherry
Reddy, Ravinder
TI HOMEOSTATIC IMBALANCE OF PURINE CATABOLISM IN SCHIZOPHRENIA POSTMORTEM
BRAIN
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 15th International Congress on Schizophrenia Research (ICOSR)
CY MAR 28-APR 01, 2015
CL Colorado Springs, CO
C1 [Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, MIRECC VISN4, Pittsburgh, PA USA.
[Yao, Jeffrey K.; Reddy, Ravinder] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Yao, Jeffrey K.; Reddy, Ravinder] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA USA.
[Leonard, Sherry] Univ Colorado, Dept Psychiat, Denver, CO 80202 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2015
VL 41
SU 1
MA 2118353
BP S297
EP S298
PG 2
WC Psychiatry
SC Psychiatry
GA CG8HO
UT WOS:000353548200784
ER
PT J
AU Diep, CQ
Peng, ZZ
Ukah, TK
Kelly, PM
Daigle, RV
Davidson, AJ
AF Diep, Cuong Q.
Peng, Zhenzhen
Ukah, Tobechukwu K.
Kelly, Paul M.
Daigle, Renee V.
Davidson, Alan J.
TI Development of the Zebrafish Mesonephros
SO GENESIS
LA English
DT Article
DE kidney; pronephros; nephron
ID KIDNEY DEVELOPMENT; NEPHRON SEGMENTATION; PRONEPHROS; EXPRESSION; GENES;
IDENTIFICATION; REGENERATION; LIM1; WT1A
AB The vertebrate kidney plays an essential role in removing metabolic waste and balancing water and salt. This is carried out by nephrons, which comprise a blood filter attached to an epithelial tubule with proximal and distal segments. In zebrafish, two nephrons are first formed as part of the embryonic kidney (pronephros) and hundreds are formed later to make up the adult kidney (mesonephros). Previous studies have focused on the development of the pronephros while considerably less is known about how the mesonephros is formed. Here, we characterize mesonephros development in zebrafish and examine the nephrons that form during larval metamorphosis. These nephrons, arising from proliferating progenitor cells that express the renal transcription factor genes wt1b, pax2a, and lhx1a, form on top of the pronephric tubules and develop a segmentation pattern similar to pronephric nephrons. We find that the pronephros acts as a scaffold for the mesonephros, where new nephrons fuse with the distal segments of the pronephric tubules to form the final branching network that characterizes the adult zebrafish kidney. genesis 53:257-269, 2015. (c) 2015 Wiley Periodicals, Inc.
C1 [Diep, Cuong Q.; Daigle, Renee V.; Davidson, Alan J.] Massachusetts Gen Hosp, Dept Med, Ctr Regenerat Med, Boston, MA 02114 USA.
[Diep, Cuong Q.; Davidson, Alan J.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Diep, Cuong Q.; Davidson, Alan J.] Harvard Stem Cell Inst, Kidney Program, Cambridge, MA USA.
[Diep, Cuong Q.; Ukah, Tobechukwu K.; Kelly, Paul M.] Indiana Univ Penn, Dept Biol, Indiana, PA 15705 USA.
[Peng, Zhenzhen; Davidson, Alan J.] Univ Auckland, Dept Mol Med & Pathol, Auckland 1142, New Zealand.
RP Davidson, AJ (reprint author), Univ Auckland, Dept Mol Med & Pathol, Sch Med Sci, Private Bag 92019, Auckland 1142, New Zealand.
EM a.davidson@auckland.ac.nz
FU Health Research Council (HRC), New Zealand; Harvard Stem Cell Institute;
American Society of Nephrology; National Institutes of Health/National
Institute of Diabetes and Digestive and Kidney Diseases [DK069403-06];
Massachusetts General Hospital; Indiana University of Pennsylvania;
Commonwealth of Pennsylvania University Biologists
FX Contract grant sponsor: Health Research Council (HRC), New Zealand;
Contract grant sponsor: Harvard Stem Cell Institute; Contract grant
sponsor: American Society of Nephrology; Contract grant sponsor:
National Institutes of Health/National Institute of Diabetes and
Digestive and Kidney Diseases, Contract grant number(s): DK069403-06;
Contract grant sponsor: Massachusetts General Hospital (Fund for Medical
Discovery); Contract grant sponsor: Indiana University of Pennsylvania
(Startup Fund, USRC Small Grant, President's Advancing Grantsmanship
Awards, the President's Strategic Initiative Fund, and the Professional
Development Fund); Contract grant sponsor: Commonwealth of Pennsylvania
University Biologists.
NR 25
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1526-954X
EI 1526-968X
J9 GENESIS
JI Genesis
PD MAR-APR
PY 2015
VL 53
IS 3-4
BP 257
EP 269
DI 10.1002/dvg.22846
PG 13
WC Developmental Biology; Genetics & Heredity
SC Developmental Biology; Genetics & Heredity
GA CH3JC
UT WOS:000353926000001
PM 25677367
ER
PT J
AU Fourman, LT
Fazeli, PK
AF Fourman, Lindsay T.
Fazeli, Pouneh K.
TI Neuroendocrine Causes of Amenorrhea-An Update
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Review
ID GONADOTROPIN-RELEASING-HORMONE; CONGENITAL ADRENAL-HYPERPLASIA; STEROID
21-HYDROXYLASE DEFICIENCY; FUNCTIONAL HYPOTHALAMIC AMENORRHEA;
SHEEHANS-SYNDROME; SERUM PROLACTIN; PITUITARY DYSFUNCTION;
LUTEINIZING-HORMONE; KALLMANN-SYNDROME; IDIOPATHIC HYPERPROLACTINEMIA
AB Context: Secondary amenorrhea-the absence of menses for three consecutive cycles-affects approximately 3-4% of reproductive age women, and infertility-the failure to conceive after 12 months of regular intercourse-affects approximately 6-10%. Neuroendocrine causes of amenorrhea and infertility, including functional hypothalamic amenorrhea and hyperprolactinemia, constitute a majority of these cases.
Objective: In this review, we discuss the physiologic, pathologic, and iatrogenic causes of amenorrhea and infertility arising from perturbations in the hypothalamic-pituitary-adrenal axis, including potential genetic causes. We focus extensively on the hormonal mechanisms involved in disrupting the hypothalamic-pituitary-ovarian axis.
Conclusions: A thorough understanding of the neuroendocrine causes of amenorrhea and infertility is critical for properly assessing patients presenting with these complaints. Prompt evaluation and treatment are essential to prevent loss of bone mass due to hypoestrogenemia and/or to achieve the time-sensitive treatment goal of conception.
C1 [Fourman, Lindsay T.; Fazeli, Pouneh K.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Fazeli, Pouneh K.] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Fazeli, PK (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, Bulfinch 457B, Boston, MA 02114 USA.
EM pkfazeli@partners.org
FU National Institutes of Health [K23-DK094820]; Claflin Distinguished
Scholar Award
FX This project was supported by National Institutes of Health grant
K23-DK094820 (to P.K.F.) and the Claflin Distinguished Scholar Award (to
P.K.F.).
NR 129
TC 7
Z9 9
U1 2
U2 9
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAR
PY 2015
VL 100
IS 3
BP 812
EP 824
DI 10.1210/jc.2014-3344
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CG5TR
UT WOS:000353358900028
PM 25581597
ER
PT J
AU McAninch, EA
Jo, S
Preite, NZ
Farkas, E
Mohacsik, P
Fekete, C
Egri, P
Gereben, B
Li, Y
Deng, YP
Patti, ME
Zevenbergen, C
Peeters, RP
Mash, DC
Bianco, AC
AF McAninch, Elizabeth A.
Jo, Sungro
Preite, Nailliw Z.
Farkas, Erzsebet
Mohacsik, Petra
Fekete, Csaba
Egri, Peter
Gereben, Balazs
Li, Yan
Deng, Youping
Patti, Mary-Elizabeth
Zevenbergen, Chantal
Peeters, Robin P.
Mash, Deborah C.
Bianco, Antonio C.
TI Prevalent Polymorphism in Thyroid Hormone-Activating Enzyme Leaves a
Genetic Fingerprint That Underlies Associated Clinical Syndromes
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID EPIDERMAL-GROWTH-FACTOR; TYPE-2 DEIODINASE; THR92ALA POLYMORPHISM;
HUNTINGTONS-DISEASE; DIO2 GENE; EXPRESSION; THYROXINE; STRESS; CELLS;
PATHWAYS
AB Context: A common polymorphism in the gene encoding the activating deiodinase (Thr92Ala-D2) is known to be associated with quality of life in millions of patients with hypothyroidism and with several organ-specific conditions. This polymorphism results in a single amino acid change within the D2 molecule where its susceptibility to ubiquitination and proteasomal degradation is regulated.
Objective: To define the molecular mechanisms underlying associated conditions in carriers of the Thr92Ala-D2 polymorphism.
Design, Setting, Patients: Microarray analyses of 19 postmortem human cerebral cortex samples were performed to establish a foundation for molecular studies via a cell model of HEK-293 cells stably expressing Thr92 or Ala92 D2.
Results: The cerebral cortex of Thr92Ala-D2 carriers exhibits a transcriptional fingerprint that includes sets of genes involved in CNS diseases, ubiquitin, mitochondrial dysfunction (chromosomal genes encoding mitochondrial proteins), inflammation, apoptosis, DNA repair, and growth factor signaling. Similar findings were made in Ala92-D2-expressing HEK-293 cells and in both cases there was no evidence that thyroid hormone signaling was affected ie, the expression level of T3-responsive genes was unchanged, but that several other genes were differentially regulated. The combined microarray analyses (brain/cells) led to the development of an 81-gene classifier that correctly predicts the genotype of homozygous brain samples. In contrast to Thr92-D2, Ala92-D2 exhibits longer half-life and was consistently found in the Golgi. A number of Golgi-related genes were down-regulated in Ala92-D2-expressing cells, but were normalized after 24-h-treatment with the antioxidant N-acetylecysteine.
Conclusions: Ala92-D2 accumulates in the Golgi, where its presence and/or ensuing oxidative stress disrupts basic cellular functions and increases pre-apoptosis. These findings are reminiscent to disease mechanisms observed in other neurodegenerative disorders such as Huntington's disease, and could contribute to the unresolved neurocognitive symptoms of affected carriers.
C1 [McAninch, Elizabeth A.; Jo, Sungro; Preite, Nailliw Z.; Bianco, Antonio C.] Rush Univ, Div Endocrinol & Metab, Med Ctr, Chicago, IL 60612 USA.
[Farkas, Erzsebet; Mohacsik, Petra; Fekete, Csaba; Egri, Peter; Gereben, Balazs] Hungarian Acad Sci, Dept Endocrine Neurobiol, Inst Expt Med, H-1083 Budapest, Hungary.
[Farkas, Erzsebet] Peter Pazmany Catholic Univ, Multidisciplinary Doctoral Sch Sci & Technol, H-1083 Budapest, Hungary.
[Mohacsik, Petra; Egri, Peter] Semmelweis Univ, Janos Szentagothai PhD Sch Neurosci, H-1085 Budapest, Hungary.
[Fekete, Csaba] Tufts Med Ctr,Boston, Div Endocrinol, Diabet & Metab, Boston, MA 02111 USA.
[Li, Yan; Deng, Youping] Rush Univ, Dept Med, Med Ctr, Chicago, IL 60612 USA.
[Patti, Mary-Elizabeth] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.
[Zevenbergen, Chantal; Peeters, Robin P.] Erasmus MC, Div Endocrinol, RotterdamThyroid Ctr, Dept Internal Med, Rotterdam, Netherlands.
[Mash, Deborah C.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
RP Bianco, AC (reprint author), Rush Univ, Div Endocrinol & Metab, Med Ctr, 1735 W Harrison St,212 Cohn Bldg, Chicago, IL 60612 USA.
EM abianco@deiodinase.org
RI Peeters, Robin/P-3603-2014;
OI Fekete, Csaba/0000-0002-8206-562X
FU National Institute of Diabetes and Digestive Kidney Diseases [DK58538];
Hungarian Brain Research Program; Hungarian Academy of Sciences; NIMH;
NINDS; NICHD; National Institutes of Health, Department of Health and
Human Services [HHSN271201300028C]
FX This work was supported by grants from the National Institute of
Diabetes and Digestive Kidney Diseases (DK58538), the Hungarian Brain
Research Program, and the Lendulet grant of the Hungarian Academy of
Sciences. The University of Miami Brain Endowment Bank is funded in part
with Federal funds from the NIMH, NINDS, and NICHD, National Institutes
of Health, Department of Health and Human Services, under Contract No.
HHSN271201300028C.
NR 46
TC 12
Z9 12
U1 0
U2 15
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAR
PY 2015
VL 100
IS 3
BP 920
EP 933
DI 10.1210/jc.2014-4092
PG 14
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CG5TR
UT WOS:000353358900040
PM 25569702
ER
PT J
AU Shaw, ND
Butler, JP
Nemati, S
Kangarloo, T
Ghassemi, M
Malhotra, A
Hall, JE
AF Shaw, N. D.
Butler, J. P.
Nemati, S.
Kangarloo, T.
Ghassemi, M.
Malhotra, A.
Hall, J. E.
TI Accumulated Deep Sleep Is a Powerful Predictor of LH Pulse Onset in
Pubertal Children
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID GONADOTROPIN-RELEASING-HORMONE; LUTEINIZING-HORMONE; APNEA SYNDROME;
SECRETION; NEURONS; GIRLS; ACTIVATION; PULSATILE; NUCLEUS;
ADENOTONSILLECTOMY
AB Context: During puberty, reactivation of the reproductive axis occurs during sleep, with LH pulses specifically tied to deep sleep. This association suggests that deep sleep may stimulate LH secretion, but there have been no interventional studies to determine the characteristics of deep sleep required for LH pulse initiation.
Objective: The objective of this study was to determine the effect of deep sleep fragmentation on LH secretion in pubertal children.
Design and Setting: Studies were performed in a clinical research center.
Subjects: Fourteen healthy pubertal children (11.3-14.1 y) participated in the study.
Interventions: Subjects were randomized to two overnight studies with polysomnography and frequent blood sampling, with or without deep sleep disruption via auditory stimuli.
Results: An average of 68.1 +/- 10.7 (+/- SE) auditory stimuli were delivered to interrupt deep sleep during the disruption night, limiting deep sleep to only brief episodes (average length disrupted 1.3 +/- 0.2 min vs normal 7.1 +/- 0.8 min, P < .001), and increasing the number of transitions between non-rapid eye movement (NREM), REM, and wake (disrupted 274.5 +/- 33.4 vs normal 131.2 +/- 8.1, P = .001). There were no differences in mean LH (normal: 3.2 +/- 0.4 vs disrupted: 3.2 +/- 0.5 IU/L), LH pulse frequency (0.6 +/- 0.06 vs 0.6 +/- 0.07 pulses/h), or LH pulse amplitude (2.8 +/- 0.4 vs 2.8 +/- 0.4 IU/L) between the two nights. Poisson process modeling demonstrated that the accumulation of deep sleep in the 20 minutes before an LH pulse, whether consolidated or fragmented, was a significant predictor of LH pulse onset (P < .001).
Conclusion: In pubertal children, nocturnal LH augmentation and pulse patterning are resistant to deep sleep fragmentation. These data suggest that, even when fragmented, deep sleep is strongly related to activation of the GnRH pulse generator.
C1 [Shaw, N. D.; Kangarloo, T.; Hall, J. E.] Massachusetts Gen Hosp, Reprod Endocrine Unit, Dept Med, Boston, MA 02114 USA.
[Shaw, N. D.; Hall, J. E.] Harvard Univ, Sch Med, Div Endocrinol, Childrens Hosp Boston,Div Sleep Med, Cambridge, MA 02138 USA.
[Butler, J. P.] Harvard Univ, Sch Med, Div Sleep & Circadian Disorders, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Butler, J. P.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Nemati, S.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
[Ghassemi, M.] MIT, Elect Engn & Comp Sci, Cambridge, MA 02142 USA.
[Malhotra, A.] Univ Calif San Diego, Div Pulm & Crit Care Med, La Jolla, CA 92093 USA.
RP Shaw, ND (reprint author), Massachusetts Gen Hosp, Reprod Endocrine Unit, BHX 5,55 Fruit St, Boston, MA 02114 USA.
EM nshaw@partners.org
OI Shaw, Natalie/0000-0002-0847-9170; Hall, Janet/0000-0003-4644-3061
FU National Institutes of Health [K23HD073304-02, K24HL093218]; Pediatric
Endocrine Society; Harvard University [1UL1TR001102-01]
FX N.D.S. received fellowship support from the National Institutes of
Health (Grant K23HD073304-02), the Pediatric Endocrine Society, and
Harvard Catalyst [The Harvard Clinical and Translational Science Center
(Award 1UL1TR001102-01)] and financial contributions from Harvard
University and its affiliated academic health care centers. A.M. is
funded by the National Institutes of Health (Grant K24HL093218).
NR 39
TC 1
Z9 1
U1 1
U2 1
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAR
PY 2015
VL 100
IS 3
BP 1062
EP 1070
DI 10.1210/jc.2014-3563
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CG5TR
UT WOS:000353358900056
PM 25490277
ER
PT J
AU Balasubramanian, R
Chew, S
MacKinnon, SE
Kang, PB
Andrews, C
Chan, WM
Engle, EC
AF Balasubramanian, Ravikumar
Chew, Sheena
MacKinnon, Sarah E.
Kang, Peter B.
Andrews, Caroline
Chan, Wai-Man
Engle, Elizabeth C.
TI Expanding the Phenotypic Spectrum and Variability of Endocrine
Abnormalities Associated With TUBB3 E410K Syndrome
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID GONADOTROPIN-RELEASING-HORMONE; KALLMANN-SYNDROME; DEFICIENCY; MUTATIONS
AB Context: A heterozygous de novo c.1228G>A mutation (E410K) in the TUBB3 gene encoding the neuronal-specific beta-tubulin isotype 3 (TUBB3) causes the TUBB3 E410K syndrome characterized by congenital fibrosis of the extraocular muscles (CFEOM), facial weakness, intellectual and social disabilities, and Kallmann syndrome (anosmia with hypogonadotropic hypogonadism). All TUBB3 E410K subjects reported to date are sporadic cases.
Objective: This study aimed to report the clinical, genetic, and molecular features of a familial presentation of the TUBB3 E410K syndrome.
Design: Case report of a mother and three affected children with clinical features of the TUBB3 E410K syndrome.
Setting: Academic Medical Center.
Main Outcome Measures: Genetic analysis of the TUBB3 gene and clinical evaluation of endocrine and nonendocrine phenotypes.
Results: A de novo TUBB3 c.1228G>A mutation arose in a female proband who displayed CFEOM, facial weakness, intellectual and social disabilities, and anosmia. However, she underwent normal sexual development at puberty and had three spontaneous pregnancies with subsequent autosomal- dominant inheritance of the mutation by her three boys. All sons displayed nonendocrine features of the TUBB3 E410K syndrome similar to their mother but, in addition, had variable features suggestive of additional endocrine abnormalities.
Conclusions: This first report of an autosomal-dominant inheritance of the TUBB3 c.1228G>A mutation in a family provides new insights into the spectrum and variability of endocrine phenotypes associated with the TUBB3 E410K syndrome. These observations emphasize the need for appropriate clinical evaluation and complicate genetic counseling of patientsandfamilies with this syndrome.
C1 [Balasubramanian, Ravikumar] Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr, Boston, MA 02114 USA.
[Balasubramanian, Ravikumar] Massachusetts Gen Hosp, Reprod Endocrine Unit, Dept Med, Boston, MA 02114 USA.
[Balasubramanian, Ravikumar; Chew, Sheena; Kang, Peter B.; Andrews, Caroline; Chan, Wai-Man; Engle, Elizabeth C.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Chew, Sheena; Kang, Peter B.; Andrews, Caroline; Chan, Wai-Man; Engle, Elizabeth C.] Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Chew, Sheena; Andrews, Caroline; Chan, Wai-Man; Engle, Elizabeth C.] Boston Childrens Hosp, Kirby Neurobiol Ctr, Boston, MA 02115 USA.
[MacKinnon, Sarah E.; Engle, Elizabeth C.] Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
[Chew, Sheena; Andrews, Caroline; Chan, Wai-Man; Engle, Elizabeth C.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
RP Engle, EC (reprint author), Boston Childrens Hosp, CLS14075,300 Longwood Ave, Boston, MA 02115 USA.
EM elizabeth.engle@childrens.harvard.edu
FU National Eye Institute of the National Institutes of Health
[R01EY12498]; Boston Children's Hospital Intellectual and Developmental
Disabilities Research Center [HD018655]; Children's Hospital
Ophthalmology Foundation; National Institute of Child Health and
Development [K23HD077043]; HHMI Medical Fellowship; Harvard Medical
School
FX This work was supported by the National Eye Institute of the National
Institutes of Health (R01EY12498 to E.C.E.), the Boston Children's
Hospital Intellectual and Developmental Disabilities Research Center
(HD018655), and the Children's Hospital Ophthalmology Foundation
(E.C.E., S.M.). R.B. is supported by a Career Development Grant from the
National Institute of Child Health and Development (K23HD077043). S.C.
was funded by an HHMI Medical Fellowship and Harvard Medical School.
E.C.E. is a Howard Hughes Medical Institute Investigator.
NR 12
TC 2
Z9 2
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAR
PY 2015
VL 100
IS 3
BP E473
EP E477
DI 10.1210/jc.2014-4107
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CG5TR
UT WOS:000353358900014
PM 25559402
ER
PT J
AU Huh, JY
Siopi, A
Mougios, V
Park, KH
Mantzoros, CS
AF Huh, Joo Young
Siopi, Aikaterina
Mougios, Vassilis
Park, Kyung Hee
Mantzoros, Christos S.
TI Irisin in Response to Exercise in Humans With and Without Metabolic
Syndrome
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID SKELETAL-MUSCLE; CELL-PROLIFERATION; MESSENGER-RNA; FNDC5; PROTEIN;
SERUM; LINES; FAT; MEN
AB Context: Irisin is a recently identified exercise-induced myokine. However, the circulating levels of irisin in response to different types of exercise in subjects with metabolic syndrome are unknown.
Objective: This study aimed to study the levels of irisin in healthy males and subjects with metabolic syndrome at baseline and in response to exercise.
Design: Each individual completed high-intensity interval exercise (HIIE), continuous moderate-intensity exercise (CME), and resistance exercise (RE) sessions in a random, crossover design. Percentage change in circulating irisin levels was examined. Two different irisin assays were used to compare the results of the RE study.
Results: Circulating irisin increased immediately after HIIE, CME, and RE and declined 1 hour later. The increase was greater in response to resistance compared with either high-intensity intermittent exercise or CME. Change in irisin in response to exercise did not differ between individuals with and without metabolic syndrome.
Conclusions: Exercise is able to increase circulating irisin levels in individuals with the metabolic syndrome as well as healthy individuals. Whether this increase may contribute to the beneficial effects of exercise on patients with the metabolic syndrome remains to be studied further.
C1 [Huh, Joo Young; Park, Kyung Hee; Mantzoros, Christos S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA.
[Siopi, Aikaterina; Mougios, Vassilis] Aristotle Univ Thessaloniki, Sch Phys Educ & Sports Sci, Thessaloniki 54124, Greece.
[Park, Kyung Hee] Hallym Univ, Sacred Heart Hosp, Dept Family Med, Gyeonggi Do 431796, South Korea.
[Mantzoros, Christos S.] Harvard Univ, Boston VA Healthcare Syst, Sch Med, Endocrinol Sect, Boston, MA USA.
RP Mantzoros, CS (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, 330 Brookline Ave,Feldberg 876, Boston, MA 02215 USA.
EM cmantzor@bidmc.harvard.edu
OI Park, Kyung Hee/0000-0001-9806-0076
FU Clinical Science Research and Development Service of the VA Office of
Research and Development; Greek State Scholarship Foundation
FX This work was supported by an award from the Clinical Science Research
and Development Service of the VA Office of Research and Development.
Part of this work was supported by a fellowship of the Greek State
Scholarship Foundation to A.S. under the program, "IKY Fellowships of
Excellence for Postgraduate Studies in Greece-SIEMENS Program."
NR 22
TC 15
Z9 17
U1 1
U2 9
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAR
PY 2015
VL 100
IS 3
BP E453
EP E457
DI 10.1210/jc.2014-2416
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CG5TR
UT WOS:000353358900010
PM 25514098
ER
PT J
AU Arya, R
White, K
AF Arya, Richa
White, Kristin
TI Cell death in development: Signaling pathways and core mechanisms
SO SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE Cell death; Drosophila; Development; Hox; Notch; Ras
ID CENTRAL-NERVOUS-SYSTEM; DEVELOPING DROSOPHILA RETINA; EMBRYONIC PATTERN
REPAIR; ANIMAL DEVELOPMENT; EGF RECEPTOR; POSTEMBRYONIC DEVELOPMENT;
CRANIOFACIAL DEVELOPMENT; CAENORHABDITIS-ELEGANS; TRANSCRIPTION FACTORS;
MAMMALIAN DEVELOPMENT
AB Programmed cell death eliminates unneeded and dangerous cells in a timely and effective manner during development. In this review, we examine the role cell death plays during development in worms, flies and mammals. We discuss signaling pathways that regulate developmental cell death, and describe how they communicate with the core cell death pathways. In most organisms, the majority of developmental cell death is seen in the nervous system. Therefore we focus on what is known about the regulation of developmental cell death in this tissue. Understanding how the cell death is regulated during development may provide insight into how this process can be manipulated in the treatment of disease. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Arya, Richa; White, Kristin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, CBRC, Boston, MA 02129 USA.
RP White, K (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, CBRC, Boston, MA 02129 USA.
EM kristin.white@cbrc2.mgh.harvard.edu
FU MGH Fund for Medical Discovery [R01GM55568, R01GM110477]
FX We would like to acknowledge funding from the MGH Fund for Medical
Discovery (R.A.) and R01GM55568 and R01GM110477 (K.W.). Tatevik
Sarkissian and Ritu Tomar provided important comments on the manuscript.
NR 158
TC 9
Z9 10
U1 5
U2 17
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1084-9521
J9 SEMIN CELL DEV BIOL
JI Semin. Cell Dev. Biol.
PD MAR
PY 2015
VL 39
BP 12
EP 19
DI 10.1016/j.semcdb.2015.02.001
PG 8
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA CG5MW
UT WOS:000353337000003
PM 25668151
ER
PT J
AU Kendall, RE
Gosser, RA
Schulz, LT
Trapskin, PJ
Caponi, B
Safdar, N
AF Kendall, Ronald E.
Gosser, Rena A.
Schulz, Lucas T.
Trapskin, Philip J.
Caponi, Bartho
Safdar, Nasia
TI Anti-diarrheat medication use in the treatment of Ebola virus-induced
diarrhea
SO TRAVEL MEDICINE AND INFECTIOUS DISEASE
LA English
DT Letter
DE Ebola; Anti-diarrheals; Supportive care; Viral gastroenteritis
ID MANAGEMENT
C1 [Kendall, Ronald E.; Gosser, Rena A.; Schulz, Lucas T.; Trapskin, Philip J.] Univ Wisconsin Hosp & Clin, Dept Pharm, Madison, WI 53705 USA.
[Caponi, Bartho] Univ Wisconsin, Div Hosp Med, Dept Med, Sch Med & Publ Hlth, Madison, WI 53705 USA.
[Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
[Safdar, Nasia] Univ Wisconsin, Div Infect Dis, Dept Med, Sch Med & Publ Hlth, Madison, WI 53705 USA.
RP Kendall, RE (reprint author), 600 Highland Ave F6-133, Madison, WI 53792 USA.
EM rkendall@uwhealth.org; rgosser@uwhealth.org
NR 6
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1477-8939
EI 1873-0442
J9 TRAVEL MED INFECT DI
JI Travel Med. Infect. Dis.
PD MAR-APR
PY 2015
VL 13
IS 2
BP 205
EP 206
DI 10.1016/j.tmaid.2015.01.003
PG 2
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA CH0VT
UT WOS:000353741200019
PM 25682446
ER
PT J
AU Pham, A
Hariri, S
Yusin, J
AF Pham, A.
Hariri, S.
Yusin, J.
TI Timing isn't everything: A case of recurrent angio-oedema
SO ALLERGOLOGIA ET IMMUNOPATHOLOGIA
LA English
DT Letter
ID CONVERTING ENZYME-INHIBITORS
C1 [Pham, A.; Hariri, S.; Yusin, J.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Pham, A (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
EM Andrewqpham@gmail.conn; Sherwinucla@yahoo.com; Joseph.Yusin2@va.gov
NR 10
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER DOYMA SL
PI BARCELONA
PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN
SN 0301-0546
EI 1578-1267
J9 ALLERGOL IMMUNOPATH
JI Allergol. Immunopath.
PD MAR-APR
PY 2015
VL 43
IS 2
BP 230
EP 231
DI 10.1016/j.aller.2014.02.001
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA CF7OO
UT WOS:000352746400022
PM 24948189
ER
PT J
AU Wilens, T
Zulauf, C
Ryland, D
Carrellas, N
Catalina-Wellington, I
AF Wilens, Timothy
Zulauf, Courtney
Ryland, Denece
Carrellas, Nicholas
Catalina-Wellington, Isela
TI Prescription Medication Misuse Among Opioid Dependent Patients Seeking
Inpatient Detoxification
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID NONMEDICAL USE; CHRONIC PAIN; CLONIDINE; DISORDER; BUPRENORPHINE;
PREVALENCE; PREDICTORS; ANALGESIA; MORTALITY; METHADONE
AB Background and ObjectivesOpioid related morbidity and mortality is heightened in context to the concomitant use of psychotropic medications. The aim of this project was to examine the extent to which opioid dependent patients seeking detoxification are using and misusing specific psychotropic agents.
MethodsAs part of a quality assurance/improvement project, we systematically assessed prospectively consecutive admissions to a public detoxification program using a self-report questionnaire to query for specific psychotropic medication use. Patients were asked about having a current prescription, appropriate use, and/or medical misuse (higher doses, using without prescription) of amphetamine salts, clonazepam, clonidine, gabapentin, and pregabalin.
ResultsWe had data on 196 admissions including 162 patients with opioid dependency. Patients receiving detoxification from opioids compared to alcohol had statistically significant higher rates of medication misuse (30% vs. 0%, respectively; (2)=12.8, p<.0003). Of opioid dependent patients receiving prescription medication, 28% reported using higher amounts of each medication than prescribed. Of opioid patients, 10% self-reported misusing clonidine, 22% gabapentin, 7% pregabalin, 25% clonazepam, 11% amphetamine salts, and 36% any of these medications.
Discussion and ConclusionsDespite the nonaddictive nature of some medications (eg, gabapentin, clonidine), high rates of medication misuse in opioid dependent patients admitted for detoxification was found and appeared similar to rates of misuse among controlled substances such as clonazepam and amphetamine salts. These data suggest that opioid dependent patients should be queried for the appropriate use of prescribed medications and that practitioners need to monitor for medication misuse in opioid dependent patients. (Am J Addict 2015;24:173-177)
C1 [Wilens, Timothy; Zulauf, Courtney; Carrellas, Nicholas] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA.
[Wilens, Timothy; Ryland, Denece; Catalina-Wellington, Isela] Andrew House Detoxificat Ctr, Bay Cove Human Serv, Quincy, MA USA.
RP Wilens, T (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol, 55 Fruit St,YAW 6A, Boston, MA 02114 USA.
EM twilens@partners.org
FU National Institute on Drug Abuse (NIDA); Euthymics; Shire; Theravance;
TRIS
FX Over the past three years Timothy Wilens receives/d research support
from, or is/has been on the advisory board for the following
Pharmaceutical Companies: National Institute on Drug Abuse (NIDA),
Euthymics, Shire, Theravance, and TRIS. Dr. Timothy Wilens is or has
been a consultant for: Bay Cove Human Services, Euthymics, Major and
Minor League Baseball, the National Football League (ERM Associates),
Shire, and TRIS. Dr. Timothy Wilens has a published book with Guilford
Press. Straight Talk About Psychiatric Medications for Kids.
NR 30
TC 7
Z9 8
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAR
PY 2015
VL 24
IS 2
BP 173
EP 177
DI 10.1111/ajad.12159
PG 5
WC Substance Abuse
SC Substance Abuse
GA CF8KI
UT WOS:000352807600012
PM 25864607
ER
PT J
AU Wang, EA
McGinnis, KA
Long, JB
Akgun, KM
Edelman, EJ
Rimland, D
Wang, KH
Justice, AC
Fiellin, DA
AF Wang, Emily A.
McGinnis, Kathleen A.
Long, Jessica B.
Akguen, Kathleen M.
Edelman, E. Jennifer
Rimland, David
Wang, Karen H.
Justice, Amy C.
Fiellin, David A.
TI Incarceration and Health Outcomes in HIV-Infected Patients: The Impact
of Substance Use, Primary Care Engagement, and Antiretroviral Adherence
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID INJECTION-DRUG USERS; ALCOHOL-USE; HIGH-RISK; VETERANS; THERAPY;
RELEASE; PRISON; ACCESS; DEATH; MEN
AB Background and ObjectivesOne in seven HIV-infected individuals is incarcerated each year. We used data from the Veterans Aging Cohort Study (VACS) to explore the relationship between incarceration and HIV disease outcomes and evaluate potential mediators of this relationship.
MethodsHIV disease outcomes included: low CD4 counts (<200 cells/mL), detectable viral RNA loads (>500 copies/mL), and the VACS Index score. We performed a mediation analysis among 1,591 HIV-infected patients to examine whether unhealthy alcohol use, drug use, primary care engagement, or antiretroviral adherence mediated observed associations.
ResultsAmong 1,591 HIV-infected patients, 47% reported having a history of incarceration. In multivariate analyses, a history of incarceration was associated with a higher VACS Index score ( 2.47, 95% CI 0.52-4.43). Mediation analysis revealed that recent drug use attenuated the association by 22% ( 1.93, 95% CI -0.06, 3.91) while other proposed mediators did not.
Conclusions and Scientific SignificanceImproving access to drug treatment when incarcerated and upon release may be an important target to improving the health of HIV-infected individuals with a history of incarceration. (Am J Addict 2015;24:178-184)
C1 [Wang, Emily A.; Long, Jessica B.; Akguen, Kathleen M.; Edelman, E. Jennifer; Wang, Karen H.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, New Haven, CT 06510 USA.
[Wang, Emily A.; Edelman, E. Jennifer; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT 06510 USA.
[McGinnis, Kathleen A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Akguen, Kathleen M.; Wang, Karen H.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
RP Wang, EA (reprint author), Yale Univ, Sch Med, Gen Internal Med, Harkness Hall Bldg A,367 Cedar St,Suite 410A, New Haven, CT 06510 USA.
EM emily.wang@yale.edu
OI Fiellin, David/0000-0002-4006-010X; Justice, Amy/0000-0003-0139-5502
FU National Institute on Drug Abuse [1R03DA031592]; National Institute on
Alcohol Abuse and Alcoholism [U01 AA 13566, U10 AA 13566]; National
Institute of Aging (NIA) [K23 AG00826]; Robert Wood Johnson Generalist
Faculty Scholar Award; NIA; National Institute of Mental Health; VA
HSR&D Research Enhancement Award Program (REAP) PRIME Project [REA
08-266]; National Heart Lung Blood Institute [K23 HL103720]; Yale
Clinical Center of Investigation's CTSA [UL1 RR024139]
FX Funding for this study was provided by National Institute on Drug Abuse
(1R03DA031592) to Dr. Wang; the NIDA had no further role in study
design; in the collection, analysis and interpretation of data; in the
writing of the report; or in the decision to submit the paper for
publication. VACS is funded by the National Institute on Alcohol Abuse
and Alcoholism (U01 AA 13566 and U10 AA 13566), National Institute of
Aging (NIA, K23 AG00826), Robert Wood Johnson Generalist Faculty Scholar
Award, an Inter-agency Agreement between NIA, National Institute of
Mental Health, and VA HSR&D Research Enhancement Award Program (REAP)
PRIME Project (REA 08-266). Emily Wang receives salary support from a
career development award from the National Heart Lung Blood Institute
(K23 HL103720) and the Yale Clinical Center of Investigation's CTSA
Grant (UL1 RR024139).
NR 34
TC 2
Z9 2
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAR
PY 2015
VL 24
IS 2
BP 178
EP 184
DI 10.1111/ajad.12177
PG 7
WC Substance Abuse
SC Substance Abuse
GA CF8KI
UT WOS:000352807600013
PM 25662297
ER
PT J
AU Walsh, TJ
Shores, MM
Fox, AE
Moore, KP
Forsberg, CW
Kinsey, CE
Heckbert, SR
Zeliadt, S
Thompson, ML
Smith, NL
Matsumoto, AM
AF Walsh, T. J.
Shores, M. M.
Fox, A. E.
Moore, K. P.
Forsberg, C. W.
Kinsey, C. E.
Heckbert, S. R.
Zeliadt, S.
Thompson, M. L.
Smith, N. L.
Matsumoto, A. M.
TI Recent trends in testosterone testing, low testosterone levels, and
testosterone treatment among Veterans
SO Andrology
LA English
DT Article
DE testosterone; trends; Veterans
ID LOW SERUM TESTOSTERONE; LATE-ONSET HYPOGONADISM; CARDIOVASCULAR-DISEASE;
ANDROGEN DEFICIENCY; INCREASED MORTALITY; OLDER MEN; PREVALENCE
AB Low serum testosterone (T) is common and increasingly prevalent with increased age. Recent studies report an epidemic' of T prescribing and concern about unnecessary T treatment. We investigated the number of men tested for T, the prevalence of low serum T levels, and initiation of T treatment among those with low T levels in men treated at Veterans Affairs (VA) facilities in the Northwest US (VISN 20). We identified male Veterans aged 40-89years and examined yearly proportions of men tested for T, found to have low T levels (total T<280ng/dL, free T<34pg/mL, or bioavailable T<84ng/dL), and subsequently treated with T from 2002 to 2011. We excluded men who had T treatment in the year prior and men with diagnoses of prostate or breast cancer. Treatment initiation was defined as the first prescription for T within a year following a low T test. From 2002 to 2011, the yearly population of eligible men in VISN 20 increased from 129247 to 163572. The proportion of men who had serum T tests increased from 3.2% in 2002 to 5.8% in 2011. Among the tested men, the percentage of men with low T levels increased from 35.0 to 47.3%. However, the proportion of men with low T levels who were given T treatment within a year decreased from 31.0 to 28.0%. Despite large increases in T testing, and detection of men with low T levels, there was a slight decrease in the proportion of men with low T levels who were treated with T. The decrease in T treatment during this time period contrasts with other studies and may be related to higher comorbidity in Veterans and/or VA formulary restrictions on the use of transdermal T formulations.
C1 [Walsh, T. J.; Heckbert, S. R.] Univ Washington, Seattle, WA 98195 USA.
[Shores, M. M.; Fox, A. E.; Moore, K. P.; Forsberg, C. W.; Kinsey, C. E.; Zeliadt, S.; Thompson, M. L.; Smith, N. L.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Thompson, M. L.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Matsumoto, A. M.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
RP Walsh, TJ (reprint author), Univ Washington, Dept Urol, 1959 NE Pacific St, Seattle, WA 98195 USA.
EM walsht@uw.edu
FU National Institutes of Health-National Institute on Aging
FX This study was supported by an R01 Grant, National Institutes of
Health-National Institute on Aging.
NR 26
TC 6
Z9 6
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-2919
EI 2047-2927
J9 ANDROLOGY-US
JI Andrology
PD MAR
PY 2015
VL 3
IS 2
BP 287
EP 292
DI 10.1111/andr.12014
PG 6
WC Andrology
SC Endocrinology & Metabolism
GA CG6HF
UT WOS:000353398800019
PM 25684636
ER
PT J
AU McCully, KS
AF McCully, Kilmer S.
TI The Active Site of Oxidative Phosphorylation and the Origin of
Hyperhomocysteinemia in Aging and Dementia
SO ANNALS OF CLINICAL AND LABORATORY SCIENCE
LA English
DT Article
DE homocysteine; cobalamin; thioretinamide; thioretinaco ozonide;
nicotinamide adenine dinucleotide; nicotinamide riboside; oxidative
phosphorylation; sirtuins; aging; dementia
ID NICOTINAMIDE-ADENINE-DINUCLEOTIDE; CHEMICAL PATHOLOGY; RIBOSIDE;
ADENOSYLMETHIONINE; HOMOCYSTEINE; METABOLISM; NUTRIENT; DISEASE; NAD(+)
AB The active site of oxidative phosphorylation and adenosine triphosphate (ATP) synthesis in mitochondria is proposed to consist of two molecules of thioretinamide bound to cobalamin, forming thioretinaco, complexed with ozone, oxygen, nicotinamide adenine dinucleotide. and inorganic phosphate, TR(2)CoO(3)O(2)NAD+H2PO4-. Reduction of the pyridinium nitrogen of the nicotinamide group by an electron from electron transport complexes initiates polymerization of phosphate with adenosine diphosphate, yielding nicotinamide riboside and ATP bound to thioretinaco ozonide oxygen. A second electron reduces oxygen to hydroperoxyl radical, releasing ATP from the active site. A proton gradient is created within F1F0 ATPase complexes of mitochondria by reaction of protons with reduced nicotinamide riboside and with hydroperoxyl radical, yielding reduced nicotinamide riboside and hydroperoxide. The hyperhomocysteinemia of aging and dementia is attributed to decreased synthesis of adenosyl methionine by thioretinaco ozonide and ATP, causing decreased allosteric activation of cystathionine synthase and decreased allosteric inhibition of methylenetetrahydrofolate reductase and resulting in dysregulation of methionine metabolism.
C1 [McCully, Kilmer S.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Pathol & Lab Med Serv, Boston, MA USA.
RP McCully, KS (reprint author), Pathol & Lab Med Serv, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.
EM kilmer.mccully@va.gov
RI McCully, Kevin/P-5141-2015
OI McCully, Kevin/0000-0001-9850-487X
NR 19
TC 5
Z9 5
U1 0
U2 2
PU ASSOC CLINICAL SCIENTISTS
PI MIDDLEBURY
PA PO BOX 1287, MIDDLEBURY, VT 05753 USA
SN 0091-7370
EI 1550-8080
J9 ANN CLIN LAB SCI
JI Ann. Clin. Lab. Sci.
PD SPR
PY 2015
VL 45
IS 2
BP 222
EP 225
PG 4
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA CG1WH
UT WOS:000353065600019
PM 25887881
ER
PT J
AU Chan, SJ
Chai, C
Lim, TW
Yamamoto, M
Lo, EH
Lai, MKP
Wong, PTH
AF Chan, Su Jing
Chai, Chou
Lim, Tze Wei
Yamamoto, Mie
Lo, Eng H.
Lai, Mitchell Kim Peng
Wong, Peter Tsun Hon
TI Cystathionine beta-Synthase Inhibition Is a Potential Therapeutic
Approach to Treatment of Ischemic Injury
SO ASN NEURO
LA English
DT Article
DE cystathioine beta-synthase; hydrogen sulfide; homocysteine; cysteine;
oxygen glucose deprivation; stroke
ID HYDROGEN-SULFIDE; CELL-DEATH; TOTAL HOMOCYSTEINE; CEREBRAL-ISCHEMIA;
OXIDATIVE STRESS; SH-SY5Y CELLS; PC12 CELLS; RAT-BRAIN; CYSTEINE; STROKE
AB Hydrogen sulfide (H2S) has been reported to exacerbate stroke outcome in experimental models. Cystathionine beta-synthase (CBS) has been implicated as the predominant H2S-producing enzyme in central nervous system. When SH-SY5Y cells were transfected to overexpress CBS, these cells were able to synthesize H2S when exposed to high levels of enzyme substrates but not substrate concentrations that may reflect normal physiological conditions. At the same time, these cells demonstrated exacerbated cell death when subjected to oxygen and glucose deprivation (OGD) together with high substrate concentrations, indicating that H2S production has a detrimental effect on cell survival. This effect could be abolished by CBS inhibition. The same effect was observed with primary astrocytes exposed to OGD and high substrates or sodium hydrosulfide. In addition, CBS was upregulated and activated by truncation in primary astrocytes subjected to OGD. When rats were subjected to permanent middle cerebral artery occlusion, CBS activation was also observed. These results imply that in acute ischemic conditions, CBS is upregulated and activated by truncation causing an increased production of H2S, which exacerbate the ischemic injuries. Therefore, CBS inhibition may be a viable approach to stroke treatment.
C1 [Chan, Su Jing; Lim, Tze Wei; Yamamoto, Mie; Lai, Mitchell Kim Peng; Wong, Peter Tsun Hon] Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117548, Singapore.
[Chai, Chou] Duke NUS Grad Med Sch, Singapore, Singapore.
[Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA.
[Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA.
RP Wong, PTH (reprint author), Natl Univ Singapore, Clin Res Ctr, Bldg MD11,05-09,10 Med Dr, Singapore 117597, Singapore.
EM peter_wong@nuhs.edu.sg
FU Biomedical Research Council [BMRC 01/1/21/19/169]
FX This work was funded by a grant from the Biomedical Research Council
(BMRC 01/1/21/19/169) awarded to PTHW.
NR 61
TC 4
Z9 4
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1759-0914
J9 ASN NEURO
JI ASN Neuro
PD MAR-APR
PY 2015
VL 7
IS 2
DI 10.1177/1759091415578711
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA CG4AU
UT WOS:000353223200001
ER
PT J
AU Whirledge, SD
Garcia, JM
Smith, RG
Lamb, DJ
AF Whirledge, Shannon D.
Garcia, Jose M.
Smith, Roy G.
Lamb, Dolores J.
TI Ghrelin Partially Protects Against Cisplatin-Induced Male Murine Gonadal
Toxicity in a GHSR-1a-Dependent Manner
SO BIOLOGY OF REPRODUCTION
LA English
DT Article
DE cell death; cisplatin; fertility; ghrelin; spermatogenesis
ID HORMONE SECRETAGOGUE RECEPTOR; HUMAN ENDOTHELIAL-CELLS; LONG-TERM
TOXICITY; TESTICULAR CANCER; RAT TESTIS; PROSTATE-CANCER; MOUSE TESTIS;
DOUBLE-BLIND; LUNG-CANCER; CHEMOTHERAPY
AB The chemotherapeutic drug cisplatin causes a number of dose-dependent side effects, including cachexia and testicular damage. Patients receiving a high cumulative dose of cisplatin may develop permanent azoospermia and subsequent infertility. Thus, the development of chemotherapeutic regimens with the optimal postsurvival quality of life (fertility) is of high importance. This study tested the hypothesis that ghrelin administration can prevent or minimize cisplatin-induced testicular damage and cachexia. Ghrelin and its receptor, the growth hormone secretagogue receptor (GHSR-1a), are expressed and function in the testis. Targeted deletion of ghrelin, or its receptor, significantly increases the rate of cell death in the testis, suggesting a protective role. Intraperitoneal administration of vehicle, ghrelin, or cisplatin alone or in combination with ghrelin, in cycles of 9 or 18 days, to adult male C57Bl/6 mice was performed. Body weight was measured daily and testicular and epididymal weight, sperm density and motility, testicular histology, and testicular cell death were analyzed at the time of euthanization. Ghrelin coadministration decreased the severity of cisplatin-induced cachexia and gonadal toxicity. Body, testicular, and epididymal weights significantly increased as testicular cell death decreased with ghrelin coadministration. The widespread damage to the seminiferous epithelium induced by cisplatin administration was less severe in mice simultaneously treated with ghrelin. Furthermore, ghrelin diminished the deleterious effects of cisplatin on testis and body weight homeostasis in wild-type but not Ghsr(-/-) mice, showing that ghrelin's actions are mediated via GHSR. Ghrelin or more stable GHSR agonists potentially offer a novel therapeutic approach to minimize the testicular damage that occurs after gonadotoxin exposure.
C1 [Whirledge, Shannon D.; Lamb, Dolores J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
[Lamb, Dolores J.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.
[Lamb, Dolores J.] Baylor Coll Med, Ctr Reprod Med, Houston, TX 77030 USA.
[Garcia, Jose M.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Endocrinol Diabet & Metab, Houston, TX 77030 USA.
[Smith, Roy G.] Scripps Res Inst, Dept Metab & Aging, Jupiter, FL USA.
RP Lamb, DJ (reprint author), Baylor Coll Med, Dept Urol, One Baylor Plaza Rm N730, Houston, TX 77030 USA.
EM dlamb@bcm.tmc.edu
FU National Institute of Kidney and Digestive Disease, National Institutes
of Health (NIH) [T32 DK007763-06]; Department of Veterans Affairs
(MREP); NIH [AG019230, HD060870, AG040583]; Department of Veterans
Affairs (SCNCDA); Department of Veterans Affairs [MERIT BX000507]
FX Supported in part by a grant from the National Institute of Kidney and
Digestive Disease, National Institutes of Health (NIH), T32 DK007763-06
to D.J.L. (trainee: S.D.W.), the Department of Veterans Affairs (MREP,
SCNCDA, and MERIT BX000507 to J.M.G.), NIH AG019230 (R.G.S.), and NIH
HD060870 and AG040583 (J.M.G.). Presented in part at the Endocrine
Society's 90th Annual Meeting, June 15-18, 2008, San Francisco,
California.
NR 69
TC 4
Z9 5
U1 0
U2 1
PU SOC STUDY REPRODUCTION
PI MADISON
PA 1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USA
SN 0006-3363
EI 1529-7268
J9 BIOL REPROD
JI Biol. Reprod.
PD MAR 1
PY 2015
VL 92
IS 3
AR 76
DI 10.1095/biolreprod.114.123570
PG 11
WC Reproductive Biology
SC Reproductive Biology
GA CG3XS
UT WOS:000353213500006
PM 25631345
ER
PT J
AU Pursnani, A
Chou, ET
Zakroysky, P
Deano, RC
Mamuya, WS
Woodard, PK
Nagurney, JT
Fleg, JL
Lee, H
Schoenfeld, D
Udelson, JE
Hoffmann, U
Truong, QA
AF Pursnani, Amit
Chou, Eric T.
Zakroysky, Pearl
Deano, Roderick C.
Mamuya, Wilfred S.
Woodard, Pamela K.
Nagurney, John T.
Fleg, Jerome L.
Lee, Hang
Schoenfeld, David
Udelson, James E.
Hoffmann, Udo
Truong, Quynh A.
TI Use of Coronary Artery Calcium Scanning Beyond Coronary Computed
Tomographic Angiography in the Emergency Department Evaluation for Acute
Chest Pain The ROMICAT II Trial
SO Circulation-Cardiovascular Imaging
LA English
DT Article
DE acute coronary syndrome; hospital emergency service; multidetector-row
computed tomography
ID AMERICAN-HEART-ASSOCIATION; ELECTRON-BEAM TOMOGRAPHY; CT ANGIOGRAPHY;
TUBE-VOLTAGE; ASSISTED TOMOGRAPHY; RADIATION-EXPOSURE; IMAGE QUALITY;
FOLLOW-UP; CALCIFICATION; RISK
AB Background-Whether a coronary artery calcium (CAC) scan provides added value to coronary computed tomographic angiography (CCTA) in emergency department patients with acute chest pain remains unsettled. We sought to determine the value of CAC scan in patients with acute chest pain undergoing CCTA.
Methods and Results-In the multicenter Rule Out Myocardial Infarction using Computer-Assisted Tomography (ROMICAT) II trial, we enrolled low-intermediate risk emergency department patients with symptoms suggesting acute coronary syndrome (ACS). In this prespecified subanalysis of 473 patients (54 +/- 8 years, 53% men) who underwent both CAC scanning and CCTA, the ACS rate was 8%. Overall, 53% of patients had CAC=0 of whom 2 (0.8%) developed ACS, whereas 7% had CAC>400 with 49% whom developed ACS. C-statistic of CAC>0 was 0.76, whereas that using the optimal cut point of CAC >= 22 was 0.81. Continuous CAC score had lower discriminatory capacity than CCTA (c-statistic, 0.86 versus 0.92; P=0.03). Compared with CCTA alone, there was no benefit combining CAC score with CCTA (c-statistic, 0.93; P=0.88) or with selective CCTA strategies after initial CAC>0 or optimal cut point CAC >= 22 (P >= 0.09). Mean radiation dose from CAC acquisition was 1.4 +/- 0.7 mSv. Higher CAC scores resulted in more nondiagnostic CCTA studies although the majority remained interpretable.
Conclusions-In emergency department patients with acute chest pain, CAC score does not provide incremental value beyond CCTA for ACS diagnosis. CAC=0 does not exclude ACS, nor a high CAC score preclude interpretation of CCTA in most patients. Thus, CAC results should not influence the decision to proceed with CCTA, and the decision to perform a CAC scan should be balanced with the additional radiation exposure required.
C1 [Pursnani, Amit; Mamuya, Wilfred S.; Hoffmann, Udo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Cardiol,Cardiac MR PET CT Program, Boston, MA USA.
[Nagurney, John T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Emergency Dept, Boston, MA USA.
[Zakroysky, Pearl; Lee, Hang; Schoenfeld, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Biostat Ctr, Boston, MA USA.
[Chou, Eric T.] Kaiser Permanente Fontana Med Ctr, Div Cardiol, Fontana, CA USA.
[Deano, Roderick C.; Truong, Quynh A.] New York Presbyterian Hosp, Weill Cornell Med Coll, Dalio Inst Cardiovasc Imaging, New York, NY 10021 USA.
[Woodard, Pamela K.] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO USA.
[Fleg, Jerome L.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA.
[Udelson, James E.] Tufts Med Ctr, Div Cardiol, Boston, MA USA.
[Udelson, James E.] Tufts Med Ctr, Ctr Cardiovasc, Boston, MA USA.
RP Truong, QA (reprint author), New York Presbyterian Hosp, Weill Cornell Med Coll, Dalio Inst Cardiovasc Imaging, 413 E 69th St,Suite 108, New York, NY 10021 USA.
EM qat9001@med.cornell.edu
FU National Institutes of Health (NIH)/National Heart, Lung, and Blood
Institute [U01HL092040, U01HL092022]; NIH [K23HL098370, L30HL093896];
[NIHT32 HL076136]
FX The study was supported by the National Institutes of Health
(NIH)/National Heart, Lung, and Blood Institute (U01HL092040 and
U01HL092022). Dr Truong was supported by the NIH (K23HL098370 and
L30HL093896). Dr Pursnani was supported by NIHT32 HL076136.
NR 35
TC 5
Z9 5
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-9651
EI 1942-0080
J9 CIRC-CARDIOVASC IMAG
JI Circ.-Cardiovasc. Imaging
PD MAR
PY 2015
VL 8
IS 3
AR e002225
DI 10.1161/CIRCIMAGING.114.002225
PG 11
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA CG5CW
UT WOS:000353309700003
ER
PT J
AU Pursnani, A
Lee, AM
Mayrhofer, T
Ahmed, W
Uthamalingam, S
Ferencik, M
Puchner, SB
Bamberg, F
Schlett, CL
Udelson, J
Hoffmann, U
Ghoshhajra, BB
AF Pursnani, Amit
Lee, Ashley M.
Mayrhofer, Thomas
Ahmed, Waleed
Uthamalingam, Shanmugam
Ferencik, Maros
Puchner, Stefan B.
Bamberg, Fabian
Schlett, Christopher L.
Udelson, James
Hoffmann, Udo
Ghoshhajra, Brian B.
TI Early Resting Myocardial Computed Tomography Perfusion for the Detection
of Acute Coronary Syndrome in Patients With Coronary Artery Disease
SO Circulation-Cardiovascular Imaging
LA English
DT Article
DE perfusion; emergency service, hospital; tomography, computed; scanners
ID ACUTE CHEST-PAIN; FRACTIONAL FLOW RESERVE; AMERICAN-HEART-ASSOCIATION;
CARDIOVASCULAR MAGNETIC-RESONANCE; RANDOMIZED CONTROLLED-TRIAL;
LEFT-VENTRICULAR FUNCTION; APPROPRIATE USE CRITERIA;
EMERGENCY-DEPARTMENT; CT ANGIOGRAPHY; CARDIAC CT
AB Background-Acute rest single-photon emission computed tomography-myocardial perfusion imaging (SPECT-MPI) has high predictive value for acute coronary syndrome (ACS) in emergency department patients. Prior studies have shown excellent agreement between rest/stress computed tomography perfusion (CTP) and SPECT-MPI, but the value of resting CTP (rCTP) in acute chest pain triage remains unclear. We sought to determine the diagnostic accuracy of early rCTP, incremental value beyond obstructive coronary artery disease (CAD; >= 50% stenosis), and compared early rCTP to late stress SPECT-MPI in patients with CAD presenting with suspicion of ACS to the emergency department.
Methods and Results-In this prespecified subanalysis of 183 patients (58.1 +/- 10.2 years; 33% women), we included patients with any CAD by coronary computed tomography angiography (CCTA) from Rule Out Myocardial Infarction Using Computer-Assisted Tomography I. rCTP was assessed semiquantitatively, blinded to CAD interpretation. Overall, 31 had ACS and 48 had abnormal rCTP. Sensitivity and specificity of rCTP for ACS were 48% (95% confidence interval [CI], 30%-67%) and 78% (95% CI, 71%-85%), respectively. rCTP predicted ACS (adjusted odds ratio, 3.40 [95% CI, 1.37-8.42]; P=0.008) independently of obstructive CAD, and sensitivity for ACS increased from 77% (95% CI, 59%-90%) for obstructive CAD to 90% (95% CI, 74%-98%) with addition of rCTP (P=0.05). In a subgroup undergoing late rest/stress SPECT-MPI (n=81), CCTA/rCTP had noninferior discriminatory value to CCTA/SPECT-MPI (area under the curve, 0.88 versus 0.90; P=0.64) using a noninferiority margin of 10%.
Conclusions-Early rCTP provides incremental value beyond obstructive CAD to detect ACS. CCTA/rCTP is noninferior to CCTA/SPECT-MPI to discriminate ACS and presents an attractive alternative to triage patients presenting with acute chest pain.
C1 [Pursnani, Amit] NorthShore Univ Hlth Syst, Div Cardiovasc, Evanston, IL USA.
[Pursnani, Amit; Lee, Ashley M.; Mayrhofer, Thomas; Ahmed, Waleed; Uthamalingam, Shanmugam; Ferencik, Maros; Puchner, Stefan B.; Hoffmann, Udo; Ghoshhajra, Brian B.] Massachusetts Gen Hosp, Dept Radiol, Div Cardiol, Cardiac MR PET CT Program, Boston, MA 02114 USA.
[Pursnani, Amit; Lee, Ashley M.; Mayrhofer, Thomas; Ahmed, Waleed; Uthamalingam, Shanmugam; Ferencik, Maros; Puchner, Stefan B.; Hoffmann, Udo; Ghoshhajra, Brian B.] Harvard Univ, Sch Med, Boston, MA USA.
[Bamberg, Fabian] Univ Munich, Klinikum Grosshadern, Dept Clin Radiol, D-80539 Munich, Germany.
[Schlett, Christopher L.] Univ Heidelberg Hosp, Dept Diagnost & Intervent Radiol, Heidelberg, Germany.
[Udelson, James] Tufts Med Ctr, Div Cardiol & Cardiovasc Ctr, Boston, MA USA.
RP Pursnani, A (reprint author), Northwestern Univ, Evanston Hosp, Div Cardiol, Walgreen Bldg 3rd Floor,2650 Ridge Ave, Evanston, IL 60201 USA.
EM apursnani@northshore.org
FU National Heart, Lung, and Blood Institute [R01 HL080053, 5K24HL113128];
National Institutes of Health [T32 HL076136]; American Heart Association
[13FTF1645000]
FX This work was supported by grants from the National Heart, Lung, and
Blood Institute (R01 HL080053 and 5K24HL113128). Drs Pursnani, Ahmed,
and Dr Uthamalingam received funding from the National Institutes of
Health T32 HL076136. Dr Ferencik was supported by a grant from the
American Heart Association 13FTF1645000
NR 39
TC 4
Z9 4
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-9651
EI 1942-0080
J9 CIRC-CARDIOVASC IMAG
JI Circ.-Cardiovasc. Imaging
PD MAR
PY 2015
VL 8
IS 3
AR e002404
DI 10.1161/CIRCIMAGING.114.002404
PG 10
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA CG5CW
UT WOS:000353309700004
PM 25752898
ER
PT J
AU Brennan, JM
Al-Hejily, W
Dai, D
Shaw, RE
Trilesskaya, M
Rao, SV
Brilakis, ES
Anstrom, KJ
Messenger, JC
Peterson, ED
Douglas, PS
Sketch, MH
AF Brennan, J. Matthew
Al-Hejily, Wesam
Dai, David
Shaw, Richard E.
Trilesskaya, Marina
Rao, Sunil V.
Brilakis, Emmanouil S.
Anstrom, Kevin J.
Messenger, John C.
Peterson, Eric D.
Douglas, Pamela S.
Sketch, Michael H., Jr.
TI Three-Year Outcomes Associated With Embolic Protection in Saphenous Vein
Graft Intervention Results in 49 325 Senior Patients in the
Medicare-Linked National Cardiovascular Data Registry CathPCI Registry
SO Circulation-Cardiovascular Interventions
LA English
DT Article
DE embolic protection devices
ID AORTOCORONARY BYPASS GRAFTS; BARE-METAL STENTS; DISTAL PROTECTION;
PERCUTANEOUS INTERVENTION; TRIAL; LESIONS; LINKING; DEVICES; EVENTS;
STILL
AB Background-Information is limited on contemporary use and outcomes of embolic protection devices (EPDs) in saphenous vein graft interventions.
Methods and Results-We formed a longitudinal cohort (2005-2009; n=49 325) by linking National Cardiovascular Data Registry CathPCI Registry to Medicare claims to examine the association between EPD use and both procedural and long-term outcomes among seniors (65+ years), adjusting for clinical factors using propensity and instrumental variable methodologies. Prespecified high-risk subgroups included acute coronary syndrome and de novo or graft body lesions. EPDs were used in 21.2% of saphenous vein grafts (median age, 75; 23% women) and were more common in acute coronary syndrome (versus non-acute coronary syndrome; 22% versus 19%), de novo (versus restenotic; 22% versus 14%), and graft body lesions (versus aortic and distal anastomosis; 24% versus 20% versus 8%, respectively). EPDs were associated with a slightly higher incidence of procedural complications, including no reflow (3.9% versus 2.8%; P<0.001), vessel dissection (1.3% versus 1.1%; P=0.05), perforation (0.7% versus 0.4%; P=0.001), and periprocedural myocardial infarction (2.8% versus 1.8%; P<0.001). By 3 years, death, myocardial infarction, and repeat revascularization occurred in 25%, 15%, and 30% of cases, respectively. EPD use was associated with a similar adjusted risk of death (propensity score-matched hazard ratio, 0.96; 95% confidence interval, 0.91-1.02), myocardial infarction (propensity score-matched hazard ratio, 1.00; 95% confidence interval, 0.93-1.09), and repeat revascularization (propensity score-matched hazard ratio, 1.02; 95% confidence interval, 0.96-1.08) in the overall cohort and high-risk subgroups.
Conclusions-In this contemporary cohort, EPDs were used more commonly among patients with high-risk clinical indications, yet there was no evidence of improved acute-or long-term outcomes. Further prospective studies are needed to support routine EPD use.
C1 [Brennan, J. Matthew; Al-Hejily, Wesam; Dai, David; Rao, Sunil V.; Anstrom, Kevin J.; Peterson, Eric D.; Douglas, Pamela S.; Sketch, Michael H., Jr.] Duke Clin Res Inst, Durham, NC USA.
[Shaw, Richard E.] Sutter Pacific Heart Ctr, San Francisco, CA USA.
[Trilesskaya, Marina] Carolina Pacific Med Ctr, San Francisco, CA USA.
[Brilakis, Emmanouil S.] Vet Affairs North Texas Healthcare Syst, Dallas, TX USA.
[Brilakis, Emmanouil S.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Messenger, John C.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA.
RP Brennan, JM (reprint author), Duke Univ, Med Ctr, Div Cardiovasc Med, 2400 Pratt St, Durham, NC 27705 USA.
EM j.matthew.brennan@dm.duke.edu
OI Brilakis, Emmanouil/0000-0001-9416-9701
FU Duke Clinical Research Institute, Durham, NC
FX This work was supported internally by the Duke Clinical Research
Institute, Durham, NC.
NR 28
TC 8
Z9 8
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-7640
EI 1941-7632
J9 CIRC-CARDIOVASC INTE
JI Circ.-Cardiovasc. Interv.
PD MAR
PY 2015
VL 8
IS 3
AR e001403
DI 10.1161/CIRCINTERVENTIONS.114.001403
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CG5CY
UT WOS:000353309900001
PM 25714391
ER
PT J
AU Schnurr, PP
Chard, KM
Ruzek, J
Chow, BK
Shih, MC
Resick, PA
Foa, EB
Marx, BP
Huang, GD
Lu, Y
AF Schnurr, Paula P.
Chard, Kathleen M.
Ruzek, Josef.
Chow, Bruce K.
Shih, Mei-Chiung
Resick, Patricia A.
Foa, Edna B.
Marx, Brian P.
Huang, Grant D.
Lu, Ying
TI Design of VA Cooperative Study #591: CERV-PTSD, Comparative
Effectiveness Research in Veterans with PTSD
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Comparative effectiveness; Posttraumatic stress disorder; Veterans;
Cognitive-behavioral therapy; Randomized clinical trial
ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-PROCESSING THERAPY; NATIONAL
COMORBIDITY SURVEY; PROLONGED EXPOSURE; SURVEY REPLICATION;
RANDOMIZED-TRIAL; AFFAIRS; PSYCHOTHERAPY; PREVALENCE; DEPRESSION
AB CERV-PTSD is a randomized controlled trial of two of the most effective treatments for PTSD, Prolonged Exposure (PE) and Cognitive Processing Therapy (CPT). Despite solid evidence that both treatments are effective, there is limited evidence about their effectiveness relative to one another. The primary objective is to compare the effectiveness of PE and CPT for reducing PTSD symptom severity in a healthcare system that offers both treatments.The secondary objective is to compare the effectiveness of PE and CPT for reducing the severity of comorbid mental health problems and service utilization as well as improving functioning and quality of life. The tertiary objective is to examine whether discrepancy between patient preferences and treatment assignment reduces the effectiveness of each treatment. Exploratory analyses will examine whether demographic and clinical characteristics predict differential response to PE and CPT. The study is designed to randomize 900 male and female veterans with PTSD due to any traumatic military event to receive PE or CPT. The standard dose of treatment is 12 weekly sessions but veterans who improve more rapidly may finish in fewer sessions and veterans who improve more slowly may have additional sessions. The primary outcome is improvement in PTSD symptoms, measured during and after treatment and then 3 and 6 months later. As a large multi-site trial with men and women, CERV-PTSD is designed to advance the delivery of care for PTSD by providing conclusive information about whether one treatment is better than the other,, overall, and for different types of patients. Published by Elsevier Inc.
C1 [Schnurr, Paula P.] Natl Ctr PTSD, Execut Div, White River Jct, VT 05009 USA.
[Schnurr, Paula P.] Geisel Sch Med Dartmouth, Hanover, NH USA.
[Chard, Kathleen M.] Cincinnati VA Med Ctr, Cincinnati, OH USA.
[Chard, Kathleen M.] Univ Cincinnati, Cincinnati, OH USA.
[Ruzek, Josef.] Natl Ctr PTSD, Disseminat & Training Div, Palo Alto, CA USA.
[Ruzek, Josef.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
[Chow, Bruce K.; Shih, Mei-Chiung; Lu, Ying] VA Cooperat Studies Program Coordinating Ctr, Palo Alto, CA USA.
[Shih, Mei-Chiung; Lu, Ying] Stanford Univ, Dept Hlth Res & Policy, Sch Med, Stanford, CA 94305 USA.
[Resick, Patricia A.] Duke Univ, Sch Med, Durham, NC USA.
[Foa, Edna B.] Univ Penn, Philadelphia, PA 19104 USA.
[Marx, Brian P.] Boston Univ, Sch Med, Natl Ctr PTSD, Behav Sci Div, Boston, MA 02118 USA.
[Marx, Brian P.] VA Boston Healthcare Syst, Boston, MA USA.
[Huang, Grant D.] Dept Vet Affairs Off Res & Dev, Cooperat Studies Program Cent Off, Washington, DC USA.
RP Schnurr, PP (reprint author), VA Med Ctr, Natl Ctr PTSD 116D, White River Jct, VT 05009 USA.
EM paula.schnurr@dartmouth.edu
FU VA Cooperative Studies Program
FX This study is being conducted with funding from the VA Cooperative
Studies Program. The views expressed in this article are those of the
authors and do not necessarily represent the views of the Department of
Veterans Affairs or any US government agency. Trial registration
information for CSP #591: clinicaltrials.gov Identifier NCT01928732.
NR 61
TC 8
Z9 8
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD MAR
PY 2015
VL 41
BP 75
EP 84
DI 10.1016/j.cct.2014.11.017
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CG0YQ
UT WOS:000353000500010
PM 25457792
ER
PT J
AU Zimmerman, RF
Belanger, ES
Pfeiffer, CD
AF Zimmerman, Robert F.
Belanger, Elizabeth S.
Pfeiffer, Christopher D.
TI Skin Infections in Returned Travelers: an Update
SO CURRENT INFECTIOUS DISEASE REPORTS
LA English
DT Article
DE Skin infection; Travel medicine; Cutaneous larva migrans; Cutaneous
leishmaniasis; Tungiasis; Myiasis; Antibiotic resistance; Skin and soft
tissue infection; Measles; Chikungunya
ID CUTANEOUS LARVA MIGRANS; GEOSENTINEL SURVEILLANCE; LEISHMANIASIS;
OUTBREAK; COMMUNITY; DIAGNOSIS; MEASLES; MILTEFOSINE; ELIMINATION;
TUNGIASIS
AB Dermatologic manifestations of travel-related illness are particularly vexing due to the broad differential diagnosis and clinicians' unfamiliarity with uncommonly seen diseases. This paper aims to educate and update the reader on selected infectious diseases in the returned traveler whose disease manifestations are primarily dermatologic. First, the evolving epidemiology of these infections is examined; understanding the geographic distribution of infectious etiologies helps refine and narrow the differential diagnosis. This is followed by a discussion of six important clinical syndromes including cutaneous larva migrans (CLM), cutaneous leishmaniasis, tungiasis, myiasis, antibiotic-resistant skin and soft tissue infection, and selected infections associated with fever and rash (e.g., measles, chikungunya virus infection, dengue fever, rickettsial spotted fevers). Familiarity with these syndromes and a situational awareness of their epidemiology will facilitate a prompt, accurate diagnosis and lead to appropriate treatment and prevention of further disease spread.
C1 [Zimmerman, Robert F.; Belanger, Elizabeth S.; Pfeiffer, Christopher D.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Pfeiffer, Christopher D.] Portland VA Med Ctr, Dept Hosp & Specialty Med, Portland, OR 97239 USA.
RP Pfeiffer, CD (reprint author), Portland VA Med Ctr, Dept Hosp & Specialty Med, POB 1034 P3-ID, Portland, OR 97239 USA.
EM pfeiffec@ohsu.edu
FU Oregon Health Authority
FX Elizabeth Belanger has no conflicts of interest. Christopher Pfeiffer
received funding for other work from Oregon Health Authority.
NR 47
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3847
EI 1534-3146
J9 CURR INFECT DIS REP
JI Curr. Infect. Dis. Rep.
PD MAR
PY 2015
VL 17
IS 3
AR 10
DI 10.1007/s11908-015-0467-8
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA CG7VY
UT WOS:000353515300003
ER
PT J
AU Moura, LMVR
Mendez, DY
De Jesus, J
Andrade, RA
Hoch, DB
AF Moura, Lidia M. V. R.
Mendez, Diego Yacaman
De Jesus, Jonathan
Andrade, Rogger A.
Hoch, Daniel B.
TI Quality care in epilepsy: Women's counseling and its association with
folic acid prescription or recommendation
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE Epilepsy Quality Measures; Epilepsy outcomes; Safety counseling; Women's
counseling; Health-care reform; Pay for performance
ID PATIENT; MANAGEMENT; PREGNANCY; SPECIALTY; KNOWLEDGE; PEOPLE
AB Objective: This study aimed to determine if annual counseling about contraception and pregnancy in the setting of treatment for epilepsy is associated with increased recommending or prescribing of folate.
Methods: This is a retrospective cohort study with medical record abstraction. We selected records from 77 women of childbearing age who had two or more visits for epilepsy at a neurology clinic. The assessment included a review of documentation from the first three visits for epilepsy within a 24-month follow-up window. We defined perfect adherence to annual counseling about the impact of epilepsy treatment on contraception or pregnancy as defect-free care for women (DFCW). A recommendation that the patient take over-the-counter folate or a prescription for folate was independently abstracted from the chart at each visit.
Results: The group of patients who received DFCW (N = 28, 36.36%) and the group who did not receive DFCW (N = 49, 63.63%) were comparable with respect to age, disease duration, baseline history of drug-resistant epilepsy (DRE), presence of concurrent psychiatric disease, epileptologist involvement, number of antiepileptic drugs (AEDs) prescribed, seizure type, and etiology. Twenty (71.4%) patients in the DFCW group and 42 (85.7%) in the non-DFCW group were not recommended or prescribed folic acid (p = 0.12).
Conclusions: Even with annual documentation of counseling about howepilepsy treatment may affect contraception and pregnancy, the "action" of prescribing or recommending folic acid during the ensuing 24 months is frequently omitted. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Moura, Lidia M. V. R.; Mendez, Diego Yacaman; De Jesus, Jonathan; Andrade, Rogger A.; Hoch, Daniel B.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Moura, LMVR (reprint author), Massachusetts Gen Hosp, Wang 720 Neurol,55 Fruit St, Boston, MA 02114 USA.
EM lidia.moura@mgh.harvard.edu; dymendez@partners.org;
jdejesus5@partners.org; raandrade@partners.org; dhoch@partners.org
FU Massachusetts General Hospital Center of Expertise in Quality and Safety
[223639]; Eisai, inc [2013D004806]
FX This study was supported by the Massachusetts General Hospital Center of
Expertise in Quality and Safety (Grant number: 223639) and the Eisai,
inc (Grant number: 2013D004806).
NR 21
TC 5
Z9 5
U1 2
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD MAR
PY 2015
VL 44
BP 151
EP 154
DI 10.1016/j.yebeh.2014.12.039
PG 4
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA CG4AI
UT WOS:000353221600027
PM 25705826
ER
PT J
AU Hall, RK
Landerman, LR
O'Hare, AM
Anderson, RA
Colon-Emeric, CS
AF Hall, Rasheeda K.
Landerman, Lawrence R.
O'Hare, Ann M.
Anderson, Ruth A.
Colon-Emeric, Cathleen S.
TI Chronic kidney disease and recurrent falls in nursing home residents: A
retrospective cohort study
SO GERIATRIC NURSING
LA English
DT Article
DE Skilled nursing facility; Renal insufficiency; Frail elderly
ID GLOMERULAR-FILTRATION-RATE; RISK-FACTORS; RENAL-INSUFFICIENCY; SERUM
CREATININE; COCKCROFT-GAULT; PREVALENCE; PREVENTION; ANEMIA;
COMPLICATIONS; EPIDEMIOLOGY
AB This study examined whether chronic kidney disease (CKD) is associated with recurrent falls in older adults in nursing homes (NHs). We used data abstracted over a six month period from 510 NH residents with a history of falls. Thirty-five percent of the NH residents had CKD. In adjusted analyses, the incidence of recurrent falls was similar in those with and without CKD [fall rate ratio (FRR) 1.00, 95% confidence interval (Cl) 0.97-1.02]. Orthostatic hypotension (FRR 1.52, 95% Cl 1.12-2.05), history of falls during the prior six month period (FRR 1.25, 95% CI 1.05-1.49), cane or walker use (FRR 1.64, 95% Cl 1.16-2.33), and ambulatory dysfunction (FRR 1.47, 95% Cl 1.23-1.75) were independently associated with increased fall rate. CKD was not an important predictor of falls in this cohort of nursing home residents with prior falls. Instead, traditional fall risk factors were much more strongly associated with recurrent falls. Published by Elsevier Inc.
C1 [Hall, Rasheeda K.] Duke Univ, Med Ctr, Div Nephrol, Dept Med, Durham, NC 27710 USA.
[Hall, Rasheeda K.; Colon-Emeric, Cathleen S.] Durham VA Geriatr Res Educ & Clin Ctr, Durham, NC 27705 USA.
[Landerman, Lawrence R.; Colon-Emeric, Cathleen S.] Duke Univ, Med Ctr, Div Geriatr, Dept Med, Durham, NC 27710 USA.
[Landerman, Lawrence R.; Anderson, Ruth A.] Duke Univ, Sch Nursing, Durham, NC 27710 USA.
[O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Dept Med, Seattle, WA 98108 USA.
[O'Hare, Ann M.] HSR&D Ctr Excellence, Seattle, WA 98108 USA.
[O'Hare, Ann M.] Univ Washington, Div Nephrol, Dept Med, Seattle, WA 98195 USA.
RP Hall, RK (reprint author), Box DUMC 2747,2424 Erwin Rd Suite 605, Durham, NC 27710 USA.
EM rasheeda.stephens@dm.duke.edu
OI Hall, Rasheeda/0000-0002-3057-4828
FU National Institute on Aging of the National Institutes of Health
[P30AG028716]; National Institute of Nursing Research [R01NR003178];
Office of Academic Affiliations, US Department of Veterans Affairs
FX Research reported in this publication was supported by the National
Institute on Aging of the National Institutes of Health under Award
Number P30AG028716. It was also supported by the National Institute of
Nursing Research (R01NR003178). The content is solely the responsibility
of the authors and does not necessarily represent the official views of
the National Institutes of Health.; Dr. Hall was supported in part by a
fellowship award from the Office of Academic Affiliations, US Department
of Veterans Affairs. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
Department of Veterans Affairs or the United States government.
NR 29
TC 1
Z9 1
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4572
EI 1528-3984
J9 GERIATR NURS
JI Geriatr. Nurs.
PD MAR-APR
PY 2015
VL 36
IS 2
BP 136
EP 141
DI 10.1016/j.gerinurse.2014.12.012
PG 6
WC Geriatrics & Gerontology; Gerontology; Nursing
SC Geriatrics & Gerontology; Nursing
GA CG3LU
UT WOS:000353182500008
PM 25616732
ER
PT J
AU Gilmore-Bykovskyi, AL
AF Gilmore-Bykovskyi, Andrea L.
TI Caregiver person-centeredness and behavioral symptoms during mealtime
interactions: Development and feasibility of a coding scheme
SO GERIATRIC NURSING
LA English
DT Article
DE Dementia; Behavioral Symptoms; Person-Centered Caregiving;
Video-observation
ID NURSING-HOME RESIDENTS; CLUSTER-RANDOMIZED-TRIAL; HIGH AGREEMENT;
OLDER-ADULTS; DEMENTIA-CARE; LOW KAPPA; INTERVENTIONS; DIFFICULTIES;
AGITATION; RELIABILITY
AB Mealtime behavioral symptoms are distressing and frequently interrupt eating for the individual experiencing them and others in the environment. A computer-assisted coding scheme was developed to measure caregiver person-centeredness and behavioral symptoms for nursing home residents with dementia during mealtime interactions. The purpose of this pilot study was to determine the feasibility, ease of use, and inter-observer reliability of the coding scheme, and to explore the clinical utility of the coding scheme. Trained observers coded 22 observations. Data collection procedures were acceptable to participants. Overall, the coding scheme proved to be feasible, easy to execute and yielded good to very good inter-observer agreement following observer re-training. The coding scheme captured clinically relevant, modifiable antecedents to mealtime behavioral symptoms, but would be enhanced by the inclusion of measures for resident engagement and consolidation of items for measuring caregiver person-centeredness that co-occurred and were difficult for observers to distinguish. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Gilmore-Bykovskyi, Andrea L.] US Dept Vet Affairs, GRECC, William S Middleton Hosp, Madison, WI 53705 USA.
[Gilmore-Bykovskyi, Andrea L.] Univ Wisconsin, Sch Nursing, Madison, WI 53705 USA.
RP Gilmore-Bykovskyi, AL (reprint author), US Dept Vet Affairs, GRECC, William S Middleton Hosp, Madison, WI 53705 USA.
EM algilmore@wisc.edu
FU National Hartford Centers of Gerontological Nursing Excellence Patricia
G. Archbold Scholar Program; Claire M. Fagin Postdoctoral Fellowship
Program; Virginia Stone Research Grant in Clinical Gerontology from the
American Nurses Foundation; Nurses Foundation of Wisconsin; University
of Wisconsin-Madison School of Nursing Eckburg Research Award; National
Center for Research Resources, National Institutes of Health
[1UL1RR025011]
FX This work was supported by the National Hartford Centers of
Gerontological Nursing Excellence Patricia G. Archbold Scholar Program
and Claire M. Fagin Postdoctoral Fellowship Program. This research was
supported by the Virginia Stone Research Grant in Clinical Gerontology
from the American Nurses Foundation, and in part by the Nurses
Foundation of Wisconsin and University of Wisconsin-Madison School of
Nursing Eckburg Research Award. Dr. Gilmore-Bykovskyi's time during
preparation of this manuscript was also supported by the William S.
Middleton Veterans Affairs Hospital in Madison, WI. This work is also
supported, in part, by the Clinical and Translational Science Award
program of the National Center for Research Resources, National
Institutes of Health (1UL1RR025011). The content is solely the
responsibility of the author and does not necessarily represent the
official views of the NIH. The author would like to acknowledge Drs.
Louis Medvene and Carissa Coleman for early consultation in planning
this research. This work was presented at the Gerontological Society of
America's 2014 Annual Scientific Meeting in Washington, D.C.
NR 30
TC 0
Z9 0
U1 5
U2 9
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4572
EI 1528-3984
J9 GERIATR NURS
JI Geriatr. Nurs.
PD MAR-APR
PY 2015
VL 36
IS 2
SU S
BP S10
EP S15
DI 10.1016/j.gerinurse.2015.02.018
PG 6
WC Geriatrics & Gerontology; Gerontology; Nursing
SC Geriatrics & Gerontology; Nursing
GA CG3LW
UT WOS:000353182700003
PM 25784080
ER
PT J
AU De Santis, ML
Myrick, H
Lamis, DA
Pelic, CP
Rhue, C
York, J
AF De Santis, Mark L.
Myrick, Hugh
Lamis, Dorian A.
Pelic, Christopher P.
Rhue, Collete
York, Janet
TI Suicide-specific Safety in the Inpatient Psychiatric Unit
SO Issues in Mental Health Nursing
LA English
DT Article
ID TOWER-OF-BABEL; MENTAL-HEALTH; COLLABORATIVE ASSESSMENT;
RISK-ASSESSMENT; EMERGENCY-DEPARTMENT; REVISED NOMENCLATURE; VA
PATIENTS; PREVENTION; MANAGEMENT; VETERANS
AB In total, 75% of suicides reported to the Joint Commission as sentinel events since 1995, have occurred in psychiatric settings. Ensuring patient safety is one of the primary tasks of inpatient psychiatric units. A review of inpatient suicide-specific safety components, inclusive of incidence and risk; guidelines for evidence-based care; environmental safety; suicide risk assessment; milieu observation and monitoring; psychotherapeutic interventions; and documentation is provided. The Veterans Health Administration (VA) has been recognized as an exemplar system in suicide prevention. A VA inpatient psychiatric unit is used to illustrate the operationalization of a culture of suicide-specific safety. We conclude by describing preliminary unit outcomes and acknowledging limitations of suicide-specific inpatient care and gaps in the current inpatient practices and research on psychotherapeutic interventions, observation, and monitoring.
C1 [De Santis, Mark L.; Pelic, Christopher P.; Rhue, Collete; York, Janet] Ralph H Johnson VAMC, Mental Hlth Serv Line, Charleston, SC USA.
[Myrick, Hugh] Med Univ S Carolina, Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Lamis, Dorian A.] Emory Univ, Sch Med, Atlanta, GA 30303 USA.
RP Lamis, DA (reprint author), Emory Univ, Sch Med, 80 Jesse Hill Jr Dr, Atlanta, GA 30303 USA.
EM Dalamis@gmail.com
OI De Santis, Mark/0000-0002-3611-1779
NR 91
TC 4
Z9 4
U1 6
U2 10
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0161-2840
EI 1096-4673
J9 ISSUES MENT HEALTH N
JI Issues Ment. Health Nurs.
PD MAR
PY 2015
VL 36
IS 3
BP 190
EP 199
DI 10.3109/01612840.2014.961625
PG 10
WC Nursing; Psychiatry
SC Nursing; Psychiatry
GA CG4ZO
UT WOS:000353298300005
PM 25898018
ER
PT J
AU Fujiwara, K
Inoue, T
Yorifuji, N
Iguchi, M
Sakanaka, T
Narabayashi, K
Kakimoto, K
Nouda, S
Okada, T
Ishida, K
Abe, Y
Masuda, D
Takeuchi, T
Fukunishi, S
Umegaki, E
Akiba, Y
Kaunitz, JD
Higuchi, K
AF Fujiwara, Kaori
Inoue, Takuya
Yorifuji, Naoki
Iguchi, Munetaka
Sakanaka, Taisuke
Narabayashi, Ken
Kakimoto, Kazuki
Nouda, Sadaharu
Okada, Toshihiko
Ishida, Kumi
Abe, Yosuke
Masuda, Daisuke
Takeuchi, Toshihisa
Fukunishi, Shinya
Umegaki, Eiji
Akiba, Yasutada
Kaunitz, Jonathan D.
Higuchi, Kazuhide
TI Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor
sitagliptin and elemental diets reduced indomethacin-induced intestinal
injury in rats via the increase of mucosal glucagon-like peptide-2
concentration
SO JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION
LA English
DT Article
DE GLP-1; GLP-2; DPP4; DPP8; sitagliptin
ID INFLAMMATORY-BOWEL-DISEASE; LOW-DOSE ASPIRIN; CROHNS-DISEASE;
BICARBONATE SECRETION; EXPERIMENTAL COLITIS; IV; MICE; TEDUGLUTIDE;
EXPRESSION; IMPACT
AB The gut incretin glucagon-like peptide-1 (GLP-1) and the intestinotropic hormone GLP-2 are released from enteroendocrine L cells in response to ingested nutrients. Treatment with an exogenous GLP-2 analogue increases intestinal villous mass and prevents intestinal injury. Since GLP-2 is rapidly degraded by dipeptidyl peptidase 4 (DPP4), DPP4 inhibition may be an effective treatment for intestinal ulcers. We measured mRNA expression and DPP enzymatic activity in intestinal segments. Mucosa! DPP activity and GLP concentrations were measured after administration of the DPP4 inhibitor sitagliptin (STG). Small intestinal ulcers were induced by indomethacin (IM) injection. STG was given before IM treatment, or orally administered after IM treatment with or without an elemental diet (ED). DPP4 mRNA expression and enzymatic activity were high in the jejunum and ileum. STG dose-dependently suppressed ileal mucosal enzyme activity. Treatment with STG prior to IM reduced small intestinal ulcer scores. Combined treatment with STG and ED accelerated intestinal ulcer healing, accompanied by increased mucosa! GLP-2 concentrations. The reduction of ulcers by ED and STG was reversed by co-administration of the GLP-2 receptor antagonist. DPP4 inhibition combined with luminal nutrients, which up-regulate mucosal concentrations of GLP-2, may be an effective therapy for the treatment of small intestinal ulcers.
C1 [Fujiwara, Kaori; Inoue, Takuya; Yorifuji, Naoki; Iguchi, Munetaka; Sakanaka, Taisuke; Narabayashi, Ken; Kakimoto, Kazuki; Nouda, Sadaharu; Okada, Toshihiko; Ishida, Kumi; Abe, Yosuke; Masuda, Daisuke; Takeuchi, Toshihisa; Fukunishi, Shinya; Umegaki, Eiji; Higuchi, Kazuhide] Osaka Med Coll, Dept Internal Med 2, Takatsuki, Osaka 5698686, Japan.
[Akiba, Yasutada; Kaunitz, Jonathan D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
[Akiba, Yasutada; Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA.
[Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90024 USA.
RP Inoue, T (reprint author), Osaka Med Coll, Dept Internal Med 2, 2-7 Daigakumachi, Takatsuki, Osaka 5698686, Japan.
EM ureuretakuwan@yahoo.co.jp
FU NIDDK NIH HHS [R01 DK054221]
NR 34
TC 4
Z9 5
U1 0
U2 3
PU JOURNAL CLINICAL BIOCHEMISTRY & NUTRITION
PI KYOTO
PA KYOTO PREFECTURAL UNIV MED, GRAD SCH MEDICAL SCIENCE, DEPT MOLECULAR
GASTROENTEROLOGY & HEPATOLOGY, KYOTO, 602-8566, JAPAN
SN 0912-0009
EI 1880-5086
J9 J CLIN BIOCHEM NUTR
JI J. Clin. Biochem. Nutr.
PD MAR 1
PY 2015
VL 56
IS 2
BP 155
EP 162
DI 10.3164/jcbn.14-111
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CG6TE
UT WOS:000353434500011
PM 25759522
ER
PT J
AU Klann, JG
Mendis, M
Phillips, LC
Goodson, AP
Rocha, BH
Goldberg, HS
Wattanasin, N
Murphy, SN
AF Klann, Jeffrey G.
Mendis, Michael
Phillips, Lori C.
Goodson, Alyssa P.
Rocha, Beatriz H.
Goldberg, Howard S.
Wattanasin, Nich
Murphy, Shawn N.
TI Taking advantage of continuity of care documents to populate a research
repository
SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
LA English
DT Article
DE Medical Informatics; Information Storage and Retrieval; Meaningful Use;
Systems Integration; Database Management Systems
ID DECISION-SUPPORT; HEALTH
AB Objective Clinical data warehouses have accelerated clinical research, but even with available open source tools, there is a high barrier to entry due to the complexity of normalizing and importing data. The Office of the National Coordinator for Health Information Technology's Meaningful Use Incentive Program now requires that electronic health record systems produce standardized consolidated clinical document architecture (C-CDA) documents. Here, we leverage this data source to create a low volume standards based import pipeline for the Informatics for Integrating Biology and the Bedside (i2b2) clinical research platform. We validate this approach by creating a small repository at Partners Healthcare automatically from C-CDA documents.
Materials and methods We designed an i2b2 extension to import C-CDAs into i2b2. It is extensible to other sites with variances in C-CDA format without requiring custom code. We also designed new ontology structures for querying the imported data.
Results We implemented our methodology at Partners Healthcare, where we developed an adapter to retrieve C-CDAs from Enterprise Services. Our current implementation supports demographics, encounters, problems, and medications. We imported approximately 17 000 clinical observations on 145 patients into i2b2 in about 24 min. We were able to perform i2b2 cohort finding queries and view patient information through SMART apps on the imported data.
Discussion This low volume import approach can serve small practices with local access to C-CDAs and will allow patient registries to import patient supplied C-CDAs. These components will soon be available open source on the i2b2 wiki.
Conclusions Our approach will lower barriers to entry in implementing i2b2 where informatics expertise or data access are limited.
C1 [Klann, Jeffrey G.; Mendis, Michael; Phillips, Lori C.; Goodson, Alyssa P.; Rocha, Beatriz H.; Goldberg, Howard S.; Wattanasin, Nich; Murphy, Shawn N.] Partners Healthcare, Boston, MA USA.
[Klann, Jeffrey G.; Rocha, Beatriz H.; Goldberg, Howard S.; Murphy, Shawn N.] Harvard Univ, Sch Med, Boston, MA USA.
[Klann, Jeffrey G.; Murphy, Shawn N.] Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
[Rocha, Beatriz H.; Goldberg, Howard S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Klann, JG (reprint author), Massachusetts Gen Hosp, Comp Sci Lab, Constitut Ctr 1, Charlestown, MA 02129 USA.
EM jeff.klann@mgh.harvard.edu
FU ONC [90TR0001/01]; NIH National Library of Medicine [U54LM00874]; NIH
NIGMS [5R01GM104303-02]
FX This work was supported in part by ONC 90TR0001/01, NIH National Library
of Medicine U54LM00874, and NIH NIGMS 5R01GM104303-02.
NR 30
TC 3
Z9 4
U1 1
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1067-5027
EI 1527-974X
J9 J AM MED INFORM ASSN
JI J. Am. Med. Inf. Assoc.
PD MAR
PY 2015
VL 22
IS 2
BP 370
EP 379
DI 10.1136/amiajnl-2014-003040
PG 10
WC Computer Science, Information Systems; Computer Science,
Interdisciplinary Applications; Health Care Sciences & Services;
Information Science & Library Science; Medical Informatics
SC Computer Science; Health Care Sciences & Services; Information Science &
Library Science; Medical Informatics
GA CF7YE
UT WOS:000352771500014
PM 25352566
ER
PT J
AU Nazi, KM
Turvey, CL
Klein, DM
Hogan, TP
Woods, SS
AF Nazi, Kim M.
Turvey, Carolyn L.
Klein, Dawn M.
Hogan, Timothy P.
Woods, Susan S.
TI VA OpenNotes: exploring the experiences of early patient adopters with
access to clinical notes
SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
LA English
DT Article
DE access; patient portal; eHealth; Open Notes; communication; veteran
ID PERSONAL HEALTH RECORDS; PATIENTS ONLINE ACCESS; MEDICAL-RECORDS;
MEANINGFUL USE; OF-VETERANS; CARE; INFORMATION; PORTALS; DOCTORS;
TRANSFORMATION
AB Objective To explore the experience of early patient adopters who accessed their clinical notes online using the Blue Button feature of the My HealtheVet portal.
Methods A web-based survey of VA patient portal users from June 22 to September 15, 2013.
Results 33.5% of respondents knew that clinical notes could be viewed, and nearly one in four (23.5%) said that they had viewed their notes at least once. The majority of VA Notes users agreed that accessing their notes will help them to do a better job of taking medications as prescribed (80.1%) and be better prepared for clinic visits (88.6%). Nine out of 10 users agreed that use of visit notes will help them understand their conditions better (91.8%), and better remember the plan for their care (91.9%). In contrast, 87% disagreed that VA Notes will make them worry more, and 88.4% disagreed that access to VA Notes will be more confusing than helpful. Users who had either contacted their provider or healthcare team (11.9%) or planned to (13.5%) primarily wanted to learn more about a health issue, medication, or test results (53.7%).
Conclusions Initial assessment of the patient experience within the first 9 months of availability provides evidence that patients both value and benefit from online access to clinical notes. These findings are congruent with OpenNotes study findings on a broader scale. Additional outreach and education is needed to enhance patient awareness. Healthcare professionals should author notes keeping in mind the opportunity patient access presents for enhanced communication.
C1 [Nazi, Kim M.] US Dept Vet Affairs, Vet & Consumers Hlth Informat Off, Off Informat & Analyt, Vet Hlth Adm, Washington, DC USA.
[Turvey, Carolyn L.; Klein, Dawn M.] Iowa City VA Hlth Care Syst, Comprehens Access & Delivery Res & Evaluat CADRE, Iowa City, IA USA.
[Turvey, Carolyn L.; Klein, Dawn M.] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA.
[Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Hosp, CHOIR, A VA HSR&D Ctr Innovat, Bedford, MA USA.
[Hogan, Timothy P.] eHlth Qual Enhancement Res Initiat, Natl eHlth QUERI Coordinating Ctr, Edith Nourse Rogers Mem Vet Hosp, Bedford, MA USA.
[Hogan, Timothy P.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Div Hlth Informat & Implementat Sci, Worcester, MA USA.
[Woods, Susan S.] VA Maine Healthcare Syst, Togus, ME USA.
[Woods, Susan S.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
RP Nazi, KM (reprint author), Vet & Consumers Hlth Informat Off, C-O 113 Holland Ave, Albany, NY 12208 USA.
EM kim.nazi@va.gov
FU Veterans Health Administration
FX Primary funding source: Veterans Health Administration.
NR 47
TC 14
Z9 14
U1 3
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1067-5027
EI 1527-974X
J9 J AM MED INFORM ASSN
JI J. Am. Med. Inf. Assoc.
PD MAR
PY 2015
VL 22
IS 2
BP 380
EP 389
DI 10.1136/amiajnl-2014-003144
PG 10
WC Computer Science, Information Systems; Computer Science,
Interdisciplinary Applications; Health Care Sciences & Services;
Information Science & Library Science; Medical Informatics
SC Computer Science; Health Care Sciences & Services; Information Science &
Library Science; Medical Informatics
GA CF7YE
UT WOS:000352771500015
PM 25352570
ER
PT J
AU Shah, AD
Schmidt, H
Sen, S
Shlipak, MG
Kanaya, AM
AF Shah, Arti D.
Schmidt, Heidi
Sen, Saunak
Shlipak, Michael G.
Kanaya, Alka M.
TI The association between body composition and cystatin C in South Asians:
Results from the MASALA study
SO OBESITY RESEARCH & CLINICAL PRACTICE
LA English
DT Article
DE Body composition; Ectopic fat; Cystatin C; South Asian
ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; ADIPOSE-TISSUE;
SUBCUTANEOUS ADIPOSITY; DIABETES-MELLITUS; ATHEROSCLEROSIS; AMERICA;
OBESITY; COHORT
AB While South Asians have high rates of obesity and kidney disease, little is known about the effect of regional body composition on kidney function. We investigated the association between body composition measures and cystatin C-based estimated glomerular filtration rate (eGFR(cysC)) in 150 immigrant South Asians. The inverse association between overall adiposity and eGFR(cysC) was attenuated by C-reactive protein (CRP), while the association of ectopic fat was completely attenuated by metabolic covariates and CRP. In immigrant South Asians, the associations between overall adiposity and ectopic fat with decreased kidney function are largely explained by metabolic alterations and inflammation. (C) 2014 Asian Oceanian Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.
C1 [Shah, Arti D.] Univ Calif San Francisco, Div Endocrinol & Metab, San Francisco, CA 94143 USA.
[Schmidt, Heidi; Kanaya, Alka M.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA USA.
[Sen, Saunak; Shlipak, Michael G.; Kanaya, Alka M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Shlipak, Michael G.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA.
RP Kanaya, AM (reprint author), 2200 Post St,Suite C-428,POB 1222, San Francisco, CA 94115 USA.
EM Arti.Shah@ucsf.edu
FU NIH [K23 HL080026-01]; NIH/NCRR UCSF-CTSI Grant [UL1 RR024131]; T32
Training Grant [5T32DK007418]; Wilsey Family Foundation; [K24HL112827];
[RO1HL093009]
FX This MASALA study was supported by the NIH [grant no. K23 HL080026-01]
and by NIH/NCRR UCSF-CTSI Grant Number UL1 RR024131. Dr. Shah was
supported by the T32 Training Grant Number 5T32DK007418 and the Wilsey
Family Foundation. Dr. Kanaya was supported by K24HL112827 and
RO1HL093009.
NR 16
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1871-403X
EI 1878-0318
J9 OBES RES CLIN PRACT
JI Obes. Res. Clin. Pract.
PD MAR-APR
PY 2015
VL 9
IS 2
BP 180
EP 183
DI 10.1016/j.orcp.2014.10.221
PG 4
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA CG1XJ
UT WOS:000353068500010
PM 25465493
ER
PT J
AU Carmona-Rubio, AE
Lee, AM
Puchner, S
Ghoshhajra, B
Sharma, UC
AF Carmona-Rubio, Andres E.
Lee, Ashley Mingshin
Puchner, Stefan
Ghoshhajra, Brian
Sharma, Umesh C.
TI A review of adherence to the guidelines for coronary CT angiography
quantitative stenosis grading thresholds in published research
SO POSTGRADUATE MEDICINE
LA English
DT Review
DE Coronary artery disease; coronary artery stenosis; coronary computerized
tomography angiography; noninvasive cardiac imaging
ID COMPUTED-TOMOGRAPHY ANGIOGRAPHY; FRACTIONAL FLOW RESERVE; ACUTE
CHEST-PAIN; INTERNATIONAL MULTICENTER REGISTRY;
AMERICAN-HEART-ASSOCIATION; ARTERY CALCIUM SCORE; DUAL-SOURCE CT;
MYOCARDIAL-PERFUSION; DIAGNOSTIC-ACCURACY; PROGNOSTIC VALUE
AB Background: The degree of coronary stenosis of potential hemodynamic significance is central to the interpretation of coronary computed tomography angiography (CCTA), but has been variably defined in the literature. Societal guidelines have attempted to address this issue via recommended thresholds. Objectives: We surveyed the various thresholds for defining significant coronary stenosis reported in research published since the introduction of the Society for Cardiovascular Computed Tomography guidelines regarding the interpretation and reporting of CCTA. Methods: We systematically reviewed the results of bibliographic searches of all original research articles on CCTA, focusing on studies reporting > 25 subjects, to assess the definitions of severity of coronary lesions as found on CCTA. To enable comparisons, we stratified the methods of reporting lesion severity into >= 50%, 50% to 69%, and "others" (including infrequent reporting methods). Results: Fifty-nine11 published studies were identified and met inclusion criteria. Eighteen studies reported the severity of coronary stenosis using a definition of 50% to 69% as moderate stenosis; 35 studies defined >= 50% coronary stenosis as "stenosis," "significant stenosis," or "obstructive lesion" without distinguishing a threshold for moderate versus severe stenosis. Six studies utilized other thresholds, such as 20% to 75%, 40% to 69%, 40% to 70%, 40% to 79%, and 50% to 75% to define moderate coronary stenosis. Conclusions: Fifty-three of 59 studies were graded in accordance with the recommended threshold of >= 50% defining potentially significant stenosis, with 18 studies reporting precisely in accordance with the guidelines-recommended thresholds of >= 50% narrowing as defining moderate stenosis and >= 70% narrowing as defining severe stenosis. Six studies were reported using alternative thresholds for significant stenosis. However, a majority of research studies published since 2009 do not follow the societal guidelines for stenosis grading, since these studies do not clearly describe the degree of coronary stenosis.
C1 [Carmona-Rubio, Andres E.] SUNY Buffalo, Sch Med, Dept Med, Buffalo, NY 14260 USA.
[Lee, Ashley Mingshin; Puchner, Stefan; Ghoshhajra, Brian; Sharma, Umesh C.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp,Cardiac MR PET CT Program, Boston, MA 02115 USA.
RP Carmona-Rubio, AE (reprint author), Erie Cty Med Ctr & Labs, David K Miller Bldg,462 Grider St, Buffalo, NY 14215 USA.
EM andresca@buffalo.edu
NR 85
TC 1
Z9 1
U1 0
U2 2
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0032-5481
EI 1941-9260
J9 POSTGRAD MED
JI Postgrad. Med.
PD MAR
PY 2015
VL 127
IS 2
BP 194
EP 201
DI 10.1080/00325481.2015.995065
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA CG7AB
UT WOS:000353453200010
PM 25540988
ER
PT J
AU Wan, ZM
Li, GA
AF Wan, Zongmiao
Li, Guoan
TI X-Stop (R) Implantation Effectively Limits Segmental Lumbar Extension
in-vivo without Altering the Kinematics of the Adjacent Levels
SO TURKISH NEUROSURGERY
LA English
DT Article
DE Interspinous process distracting device; In-vivo; Kinematics; Adjacent
segments
ID NEUROGENIC INTERMITTENT CLAUDICATION; INTERSPINAL PROCESS DECOMPRESSION;
X-STOP DEVICE; SPINAL STENOSIS; DEGENERATION; BIOMECHANICS; FLEXIBILITY;
MULTICENTER; FUSION; MOTION
AB AIM: To evaluate the in-vivo three-dimensional (3D) vertebral kinematics of the implanted and adjacent segments after implantation of the interspinous process distracting (ISP) device during various functional activities.
MATERIAL and METHODS: Eight patients with lumbar spinal stenosis (LSS) scheduled for X-Stop (R) surgery were recruited. Prior to surgery, patients were scanned with computed tomography/magnetic resonance imaging (CT/MRI) in order to construct 3D L2 to 51 vertebral models. The lumbar spines of the patients were then imaged using two fluoroscopes while they performed seven functional activities before and after X-Stop (R) surgeries. The in-vivo 3D vertebral positions were determined in the dual fluoroscopic images using an established 2D-3D matching method.The vertebral 3D ranges of motion (ROM) of the implanted and cranial-caudal adjacent levels were then measured.
RESULTS: Primary ROMs of the implanted segments were significantly decreased (p<0.05) by 50.2% only at torso extension, from preoperative 2.5 +/- 1.4 degrees to postoperative 1.1 +/- 0.5 degrees, but not significantly (p>0.05) at flexion, twisting and lateral bending. Primary ROM and the coupled translations and rotations of the implanted and the adjacent levels were not significantly changed during each posture.
CONCLUSION: X-Stop (R) implantation reduced the in-vivo range of extension by 50.2% at the implanted segment without disturbing 3D kinematics at the adjacent segments.
C1 [Wan, Zongmiao] Nanchang Univ, Affiliated Hosp 1, Dept Orthopaed, Nanchang, Jiangxi, Peoples R China.
[Li, Guoan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab,Dept Orthopaed, Boston, MA USA.
RP Wan, ZM (reprint author), Nanchang Univ, Affiliated Hosp 1, Dept Orthopaed, Nanchang, Jiangxi, Peoples R China.
EM zongmiao2008@gmail.com
NR 26
TC 0
Z9 0
U1 0
U2 1
PU TURKISH NEUROSURGICAL SOC
PI BAHCELIEVLER
PA TASKENT CADDESI 13-4, BAHCELIEVLER, ANKARA 06500, TURKEY
SN 1019-5149
J9 TURK NEUROSURG
JI Turk. Neurosurg.
PD MAR
PY 2015
VL 25
IS 2
BP 279
EP 284
DI 10.5137/1019-5149.JTN.10135-13.0
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA CG0AH
UT WOS:000352928500014
PM 26014013
ER
PT J
AU Dunn, IF
Chiocca, EA
AF Dunn, Ian F.
Chiocca, E. Antonio
TI Academic Productivity in Today's Training Climate: A Fellowship's impact
SO WORLD NEUROSURGERY
LA English
DT Editorial Material
DE Academic productivity; Academic promotion; Academic rank; H-index;
Neurological surgery fellowships; Neurological surgery fellowship
training; Neurological surgery; Scholarly impact; Scholarly productivity
C1 [Dunn, Ian F.; Chiocca, E. Antonio] Harvard Univ, Sch Med, Dept Neurosurg, Inst Neurosci,Brigham & Womens Faulkner Hosp, Boston, MA 02163 USA.
[Chiocca, E. Antonio] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA.
RP Chiocca, EA (reprint author), Harvard Univ, Sch Med, Dept Neurosurg, Inst Neurosci,Brigham & Womens Faulkner Hosp, Boston, MA 02163 USA.
EM EAChiocca@partners.org
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2015
VL 83
IS 3
BP 328
EP 329
DI 10.1016/j.wneu.2014.10.060
PG 2
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA CG1MN
UT WOS:000353036900022
PM 24176836
ER
PT J
AU Abd-El-Barr, MM
Chiocca, EA
AF Abd-El-Barr, Muhammad M.
Chiocca, E. Antonio
TI No Free Lunch: Secondary Neoplasms After Stereotactic Radiation
SO WORLD NEUROSURGERY
LA English
DT Editorial Material
DE Dedifferentiation; Late complications; Malignant transformation;
Secondary neoplasm; Stereotactic radiosurgery
ID ARTERIOVENOUS-MALFORMATIONS; RADIOSURGERY; RADIOTHERAPY; RESECTION;
GLIOMAS; BRAIN; RISK
C1 [Chiocca, E. Antonio] Harvard Univ, Sch Med, Dept Neurosurg, Inst Neurosci,Brigham & Womens Faulkner Hosp, Boston, MA 02163 USA.
Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA.
RP Chiocca, EA (reprint author), Harvard Univ, Sch Med, Dept Neurosurg, Inst Neurosci,Brigham & Womens Faulkner Hosp, Boston, MA 02163 USA.
EM EAChiocca@partners.org
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2015
VL 83
IS 3
BP 330
EP 331
DI 10.1016/j.wneu.2014.02.016
PG 2
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA CG1MN
UT WOS:000353036900023
PM 24534062
ER
PT J
AU Carpenter, GSJ
Carpenter, TP
Kimbrel, NA
Flynn, EJ
Pennington, ML
Cammarata, C
Zimering, RT
Kamholz, BW
Gulliver, SB
AF Carpenter, Grace Stephanie J.
Carpenter, Thomas P.
Kimbrel, Nathan A.
Flynn, Elisa J.
Pennington, Michelle L.
Cammarata, Claire
Zimering, Rose T.
Kamholz, Barbara W.
Gulliver, Suzy B.
TI Social Support, Stress, and Suicidal Ideation in Professional
Firefighters
SO AMERICAN JOURNAL OF HEALTH BEHAVIOR
LA English
DT Article
DE suicidal ideation; social support; stress; firefighters
ID POSTTRAUMATIC-STRESS; OCCUPATIONAL STRESS; LIFE STRESS; DEPRESSIVE
SYMPTOMS; RISK-FACTORS; FOLLOW-UP; BEHAVIOR; HOPELESSNESS; DISORDER;
MODEL
AB Objective: To hypothesize that social support may protect against the effect of firefighter stress on suicidal ideation. Methods: Overall, 334 firefighters completed measures of occupational stress, social support, and suicidal ideation. Results: At high levels of social support, no association was observed between occupational stress and suicidal ideation (phi = -.06, ns); however, when social support was low, occupational stress showed a positive association with suicidal ideation (phi = .16, p < .05). Conclusions: The association between occupational stress and suicidal ideation may be reduced by social support. Further research on this topic is warranted.
C1 [Carpenter, Grace Stephanie J.; Flynn, Elisa J.; Pennington, Michelle L.; Gulliver, Suzy B.] Baylor Scott & White Warriors Res Inst, Waco, TX 76708 USA.
[Carpenter, Thomas P.] Seattle Pacific Univ, Seattle, WA 98119 USA.
[Kimbrel, Nathan A.] Durham Vet Affairs VA Med Ctr, Durham, NC USA.
[Cammarata, Claire] New York City Fire Dept Counseling Serv Unit, New York, NY USA.
[Zimering, Rose T.; Kamholz, Barbara W.] VA Boston Healthcare Syst, Outpatient Mental Hlth, Boston, MA USA.
RP Gulliver, SB (reprint author), Baylor Scott & White Warriors Res Inst, Waco, TX 76708 USA.
EM suzybird@aol.com
RI Kimbrel, Nathan/P-3109-2016
OI Kimbrel, Nathan/0000-0001-7218-1005
FU FEMA Award [EMW2010FP00597]; NIMH R21 Award [1R21M-H06458401A2]; Career
Development Award-2 from the Clinical Science Research and Development
Service of the VA Office of Research and Development
[1IK-2CX000525-01A1]
FX This research was supported by a FEMA Award (EMW2010FP00597) entitled
"Motivational intervention to maximize peer behavioral health awareness
and skills" and a NIMH R21 Award (1R21M-H06458401A2) "Developing group
treatments for acute stress disorder." The third author was supported by
a Career Development Award-2 (1IK-2CX000525-01A1) from the Clinical
Science Research and Development Service of the VA Office of Research
and Development. The views expressed in this article are those of the
authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or the United States government.
NR 40
TC 7
Z9 7
U1 9
U2 15
PU PNG PUBLICATIONS
PI OAK RIDGE
PA 2205-K OAK RIDGE RD, #115, OAK RIDGE, NC 27310 USA
SN 1945-7359
J9 AM J HEALTH BEHAV
JI Am. J. Health Behav.
PD MAR
PY 2015
VL 39
IS 2
BP 191
EP 196
DI 10.5993/AJHB.39.2.5
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CF4SS
UT WOS:000352542300005
PM 25564831
ER
PT J
AU Rao, DR
Sordillo, JE
Kopel, LS
Gaffin, JM
Sheehan, WJ
Hoffman, E
Ozonoff, A
Gold, DR
Phipatanakul, W
AF Rao, Devika R.
Sordillo, Joanne E.
Kopel, Lianne S.
Gaffin, Jonathan M.
Sheehan, William J.
Hoffman, Elaine
Ozonoff, Al
Gold, Diane R.
Phipatanakul, Wanda
TI Association between allergic sensitization and exhaled nitric oxide in
children in the School Inner-City Asthma Study
SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
LA English
DT Letter
ID ATOPY; AGE
C1 [Rao, Devika R.] Univ Texas SW Med Ctr Dallas, Div Resp Med, Dallas, TX 75390 USA.
[Sordillo, Joanne E.; Gold, Diane R.; Phipatanakul, Wanda] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Kopel, Lianne S.; Gaffin, Jonathan M.] Div Resp Dis, Boston, MA USA.
[Sheehan, William J.; Phipatanakul, Wanda] Div Allergy & Immunol, Boston, MA USA.
[Kopel, Lianne S.; Gaffin, Jonathan M.; Sheehan, William J.; Phipatanakul, Wanda] Boston Childrens Hosp, Boston, MA USA.
[Kopel, Lianne S.; Gaffin, Jonathan M.; Sheehan, William J.; Hoffman, Elaine; Gold, Diane R.; Phipatanakul, Wanda] Harvard Univ, Sch Med, Boston, MA USA.
[Hoffman, Elaine] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.
[Ozonoff, Al] Boston Childrens Hosp, Ctr Patient Safety & Qual Res, Boston, MA USA.
[Ozonoff, Al] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Rao, DR (reprint author), Univ Texas SW Med Ctr Dallas, Div Resp Med, Dallas, TX 75390 USA.
EM wanda.phipatanakul@childrens.harvard.edu
FU NCATS NIH HHS [UL1 TR001102]; NHLBI NIH HHS [U10 HL098102, U10 HL
098102]; NIAID NIH HHS [K23 AI106945, K23 AI104780, R01 AI 073964,, R01
AI073964, K24 AI106822, K24 AI 106822, R01 AI 073964-02S1, K23 AI
106945]
NR 11
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1081-1206
EI 1534-4436
J9 ANN ALLERG ASTHMA IM
JI Ann. Allergy Asthma Immunol.
PD MAR
PY 2015
VL 114
IS 3
BP 256
EP 257
DI 10.1016/j.anai.2014.12.004
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA CF1ML
UT WOS:000352309800027
PM 25595887
ER
PT J
AU Rao, DR
Sordillo, JE
Kopel, LS
Gaffin, JM
Sheehan, WJ
Hoffman, E
Ozonoff, A
Gold, DR
Phipatanakul, W
AF Rao, Devika R.
Sordillo, Joanne E.
Kopel, Lianne S.
Gaffin, Jonathan M.
Sheehan, William J.
Hoffman, Elaine
Ozonoff, Al
Gold, Diane R.
Phipatanakul, Wanda
TI Eosinophilic esophagitis associated with Cynanchum wilfordii
SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
LA English
DT Letter
ID EXHALED NITRIC-OXIDE; CHILDREN; ASTHMA; SENSITIZATION; ALLERGEN; ATOPY;
AGE
C1 [Rao, Devika R.] Univ Texas SW Med Ctr Dallas, Div Resp Med, Dallas, TX 75390 USA.
[Sordillo, Joanne E.; Gold, Diane R.; Phipatanakul, Wanda] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Kopel, Lianne S.; Gaffin, Jonathan M.] Div Resp Dis, Boston, MA USA.
[Sheehan, William J.; Phipatanakul, Wanda] Div Allergy & Immunol, Boston, MA USA.
[Kopel, Lianne S.; Gaffin, Jonathan M.; Sheehan, William J.; Phipatanakul, Wanda] Boston Childrens Hosp, Boston, MA USA.
[Kopel, Lianne S.; Gaffin, Jonathan M.; Sheehan, William J.; Hoffman, Elaine; Gold, Diane R.; Phipatanakul, Wanda] Harvard Univ, Sch Med, Boston, MA USA.
[Hoffman, Elaine] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.
[Ozonoff, Al] Boston Childrens Hosp, Ctr Patient Safety & Qual Res, Boston, MA USA.
[Ozonoff, Al] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Rao, DR (reprint author), Univ Texas SW Med Ctr Dallas, Div Resp Med, Dallas, TX 75390 USA.
EM wanda.phipatanakul@childrens.harvard.edu
OI Park, Hae-Sim/0000-0003-2614-0303
NR 11
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1081-1206
EI 1534-4436
J9 ANN ALLERG ASTHMA IM
JI Ann. Allergy Asthma Immunol.
PD MAR
PY 2015
VL 114
IS 3
BP 257
EP +
DI 10.1016/j.anai.2014.12.010
PG 3
WC Allergy; Immunology
SC Allergy; Immunology
GA CF1ML
UT WOS:000352309800028
ER
PT J
AU Shields, RK
Nguyen, MH
Potoski, BA
Press, EG
Chen, L
Kreiswirth, BN
Clarke, LG
Eschenauer, GA
Clancy, CJ
AF Shields, Ryan K.
Nguyen, M. Hong
Potoski, Brian A.
Press, Ellen G.
Chen, Liang
Kreiswirth, Barry N.
Clarke, Lloyd G.
Eschenauer, Gregory A.
Clancy, Cornelius J.
TI Doripenem MICs and ompK36 Porin Genotypes of Sequence Type 258,
KPC-Producing Klebsiella pneumoniae May Predict Responses to
Carbapenem-Colistin Combination Therapy among Patients with Bacteremia
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID CRITICALLY-ILL PATIENTS; RESISTANT; ENTEROBACTERIACEAE; MORTALITY
AB Treatment failures of a carbapenem-colistin regimen among patients with bacteremia due to sequence type 258 (ST258), KPC-2-producing Klebsiella pneumoniae were significantly more likely if both agents were inactive in vitro, as defined by a colistin MIC of >2 mu g/ml and the presence of either a major ompK36 porin mutation (guanine and alanine insertions at amino acids 134 and 135 [ins aa 134-135 GD], IS5 promoter insertion [P = 0.007]) or a doripenem MIC of >8 mu g/ml (P = 0.01). Major ompK36 mutations among KPC-K. pneumoniae strains are important determinants of carbapenem-colistin responses in vitro and in vivo.
C1 [Shields, Ryan K.; Nguyen, M. Hong; Press, Ellen G.; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Shields, Ryan K.; Nguyen, M. Hong; Potoski, Brian A.; Clarke, Lloyd G.; Eschenauer, Gregory A.] Univ Pittsburgh, Med Ctr, Antibiot Management Program, Pittsburgh, PA USA.
[Shields, Ryan K.; Nguyen, M. Hong; Clancy, Cornelius J.] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA.
[Chen, Liang; Kreiswirth, Barry N.] Rutgers State Univ, New Jersey Med Sch, Publ Hlth Res Inst, Newark, NJ 07102 USA.
[Eschenauer, Gregory A.] Univ Pittsburgh, Med Ctr, Dept Pharm, Pittsburgh, PA USA.
[Potoski, Brian A.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA.
[Clancy, Cornelius J.] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA.
RP Nguyen, MH (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
EM mhn5@pitt.edu
FU University of Pittsburgh Medical Center; National Center for Advanced
Translational Sciences of the National Institutes of Health (NIH) [KL2
RR024154]
FX This project was supported by funding provided to the XDR Pathogen
Laboratory by the University of Pittsburgh Medical Center and by the
National Center for Advanced Translational Sciences of the National
Institutes of Health (NIH) under award no. KL2 RR024154 given to R.K.S.
NR 15
TC 10
Z9 10
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAR
PY 2015
VL 59
IS 3
BP 1505
EP 1509
DI 10.1128/AAC.03894-14
PG 5
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA CF4VF
UT WOS:000352550000016
PM 25534733
ER
PT J
AU Van Laar, TA
Chen, T
You, T
Leung, KP
AF Van Laar, Tricia A.
Chen, Tsute
You, Tao
Leung, Kai P.
TI Sublethal Concentrations of Carbapenems Alter Cell Morphology and
Genomic Expression of Klebsiella pneumoniae Biofilms
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; LARGE GENE LISTS; ESCHERICHIA-COLI;
PSEUDOMONAS-AERUGINOSA; SUBINHIBITORY CONCENTRATIONS;
MOLECULAR-MECHANISMS; IN-VIVO; ANTIBIOTICS; IMIPENEM; DNA
AB Klebsiella pneumoniae, a Gram-negative bacterium, is normally associated with pneumonia in patients with weakened immune systems. However, it is also a prevalent nosocomial infectious agent that can be found in infected surgical sites and combat wounds. Many of these clinical strains display multidrug resistance. We have worked with a clinical strain of K. pneumoniae that was initially isolated from a wound of an injured soldier. This strain demonstrated resistance to many commonly used antibiotics but sensitivity to carbapenems. This isolate was capable of forming biofilms in vitro, contributing to its increased antibiotic resistance and impaired clearance. We were interested in determining how sublethal concentrations of carbapenem treatment specifically affect K. pneumoniae biofilms both in morphology and in genomic expression. Scanning electron microscopy showed striking morphological differences between untreated and treated biofilms, including rounding, blebbing, and dimpling of treated cells. Comparative transcriptome analysis using RNA sequencing (RNA-Seq) technology identified a large number of open reading frames (ORFs) differentially regulated in response to carbapenem treatment at 2 and 24 h. ORFs upregulated with carbapenem treatment included genes involved in resistance, as well as those coding for antiporters and autoinducers. ORFs downregulated included those coding for metal transporters, membrane biosynthesis proteins, and motility proteins. Quantitative real-time PCR validated the general trend of some of these differentially regulated ORFs. Treatment of K. pneumoniae biofilms with sublethal concentrations of carbapenems induced a wide range of phenotypic and gene expression changes. This study reveals some of the mechanisms underlying how sublethal amounts of carbapenems could affect the overall fitness and pathogenic potential of K. pneumoniae biofilm cells.
C1 [Van Laar, Tricia A.; You, Tao; Leung, Kai P.] US Army Dent & Trauma Res Detachment, Microbiol Branch, Inst Surg Res, Jbsa Ft Sam Houston, TX 78234 USA.
[Chen, Tsute] Forsyth Inst, Cambridge, MA USA.
RP Leung, KP (reprint author), US Army Dent & Trauma Res Detachment, Microbiol Branch, Inst Surg Res, Jbsa Ft Sam Houston, TX 78234 USA.
EM kai.p.leung.civ@mail.mil
OI Van Laar, Tricia/0000-0002-4654-8501
FU U.S. Army Medical Research and Materiel Command, Combat Casualty Care
Research Directorate; Research Associateship Program from the National
Research Council
FX This work was supported by the U.S. Army Medical Research and Materiel
Command, Combat Casualty Care Research Directorate and the Research
Associateship Program from the National Research Council (T.A.V.L.).
NR 67
TC 4
Z9 4
U1 1
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAR
PY 2015
VL 59
IS 3
BP 1712
EP 1722
DI 10.1128/AAC.04581-14
PG 11
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA CF4VF
UT WOS:000352550000042
PM 25583711
ER
PT J
AU Jayamani, E
Rajamuthiah, R
Larkins-Ford, J
Fuchs, BB
Conery, AL
Vilcinskas, A
Ausubel, FM
Mylonakis, E
AF Jayamani, Elamparithi
Rajamuthiah, Rajmohan
Larkins-Ford, Jonah
Fuchs, Beth Burgwyn
Conery, Annie L.
Vilcinskas, Andreas
Ausubel, Frederick M.
Mylonakis, Eleftherios
TI Insect-Derived Cecropins Display Activity against Acinetobacter
baumannii in a Whole-Animal High-Throughput Caenorhabditis elegans Model
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID INFECTIOUS-DISEASES-SOCIETY; HOST GALLERIA-MELLONELLA; ANTIMICROBIAL
PEPTIDES; POLYMYXIN-B; VIRULENCE FACTORS; ESCHERICHIA-COLI; DEFENSE
PEPTIDES; INDUCIBLE GENES; DRUG DISCOVERY; NO ESKAPE
AB The rise of multidrug-resistant Acinetobacter baumannii and a concomitant decrease in antibiotic treatment options warrants a search for new classes of antibacterial agents. We have found that A. baumannii is pathogenic and lethal to the model host organism Caenorhabditis elegans and have exploited this phenomenon to develop an automated, high-throughput, high-content screening assay in liquid culture that can be used to identify novel antibiotics effective against A. baumannii. The screening assay involves coincubating C. elegans with A. baumannii in 384-well plates containing potential antibacterial compounds. At the end of the incubation period, worms are stained with a dye that stains only dead animals, and images are acquired using automated microscopy and then analyzed using an automated image analysis program. This robust assay yields a Z' factor consistently greater than 0.7. In a pilot experiment to test the efficacy of the assay, we screened a small custom library of synthetic antimicrobial peptides (AMPs) that were synthesized using publicly available sequence data and/or transcriptomic data from immune-challenged insects. We identified cecropin A and 14 other cecropin or cecropin-like peptides that were able to enhance C. elegans survival in the presence of A. baumannii. Interestingly, one particular hit, BR003-cecropin A, a cationic peptide synthesized by the mosquito Aedes aegypti, showed antibiotic activity against a panel of Gram-negative bacteria and exhibited a low MIC (5 mu g/ml) against A. baumannii. BR003-cecropin A causes membrane permeability in A. baumannii, which could be the underlying mechanism of its lethality.
C1 [Jayamani, Elamparithi; Rajamuthiah, Rajmohan; Fuchs, Beth Burgwyn; Mylonakis, Eleftherios] Brown Univ, Rhode Isl Hosp, Div Infect Dis, Alpert Med Sch, Providence, RI 02903 USA.
[Jayamani, Elamparithi; Rajamuthiah, Rajmohan; Larkins-Ford, Jonah; Fuchs, Beth Burgwyn; Conery, Annie L.; Ausubel, Frederick M.; Mylonakis, Eleftherios] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Vilcinskas, Andreas] Univ Giessen, Inst Phytopathol & Appl Zool, D-35390 Giessen, Germany.
RP Mylonakis, E (reprint author), Brown Univ, Rhode Isl Hosp, Div Infect Dis, Alpert Med Sch, Providence, RI 02903 USA.
EM emylonakis@lifespan.org
FU NIH [R01 AI085581]
FX We acknowledge NIH grant R01 AI085581.
NR 76
TC 8
Z9 8
U1 2
U2 15
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAR
PY 2015
VL 59
IS 3
BP 1733
EP 1742
DI 10.1128/AAC.04198-14
PG 10
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA CF4VF
UT WOS:000352550000044
PM 25583713
ER
PT J
AU Jung, M
Choi, M
Lee, TR
AF Jung, Minsoo
Choi, Mankyu
Lee, Tae-Ro
TI Determinants of Public Phobia About Infectious Diseases in South Korea:
Effect of Health Communication and Gender Difference
SO ASIA-PACIFIC JOURNAL OF PUBLIC HEALTH
LA English
DT Article
DE risk perception; disease phobia; bovine spongiform encephalopathy;
highly pathogenic avian influenza; mass media; health communication
ID MAD-COW-DISEASE; RISK PERCEPTION; SARS; MEDIA; REPRESENTATIONS;
MANAGEMENT; EPIDEMIC; BELIEFS
AB This study investigated the individual and social determinants of the public's phobia of infectious diseases in South Korea, where collective action was recently fueled by the public phobia over mad cow disease (bovine spongiform encephalopathy [BSE]). Gender-specific multivariate regression was used to compare the public perception of BSE and highly pathogenic avian influenza (HPAI). The analysis results differentiated between the determinants of the phobia for the 2 diseases, BSE and HPAI (N = 1002). As with HIV/AIDS and leprosy, the public fear of HPAI was expressed as a disease phobia that seeks to ensure the social exclusion of infection sources, whereas the fear of BSE was influenced by social and communication factors. Therefore, BSE, unlike previous HPAI, can be rapidly amplified amid the growing distrust in health communication, in which case the social determinants of disease phobia are associated with communicator trust, social values, and political attitude toward diseases rather than disease perception.
C1 [Jung, Minsoo] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[Jung, Minsoo] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02215 USA.
[Choi, Mankyu; Lee, Tae-Ro] Korea Univ, Dept Healthcare Management, Seoul, South Korea.
RP Jung, M (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, 450 Brookline Ave,LW 601, Boston, MA 02215 USA.
EM minsoo_jung@dfci.harvard.edu
OI Jung, Minsoo/0000-0003-3317-6507
FU National Research Foundation of Korea - Korean Government
[NRF-2011-357-E00028]
FX This work was supported by National Research Foundation of Korea Grant
funded by the Korean Government (NRF-2011-357-E00028) to Dr Minsoo Jung
(principal investigator).
NR 30
TC 0
Z9 0
U1 1
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1010-5395
EI 1941-2479
J9 ASIA-PAC J PUBLIC HE
JI Asia-Pac. J. Public Health
PD MAR
PY 2015
VL 27
IS 2
BP NP833
EP NP843
DI 10.1177/1010539513475653
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CF5GT
UT WOS:000352586200082
PM 23430887
ER
PT J
AU Ventz, S
Trippa, L
AF Ventz, Steffen
Trippa, Lorenzo
TI Bayesian Designs and the Control of Frequentist Characteristics: A
Practical Solution
SO BIOMETRICS
LA English
DT Article
DE Bayesian design; Clinical trials; Decision theory; Frequentist
constraints
ID DECISION-THEORETIC DESIGNS; CLINICAL-TRIALS; POWER
AB Frequentist concepts, such as the control of the type I error or the false discovery rate, are well established in the medical literature and often required by regulators. Most Bayesian designs are defined without explicit considerations of frequentist characteristics. Once the Bayesian design is structured, statisticians use simulations and adjust tuning parameters to comply with a set of targeted operating characteristics. These adjustments affect the use of prior information and utility functions. Here we consider a Bayesian decision theoretic approach for experimental designs with explicit frequentist requisites. We define optimal designs under a set of constraints required by a regulator. Our approach combines the use of interpretable utility functions with frequentist criteria, and selects an optimal design that satisfies a set of required operating characteristics. We illustrate the approach using a group-sequential multi-arm Phase II trial and a bridging trial.
C1 Harvard Univ, Sch Publ Hlth, Dept Biostat & Computat Biol, Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
RP Ventz, S (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat & Computat Biol, Dana Farber Canc Inst, 665 Huntington Ave, Boston, MA 02115 USA.
EM steffen@jimmy.harvard.edu
NR 36
TC 2
Z9 2
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0006-341X
EI 1541-0420
J9 BIOMETRICS
JI Biometrics
PD MAR
PY 2015
VL 71
IS 1
BP 218
EP 226
DI 10.1111/biom.12226
PG 9
WC Biology; Mathematical & Computational Biology; Statistics & Probability
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
Biology; Mathematics
GA CF5GO
UT WOS:000352585700024
PM 25196832
ER
PT J
AU Kushwaha, D
O'Leary, C
Cron, KR
Deraska, P
Zhu, KY
D'Andrea, AD
Kozono, D
AF Kushwaha, Deepa
O'Leary, Colin
Cron, Kyle R.
Deraska, Peter
Zhu, Kaya
D'Andrea, Alan D.
Kozono, David
TI USP9X inhibition promotes radiation-induced apoptosis in non-small cell
lung cancer cells expressing mid-to-high MCL1
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE apoptosis; lung cancer; MCL1; radiosensitizing agents; RNAi screen;
USP9X; DUB; deubiquitinase; IR; ionizing radiation; NSCLC; non-small
cell lung cancer; RT; radiotherapy; shRNA; short hairpin RNA; siRNA;
small interfering RNA (siRNA)
ID PANCREATIC DUCTAL ADENOCARCINOMA; DEUBIQUITINATING ENZYMES; FAM/USP9X
AB Background and Purpose: Radiotherapy (RT) is vital for the treatment of locally advanced non-small cell lung cancer (NSCLC), yet its delivery is limited by tolerances of adjacent organs. We sought therefore to identify and characterize gene targets whose inhibition may improve RT. Materials and Methods: Whole genome pooled shRNA cytotoxicity screens were performed in A549 and NCI-H460 using a retroviral library of 74,705 sequences. Cells were propagated with or without daily radiation Monday-Friday. Radiosensitization by top differential dropout hits was assessed by clonogenic assays. Apoptosis was assessed using a caspase 3/7 cell-based activity assay and by annexin V-FITC and PI staining. MCL1 expression was assessed by qPCR and Western blotting. Results: USP9X, a deubiquitinase, was a top hit among druggable gene products. WP1130, a small molecule USP9X inhibitor, showed synergistic cytotoxicity with IR. MCL1, an anti-apoptotic protein deubiquitinated by USP9X, decreased with USP9X inhibition and IR. This was accompanied by increases in caspase 3/7 activity and apoptosis. In a panel of NSCLC lines, MCL1 and USP9X protein and gene expression levels were highly correlated. Lines showing high levels of MCL1 expression were the most sensitive to USP9X inhibition. Conclusions: These data support the use of MCL1 expression as a predictive biomarker for USP9X inhibitors in NSCLC therapy.
C1 [Kushwaha, Deepa; O'Leary, Colin; Cron, Kyle R.; Deraska, Peter; Zhu, Kaya; D'Andrea, Alan D.; Kozono, David] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[D'Andrea, Alan D.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
RP Kozono, D (reprint author), Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
EM dkozono@lroc.harvard.edu
FU American Society for Radiation Oncology (ASTRO); Joint Center for
Radiation Therapy Foundation; Dana-Farber/Harvard Cancer Center SPORE
Developmental Research Project Award in Lung Cancer Research; National
Cancer Institute of the National Institutes of Health [K08CA172354]
FX DK is supported by the American Society for Radiation Oncology (ASTRO)
Junior Faculty Career Research Training Award, a Joint Center for
Radiation Therapy Foundation Grant, a Dana-Farber/Harvard Cancer Center
SPORE Developmental Research Project Award in Lung Cancer Research and
the National Cancer Institute of the National Institutes of Health under
Award Number K08CA172354.
NR 26
TC 4
Z9 5
U1 1
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD MAR
PY 2015
VL 16
IS 3
BP 392
EP 401
DI 10.1080/15384047.2014.1002358
PG 10
WC Oncology
SC Oncology
GA CF5OQ
UT WOS:000352607000006
PM 25692226
ER
PT J
AU Paul, S
Goyal, A
Duncan, LM
Smith, GP
AF Paul, Suchismita
Goyal, Amrita
Duncan, Lyn M.
Smith, Gideon P.
TI Granulomatous reaction to liquid injectable silicone for gluteal
enhancement: review of management options and success of doxycycline
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE doxycycline; granuloma; liquid silicone; mycobacterial infection
ID SOFT-TISSUE AUGMENTATION
AB Liquid injectable silicone (LIS) for cosmetic purposes has been widely available and commonly used for almost half a century. An increase in buttock augmentation procedures because of patients wanting to emulate the look of some celebrities has recently highlighted cases in the media of unsafe administration of liquid silicone injections. Severe complications including death have been reported. In this article, we report a case in which liquid silicone was injected in the patient's gluteal tissue resulting in granulomatous reactions in the surrounding tissues. The patient responded well to doxycycline, presumably because of both its antimicrobial properties and immunomodulatory effects.
C1 [Paul, Suchismita; Goyal, Amrita] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Duncan, Lyn M.] Massachusetts Gen Hosp, Pathol Serv, Dermatopathol Unit, Boston, MA 02114 USA.
[Smith, Gideon P.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
RP Paul, S (reprint author), Harvard Univ, Sch Med, 25 Shattuck St, Boston, MA 02115 USA.
EM suchismita_paul@hms.harvard.edu
NR 15
TC 1
Z9 1
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD MAR-APR
PY 2015
VL 28
IS 2
BP 98
EP 101
DI 10.1111/dth.12204
PG 4
WC Dermatology
SC Dermatology
GA CF5XO
UT WOS:000352630800012
PM 25649644
ER
PT J
AU Cury, RC
Kitt, TM
Feaheny, K
Blankstein, R
Ghoshhajra, BB
Budoff, MJ
Leipsic, J
Min, JK
Akin, J
George, RT
AF Cury, Ricardo C.
Kitt, Therese M.
Feaheny, Kathleen
Blankstein, Ron
Ghoshhajra, Brian B.
Budoff, Matthew J.
Leipsic, Jonathon
Min, James K.
Akin, Jamie
George, Richard T.
TI A randomized, multicenter, multivendor study of myocardial perfusion
imaging with regadenoson CT perfusion vs single photon emission CT
SO JOURNAL OF CARDIOVASCULAR COMPUTED TOMOGRAPHY
LA English
DT Article
DE Regadenoson; CT perfusion; Myocardial ischemia; Single photon emission
CT
ID CORONARY-ARTERY-DISEASE; INCREMENTAL PROGNOSTIC VALUE; COMPUTED
TOMOGRAPHIC ANGIOGRAPHY; DIAGNOSTIC PERFORMANCE; MULTIDETECTOR CT;
MEDICAL THERAPY; ADENOSINE; ISCHEMIA; REVASCULARIZATION; SPECT
AB Background: Myocardial CT perfusion (CTP) is a promising tool for the detection of myocardial ischemia. We hypothesize that regadenoson CTP is noninferior to regadenoson single photon emission CT (SPECT) for detecting or excluding myocardial ischemia.
Methods: Patients (men >= 45 years; women >= 50 years) with known or suspected coronary artery disease (n = 124) were randomized to 1 of 2 diagnostic sequences: rest and regadenoson SPECT on day 1, then regadenoson CTP and rest CTP (and coronary CT angiography [CTA]) (CTA; same acquisition) on day 2 or regadenoson CTP and rest CTP (and CTA) on Day 1, then rest and regadenoson SPECT on day 2. Scanning platforms included 64-, 128-, 256-, and 320-slice systems. The primary analysis examined the agreement rate between CTP and SPECT for detecting or excluding reversible ischemia in >= 2 myocardial segments as assessed by independent, blinded readers.
Results: Complete and interpretable CTP and SPECT scans were obtained for 110 patients. Regadenoson CTP was noninferior to SPECT for detecting or excluding reversible ischemia with an agreement rate of 0.87 (95% confidence interval [CI], 0.77-0.97) and sensitivity and specificity of 0.90 (95% CI, 0.71-1.00) and 0.84 (95% CI, 0.77-0.91), respectively. The agreement rate for detecting or excluding >= 1 fixed defects by regadenoson CTP and SPECT was 0.86 (95% CI, 0.74-0.98). With SPECT as the reference standard, the diagnostic accuracies for detecting or excluding ischemia by regadenoson CTP and CTA alone were 0.85 (95% CI, 0.78-0.91) and 0.69 (95% CI, 0.60-0.77), respectively.
Conclusions: This study establishes the noninferiority of regadenoson CTP to SPECT for detecting or excluding myocardial ischemia. (C) 2015 The Authors. Published by Elsevier Inc.
C1 [Cury, Ricardo C.] Baptist Hosp Miami, Dept Radiol, Miami, FL 33176 USA.
[Cury, Ricardo C.] Miami Cardiac & Vasc Inst, Miami, FL USA.
[Kitt, Therese M.] Astellas Sci & Med Affairs Inc, Northbrook, IL USA.
[Feaheny, Kathleen; Akin, Jamie] Astellas Pharrna Global Dev Inc, Northbrook, IL USA.
[Blankstein, Ron] Brigham & Womens Hosp, Dept Radiol, Div Cardiovasc, Boston, MA 02115 USA.
[Blankstein, Ron; Ghoshhajra, Brian B.] Harvard Univ, Sch Med, Boston, MA USA.
[Ghoshhajra, Brian B.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Budoff, Matthew J.] Harbor UCLA, Med Ctr, Dept Med, Los Angeles, CA USA.
[Leipsic, Jonathon] St Pauls Hosp, Dept Med Imaging, Div Cardiol, Vancouver, BC V6Z 1Y6, Canada.
[Min, James K.] Weill Cornell Med Coll, Dept Radiol, New York, NY USA.
[Min, James K.] New York Presbyterian Hosp, New York, NY USA.
[George, Richard T.] Johns Hopkins Univ, Dept Med, Div Cardiol, Baltimore, MD USA.
RP Cury, RC (reprint author), Baptist Hosp Miami, Dept Radiol, 8900 North Kendall Dr, Miami, FL 33176 USA.
EM rcury@baptisthealth.net
OI Budoff, Matthew/0000-0002-9616-1946
FU Astellas; GE Healthcare; Heartflow; Abbott Vascular; ICON Medical
Imaging; Toshiba; Astellas Pharma Global Development; Astellas
Scientific and Medical Affairs, Inc.
FX Ricardo C. Cury has received grants and research support from Astellas.
Therese M. Kitt, Kathleen Feaheny, and Jamie Akin are employees of
Astellas. Ron Blankstein has received grants and research support from
Astellas. Matthew J. Budoff has received grants and research support
from Astellas and GE Healthcare. Jonathon Leipsic has received
consulting fees and honoraria from GE Healthcare and Heartflow and fees
for image reading from ICON and Astellas for this study. James K. Min
has research agreements with Philips Healthcare and Vital Images, has
received consulting fees and honoraria from Abbott Vascular, GE
Healthcare, and Heartflow, has served on medical advisory boards for
Arineta, and holds equity interest in Autoplaq, MDDX, and TC3. Richard
T. George has received consulting fees and honoraria from ICON Medical
Imaging, has served on advisory boards for Astellas, has received grants
and research support from Toshiba and GE Healthcare, educational grants
from Toshiba, holds a patent for an x-ray CT apparatus and myocardial
perfusion image generating system (US 7,853,309, issued December 2010),
and has a pending patent for "combined multi-detector CT angiography and
CT myocardial perfusion imaging for the diagnosis of coronary artery
disease" (US 201110110,488, filed September 2008). Brian B. Ghoshhajra
has no potential conflicts of interest to declare.; The study was
supported by Astellas Pharma Global Development. Medical writing support
was provided by Emily Howard and Tara N Miller, PhD, and by medical
writers at Envision Scientific Solutions, and was funded by Astellas
Scientific and Medical Affairs, Inc.
NR 35
TC 12
Z9 13
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-5925
J9 J CARDIOVASC COMPUT
JI J. Cardiovasc. Comput. Tomogr.
PD MAR-APR
PY 2015
VL 9
IS 2
BP 103
EP 112
DI 10.1016/j.jcct.2015.01.002
PG 10
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA CF8QP
UT WOS:000352827300003
PM 25726411
ER
PT J
AU Atreya, CE
Corcoran, RB
Kopetz, S
AF Atreya, Chloe E.
Corcoran, Ryan B.
Kopetz, Scott
TI Expanded RAS: Refining the Patient Population
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID METASTATIC COLORECTAL-CANCER; KRAS WILD-TYPE; 1ST-LINE TREATMENT;
ACQUIRED-RESISTANCE; PHASE-III; MUTATIONS; CETUXIMAB; CHEMOTHERAPY;
PANITUMUMAB; TRIAL
C1 [Atreya, Chloe E.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Corcoran, Ryan B.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Corcoran, Ryan B.] Harvard Univ, Sch Med, Boston, MA USA.
[Kopetz, Scott] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
RP Atreya, CE (reprint author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
EM chloe.atreya@ucsf.edu
FU NCI NIH HHS [R01 CA184843, K08 CA166510, K08 CA175153, K08CA175143, P30
CA016672, R01 CA172670, R01CA172670, R01CA184843]
NR 38
TC 27
Z9 27
U1 0
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
BP 682
EP 685
DI 10.1200/JCO.2014.58.9325
PG 4
WC Oncology
SC Oncology
GA CF4MW
UT WOS:000352524200006
PM 25584005
ER
PT J
AU McCormick, B
Winter, K
Hudis, C
Kuerer, HM
Rakovitch, E
Smith, BL
Sneige, N
Moughan, J
Shah, A
Germain, I
Hartford, AC
Rashtian, A
Walker, EM
Yuen, A
Strom, EA
Wilcox, JL
Vallow, LA
Small, W
Pu, AT
Kerlin, K
White, J
AF McCormick, Beryl
Winter, Kathryn
Hudis, Clifford
Kuerer, Henry Mark
Rakovitch, Eileen
Smith, Barbara L.
Sneige, Nour
Moughan, Jennifer
Shah, Amit
Germain, Isabelle
Hartford, Alan C.
Rashtian, Afshin
Walker, Eleanor M.
Yuen, Albert
Strom, Eric A.
Wilcox, Jeannette L.
Vallow, Laura A.
Small, William, Jr.
Pu, Anthony T.
Kerlin, Kevin
White, Julia
TI RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma
In Situ Comparing Radiotherapy With Observation
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID BREAST-CONSERVING SURGERY; SURGICAL ADJUVANT BREAST; 20-YEAR FOLLOW-UP;
LOCAL RECURRENCE; CLINICAL-TRIALS; CANCER; IRRADIATION; MASTECTOMY;
LUMPECTOMY; TAMOXIFEN
AB Purpose
The Radiation Therapy Oncology Group 9804 study identified good-risk patients with ductal carcinoma in situ (DCIS), a breast cancer diagnosis found frequently in mammographically detected cancers, to test the benefit of radiotherapy (RT) after breast-conserving surgery compared with observation.
Patients and Methods
This prospective randomized trial (1998 to 2006) in women with mammographically detected low- or intermediate-grade DCIS, measuring less than 2.5 cm with margins 3 mm, compared RT with observation after surgery. The study was designed for 1,790 patients but was closed early because of lower than projected accrual. Six hundred thirty-six patients from the United States and Canada were entered; tamoxifen use (62%) was optional. Ipsilateral local failure (LF) was the primary end point; LF and contralateral failure were estimated using cumulative incidence, and overall and disease-free survival were estimated using the Kaplan-Meier method.
Results
Median follow-up time was 7.17 years (range, 0.01 to 11.33 years). Two LFs occurred in the RT arm, and 19 occurred in the observation arm. At 7 years, the LF rate was 0.9% (95% CI, 0.0% to 2.2%) in the RT arm versus 6.7% (95% CI, 3.2% to 9.6%) in the observation arm (hazard ratio, 0.11; 95% CI, 0.03 to 0.47; P < .001). Grade 1 to 2 acute toxicities occurred in 30% and 76% of patients in the observation and RT arms, respectively; grade 3 or 4 toxicities occurred in 4.0% and 4.2% of patients, respectively. Late RT toxicity was grade 1 in 30%, grade 2 in 4.6%, and grade 3 in 0.7% of patients.
Conclusion
In this good-risk subset of patients with DCIS, with a median follow-up of 7 years, the LF rate was low with observation but was decreased significantly with the addition of RT. Longer follow-up is planned because the timeline for LF in this setting seems protracted. (C) 2015 by American Society of Clinical Oncology
C1 [McCormick, Beryl; Hudis, Clifford] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
[Winter, Kathryn; Moughan, Jennifer] Radiat Therapy Oncol Grp Stat Ctr, Philadelphia, PA USA.
[Shah, Amit] York Canc Ctr, York, N Yorkshire, England.
[Yuen, Albert] Reading Hosp Med Ctr, Reading, PA USA.
[Kuerer, Henry Mark; Sneige, Nour; Strom, Eric A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Smith, Barbara L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hartford, Alan C.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[Rashtian, Afshin] Univ So Calif, Los Angeles, CA USA.
[Pu, Anthony T.] Radiol Associates Sacramento, Sacramento, CA USA.
[Walker, Eleanor M.] Henry Ford Hosp, Detroit, MI 48202 USA.
[Wilcox, Jeannette L.] Greenville SC Community Clin Oncol Program CCOP, Greenville, SC USA.
[Vallow, Laura A.] Mayo Clin, Jacksonville, FL 32224 USA.
[Small, William, Jr.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Kerlin, Kevin] Southeast Canc Control Consortium CCOP, Winston Salem, NC USA.
[White, Julia] Ohio State Univ, James Canc Hosp, Columbus, OH 43210 USA.
[Rakovitch, Eileen] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada.
[Germain, Isabelle] LHotel Dieu Quebec, Quebec City, PQ, Canada.
RP McCormick, B (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.
EM mccormib@mskcc.org
FU Radiation Therapy Oncology Group [U10 CA 21661]; Community Clinical
Oncology Program Grant from the National Cancer Institute [U10 CA 37422]
FX Supported by Radiation Therapy Oncology Group Grant No. U10 CA 21661 and
Community Clinical Oncology Program Grant No. U10 CA 37422 from the
National Cancer Institute.
NR 26
TC 59
Z9 61
U1 2
U2 9
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
BP 709
EP 715
DI 10.1200/JCO.2014.57.9029
PG 7
WC Oncology
SC Oncology
GA CF4MW
UT WOS:000352524200010
PM 25605856
ER
PT J
AU Bekelman, JE
Mitra, N
Handorf, EA
Uzzo, RG
Hahn, SA
Polsky, D
Armstrong, K
AF Bekelman, Justin E.
Mitra, Nandita
Handorf, Elizabeth A.
Uzzo, Robert G.
Hahn, Stephen A.
Polsky, Daniel
Armstrong, Katrina
TI Effectiveness of Androgen-Deprivation Therapy and Radiotherapy for Older
Men With Locally Advanced Prostate Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID PROPENSITY SCORE; SURVIVAL; RISK; COMORBIDITY; DATABASE; DISEASE;
IMPACT; DEATH; TRIAL; AGE
AB Purpose
We examined whether the survival advantage of androgen-deprivation therapy with radiotherapy (ADT plus RT) relative to ADT alone for men with locally advanced prostate cancer reported in two randomized trials holds in real-world clinical practice and extended the evidence to patients poorly represented in the trials.
Methods
We conducted nonrandomized effectiveness studies of ADT plus RT versus ADT in three groups of patients diagnosed between 1995 and 2007 and observed through 2009 in the SEER-Medicare data set: (1) the randomized clinical trial (RCT) cohort, which included men age 65 to 75 years and was most consistent with participants in the randomized trials; (2) the elderly cohort, which included men age > 75 years with locally advanced prostate cancer; and (3) the screen-detected cohort, which included men age >= 65 years with screen-detected high-risk prostate cancer. We evaluated cause-specific and all-cause mortality using propensity score, instrumental variable (IV), and sensitivity analyses.
Results
In the RCT cohort, ADT plus RT was associated with reduced cause-specific and all-cause mortality relative to ADT alone (cause-specific propensity score-adjusted hazard ratio [HR], 0.43; 95% CI, 0.37 to 0.49; all-cause propensity score-adjusted HR, 0.63; 95% CI, 0.59 to 0.67). Effectiveness estimates for the RCT cohort were not significantly different from those from randomized trials (P > .1). In the elderly and screen-detected cohorts, ADT plus RT was also associated with reduced cause-specific and all-cause mortality. IV analyses produced estimates similar to those from propensity score-adjusted methods.
Conclusion
Older men with locally advanced or screen-detected high-risk prostate cancer who receive ADT alone risk decrements in cause-specific and overall survival. (C) 2015 by American Society of Clinical Oncology
C1 [Bekelman, Justin E.; Mitra, Nandita; Hahn, Stephen A.; Polsky, Daniel] Univ Penn, Philadelphia, PA 19104 USA.
[Handorf, Elizabeth A.; Uzzo, Robert G.] Fox Chase Canc Ctr, Boston, MA USA.
[Armstrong, Katrina] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Bekelman, JE (reprint author), Univ Penn, Perelman Sch Med, Abramson Canc Ctr, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM bekelman@uphs.upenn.edu
FU National Institutes of Health [RC4-CA155809]; National Cancer Institute
[RC2-CA148310, K12-CA076931, K07-CA163616, UC2-CA148310]; US Public
Health Service [P30-CA016520, P30-CA06927]; American Cancer Society
[MRSG-121988]
FX Supported by Grants No. RC4-CA155809 from the National Institutes of
Health, Nos. RC2-CA148310, K12-CA076931, K07-CA163616, and UC2-CA148310
from the National Cancer Institute, Nos. P30-CA016520 and P30-CA06927
from the US Public Health Service, and No. MRSG-121988 from the American
Cancer Society.
NR 33
TC 19
Z9 19
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
BP 716
EP 722
DI 10.1200/JCO.2014.57.2743
PG 7
WC Oncology
SC Oncology
GA CF4MW
UT WOS:000352524200011
PM 25559808
ER
PT J
AU Wagner, LI
Zhao, FM
Hong, FX
Williams, ME
Gascoyne, RD
Krauss, JC
Advani, RH
Go, RS
Habermann, TM
Leach, JW
O'Connor, B
Schuster, SJ
Cella, D
Horning, SJ
Kahl, BS
AF Wagner, Lynne I.
Zhao, Fengmin
Hong, Fangxin
Williams, Michael E.
Gascoyne, Randy D.
Krauss, John C.
Advani, Ranjana H.
Go, Ronald S.
Habermann, Thomas M.
Leach, Joseph W.
O'Connor, Brian
Schuster, Stephen J.
Cella, David
Horning, Sandra J.
Kahl, Brad S.
TI Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor
Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab
Dosing Regimens: Results From ECOG Trial E4402 (RESORT)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID LONG-TERM SURVIVORS; TOP 5 LIST; FOLLICULAR LYMPHOMA; FUNCTIONAL
ASSESSMENT; CLINICAL ONCOLOGY; MENTAL ADJUSTMENT; AMERICAN SOCIETY;
DEPRESSION SCALE; HOSPITAL ANXIETY; CANCER-PATIENTS
AB Purpose
The purpose of this study was to compare illness-related anxiety among participants in the Rituximab Extended Schedule or Retreatment Trial (RESORT) randomly assigned to maintenance rituximab (MR) versus rituximab re-treatment (RR). A secondary objective was to examine whether the superiority of MR versus RR on anxiety depended on illness-related coping style.
Patients and Methods
Patients (N = 253) completed patient-reported outcome (PRO) measures at random assignment to MR or RR (baseline); at 3, 6, 12, 24, 36, and 48 months after random assignment; and at rituximab failure. PRO measures assessed illness-related anxiety and coping style, and secondary end points including general anxiety, worry and interference with emotional well-being, depression, and health-related quality of life (HRQoL). Patients were classified as using an active or avoidant illness-related coping style. Independent sample t tests and linear mixed-effects models were used to identify treatment arm differences on PRO end points and differences based on coping style.
Results
Illness-related anxiety was comparable between treatment arms at all time points (P > .05), regardless of coping style (active or avoidant). Illness-related anxiety and general anxiety significantly decreased over time on both arms. HRQoL scores were relatively stable and did not change significantly from baseline for both arms. An avoidant coping style was associated with significantly higher anxiety (18% and 13% exceeded clinical cutoff points at baseline and 6 months, respectively) and poorer HRQoL compared with an active coping style (P < .001), regardless of treatment arm assignment.
Conclusion
Surveillance until RR at progression was not associated with increased anxiety compared with MR, regardless of coping style. Avoidant coping was associated with higher anxiety and poorer HRQoL. (C) 2015 by American Society of Clinical Oncology
C1 [Wagner, Lynne I.; Cella, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Zhao, Fengmin; Hong, Fangxin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Williams, Michael E.] Univ Virginia, Charlottesville, VA USA.
[Krauss, John C.] Univ Michigan, Ann Arbor, MI USA.
[Advani, Ranjana H.] Stanford Univ, Stanford, CA 94305 USA.
[Horning, Sandra J.] Genentech Inc, South San Francisco, CA USA.
[Kahl, Brad S.] Univ Wisconsin, Madison, WI USA.
[Habermann, Thomas M.] Mayo Clin, Rochester, MN USA.
[Leach, Joseph W.] Metro Minnesota Community Clin Oncol Program, Minneapolis, MN USA.
[O'Connor, Brian] Frederick Mem Hlth Syst, Frederick, MD USA.
[Schuster, Stephen J.] Univ Penn, Philadelphia, PA 19104 USA.
[Gascoyne, Randy D.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
RP Wagner, LI (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, 633 N St Clair St,19th Floor, Chicago, IL 60611 USA.
EM lwagner@northwestern.edu
FU National Cancer Institute, National Institutes of Health [CA21115,
CA23318, CA66636, CA49957, CA21076, C47145, CA035267, C46116, C45488,
C43650]; Department of Health and Human Services
FX Supported in part by Public Health Service Grants No. CA21115, CA23318,
CA66636, CA49957, CA21076, C47145, C43650, CA035267, C46116, CA21076,
C45488, and C43650 from the National Cancer Institute, National
Institutes of Health, and the Department of Health and Human Services.
NR 43
TC 8
Z9 8
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
BP 740
EP 748
DI 10.1200/JCO.2014.57.6801
PG 9
WC Oncology
SC Oncology
GA CF4MW
UT WOS:000352524200014
PM 25605841
ER
PT J
AU Park, ER
Kirchhoff, AC
Perez, GK
Leisenring, W
Weissman, JS
Donelan, K
Mertens, AC
Reschovsky, JD
Armstrong, GT
Robison, LL
Franklin, M
Hyland, KA
Diller, LR
Recklitis, CJ
Kuhlthau, KA
AF Park, Elyse R.
Kirchhoff, Anne C.
Perez, Giselle K.
Leisenring, Wendy
Weissman, Joel S.
Donelan, Karen
Mertens, Ann C.
Reschovsky, James D.
Armstrong, Gregory T.
Robison, Leslie L.
Franklin, Mariel
Hyland, Kelly A.
Diller, Lisa R.
Recklitis, Christopher J.
Kuhlthau, Karen A.
TI Childhood Cancer Survivor Study Participants' Perceptions and
Understanding of the Affordable Care Act
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID PEDIATRIC CANCER; COVERAGE
AB Purpose
The Patient Protection and Affordable Care Act (ACA) established provisions intended to increase access to affordable health insurance and thus increase access to medical care and long-term surveillance for populations with pre-existing conditions. However, childhood cancer survivors' coverage priorities and familiarity with the ACA are unknown.
Methods
Between May 2011 and April 2012, we surveyed a randomly selected, age-stratified sample of 698 survivors and 210 siblings from the Childhood Cancer Survivor Study.
Results
Overall, 89.8% of survivors and 92.1% of siblings were insured. Many features of insurance coverage that survivors considered very important are addressed by the ACA, including increased availability of primary care (94.6%), no waiting period before coverage initiation (79.0%), and affordable premiums (88.1%). Survivors were more likely than siblings to deem primary care physician coverage and choice, protections from costs due to pre-existing conditions, and no start-up period as very important (P < .05 for all). Only 27.3% of survivors and 26.2% of siblings reported familiarity with the ACA (12.1% of uninsured v 29.0% of insured survivors; odds ratio, 2.86; 95% CI, 1.28 to 6.36). Only 21.3% of survivors and 18.9% of siblings believed the ACA would make it more likely that they would get quality coverage. Survivors' and siblings' concerns about the ACA included increased costs, decreased access to and quality of care, and negative impact on employers and employees.
Conclusion
Although survivors' coverage preferences match many ACA provisions, survivors, particularly uninsured survivors, were not familiar with the ACA. Education and assistance, perhaps through cancer survivor navigation, are critically needed to ensure that survivors access coverage and benefits. (C) 2015 by American Society of Clinical Oncology
C1 [Park, Elyse R.; Perez, Giselle K.; Donelan, Karen; Franklin, Mariel; Kuhlthau, Karen A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Weissman, Joel S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Diller, Lisa R.; Recklitis, Christopher J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kirchhoff, Anne C.] Huntsman Canc Inst, Salt Lake City, UT USA.
[Leisenring, Wendy] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Mertens, Ann C.] Emory Univ, Sch Med, Atlanta, GA USA.
[Reschovsky, James D.] Math Policy Res, Washington, DC USA.
[Armstrong, Gregory T.; Robison, Leslie L.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
RP Park, ER (reprint author), Massachusetts Gen Hosp, 50 Staniford St,Ste 901, Boston, MA 02114 USA.
EM epark@partners.org
FU Livestrong Foundation; National Cancer Institute [U24 CA55727]; Cancer
Center Support (CORE) Grant [CA21765]; American Lebanese-Syrian
Associated Charities
FX Supported by the Livestrong Foundation and National Cancer Institute
(Grant No. U24 CA55727, G.T. Armstrong, principal investigator). Support
to St Jude Children's Research Hospital also provided by Cancer Center
Support (CORE) Grant No. CA21765 (R. Gilbertson, principal investigator)
and the American Lebanese-Syrian Associated Charities.
NR 14
TC 7
Z9 7
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
BP 764
EP 772
DI 10.1200/JCO.2014.58.0993
PG 9
WC Oncology
SC Oncology
GA CF4MW
UT WOS:000352524200017
PM 25646189
ER
PT J
AU Mitsiades, CS
AF Mitsiades, Constantine S.
TI Therapeutic Landscape of Carfilzomib and Other Modulators of the
Ubiquitin-Proteasome Pathway
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID REFRACTORY MULTIPLE-MYELOMA; LOW-DOSE DEXAMETHASONE; PROTEIN-QUALITY
CONTROL; MANTLE CELL LYMPHOMA; PHASE-I TRIAL; WALDENSTROMS
MACROGLOBULINEMIA; HEMATOLOGIC MALIGNANCIES; IRREVERSIBLE INHIBITOR;
COMBINATION THERAPY; PRECLINICAL MODELS
C1 [Mitsiades, Constantine S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mitsiades, Constantine S.] Harvard Univ, Sch Med, Boston, MA USA.
RP Mitsiades, CS (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
FU National Institutes of Health [R01 CA127435, R01 CA179483, P01
CA155258]; Shawna Ashlee Corman Investigatorship in Multiple Myeloma
Research; de Gunzburg Myeloma Research Fund; Cobb Family Myeloma
Research Fund; Chambers Family Advanced Myeloma Research Fund; Leukemia
and Lymphoma Society Translational Research Program; Elsa U. Pardee
Foundation; Multiple Myeloma Research Foundation; Quest for Cure Program
FX Supported by Grants No. R01 CA127435, R01 CA179483, and P01 CA155258
(C.S.M.) from the National Institutes of Health, by the Shawna Ashlee
Corman Investigatorship in Multiple Myeloma Research, the de Gunzburg
Myeloma Research Fund, the Cobb Family Myeloma Research Fund, the
Chambers Family Advanced Myeloma Research Fund, the Leukemia and
Lymphoma Society Translational Research Program and Quest for Cure
Program, the Elsa U. Pardee Foundation, and the Multiple Myeloma
Research Foundation.
NR 76
TC 3
Z9 3
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
BP 782
EP 785
DI 10.1200/JCO.2014.55.5748
PG 4
WC Oncology
SC Oncology
GA CF4MW
UT WOS:000352524200019
PM 25605842
ER
PT J
AU Masters, GA
Krilov, L
Bailey, HH
Brose, MS
Burstein, H
Diller, LR
Dizon, DS
Fine, HA
Kalemkerian, GP
Moasser, M
Neuss, MN
O'Day, SJ
Odenike, O
Ryan, CJ
Schilsky, RL
Schwartz, GK
Venook, AP
Wong, SL
Patel, JD
AF Masters, Gregory A.
Krilov, Lada
Bailey, Howard H.
Brose, Marcia S.
Burstein, Harold
Diller, Lisa R.
Dizon, Don S.
Fine, Howard A.
Kalemkerian, Gregory P.
Moasser, Mark
Neuss, Michael N.
O'Day, Steven J.
Odenike, Olatoyosi
Ryan, Charles J.
Schilsky, Richard L.
Schwartz, Gary K.
Venook, Alan P.
Wong, Sandra L.
Patel, Jyoti D.
TI Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer
From the American Society of Clinical Oncology
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID SMALL-CELL CARCINOMA; ACTIVATING ACVR1 MUTATIONS; EARLY PALLIATIVE CARE;
SERVICES TASK-FORCE; LUNG-CANCER; HYPERCALCEMIC TYPE; SMARCA4 MUTATIONS;
TRIAL; OVARY; RISK
C1 [Masters, Gregory A.] Helen F Graham Canc Ctr, Newark, DE USA.
[Krilov, Lada; Schilsky, Richard L.] Amer Soc Clin Oncol, Alexandria, VA 22314 USA.
[Bailey, Howard H.] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA.
[Brose, Marcia S.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Burstein, Harold; Diller, Lisa R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dizon, Don S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Fine, Howard A.] NYU, Langone Med Ctr, New York, NY USA.
[Schwartz, Gary K.] Columbia Univ, Med Ctr, New York, NY USA.
[Kalemkerian, Gregory P.] Univ Michigan Hlth Syst, Ann Arbor, MI USA.
[Wong, Sandra L.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Moasser, Mark] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Ryan, Charles J.; Venook, Alan P.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[O'Day, Steven J.] Beverly Hills Hlth Ctr, Beverly Hills, CA USA.
[Neuss, Michael N.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Odenike, Olatoyosi] Univ Chicago, Chicago, IL 60637 USA.
[Patel, Jyoti D.] Northwestern Univ, Chicago, IL 60611 USA.
RP Krilov, L (reprint author), Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA.
EM lada.krilov@asco.org
FU Eli Lilly/ImClone; Bayer HealthCare Pharmaceuticals (Inst); Eisai
(Inst); Novartis (Inst); Roche/Genentech (Inst); Exelixis (Inst); Merck
(Inst); OncoMed (Inst); GlaxoSmithKline (Inst); Millennium
Pharmaceuticals (Inst); Pfizer (Inst); Merck, Bristol-Myers Squibb;
Novartis; Amgen; Spectrum Pharmaceuticals (Inst); Celgene (Inst); Incyte
(Inst); Astex Therapeutics (Inst); S*Bio (Inst); sanofi-aventis (Inst);
Suneisis (Inst); NS-Pharma (Inst); MEI Pharma (Inst); sanofi-aventis;
Bayer Pharmaceuticals (Inst); Onyx Pharmaceuticals (Inst);
Genentech/Roche (Inst); Bristol-Myers Squibb (Inst)
FX Research Funding: Eli Lilly/ImClone; Research Funding: Bayer HealthCare
Pharmaceuticals (Inst), Eisai (Inst), Novartis (Inst), Roche/Genentech
(Inst), Exelixis (Inst); Research Funding: Merck (Inst), OncoMed (Inst),
Novartis (Inst), GlaxoSmithKline (Inst), Millennium Pharmaceuticals
(Inst), Pfizer (Inst); Research Funding: Merck, Bristol-Myers Squibb,
Novartis, Amgen; Research Funding: Eisai (Inst), Spectrum
Pharmaceuticals (Inst), Celgene (Inst), Incyte (Inst), Astex
Therapeutics (Inst), S*Bio (Inst), sanofi-aventis (Inst), Suneisis
(Inst), NS-Pharma (Inst), MEI Pharma (Inst); Research Funding:
sanofi-aventis; Research Funding: Bayer Pharmaceuticals (Inst), Onyx
Pharmaceuticals (Inst), Genentech/Roche (Inst), Bristol-Myers Squibb
(Inst), GlaxoSmithKline (Inst)
NR 46
TC 34
Z9 35
U1 1
U2 10
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2015
VL 33
IS 7
BP 786
EP 809
DI 10.1200/JCO.2014.59.9746
PG 24
WC Oncology
SC Oncology
GA CF4MW
UT WOS:000352524200020
PM 25605863
ER
PT J
AU Sarris, J
Logan, AC
Akbaraly, TN
Amminger, GP
Balanza-Martinez, V
Freeman, MP
Hibbeln, J
Matsuoka, Y
Mischoulon, D
Mizoue, T
Nanri, A
Nishi, D
Ramsey, D
Rucklidge, JJ
Sanchez-Villegas, A
Scholey, A
Su, KP
Jacka, FN
AF Sarris, Jerome
Logan, Alan C.
Akbaraly, Tasnime N.
Amminger, G. Paul
Balanza-Martinez, Vicent
Freeman, Marlene P.
Hibbeln, Joseph
Matsuoka, Yutaka
Mischoulon, David
Mizoue, Tetsuya
Nanri, Akiko
Nishi, Daisuke
Ramsey, Drew
Rucklidge, Julia J.
Sanchez-Villegas, Almudena
Scholey, Andrew
Su, Kuan-Pin
Jacka, Felice N.
CA Int Soc Nutr Psychiat Res
TI Nutritional medicine as mainstream in psychiatry
SO LANCET PSYCHIATRY
LA English
DT Editorial Material
ID S-ADENOSYL METHIONINE; DUTCH-HUNGER-WINTER; DIETARY PATTERNS;
MENTAL-HEALTH; PRENATAL EXPOSURE; MAJOR DEPRESSION; ADULTS; EFFICACY;
TRIAL; METAANALYSIS
AB Psychiatry is at an important juncture, with the current pharmacologically focused model having achieved modest benefits in addressing the burden of poor mental health worldwide. Although the determinants of mental health are complex, the emerging and compelling evidence for nutrition as a crucial factor in the high prevalence and incidence of mental disorders suggests that diet is as important to psychiatry as it is to cardiology, endocrinology, and gastroenterology. Evidence is steadily growing for the relation between dietary quality (and potential nutritional deficiencies) and mental health, and for the select use of nutrient-based supplements to address deficiencies, or as monotherapies or augmentation therapies. We present a viewpoint from an international collaboration of academics (members of the International Society for Nutritional Psychiatry Research), in which we provide a context and overview of the current evidence in this emerging field of research, and discuss the future direction. We advocate recognition of diet and nutrition as central determinants of both physical and mental health.
C1 [Sarris, Jerome] Univ Melbourne, Melbourne Clin, Melbourne, Vic, Australia.
[Jacka, Felice N.] Univ Melbourne, Royal Melbourne Hosp, Dept Psychiat, Melbourne, Vic 3050, Australia.
[Sarris, Jerome; Scholey, Andrew] Swinburne Univ Technol, Ctr Human Psychopharmacol, Hawthorn, Vic 3122, Australia.
[Logan, Alan C.] CAMNR, Calabasas, CA USA.
[Akbaraly, Tasnime N.] Univ Montpellier, INSERM, U710, F-34059 Montpellier, France.
[Akbaraly, Tasnime N.] UCL, Dept Epidemiol & Publ Hlth, London, England.
[Amminger, G. Paul] Orygen Youth Hlth Res Ctr, Parkville, Vic, Australia.
[Balanza-Martinez, Vicent] La Fe Univ, Teaching Unit Psychiat & Psychol Med, Valencia, Spain.
[Balanza-Martinez, Vicent] Univ Valencia, Polytech Hosp, Sch Med, Ctr Invest Biomed Red Salud Mental CIBERSAM, Valencia, Spain.
[Freeman, Marlene P.] Massachusetts Gen Hosp, Perinatal & Reprod Psychiat, Boston, MA 02114 USA.
[Mischoulon, David] Massachusetts Gen Hosp, Depress & Clincal Res Program, Boston, MA 02114 USA.
[Hibbeln, Joseph] NIAAA, NIH, Bethesda, MD USA.
[Matsuoka, Yutaka] Natl Ctr Neurol & Psychiat, Dept Clin Epidemiol, Translat Med Ctr, Kodaira, Tokyo, Japan.
[Nishi, Daisuke] Natl Ctr Neurol & Psychiat, Natl Inst Mental Hlth, Dept Mental Hlth Policy & Evaluat, Kodaira, Tokyo, Japan.
[Mizoue, Tetsuya; Nanri, Akiko] Natl Ctr Global Hlth & Med, Dept Epidemiol & Prevent, Ctr Clin Sci, Shijuku Ku, Tokyo, Japan.
[Ramsey, Drew] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA.
[Rucklidge, Julia J.] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand.
[Sanchez-Villegas, Almudena] Univ Las Palmas Gran Canaria, Dept Clin Sci, Las Palmas Gran Canaria, Spain.
[Su, Kuan-Pin] China Med Univ, Dept Psychiat, Taichung, Taiwan.
[Su, Kuan-Pin] China Med Univ, Mind Body Interface Lab MBI Lab, China Med Univ Hosp, Taichung, Taiwan.
[Su, Kuan-Pin] China Med Univ, Grad Inst Neural & Cognit Sci, Taichung, Taiwan.
[Jacka, Felice N.] Deakin Univ, Sch Med, IMPACT Strateg Res Ctr, Geelong, Vic 3217, Australia.
[Jacka, Felice N.] Murdoch Childrens Res Ctr, Parkville, Vic, Australia.
[Jacka, Felice N.] Hosp Rd Prince Wales Hosp, Black Dog Inst, Randwick, NSW, Australia.
RP Sarris, J (reprint author), Melbourne Clin, 2 Salisbury St, Melbourne, Vic 3121, Australia.
EM jsarris@unimelb.edu.au
FU Integria Health; Blackmores; Bioceuticals; Taki Mai; Pepsico; HealthEd;
Soho-Flordis; Pfizer; Elsevier; Society for Medicinal Plant and Natural
Product Research; CR Roper Fellowship; National Health and Medical
Research Council (NHMRC); Genuine Health (Toronto, Canada); Angelini;
AstraZeneca; Bristol-Myers-Squibb; Janssen; Juste; Lilly; Lundbeck;
Otsuka; Spanish Ministry of Science and Innovation; Fundacion Alicia
Koplowitz; Takeda; Genentech; Johnson Johnson; JDS Therapeutics; Japan
Science and Technology Agency; National Center of Neurology and
Psychiatry (Japan); Ministry of Health, Labour, and Welfare of Japan;
Mochida Pharmaceutical Co; Takeda Pharmaceutical Company; Suntory
Wellness; Eli Lilly Japan KK; Otsuka Pharmaceutical Co; DHA & EPA
Association; Bowman Family Foundation; FisherWallace; Nordic Naturals;
Methylation Sciences; PharmoRx Therapeutics; Japan Society for the
Promotion of Science; National Center for Global Health and Medicine
(Japan); National Cancer Center (Japan); Industrial Health Foundation;
Uehara Memorial Foundation; Otsuka Pharmaceutical Co.; Foundation for
Total Health Promotion; Qol Co; NTT DoCoMo; Emotional Quotient Academy;
Biotechnology and Biological Sciences Research Council (UK); Australian
Research Council; NHMRC; British Psychological Society; Australian Wine
Research Institute; Abbott Nutrition; Arla Foods; Bayer Healthcare;
Cognis; Cyvex; GlaxoSmithKline Nutrition; Masterfoods; Martek; Naturex;
Nestle; Neurobrands; Sanofi; Verdure Sciences; Wrigley; Barilla; Danone;
Flordis; GlaxoSmithKline Healthcare; Kraft; Novartis; Unilever; National
Science Council; National Health Research Institute; China Medical
University in Taiwan; Royal Society (UK); National Centre for Research
and Development (Poland); Brain and Behaviour Research Institute (USA);
Australian Rotary Health; Geelong Medical Research Foundation; Ian
Potter Foundation; Eli Lilly; Meat and Livestock Board Australia;
University of Melbourne; Sanofi -Synthelabo; Janssen Cilag; Servier;
Health Ed; Network Nutrition; Angelini Farmaceutica
FX JS has received honoraria, research support, royalties, consultancy, or
travel grant funding from Integria Health, Blackmores, Bioceuticals,
Taki Mai, Pepsico, HealthEd, Soho-Flordis, Pfizer, Elsevier,the Society
for Medicinal Plant and Natural Product Research, CR Roper Fellowship,
and the National Health and Medical Research Council (NHMRC). ACL has
received consulting fees from Genuine Health (Toronto, Canada). VB-M has
received grants, and served as consultant, adviser, or continuing
medical education (CME) speaker during the past 3 years for the
following entities: Angelini, AstraZeneca, Bristol-Myers-Squibb,
Janssen, Juste, Lilly, Lundbeck, Otsuka, the Spanish Ministry of Science
and Innovation, and Fundacion Alicia Koplowitz. MPF has received funding
for advisory board positions, or consulting, from: Takeda, Otsuka,
Lundbeck, Genentech, Johnson & Johnson, and JDS Therapeutics; pending
research support from Takeda; and for medical editing for DSM
Nutritionals and GOED Omega-3. YM has received research support from the
Japan Science and Technology Agency, National Center of Neurology and
Psychiatry (Japan), the Ministry of Health, Labour, and Welfare of
Japan, and has been a paid speaker for Mochida Pharmaceutical Co, Takeda
Pharmaceutical Company, Suntory Wellness, Eli Lilly Japan KK, Otsuka
Pharmaceutical Co, and DHA & EPA Association. DM has received research
support from the Bowman Family Foundation, FisherWallace, Nordic
Naturals, Methylation Sciences, and PharmoRx Therapeutics. He has
received honoraria for consulting, speaking, and writing from Pamlab,
and the Massachusetts General Hospital Psychiatry Academy. He has
received royalties from Lippincott Williams & Wilkins for the published
book Natural medications for psychiatric disorders: considering the
alternatives. TM has received research grants from the Japan Society for
the Promotion of Science, the National Center for Global Health and
Medicine (Japan), the National Cancer Center (Japan), the Ministry of
Health, Labour, and Welfare of Japan, the Industrial Health Foundation,
the Uehara Memorial Foundation, and Otsuka Pharmaceutical Co. DN has
received research support from the Japan Society for the Promotion of
Science and the Foundation for Total Health Promotion, and lecture fees
from Qol Co, DHA & EPA Association, NTT DoCoMo, and Emotional Quotient
Academy. AS has received funding from the Biotechnology and Biological
Sciences Research Council (UK), The Australian Research Council, the
NHMRC, the British Psychological Society, the Australian Wine Research
Institute, Abbott Nutrition, Arla Foods, Bayer Healthcare, Cognis,
Cyvex, GlaxoSmithKline Nutrition, Masterfoods, Martek, Naturex, Nestle,
Neurobrands, Sanofi, Verdure Sciences, and Wrigley, and received speaker
fees from Abbott Nutrition, Barilla, Bayer Healthcare, Danone, Flordis,
GlaxoSmithKline Healthcare, Kraft, Masterfoods, Martek, Novartis,
Unilever, and Wrigley. K-PS has received research grants from the
National Science Council, National Health Research Institute, and China
Medical University in Taiwan, and joint research grants from the Royal
Society (UK) and National Centre for Research and Development (Poland).;
FNJ has received grants and research support from the Brain and
Behaviour Research Institute (USA), the NHMRC, Australian Rotary Health,
the Geelong Medical Research Foundation, the Ian Potter Foundation, Eli
Lilly, the Meat and Livestock Board Australia, and The University of
Melbourne, and has been a paid speaker for Sanofi -Synthelabo, Janssen
Cilag, Servier, Pfizer, Health Ed, Network Nutrition, Angelini
Farmaceutica, and Eli Lilly.
NR 31
TC 38
Z9 38
U1 8
U2 51
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2215-0374
J9 LANCET PSYCHIAT
JI Lancet Psychiatry
PD MAR
PY 2015
VL 2
IS 3
BP 271
EP 274
DI 10.1016/S2215-0366(14)00051-0
PG 4
WC Psychiatry
SC Psychiatry
GA CF6ZX
UT WOS:000352706800025
PM 26359904
ER
PT J
AU Saddawi-Konefka, D
Alston, TA
AF Saddawi-Konefka, D.
Alston, T. A.
TI An electrocardiographic monitor for reducing hemodynamic suspense during
suspension laryngoscopy
SO MINERVA ANESTESIOLOGICA
LA English
DT Editorial Material
ID HEART-RATE-VARIABILITY
C1 [Saddawi-Konefka, D.; Alston, T. A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
RP Alston, TA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
EM talston@mgh.harvard.edu
NR 20
TC 1
Z9 1
U1 0
U2 0
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0375-9393
EI 1827-1596
J9 MINERVA ANESTESIOL
JI Minerva Anestesiol.
PD MAR
PY 2015
VL 81
IS 3
BP 255
EP 257
PG 3
WC Anesthesiology; Critical Care Medicine
SC Anesthesiology; General & Internal Medicine
GA CF7OZ
UT WOS:000352747500003
PM 25220558
ER
PT J
AU Patsoukis, N
Bardhan, K
Chatterjee, P
Sari, D
Liu, BL
Bell, LN
Karoly, ED
Freeman, GJ
Petkova, V
Seth, P
Li, LQ
Boussiotis, VA
AF Patsoukis, Nikolaos
Bardhan, Kankana
Chatterjee, Pranam
Sari, Duygu
Liu, Bianling
Bell, Lauren N.
Karoly, Edward D.
Freeman, Gordon J.
Petkova, Victoria
Seth, Pankaj
Li, Lequn
Boussiotis, Vassiliki A.
TI PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and
promoting lipolysis and fatty acid oxidation
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CHRONIC VIRAL-INFECTION; RESPIRATORY CAPACITY; DISEASE PROGRESSION;
SIGNALING PATHWAY; LIPID-METABOLISM; TUMOR-GROWTH; ACTIVATION;
EXPRESSION; MEMORY; CTLA-4
AB During activation, T cells undergo metabolic reprogramming, which imprints distinct functional fates. We determined that on PD-1 ligation, activated T cells are unable to engage in glycolysis or amino acid metabolism but have an increased rate of fatty acid beta-oxidation (FAO). PD-1 promotes FAO of endogenous lipids by increasing expression of CPT1A, and inducing lipolysis as indicated by elevation of the lipase ATGL, the lipolysis marker glycerol and release of fatty acids. Conversely, CTLA-4 inhibits glycolysis without augmenting FAO, suggesting that CTLA-4 sustains the metabolic profile of non-activated cells. Because T cells utilize glycolysis during differentiation to effectors, our findings reveal a metabolic mechanism responsible for PD-1-mediated blockade of T-effector cell differentiation. The enhancement of FAO provides a mechanistic explanation for the longevity of T cells receiving PD-1 signals in patients with chronic infections and cancer, and for their capacity to be reinvigorated by PD-1 blockade.
C1 [Patsoukis, Nikolaos; Bardhan, Kankana; Chatterjee, Pranam; Sari, Duygu; Liu, Bianling; Petkova, Victoria; Li, Lequn; Boussiotis, Vassiliki A.] Harvard Univ, Sch Med, Div Hematol Oncol, Boston, MA 02215 USA.
[Patsoukis, Nikolaos; Bardhan, Kankana; Chatterjee, Pranam; Sari, Duygu; Liu, Bianling; Petkova, Victoria; Seth, Pankaj; Li, Lequn; Boussiotis, Vassiliki A.] Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Patsoukis, Nikolaos; Bardhan, Kankana; Chatterjee, Pranam; Sari, Duygu; Liu, Bianling; Petkova, Victoria; Seth, Pankaj; Li, Lequn; Boussiotis, Vassiliki A.] Harvard Univ, Sch Med, Beth Israel Deaconess Canc Ctr, Boston, MA 02215 USA.
[Bell, Lauren N.; Karoly, Edward D.] Metabolon Inc, Durham, NC 27713 USA.
[Freeman, Gordon J.] Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02284 USA.
[Seth, Pankaj] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Interdisciplinary Med & Biotechnol, Boston, MA 02215 USA.
RP Boussiotis, VA (reprint author), Harvard Univ, Sch Med, Div Hematol Oncol, 330 Brookline Ave, Boston, MA 02215 USA.
EM vboussio@bidmc.harvard.edu
FU NIH [CA183605, AI098129, AI056299, HHSN2722018C]
FX This work was supported by NIH grants CA183605 and AI098129 (to V.A.B.)
and AI056299 and HHSN2722018C (to G.J.F.).
NR 60
TC 55
Z9 56
U1 9
U2 28
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2015
VL 6
AR 6692
DI 10.1038/ncomms7692
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG1OR
UT WOS:000353043100001
PM 25809635
ER
PT J
AU Reardon, DA
Nabors, LB
Mason, WP
Perry, JR
Shapiro, W
Kavan, P
Mathieu, D
Phuphanich, S
Cseh, A
Fu, YL
Cong, J
Wind, S
Eisenstat, DD
AF Reardon, David A.
Nabors, Louis B.
Mason, Warren P.
Perry, James R.
Shapiro, William
Kavan, Petr
Mathieu, David
Phuphanich, Surasak
Cseh, Agnieszka
Fu, Yali
Cong, Julie
Wind, Sven
Eisenstat, David D.
CA BI 1200 36 Trial Grp
Canadian Brain Tumour Consortium
TI Phase I/randomized phase II study of afatinib, an irreversible ErbB
family blocker, with or without protracted temozolomide in adults with
recurrent glioblastoma
SO NEURO-ONCOLOGY
LA English
DT Article
DE afatinib; EGFRvIII; ErbB family; glioblastoma; temozolomide
ID NEWLY-DIAGNOSED GLIOBLASTOMA; GROWTH-FACTOR-RECEPTOR; EGFR KINASE
INHIBITORS; NEURO-ONCOLOGIA GICNO; HIGH-GRADE GLIOMAS; CELL LUNG-CANCER;
OPEN-LABEL; RADIATION-THERAPY; MALIGNANT GLIOMA; RANDOMIZED-TRIAL
AB Background. This phase I/II trial evaluated the maximum tolerated dose (MTD) and pharmacokinetics of afatinib plus temozolomide as well as the efficacy and safety of afatinib as monotherapy (A) or with temozolomide (AT) vs temozolomide monotherapy (T) in patients with recurrent glioblastoma (GBM).
Methods. Phase I followed a traditional 3 + 3 dose-escalation design to determine MTD. Treatment cohorts were: afatinib 20, 40, and 50 mg/day (plus temozolomide 75 mg/m(2)/day for 21 days per 28-day cycle). In phase II, participants were randomized (stratified by age and KPS) to receive A, T or AT; A was dosed at 40 mg/day and T at 75 mg/m(2) for 21 of 28 days. Primary endpoint was progression-free survival rate at 6 months (PFS-6). Participants were treated until intolerable adverse events (AEs) or disease progression.
Results. Recommended phase II dose was 40 mg/day (A) + T based on safety data from phase I (n = 32). Most frequent AEs in phase II (n = 119) were diarrhea (71% [A], 82% [AT]) and rash (71% [A] and 69% [AT]). Afatinib and temozolomide pharmacokinetics were unaffected by coadministration. Independently assessed PFS-6 rate was 3% (A), 10% (AT), and 23% (T). Median PFS was longer in afatinib-treated participants with epidermal growth factor receptor (EFGR) vIII-positive tumors versus EGFRvIII-negative tumors. Best overall response included partial response in 1 (A), 2 (AT), and 4 (T) participants and stable disease in 14 (A), 14 (AT), and 21 (T) participants.
Conclusions. Afatinib has a manageable safety profile but limited single-agent activity in unselected recurrent GBM patients.
C1 [Reardon, David A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Nabors, Louis B.] Univ Alabama Birmingham, Birmingham, AL USA.
[Mason, Warren P.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
[Perry, James R.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada.
[Shapiro, William] Barrow Neurol Inst, Phoenix, AZ 85013 USA.
[Kavan, Petr] McGill Univ, Dept Med Oncol, Montreal, PQ, Canada.
[Mathieu, David] Ctr Hosp Univ Sherbrooke, Sherbrooke, PQ, Canada.
[Phuphanich, Surasak; Cseh, Agnieszka] Cedars Sinai Med Ctr, Johnnie Cochran Brain Tumor Ctr, Los Angeles, CA 90048 USA.
[Cseh, Agnieszka] Boehringer Ingelheim RCV GmbH & Co KG, A-1120 Vienna, Austria.
[Fu, Yali; Cong, Julie] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA.
[Wind, Sven] Boehringer Ingelheim Pharma GmbH & Co KG, D-88400 Biberach, Germany.
[Eisenstat, David D.] CancerCare Manitoba, Winnipeg, MB, Canada.
RP Reardon, DA (reprint author), Dana Farber Canc Inst, Ctr Neurooncol, 450 Brookline Ave,SW G460F, Boston, MA 02115 USA.
EM david_reardon@dfci.harvard.edu; eisensta@ualberta.ca
FU Boehringer Ingelheim
FX This study was supported by Boehringer Ingelheim. The authors were fully
responsible for all content and editorial decisions, were involved at
all stages of manuscript development, and have approved the final
version. Medical writing assistance, supported financially by Boehringer
Ingelheim, was provided by Anusha Bolonna, of Ogilvy Healthworld, during
the preparation of this article.
NR 45
TC 9
Z9 9
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD MAR
PY 2015
VL 17
IS 3
BP 430
EP 439
DI 10.1093/neuonc/nou160
PG 10
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA CF3WM
UT WOS:000352479700015
PM 25140039
ER
PT J
AU Luke, JJ
Triozzi, PL
McKenna, KC
Van Meir, EG
Gershenwald, JE
Bastian, BC
Gutkind, JS
Bowcock, AM
Streicher, HZ
Patel, PM
Sato, T
Sossman, JA
Sznol, M
Welch, J
Thurin, M
Selig, S
Flaherty, KT
Carvajal, RD
AF Luke, Jason J.
Triozzi, Pierre L.
McKenna, Kyle C.
Van Meir, Erwin G.
Gershenwald, Jeffrey E.
Bastian, Boris C.
Gutkind, J. Silvio
Bowcock, Anne M.
Streicher, Howard Z.
Patel, Poulam M.
Sato, Takami
Sossman, Jeffery A.
Sznol, Mario
Welch, Jack
Thurin, Magdalena
Selig, Sara
Flaherty, Keith T.
Carvajal, Richard D.
TI Biology of advanced uveal melanoma and next steps for clinical
therapeutics
SO PIGMENT CELL & MELANOMA RESEARCH
LA English
DT Review
DE Ocular; Uveal; Melanoma; MEK; GNAQ; GNA11; metastasis; cancer
ID INDUCIBLE FACTOR PATHWAY; PROTEIN-KINASE-C; PHASE-II TRIAL;
GROWTH-FACTOR RECEPTOR; IMMUNE PRIVILEGE; OCULAR MELANOMA; METASTATIC
MELANOMA; ANTERIOR-CHAMBER; TUMOR-CELLS; LYMPHOCYTIC INFILTRATION
AB Uveal melanoma is the most common intraocular malignancy although it is a rare subset of all melanomas. Uveal melanoma has distinct biology relative to cutaneous melanoma, with widely divergent patient outcomes. Patients diagnosed with a primary uveal melanoma can be stratified for risk of metastasis by cytogenetics or gene expression profiling, with approximately half of patients developing metastatic disease, predominately hepatic in location, over a 15-yr period. Historically, no systemic therapy has been associated with a clear clinical benefit for patients with advanced disease, and median survival remains poor. Here, as a joint effort between the Melanoma Research Foundation's ocular melanoma initiative, CURE OM and the National Cancer Institute, the current understanding of the molecular and immunobiology of uveal melanoma is reviewed, and on-going laboratory research into the disease is highlighted. Finally, recent investigations relevant to clinical management via targeted and immunotherpies are reviewed, and next steps in the development of clinical therapeutics are discussed.
C1 [Luke, Jason J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Triozzi, Pierre L.] Wake Forest Univ, Ctr Canc, Winston Salem, NC 27109 USA.
[McKenna, Kyle C.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
[Van Meir, Erwin G.] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA.
[Gershenwald, Jeffrey E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Bastian, Boris C.] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Gutkind, J. Silvio] Natl Inst Dent & Craniofacial Res, Bethesda, MD USA.
[Bowcock, Anne M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England.
[Streicher, Howard Z.; Welch, Jack; Thurin, Magdalena] NCI, Bethesda, MD 20892 USA.
[Patel, Poulam M.] Univ Nottingham, Nottingham NG7 2RD, England.
[Sato, Takami] Thomas Jefferson Univ, Vanderbilt Ingram Canc Ctr, Ctr Canc, Philadelphia, PA 19107 USA.
[Sossman, Jeffery A.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37235 USA.
[Sznol, Mario] Yale Univ, Yale Canc Ctr, New Haven, CT USA.
[Selig, Sara] Brigham & Womans Hosp, Washington, DC USA.
[Selig, Sara] Melanoma Res Fdn, CURE OM, Washington, DC USA.
[Flaherty, Keith T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA.
[Carvajal, Richard D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
RP Luke, JJ (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM Jason_Luke@dfci.harvard.edu
OI Bowcock, Anne/0000-0001-8691-9090
FU NIH [R01 CA16187001, R01 CA142873, CA116804, CA176001, CA180805]; Samuel
Waxman Cancer Research Foundation
FX We thank Elisha Roberson for helpful comments in review of the
manuscript. Anne Bowcock acknowledges funding via NIH R01 CA16187001.
Boris Bastian acknowledges funding via NIH R01 CA142873. Erwin G. Van
Meir acknowledges funding NIH CA116804, CA176001, and CA180805 and the
Samuel Waxman Cancer Research Foundation.
NR 118
TC 16
Z9 16
U1 1
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-1471
EI 1755-148X
J9 PIGM CELL MELANOMA R
JI Pigment Cell Melanoma Res.
PD MAR
PY 2015
VL 28
IS 2
BP 135
EP 147
DI 10.1111/pcmr.12304
PG 13
WC Oncology; Cell Biology; Dermatology
SC Oncology; Cell Biology; Dermatology
GA CF8OJ
UT WOS:000352821100007
PM 25113308
ER
PT J
AU Webster, MR
Xu, M
Kinzler, KA
Kaur, A
Appleton, J
O'Connell, MP
Marchbank, K
Valiga, A
Dang, VM
Perego, M
Zhang, G
Slipicevic, A
Keeney, F
Lehrmann, E
Wood, W
Becker, KG
Kossenkov, AV
Frederick, DT
Flaherty, KT
Xu, XW
Herlyn, M
Murphy, ME
Weeraratna, AT
AF Webster, Marie R.
Xu, Mai
Kinzler, Kathryn A.
Kaur, Amanpreet
Appleton, Jessica
O'Connell, Michael P.
Marchbank, Katie
Valiga, Alexander
Dang, Vanessa M.
Perego, Michela
Zhang, Gao
Slipicevic, Ana
Keeney, Frederick
Lehrmann, Elin
Wood, William, III
Becker, Kevin G.
Kossenkov, Andrew V.
Frederick, Dennie T.
Flaherty, Keith T.
Xu, Xiaowei
Herlyn, Meenhard
Murphy, Maureen E.
Weeraratna, Ashani T.
TI Wnt5A promotes an adaptive, senescent-like stress response, while
continuing to drive invasion in melanoma cells
SO PIGMENT CELL & MELANOMA RESEARCH
LA English
DT Article
DE Wnt5A; BRAF; senescence; metastasis; therapy resistance
ID CANCER-THERAPY; CELLULAR SENESCENCE; INHIBITION; VEMURAFENIB;
RESISTANCE; PHOSPHORYLATION; BRAF(V600E); SUPPRESSION; EXPRESSION;
PHENOTYPE
AB We have previously shown that Wnt5A drives invasion in melanoma. We have also shown that Wnt5A promotes resistance to therapy designed to target the BRAF(V600E) mutation in melanoma. Here, we show that melanomas characterized by high levels of Wnt5A respond to therapeutic stress by increasing p21 and expressing classical markers of senescence, including positivity for senescence-associated beta-galactosidase (SA-beta-gal), senescence-associated heterochromatic foci (SAHF), H3K9Me chromatin marks, and PML bodies. We find that despite this, these cells retain their ability to migrate and invade. Further, despite the expression of classic markers of senescence such as SA-beta-gal and SAHF, these Wnt5A-high cells are able to colonize the lungs in in vivo tail vein colony-forming assays. This clearly underscores the fact that these markers do not indicate true senescence in these cells, but instead an adaptive stress response that allows the cells to evade therapy and invade. Notably, silencing Wnt5A reduces expression of these markers and decreases invasiveness. The combined data point to Wnt5A as a master regulator of an adaptive stress response in melanoma, which may contribute to therapy resistance.
C1 [Webster, Marie R.; Kaur, Amanpreet; Appleton, Jessica; O'Connell, Michael P.; Marchbank, Katie; Valiga, Alexander; Dang, Vanessa M.; Perego, Michela; Zhang, Gao; Slipicevic, Ana; Keeney, Frederick; Kossenkov, Andrew V.; Herlyn, Meenhard; Murphy, Maureen E.; Weeraratna, Ashani T.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.
[Xu, Mai; Kinzler, Kathryn A.; Lehrmann, Elin; Wood, William, III; Becker, Kevin G.] NIA, NIH, Baltimore, MD 21224 USA.
[Frederick, Dennie T.; Flaherty, Keith T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Xu, Xiaowei] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
RP Weeraratna, AT (reprint author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.
EM aweeraratna@wistar.org
RI Zhang, Gao/D-3471-2017
FU National Institute on Aging, Baltimore, MD; PA Department of Health
(CURE); CCSG [P30 CA010815]; [P01 CA 114046-06]; [T32 CA 9171-36];
[RO1 CA174746-01]
FX We thank Drs Chi V. Dang (Abramson Cancer Center, University of
Pennsylvania, Philadelphia, PA, USA), Kenneth Kinzler (Sidney Kimmel
Cancer Center, Johns Hopkins University), Mina Bissell (Lawrence
Berkeley Laboratories, CA, USA), Daniel Peeper (Netherlands Cancer
Institute), Andrew Aplin (Thomas Jefferson University, PA, USA), and
Rugang Zhang, Dmitry Gabrilovich and Dario Altieri (The Wistar
Institute) for critical reading of the manuscript. We thank Dr. Jessie
Villanueva (The Wistar Institute) for the use of the WM983B-resistant
cells. We thank Dr. Kate Nathanson for assistance with sequencing of the
cell lines. We also thank Dr. Qin Liu for assistance with statistics.
This work was supported in part by funds from the Intramural Program of
the National Institute on Aging, Baltimore, MD, The PA Department of
Health (CURE funding) to ATW, MPO, MRW and P01 CA 114046-06 (MH, ATW,
GZ, KM, MEM), T32 CA 9171-36 (MRW) and RO1 CA174746-01 (ATW, AK, QL).
Core facilities at the Wistar are supported by the CCSG grant P30
CA010815.
NR 34
TC 8
Z9 8
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-1471
EI 1755-148X
J9 PIGM CELL MELANOMA R
JI Pigment Cell Melanoma Res.
PD MAR
PY 2015
VL 28
IS 2
BP 184
EP 195
DI 10.1111/pcmr.12330
PG 12
WC Oncology; Cell Biology; Dermatology
SC Oncology; Cell Biology; Dermatology
GA CF8OJ
UT WOS:000352821100011
PM 25407936
ER
PT J
AU Sanhueza, M
Chai, A
Smith, C
McCray, BA
Simpson, TI
Taylor, JP
Pennetta, G
AF Sanhueza, Mario
Chai, Andrea
Smith, Colin
McCray, Brett A.
Simpson, T. Ian
Taylor, J. Paul
Pennetta, Giuseppa
TI Network Analyses Reveal Novel Aspects of ALS Pathogenesis
SO PLOS GENETICS
LA English
DT Article
ID AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE;
ENDOPLASMIC-RETICULUM; UBIQUITIN LIGASES; VAPB INTERACTS; PROTEIN VAPB;
DROSOPHILA-MELANOGASTER; CALCIUM HOMEOSTASIS; GENE-EXPRESSION; LIPID
DROPLETS
AB Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by selective loss of motor neurons, muscle atrophy and paralysis. Mutations in the human VAMP-associated protein B (hVAPB) cause a heterogeneous group of motor neuron diseases including ALS8. Despite extensive research, the molecular mechanisms underlying ALS pathogenesis remain largely unknown. Genetic screens for key interactors of hVAPB activity in the intact nervous system, however, represent a fundamental approach towards understanding the in vivo function of hVAPB and its role in ALS pathogenesis. Targeted expression of the disease-causing allele leads to neurodegeneration and progressive decline in motor performance when expressed in the adult Drosophila, eye or in its entire nervous system, respectively. By using these two phenotypic readouts, we carried out a systematic survey of the Drosophila genome to identify modifiers of hVAPB-induced neurotoxicity. Modifiers cluster in a diverse array of biological functions including processes and genes that have been previously linked to hVAPB function, such as proteolysis and vesicular trafficking. In addition to established mechanisms, the screen identified endocytic trafficking and genes controlling proliferation and apoptosis as potent modifiers of ALS8-mediated defects. Surprisingly, the list of modifiers was mostly enriched for proteins linked to lipid droplet biogenesis and dynamics. Computational analysis reveals that most modifiers can be linked into a complex network of interacting genes, and that the human genes homologous to the Drosophila modifiers can be assembled into an interacting network largely overlapping with that in flies. Identity markers of the endocytic process were also found to abnormally accumulate in ALS patients, further supporting the relevance of the fly data for human biology. Collectively, these results not only lead to a better understanding of hVAPB function but also point to potentially relevant targets for therapeutic intervention.
C1 [Sanhueza, Mario; Chai, Andrea; Pennetta, Giuseppa] Univ Edinburgh, Ctr Integrat Physiol, Edinburgh, Midlothian, Scotland.
[Sanhueza, Mario; Chai, Andrea; Pennetta, Giuseppa] Univ Edinburgh, Euan MacDonald Ctr Motor Neuron Dis Res, Edinburgh, Midlothian, Scotland.
[Chai, Andrea] Baylor Coll Med, Jan & Dan Duncan Neurol Res Inst, Dept Mol & Human Genet, Houston, TX 77030 USA.
[Smith, Colin] Univ Edinburgh, Acad Dept Neuropathol, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland.
[McCray, Brett A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Cambridge, MA 02138 USA.
[Simpson, T. Ian] Univ Edinburgh, Biomath & Stat Scotland, Edinburgh EH8 9YL, Midlothian, Scotland.
[Simpson, T. Ian] Univ Edinburgh, Sch Informat, Inst Adapt & Neural Computat, Edinburgh EH8 9YL, Midlothian, Scotland.
[Taylor, J. Paul] St Jude Childrens Res Hosp, Dept Cell & Mol Biol, Memphis, TN 38105 USA.
RP Sanhueza, M (reprint author), Univ Edinburgh, Ctr Integrat Physiol, Edinburgh, Midlothian, Scotland.
EM g.pennetta@ed.ac.uk
RI Simpson, Ian/B-4722-2011
OI Simpson, Ian/0000-0003-0495-7187
FU Wellcome Trust [Pennetta8920]; Motor Neuron Disease Association
[Pennetta6231]; MND Scotland Association [Pennetta40851]
FX Our work was supported by a Wellcome Trust (http://www.wellcome.ac.uk)
research grant (to GP, grant number: Pennetta8920), by a Motor Neuron
Disease Association (http://www.mndassociation.org) fellowship (to GP,
grant number: Pennetta6231) and by a MND Scotland Association
(http://www.mndscotland.org.uk) fellowship (to GP, grant number:
Pennetta40851). The funders had no role in study design, data collection
and analysis, decision to publish or preparation of the manuscript.
NR 94
TC 9
Z9 9
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7390
EI 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD MAR
PY 2015
VL 11
IS 3
AR e1005107
DI 10.1371/journal.pgen.1005107
PG 32
WC Genetics & Heredity
SC Genetics & Heredity
GA CE9XO
UT WOS:000352197100072
PM 25826266
ER
PT J
AU Ye, L
Morse, LR
Zhang, L
Sasaki, H
Mills, JC
Odgren, PR
Sibbel, G
Stanley, JRL
Wong, G
Zamarioli, A
Battaglino, RA
AF Ye, Liang
Morse, Leslie R.
Zhang, Li
Sasaki, Hajime
Mills, Jason C.
Odgren, Paul R.
Sibbel, Greg
Stanley, James R. L.
Wong, Gee
Zamarioli, Ariane
Battaglino, Ricardo A.
TI Osteopetrorickets due to Snx10 Deficiency in Mice Results from Both
Failed Osteoclast Activity and Loss of Gastric Acid-Dependent Calcium
Absorption
SO PLOS GENETICS
LA English
DT Article
ID BONE MASS; MALIGNANT OSTEOPETROSIS; RESORBING OSTEOCLASTS; TARGETED
DISRUPTION; CL-/HCO3-EXCHANGER; CELLS; TRAFFICKING; EXPRESSION;
MUTATION; GENE
AB Mutations in sorting nexin 10 (Snx10) have recently been found to account for roughly 4% of all human malignant osteopetrosis, some of them fatal. To study the disease pathogenesis, we investigated the expression of Snx10 and created mouse models in which Snx10 was knocked down globally or knocked out in osteoclasts. Endocytosis is severely defective in Snx10-deficent osteoclasts, as is extracellular acidification, ruffled border formation, and bone resorption. We also discovered that Snx10 is highly expressed in stomach epithelium, with mutations leading to high stomach pH and low calcium solubilization. Global Snx10-deficiency in mice results in a combined phenotype: osteopetrosis (due to osteoclast defect) and rickets (due to high stomach pH and low calcium availability, resulting in impaired bone mineralization). Osteopetrorickets, the paradoxical association of insufficient mineralization in the context of a positive total body calcium balance, is thought to occur due to the inability of the osteoclasts to maintain normal calcium-phosphorus homeostasis. However, osteoclast-specific Snx10 knockout had no effect on calcium balance, and therefore led to severe osteopetrosis without rickets. Moreover, supplementation with calcium gluconate rescued mice from the rachitic phenotype and dramatically extended life span in global Snx10-deficient mice, suggesting that this may be a life-saving component of the clinical approach to Snx10-dependent human osteopetrosis that has previously gone unrecognized. We conclude that tissue-specific effects of Snx10 mutation need to be considered in clinical approaches to this disease entity. Reliance solely on hematopoietic stem cell transplantation can leave hypocalcemia uncorrected with sometimes fatal consequences. These studies established an essential role for Snx10 in bone homeostasis and underscore the importance of gastric acidification in calcium uptake.
C1 [Ye, Liang; Morse, Leslie R.; Zhang, Li; Battaglino, Ricardo A.] Forsyth Inst, Dept Mineralized Tissue Biol, Cambridge, MA 02142 USA.
[Ye, Liang; Sasaki, Hajime; Battaglino, Ricardo A.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Morse, Leslie R.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
[Morse, Leslie R.] Spaulding Rehabil Hosp, Boston, MA USA.
[Sasaki, Hajime] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA USA.
[Mills, Jason C.; Sibbel, Greg] Washington Univ, Sch Med, Div Gastroenterol, Dept Med, St Louis, MO 63110 USA.
[Odgren, Paul R.] Univ Massachusetts, Sch Med, Dept Cell & Dev Biol, Worcester, MA USA.
[Stanley, James R. L.; Wong, Gee] CBSET Inc, Lexington, MA USA.
[Zamarioli, Ariane] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Biomech Med & Rehabil, Sao Paulo, Brazil.
RP Ye, L (reprint author), Forsyth Inst, Dept Mineralized Tissue Biol, Cambridge, MA 02142 USA.
EM rbattaglino@forsyth.org
RI battaglino, ricardo/D-2892-2015; Zamarioli, Ariane/K-7001-2012; Morse,
Leslie/C-9442-2015
OI Zamarioli, Ariane/0000-0002-7939-0528; Morse, Leslie/0000-0002-7426-6341
FU Advanced Imaging and Tissue Analysis Core of the Washington University
Digestive Diseases Research Core Centers [NIH2P30 DK052574-12]; NIH from
the National Institute of Diabetes and Digestive and Kidney [R01
DK094989-01]; NIH from the National Institute of Arthritis and
Musculoskeletal and Skin Diseases [RO1 AR061504]
FX This study was supported by the following grants: Advanced Imaging and
Tissue Analysis Core of the Washington University Digestive Diseases
Research Core Centers (NIH2P30 DK052574-12) to JCM, NIH R01 DK094989-01
from the National Institute of Diabetes and Digestive and Kidney to JCM,
and NIH RO1 AR061504 from the National Institute of Arthritis and
Musculoskeletal and Skin Diseases to PRO. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 50
TC 2
Z9 3
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7390
EI 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD MAR
PY 2015
VL 11
IS 3
AR e1005057
DI 10.1371/journal.pgen.1005057
PG 25
WC Genetics & Heredity
SC Genetics & Heredity
GA CE9XO
UT WOS:000352197100043
PM 25811986
ER
PT J
AU Cortese, BM
Uhde, TW
LaRowe, SD
Stein, SV
Freeman, WC
McClernon, FJ
Brady, KT
Hartwell, KJ
AF Cortese, Bernadette M.
Uhde, Thomas W.
LaRowe, Steven D.
Stein, Sarah V.
Freeman, W. Connor
McClernon, F. Joseph
Brady, Kathleen T.
Hartwell, Karen J.
TI Olfactory Cue Reactivity in Nicotine-Dependent Adult Smokers
SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS
LA English
DT Article
DE smoking; odor cues; craving; tobacco dependence; cue reactivity
ID IN-VIVO; SMOKING-CESSATION; ALCOHOLICS; GENDER; INDUCTION; DRINKERS;
STIMULI; PLACEBO; TRIAL; SMELL
AB Cue-elicited reactivity is a significant factor in relapse during smoking quit attempts. Previous research has focused primarily on visual smoking cues, with very limited research examining reactivity to olfactory triggers. Twenty-six adult non-treatment-seeking, nicotine-dependent smokers were exposed to 7 odorants during a cue-reactivity session measuring heart rate, skin conductance, and subjective craving. Cues included 2 cigarette odors (fresh tobacco and cigarette smoke), 2 odors previously identified as smoking-related (freshly mowed grass and coffee), 2 odors previously identified as unrelated to smoking (lavender and burned rubber), and 1 odorless control (propylene glycol). Pairwise comparisons demonstrated that subjective intensity of craving was significantly higher following exposure to the fresh tobacco odor compared with the odorless control (p < .01). A significant main effect for cue type on a physiological measure of arousal was also revealed, with a fresh tobacco odor-elicited significant increase in skin conductance level compared with the odorless control. However, no main effect of cue type on heart rate was found (p = .25). The results of the present study indicate that cigarette odor is an effective olfactory cue that heightens both subjective craving and increases skin conductance in smokers. Future research is needed to evaluate whether avoidance of these odors, or extinction of responses to them, can reduce relapse risk during smoking quit attempts.
C1 [Cortese, Bernadette M.; Uhde, Thomas W.; LaRowe, Steven D.; Stein, Sarah V.; Freeman, W. Connor; Brady, Kathleen T.; Hartwell, Karen J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[LaRowe, Steven D.; Brady, Kathleen T.; Hartwell, Karen J.] Ralph H Johnson VAMC, Charleston, SC USA.
[McClernon, F. Joseph] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27706 USA.
RP Cortese, BM (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, MSC 861, Charleston, SC 29425 USA.
EM corteseb@musc.edu
FU Medical University of South Carolina's South Carolina Clinical and
Translational Research Institute (SCTR) [UL1 RR029882]; NIMH
[K01MH090548]
FX This research was supported by the Medical University of South
Carolina's South Carolina Clinical and Translational Research Institute
(SCTR) Grant UL1 RR029882 (Karen J. Hartwell) and by NIMH Grant
K01MH090548 (Bernadette M. Cortese). We thank Max Owens and Todd LeMatty
for their assistance during data acquisition and the preparation of this
article. We also thank ScentAir Corporation, Charlotte, NC for providing
the odorants.
NR 34
TC 3
Z9 3
U1 0
U2 3
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0893-164X
EI 1939-1501
J9 PSYCHOL ADDICT BEHAV
JI Psychol. Addict. Behav.
PD MAR
PY 2015
VL 29
IS 1
BP 91
EP 96
DI 10.1037/adb0000018
PG 6
WC Substance Abuse; Psychology, Multidisciplinary
SC Substance Abuse; Psychology
GA CF1PD
UT WOS:000352318200011
PM 25180553
ER
PT J
AU Meterko, M
Restuccia, JD
Stolzmann, K
Mohr, D
Brennan, C
Glasgow, J
Kaboli, P
AF Meterko, Mark
Restuccia, Joseph D.
Stolzmann, Kelly
Mohr, David
Brennan, Caitlin
Glasgow, Justin
Kaboli, Peter
TI RESPONSE RATES, NONRESPONSE BIAS, AND DATA QUALITY RESULTS FROM A
NATIONAL SURVEY OF SENIOR HEALTHCARE LEADERS
SO PUBLIC OPINION QUARTERLY
LA English
DT Article
AB Survey response rate is regarded as a key data-quality indicator, yet response rate is not necessarily predictive of nonresponse bias. Our study objective was to use a high-response-rate survey to assess nonresponse bias across successive waves. This survey of healthcare leaders utilized a web-based, self-report format with an initial invitation and four nonrespondent follow-ups. Across five waves, comparisons were made for demographic and facility characteristics, proportion of items completed, and distribution of three question types: factual reports of customized categorical responses; single-item evaluations using five-point Likert scales; and multi-item scales, across four-or five-point Likert scales. The overall response rate was 95 percent (118/124); waves did not differ by demographic and facility characteristics or missing data. Across waves, there were no significant differences between responses to two factual report questions or the single-or multi-item scale measures of attitudes. According to a "what-if" analysis of cumulative results by wave, the same conclusions would have been reached if data collection had been halted at earlier points in time. Precision and statistical power increased as number of respondents accumulated by wave. The high response rate facilitated studying the impact of nonresponse bias by wave. Although high response rates are desirable because of precision and power, as survey fatigue increases, absolute thresholds representing "adequate" response rates may be less realistic. Results from "low" response-rate surveys should be considered on their merits, as they may accurately represent attitudes of the population. Therefore, low response rates should not be cited as reasons to dismiss results as uninformative.
C1 [Meterko, Mark; Restuccia, Joseph D.; Stolzmann, Kelly; Mohr, David] Boston VA Healthcare Syst, CHOIR, Boston, MA USA.
[Meterko, Mark; Mohr, David] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Restuccia, Joseph D.] Boston Univ, Sch Management, Boston, MA 02215 USA.
[Brennan, Caitlin] NIH, Outcomes Management, Dept Nursing Res & Practice Dev, Ctr Clin, Bethesda, MD 20892 USA.
[Glasgow, Justin] Christiana Care Hlth Syst, Wilmington, DE USA.
[Kaboli, Peter] Iowa City VAMC, CADRE Ctr, Iowa City, IA 52246 USA.
[Kaboli, Peter] Univ Iowa, Carver Coll Med, Internal Med, Iowa City, IA USA.
RP Kaboli, P (reprint author), Iowa City VAMC, CADRE Ctr, Mailstop 152,601 Highway West, Iowa City, IA 52246 USA.
EM peter.kaboli@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development (HSRD) Service [REA 09-220];
Comprehensive Access & Delivery Research and Evaluation (CADRE) Center
at the Iowa City VAMC [CIN 13-412]; HSR&D Center for Healthcare
Organization and Implementation Research (CHOIR) at the Boston VA
Healthcare System [HFP 04-145]
FX MARK METERKO is an investigator at the Center for Healthcare
Organization and Implementation Research (CHOIR) at the Boston VA
Healthcare System, Boston, MA, USA, and research associate professor at
the Boston University School of Public Health, Boston, MA, USA. JOSEPH
D. RESTUCCIA is an investigator at the Center for Healthcare
Organization and Implementation Research (CHOIR) at the Boston VA
Healthcare System, Boston, MA, USA, and professor at the Boston
University School of Management, Boston, MA, USA. KELLY STOLZMANN is a
research analyst at the Center for Healthcare Organization and
Implementation Research (CHOIR) at the Boston VA Healthcare System,
Boston, MA, USA. DAVID MOHR is an investigator at the Center for
Healthcare Organization and Implementation Research (CHOIR) at the
Boston VA Healthcare System, Boston, MA, USA, and research assistant
professor at the Boston University School of Public Health, Boston, MA,
US. CAITLIN BRENNAN is Program Director for Outcomes Management,
Department of Nursing Research and Practice Development, National
Institutes of Health Clinical Center, Bethesda, MD, USA. JUSTIN GLASGOW
is an internal medicine resident at Christiana Care Health System,
Wilmington, DE, USA. PETER KABOLI is an investigator at the
Comprehensive Access and Delivery Research and Evaluation (CADRE) Center
at the Iowa City VA Healthcare System, Iowa City, IA, USA, and professor
of internal medicine, University of Iowa Carver College of Medicine,
Iowa City, IA, USA. The work reported here was supported by the
Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development (HSR&D) Service [REA 09-220 to M.M.,
J.D.R., K.S., D.M., and P.K.], the Comprehensive Access & Delivery
Research and Evaluation (CADRE) Center at the Iowa City VAMC [CIN 13-412
to P.K. and J.G.], and the HSR&D Center for Healthcare Organization and
Implementation Research (CHOIR) at the Boston VA Healthcare System [HFP
04-145 to M.M., J.D.R., K.S., D.M., and C.B.]. The authors wish to thank
Errol Baker, Erol Pekoz, and Michael Shwartz for their thoughtful advice
regarding sampling, population, and power analysis issues associated
with this study. All three individuals are affiliated with the Center
for Healthcare Organization and Implementation Research (CHOIR), VA
Boston Healthcare System. Views expressed in this article are those of
the authors and do not necessarily represent the views of the Department
of Veterans Affairs. *Address correspondence to Peter J. Kaboli, MD, MS,
Iowa City VAMC, Comprehensive Access & Delivery Research and Evaluation
(CADRE) Center, Mailstop 152, 601 Highway West, Iowa City, IA 52246,
USA; e-mail: peter.kaboli@va.gov.
NR 17
TC 1
Z9 1
U1 3
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0033-362X
EI 1537-5331
J9 PUBLIC OPIN QUART
JI Public Opin. Q.
PD SPR
PY 2015
VL 79
IS 1
BP 130
EP 144
DI 10.1093/poq/nfu052
PG 15
WC Communication; Political Science; Social Sciences, Interdisciplinary
SC Communication; Government & Law; Social Sciences - Other Topics
GA CF4RE
UT WOS:000352537500006
ER
PT J
AU Manian, FA
AF Manian, Farrin A.
TI Time to Dedifferentiate
SO SOUTHERN MEDICAL JOURNAL
LA English
DT Editorial Material
ID EDUCATION
C1 [Manian, Farrin A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RP Manian, FA (reprint author), Dept Med, 50 Staniford St,Suite 503 B, Boston, MA 02114 USA.
EM Fmanian@mgh.harvard.edu
NR 9
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0038-4348
EI 1541-8243
J9 SOUTH MED J
JI South.Med.J.
PD MAR
PY 2015
VL 108
IS 3
BP 198
EP 199
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA CF4FV
UT WOS:000352505100012
PM 25772056
ER
PT J
AU Satyanarayana, G
Hammond, SP
Broge, TA
Mackenzie, MR
Viscidi, R
Politikos, I
Koralnik, IJ
Cutler, CS
Ballen, K
Boussiotis, V
Marty, FM
Tan, CS
AF Satyanarayana, Gowri
Hammond, Sarah P.
Broge, Thomas A., Jr.
Mackenzie, Matthew R.
Viscidi, Raphael
Politikos, Ioannis
Koralnik, Igor J.
Cutler, Corey S.
Ballen, Karen
Boussiotis, Vassiliki
Marty, Francisco M.
Tan, Chen Sabrina
TI BK polyomavirus reactivation after reduced-intensity double umbilical
cord blood cell transplantation
SO TRANSPLANT IMMUNOLOGY
LA English
DT Article
DE BK polyomavirus; Hemorrhagic cystitis; Viral reactivation
ID BONE-MARROW-TRANSPLANTATION; HEMORRHAGIC CYSTITIS; VIRUS-INFECTION;
IMMUNE RECONSTITUTION; RECIPIENTS; NEPHROPATHY; ASSOCIATION; DISEASE;
LOAD
AB Serial serum samples from 27 patients who underwent double umbilical cord blood transplantation (dUCBT) were analyzed for BK polyomavirus (BKPyV) DNA by real-time PCR and BKPyV-specific immune globulin by ELISA. Clinical data were collected on all patients. All pre-transplant sera had detectable anti-BKPyV IgG. Fifteen patients (56%) had detectable serum BKPyV DNA (median 8.9 x 10(4) copies/ml; range 4.1 x 10(3)-7.9 x 10(6) copies/ml) a median of 40 days (range, 27-733 days) after dUCBT, with highest viral loads on Day 100 assessment. The cumulative probability of developing BKPyV viremia by Day 100 was 0.52 (95% CI, 033-0.71). Six of 15 patients with BKPyV viremia experienced hemorrhagic cystitis by Day 100. By Day 100, there was a trend towards higher BKPyV viral loads in sera of patients with hemorrhagic cystitis than in those BKPyV viremic patients without hemorrhagic cystitis (p = 0.06). BKPyV viremia was associated with significantly higher anti-BKPyV IgM values at 6 months post-dUCBT (P = 0.003). BKPyV viremia occurs early after dUBCT and is associated with a detectable humoral immune response by 6 months post-dUBCT. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Satyanarayana, Gowri; Tan, Chen Sabrina] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.
[Broge, Thomas A., Jr.; Mackenzie, Matthew R.; Koralnik, Igor J.; Tan, Chen Sabrina] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.
[Satyanarayana, Gowri] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA.
[Broge, Thomas A., Jr.; Mackenzie, Matthew R.; Politikos, Ioannis; Koralnik, Igor J.; Boussiotis, Vassiliki; Tan, Chen Sabrina] Beth Israel Deaconess Med Ctr, Dept Neurol, Div Neurovirol, Boston, MA 02215 USA.
[Satyanarayana, Gowri; Hammond, Sarah P.; Marty, Francisco M.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Viscidi, Raphael] Johns Hopkins Univ, Med Ctr, Div Dev Neurovirol, Baltimore, MD 21218 USA.
[Cutler, Corey S.; Marty, Francisco M.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA.
[Ballen, Karen] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA.
RP Tan, CS (reprint author), Beth Israel Deaconess Med Ctr, E-CLS 1011,330 Brookline Ave, Boston, MA 02215 USA.
EM ctan@bidmc.hanrard.edu
FU NIH grant [R01 NS 047029, NS 074995, NS R56 041198, K24 NS 060950, K08
NS 064215-01]; Harvard Catalyst/The Harvard Clinical and Translational
Science Center (NCRR); Harvard Catalyst/The Harvard Clinical and
Translational Science Center (NCATS); Harvard Catalyst/The Harvard
Clinical and Translational Science Center (NIH Award) [UL1 TR001102];
Harvard University
FX This work was conducted in part with support from NIH grants R01 NS
047029 and NS 074995, NS R56 041198, and K24 NS 060950 to IJK, and NIH
grant K08 NS 064215-01 to CST.; This work was conducted with support
from Harvard Catalyst/The Harvard Clinical and Translational Science
Center (NCRR and NCATS, NIH Award UL1 TR001102) and financial
contributions from Harvard University and its affiliated academic
healthcare centers.
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0966-3274
EI 2210-3384
J9 TRANSPL IMMUNOL
JI Transpl. Immunol.
PD MAR
PY 2015
VL 32
IS 2
BP 116
EP 120
DI 10.1016/j.trim.2014.12.002
PG 5
WC Immunology; Transplantation
SC Immunology; Transplantation
GA CG1YT
UT WOS:000353072800009
PM 25536223
ER
PT J
AU Maughan, BC
Seigel, TA
Napoli, AM
AF Maughan, Brandon C.
Seigel, Todd A.
Napoli, Anthony M.
TI PLETH VARIABILITY INDEX AND FLUID RESPONSIVENESS OF HEMODYNAMICALLY
STABLE PATIENTS AFTER CARDIOTHORACIC SURGERY
SO AMERICAN JOURNAL OF CRITICAL CARE
LA English
DT Article
ID CARDIOPULMONARY BYPASS; CARDIAC-SURGERY; PREDICTION
AB Background Fluid responsiveness is a measure of preload dependence and is defined as an increase in cardiac output due to volume expansion. Recent publications have suggested that variation in amplitude of the pulse oximetry waveform may be predictive of fluid responsiveness. The pleth variability index (PVI) was developed as a noninvasive bedside measurement of this variation in the pulse oximetry waveform.
Objectives To measure the discriminatory value of PVI for predicting fluid responsiveness as measured by pulmonary artery catheter thermodilution in patients after cardiothoracic surgery.
Methods A prospective observational study of hemodynamically stable postoperative cardiac surgery patients with pulmonary artery catheters. A fingertip sensor was used to measure PVI. Vital signs, PVI, and cardiac index were measured before, during, and after passive leg raise. Fluid responsiveness was defined by increase in cardiac index of greater than 15% during passive leg raise. The discriminatory value of PVI was assessed by using the Wilcoxon method to measure the area under the receiver operating curve.
Results In 13 months, 47 patients (24 receiving mechanical ventilation, 23 spontaneously breathing) were enrolled. Fluid responsiveness was noted in 42% of intubated patients and 48% of spontaneously breathing patients. PVI was not adequate to discriminate fluid responsiveness in intubated patients (area under curve, 0.63; P=.16) or spontaneously breathing patients (area under curve, 0.41; P=.75).
Conclusions Among postoperative cardiac surgery patients, PVI is not reliable for predicting fluid responsiveness as measured by pulmonary artery catheter thermodilution, regardless of ventilatory status.
C1 Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Emergency Med, Providence, RI 02912 USA.
[Maughan, Brandon C.] Univ Penn, Vet Affairs Med Ctr, Robert Wood Johnson Clin Scholar Philadelphia, Philadelphia, PA 19104 USA.
[Seigel, Todd A.] Kaiser Oakland Med Ctr, Dept Emergency Med & Crit Care, Oakland, CA USA.
[Napoli, Anthony M.] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Providence, RI 02912 USA.
RP Maughan, BC (reprint author), Univ Penn, 423 Guardian Ave,Blockley Hall 1303A, Philadelphia, PA 19104 USA.
EM Brandon.Maughan@uphs.upenn.edu
NR 14
TC 0
Z9 0
U1 2
U2 2
PU AMER ASSOC CRITICAL CARE NURSES
PI ALISO VIEJO
PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA
SN 1062-3264
EI 1937-710X
J9 AM J CRIT CARE
JI Am. J. Crit. Care
PD MAR 1
PY 2015
VL 24
IS 2
BP 172
EP 175
DI 10.4037/ajcc2015864
PG 4
WC Critical Care Medicine; Nursing
SC General & Internal Medicine; Nursing
GA CE8XL
UT WOS:000352127300011
PM 25727278
ER
PT J
AU Yanke, E
Zellmer, C
Van Hoof, S
Moriarty, H
Carayon, P
Safdar, N
AF Yanke, Eric
Zellmer, Caroline
Van Hoof, Sarah
Moriarty, Helene
Carayon, Pascale
Safdar, Nasia
TI Understanding the current state of infection prevention to prevent
Clostridium difficile infection: A human factors and systems engineering
approach
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE Clostridium difficile; Contact precautions; Infection control; Human
factors; Systems engineering
ID HAND HYGIENE COMPLIANCE; HEALTH-CARE WORKERS; CONTACT PRECAUTIONS;
PATIENT SAFETY; BURDEN; VISITORS; DIARRHEA
AB Background: Achieving and sustaining high levels of health care worker (HCW) compliance with contact isolation precautions is challenging. The aim of this study was to determine HCW work system barriers to and facilitators of adherence to contact isolation for patients with suspected or confirmed Clostridium difficile infection (CDI) using a human factors and systems engineering approach.
Methods: This prospective cohort study took place between September 2013 and November 2013 at a large academic medical center (hospital A) and an affiliated Veterans Administration hospital (hospital B). A human factors engineering (HFE) model for patient safety, the Systems Engineering Initiative for Patient Safety model, was used to guide work system analysis and direct observation data collection. There were 288 observations conducted. HCWs and visitors were assessed for compliance with all components of contact isolation precautions (hand hygiene, gowning, and gloving) before and after patient contact. Time required to complete contact isolation precautions was measured, and adequacy of contact isolation supplies was assessed.
Results: Full compliance with contact isolation precautions was low at both hospitals A (7%) and B (22%). Lack of appropriate hand hygiene prior to room entry (compliance for hospital A: 18%; compliance for hospital B: 29%) was the most common reason for lack of full compliance. More time was required for full compliance compared with compliance with no components of contact isolation precautions before patient room entry, inside patient room, and after patient room exit (59.9 vs 3.2 seconds, P <. 001; 507.3 vs 149.7 seconds, P = .006; 15.2 vs 1.3 seconds, P <.001, respectively). Compliance was lower when contact isolation supplies were inadequate (4% vs 16%, P = .005).
Conclusions: Adherence to contact isolation precautions for CDI is a complex, time-consuming process. HFE analysis indicates that multiple work system components serve as barriers and facilitators to full compliance with contact isolation precautions and should be addressed further to prevent CDI. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc.
C1 [Yanke, Eric] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA.
[Zellmer, Caroline] Univ Wisconsin, Coll Agr & Life Sci, Madison, WI 53706 USA.
[Van Hoof, Sarah] Univ Wisconsin Hosp & Clin, Dept Infect Control, Madison, WI 53792 USA.
[Moriarty, Helene] Villanova Univ, Coll Nursing, Villanova, PA 19085 USA.
[Moriarty, Helene] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Carayon, Pascale] Univ Wisconsin, Dept Ind & Syst Engn, Ctr Qual & Prod Improvement, Madison, WI USA.
[Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Safdar, Nasia] Univ Wisconsin, Sch Med, Dept Med, Div Infect Dis, Madison, WI USA.
[Safdar, Nasia] Univ Wisconsin, Infect Control Dept, Madison, WI USA.
RP Safdar, N (reprint author), UWMF Centennial Bldg,1685 Highland Ave, Madison, WI 53705 USA.
EM ns2@medicine.wisc.edu
FU Veterans Affairs MERIT award; University of Wisconsin Institute for
Clinical and Translational Research; Clinical and Translational Science
Award program; National Center for Advancing Translational Sciences
[9U54TR000021]
FX Dr. Safdar is supported by a Veterans Affairs MERIT award. Dr. Carayon
is supported by the University of Wisconsin Institute for Clinical and
Translational Research and the Clinical and Translational Science Award
program, previously through the National Center for Research Resources
(grant no. 1UL1RR025011), and now by the National Center for Advancing
Translational Sciences (grant no. 9U54TR000021).
NR 23
TC 6
Z9 6
U1 3
U2 11
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
EI 1527-3296
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD MAR
PY 2015
VL 43
IS 3
BP 241
EP 247
DI 10.1016/j.ajic.2014.11.026
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA CE8PQ
UT WOS:000352106200006
PM 25728149
ER
PT J
AU Khan, A
Rao, A
Reyes-Sacin, C
Hayakawa, K
Szpunar, S
Riederer, K
Kaye, K
Fishbain, JT
Levine, D
AF Khan, Amber
Rao, Amitha
Reyes-Sacin, Carlos
Hayakawa, Kayoko
Szpunar, Susan
Riederer, Kathleen
Kaye, Keith
Fishbain, Joel T.
Levine, Diane
TI Use of portable electronic devices in a hospital setting and their
potential for bacterial colonization
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE Mobile electronic devices; Contamination
ID MOBILE PHONES; CONTAMINATION; PHYSICIANS
AB Portable electronic devices are increasingly being used in the hospital setting. As with other fomites, these devices represent a potential reservoir for the transmission of pathogens. We conducted a convenience sampling of devices in 2 large medical centers to identify bacterial colonization rates and potential risk factors. Copyright (C) 2015 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc.
C1 [Khan, Amber; Levine, Diane] Detroit Med Ctr, Dept Internal Med, Detroit, MI USA.
[Khan, Amber; Kaye, Keith; Levine, Diane] Wayne State Univ, Sch Med, Detroit, MI USA.
[Rao, Amitha] Michael E Debakey Vet Adm Med Ctr, Dept Primary Care Med, Houston, TX USA.
[Reyes-Sacin, Carlos] Med AIDS Outreach Alabama, Dept Infect Dis, Montgomery, AL USA.
[Hayakawa, Kayoko] Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Tokyo, Japan.
[Szpunar, Susan; Riederer, Kathleen] St John Hosp & Med Ctr, Dept Grad Med Educ, Detroit, MI USA.
[Kaye, Keith] St John Hosp & Med Ctr, Div Infect Dis, Dept Internal Med, Detroit, MI USA.
[Fishbain, Joel T.] Detroit Med Ctr, Div Infect Dis, Detroit, MI USA.
RP Khan, A (reprint author), Detroit Receiving Hosp & Univ Hlth Ctr, 4201 St Antoine,UHC 2E, Detroit, MI 48201 USA.
EM amkha@med.wayne.edu
NR 7
TC 3
Z9 3
U1 2
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
EI 1527-3296
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD MAR
PY 2015
VL 43
IS 3
BP 286
EP 288
DI 10.1016/j.ajic.2014.11.013
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA CE8PQ
UT WOS:000352106200015
PM 25557772
ER
PT J
AU Lee, JH
Cho, MH
Hersh, CP
McDonald, MLN
Wells, JM
Dransfield, MT
Bowler, RP
Lynch, DA
Lomas, DA
Crapo, JD
Silverman, EK
AF Lee, Jin Hwa
Cho, Michael H.
Hersh, Craig P.
McDonald, Merry-Lynn N.
Wells, J. Michael
Dransfield, Mark T.
Bowler, Russell P.
Lynch, David A.
Lomas, David A.
Crapo, James D.
Silverman, Edwin K.
CA COPDGene Investigators
ECLIPSE Investigators
TI IREB2 and GALC Are Associated with Pulmonary Artery Enlargement in
Chronic Obstructive Pulmonary Disease
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE chronic obstructive pulmonary disease; genome-wide association;
pulmonary hypertension; subtyping
ID GENOME-WIDE ASSOCIATION; AIR-FLOW OBSTRUCTION; IRON HOMEOSTASIS; LUNG
TRANSPLANTATION; CHRONIC-BRONCHITIS; COPD PATIENTS; HYPERTENSION;
EMPHYSEMA; SUSCEPTIBILITY; METAANALYSIS
AB Pulmonary hypertension is associated with advanced chronic obstructive pulmonary disease (COPD), although pulmonary vascular changes occur early in the course of the disease. Pulmonary artery (PA) enlargement (PAE) measured by computed tomography correlates with pulmonary hypertension and COPD exacerbation frequency. Genome-wide association studies of PAE in subjects with COPD have not been reported. To investigate whether genetic variants are associated with PAE within subjects with COPD, we investigated data from current and former smokers from the COPDGene Study and the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study. The ratio of the diameter of the PA to the diameter of the aorta (A) was measured using computed tomography. PAE was defined as PA/A greater than 1. A genome-wide association study for COPD with PAE was performed using subjects with COPD without PAE (PA/A <= 1) as a control group. A secondary analysis used smokers with normal spirometry as a control group. Genotyping was performed on Illumina platforms. The results were summarized using fixed-effect meta-analysis. Both meta-analyses revealed a genome-wide significant locus on chromosome 15q25.1 in IREB2 (COPD with versus without PAE, rs7181486; odds ratio [OR] = 1.32; P = 2.10 x 10(-8); versus smoking control subjects, rs2009746; OR = 1.42; P= 1.32 x 10(-9)). PAE was also associated with a region on 14q31.3 near the GALC gene (rs7140285; OR = 1.55; P = 3.75 x 10(-8)). Genetic variants near IREB2 and GALC likely contribute to genetic susceptibility to PAE associated with COPD. This study provides evidence for genetic heterogeneity associated with a clinically important COPD vascular subtype.
C1 [Lee, Jin Hwa; Cho, Michael H.; Hersh, Craig P.; McDonald, Merry-Lynn N.; Silverman, Edwin K.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Cho, Michael H.; Hersh, Craig P.; Silverman, Edwin K.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
[Lee, Jin Hwa] Ewha Womans Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Seoul, South Korea.
[Wells, J. Michael; Dransfield, Mark T.] Univ Alabama Birmingham, Lung Hlth Ctr, Div Pulm Allergy & Crit Care, Birmingham, AL USA.
[Wells, J. Michael; Dransfield, Mark T.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Bowler, Russell P.; Lynch, David A.; Crapo, James D.] Natl Jewish Hlth, Div Pulm & Crit Care, Denver, CO USA.
[Lomas, David A.] UCL, Wolfson Inst Biomed Res, London, England.
RP Silverman, EK (reprint author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.
EM jinhwalee@ewha.ac.kr; ed.silverman@channing.harvard.edu
RI Agusti Garcia-Navarro, Alvar/F-4474-2015; Mattheisen,
Manuel/B-4949-2012; Coxson, Harvey/A-9861-2017
OI MacNee, William/0000-0002-3692-1448; Comellas,
Alejandro/0000-0003-1521-7520; Agusti Garcia-Navarro,
Alvar/0000-0003-3271-3788; Mattheisen, Manuel/0000-0002-8442-493X;
Coxson, Harvey/0000-0001-5750-9711
FU National Institutes of Health [R01 HL089856, R01 HL075478, R01HL089897,
P01 HL105339, K08 HL097029, R01 HL113264]; COPD Foundation; GSK
FX This work was supported by National Institutes of Health grants R01
HL089856 (E.K.S.), R01 HL075478 (E.K.S), R01HL089897 (J.D.C.), P01
HL105339 (E.K.S.), K08 HL097029 (M.H.C), and R01 HL113264 (M.H.C.). The
COPDGene study (NCT00608764) is also supported by the COPD Foundation
through contributions made to an industry advisory board comprised of
AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Siemens, Sunovion
and GlaxoSmithKline (GSK). The Evaluation of COPD Longitudinally to
Identify Predictive Surrogate Endpoints study (NCT00292552; GSK code
SCO104960) was sponsored by GSK.
NR 56
TC 3
Z9 4
U1 1
U2 5
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAR
PY 2015
VL 52
IS 3
BP 365
EP 376
DI 10.1165/rcmb.2014-0210OC
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA CF0BS
UT WOS:000352208100010
PM 25101718
ER
PT J
AU Thaler, NS
Sayegh, P
Kim, MS
Castellon, SA
Hinkin, CH
AF Thaler, Nicholas S.
Sayegh, Philip
Kim, Michelle S.
Castellon, Steven A.
Hinkin, Charles H.
TI Interactive Effects of Neurocognitive Impairment and Substance Use on
Antiretroviral Non-adherence in HIV Disease
SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY
LA English
DT Article
DE HIV/AIDS; Drug and alcohol abuse
ID MEDICATION ADHERENCE; NEUROPSYCHOLOGICAL IMPAIRMENT; INFECTED
INDIVIDUALS; DEPRESSIVE SYMPTOMS; PROSPECTIVE MEMORY; VIRAL SUPPRESSION;
DRUG-USE; ADULTS; METHAMPHETAMINE; PREDICTORS
AB While numerous studies have established the adverse independent effects of clinical conditions including neurocognitive dysfunction, psychiatric illness, and substance abuse/dependence on medication adherence among HIV-infected adults, fewer have studied their interactive effects. The current study examined this issue among 204 HIV-infected participants based upon current neurocognitive functioning and DSM-IV-diagnosed psychiatric illness and current substance abuse or dependence. Results confirmed that participants with any of these risk factors demonstrated poorer adherence than individuals with no risk factors. A neurocognitive status x substance abuse/dependence interaction was also identified such that participants with impaired neurocognition and a co-occurring substance abuse/dependence diagnosis demonstrated the poorest adherence. Results confirm the deleterious impact of these risk factors in isolation and also identify a specific interactive effect for individuals with comorbid neurocognitive impairment and a substance abuse/dependence disorder. Findings highlight the need for interventions that simultaneously address these problems.
C1 [Thaler, Nicholas S.; Sayegh, Philip; Castellon, Steven A.; Hinkin, Charles H.] Univ Calif Los Angeles, Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Kim, Michelle S.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Castellon, Steven A.; Hinkin, Charles H.] VA Greater Los Angeles Healthcare Syst, Dept Psychol, Los Angeles, CA USA.
RP Thaler, NS (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,C8-735, Los Angeles, CA 90024 USA.
EM Nthaler@mednet.ucla.edu
FU National Institutes of Health [R01 DA13799]; National Institutes of
Health Ruth L. Kirschstein National Research Service award [T32 MH19535]
FX This work was supported by National Institutes of Health grant R01
DA13799 and the National Institutes of Health Ruth L. Kirschstein
National Research Service award T32 MH19535.
NR 35
TC 3
Z9 3
U1 3
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0887-6177
EI 1873-5843
J9 ARCH CLIN NEUROPSYCH
JI Arch. Clin. Neuropsychol.
PD MAR
PY 2015
VL 30
IS 2
BP 114
EP 121
DI 10.1093/arclin/acu092
PG 8
WC Psychology, Clinical; Psychology
SC Psychology
GA CF0JP
UT WOS:000352230000003
PM 25589442
ER
PT J
AU Gil, M
Kawai, T
Ishikawa-Nagai, S
Da Silva, J
Nagai, M
AF Gil, Mindy
Kawai, Toshihisa
Ishikawa-Nagai, Shigemi
Da Silva, John
Nagai, Masazumi
TI Identification of putative bone anabolic peptides targeting adherent
plasma membrane
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Peptide display library; Adherent plasma membrane; Bone matrix;
Biomaterial; Osteoblast; Differentiation
ID VIVO PHAGE DISPLAY; EXTRACELLULAR-MATRIX; DIFFERENTIATION; REPAIR
AB Bone matrix provides unknown essential cues for osteoblast lineage cells to develop, grow, repair and remodel bones via adherent plasma membrane. Because of its tight sealing with bone matrix in vivo and culture surface in vitro as well, the adherent plasma membrane has been unveiled target of investigation to date. Herein, we report a new approach to explore the adherence plasma membrane of osteoblasts with biofunctional peptide candidates in a bacterial peptide library. To accomplish this, human osteoblast like hFOB 1.19 cells were cultured on porous filter with 8 gm pore through which bacterial peptides were allowed to meet the membrane for affinity selection. The affinity-selected peptides were coated on culture plate to further evaluate their influence on osteoblastic cell adhesion, as well as expressions of osteoblast differentiation markers, alkaline phosphatase and osteocalcin. Finally, the serial screenings identified two prominent active peptides that enhanced the differentiation markers nearly to the same level as a control peptide of bone morphogenetic protein-2. Osteogenic activity is expected for the peptides when immobilized on bone implant surface. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Gil, Mindy; Kawai, Toshihisa] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Kawai, Toshihisa; Nagai, Masazumi] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA 02142 USA.
[Ishikawa-Nagai, Shigemi; Da Silva, John] Harvard Univ, Sch Dent Med, Restorat Dent & Biomat Sci, Boston, MA 02115 USA.
RP Nagai, M (reprint author), Forsyth Inst, Dept Immunol & Infect Dis, 245 First St, Cambridge, MA 02142 USA.
EM mnagai@forsyth.org
FU ITT Foundation, Basel, Switzerland [673_2009]; American Academy of
Implant Dentistry Foundation (Student Research Grant)
FX This study was supported by the ITT Foundation, Basel, Switzerland
(673_2009) and the American Academy of Implant Dentistry Foundation
(Student Research Grant).
NR 16
TC 1
Z9 1
U1 1
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR
PY 2015
VL 459
IS 1
BP 71
EP 74
DI 10.1016/j.bbrc.2015.02.071
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA CE8UU
UT WOS:000352120400012
PM 25721672
ER
PT J
AU Purdy, E
Thoma, B
Bednarczyk, J
Migneault, D
Sherbino, J
AF Purdy, Eve
Thoma, Brent
Bednarczyk, Joseph
Migneault, David
Sherbino, Jonathan
TI The use of free online educational resources by Canadian emergency
medicine residents and program directors
SO CANADIAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
DE open educational resources; medical education; social media
ID SOCIAL MEDIA; GENERATION; FOAM
AB Introduction: Online educational resources (OERs) are increasingly available for emergency medicine (EM) education. This study describes and compares the use of free OERs by the Royal College of Physicians and Surgeons of Canada (RCPSC) EM residents and program directors (PDs) and investigates the relationship between the use of OERs and peer-reviewed literature.
Methods: A bilingual, online survey was distributed to RCPSC-EM residents and PDs using a modified Dillman method. The chi-square test and Fisher's exact test were used to compare the responses of residents and PDs.
Results: The survey was completed by 214/350 (61%) residents and 11/14 (79%) PDs. Free OERs were used by residents most frequently for general EM education (99.5%), procedural skills training (96%), and learning to interpret diagnostic tests (92%). OER modalities used most frequently included wikis (95%), file-sharing websites (95%), e-textbooks (94%), and podcasts (91%). Residents used wikis, podcasts, vodcasts, and file-sharing websites significantly more frequently than PDs. Relative to PDs, residents found entertainment value to be more important for choosing OERs (p< 0.01). Some residents (23%) did not feel that literature references were important, whereas all PDs did. Both groups reported that OERs increased the amount of peer-reviewed literature (75% and 60%, respectively) that they read.
Conclusions: EM residents make extensive use of OERs and differ from their PDs in the importance that they place on their entertainment value and incorporation of peer-reviewed references. OERs may increase the use of peer-reviewed literature in both groups. Given the prevalence of OER use for core educational goals among RCPSC-EM trainees, future efforts to facilitate critical appraisal and appropriate resource selection are warranted.
C1 [Purdy, Eve] Queens Univ, Sch Med, Kingston, ON, Canada.
[Thoma, Brent] Massachusetts Gen Hosp, Dept Emergency Med, Learning Lab, Boston, MA 02114 USA.
[Thoma, Brent] Massachusetts Gen Hosp, Dept Emergency Med, Div Med Simulat, Boston, MA 02114 USA.
[Thoma, Brent] Univ Saskatchewan, Emergency Med, Saskatoon, SK, Canada.
[Bednarczyk, Joseph] Univ Manitoba, Dept Emergency Med, Winnipeg, MB, Canada.
[Migneault, David] Univ British Columbia, Dept Emergency Med, Vancouver, BC V5Z 1M9, Canada.
[Sherbino, Jonathan] McMaster Univ, Div Emergency Med, Hamilton, ON, Canada.
RP Thoma, B (reprint author), Royal Univ Hosp, Emergency Med Residency Program, Room 2686,103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada.
EM brent.thoma@usask.ca
OI Thoma, Brent/0000-0003-1124-5786
NR 24
TC 12
Z9 12
U1 0
U2 7
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1481-8035
EI 1481-8043
J9 CAN J EMERG MED
JI Can. J. Emerg. Med.
PD MAR
PY 2015
VL 17
IS 2
BP 101
EP 106
DI 10.1017/cem.2014.73
PG 6
WC Emergency Medicine
SC Emergency Medicine
GA CE8LY
UT WOS:000352095100001
PM 25927253
ER
PT J
AU Atkinson, P
Bowra, J
Lambert, M
Lamprecht, H
Noble, V
Jarman, B
AF Atkinson, Paul
Bowra, Justin
Lambert, Mike
Lamprecht, Hein
Noble, Vicki
Jarman, Bob
TI International Federation for Emergency Medicine Point of Care Ultrasound
Curriculum
SO CANADIAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
DE Point of Care Ultrasound; International Curriculum; Education;
Competency Assessment
AB To meet a critical and growing need for a standardized approach to emergency point of care ultrasound (PoCUS) worldwide, emergency physicians must be trained to deliver and teach this skill in an accepted and reliable format. Currently, there is no globally recognized, standard PoCUS curriculum that defines the accepted applications, as well as standards for training and practice of PoCUS by specialists and trainees in emergency medicine. To address this deficit, the International Federation for Emergency Medicine (IFEM) convened a sub-committee of international experts in PoCUS to outline a curriculum for training of specialists in emergency PoCUS. This curriculum document represents the consensus of recommendations by this sub-committee. The curriculum is designed to provide a framework for PoCUS education in emergency medicine. The focus is on the processes required to select core and enhanced applications, as well as the key elements required for the delivery of PoCUS training from introduction through to continuing professional development and skill maintenance. It is designed not to be prescriptive but to assist educators and emergency medicine leadership to advance PoCUS education in emergency medicine no matter the training venue. The content of this curriculum is relevant not just for communities with mature emergency medicine systems but in particular for developing nations or for nations seeking to develop PoCUS training programs within the current educational structure. We anticipate that there will be wide variability in how this curriculum is implemented and taught, reflecting the existing educational environment, resources and goals of educational programs.
C1 [Atkinson, Paul] Dalhousie Univ, Halifax, NS, Canada.
[Atkinson, Paul] St Johns Hosp, St John, NB, Canada.
[Bowra, Justin] Sydney Adventist Hosp, Wahroonga, NSW, Australia.
[Bowra, Justin] Univ Sydney, Sydney, NSW 2006, Australia.
[Lambert, Mike] Advocate Christ Med Ctr, Dept Emergency Med, Oak Lawn, IL USA.
[Lamprecht, Hein] Univ Stellenbosch, Joint Div Emergency Med, ZA-7600 Stellenbosch, South Africa.
[Lamprecht, Hein] Univ Cape Town, ZA-7925 Cape Town, South Africa.
[Noble, Vicki] Massachusetts Gen Hosp, Div Emergency Ultrasound, Boston, MA 02114 USA.
[Noble, Vicki] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Jarman, Bob] Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
[Jarman, Bob] Univ Teesside, Middlesbrough, Cleveland, England.
RP Atkinson, P (reprint author), Care of Reardon C, Int Federat Emergency Med, 34 Jeffcott St, W Melbourne, Vic 3003, Australia.
EM ifem@acem.org.au
NR 0
TC 4
Z9 4
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1481-8035
EI 1481-8043
J9 CAN J EMERG MED
JI Can. J. Emerg. Med.
PD MAR
PY 2015
VL 17
IS 2
BP 161
EP 170
DI 10.1017/cem.2015.8
PG 10
WC Emergency Medicine
SC Emergency Medicine
GA CE8LY
UT WOS:000352095100019
PM 26052968
ER
PT J
AU Thoma, B
Chan, T
Desouza, N
Lin, M
AF Thoma, Brent
Chan, Teresa
Desouza, Natalie
Lin, Michelle
TI Implementing peer review at an emergency medicine blog: bridging the gap
between educators and clinical experts
SO CANADIAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
DE knowledge translation; medical blog; medical education; peer review
ID KNOWLEDGE TRANSLATION
AB Emergency physicians are leaders in the "free open-access meducation" (FOAM) movement. The mandate of FOAM is to create open-access education and knowledge translation resources for trainees and practicing physicians (e.g., blogs, podcasts, and vodcasts). Critics of FOAM have suggested that because such resources can be easily published online without quality control mechanisms, unreviewed FOAM resources may be erroneous or biased. We present a new initiative to incorporate open, expert, peer review into an established academic medical blog. Experts provided either pre- or postpublication reviews that were visible to blog readers. This article outlines the details of this initiative and discusses the potentially transformative impact of this educational innovation.
C1 [Thoma, Brent] Massachusetts Gen Hosp, Dept Emergency Med, Learning Lab, Boston, MA 02114 USA.
[Thoma, Brent] Massachusetts Gen Hosp, Dept Emergency Med, Div Med Simulat, Boston, MA 02114 USA.
[Thoma, Brent] Univ Saskatchewan, Dept Emergency Med, Saskatoon, SK, Canada.
[Thoma, Brent; Chan, Teresa; Lin, Michelle] MedEdLIFE Res Collaborat, San Francisco, CA USA.
[Chan, Teresa] McMaster Univ, Dept Med, Div Emergency Med, Hamilton, ON, Canada.
[Chan, Teresa] Univ Illinois, Coll Med, Dept Med Educ, Chicago, IL USA.
[Desouza, Natalie; Lin, Michelle] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA.
RP Thoma, B (reprint author), Royal Univ Hosp, EM Residency Training Program, Room 2686,103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada.
EM brent.thoma@usask.ca
OI Chan, Teresa/0000-0001-6104-462X; Thoma, Brent/0000-0003-1124-5786
NR 6
TC 5
Z9 5
U1 1
U2 4
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1481-8035
EI 1481-8043
J9 CAN J EMERG MED
JI Can. J. Emerg. Med.
PD MAR
PY 2015
VL 17
IS 2
BP 188
EP 191
DI 10.2310/8000.2014.141393
PG 4
WC Emergency Medicine
SC Emergency Medicine
GA CE8LY
UT WOS:000352095100011
PM 25927262
ER
PT J
AU Castro, CM
Im, H
Le, C
Lee, H
Weissleder, R
Birrer, MJ
AF Castro, Cesar M.
Im, Hyungsoon
Le, Christine
Lee, Hakho
Weissleder, Ralph
Birrer, Michael J.
TI Exploring alternative ovarian cancer biomarkers using innovative
nanotechnology strategies
SO CANCER AND METASTASIS REVIEWS
LA English
DT Review
DE Ovarian cancer; Biomarkers; Circulating tumor cells; Ascites; Exosomes;
Microfluidics; Nuclearmagnetic resonance; Nanotechnology
ID CIRCULATING TUMOR-CELLS; EXOSOMES; RESONANCE
AB Our increased understanding of ovarian cancer's blueprints (mediated by DNA and RNA) and behavior (mediated by proteins) points to wide differences across patients that cannot be depicted by histology alone. Conventional diagnosis usually entails an adequate tissue biopsy, which limits serial testing. There is thus a motivation to shift towards easier to obtain clinical samples (e.g., ascites or blood). In response, investigators are increasingly leveraging alternative circulating biomarkers in blood or proximal fluids and harnessing novel profiling platforms to help explore treatment-related effects on such biomarkers in serial fashion. In this review, we discuss how new nanotechnologies we developed intersect with alternative ovarian cancer biomarkers for improved understanding of metastases and therapeutic response.
C1 [Castro, Cesar M.; Birrer, Michael J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Castro, Cesar M.; Im, Hyungsoon; Le, Christine; Lee, Hakho; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
RP Castro, CM (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA.
EM Castro.Cesar@mgh.harvard.edu; mbirrer@partners.org
RI Im, Hyungsoon/A-3178-2009
OI Im, Hyungsoon/0000-0002-0626-1346
FU NCI NIH HHS [R33 CA202064, R01 CA204019]
NR 24
TC 1
Z9 1
U1 4
U2 25
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-7659
EI 1573-7233
J9 CANCER METAST REV
JI Cancer Metastasis Rev.
PD MAR
PY 2015
VL 34
IS 1
BP 75
EP 82
DI 10.1007/s10555-014-9546-9
PG 8
WC Oncology
SC Oncology
GA CE9ZX
UT WOS:000352203400007
PM 25543192
ER
PT J
AU Hammerman, PS
Hayes, DN
Grandis, JR
AF Hammerman, Peter S.
Hayes, D. Neil
Grandis, Jennifer R.
TI Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell
Carcinomas
SO CANCER DISCOVERY
LA English
DT Article
ID HUMAN-PAPILLOMAVIRUS; OROPHARYNGEAL CANCER; UNITED-STATES; COPY NUMBER;
EXPRESSION; MUTATIONS; RECURRENT; PATHWAY; SUBSET; TUMORS
C1 [Hammerman, Peter S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Hammerman, Peter S.] Broad Inst Harvard & MIT, Canc Program, Cambridge, MA USA.
[Hayes, D. Neil] Univ N Carolina, Lineberger Canc Res Ctr, Dept Hematol Oncol, Chapel Hill, NC 27599 USA.
[Grandis, Jennifer R.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15213 USA.
[Grandis, Jennifer R.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA.
[Grandis, Jennifer R.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA.
RP Grandis, JR (reprint author), Univ Pittsburgh, Sch Med, W912 Biomed Sci Tower,Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM grandisjr@upmc.edu
FU NCATS NIH HHS [UL1 TR000005]; NCI NIH HHS [K08 CA163677, P50 CA097190,
R01 CA098372]; NIDCR NIH HHS [R01 DE023685]
NR 36
TC 10
Z9 10
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD MAR
PY 2015
VL 5
IS 3
BP 239
EP 244
DI 10.1158/2159-8290.CD-14-1205
PG 6
WC Oncology
SC Oncology
GA CF2IV
UT WOS:000352371900020
PM 25643909
ER
PT J
AU Van Rechem, C
Black, JC
Greninger, P
Zhao, Y
Donado, C
Burrowes, PD
Ladd, B
Christiani, DC
Benes, CH
Whetstine, JR
AF Van Rechem, Capucine
Black, Joshua C.
Greninger, Patricia
Zhao, Yang
Donado, Carlos
Burrowes, Paul D.
Ladd, Brendon
Christiani, David C.
Benes, Cyril H.
Whetstine, Johnathan R.
TI A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A
Associates with Increased Sensitivity to mTOR Inhibitors
SO CANCER DISCOVERY
LA English
DT Article
ID CELL LUNG-CANCER; NATURAL-SELECTION; KINASE INHIBITOR; METHYLATION;
PATHWAY; SURVIVAL; IMPACT; TARGET; JMJD2A
AB SNPs occur within chromatin-modulating factors; however, little is known about how these variants within the coding sequence affect cancer progression or treatment. Therefore, there is a need to establish their biochemical and/or molecular contribution, their use in subclassifying patients, and their impact on therapeutic response. In this report, we demonstrate that coding SNP-A482 within the lysine tridemethylase gene KDM4A/JMJD2A has different allelic frequencies across ethnic populations, associates with differential outcome in patients with non-small cell lung cancer (NSCLC), and promotes KDM4A protein turnover. Using an unbiased drug screen against 87 preclinical and clinical compounds, we demonstrate that homozygous SNP-A482 cells have increased mTOR inhibitor sensitivity. mTOR inhibitors significantly reduce SNP-A482 protein levels, which parallels the increased drug sensitivity observed with KDM4A depletion. Our data emphasize the importance of using variant status as candidate biomarkers and highlight the importance of studying SNPs in chromatin modifiers to achieve better targeted therapy.
SIGNIFICANCE: This report documents the first coding SNP within a lysine demethylase that associates with worse outcome in patients with NSCLC. We demonstrate that this coding SNP alters the protein turnover and associates with increased mTOR inhibitor sensitivity, which identifies a candidate biomarker for mTOR inhibitor therapy and a therapeutic target for combination therapy.
C1 [Van Rechem, Capucine; Black, Joshua C.; Greninger, Patricia; Donado, Carlos; Burrowes, Paul D.; Ladd, Brendon; Benes, Cyril H.; Whetstine, Johnathan R.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
[Van Rechem, Capucine; Black, Joshua C.; Greninger, Patricia; Donado, Carlos; Burrowes, Paul D.; Ladd, Brendon; Benes, Cyril H.; Whetstine, Johnathan R.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Zhao, Yang; Christiani, David C.] Harvard Univ, Harvard Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA.
[Zhao, Yang] Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Nanjing, Jiangsu, Peoples R China.
[Christiani, David C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA USA.
RP Whetstine, JR (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Canc Ctr, Bldg 149,Room 7-213,13th St, Charlestown, MA 02129 USA.
EM jwhetstine@hms.harvard.edu
RI Black, Joshua/Q-2484-2015
FU American Cancer Society Basic Scholar Grant; MGH Proton Beam Federal
Share Grant [CA059267]; NIH [R01GM097360, U54 HG006097]; NIH (NCI)
[5R01CA92824]; American Lung Association Lung Cancer Discovery Award;
Fund for Medical Discovery; Marsha Rivkin Center for Ovarian Cancer
Research; MGH ECOR Tosteson Postdoctoral Fellowship; Jane Coffin Childs
Memorial Fund for Medical Research
FX The studies conducted in this article were funded by an American Cancer
Society Basic Scholar Grant, an MGH Proton Beam Federal Share Grant
(CA059267), and NIH R01GM097360 (to J.R. Whetstine); NIH (NCI) grant
5R01CA92824 (to D.C. Christiani); and NIH grant U54 HG006097 (to C.H.
Benes). J.R. Whetstine is the Tepper Family MGH Research Scholar and a
Leukemia and Lymphoma Society Scholar, as well as a recipient of the
American Lung Association Lung Cancer Discovery Award. A postdoctoral
fellowship was provided by the Fund for Medical Discovery to C. Van
Rechem. C. Van Rechem is the 2014 Skacel Family Marsha Rivkin Center for
Ovarian Cancer Research Scholar. This research was supported in part by
a grant from the Marsha Rivkin Center for Ovarian Cancer Research. J.C.
Black was a fellow of The Jane Coffin Childs Memorial Fund for Medical
Research and is supported by an MGH ECOR Tosteson Postdoctoral
Fellowship. This investigation has also been aided by a grant from The
Jane Coffin Childs Memorial Fund for Medical Research.
NR 25
TC 11
Z9 11
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD MAR
PY 2015
VL 5
IS 3
BP 245
EP 254
DI 10.1158/2159-8290.CD-14-1159
PG 10
WC Oncology
SC Oncology
GA CF2IV
UT WOS:000352371900021
PM 25564517
ER
PT J
AU Van Rechem, C
Black, JC
Boukhali, M
Aryee, MJ
Graslund, S
Haas, W
Benes, CH
Whetstine, JR
AF Van Rechem, Capucine
Black, Joshua C.
Boukhali, Myriam
Aryee, Martin J.
Graeslund, Susanne
Haas, Wilhelm
Benes, Cyril H.
Whetstine, Johnathan R.
TI Lysine Demethylase KDM4A Associates with Translation Machinery and
Regulates Protein Synthesis
SO CANCER DISCOVERY
LA English
DT Article
ID MTOR SIGNALING PATHWAY; CANCER-CELLS; METHYLATION; PROLIFERATION;
INHIBITORS; IMPACT
AB Chromatin-modifying enzymes are predominantly nuclear; however, these factors are also localized to the cytoplasm, and very little is known about their role in this compartment. In this report, we reveal a non-chromatin-linked role for the lysine-specific demethylase KDM4A. We demonstrate that KDM4A interacts with the translation initiation complex and affects the distribution of translation initiation factors within polysome fractions. Furthermore, KDM4A depletion reduced protein synthesis and enhanced the protein synthesis suppression observed with mTOR inhibitors, which paralleled an increased sensitivity to these drugs. Finally, we demonstrate that JIB-04, a JmjC demethylase inhibitor, suppresses translation initiation and enhances mTOR inhibitor sensitivity. These data highlight an unexpected cytoplasmic role for KDM4A in regulating protein synthesis and suggest novel potential therapeutic applications for this class of enzyme.
SIGNIFICANCE: This report documents an unexpected cytoplasmic role for the lysine demethylase KDM4A. We demonstrate that KDM4A interacts with the translation initiation machinery, regulates protein synthesis and, upon coinhibition with mTOR inhibitors, enhances the translation suppression and cell sensitivity to these therapeutics. (C) 2015 AACR.
C1 [Van Rechem, Capucine; Black, Joshua C.; Boukhali, Myriam; Haas, Wilhelm; Benes, Cyril H.; Whetstine, Johnathan R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.
[Van Rechem, Capucine; Black, Joshua C.; Boukhali, Myriam; Aryee, Martin J.; Haas, Wilhelm; Benes, Cyril H.; Whetstine, Johnathan R.] Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA.
[Aryee, Martin J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Charlestown, MA 02129 USA.
[Graeslund, Susanne] Univ Toronto, Struct Genom Consortium, Toronto, ON, Canada.
RP Whetstine, JR (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Canc Ctr, Bldg 149,Room 7-213,13th St, Charlestown, MA 02129 USA.
EM jwhetstine@hms.harvard.edu
RI Black, Joshua/Q-2484-2015
FU American Cancer Society Basic Scholar Grant; Massachusetts General
Hospital (MGH) Proton Beam Federal Share Grant [CA059267]; NIH
[R01GM097360, U54 HG006097]; American Lung Association Lung Cancer
Discovery Award; Fund for Medical Discovery; Marsha Rivkin Center for
Ovarian Cancer Research
FX The studies conducted in this article were funded by the following: the
American Cancer Society Basic Scholar Grant, the Massachusetts General
Hospital (MGH) Proton Beam Federal Share Grant (CA059267), and NIH
R01GM097360 to J.R. Whetstine; and NIH U54 HG006097 to C.H. Benes. J.R.
Whetstine is the Tepper Family MGH Research Scholar and a Leukemia and
Lymphoma Society Scholar, as well as a recipient of the American Lung
Association Lung Cancer Discovery Award. A postdoctoral fellowship was
provided by the Fund for Medical Discovery to C. Van Rechem. C. Van
Rechem is the 2014 Skacel Family Marsha Rivkin Center for Ovarian Cancer
Research Scholar. This research was supported, in part, by a grant from
the Marsha Rivkin Center for Ovarian Cancer Research.
NR 25
TC 13
Z9 13
U1 1
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD MAR
PY 2015
VL 5
IS 3
BP 255
EP 263
DI 10.1158/2159-8290.CD-14-1326
PG 9
WC Oncology
SC Oncology
GA CF2IV
UT WOS:000352371900022
PM 25564516
ER
PT J
AU Paraiso, KHT
Das Thakur, M
Fang, B
Koomen, JM
Fedorenko, IV
John, JK
Tsao, H
Flaherty, KT
Sondak, VK
Messina, JL
Pasquale, EB
Villagra, A
Rao, UN
Kirkwood, JM
Meier, F
Sloot, S
Gibney, GT
Stuart, D
Tawbi, H
Smalley, KSM
AF Paraiso, Kim H. T.
Das Thakur, Meghna
Fang, Bin
Koomen, John M.
Fedorenko, Inna V.
John, Jobin K.
Tsao, Hensin
Flaherty, Keith T.
Sondak, Vernon K.
Messina, Jane L.
Pasquale, Elena B.
Villagra, Alejandro
Rao, Uma N.
Kirkwood, John M.
Meier, Friedegund
Sloot, Sarah
Gibney, Geoffrey T.
Stuart, Darrin
Tawbi, Hussein
Smalley, Keiran S. M.
TI Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted
Therapy-Mediated Metastatic Melanoma Phenotype
SO CANCER DISCOVERY
LA English
DT Article
ID ACQUIRED-RESISTANCE; MUTANT MELANOMA; MEK INHIBITION; UP-REGULATION;
BRAF; PLASTICITY; RECEPTORS; INVASION; VEMURAFENIB; CELLS
AB Many patients with BRAF inhibitor resistance can develop disease at new sites, suggesting that drug-induced selection pressure drives metastasis. Here, we used mass spectrometry-based phosphoproteomic screening to uncover ligand-independent EPHA2 signaling as an adaptation to BRAF inhibitor therapy that led to the adoption of a metastatic phenotype. The EPHA2-mediated invasion was AKT-dependent and readily reversible upon removal of the drug as well as through PI3K and AKT inhibition. In xenograft models, BRAF inhibition led to the development of EPHA2-positive metastases. A retrospective analysis of patients with melanoma on BRAF inhibitor therapy showed that 68% of those failing therapy develop metastases at new disease sites, compared with 35% of patients on dacarbazine. Further IHC staining of melanoma specimens taken from patients on BRAF inhibitor therapy as well as metastatic samples taken from patients failing therapy showed increased EPHA2 staining. We suggest that inhibition of ligand-independent EPHA2 signaling may limit metastases associated with BRAF inhibitor therapy.
SIGNIFICANCE: This study provides evidence that BRAF inhibition promotes the adoption of a reversible, therapy-driven metastatic phenotype in melanoma. The cotargeting of ligand-independent EPHA2 signaling and BRAF may be one strategy to prevent the development of therapy-mediated disease at new sites. (C) 2014 AACR.
C1 [Paraiso, Kim H. T.; Koomen, John M.; John, Jobin K.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA.
[Das Thakur, Meghna; Stuart, Darrin] Novartis Inst Biomed Res, Emeryville, CA USA.
[Fang, Bin] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Prote Core, Tampa, FL 33612 USA.
[Fedorenko, Inna V.; Smalley, Keiran S. M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, Tampa, FL 33612 USA.
[Tsao, Hensin] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Flaherty, Keith T.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Sondak, Vernon K.; Messina, Jane L.; Sloot, Sarah; Gibney, Geoffrey T.; Smalley, Keiran S. M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL 33612 USA.
[Messina, Jane L.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Anat Pathol, Tampa, FL 33612 USA.
[Pasquale, Elena B.] Sanford Burnham Med Res Inst, La Jolla, CA USA.
[Villagra, Alejandro] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL 33612 USA.
[Rao, Uma N.; Kirkwood, John M.; Tawbi, Hussein] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol,Canc Inst, Pittsburgh, PA 15213 USA.
[Meier, Friedegund] Univ Tubingen, Dept Dermatooncol, Tubingen, Germany.
RP Smalley, KSM (reprint author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.
EM keiran.smalley@moffitt.org
RI Fedorenko, Inna/G-9016-2015
OI Fedorenko, Inna/0000-0002-6796-9145
FU NIH [R01 CA161107-01, P50 CA168536-01A1]; Melanoma and Sarcoma Groningen
Foundation; Joanna M. Nicolay Melanoma Foundation
FX Work in the Smalley laboratory is supported by R01 CA161107-01 and SPORE
grant P50 CA168536-01A1 from the NIH. S. Sloot received a grant from the
Melanoma and Sarcoma Groningen Foundation. I.V. Fedorenko was supported
by the Joanna M. Nicolay Melanoma Foundation.
NR 29
TC 20
Z9 20
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD MAR
PY 2015
VL 5
IS 3
BP 264
EP 273
DI 10.1158/2159-8290.CD-14-0293
PG 10
WC Oncology
SC Oncology
GA CF2IV
UT WOS:000352371900023
PM 25542447
ER
PT J
AU Miao, BC
Ji, ZY
Tan, L
Taylor, M
Zhang, JM
Choi, HG
Frederick, DT
Kumar, R
Wargo, JA
Flaherty, KT
Gray, NS
Tsao, H
AF Miao, Benchun
Ji, Zhenyu
Tan, Li
Taylor, Michael
Zhang, Jianming
Choi, Hwan Geun
Frederick, Dennie T.
Kumar, Raj
Wargo, Jennifer A.
Flaherty, Keith T.
Gray, Nathanael S.
Tsao, Hensin
TI EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic
Target in Melanoma
SO CANCER DISCOVERY
LA English
DT Article
ID RECEPTOR TYROSINE KINASE; BRAF INHIBITOR RESISTANCE; UP-REGULATION;
ACQUIRED-RESISTANCE; MUTANT MELANOMA; MAPK PATHWAY; CANCER; EXPRESSION;
ACTIVATION; MUTATIONS
AB BRAF V600E is the most common oncogenic lesion in melanoma and results in constitutive activation of the MAPK pathway and uncontrolled cell growth. Selective BRAF inhibitors such as vemurafenib have been shown to neutralize oncogenic signaling, restrain cellular growth, and improve patient outcome. Although several mechanisms of vemurafenib resistance have been described, directed solutions to overcome these resistance lesions are still lacking. Herein, we found that vemurafenib resistance can be (i) mediated by EPHA2, a member of the largest receptor tyrosine kinases (RTK) subfamily erythropoietin-producing hepatocellular (EPH) receptors, and (ii) associated with a greater phenotypic dependence on EPHA2. Furthermore, we developed a series of first-in-class EPHA2 inhibitors and show that these new compounds potently induce apoptosis, suppress viability, and abrogate tumorigenic growth of melanoma cells, including those that are resistant to vemurafenib. These results provide proof of concept that RTK-guided growth, and therapeutic resistance, can be prospectively defined and selectively targeted.
SIGNIFICANCE: In this study, we show that resistance to selective BRAF inhibitors can be mediated by the RTK EPHA2. Furthermore, direct targeting of EPHA2 can successfully suppress melanoma growth and mitigate therapeutic resistance.
C1 [Miao, Benchun; Ji, Zhenyu; Taylor, Michael; Kumar, Raj; Tsao, Hensin] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Miao, Benchun; Ji, Zhenyu; Kumar, Raj; Tsao, Hensin] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Tan, Li; Zhang, Jianming; Choi, Hwan Geun; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Tan, Li; Choi, Hwan Geun; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Frederick, Dennie T.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA.
[Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Surg Oncol, Houston, TX 77030 USA.
[Flaherty, Keith T.] Massachusetts Gen Hosp, Div Med Oncol, Boston, MA 02114 USA.
[Flaherty, Keith T.; Tsao, Hensin] Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02114 USA.
RP Tsao, H (reprint author), Massachusetts Gen Hosp, Edwards 211,55 Fruit St, Boston, MA 02114 USA.
EM htsao@partners.org
FU NIH [K24 CA149202, P01CA163222, 5T32AR007098, 5T32CA071345, R01
CA173469]; American Skin Association
FX This work was supported in part by the NIH (K24 CA149202 to H. Tsao;
P01CA163222 to H. Tsao, K.T. Flaherty, and D.T. Frederick; 5T32AR007098
to B. Miao; 5T32CA071345 to Z.Ji; and R01 CA173469 to N.S. Gray), the
American Skin Association (to H. Tsao), and the generous donors to the
MGH Millennium Melanoma Fund (to H. Tsao).
NR 44
TC 20
Z9 20
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD MAR
PY 2015
VL 5
IS 3
BP 274
EP 287
DI 10.1158/2159-8290.CD-14-0295
PG 14
WC Oncology
SC Oncology
GA CF2IV
UT WOS:000352371900024
PM 25542448
ER
PT J
AU Kleppe, M
Kwak, M
Koppikar, P
Riester, M
Keller, M
Bastian, L
Hricik, T
Bhagwat, N
McKenney, AS
Papalexi, E
Abdel-Wahab, O
Rampal, R
Marubayashi, S
Chen, JJ
Romanet, V
Fridman, JS
Bromberg, J
Teruya-Feldstein, J
Murakami, M
Radimerski, T
Michor, F
Fan, R
Levine, RL
AF Kleppe, Maria
Kwak, Minsuk
Koppikar, Priya
Riester, Markus
Keller, Matthew
Bastian, Lennart
Hricik, Todd
Bhagwat, Neha
McKenney, Anna Sophia
Papalexi, Efthymia
Abdel-Wahab, Omar
Rampal, Raajit
Marubayashi, Sachie
Chen, Jonathan J.
Romanet, Vincent
Fridman, Jordan S.
Bromberg, Jacqueline
Teruya-Feldstein, Julie
Murakami, Masato
Radimerski, Thomas
Michor, Franziska
Fan, Rong
Levine, Ross L.
TI JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells
Contributes to MPN Pathogenesis and Therapeutic Response
SO CANCER DISCOVERY
LA English
DT Article
ID TYROSINE KINASE JAK2; MYELOPROLIFERATIVE NEOPLASMS; HEMATOPOIETIC STEM;
POLYCYTHEMIA-VERA; MYELOID METAPLASIA; PROGENITOR CELLS; MUTATION;
MYELOFIBROSIS; INHIBITOR; INCB018424
AB The identification of JAK2/MPL mutations in patients with myeloproliferative neoplasms (MPN) has led to the clinical development of JAK kinase inhibitors, including ruxolitinib. Ruxolitinib reduces splenomegaly and systemic symptoms in myelofibrosis and improves overall survival; however, the mechanism by which JAK inhibitors achieve efficacy has not been delineated. Patients with MPN present with increased levels of circulating proinflammatory cytokines, which are mitigated by JAK inhibitor therapy. We sought to elucidate mechanisms by which JAK inhibitors attenuate cytokine-mediated pathophysiology. Single-cell profiling demonstrated that hematopoietic cells from myelofibrosis models and patient samples aberrantly secrete inflammatory cytokines. Panhematopoietic Stat3 deletion reduced disease severity and attenuated cytokine secretion, with similar efficacy as observed with ruxolitinib therapy. In contrast, Stat3 deletion restricted to MPN cells did not reduce disease severity or cytokine production. Consistent with these observations, we found that malignant and nonmalignant cells aberrantly secrete cytokines and JAK inhibition reduces cytokine production from both populations.
SIGNIFICANCE: Our results demonstrate that JAK-STAT3-mediated cytokine production from malignant and nonmalignant cells contributes to MPN pathogenesis and that JAK inhibition in both populations is required for therapeutic effi cacy. These findings provide novel insight into the mechanisms by which JAK kinase inhibition achieves therapeutic effi cacy in MPNs. (C) 2015 AACR.
C1 [Kleppe, Maria; Koppikar, Priya; Keller, Matthew; Bastian, Lennart; Hricik, Todd; Bhagwat, Neha; McKenney, Anna Sophia; Papalexi, Efthymia; Abdel-Wahab, Omar; Rampal, Raajit; Marubayashi, Sachie; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.
[Kwak, Minsuk; Chen, Jonathan J.; Fan, Rong] Yale Univ, Dept Biomed Engn, New Haven, CT USA.
[Riester, Markus; Michor, Franziska] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Riester, Markus; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Bhagwat, Neha; McKenney, Anna Sophia] Gerstner Sloan Kettering Grad Sch Biomed Sci, New York, NY USA.
[McKenney, Anna Sophia] Weill Cornell Rockefeller Sloan Kettering Triinst, New York, NY USA.
[Abdel-Wahab, Omar; Rampal, Raajit] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10065 USA.
[Romanet, Vincent; Murakami, Masato; Radimerski, Thomas] Novartis Inst BioMed Res, Dis Area Oncol, Basel, Switzerland.
[Fridman, Jordan S.] Incyte Corp, Wilmington, DE USA.
[Bromberg, Jacqueline] Mem Sloan Kettering Canc Ctr, Dept Med, Breast Canc Serv, New York, NY 10065 USA.
[Teruya-Feldstein, Julie] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA.
[Fan, Rong] Yale Comprehens Canc Ctr, New Haven, CT USA.
RP Levine, RL (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, Human Oncol & Pathogenesis Program, Leukemia Serv, 415 East 68th St,1275 York Ave,Box 20, New York, NY 10065 USA.
EM rong.fan@yale.edu; leviner@mskcc.org
OI Abdel-Wahab, Omar/0000-0002-3907-6171
FU Dana-Farber Cancer Institute's Physical Sciences Oncology Center
[U54CA143798-01]; NCI [1R01CA151949-01, 1R01CA138234-01]; NIDDK
[1U01DK104331-01]; EMBO Long-Term Fellowship; National Institute of
General Medical Sciences of the NIH [T32GM007739]
FX This work was supported by the Dana-Farber Cancer Institute's Physical
Sciences Oncology Center (U54CA143798-01), to R.L. Levine, R. Fan, M.
Riester, and F. Michor; NCI 1R01CA151949-01 to R.L. Levine; and NCI
1R01CA138234-01 to F. Michor and R.L. Levine, and partly by NIDDK
1U01DK104331-01 to R. Fan and R.L. Levine. M. Kleppe is a fellow of the
Leukemia and Lymphoma Society and was previously supported by an EMBO
Long-Term Fellowship. A.S. McKenney was supported by a Medical Scientist
Training Program grant from the National Institute of General Medical
Sciences of the NIH under award number T32GM007739 to the Weill
Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program.
NR 34
TC 32
Z9 32
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD MAR
PY 2015
VL 5
IS 3
BP 316
EP 331
DI 10.1158/2159-8290.CD-14-0736
PG 16
WC Oncology
SC Oncology
GA CF2IV
UT WOS:000352371900027
PM 25572172
ER
PT J
AU Sabado, RL
Pavlick, A
Gnjatic, S
Cruz, CM
Vengco, I
Hasan, F
Spadaccia, M
Darvishian, F
Chiriboga, L
Holman, RM
Escalon, J
Muren, C
Escano, C
Yepes, E
Sharpe, D
Vasilakos, JP
Rolnitzsky, L
Goldberg, JD
Mandeli, J
Adams, S
Jungbluth, A
Pan, L
Venhaus, R
Ott, PA
Bhardwaj, N
AF Sabado, Rachel Lubong
Pavlick, Anna
Gnjatic, Sacha
Cruz, Crystal M.
Vengco, Isabelita
Hasan, Farah
Spadaccia, Meredith
Darvishian, Farbod
Chiriboga, Luis
Holman, Rose Marie
Escalon, Juliet
Muren, Caroline
Escano, Crystal
Yepes, Ethel
Sharpe, Dunbar
Vasilakos, John P.
Rolnitzsky, Linda
Goldberg, Judith D.
Mandeli, John
Adams, Sylvia
Jungbluth, Achim
Pan, Linda
Venhaus, Ralph
Ott, Patrick A.
Bhardwaj, Nina
TI Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination
in Patients with High-Risk Melanoma
SO CANCER IMMUNOLOGY RESEARCH
LA English
DT Article
ID REGULATORY T-CELLS; IMMUNE-RESPONSES; PEPTIDE VACCINE; RECEPTOR
AGONISTS; CLINICAL BENEFIT; DENDRITIC CELLS; CANCER-PATIENTS; TLR7
AGONIST; ANTIGEN; INDUCTION
AB The Toll-like receptor (TLR) 7/8 agonist resiquimod has been used as an immune adjuvant in cancer vaccines. We evaluated the safety and immunogenicity of the cancer testis antigen NY-ESO-1 given in combination with Montanide (Seppic) with or without resiquimod in patients with high-risk melanoma. In part I of the study, patients received 100 mu g of full-length NY-ESO-1 protein emulsified in 1.25 mL of Montanide (day 1) followed by topical application of 1,000 mg of 0.2% resiquimod gel on days 1 and 3 (cohort 1) versus days 1, 3, and 5 (cohort 2) of a 21-day cycle. In part II, patients were randomized to receive 100-mu g NY-ESO-1 protein plus Montanide (day 1) followed by topical application of placebo gel [(arm A; n = 8) or 1,000 mg of 0.2% resiquimod gel (arm B; n = 12)] using the dosing regimen established in part I. The vaccine regimens were generally well tolerated. NY-ESO-1-specific humoral responses were induced or boosted in all patients, many of whom had high titer antibodies. In part II, 16 of 20 patients in both arms had NY-ESO-1-specific CD4(+) T-cell responses. CD8(+) T-cell responses were only seen in 3 of 12 patients in arm B. Patients with TLR7 SNP rs179008 had a greater likelihood of developing NY-ESO-1-specific CD8(+) responses. In conclusion, NY-ESO-1 protein in combination with Montanide with or without topical resiquimod is safe and induces both antibody and CD4(+) T-cell responses in the majority of patients; the small proportion of CD8(+) T-cell responses suggests that the addition of topical resiquimod to Montanide is not sufficient to induce consistent NY-ESO-1-specific CD8(+) T-cell responses. (C) 2015 AACR.
C1 [Sabado, Rachel Lubong; Pavlick, Anna; Cruz, Crystal M.; Vengco, Isabelita; Hasan, Farah; Spadaccia, Meredith; Holman, Rose Marie; Escalon, Juliet; Muren, Caroline; Escano, Crystal; Yepes, Ethel; Sharpe, Dunbar; Adams, Sylvia; Ott, Patrick A.; Bhardwaj, Nina] NYU, Sch Med, Inst Canc, New York, NY USA.
[Sabado, Rachel Lubong; Gnjatic, Sacha; Mandeli, John; Bhardwaj, Nina] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Boston, MA USA.
[Gnjatic, Sacha; Pan, Linda; Venhaus, Ralph] Ludwig Inst Canc Res, Boston, MA USA.
[Darvishian, Farbod; Chiriboga, Luis; Bhardwaj, Nina] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA.
[Vasilakos, John P.] 3M Drug Delivery Syst Div, Boston, MA USA.
[Rolnitzsky, Linda; Goldberg, Judith D.] NYU, Sch Med, Div Biostat, New York, NY USA.
[Jungbluth, Achim] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
[Ott, Patrick A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Bhardwaj, N (reprint author), Icahn Sch Med Mt Sinai, Hess Ctr Sci & Med, Tisch Canc Inst, 1470 Madison Ave,5-116, New York, NY 10029 USA.
EM Nina.Bhardwaj@mssm.edu
OI Hasan, Farah/0000-0001-6941-7822; Chiriboga, Luis/0000-0002-2028-6873;
Goldberg, Judith D./0000-0003-3758-6976
FU Ludwig Institute for Cancer Research; Cancer Research Institute, Cancer
Vaccine Collaborative; Cancer Vaccine Collaborative for Immunological
Monitoring; New York University Cancer Center Support Grant [5 P30
CA16087]
FX This study was sponsored and funded by the Ludwig Institute for Cancer
Research with a supplemental grant from the Cancer Research Institute as
part of the Cancer Vaccine Collaborative. S. Gnjatic was supported by a
grant from the Cancer Vaccine Collaborative for Immunological
Monitoring. J.D. Goldberg and L. Rolnitzky were supported by 5 P30
CA16087 New York University Cancer Center Support Grant 5 P30 CA16087.
NR 46
TC 12
Z9 13
U1 1
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2326-6066
EI 2326-6074
J9 CANCER IMMUNOL RES
JI Cancer Immunol. Res.
PD MAR
PY 2015
VL 3
IS 3
BP 278
EP 287
DI 10.1158/2326-6066.CIR-14-0202
PG 10
WC Oncology; Immunology
SC Oncology; Immunology
GA CF2LP
UT WOS:000352379100007
PM 25633712
ER
PT J
AU Johnson, DB
Lovly, CM
Flavin, M
Panageas, KS
Ayers, GD
Zhao, ZG
Iams, WT
Colgan, M
DeNoble, S
Terry, CR
Berry, EG
Iafrate, AJ
Sullivan, RJ
Carvajal, RD
Sosman, JA
AF Johnson, Douglas B.
Lovly, Christine M.
Flavin, Marisa
Panageas, Katherine S.
Ayers, Gregory D.
Zhao, Zhiguo
Iams, Wade T.
Colgan, Marta
DeNoble, Sarah
Terry, Charles R.
Berry, Elizabeth G.
Iafrate, A. John
Sullivan, Ryan J.
Carvajal, Richard D.
Sosman, Jeffrey A.
TI Impact of NRAS Mutations for Patients with Advanced Melanoma Treated
with Immune Therapies
SO CANCER IMMUNOLOGY RESEARCH
LA English
DT Article
ID METASTATIC MELANOMA; CLINICAL-RESPONSE; IPILIMUMAB; EXPRESSION; SAFETY;
CARCINOMA; NIVOLUMAB; ANTI-PD-1; CANCER; B7-H1
AB Activating NRAS mutations are found in 15% to 20% of melanomas. Immune therapies have become a mainstay in advanced melanoma treatment. We sought to evaluate whether tumor genotype (e.g., NRAS mutations) correlates with benefit from immune therapy in melanoma. We identified 229 patients with melanoma treated with immune therapies [IL2, ipilimumab, or anti-programmed cell death-1/ligand-1 (PD-1/PD-L1)] at three centers and compared clinical outcomes following immune therapy for patients with or without NRAS mutations. Of the 229 patients with melanoma, 60 had NRAS mutation, 53 had BRAF mutation, and 116 had NRAS/BRAF wild type. The NRAS-mutant cohort had superior or a trend to superior outcomes compared with the other cohorts in terms of response to first-line immune therapy (28% vs. 16%, P = 0.04), response to any line of immune therapy (32% vs. 20%, P = 0.07), clinical benefit (response + stable disease lasting >= 24 weeks; 50% vs. 31%, P < 0.01), and progression-free survival (median, 4.1 vs. 2.9 months, P = 0.09). Benefit from anti-PD-1/PD-L1 was particularly marked in the NRAS cohort (clinical benefit rate 73% vs. 35%). In an independent group of patient samples, NRAS-mutant melanoma had higher PD-L1 expression (although not statistically significant) compared with other genotypes (8/12 vs. 9/20 samples with >= 1% expression; 6/12 vs. 6/20 samples with >= 5% expression), suggesting a potential mechanism for the clinical results. This retrospective study suggests that NRAS mutations in advanced melanoma correlate with increased benefit from immune-based therapies compared with other genetic subtypes. If confirmed by prospective studies, this may be explained in part by high rates of PD-L1 expression. (C) 2015 AACR.
C1 [Johnson, Douglas B.; Lovly, Christine M.; Iams, Wade T.; Terry, Charles R.; Berry, Elizabeth G.; Sosman, Jeffrey A.] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA.
[Johnson, Douglas B.; Lovly, Christine M.; Iams, Wade T.; Terry, Charles R.; Berry, Elizabeth G.; Sosman, Jeffrey A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Flavin, Marisa; Panageas, Katherine S.; Colgan, Marta] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Ayers, Gregory D.; Zhao, Zhiguo] Vanderbilt Univ, Sch Med, Ctr Quantitat Sci, Nashville, TN 37212 USA.
[DeNoble, Sarah; Iafrate, A. John; Sullivan, Ryan J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Carvajal, Richard D.] Columbia Univ, Med Ctr, New York, NY USA.
RP Johnson, DB (reprint author), Vanderbilt Univ, Med Ctr, 777 Preston Res Bldg, Nashville, TN 37232 USA.
EM douglas.b.johnson@vanderbilt.edu
FU NIH [K12 CA0906525, K24]; Damon Runyon Clinical Investigator Award;
American Cancer Society Professorship; Ingram Professorship; CTSA from
the National Center for Advancing Translational Sciences [UL1TR000445];
Anbinder Fund
FX This study was supported by NIH K12 CA0906525 (to D.B. Johnson and C.M
Lovly) and a Damon Runyon Clinical Investigator Award. J.A. Sosman was
supported by an NIH K24 grant, an American Cancer Society Professorship,
and an Ingram Professorship. The project described was supported by CTSA
award no. UL1TR000445 from the National Center for Advancing
Translational Sciences. The MSKCC Sequenom facility was supported by the
Anbinder Fund.
NR 34
TC 25
Z9 25
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2326-6066
EI 2326-6074
J9 CANCER IMMUNOL RES
JI Cancer Immunol. Res.
PD MAR
PY 2015
VL 3
IS 3
BP 288
EP 295
DI 10.1158/2326-6066.CIR-14-0207
PG 8
WC Oncology; Immunology
SC Oncology; Immunology
GA CF2LP
UT WOS:000352379100008
PM 25736262
ER
PT J
AU Dhakal, BP
Malhotra, R
Murphy, RM
Pappagianopoulos, PP
Baggish, AL
Weiner, RB
Houstis, NE
Eisman, AS
Hough, SS
Lewis, GD
AF Dhakal, Bishnu P.
Malhotra, Rajeev
Murphy, Ryan M.
Pappagianopoulos, Paul P.
Baggish, Aaron L.
Weiner, Rory B.
Houstis, Nicholas E.
Eisman, Aaron S.
Hough, Stacyann S.
Lewis, Gregory D.
TI Mechanisms of Exercise Intolerance in Heart Failure With Preserved
Ejection Fraction The Role of Abnormal Peripheral Oxygen Extraction
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE diastole; exercise; heart failure
ID MAXIMAL UPRIGHT EXERCISE; SKELETAL-MUSCLE; CHRONOTROPIC INCOMPETENCE;
CARDIAC-OUTPUT; OLDER PATIENTS; STROKE VOLUME; RATE RESPONSE;
BLOOD-FLOW; CAPACITY; TRIAL
AB Background-Exercise capacity as measured by peak oxygen uptake (Vo(2)) is similarly impaired in patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). However, characterization of how each component of Vo(2) changes in response to incremental exercise in HFpEF versus HFrEF has not been previously defined. We hypothesized that abnormally low peripheral o(2) extraction (arterio-mixed venous o(2) content difference, [C(a-v)o(2)]) during exercise significantly contributes to impaired exercise capacity in HFpEF.
Methods and Results-We performed maximum incremental cardiopulmonary exercise testing with invasive hemodynamic monitoring on 104 patients with symptomatic NYHA II to IV heart failure (HFpEF, n=48, peak Vo(2)=13.9 +/- 0.5 mL kg(-1) min(-1), mean +/- SEM, and HFrEF, n= 56, peak Vo(2) = 12.1 +/- 0.5 mL kg(-1) min(-1)) and 24 control subjects (peak Vo(2) 27.0 +/- 1.7 mL kg(-1) min(-1)). Peak exercise C(a-v)o(2) was lower in HFpEF compared with HFrEF (11.5 +/- 0.27 versus 13.5 +/- 0.34 mL/dL, respectively, P<0.0001), despite no differences in age, hemoglobin level, peak respiratory exchange ratio, Cao(2), or cardiac filling pressures. Peak C(a-v)o(2) and peak heart rate emerged as the leading predictors of peak Vo(2) in HFpEF. Impaired peripheral o(2) extraction was the predominant limiting factor to exercise capacity in 40% of patients with HFpEF and was closely related to elevated systemic blood pressure during exercise (r=0.49, P=0.0005).
Conclusions-In the first study to directly measure C(a-v)o(2) throughout exercise in HFpEF, HFrEF, and normals, we found that peak C(a-v)o(2) was a major determinant of exercise capacity in HFpEF. The important functional limitation imposed by impaired o(2) extraction may reflect intrinsic abnormalities in skeletal muscle or peripheral microvascular function, and represents a potential target for therapeutic intervention.
C1 [Dhakal, Bishnu P.; Malhotra, Rajeev; Murphy, Ryan M.; Baggish, Aaron L.; Weiner, Rory B.; Houstis, Nicholas E.; Eisman, Aaron S.; Lewis, Gregory D.] Harvard Univ, Sch Med, Dept Med, Div Cardiol,Massachusetts Gen Hosp, Boston, MA USA.
[Pappagianopoulos, Paul P.; Hough, Stacyann S.; Lewis, Gregory D.] Harvard Univ, Sch Med, Dept Med, Pulm & Crit Care Unit,Massachusetts Gen Hosp, Boston, MA USA.
RP Lewis, GD (reprint author), Massachusetts Gen Hosp, Heart Failure & Cardiac Transplantat Unit, Bigelow 800,55 Fruit St, Boston, MA 02114 USA.
EM glewis@partners.org
OI Malhotra, Rajeev/0000-0003-0120-4630
FU Hassenfeld Clinical Scholars Program; Massachusetts General Hospital
Cardiac Performance Program; [K23 HL091106]; [R01 HL119154]
FX This work was supported by K23 HL091106, R01 HL119154, the Hassenfeld
Clinical Scholars Program (Dr Lewis and A.S. Eisman), and the
Massachusetts General Hospital Cardiac Performance Program (Drs Baggish,
Weiner, and Lewis)
NR 60
TC 50
Z9 50
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-3289
EI 1941-3297
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD MAR
PY 2015
VL 8
IS 2
BP 286
EP +
DI 10.1161/CIRCHEARTFAILURE.114.001825
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CF0JL
UT WOS:000352229500009
PM 25344549
ER
PT J
AU Nathan, AS
Loukas, B
Moko, L
Wu, F
Rhodes, J
Rathod, RH
Systrom, DM
Tikkanen, AU
Shafer, K
Lewis, GD
Landzberg, MJ
Opotowsky, AR
AF Nathan, Ashwin S.
Loukas, Brittani
Moko, Lilamarie
Wu, Fred
Rhodes, Jonathan
Rathod, Rahul H.
Systrom, David M.
Tikkanen, Ana Ubeda
Shafer, Keri
Lewis, Gregory D.
Landzberg, Michael J.
Opotowsky, Alexander R.
TI Exercise Oscillatory Ventilation in Patients With Fontan Physiology
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE cardiopulmonary exercise test; Cheyne-Stokes respiration; exercise;
Fontan procedure; heart defects, congenital; ventilation
ID CHRONIC HEART-FAILURE; AMBULATORY PATIENTS; CARDIAC TRANSPLANTATION;
RISK STRATIFICATION; OXYGEN-CONSUMPTION; AEROBIC CAPACITY; PROGNOSTIC
VALUE; MORTALITY; ADULTS; CHILDREN
AB Background-Exercise oscillatory ventilation (EOV) refers to regular oscillations in minute ventilation (V-E) during exercise. Its presence correlates with heart failure severity and worse prognosis in adults with acquired heart failure. We evaluated the prevalence and predictive value of EOV in patients with single ventricle Fontan physiology.
Methods and Results-We performed a cross-sectional analysis and prospective survival analysis of patients who had undergone a Fontan procedure and subsequent cardiopulmonary exercise test. Data were reviewed for baseline characteristics and incident mortality, heart transplant, or nonelective cardiovascular hospitalization. EOV was defined as regular oscillations for >60% of exercise duration with amplitude > 15% of average V-E. Survival analysis was performed using Cox regression. Among 253 subjects, EOV was present in 37.5%. Patients with EOV were younger (18.8 +/- 9.0 versus 21.7 +/- 10.1 years; P=0.02). EOV was associated with higher New York Heart Association functional class (P=0.02) and V-E/V-CO2 slope (36.8 +/- 6.9 versus 33.7 +/- 5.7; P=0.0002), but not with peak Vo(2) (59.7 +/- 14.3 versus 61.0 +/- 16.0% predicted; P=0.52) or noninvasive measures of cardiac function. The presence of EOV was associated with slightly lower mean cardiac index but other invasive hemodynamic variables were similar. During a median follow-up of 5.5 years, 22 patients underwent transplant or died (n=19 primary deaths, 3 transplants with 2 subsequent deaths). EOV was associated with increased risk of death or transplant (hazard ratio, 3.9; 95% confidence interval, 1.5-10.0; P=0.002) and also predicted the combined outcome of death, transplant, or nonelective cardiovascular hospitalization after adjusting for New York Heart Association functional class, peak Vo(2), and other covariates (multivariable hazard ratio, 2.0; 95% confidence interval, 1.2-3.6; P=0.01).
Conclusions-EOV is common in the Fontan population and strongly predicts lower transplant-free survival.
C1 [Nathan, Ashwin S.; Wu, Fred; Systrom, David M.; Shafer, Keri; Landzberg, Michael J.; Opotowsky, Alexander R.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Loukas, Brittani; Moko, Lilamarie; Wu, Fred; Rhodes, Jonathan; Rathod, Rahul H.; Tikkanen, Ana Ubeda; Shafer, Keri; Landzberg, Michael J.; Opotowsky, Alexander R.] Boston Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA.
[Tikkanen, Ana Ubeda] Boston Childrens Hosp, Dept Cardiovasc Surg, Boston, MA 02115 USA.
[Lewis, Gregory D.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RP Opotowsky, AR (reprint author), Boston Childrens Hosp, Dept Cardiol, 300 Longwood Ave, Boston, MA 02115 USA.
EM alexander.opotowsky@cardio.chboston.org
FU National Heart, Lung, and Blood Institute [HL068269, HL068270, HL068279,
HL068281, HL068285, HL068292, HL068290, HL068288]; Dunlevie Family Fund
FX This work was supported by U01 grants from the National Heart, Lung, and
Blood Institute (HL068269, HL068270, HL068279, HL068281, HL068285,
HL068292, HL068290, and HL068288). The contents are solely the
responsibility of the authors and do not necessarily represent the
official views of National Heart, Lung, and Blood Institute or National
Institutes of Health. Drs Opotowsky, Shafer, Landzberg, and Wu were
supported by the Dunlevie Family Fund.
NR 45
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-3289
EI 1941-3297
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD MAR
PY 2015
VL 8
IS 2
BP 304
EP 311
DI 10.1161/CIRCHEARTFAILURE.114.001749
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CF0JL
UT WOS:000352229500011
PM 25550441
ER
PT J
AU Teicher, BA
Anderson, KC
AF Teicher, Beverly A.
Anderson, Kenneth C.
TI CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341
SO CLINICAL CANCER RESEARCH
LA English
DT Editorial Material
ID PROTEASOME INHIBITOR PS-341; HEMATOLOGIC MALIGNANCIES; KAPPA-B; MYELOMA;
ACTIVATION; MLN9708; CELLS
AB Proteasome inhibitors have a 20-year history in cancer therapy. The first proteasome inhibitor, bortezomib, a breakthrough treatment for multiple myeloma, moved rapidly through development from the bench in 1994 to first FDA approval in 2003. Clinical Cancer Research has chronicled the development of proteasome inhibitors with publication of reports on bortezo (MLN9708). (C) 2015 AACR.
C1 [Teicher, Beverly A.] NCI, Div Canc Treatment & Diag, Rockville, MD USA.
[Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Teicher, BA (reprint author), NCI, NIH, 9609 Med Ctr Dr,RM 4-W602,MSC 9735, Bethesda, MD 20892 USA.
EM Beverly.Teicher@nih.gov
FU Intramural NIH HHS [Z99 CA999999]
NR 11
TC 6
Z9 6
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR
PY 2015
VL 21
IS 5
BP 939
EP 941
DI 10.1158/1078-0432.CCR-14-2549
PG 3
WC Oncology
SC Oncology
GA CE6XZ
UT WOS:000351982800001
PM 25733705
ER
PT J
AU Goldman, J
Eckhardt, SG
Borad, MJ
Curtis, KK
Hidalgo, M
Calvo, E
Ryan, DP
Wirth, LJ
Parikh, A
Partyka, J
Faessel, H
Gangolli, E
Stewart, S
Rosen, LS
Bowles, DW
AF Goldman, Jonathan
Eckhardt, S. Gail
Borad, Mitesh J.
Curtis, Kelly K.
Hidalgo, Manuel
Calvo, Emiliano
Ryan, David P.
Wirth, Lori J.
Parikh, Asit
Partyka, James
Faessel, Helene
Gangolli, Esha
Stewart, Sally
Rosen, Lee S.
Bowles, Daniel W.
TI Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog
Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid
Tumors
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID BASAL-CELL CARCINOMAS; SONIC HEDGEHOG; HUMAN HOMOLOG; CANCER; MUTATIONS;
EFFICACY; RECEPTOR; MODEL; PTCH
AB Purpose: This first-in-human study assessed safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of single and multiple doses of TAK-441, an investigational inhibitor of the Hedgehog signaling pathway.
Experimental Design: Patients with advanced, solid tumors received daily oral TAK-441 (50-1,600 mg/day); daily dose was doubled in each subsequent cohort until the maximum tolerated/ feasible dose (MTD/MFD) was reached. Blood was collected to evaluate TAK-441 plasma concentrations. Skin biopsies were obtained to evaluate suppression of the Hedgehog-regulated gene Gli1.
Results: Thirty-four patients were enrolled (median age 59). The most common diagnoses were colorectal cancer (26%), basal cell carcinoma (BCC, 21%), and pancreatic cancer (9%). The MFD of 1,600 mg/day (based on tablet size and strength) was considered the MTD. Dose-limiting toxicities included muscle spasms and fatigue. Grade >= 3 treatment-emergent adverse events, regardless of causality, occurred in 15 patients (44%), of which hyponatremia (n = 4) and fatigue (n = 3) were most common. Oral absorption was fairly rapid; median T-max was 2.0 to 4.0 hours after a single dose. Mean elimination half-life was 13.5 to 22.6 hours. Systemic exposure of TAK-441 based on the area under the plasma concentrationtime curve was linear across the dose range. Gli1 expression in skin biopsies was strongly inhibited at all dose levels. Best response was partial response (1 patient with BCC) and stable disease (7 patients with various solid tumors).
Conclusions: TAK-441 was generally well tolerated up to MFD of 1,600 mg/day, with preliminary antitumor activity. Further study of TAK-441 may be appropriate in populations selected for tumors with ligand-dependent or independent Hedgehog signaling.
C1 [Goldman, Jonathan; Stewart, Sally; Rosen, Lee S.] UCLA Hematol & Oncol, Santa Monica, CA 90404 USA.
[Eckhardt, S. Gail; Bowles, Daniel W.] Univ Colorado, Ctr Canc, Aurora, CO USA.
[Borad, Mitesh J.; Curtis, Kelly K.] Mayo Clin, Scottsdale, AZ USA.
[Hidalgo, Manuel; Calvo, Emiliano] START Madrid, Ctr Integral Oncol Clara Campal, Madrid, Spain.
[Ryan, David P.; Wirth, Lori J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Parikh, Asit] Takeda Pharmaceut Int Co, Deerfield, IL USA.
[Partyka, James; Faessel, Helene; Gangolli, Esha] Takeda Pharmaceut Int Co, Cambridge, MA USA.
RP Goldman, J (reprint author), UCLA Hematol & Oncol, Drug Dev, Clin Trials Thorac Oncol, 2020 Santa Monica Blvd,Suite 600, Santa Monica, CA 90404 USA.
EM JWGoldman@mednet.ucla.edu
RI HIDALGO, MANUEL/I-4995-2015
OI HIDALGO, MANUEL/0000-0002-3765-3318
FU Takeda Pharmaceuticals International Co.
FX Financial support for the conduct of this study was provided by Takeda
Pharmaceuticals International Co. and financial support for medical
writing and editorial assistance was provided by Millennium: The Takeda
Oncology Company.
NR 29
TC 7
Z9 7
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR
PY 2015
VL 21
IS 5
BP 1002
EP 1009
DI 10.1158/1078-0432.CCR-14-1234
PG 8
WC Oncology
SC Oncology
GA CE6XZ
UT WOS:000351982800012
PM 25501576
ER
PT J
AU Piesche, M
Ho, VT
Kim, H
Nakazaki, Y
Nehil, M
Yaghi, NK
Kolodin, D
Weiser, J
Altevogt, P
Kiefel, H
Alyea, EP
Antin, JH
Cutler, C
Koreth, J
Canning, C
Ritz, J
Soiffer, RJ
Dranoff, G
AF Piesche, Matthias
Ho, Vincent T.
Kim, Haesook
Nakazaki, Yukoh
Nehil, Michael
Yaghi, Nasser K.
Kolodin, Dmitriy
Weiser, Jeremy
Altevogt, Peter
Kiefel, Helena
Alyea, Edwin P.
Antin, Joseph H.
Cutler, Corey
Koreth, John
Canning, Christine
Ritz, Jerome
Soiffer, Robert J.
Dranoff, Glenn
TI Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia
Reactions
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; MEDIATED TUMOR
DESTRUCTION; BONE-MARROW-TRANSPLANTATION; CD8(+) T-CELLS; ADHESION
MOLECULE; CANCER; RESPONSES; IMMUNITY; THERAPY
AB Purpose: The graft-versus-leukemia (GVL) reaction is an important example of immune-mediated tumor destruction. A coordinated humoral and cellular response accomplishes leukemia cell killing, but the specific targets remain largely uncharacterized. To learn more about the antigens that elicit antibodies during GVL reactions, we analyzed patients with advanced myelodysplasia (MDS) and acute myelogenous leukemia (AML) who received an autologous, granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor cell vaccine early after allogeneic hematopoietic stem cell transplantation (HSCT).
Experimental Design: A combination of tumor-derived cDNA expression library screening, protein microarrays, and antigen-specific ELISAs were used to characterize sera obtained longitudinally from 15 patients with AML/MDS who were vaccinated early after allogeneic HSCT.
Results: A broad, therapy-induced antibody response was uncovered, which primarily targeted intracellular proteins that function in growth, transcription/translation, metabolism, and homeostasis. Unexpectedly, antibodies were also elicited against eight secreted angiogenic cytokines that play critical roles in leukemogenesis. Antibodies to the angiogenic cytokines were evident early after therapy, and in some patients manifested a diversification in reactivity over time. Patients that developed antibodies to multiple angiogenic cytokines showed prolonged remission and survival.
Conclusions: These results reveal a potent humoral response during GVL reactions induced with vaccination early after allogeneic HSCT and raise the possibility that antibodies, in conjunction with natural killer cells and T lymphocytes, may contribute to immune-mediated control of myeloid leukemias.
C1 [Piesche, Matthias; Ho, Vincent T.; Nakazaki, Yukoh; Nehil, Michael; Yaghi, Nasser K.; Weiser, Jeremy; Alyea, Edwin P.; Antin, Joseph H.; Cutler, Corey; Koreth, John; Canning, Christine; Ritz, Jerome; Soiffer, Robert J.; Dranoff, Glenn] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Piesche, Matthias; Ho, Vincent T.; Nakazaki, Yukoh; Nehil, Michael; Yaghi, Nasser K.; Weiser, Jeremy; Alyea, Edwin P.; Antin, Joseph H.; Cutler, Corey; Koreth, John; Canning, Christine; Ritz, Jerome; Soiffer, Robert J.; Dranoff, Glenn] Brigham & Womens Hosp, Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
[Piesche, Matthias; Ho, Vincent T.; Nakazaki, Yukoh; Nehil, Michael; Yaghi, Nasser K.; Weiser, Jeremy; Alyea, Edwin P.; Antin, Joseph H.; Cutler, Corey; Koreth, John; Canning, Christine; Ritz, Jerome; Soiffer, Robert J.; Dranoff, Glenn] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Piesche, Matthias; Ho, Vincent T.; Nakazaki, Yukoh; Nehil, Michael; Yaghi, Nasser K.; Weiser, Jeremy; Alyea, Edwin P.; Antin, Joseph H.; Cutler, Corey; Koreth, John; Canning, Christine; Ritz, Jerome; Soiffer, Robert J.; Dranoff, Glenn] Harvard Univ, Sch Med, Boston, MA USA.
[Kim, Haesook] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Kim, Haesook] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Kolodin, Dmitriy] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Div Immunol, Boston, MA 02115 USA.
[Altevogt, Peter; Kiefel, Helena] German Canc Res Ctr, Translat Immunol, Heidelberg, Germany.
RP Dranoff, G (reprint author), Dana Farber Canc Inst, 44 Binney St,Dana 520C,450 Brookline Ave, Boston, MA 02215 USA.
EM glenn_dranoff@dfci.harvard.edu
OI Piesche, Matthias/0000-0002-9050-1946; Ritz, Jerome/0000-0001-5526-4669
FU Leukemia & Lymphoma Society; NCI [R01CA143083, P01CA78378]; Research
Foundation for the Treatment of Ovarian Cancer; Stand Up To
Cancer-Cancer Research Institute Cancer Immunology Dream Team
Translational Research Grant [SU2C-AACR-DT1012]
FX This work was supported with NCI R01CA143083, P01CA78378, the Leukemia &
Lymphoma Society, the Research Foundation for the Treatment of Ovarian
Cancer, and a Stand Up To Cancer-Cancer Research Institute Cancer
Immunology Dream Team Translational Research Grant (SU2C-AACR-DT1012).
Stand Up To Cancer is a program of the Entertainment Industry Foundation
administered by the American Association for Cancer Research.
NR 50
TC 3
Z9 3
U1 1
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR
PY 2015
VL 21
IS 5
BP 1010
EP 1018
DI 10.1158/1078-0432.CCR-14-1956
PG 9
WC Oncology
SC Oncology
GA CE6XZ
UT WOS:000351982800013
PM 25538258
ER
PT J
AU Rothenberg, SM
McFadden, DG
Palmer, EL
Daniels, GH
Wirth, LJ
AF Rothenberg, S. Michael
McFadden, David G.
Palmer, Edwin L.
Daniels, Gilbert H.
Wirth, Lori J.
TI Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic
Papillary Thyroid Cancer with Dabrafenib
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID BRAF(V600E); EXPRESSION; MUTATION; CARCINOMA; DEDIFFERENTIATION;
INHIBITION; PREVALENCE; THERAPY; I-124; GENES
AB Purpose: To determine whether the selective BRAF inhibitor, dabrafenib, can stimulate radioiodine uptake in BRAF V600E-mutated unresectable or metastatic iodine-refractory papillary thyroid cancer (PTC).
Experimental Design: Ten patients with BRAF V600Emutant iodine-refractory PTC were enrolled. Absence of radioiodine uptake on iodine-131 whole body scan obtained within 14 months of study entry was required. Each patient received dabrafenib (150 mg twice daily) for 25 days before thyrotropin a-stimulated iodine-131 whole body scan (4 mCi/148 MBq). Patients whose scan showed new sites of radioiodine uptake remained on dabrafenib for 17 more days, and then were treated with 150 mCi (5.5 GBq) iodine-131. The primary endpoint of the study was the percentage of patients with new radioiodine uptake after treatment with dabrafenib.
Results: Six of 10 patients (60%) demonstrated new radioiodine uptake on whole body scan after treatment with dabrafenib. All 6 were treated with 5.5 GBq iodine-131. Two patients had partial responses and 4 patients had stable disease on standard radiographic restaging at 3 months. Thyroglobulin decreased in 4 of 6 treated patients. One patient developed squamous cell carcinoma of the skin. There were no other significant adverse events attributed to dabrafenib.
Conclusions: Dabrafenib can stimulate radioiodine uptake in patients with metastatic BRAF V600E-mutant iodine-refractory PTC, representing a potential new therapeutic approach for these patients.
C1 [Rothenberg, S. Michael; McFadden, David G.; Daniels, Gilbert H.; Wirth, Lori J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Rothenberg, S. Michael; McFadden, David G.; Palmer, Edwin L.; Daniels, Gilbert H.; Wirth, Lori J.] Harvard Univ, Sch Med, Boston, MA USA.
[Rothenberg, S. Michael; McFadden, David G.; Daniels, Gilbert H.; Wirth, Lori J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[McFadden, David G.; Daniels, Gilbert H.] Massachusetts Gen Hosp, Thyroid Unit, Boston, MA 02114 USA.
[Palmer, Edwin L.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Wirth, LJ (reprint author), Massachusetts Gen Hosp, Ctr Canc, Yawkey 7B,55 Fruit St, Boston, MA 02114 USA.
EM lwirth@mgh.harvard.edu
FU GlaxoSmithKline; Ellison Foundation; [K08DE020139]; [K08CA160658]
FX This work was supported in part by GlaxoSmithKline and a grant from the
Ellison Foundation (to G.H. Daniels). S.M. Rothenberg was supported by
K08DE020139 and D.G. McFadden was supported by K08CA160658.
NR 25
TC 30
Z9 32
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR
PY 2015
VL 21
IS 5
BP 1028
EP 1035
DI 10.1158/1078-0432.CCR-14-2915
PG 8
WC Oncology
SC Oncology
GA CE6XZ
UT WOS:000351982800015
PM 25549723
ER
PT J
AU Wagner, AJ
Messersmith, WA
Shaik, MN
Li, S
Zheng, XX
McLachlan, KR
Cesari, R
Courtney, R
Levin, WJ
El-Khoueiry, AB
AF Wagner, Andrew J.
Messersmith, Wells A.
Shaik, M. Naveed
Li, Sherry
Zheng, Xianxian
McLachlan, Karen R.
Cesari, Rossano
Courtney, Rachel
Levin, Wendy J.
El-Khoueiry, Anthony B.
TI A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients
with Advanced Solid Tumors
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PANCREATIC-CANCER; PATHWAY; TARGET; CELLS; CARCINOGENESIS; METASTASIS;
CARCINOMAS; ACTIVATION; MECHANISMS; MUTATIONS
AB Purpose: To estimate the maximum tolerated dose (MTD) of single-agent PF-04449913, and to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity in patients with advanced tumors.
Experimental Design: A 3-3 design was used in this open-label, multicenter, phase I study and dose escalation/de-escalation applied until identification of the MTD. PF-04449913 was orally administered once daily in continuous 28-day treatment cycles. The starting dose was 80 mg.
Results: A total of 23 patients were enrolled; 19 were evaluable for first-cycle dose-limiting toxicity (DLT). The first-cycle DLT rate at the 640 mg dose level was 33.3%, and the MTD was estimated to be 320 mg once daily. The recommended phase II dose was not determined. PF-04449913 was generally well tolerated at doses of 80 to 320 mg once daily. The most common treatment-related adverse events (AE) were grade 1-2 dysgeusia, fatigue, decreased appetite, nausea, dizziness, dehydration, and diarrhea. Treatment- related grade 3 AEs only occurred in patients receiving PF-04449913 640 mg once daily. No treatment-related grade 4-5 AEs were reported. Pharmacokinetic analysis indicated a generally dose-proportional kinetics with biphasic elimination, supporting once-daily dosing. PF-04449913 modulated hedgehog signaling at the dose levels tested, as demonstrated by > 80% downregulation of GLI1 expression in the skin of treated patients. Eight patients (34.8%) achieved stable disease; none had complete or partial response. Three patients with disease progression at enrollment had prolonged disease stabilization (> 6 months).
Conclusions: The results obtained in this study support further evaluation of PF-04449913 in patients with advanced solid tumors.
C1 [Wagner, Andrew J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Messersmith, Wells A.] Univ Colorado, Ctr Canc, Aurora, CO USA.
[Shaik, M. Naveed; Zheng, Xianxian; McLachlan, Karen R.; Courtney, Rachel; Levin, Wendy J.] Pfizer Oncol, La Jolla, CA USA.
[Li, Sherry] Pfizer China Res & Dev Ctr, Shanghai, Peoples R China.
[Cesari, Rossano] Pfizer Oncol, Milan, Italy.
[El-Khoueiry, Anthony B.] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
RP Wagner, AJ (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol,Dept Med, Boston, MA 02215 USA.
EM Andrew_Wagner@dfci.harvard.edu
FU Pfizer Inc.; Virginia; D.K. Ludwig Fund for Cancer Research
FX This study was sponsored by Pfizer Inc. A.J. Wagner was supported by the
Virginia and D.K. Ludwig Fund for Cancer Research. Medical writing
support was provided by M. Nori and S. Mariani of Engage Scientific
Solutions, and was funded by Pfizer Inc.
NR 31
TC 9
Z9 9
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR
PY 2015
VL 21
IS 5
BP 1044
EP 1051
DI 10.1158/1078-0432.CCR-14-1116
PG 8
WC Oncology
SC Oncology
GA CE6XZ
UT WOS:000351982800017
PM 25388167
ER
PT J
AU Choueiri, TK
Figueroa, DJ
Fay, AP
Signoretti, S
Liu, Y
Gagnon, R
Deen, K
Carpenter, C
Benson, P
Ho, TH
Pandite, L
de Souza, P
Powles, T
Motzer, RJ
AF Choueiri, Toni K.
Figueroa, David J.
Fay, Andre P.
Signoretti, Sabina
Liu, Yuan
Gagnon, Robert
Deen, Keith
Carpenter, Christopher
Benson, Peter
Ho, Thai H.
Pandite, Lini
de Souza, Paul
Powles, Thomas
Motzer, Robert J.
TI Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients
with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from
COMPARZ, a Randomized Controlled Trial
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CD8(+) T-LYMPHOCYTES; CANCER; B7-H1; THERAPY; RESISTANCE; PROGNOSIS;
MOLECULE; PATHWAY; KIDNEY; LUNG
AB Purpose: The interaction of programmed death-1 ligand (PD-L1) with its receptor (PD-1) on T cells inactivates antitumor immune responses. PD-L1 expression has been associated with poor outcomes in renal cell carcinoma (RCC) but has not been investigated in advanced RCC patients receiving vascular endothelial growth factor (VEGF)-targeted therapy.
Experimental Design: Formalin-fixed paraffin-embedded (specimens were collected at baseline from patients in the COMPARZ trial. Tumor cell PD-L1 expression by immunohistochemistry was evaluated using H-score (HS). Dual PD-L1/CD68 staining was used to differentiate PD-L1 tumor expression from tumor-associated macrophages. Intratumor CD8-positive T cells were quantified morphometrically. Associations between biomarkers and survival were investigated using the log-rank test.
Results: HS data were available from 453 of 1110 patients. Sixty-four percent of patients had negative PD-L1 expression (HS=0). Patients with HS>55 (n=59, 13%) had significantly shorter overall survival (OS) than those with HS=55 in both pazopanib and sunitinib arms (median 15.1 vs 35.6 and 15.3 vs 27.8 months, respectively, P=0.03). In both arms, median OS was shortest in patients with HS>55 and intratumor CD8-positive T-cell counts >300 (9.6 and 11.9 months with pazopanib and sunitinib, respectively). Median OS in patients with HS=55 and CD8-positive T-cell counts =300 was 36.8 and 28.0 months with pazopanib and sunitinib, respectively. Progression-free survival results were similar to OS results.
Conclusions: Increased tumor cell PD-L1, or PD-L1 plus tumor CD8-positive T-cell counts, were associated with shorter survival in metastatic RCC patients receiving VEGF-targeted agents. These findings may have implications for future design of randomized clinical trials in advanced RCC.
C1 [Choueiri, Toni K.; Fay, Andre P.; Signoretti, Sabina] Harvard Univ, Brigham & Womens Hosp, Sch Med, Kidney Canc Ctr,Dana Farber Canc Inst, Boston, MA 02115 USA.
[Figueroa, David J.; Liu, Yuan; Gagnon, Robert; Deen, Keith; Carpenter, Christopher] GlaxoSmithKline, Collegeville, PA USA.
[Benson, Peter] MEDTOX Labs, St Paul, MN USA.
[Ho, Thai H.] Mayo Clin Arizona, Scottsdale, AZ USA.
[Pandite, Lini] GlaxoSmithKline, Res Triangle Pk, NC USA.
[de Souza, Paul] Univ Western Sydney, Ingham Inst, Liverpool, NSW, Australia.
[Powles, Thomas] Queen Mary Univ London, Barts Expt Canc Med Ctr, Barts Canc Inst, London, England.
[Motzer, Robert J.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
RP Choueiri, TK (reprint author), Dana Farber Canc Inst, Kidney Canc Ctr, 450 Brookline Ave,DANA 1230, Boston, MA 02215 USA.
EM toni_choueiri@dfci.harvard.edu
FU GlaxoSmithKline Pharmaceuticals; Trust family; Loker Pinard; Michael
Brigham Funds for Kidney Cancer Research at Dana-Farber Cancer
Institute; Dana-Farber/Harvard Cancer Center Kidney Cancer Program;
Dana-Farber/Harvard Cancer Center Kidney Cancer [SPORE P50 CA101942 01]
FX This work was funded in part by GlaxoSmithKline Pharmaceuticals, the
Trust family, Loker Pinard, and Michael Brigham Funds for Kidney Cancer
Research (to T.K. Choueiri) at Dana-Farber Cancer Institute, the
Dana-Farber/Harvard Cancer Center Kidney Cancer Program, and the
Dana-Farber/Harvard Cancer Center Kidney Cancer SPORE P50 CA101942 01.
NR 34
TC 37
Z9 37
U1 3
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR
PY 2015
VL 21
IS 5
BP 1071
EP 1077
DI 10.1158/1078-0432.CCR-14-1993
PG 7
WC Oncology
SC Oncology
GA CE6XZ
UT WOS:000351982800020
PM 25538263
ER
PT J
AU Magbanua, MJM
Carey, LA
DeLuca, A
Hwang, J
Scott, JH
Rimawi, MF
Mayer, EL
Marcom, PK
Liu, MC
Esteva, FJ
Park, JW
Rugo, HS
AF Magbanua, Mark Jesus M.
Carey, Lisa A.
DeLuca, Amy
Hwang, Jimmy
Scott, Janet H.
Rimawi, Mothaffar F.
Mayer, Erica L.
Marcom, P. Kelly
Liu, Minetta C.
Esteva, Francisco J.
Park, John W.
Rugo, Hope S.
CA Translational Breast Canc Res Cons
TI Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast
Cancers
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PERIPHERAL-BLOOD; PROSTATE-CANCER; CHEMOTHERAPY; SURVIVAL; PROGRESSION;
TRIAL
AB Purpose: Recent developments in rare-cell technology have led to improved blood-based assays that allow for the reliable detection, enumeration, and more recently, genomic profiling of circulating tumor cells (CTC). We evaluated two different approaches for enumeration of CTCs in a prospective therapeutic study of patients with metastatic triple-negative breast cancer (TNBC).
Experimental Design: The CellSearch system, a commercially available and U.S. Food and Drug Administration (FDA)-cleared assay for CTC enumeration, and IE/FC, an alternative method using EPCAM-based immunomagnetic enrichment and flow cytometry that maintains cell viability, were used to enumerate CTCs in the blood of patients with metastatic TNBC. CTC numbers were assessed at baseline and 7 to 14 days after initiation of therapy with cetuximab +/- carboplatin in a phase II multicenter clinical trial (TBCRC 001).
Results: CTC numbers from two methods were significantly correlated at baseline (r = 0.62) and at 7 to 14 days (r = 0.53). Baseline CTCs showed no association with time-to-progression (TTP), whereas CTCs at 7 to 14 days were significantly correlated with TTP (CellSearch P = 0.02; IE/FC P = 0.03). CTCs at both time points were significantly associated with overall survival (OS) [CellSearch: baseline (P = 0.0001) and 7 to 14 days (P < 0.0001); IE/FC: baseline (P = 0.0009) and 7 to 14 days (P = 0.0086)].
Conclusions: Our findings demonstrate that CTC enumeration by two different assays was highly concordant. In addition, results of both assays were significantly correlated with TTP and OS in patients with TNBC. The IE/FC method is also easily adapted (C)2014 AACR.
C1 [Magbanua, Mark Jesus M.; DeLuca, Amy; Hwang, Jimmy; Scott, Janet H.; Park, John W.; Rugo, Hope S.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA.
[Carey, Lisa A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Rimawi, Mothaffar F.] Baylor Univ, Coll Med, Houston, TX 77030 USA.
[Mayer, Erica L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Marcom, P. Kelly] Duke Univ, Med Ctr, Durham, NC USA.
[Liu, Minetta C.] Georgetown Univ, Washington, DC USA.
[Esteva, Francisco J.] NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA.
RP Rugo, HS (reprint author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Box 1710 1600 Divisadero St, San Francisco, CA 94115 USA.
EM hrugo@medicine.ucsf.edu
OI Esteva, Francisco/0000-0003-2437-3920
FU Avon Partners-for-Progress; Bristol-Myers Squibb; Breast Cancer Research
Foundation; Avon Foundation; Susan G. Komen for the Cure through the
Translational Breast Cancer Research Consortium
FX This study was funded by the Avon Partners-for-Progress (to L.A. Carey
and H.S. Rugo), and Bristol-Myers Squibb. Veridex provided technology
(CellSearch System) and materials for CTC enumeration. Additional
funding was provided by the Breast Cancer Research Foundation, the Avon
Foundation, and Susan G. Komen for the Cure through the Translational
Breast Cancer Research Consortium.
NR 34
TC 11
Z9 11
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR
PY 2015
VL 21
IS 5
BP 1098
EP 1105
DI 10.1158/1078-0432.CCR-14-1948
PG 8
WC Oncology
SC Oncology
GA CE6XZ
UT WOS:000351982800023
PM 25524311
ER
PT J
AU Dalva-Aydemir, S
Bajpai, R
Martinez, M
Adekola, KUA
Kandela, I
Wei, CY
Singhal, S
Koblinski, JE
Raje, NS
Rosen, ST
Shanmugam, M
AF Dalva-Aydemir, Sevim
Bajpai, Richa
Martinez, Maylyn
Adekola, Kehinde U. A.
Kandela, Irawati
Wei, Changyong
Singhal, Seema
Koblinski, Jennifer E.
Raje, Noopur S.
Rosen, Steven T.
Shanmugam, Mala
TI Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved
Ritonavir and Metformin
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HIV PROTEASE INHIBITORS; CANCER-CELLS; GLUCOSE-METABOLISM;
INSULIN-RESISTANCE; RESPIRATORY-CHAIN; MCL-1; SURVIVAL; APOPTOSIS;
THERAPY; KINASE
AB Purpose: We have previously demonstrated that ritonavir targeting of glycolysis is growth inhibitory and cytotoxic in a subset of multiple myeloma cells. In this study, our objective was to investigate themetabolic basis of resistance to ritonavir and to determine the utility of cotreatment with the mitochondrial complex I inhibitor metformin to target compensatory metabolism.
Experimental Design: We determined combination indices for ritonavir and metformin, impact on myeloma cell lines, patient samples, and myeloma xenograft growth. Additional evaluation in breast, melanoma, and ovarian cancer cell lines was also performed. Signaling connected to suppression of the prosurvival BCL-2 family member MCL-1 was evaluated in multiple myeloma cell lines and tumor lysates. Reliance on oxidative metabolism was determined by evaluation of oxygen consumption, and dependence on glutamine was assessed by estimation of viability upon metabolite withdrawal in the context of specific metabolic perturbations.
Results: Ritonavir-treated multiple myeloma cells exhibited increased reliance on glutamine metabolism. Ritonavir sensitized multiple myeloma cells to metformin, effectively eliciting cytotoxicity both in vitro and in an in vivo xenograft model of multiple myeloma and in breast, ovarian, and melanoma cancer cell lines. Ritonavir and metformin effectively suppressed AKT and mTORC1 phosphorylation and prosurvival BCL-2 family member MCL-1 expression in multiple myeloma cell lines in vitro and in vivo.
Conclusions: FDA-approved ritonavir and metformin effectively target multiple myeloma cell metabolism to elicit cytotoxicity in multiple myeloma. Our studies warrant further investigation into repurposing ritonavir and metformin to target the metabolic plasticity of myeloma to more broadly target myeloma heterogeneity and prevent the reemergence of chemoresistant aggressive multiple myeloma.
C1 [Dalva-Aydemir, Sevim; Martinez, Maylyn; Adekola, Kehinde U. A.; Singhal, Seema; Koblinski, Jennifer E.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Bajpai, Richa; Wei, Changyong; Shanmugam, Mala] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.
[Kandela, Irawati] Northwestern Univ, Chem Life Proc Inst, Chicago, IL 60611 USA.
[Singhal, Seema] Northwestern Univ, Feinberg Sch Med, Div Hematol & Oncol, Chicago, IL 60611 USA.
[Raje, Noopur S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rosen, Steven T.] City Hope Natl Med Ctr, Duarte, CA USA.
RP Shanmugam, M (reprint author), Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.
EM mala.shan@emory.edu
FU Robert H.L.C.C center; Wendy Will Case Cancer Foundation [SP0012544];
American Cancer Society (IL division) [188679]; American Cancer Society
[RSG-11-254-01-CSM]; Robert H. Lurie Cancer Center - NCI CCSG [P30
CA060553]
FX This work was supported by Robert H.L.C.C center gift fund (to S.T.
Rosen), Wendy Will Case Cancer Foundation grant SP0012544 (to M.
Shanmugam), American Cancer Society (IL division grant #188679; to M.
Shanmugam), and the American Cancer Society (Research scholar grant
RSG-11-254-01-CSM; to M. Shanmugam). All animal studies were performed
by Dr. Irawati Kandela and IHC staining by Andrey Ugolkov at the
Northwestern University Center for Developmental Therapeutics core
funded by the Robert H. Lurie Cancer Center, generously supported by NCI
CCSG P30 CA060553 core grant.
NR 46
TC 10
Z9 10
U1 4
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR
PY 2015
VL 21
IS 5
BP 1161
EP 1171
DI 10.1158/1078-0432.CCR-14-1088
PG 11
WC Oncology
SC Oncology
GA CE6XZ
UT WOS:000351982800029
PM 25542900
ER
PT J
AU Scott, MG
Gronowski, AM
Reid, IR
Holick, MF
Thadhani, R
Phinney, K
AF Scott, Mitchell G.
Gronowski, Ann M.
Reid, Ian R.
Holick, Michael F.
Thadhani, Ravi
Phinney, Karen
TI Vitamin D: The More We Know, the Less We Know
SO CLINICAL CHEMISTRY
LA English
DT Editorial Material
C1 [Scott, Mitchell G.; Gronowski, Ann M.] Washington Univ, Sch Med, Div Lab & Genom Med, St Louis, MO 63110 USA.
[Reid, Ian R.] Univ Auckland, Med, Auckland 1, New Zealand.
[Holick, Michael F.] Boston Univ, Med Ctr, Bone Hlth Care Clin, Med Physiol & Biophys,Gen Clin Res Unit, Boston, MA 02215 USA.
[Thadhani, Ravi] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nephrol,Med, Boston, MA 02114 USA.
[Phinney, Karen] NIST, Biomol Measurement Div, Grp Leader Bioanalyt Sci, Gaithersburg, MD 20899 USA.
RP Gronowski, AM (reprint author), Washington Univ, Sch Med, Div Lab & Genom Med, Box 8118,660 S Euclid, St Louis, MO 63110 USA.
EM gronowski@wustl.edu
NR 4
TC 7
Z9 8
U1 1
U2 10
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
EI 1530-8561
J9 CLIN CHEM
JI Clin. Chem.
PD MAR
PY 2015
VL 61
IS 3
BP 462
EP 465
DI 10.1373/clinchem.2014.222521
PG 4
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA CE9JX
UT WOS:000352161300004
PM 25056405
ER
PT J
AU Lang, RM
Badano, LP
Mor-Avi, V
Afilalo, J
Armstrong, A
Ernande, L
Flachskampf, FA
Foster, E
Goldstein, SA
Kuznetsova, T
Lancellotti, P
Muraru, D
Picard, MH
Rietzschel, ER
Rudski, L
Spencer, KT
Tsang, W
Voigt, JU
AF Lang, Roberto M.
Badano, Luigi P.
Mor-Avi, Victor
Afilalo, Jonathan
Armstrong, Anderson
Ernande, Laura
Flachskampf, Frank A.
Foster, Elyse
Goldstein, Steven A.
Kuznetsova, Tatiana
Lancellotti, Patrizio
Muraru, Denisa
Picard, Michael H.
Rietzschel, Ernst R.
Rudski, Lawrence
Spencer, Kirk T.
Tsang, Wendy
Voigt, Jens-Uwe
TI Recommendations for Cardiac Chamber Quantification by Echocardiography
in Adults: An Update from the American Society of Echocardiography and
the European Association of Cardiovascular Imaging
SO EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING
LA English
DT Article
DE Adult echocardiography; Transthoracic echocardiography; Ventricular
function; Normal values
ID LEFT ATRIAL VOLUME; AORTIC-VALVE IMPLANTATION; TIME 3-DIMENSIONAL
ECHOCARDIOGRAPHY; LEFT-VENTRICULAR MASS; ACUTE MYOCARDIAL-INFARCTION;
INFERIOR VENA-CAVA; MULTIDETECTOR COMPUTED-TOMOGRAPHY; SPECKLE-TRACKING
ECHOCARDIOGRAPHY; GLOBAL LONGITUDINAL STRAIN; PATIENTS
GREATER-THAN-OR-EQUAL-TO-65 YEARS
AB The rapid technological developments of the past decade and the changes in echocardiographic practice brought about by these developments have resulted in the need for updated recommendations to the previously published guidelines for cardiac chamber quantification, which was the goal of the joint writing group assembled by the American Society of Echocardiography and the European Association of Cardiovascular Imaging. This document provides updated normal values for all four cardiac chambers, including three-dimensional echocardiography and myocardial deformation, when possible, on the basis of considerably larger numbers of normal subjects, compiled from multiple databases. In addition, this document attempts to eliminate several minor discrepancies that existed between previously published guidelines.
C1 [Lang, Roberto M.; Mor-Avi, Victor; Spencer, Kirk T.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
[Badano, Luigi P.; Muraru, Denisa] Univ Padua, Padua, Italy.
[Afilalo, Jonathan; Rudski, Lawrence] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada.
[Armstrong, Anderson] Johns Hopkins Univ, Baltimore, MD USA.
[Ernande, Laura] INSERM U955, Creteil, France.
[Ernande, Laura] Hop Henri Mondor, F-94010 Creteil, France.
[Flachskampf, Frank A.] Uppsala Univ, Uppsala, Sweden.
[Foster, Elyse] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Goldstein, Steven A.] Medstar Washington Hosp Ctr, Washington, DC USA.
[Kuznetsova, Tatiana; Voigt, Jens-Uwe] Univ Hosp Leuven, Leuven, Belgium.
[Lancellotti, Patrizio] Univ Liege, Liege, Belgium.
[Picard, Michael H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Picard, Michael H.] Harvard Univ, Sch Med, Boston, MA USA.
[Rietzschel, Ernst R.] Ghent Univ Hosp, Ghent, Belgium.
[Tsang, Wendy] Univ Toronto, Toronto, ON, Canada.
RP Lang, RM (reprint author), Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
OI Mor-Avi, Victor/0000-0001-7932-6473; Badano, Luigi/0000-0002-0379-3283;
Picard, Michael/0000-0002-9264-3243
FU GE Healthcare; Siemens; Abbott Vascular Structural Heart; Philips
Medical Systems; Esaote
FX The following authors reported relationships with one or more commercial
interests: Luigi P. Badano, MD, PhD, FESC, received grants from GE
Healthcare, Siemens, and Esaote and serves on the speakers' bureau for
GE Healthcare. Elyse Foster, MD, FASE, received grant support from
Abbott Vascular Structural Heart. Roberto M. Lang, MD, FASE, FESC,
received grants from and serves on the speakers' bureau and advisory
board for Philips Medical Systems. Denisa Muraru, MD, received research
equipment from and served as a consultant for GE Healthcare. Lawrence
Rudski, MD, FASE, holds stock in GE. Drs Lang and Badano co-chaired the
Writing Group.
NR 206
TC 314
Z9 322
U1 11
U2 33
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2047-2404
EI 2047-2412
J9 EUR HEART J-CARD IMG
JI Eur. Heart J.-Cardiovasc. Imaging
PD MAR
PY 2015
VL 16
IS 3
BP 233
EP 271
DI 10.1093/ehjci/jev014
PG 39
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CE9YE
UT WOS:000352198800001
PM 25712077
ER
PT J
AU Dal-Bianco, JP
Levine, RA
AF Dal-Bianco, Jacob P.
Levine, Robert A.
TI The mitral valve is an actively adapting tissue: new imaging evidence
SO EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING
LA English
DT Editorial Material
ID COMPENSATORY MECHANISM; LEAFLET ADAPTATION; HEART-FAILURE;
REGURGITATION; CARDIOMYOPATHY; ANATOMY; MATRIX
C1 [Dal-Bianco, Jacob P.; Levine, Robert A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
RP Dal-Bianco, JP (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St,Yawkey 5E, Boston, MA 02114 USA.
EM jdalbianco@partners.org
FU NHLBI NIH HHS [R01 HL72265, K24 HL67434, HL109506]
NR 15
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2047-2404
EI 2047-2412
J9 EUR HEART J-CARD IMG
JI Eur. Heart J.-Cardiovasc. Imaging
PD MAR
PY 2015
VL 16
IS 3
BP 286
EP 287
DI 10.1093/ehjci/jeu300
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CE9YE
UT WOS:000352198800007
PM 25617031
ER
PT J
AU Redler, S
Petukhova, L
Ripke, S
Huang, H
Menelaou, A
Becker, T
Heilmann, S
Yamany, T
Duvic, M
Hordinsky, M
Norris, D
Price, V
Mackay-Wiggan, J
de Jong, A
DeStefano, G
Moebus, S
Bohm, M
Blume-Peytavi, U
Wolff, H
Lutz, G
Kruse, R
Bian, L
Amos, C
Lee, A
Gregersen, P
Blaumeiser, B
Altshuler, D
Clynes, R
de Bakker, PI
Nothen, MM
Daly, MJ
Christiano, AM
Betz, RC
AF Redler, S.
Petukhova, L.
Ripke, S.
Huang, H.
Menelaou, A.
Becker, T.
Heilmann, S.
Yamany, T.
Duvic, M.
Hordinsky, M.
Norris, D.
Price, V.
Mackay-Wiggan, J.
de Jong, A.
DeStefano, G.
Moebus, S.
Boehm, M.
Blume-Peytavi, U.
Wolff, H.
Lutz, G.
Kruse, R.
Bian, L.
Amos, C.
Lee, A.
Gregersen, P.
Blaumeiser, B.
Altshuler, D.
Clynes, R.
de Bakker, P. I.
Noethen, M. M.
Daly, M. J.
Christiano, A. M.
Betz, R. C.
TI Meta-analysis of genome-wide association studies in alopecia areata
resolves HLA associations and reveals two new susceptibility loci
SO EXPERIMENTAL DERMATOLOGY
LA English
DT Meeting Abstract
CT 42nd Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung
(ADF)
CY MAR 05-07, 2015
CL Ulm, GERMANY
SP Arbeitsgemeinschaft Dermatologische Forsch
C1 [Redler, S.; Heilmann, S.; Noethen, M. M.; Betz, R. C.] Univ Bonn, Inst Human Genet, Bonn, Germany.
[Petukhova, L.; Yamany, T.; Mackay-Wiggan, J.; de Jong, A.; Bian, L.; Clynes, R.; Christiano, A. M.] Columbia Univ, Dept Dermatol, New York, NY 10027 USA.
[Petukhova, L.] Columbia Univ, Dept Epidemiol, New York, NY USA.
[Ripke, S.; Huang, H.; Altshuler, D.; Daly, M. J.] Massachusetts Gen Hosp, Analyt & Transfat Genet Unit, Boston, MA 02114 USA.
[Ripke, S.; Huang, H.; Altshuler, D.; Daly, M. J.] Harvard Univ, Sch Med, Boston, MA USA.
[Ripke, S.; Huang, H.; Altshuler, D.; Daly, M. J.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA.
[Menelaou, A.; de Bakker, P. I.] Univ Med Ctr Utrecht, Dept Med Genet, Utrecht, Netherlands.
[Becker, T.] German Ctr Neurodegenerat Dis, Bonn, Germany.
[Becker, T.] Univ Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
[Heilmann, S.; Noethen, M. M.] Univ Bonn, Dept Genom, Life & Brain Ctr, Boston, Germany.
[Duvic, M.] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA.
[Hordinsky, M.] Univ Minnesota, Dept Dermatol, Minneapolis, MN 55455 USA.
[Norris, D.] Univ Colorado, Dept Dermatol, Boulder, CO 80309 USA.
[Price, V.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[DeStefano, G.; Christiano, A. M.] Columbia Univ, Dept Genet & Dev, New York, NY USA.
[Moebus, S.] Univ Duisburg Essen, Inst Med Informat Biometry & Epidemiol, Essen, Germany.
[Boehm, M.] Univ Munster, Dept Dermatol, D-48149 Munster, Germany.
[Blume-Peytavi, U.] Charite, Dept Dermatol & Allergy, Clin Res Ctr Hair & Skin Sci, D-13353 Berlin, Germany.
[Wolff, H.] Univ Munich, Dept Dermatol, D-80539 Munich, Germany.
[Amos, C.] Dartmouth Coll, Community & Family Med & Genet, Hanover, NH 03755 USA.
[Lee, A.; Gregersen, P.] Feinstein Inst Med Res, Manhasset, NY USA.
[Blaumeiser, B.] Univ Antwerp, Dept Med Genet, B-2020 Antwerp, Belgium.
[Clynes, R.] Columbia Univ, Dept Med, New York, NY USA.
[de Bakker, P. I.] Univ Med Ctr Utrecht, Dept Epidemiol, Utrecht, Netherlands.
RI de Bakker, Paul/B-8730-2009
OI de Bakker, Paul/0000-0001-7735-7858
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0906-6705
EI 1600-0625
J9 EXP DERMATOL
JI Exp. Dermatol.
PD MAR
PY 2015
VL 24
IS 3
MA P097
BP E17
EP E17
PG 1
WC Dermatology
SC Dermatology
GA CE6IB
UT WOS:000351939000098
ER
PT J
AU An, G
Acharya, C
Deng, SH
Yi, SH
Xu, Y
Qin, XQ
Sui, WW
Li, ZJ
Shi, LH
Zang, MR
Feng, XY
Hao, M
Zou, DH
Zhao, YZ
Qi, JY
Cheng, T
Ru, K
Wang, JX
Tai, YT
Qiu, LG
AF An, Gang
Acharya, Chirag
Deng, Shuhui
Yi, Shuhua
Xu, Yan
Qin, Xiaoqi
Sui, Weiwei
Li, Zengjun
Shi, Lihui
Zang, Meirong
Feng, Xiaoyan
Hao, Mu
Zou, Dehui
Zhao, Yaozhong
Qi, Junyuan
Cheng, Tao
Ru, Kun
Wang, Jianxiang
Tai, Yu-Tzu
Qiu, Lugui
TI Cytogenetic and clinical marks for defining high-risk myeloma in the
context of bortezomib treatment
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
ID STEM-CELL TRANSPLANTATION; LENALIDOMIDE PLUS DEXAMETHASONE;
MULTIPLE-MYELOMA; DELETION; PROGNOSIS; SURVIVAL; T(4/14);
CLASSIFICATION; ABNORMALITIES; CHEMOTHERAPY
AB Multiple myeloma (MM) is a heterogeneous disease, and the benefit from bortezomib treatment is not uniform among all patients subgroups. Currently, little inform-nation is available to predict patients response to bortezomib treatment. In this study, we aimed to identify patients benefiting minimally from bortezomib as part of first-line therapy and to define high-risk MM in the context of bortezomib treatment. We compared the effect of a bortezomib-based treatment (arm B) with that of a treatment without bortezomib (arm A) on different genetic patient subgroups in a series of 273 cases of newly diagnosed MM. These patients were enrolled in a prospective, non-randomized clinical trial (BDH 2008/02). A subgroup of patients exhibiting little benefit from bortezomib treatment was identified. These patients had at least one of the following characteristics: del(17p13), 1q21 gain, or high lactate dehydrogenase levels. In this subgroup, survival of patients treated with bortezomib was comparable (progression-free survival: 14.0 vs. 15.0 months, p = 0.992; overall survival: 21.0 vs. 14.0 months,p = 0.472) to that of patients undergoing thalidomide-based treatment. We propose that all patients with newly diagnosed MM should be evaluated for these three markers before bortezomib treatment. Other novel drugs and alternative therapeutic strategies are needed for patients with such markers. Copyright (C) 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.
C1 [An, Gang; Deng, Shuhui; Yi, Shuhua; Xu, Yan; Qin, Xiaoqi; Sui, Weiwei; Li, Zengjun; Shi, Lihui; Zang, Meirong; Feng, Xiaoyan; Hao, Mu; Zou, Dehui; Zhao, Yaozhong; Qi, Junyuan; Cheng, Tao; Ru, Kun; Wang, Jianxiang; Qiu, Lugui] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China.
[An, Gang; Deng, Shuhui; Yi, Shuhua; Xu, Yan; Qin, Xiaoqi; Sui, Weiwei; Li, Zengjun; Shi, Lihui; Zang, Meirong; Feng, Xiaoyan; Hao, Mu; Zou, Dehui; Zhao, Yaozhong; Qi, Junyuan; Cheng, Tao; Ru, Kun; Wang, Jianxiang; Qiu, Lugui] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China.
[An, Gang; Deng, Shuhui; Yi, Shuhua; Xu, Yan; Qin, Xiaoqi; Sui, Weiwei; Li, Zengjun; Shi, Lihui; Zang, Meirong; Feng, Xiaoyan; Hao, Mu; Zou, Dehui; Zhao, Yaozhong; Qi, Junyuan; Cheng, Tao; Ru, Kun; Wang, Jianxiang; Qiu, Lugui] Peking Union Med Coll, Tianjin, Peoples R China.
[Acharya, Chirag; Tai, Yu-Tzu] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Acharya, Chirag; Tai, Yu-Tzu] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Ctr, Boston, MA 02115 USA.
RP Qiu, LG (reprint author), Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China.
EM drqiu99@medmail.com.cn
FU National Natural Science Fund [81400175, 81172255, 81370632]; Clinical
Research Program of the Ministry of Health (Key Project); Special Key
Anticancer Research and Development Program of Tianjin Municipality
[12ZCDZSY17600]; Union Youth Research Fund of Peking Union Medical
College; Doctoral Foundation [20131106120037]
FX This study was supported by the National Natural Science Fund (81400175,
81172255, 81370632), the Clinical Research Program of the Ministry of
Health (Key Project 2010 to 2012), the Special Key Anticancer Research
and Development Program of Tianjin Municipality (12ZCDZSY17600), the
Union Youth Research Fund of Peking Union Medical College (2012-2013),
and the Doctoral Foundation (20131106120037)
NR 29
TC 1
Z9 1
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
EI 1873-2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD MAR
PY 2015
VL 43
IS 3
BP 168
EP 176
DI 10.1016/j.exphem.2014.11.004
PG 9
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA CE9PZ
UT WOS:000352177200003
PM 25462022
ER
PT J
AU Vanegas, JC
Afeiche, MC
Gaskins, AJ
Minguez-Alarcon, L
Williams, PL
Wright, DL
Toth, TL
Hauser, R
Chavarro, JE
AF Vanegas, Jose C.
Afeiche, Myriam C.
Gaskins, Audrey J.
Minguez-Alarcon, Lidia
Williams, Paige L.
Wright, Diane L.
Toth, Thomas L.
Hauser, Russ
Chavarro, Jorge E.
TI Soy food intake and treatment outcomes of women undergoing assisted
reproductive technology
SO FERTILITY AND STERILITY
LA English
DT Article
DE Cohort studies; isoflavones; phytoestrogens; soy foods; assisted
reproductive techniques
ID ESTROGEN-RECEPTOR-ALPHA; DIETARY PATTERNS; RANDOMIZED-TRIAL; SEMEN
QUALITY; MEN; PHYTOESTROGEN; INFERTILITY; CELLS; PREGNANCY; AGONIST
AB Objective: To study the relation of dietary phytoestrogens intake and clinical outcomes of women undergoing infertility treatment with the use of assisted reproductive technology (ART).
Design: Prospective cohort study.
Setting: Fertility center.
Patient(s): A total of 315 women who collectively underwent 520 ART cycles from 2007 to 2013.
Intervention(s): None.
Main Outcome Measure(s): Implantation, clinical pregnancy, and live birth rates per initiated cycle.
Result(s): Soy isoflavones intake was positively related to live birth rates in ART. Compared with women who did not consume soy isoflavones, the multivariable-adjusted odds ratios of live birth (95% confidence interval) for women in increasing categories of soy isoflavones intake were 1.32 (0.76-2.27) for women consuming 0.54-2.63 mg/d, 1.87 (1.12-3.14) for women consuming 2.64-7.55 mg/d, and 1.77 (1.03-3.03) for women consuming 7.56-27.89 mg/d.
Conclusion(s): Dietary soy intake was positively related to the probability of having a live birth during infertility treatment with ART. ((c) 2015 by American Society for Reproductive Medicine.)
C1 [Vanegas, Jose C.] Pontificia Univ Javeriana, Sch Med, Bogota, Colombia.
[Afeiche, Myriam C.; Minguez-Alarcon, Lidia; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Gaskins, Audrey J.; Chavarro, Jorge E.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Gaskins, Audrey J.; Hauser, Russ; Chavarro, Jorge E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Williams, Paige L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Wright, Diane L.; Toth, Thomas L.; Hauser, Russ] Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Boston, MA 02114 USA.
[Wright, Diane L.; Toth, Thomas L.; Hauser, Russ; Chavarro, Jorge E.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Chavarro, Jorge E.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
RP Chavarro, JE (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
EM jchavarr@hsph.harvard.edu
FU National Institutes of Health [ES022955, R01ES009718, R01ES000002,
P30DK46200, T32DK007703]
FX Supported by National Institutes of Health grants ES022955, R01ES009718,
R01ES000002, P30DK46200, and T32DK007703.
NR 28
TC 4
Z9 4
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD MAR
PY 2015
VL 103
IS 3
BP 749
EP U467
DI 10.1016/j.fertnstert.2014.12.104
PG 9
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA CE8QN
UT WOS:000352109000029
PM 25577465
ER
PT J
AU Merker, VL
Murphy, TP
Hughes, JB
Muzikansky, A
Hughes, MR
Souter, I
Plotkin, SR
AF Merker, Vanessa L.
Murphy, Timothy P.
Hughes, J. Bryan
Muzikansky, Alona
Hughes, Mark R.
Souter, Irene
Plotkin, Scott R.
TI Outcomes of preimplantation genetic diagnosis in neurofibromatosis type
1
SO FERTILITY AND STERILITY
LA English
DT Article
DE PGD; NF1; fertility; pregnancy; in vitro fertilization; genetic
counseling
ID DNA AMPLIFICATION; BLASTOCYST BIOPSY; DATA-COLLECTION; HUMAN EMBRYOS;
EXPERIENCE; CYCLES; PGD; FERTILIZATION; DEFECTS; BIRTH
AB Objective: To examine the effect of patient and facility level factors on the success of preimplantation genetic diagnosis (PGD) in patients with neurofibromatosis 1 (NF1).
Design: Retrospective review.
Setting: Large PGD reference laboratory.
Patient(s): All patients with NF1 referred from June 2004 to May 2013.
Intervention(s): None.
Main Outcome Measure(s): Embryos' NF1 mutation status and live birth rates.
Result(s): Seventy-seven couples underwent 156 PGD cycles during the study period. The average maternal age at the time of embryo biopsy was 33.2 years. The majority of embryos had a day 3 single blastomere biopsy without aneuploidy screening. A diagnosis was obtained for 80% of biopsied embryos; 20% of biopsies were nondiagnostic due to technical failures. Diagnosis was more often obtained for embryos of parents with familial disease and for embryos biopsied at centers that referred multiple NF1 cases. Among diagnosed embryos, 483/1,060 (46%) were unaffected by the parental NF1 mutation. Twenty-two (14%) of the 156 cycles had a confirmed live birth; if the observed success rate is applied to cycles with unknown outcomes, 33/156 (21%) cycles are expected to have resulted in live birth. In multivariate logistic regression, having a live birth was significantly associated with having more unaffected embryos available for transfer (odds ratio 1.33 per additional embryo, 95% confidence interval 1.02-1.72).
Conclusion(s): Advances in biopsy and diagnostic techniques which increase the number of unaffected embryos identified may improve live birth rates for patients with NF1. Clinicians should counsel patients about their fertility and reproductive options early, with the use of disease-specific data, to set appropriate expectations for the PGD process. ((c) 2015 by American Society for Reproductive Medicine.)
C1 [Merker, Vanessa L.; Murphy, Timothy P.; Plotkin, Scott R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Merker, Vanessa L.; Murphy, Timothy P.; Plotkin, Scott R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Muzikansky, Alona] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Souter, Irene] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Hughes, J. Bryan; Hughes, Mark R.] Genesis Genet, Plymouth, MI USA.
RP Plotkin, SR (reprint author), Massachusetts Gen Hosp, Pappas Ctr Neurooncol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA.
EM splotkin@mgh.harvard.edu
OI Merker, Vanessa/0000-0002-4542-5227
FU Alvan T. and Viola D. Fuller-American Cancer Society
FX V.L.M. received travel expenses from Genesis Genetics. T.P.M. received
funding from the Alvan T. and Viola D. Fuller-American Cancer Society
Junior Research Fellowship. J.B.H. is employed by Genesis Genetics. A.M.
has nothing to disclose. M.R.H. has a financial interest in Genesis
Genetics. I.S. has nothing to disclose. S.R.P. has nothing to disclose.
NR 26
TC 1
Z9 2
U1 4
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD MAR
PY 2015
VL 103
IS 3
BP 761
EP U481
DI 10.1016/j.fertnstert.2014.11.021
PG 9
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA CE8QN
UT WOS:000352109000031
PM 25557241
ER
PT J
AU Von Delft, A
Dramowski, A
Khosa, C
Kotze, K
Lederer, P
Mosidi, T
Peters, JA
Smith, J
van der Westhuizen, HM
von Delft, D
Willems, B
Bates, M
Craig, G
Maeurer, M
Marais, BJ
Mwaba, P
Nunes, EA
Nyirenda, T
Oliver, M
Zumla, A
AF von Delft, Arne
Dramowski, Angela
Khosa, Celso
Kotze, Koot
Lederer, Philip
Mosidi, Thato
Peters, Jurgens A.
Smith, Jonathan
van der Westhuizen, Helene-Mari
von Delft, Dalene
Willems, Bart
Bates, Matthew
Craig, Gill
Maeurer, Markus
Marais, Ben J.
Mwaba, Peter
Nunes, Elizabete A.
Nyirenda, Thomas
Oliver, Matt
Zumla, Alimuddin
TI Why healthcare workers are sick of TB
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Tuberculosis (TB); Multidrug- & Extensively Drug-Resistant TB (MDR-TB &
XDR-TB); Healthcare worker (occupational); Infection control;
Prevention; Stigma
ID DRUG-RESISTANT TUBERCULOSIS; MULTIDRUG-RESISTANT; SOUTH-AFRICA; MDR-TB;
XDR-TB; FLUOROQUINOLONES; METAANALYSIS; BEHAVIOR; SPREAD; MALAWI
AB Dr Thato Mosidi never expected to be diagnosed with tuberculosis (TB), despite widely prevalent exposure and very limited infection control measures. The life-threatening diagnosis of primary extensively drug-resistant TB (XDR-TB) came as an even greater shock. The inconvenient truth is that, rather than being protected, Dr Mosidi and thousands of her healthcare colleagues are at an increased risk of TB and especially drug-resistant TB. In this viewpoint paper we debunk the widely held false belief that healthcare workers are somehow immune to TB disease (TB-proof) and explore some of the key factors contributing to the pervasive stigmatization and subsequent non-disclosure of occupational TB. Our front-line workers are some of the first to suffer the consequences of a progressively more resistant and fatal TB epidemic, and urgent interventions are needed to ensure the safety and continued availability of these precious healthcare resources. These include the rapid development and scale-up of improved diagnostic and treatment options, strengthened infection control measures, and focused interventions to tackle stigma and discrimination in all its forms. We call our colleagues to action to protect themselves and those they care for. (c) 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [von Delft, Arne; Dramowski, Angela; Khosa, Celso; Kotze, Koot; Lederer, Philip; Mosidi, Thato; Peters, Jurgens A.; Smith, Jonathan; van der Westhuizen, Helene-Mari; von Delft, Dalene; Willems, Bart; Zumla, Alimuddin] TB Proof, New York, NY 10010 USA.
[von Delft, Arne] Univ Cape Town, Fac Hlth Sci, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa.
[Dramowski, Angela] Univ Stellenbosch, Dept Paediat & Child Hlth, Paediat Infect Dis, Cape Town, South Africa.
[Khosa, Celso] Minist Hlth, Inst Nacl Saude, Maputo, Mozambique.
[Kotze, Koot; van der Westhuizen, Helene-Mari; Willems, Bart] Univ Stellenbosch, Div Community Hlth, Cape Town, South Africa.
[Lederer, Philip] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
[Mosidi, Thato] Resp & Meningeal Pathogens Unit, Wits Hlth Consortium, Johannesburg, South Africa.
[Smith, Jonathan] Emory Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA.
[Smith, Jonathan] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
[Smith, Jonathan] Visual Epidemiol, New Haven, CT USA.
[Bates, Matthew] Univ Teaching Hosp, UNZA UCLMS Project, Lusaka, Zambia.
[Smith, Jonathan] City Univ London, London EC1V 0HB, England.
[Maeurer, Markus] Karolinska Inst, Stockholm, Sweden.
[Marais, Ben J.] Univ Sydney, Childrens Hosp Westmead, Sydney, NSW 2006, Australia.
[Marais, Ben J.] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur MBI, Sydney, NSW 2006, Australia.
[Nunes, Elizabete A.] Maputo Cent Hosp, Maputo, Mozambique.
[Nyirenda, Thomas] European & Developing Countries Clin Trials Partn, Cape Town, South Africa.
[Oliver, Matt] UK All Party Parliamentary Grp Global TB, London, England.
[Zumla, Alimuddin] UCL, Div Infect & Immun, London, England.
[Zumla, Alimuddin] Univ Coll London Hosp, NIHR Biomed Res Ctr, London, England.
RP Von Delft, A (reprint author), TB Proof, New York, NY 10010 USA.
EM vuzumsi@gmail.com
OI Zumla, Alimuddin/0000-0002-5111-5735
NR 39
TC 12
Z9 13
U1 1
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD MAR
PY 2015
VL 32
SI SI
BP 147
EP 151
DI 10.1016/j.ijid.2014.12.003
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA CF2TW
UT WOS:000352401500025
PM 25809771
ER
PT J
AU Schnabolk, G
Coughlin, B
Joseph, K
Kunchithapautham, K
Bandyopadhyay, M
O'Quinn, EC
Nowling, T
Rohrer, B
AF Schnabolk, Gloriane
Coughlin, Beth
Joseph, Kusumam
Kunchithapautham, Kannan
Bandyopadhyay, Mausumi
O'Quinn, Elizabeth C.
Nowling, Tamara
Rohrer, Baerbel
TI Local Production of the Alternative Pathway Component Factor B Is
Sufficient to Promote Laser-Induced Choroidal Neovascularization
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE alternative complement pathway; complement factor B; RPE-specific
transgenic mouse; choroidal neovascularization; age-related macular
degeneration
ID COMPLEMENT FACTOR-H; PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION;
OXIDATIVE STRESS; MEDIATED INJURY; LECTIN PATHWAY; MOUSE MODEL; AGE;
ACTIVATION; RISK
AB PURPOSE. Complement factor B (CFB) is a required component of the alternative pathway (AP) of complement, and CFB polymorphisms are associated with age-related macular degeneration (AMD) risk. Complement factor B is made in the liver, but expression has also been detected in retina and retinal pigment epithelium (RPE)-choroid. We investigated whether production of CFB by the RPE can promote AP activation in mouse choroidal neovascularization (CNV).
METHODS. Transgenic mice expressing CFB under the RPE65 promoter were generated and crossed onto factor B-deficient (CFB-KO) mice. Biological activity was determined in vitro using RPE monolayers and in vivo using laser-induced CNV. Contribution of systemic CFB was investigated using CFB-KO reconstituted with CFB-sufficient serum.
RESULTS. Transgenic mice (CFB-tg) expressed CFB in RPE-choroid; no CFB was detected in serum. Cultured CFB-tg RPE monolayers secreted CFB apically and basally upon exposure to oxidative stress that was biologically active. Choroidal neovascularization sizes were comparable between wild-type and CFB-tg mice, but significantly increased when compared to lesions in CFB-KO mice. Injections of CFB-sufficient serum into CFB-KO mice resulted in partial reconstitution of systemic AP activity and significantly increased CNV size.
CONCLUSIONS. Mouse RPE cells express and secrete CFB sufficient to promote RPE damage and CNV. This further supports that local complement production may regulate disease processes; however, the reconstitution experiments suggest that additional components may be sequestered from the bloodstream. Understanding the process of ocular complement production and regulation will further our understanding of the AMD disease process and the requirements of a complement-based therapeutic.
C1 [Schnabolk, Gloriane; Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA.
[Coughlin, Beth; Joseph, Kusumam; Kunchithapautham, Kannan; Bandyopadhyay, Mausumi; O'Quinn, Elizabeth C.; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
[Nowling, Tamara] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA.
RP Rohrer, B (reprint author), Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM rohrer@musc.edu
FU National Institutes of Health (NIH) [R01EY019320]; Department for
Veteran Affairs Merit Award [RX000444]; Beckman Initiative for Macular
Research; Medical University of South Carolina from Research to Prevent
Blindness (RPB), New York, New York, United States; NIH [C06RR015455];
[AR053376]; [R03-NIAMS]
FX Supported in the laboratory of BR in part by the National Institutes of
Health (NIH R01EY019320); Department for Veteran Affairs Merit Award
RX000444; the Beckman Initiative for Macular Research; an unrestricted
grant to the Medical University of South Carolina from Research to
Prevent Blindness (RPB), New York, New York, United States; and in the
laboratory of TN by Grant AR053376 (R03-NIAMS). Animal studies were
conducted in a facility constructed with support from NIH C06RR015455.
NR 50
TC 3
Z9 3
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2015
VL 56
IS 3
BP 1850
EP 1863
DI 10.1167/iovs.14-15910
PG 14
WC Ophthalmology
SC Ophthalmology
GA CE9BF
UT WOS:000352137600057
PM 25593023
ER
PT J
AU Jalbert, JJ
Nguyen, LL
Gerhard-Herman, MD
Jaff, MR
White, CJ
Rothman, AT
Seeger, JD
Kumamaru, H
Williams, LA
Chen, CY
Liu, J
Tsai, TT
Aronow, HD
Johnston, JA
Brott, TG
Setoguchi, S
AF Jalbert, Jessica J.
Nguyen, Louis L.
Gerhard-Herman, Marie D.
Jaff, Michael R.
White, Christopher J.
Rothman, Andrew T.
Seeger, John D.
Kumamaru, Hiraku
Williams, Lauren A.
Chen, Chih-Ying
Liu, Jun
Tsai, Thomas T.
Aronow, Herbert D.
Johnston, Joseph A.
Brott, Thomas G.
Setoguchi, Soko
TI Outcomes After Carotid Artery Stenting in Medicare Beneficiaries, 2005
to 2009
SO JAMA NEUROLOGY
LA English
DT Article
ID LEAD-IN PHASE; REVASCULARIZATION ENDARTERECTOMY; SUBGROUP ANALYSIS;
CLINICAL-TRIAL; 30-DAY STROKE; RISK-FACTORS; DEATH RATES; ANGIOPLASTY;
STENOSIS; REGISTRY
AB IMPORTANCE Despite increased carotid artery stenting (CAS) dissemination following the 2005 National Coverage Determination, to our knowledge, periprocedural and long-term outcomes have not been described among Medicare beneficiaries.
OBJECTIVE To describe the incidence of outcomes during and after the periprocedural period among Medicare beneficiaries undergoing CAS.
DESIGN, SETTING, AND PARTICIPANTS Observational study with a mean follow-up time of approximately 2 years among 22 516 fee-for-service Medicare beneficiaries at least 66 years old undergoing CAS (2005-2009) who were linked to the Centers for Medicare & Medicaid Services' CAS database. Database procedure dates were required to fall during a Medicare hospitalization for CAS.
MAIN OUTCOMES AND MEASURES Periprocedural (30-day) and long-term risks of mortality and stroke or transient ischemic attack, as well as periprocedural myocardial infarction. Subgroups were based on sociodemographic, clinical, and center-level factors, as well as the Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial or Carotid Revascularization Endarterectomy vs Stenting Trial (CREST) enrollment criteria.
RESULTS The mean patient age was 76.3 years, 60.5% were male, 93.8% were of white race, 91.2% were at high surgical risk, 47.4% were symptomatic, and 97.4% had carotid stenosis of at least 70%. Crude 30-day mortality, stroke or transient ischemic attack, and myocardial infarction risks were 1.7%(95% CI, 1.5%-1.8%), 3.3%(95% CI, 3.0%-3.5%), and 2.5%(95% CI, 2.3%-2.7%), respectively. Mortality during a mean follow-up time of 2 years was 32.0% (95% CI, 31.0%-33.0%), with rates of 37.3%(95% CI, 35.8%-38.7%) among symptomatic patients and 27.7%(95% CI, 26.4%-28.9%) among asymptomatic patients. Older age, symptomatic carotid stenosis, and nonelective hospital admission were associated with increased adjusted hazards of mortality and stroke or transient ischemic attack during and after the periprocedural period. The presence of a stroke center, government ownership, and a hospital bed capacity of 500 or more were associated with increased adjusted hazards of periprocedural mortality and stroke or transient ischemic attack. Few patients met the SAPPHIRE trial or CREST enrollment criteria primarily because physicians did not meet proficiency requirements either due to exceeding periprocedural complication trial thresholds or not meeting minimum CAS volume requirements.
CONCLUSIONS AND RELEVANCE Competing risks may limit the benefits of CAS in certain Medicare beneficiaries, particularly among older and symptomatic patients who have higher periprocedural and long-term mortality risks. The generalizability of trials like the SAPPHIRE or CREST to the Medicare population may be limited, underscoring the need to evaluate real-world effectiveness of carotid stenosis treatments.
C1 [Jalbert, Jessica J.; Rothman, Andrew T.; Seeger, John D.; Kumamaru, Hiraku; Williams, Lauren A.; Chen, Chih-Ying; Liu, Jun; Setoguchi, Soko] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol, Boston, MA 02115 USA.
[Jalbert, Jessica J.] LASER ANALYT, New York, NY USA.
[Nguyen, Louis L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Vasc & Endovasc Surg, Boston, MA 02115 USA.
[Gerhard-Herman, Marie D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med, Boston, MA 02115 USA.
[Jaff, Michael R.] Massachusetts Gen Hosp, Div Cardiovasc Med, Boston, MA 02114 USA.
[White, Christopher J.] Ochsner Med Ctr, Ochsner Clin Sch, New Orleans, LA USA.
[Seeger, John D.] Optumlnsight Epidemiol, Waltham, MA USA.
[Tsai, Thomas T.] Univ Colorado, Denver Vet Affairs Med Ctr, Div Cardiol, Denver, CO 80202 USA.
[Aronow, Herbert D.] St Joseph Mercy Ann Arbor, Div Cardiovasc Med, Ann Arbor, MI USA.
[Johnston, Joseph A.] Eli Lilly & Co, Lilly Res Labs, Global Hlth Outcomes, Indianapolis, IN 46285 USA.
[Brott, Thomas G.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
[Setoguchi, Soko] Duke Clin Res Inst, Dept Med, Durham, NC USA.
RP Setoguchi, S (reprint author), Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA.
EM soko@post.harvard.edu
RI White, Christopher/J-6686-2012
OI White, Christopher/0000-0001-8618-7539
FU Agency for Healthcare Research and Quality, US Department of Health and
Human Services, as part of the Developing Evidence to Inform Decisions
About Effectiveness Network [HHSA290-2005-0016-I-T08]; Centers for
Medicare & Medicaid Services, US Department of Health and Human Services
[500-2010-00001I-T06, 500-2010-00001I T02]
FX This project is funded by contract HHSA290-2005-0016-I-T08 from the
Agency for Healthcare Research and Quality, US Department of Health and
Human Services, as part of the Developing Evidence to Inform Decisions
About Effectiveness Network and by interagency agreement contract
500-2010-00001I-T06 and carotid endarterectomy contract 500-2010-00001I
T02 from the Centers for Medicare & Medicaid Services, US Department of
Health and Human Services.
NR 39
TC 16
Z9 17
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6149
EI 2168-6157
J9 JAMA NEUROL
JI JAMA Neurol.
PD MAR
PY 2015
VL 72
IS 3
BP 276
EP 286
DI 10.1001/jamaneurol.2014.3638
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA CE9IJ
UT WOS:000352157200007
PM 25580726
ER
PT J
AU Fleisher, AS
Chen, KW
Quiroz, YT
Jakimovich, LJ
Gomez, MG
Langois, CM
Langbaum, JBS
Roontiva, A
Thiyyagura, P
Lee, W
Ayutyanont, N
Lopez, L
Moreno, S
Munoz, C
Tirado, V
Acosta-Baena, N
Fagan, AM
Giraldo, M
Garcia, G
Huentelman, MJ
Tariot, PN
Lopera, F
Reiman, EM
AF Fleisher, Adam S.
Chen, Kewei
Quiroz, Yakeel T.
Jakimovich, Laura J.
Gutierrez Gomez, Madelyn
Langois, Carolyn M.
Langbaum, Jessica B. S.
Roontiva, Auttawut
Thiyyagura, Pradeep
Lee, Wendy
Ayutyanont, Napatkamon
Lopez, Liliana
Moreno, Sonia
Munoz, Claudia
Tirado, Victoria
Acosta-Baena, Natalia
Fagan, Anne M.
Giraldo, Margarita
Garcia, Gloria
Huentelman, Matthew J.
Tariot, Pierre N.
Lopera, Francisco
Reiman, Eric M.
TI Associations Between Biomarkers and Age in the Presenilin 1 E280A
Autosomal Dominant Alzheimer Disease Kindred A Cross-sectional Study
SO JAMA NEUROLOGY
LA English
DT Article
ID AMYLOID-BETA DEPOSITION; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE;
MUTATION CARRIERS; APOLIPOPROTEIN-E; BRAIN; MRI; RECOMMENDATIONS;
WORKGROUPS; DEMENTIA
AB IMPORTANCE Age-associated changes in brain imaging and fluid biomarkers are characterized and compared in presenilin 1 (PSEN1) E280A mutation carriers and noncarriers from the world's largest known autosomal dominant Alzheimer disease (AD) kindred.
OBJECTIVE To characterize and compare age-associated changes in brain imaging and fluid biomarkers in PSEN1 E280A mutation carriers and noncarriers.
DESIGN, SETTING, AND PARTICIPANTS Cross-sectional measures of F-18-florbetapir positron emission tomography, F-18-fludeoxyglucose positron emission tomography, structural magnetic resonance imaging, cerebrospinal fluid (CSF), and plasma biomarkers of AD were assessed from 54 PSEN1 E280A kindred members (age range, 20-59 years).
MAIN OUTCOMES AND MEASURES We used brain mapping algorithms to compare regional cerebral metabolic rates for glucose and gray matter volumes in cognitively unimpaired mutation carriers and noncarriers. We used regression analyses to characterize associations between age and the mean cortical to pontine F-18-florbetapir standard uptake value ratios, precuneus cerebral metabolic rates for glucose, hippocampal gray matter volume, CSF A beta 1-42, total tau and phosphorylated tau(181), and plasma A beta measurements. Age at onset of progressive biomarker changes that distinguish carriers from noncarriers was estimated using best-fitting regression models.
RESULTS Compared with noncarriers, cognitively unimpaired mutation carriers had significantly lower precuneus cerebral metabolic rates for glucose, smaller hippocampal volume, lower CSF A beta 1-42, higher CSF total tau and phosphorylated tau(181), and higher plasma A beta 1-42 measurements. Sequential changes in biomarkers were seen at age 20 years (95% CI, 14-24 years) for CSF A beta 1-42, age 16 years (95% CI, 11-24 years) for the mean cortical F-18-florbetapir standard uptake value ratio, age 15 years (95% CI, 10-24 years) for precuneus cerebral metabolic rate for glucose, age 15 years (95% CI, 7-20 years) for CSF total tau, age 13 years (95% CI, 8-19 years) for phosphorylated tau181, and age 6 years (95% CI, 1-10 years) for hippocampal volume, with cognitive decline up to 6 years before the kindred's estimated median age of 44 years (95% CI, 43-45 years) at mild cognitive impairment diagnosis. No age-associated findings were seen in plasma A beta 1-42 or A beta 1-40.
CONCLUSIONS AND RELEVANCE This cross-sectional study provides additional information about the course of different AD biomarkers in the preclinical and clinical stages of autosomal dominant AD.
C1 [Fleisher, Adam S.] Eli Lilly & Co, Indianapolis, IN 46285 USA.
[Fleisher, Adam S.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Fleisher, Adam S.; Chen, Kewei; Langbaum, Jessica B. S.; Roontiva, Auttawut; Thiyyagura, Pradeep; Lee, Wendy; Ayutyanont, Napatkamon; Huentelman, Matthew J.; Tariot, Pierre N.; Reiman, Eric M.] Arizona Alzheimers Consortium, Phoenix, AZ USA.
[Fleisher, Adam S.; Chen, Kewei; Jakimovich, Laura J.; Langois, Carolyn M.; Langbaum, Jessica B. S.; Roontiva, Auttawut; Thiyyagura, Pradeep; Lee, Wendy; Ayutyanont, Napatkamon; Tariot, Pierre N.; Reiman, Eric M.] Banner Alzheimers Inst, Phoenix, AZ USA.
[Chen, Kewei] Arizona State Univ, Dept Math & Stat, Tempe, AZ USA.
[Quiroz, Yakeel T.; Huentelman, Matthew J.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Quiroz, Yakeel T.; Gutierrez Gomez, Madelyn; Lopez, Liliana; Moreno, Sonia; Munoz, Claudia; Tirado, Victoria; Acosta-Baena, Natalia; Giraldo, Margarita; Garcia, Gloria; Lopera, Francisco] Univ Antioquia, Grp Neurociencias, Medellin, Colombia.
[Fagan, Anne M.] Washington Univ Sch Med, Dept Neurol, St Louis, MO USA.
[Tariot, Pierre N.; Reiman, Eric M.] Univ Arizona, Dept Psychiat, Phoenix, AZ USA.
[Reiman, Eric M.] Translat Genom Res Inst, Div Neurogen, Phoenix, AZ USA.
RP Fleisher, AS (reprint author), Banner Alzheimers Inst, 901 E Willetta St, Phoenix, AZ 85006 USA.
EM adam.fleisher@bannerhealth.com
FU Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly and
Company); FIL Foundation; Banner Alzheimer's Foundation; Avid
Radiopharmaceuticals; Nomis Foundation; Forget Me Not Initiative;
Colciencias; Universidad de Antioquia [111554531651]; National Institute
on Aging [RO1 AG031581, P30 AG19610, U19 AG03243806, RF1 AG041705,
RO1AG041232]; State of Arizona
FX 18F-florbetapir positron emission tomography data were
acquired with financial support from Avid Radiopharmaceuticals (a wholly
owned subsidiary of Eli Lilly and Company) as noted in our group's
previous study.5 This study was supported by the FIL
Foundation, Banner Alzheimer's Foundation, Avid Radiopharmaceuticals,
Nomis Foundation, Forget Me Not Initiative, Colciencias, grant
111554531651 from the Universidad de Antioquia, and grants RO1 AG031581,
P30 AG19610, U19 AG03243806, RF1 AG041705, and RO1AG041232 from the
National Institute on Aging and the State of Arizona.
NR 35
TC 21
Z9 21
U1 2
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6149
EI 2168-6157
J9 JAMA NEUROL
JI JAMA Neurol.
PD MAR
PY 2015
VL 72
IS 3
BP 316
EP 324
DI 10.1001/jamaneurol.2014.3314
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA CE9IJ
UT WOS:000352157200012
PM 25580592
ER
PT J
AU Kaup, AR
Nettiksimmons, J
Harris, TB
Sink, KM
Satterfield, S
Metti, AL
Ayonayon, HN
Yaffe, K
AF Kaup, Allison R.
Nettiksimmons, Jasmine
Harris, Tamara B.
Sink, Kaycee M.
Satterfield, Suzanne
Metti, Andrea L.
Ayonayon, Hilsa N.
Yaffe, Kristine
CA Hlth Aging Body Composition Hlth
TI Cognitive Resilience to Apolipoprotein E epsilon 4 Contributing Factors
in Black and White Older Adults
SO JAMA NEUROLOGY
LA English
DT Article
ID ALZHEIMER-DISEASE; AFRICAN-AMERICANS; BODY-COMPOSITION; VARIABLE
IMPORTANCE; METABOLIC SYNDROME; RANDOM FORESTS; APOE GENOTYPE;
RISK-FACTORS; DEMENTIA; COMMUNITY
AB IMPORTANCE Apolipoprotein E (APOE) epsilon 4 is an established risk factor for cognitive decline and the development of dementia, but other factors may help to minimize its effects.
OBJECTIVE Using APOE epsilon 4 as an indicator of high risk, we investigated factors associated with cognitive resilience among black and white older adults who are APOE epsilon 4 carriers.
DESIGN, SETTING, AND PARTICIPANTS Participants included 2487 community-dwelling older (aged 69-80 years at baseline) black and white adults examined at 2 community clinics in the prospective cohort Health, Aging, and Body Composition (Health ABC) study. The baseline visits occurred from May 1997 through June 1998. Our primary analytic cohort consisted of 670 APOE epsilon 4 carriers (329 black and 341 white participants) who were free of cognitive impairment at baseline and underwent repeated cognitive testing during an 11-year follow-up (through 2008) using the Modified Mini-Mental State Examination.
MAIN OUTCOMES AND MEASURES We stratified all analyses by race. Using the Modified Mini-Mental State Examination scores, we assessed normative cognitive change in the entire cohort (n = 2487) and classified the APOE epsilon 4 carriers as being cognitively resilient vs nonresilient by comparing their cognitive trajectories with those of the entire cohort. We then conducted bivariate analyses and multivariable random forest and logistic regression analyses to explore factors predictive of cognitive resilience in APOE epsilon 4 carriers.
RESULTS Among white APOE epsilon 4 carriers, the strongest predictors of cognitive resilience were, in relative order of importance, no recent negative life events, a higher literacy level, advanced age, a higher educational level, and more time spent reading. Among black APOE epsilon 4 carriers, the strongest predictors of cognitive resilience were, in relative order of importance, a higher literacy level, a higher educational level, female sex, and the absence of diabetes mellitus. In follow-up logistic regression models, higher literacy level (adjusted odds ratio [OR], 9.50 [95% CI, 2.67-60.89]), a higher educational level (adjusted OR for college graduate vs less than high school, 3.81 [95% CI, 1.13-17.56]), and age (adjusted OR for 73-76 vs 69-72 years, 2.01 [95% CI, 1.13-3.63]) had significant independent effects in predicting cognitive resilience among white APOE epsilon 4 carriers. Among black APOE epsilon 4 carriers, a higher literacy level (adjusted OR, 2.27 [95% CI, 1.29-4.06]) and a higher educational level (adjusted OR for high school graduate/some college vs less than high school, 2.86 [95% CI, 1.54-5.49]; adjusted OR for college graduate vs less than high school, 2.52 [95% CI, 1.14-5.62]) had significant independent effects in predicting cognitive resilience.
CONCLUSIONS AND RELEVANCE Although APOE epsilon 4 carriers are at high risk for cognitive decline, our findings suggest possible intervention targets, including the enhancement of cognitive reserve and improvement of other psychosocial and health factors, to promote cognitive resilience among black and white APOE epsilon 4 carriers.
C1 [Kaup, Allison R.; Yaffe, Kristine] San Francisco VA Med Ctr, Sierra Pacific Mental Illness Res Educ & Clin Ctr, San Francisco, CA 94121 USA.
[Kaup, Allison R.; Nettiksimmons, Jasmine; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Harris, Tamara B.] NIA, Lab Epidemiol & Populat Sci, Intramural Res Program, Bethesda, MD 20892 USA.
[Sink, Kaycee M.] Wake Forest Sch Med, Dept Med, Sect Gerontol & Geriatr Med, Winston Salem, NC USA.
[Satterfield, Suzanne] Univ Tennessee Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA.
[Metti, Andrea L.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Ayonayon, Hilsa N.; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
RP Kaup, AR (reprint author), San Francisco VA Med Ctr, Sierra Pacific Mental Illness Res Educ & Clin Ctr, 4150 Clement St,Mail Code T16H, San Francisco, CA 94121 USA.
EM allison.kaup@ucsf.edu
FU NIA [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050,
K24AG031155]; National Institute on Nursing Research [R01-NR012459];
NIA/NIH; Department of Veterans Affairs Office of Academic Affiliations
Advanced Fellowship Program in Mental Illness Research and Treatment;
Medical Research Service of the San Francisco Veterans Affairs Medical
Center; Sierra Pacific Mental Illness Research, Education, and Clinical
Center
FX This study was supported by contracts N01-AG-6-2101, N01-AG-6-2103, and
N01-AG-6-2106 and grant R01-AG028050 from the NIA; by grant R01-NR012459
from the National Institute on Nursing Research; and in part by the
Intramural Research Program of the NIA/NIH, all of which supported the
design and conduct of the study; collection, management, analysis, and
interpretation of the data; and review and approval of the manuscript.
This study was also supported by grant K24AG031155 from the NIA (Dr
Yaffe), which supported the design and conduct of the study, analysis
and interpretation of the data, preparation and review of the
manuscript, and decision to submit the manuscript for publication.
Preparation of the manuscript was supported by the Department of
Veterans Affairs Office of Academic Affiliations Advanced Fellowship
Program in Mental Illness Research and Treatment, the Medical Research
Service of the San Francisco Veterans Affairs Medical Center, and the
Sierra Pacific Mental Illness Research, Education, and Clinical Center.
NR 38
TC 5
Z9 5
U1 1
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6149
EI 2168-6157
J9 JAMA NEUROL
JI JAMA Neurol.
PD MAR
PY 2015
VL 72
IS 3
BP 340
EP 348
DI 10.1001/jamaneurol.2014.3978
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA CE9IJ
UT WOS:000352157200015
PM 25599330
ER
PT J
AU Etherton, MR
Neagu, MR
Oakley, DH
Koch, MJ
Shin, JH
Frosch, MP
Berkowitz, AL
Dietrich, J
AF Etherton, Mark R.
Neagu, Martha R.
Oakley, Derek H.
Koch, Matthew J.
Shin, John H.
Frosch, Matthew P.
Berkowitz, Aaron L.
Dietrich, Jorg
TI A 20-Year-Old Man With Back Pain and Lower Extremity Weakness
SO JAMA NEUROLOGY
LA English
DT Article
ID SPINAL-CORD TUMORS; GLIOBLASTOMA-MULTIFORME; MYELITIS
AB A 20-year-old man presented with 1 week of low back pain and progressive lower extremity weakness. Results of cerebrospinal fluid analysis demonstrated elevated total protein and a mildly elevated white blood cell count with lymphocytic predominance. Findings from imaging studies revealed a multifocal, heterogeneously enhancing, intramedullary lesion involving the cervicothoracic spinal cord and nodular enhancement of the cauda equina. The patient eventually underwent spinal surgery for tissue diagnosis. The differential diagnosis, pathologic findings, and diagnosis are discussed.
C1 [Etherton, Mark R.; Neagu, Martha R.; Dietrich, Jorg] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Etherton, Mark R.; Neagu, Martha R.; Berkowitz, Aaron L.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Etherton, Mark R.; Neagu, Martha R.; Oakley, Derek H.; Koch, Matthew J.; Shin, John H.; Frosch, Matthew P.; Berkowitz, Aaron L.; Dietrich, Jorg] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Oakley, Derek H.; Frosch, Matthew P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Koch, Matthew J.; Shin, John H.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Dietrich, Jorg] Massachusetts Gen Hosp, Div Neurooncol, Boston, MA 02114 USA.
RP Etherton, MR (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St,WACC 720, Boston, MA 02114 USA.
EM metherton@partners.org
NR 14
TC 0
Z9 0
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6149
EI 2168-6157
J9 JAMA NEUROL
JI JAMA Neurol.
PD MAR
PY 2015
VL 72
IS 3
BP 363
EP 366
DI 10.1001/jamaneurol.2014.3833
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA CE9IJ
UT WOS:000352157200018
PM 25621865
ER
PT J
AU Sakanaka, T
Inoue, T
Yorifuji, N
Iguchi, M
Fujiwara, K
Narabayashi, K
Kakimoto, K
Nouda, S
Okada, T
Kuramoto, T
Ishida, K
Abe, Y
Takeuchi, T
Umegaki, E
Akiba, Y
Kaunitz, JD
Higuchi, K
AF Sakanaka, Taisuke
Inoue, Takuya
Yorifuji, Naoki
Iguchi, Munetaka
Fujiwara, Kaori
Narabayashi, Ken
Kakimoto, Kazuki
Nouda, Sadaharu
Okada, Toshihiko
Kuramoto, Takanori
Ishida, Kumi
Abe, Yosuke
Takeuchi, Toshihisa
Umegaki, Eiji
Akiba, Yasutada
Kaunitz, Jonathan D.
Higuchi, Kazuhide
TI The effects of a TGR5 agonist and a dipeptidyl peptidase IV inhibitor on
dextran sulfate sodium-induced colitis in mice
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article; Proceedings Paper
CT 15th Taishotoyama International Symposium on Gastroenterology
CY SEP 26-28, 2013
CL Tokyo, JAPAN
DE dextran sulfate sodium; DPPIV; GLP-2; sitagliptin; TGR5
ID L CELLS; EXPRESSION; SECRETION; ACID; LOCALIZATION; RAT
AB Background and AimLuminal nutrients stimulate enteroendocrine L cells to release gut hormones, including intestinotrophic glucagon-like peptide-2 (GLP-2). Because L cells express the bile acid receptor TGR5 and dipeptidyl peptidase-IV (DPPIV) rapidly degrades GLPs, we hypothesized that luminal TGR5 activation may attenuate intestinal injury via GLP-2 release, which is enhanced by DPPIV inhibition.
MethodsIntestinal injury was induced in mice by administration of dextran sulfate sodium (DSS) in drinking water (free access to water containing 5% DSS for 7 days). The selective TGR5 agonist betulinic acid (BTA) and the DPPIV inhibitor sitagliptin phosphate monohydrate (STG) were administered orally for 7 days. Male C57BL/6 mice (6-7 weeks old) were divided into five groups: normal control group, disease control group, BTA low group (drinking water containing 15mg/L BTA), BTA high group (50mg/L BTA), and BTA high+STG (3mg/kg, i.g.) group.
ResultsThe selective TGR5 agonist BTA dose-dependently suppressed disease activity index and mRNA expression of the pro-inflammatory cytokines interleukin (IL)-1, IL-6, and tumor necrosis factor- in the colon. Nevertheless, STG administration had little additive effect on BTA-induced protection. Fibroblast activation protein mRNA expression, but not expression of other DPP family members, was increased in the colon of DSS-treated mice with increased mucosal DPPIV. Co-administration of the selective GLP-2 antagonist GLP-2 (3-33) reversed the effect of BTA.
ConclusionThe selective TGR5 agonist BTA ameliorated DSS-induced colitis in mice via the GLP-2 pathway with no effect of DPPIV inhibition, suggesting that other DPP enzymatic activity is involved in GLP-2 degradation.
C1 [Sakanaka, Taisuke; Inoue, Takuya; Yorifuji, Naoki; Iguchi, Munetaka; Fujiwara, Kaori; Narabayashi, Ken; Kakimoto, Kazuki; Nouda, Sadaharu; Okada, Toshihiko; Kuramoto, Takanori; Ishida, Kumi; Abe, Yosuke; Takeuchi, Toshihisa; Umegaki, Eiji; Higuchi, Kazuhide] Osaka Med Coll, Dept Internal Med 2, Takatsuki, Osaka 5698686, Japan.
[Akiba, Yasutada; Kaunitz, Jonathan D.] Univ Calif Los Angeles, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
EM ureuretakuwan@yahoo.co.jp
FU Intramural VA [VA999999]; NIDDK NIH HHS [R01 DK054221, P30 DK041301]
NR 27
TC 5
Z9 5
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
EI 1440-1746
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD MAR
PY 2015
VL 30
SU 1
SI SI
BP 60
EP 65
DI 10.1111/jgh.12740
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CF0IU
UT WOS:000352227600013
PM 25827806
ER
PT J
AU Fung, V
Price, M
Busch, AB
Nierenberg, A
Landrum, MB
Ongur, D
Newhouse, JP
Hsu, J
AF Fung, Vicki
Price, Mary
Busch, Alisa B.
Nierenberg, Andrew
Landrum, Mary Beth
Ongur, Dost
Newhouse, Joseph P.
Hsu, John
TI Medicare Mental Health Cost-sharing Parity and Quality of Care for
Beneficiaries with Schizophrenia
SO JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT CTR MENTAL HEALTH POLICY & ECONOMICS-ICMPE
PI MILANO
PA VIA DANIELE CRESPI 7, MILANO, 20123, ITALY
SN 1091-4358
J9 J MENT HEALTH POLICY
JI J. Ment. Health Policy Econ.
PD MAR
PY 2015
VL 18
SU 1
BP S14
EP S14
PG 1
WC Health Policy & Services; Psychiatry
SC Health Care Sciences & Services; Psychiatry
GA CF4LX
UT WOS:000352521700029
ER
PT J
AU Hodgkin, D
Merrick, EL
O'Brien, P
Lee, S
Deckersbach, T
Nierenberg, AA
AF Hodgkin, Dominic
Merrick, Elizabeth L.
O'Brien, Peggy
Lee, Sue
Deckersbach, Thilo
Nierenberg, Andrew A.
TI The Extent and Predictors of Clinical Inertia in Medication Treatment of
Bipolar Disorder
SO JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS
LA English
DT Meeting Abstract
C1 [Hodgkin, Dominic; Merrick, Elizabeth L.; O'Brien, Peggy; Lee, Sue] Brandeis Univ, Heller Sch Social Policy & Management, Inst Behav Hlth, Waltham, MA USA.
[Deckersbach, Thilo; Nierenberg, Andrew A.] Massachusetts Gen Hosp, Bipolar Clin & Res Program, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU INT CTR MENTAL HEALTH POLICY & ECONOMICS-ICMPE
PI MILANO
PA VIA DANIELE CRESPI 7, MILANO, 20123, ITALY
SN 1091-4358
J9 J MENT HEALTH POLICY
JI J. Ment. Health Policy Econ.
PD MAR
PY 2015
VL 18
SU 1
BP S21
EP S21
PG 1
WC Health Policy & Services; Psychiatry
SC Health Care Sciences & Services; Psychiatry
GA CF4LX
UT WOS:000352521700044
ER
PT J
AU Hsu, J
Huang, J
Fireman, B
Singer, D
Ongur, D
Fang, V
AF Hsu, John
Huang, Jie
Fireman, Bruce
Singer, Danny
Ongur, Dost
Fang, Vicki
TI Adherence to Psychotropic and Medical Therapy among Patients with Severe
Mental Illnesses: Being of Two Minds?
SO JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS
LA English
DT Meeting Abstract
C1 [Hsu, John; Huang, Jie; Fireman, Bruce; Singer, Danny; Ongur, Dost; Fang, Vicki] Harvard Univ, Massachusetts Gen Hosp, McLean Hosp, Sch Med,Kaiser Fdn Res Inst, Cambridge, MA 02138 USA.
FU [R01MH090284]; [R01MH104560]
FX R01MH090284, R01MH104560.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT CTR MENTAL HEALTH POLICY & ECONOMICS-ICMPE
PI MILANO
PA VIA DANIELE CRESPI 7, MILANO, 20123, ITALY
SN 1091-4358
J9 J MENT HEALTH POLICY
JI J. Ment. Health Policy Econ.
PD MAR
PY 2015
VL 18
SU 1
BP S22
EP S23
PG 2
WC Health Policy & Services; Psychiatry
SC Health Care Sciences & Services; Psychiatry
GA CF4LX
UT WOS:000352521700046
ER
PT J
AU Hsu, J
Price, M
Ongur, D
Busch, A
New-House, J
Fung, V
AF Hsu, John
Price, Maggie
Ongur, Dost
Busch, Alisa
New-house, Joseph
Fung, Vicki
TI Whither and To Whom Must I Wander: Geographic Distribution of Mental
Health Provider Supply and the Role of Non-Physician Providers
SO JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS
LA English
DT Meeting Abstract
C1 [Hsu, John; Price, Maggie; Ongur, Dost; Busch, Alisa; New-house, Joseph; Fung, Vicki] Harvard Univ, Massachusetts Gen Hosp, McLean Hosp, Sch Med, Cambridge, MA 02138 USA.
FU [R01MH090284]; [R01MH104560]; [P01AG032952]
FX R01MH090284, R01MH104560, P01AG032952.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT CTR MENTAL HEALTH POLICY & ECONOMICS-ICMPE
PI MILANO
PA VIA DANIELE CRESPI 7, MILANO, 20123, ITALY
SN 1091-4358
J9 J MENT HEALTH POLICY
JI J. Ment. Health Policy Econ.
PD MAR
PY 2015
VL 18
SU 1
BP S23
EP S23
PG 1
WC Health Policy & Services; Psychiatry
SC Health Care Sciences & Services; Psychiatry
GA CF4LX
UT WOS:000352521700047
ER
PT J
AU Eaton, JL
Mohr, DC
Gallarde, S
Hodgson, MJ
AF Eaton, Jennifer L.
Mohr, David C.
Gallarde, Sheryl
Hodgson, Michael J.
TI Impact of Clinical Quality on Employee Choice of Providers for Workers'
Compensation-Related Medical Care
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID SPECIALTY BOARD CERTIFICATION; HEALTH-CARE; OCCUPATIONAL-MEDICINE; COST;
OUTCOMES; PROGRAM; RETURN
AB Objective: The study examined the relationship between onsite occupational health practice characteristics, provider choice, and workers' compensation outcome metrics. Methods: Cross-sectional survey of 140 medical center occupational health clinics within the Department of Veterans Affairs. Multivariate regression models examined how specific clinical quality factors influenced provider choice and workers' compensation measures. Results: Several practice characteristics were associated with higher rates of in-house care selection-longer hours of operation, greater availability of workers' compensation-related medical services, clinic administration by a board certified physician, physician tenure, and adherence to clinical practice guidelines. Access to onsite, occupational and environmental medicine certified physician-directed care was associated with reductions in disability duration among injured healthcare workers. Conclusions: These findings suggest that occupational medicine board certification can positively impact provider choice among fully insured patients, which may have implications for other healthcare systems.
C1 [Eaton, Jennifer L.] Vet Hlth Adm, Off Publ Hlth, Occupat Hlth Grp, Washington, DC 20006 USA.
[Eaton, Jennifer L.] VA Med Ctr, War Related Illness & Injury Study Ctr, Washington, DC USA.
[Mohr, David C.] VA Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res, Dept Vet Affairs, Boston, MA USA.
[Mohr, David C.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA.
[Gallarde, Sheryl] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Eaton, JL (reprint author), Vet Hlth Adm, Off Publ Hlth, Occupat Hlth Grp, 1717 H St NW Rm 504, Washington, DC 20006 USA.
EM Jennifer.Lipkowitz-Eaton@va.gov
FU Veterans Health Administration
FX This work was supported by operational funds in the Veterans Health
Administration.
NR 27
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1076-2752
EI 1536-5948
J9 J OCCUP ENVIRON MED
JI J. Occup. Environ. Med.
PD MAR
PY 2015
VL 57
IS 3
SU S
BP S31
EP S35
DI 10.1097/JOM.0000000000000387
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CF4GO
UT WOS:000352507000006
PM 25741612
ER
PT J
AU Turner, PV
Pekow, C
Clark, JM
Vergara, P
Bayne, K
White, WJ
Kurosawa, TM
Seok, SH
Baneux, P
AF Turner, Patricia V.
Pekow, Cynthia
Clark, Judy MacArthur
Vergara, Patri
Bayne, Kathryn
White, William J.
Kurosawa, Tsutomu Miki
Seok, Seung-Hyeok
Baneux, Philippe
TI Roles of the International Council for Laboratory Animal Science (ICLAS)
and International Association of Colleges of Laboratory Animal Medicine
(IACLAM) in the Global Organization and Support of 3Rs Advances in
Laboratory Animal Science
SO JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE
LA English
DT Article
ID VETERINARY-CARE; HARMONIZATION; GUIDELINES; NEEDS
AB Practical implementation of the 3Rs at national and regional levels around the world requires long-term commitment, backing, and coordinated efforts by international associations for laboratory animal medicine and science, including the International Association of Colleges of Laboratory Animal Medicine (IACLAM) and the International Council for Laboratory Animal Science (ICLAS). Together these organizations support the efforts of regional organization and communities of laboratory animal science professionals as well as the development of local associations and professional colleges that promote the training and continuing education of research facility personnel and veterinary specialists. The recent formation of a World Organization for Animal Health (OIE) Collaborating Center for Laboratory Animal Science and Welfare emphasizes the need for research into initiatives promoting laboratory animal welfare, particularly in emerging economies and regions with nascent associations of laboratory animal science.
C1 [Turner, Patricia V.] Univ Guelph, Dept Pathobiol, Guelph, ON N1G 2W1, Canada.
[Pekow, Cynthia] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA.
[Clark, Judy MacArthur] Home Off, Anim Sci Regulat Unit, London, England.
[Vergara, Patri] Autonomous Univ Barcelona, Fac Vet Med, Physiol Unit, Barcelona, Spain.
[Bayne, Kathryn] Assoc Assessment & Accreditat Lab Anim Care Int, Frederick, MD USA.
[White, William J.] Charles River, Vet & Profess Serv, Wilmington, MA USA.
[Kurosawa, Tsutomu Miki] Osaka Univ, Inst Expt Anim Sci, Dept Lab Anim Med, Osaka, Japan.
[Seok, Seung-Hyeok] Seoul Natl Univ, Dept Microbiol & Immunol, Seoul, South Korea.
[Baneux, Philippe] Cornell Univ, Cornell Ctr Anim Resources & Educ, Ithaca, NY USA.
RP Turner, PV (reprint author), Univ Guelph, Dept Pathobiol, Guelph, ON N1G 2W1, Canada.
EM pvturner@uoguelph.ca
RI Vergara, Patrocinio/M-6468-2013
OI Vergara, Patrocinio/0000-0002-9220-6406
NR 22
TC 3
Z9 3
U1 0
U2 2
PU AMER ASSOC LABORATORY ANIMAL SCIENCE
PI MEMPHIS
PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA
SN 1559-6109
J9 J AM ASSOC LAB ANIM
JI J. Amer. Assoc. Lab. Anim. Sci.
PD MAR
PY 2015
VL 54
IS 2
BP 174
EP 180
PG 7
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA CE8UJ
UT WOS:000352119300009
PM 25836964
ER
PT J
AU Friedlander, AH
Hazboun, RC
AF Friedlander, Arthur H.
Hazboun, Renna C.
TI ANTIBIOTICS AND IMPLANTS
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Editorial Material
C1 [Friedlander, Arthur H.] VA Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA 90073 USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Hosp Dent Serv, Oral & Maxillofacial Surg, Los Angeles, CA USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Hosp Dent Serv, Qual Assurance, Los Angeles, CA USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA.
[Hazboun, Renna C.] VA Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Res, Los Angeles, CA USA.
RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA 90073 USA.
NR 4
TC 0
Z9 0
U1 0
U2 1
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
EI 1943-4723
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD MAR
PY 2015
VL 146
IS 3
BP 146
EP 146
DI 10.1016/j.adaj.2015.01.008
PG 1
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA CE9GR
UT WOS:000352152600006
PM 25726341
ER
PT J
AU Tierney, ESS
Gauvreau, K
Jaff, MR
Gal, D
Nourse, SE
Trevey, S
O'Neill, S
Baker, A
Newburger, JW
Colan, SD
AF Tierney, Elif Seda Selamet
Gauvreau, Kimberlee
Jaff, Michael R.
Gal, Dana
Nourse, Susan E.
Trevey, Shari
O'Neill, Stephen
Baker, Annette
Newburger, Jane W.
Colan, Steven D.
TI Carotid Artery Intima-Media Thickness Measurements in the Youth:
Reproducibility and Technical Considerations
SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
LA English
DT Article
DE Carotid artery IMT; Youth; Reproducibility; Variability; Carotid artery
ultrasound; Atherosclerosis
ID LOW-DENSITY-LIPOPROTEIN; FAMILIAL HYPERCHOLESTEROLEMIA; WALL THICKNESS;
ENDOTHELIAL DYSFUNCTION; YOUNG-ADULTS; RISK-FACTORS; CHILDREN; DISEASE;
ATHEROSCLEROSIS; PROGRESSION
AB Background: Carotid artery intima-media thickness (CIMT), a marker of atherosclerosis, is increased in youth at risk for future cardiovascular disease. Some pediatric studies have used CIMT as a primary outcome in clinical trials, yet data are limited on the standardization of methodology in children. The goal of this study was to evaluate reproducibility of CIMT measurements using two different measurement techniques.
Methods: Carotid artery ultrasound studies of children and adolescents obtained as a component of a research study in Kawasaki syndrome were retrospectively analyzed. The CIMTs of both common carotid arteries (CCAs) were measured by one of two sonographers at the time in the cardiac cycle when resolution subjectively was determined to be optimal (Opt-CIMT). These sonographers blindly remeasured a random sample of studies of their own and each other's, using the same method. Another observer made CIMT measurements using exclusively frames on the R wave (R-CIMT). A fourth observer independently measured a random sample of studies twice with the R-CIMT method.
Results: Carotid artery images from 184 subjects (mean age, 14.7 +/- 2.2 years) were analyzed. The intraclass correlation coefficient for interobserver variability was 0.86 (95% confidence interval [CI], 0.69-0.94) compared with 0.85 (95% CI, 0.65-0.93) for the right and 0.86 (95% CI, 0.67-0.94) versus 0.95 (95% CI, 0.87-0.98) for the left CCA for Opt-CIMT and R-CIMT, respectively. R-CIMT was significantly thicker than Opt-CIMT (right CCA, 0.439 +/- 0.030 vs 0.428 +/- 0.024 mm, P < .001; left CCA, 0.446 +/- 0.030 vs 0.434 +/- 0.025 mm, P < .001).
Conclusion: Pediatric CIMT measurements have excellent reproducibility when the same methodology is applied but vary significantly throughout the cardiac cycle. This report highlights the need to standardize CIMT measurements in the youth and supports the use of electrocardiographic timing, as recommended in adults, in pediatric longitudinal studies.
C1 [Tierney, Elif Seda Selamet; Gauvreau, Kimberlee; Gal, Dana; Trevey, Shari; O'Neill, Stephen; Baker, Annette; Newburger, Jane W.; Colan, Steven D.] Childrens Hosp Boston, Dept Cardiol, Boston, MA USA.
[Tierney, Elif Seda Selamet; Gauvreau, Kimberlee; Gal, Dana; Trevey, Shari; O'Neill, Stephen; Baker, Annette; Newburger, Jane W.; Colan, Steven D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Tierney, Elif Seda Selamet; Nourse, Susan E.] Stanford Univ, Div Pediat Cardiol, Dept Pediat, Palo Alto, CA 94304 USA.
[Jaff, Michael R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Cardiol, Boston, MA USA.
RP Tierney, ESS (reprint author), Stanford Univ, Pediat Heart Ctr, 750 Welch Rd,Suite 350,Mail Code 5731, Palo Alto, CA 94304 USA.
EM tierneys@stanford.edu
OI Colan, Steven/0000-0002-7941-0947
FU American Heart Association; National Scientist Development Award; Farb
and McCance Family Funds
FX This study was supported by the American Heart Association, a National
Scientist Development Award, and the Farb and McCance Family Funds.
NR 41
TC 5
Z9 6
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0894-7317
J9 J AM SOC ECHOCARDIOG
JI J. Am. Soc. Echocardiogr.
PD MAR
PY 2015
VL 28
IS 3
BP 309
EP 316
DI 10.1016/j.echo.2014.10.004
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CE9DR
UT WOS:000352144400007
ER
PT J
AU Niederst, MJ
Sequist, LV
Poirier, JT
Mermel, CH
Lockerman, EL
Garcia, AR
Katayama, R
Costa, C
Ross, KN
Moran, T
Howe, E
Fulton, LE
Mulvey, HE
Bernardo, LA
Mohamoud, F
Miyoshi, N
VanderLaan, PA
Costa, DB
Janne, PA
Borger, DR
Ramaswamy, S
Shioda, T
Iafrate, AJ
Getz, G
Rudin, CM
Mino-Kenudson, M
Engelman, JA
AF Niederst, Matthew J.
Sequist, Lecia V.
Poirier, John T.
Mermel, Craig H.
Lockerman, Elizabeth L.
Garcia, Angel R.
Katayama, Ryohei
Costa, Carlotta
Ross, Kenneth N.
Moran, Teresa
Howe, Emily
Fulton, Linnea E.
Mulvey, Hillary E.
Bernardo, Lindsay A.
Mohamoud, Farhiya
Miyoshi, Norikatsu
VanderLaan, Paul A.
Costa, Daniel B.
Jaenne, Pasi A.
Borger, Darrell R.
Ramaswamy, Sridhar
Shioda, Toshi
Iafrate, Anthony J.
Getz, Gad
Rudin, Charles M.
Mino-Kenudson, Mari
Engelman, Jeffrey A.
TI RB loss in resistant EGFR mutant lung adenocarcinomas that transform to
small-cell lung cancer
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; ACQUIRED-RESISTANCE; KINASE INHIBITORS;
DRUG-SENSITIVITY; MUTATION; GEFITINIB; AMPLIFICATION; CHEMOTHERAPY;
MODELS; GENE
AB Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous treatment. A fundamental histological transformation from NSCLC to small-cell lung cancer (SCLC) is observed in a subset of the resistant cancers, but the molecular changes associated with this transformation remain unknown. Analysis of tumour samples and cell lines derived from resistant EGFR mutant patients revealed that Retinoblastoma (RB) is lost in 100% of these SCLC transformed cases, but rarely in those that remain NSCLC. Further, increased neuroendocrine marker and decreased EGFR expression as well as greater sensitivity to BCL2 family inhibition are observed in resistant SCLC transformed cancers compared with resistant NSCLCs. Together, these findings suggest that this subset of resistant cancers ultimately adopt many of the molecular and phenotypic characteristics of classical SCLC.
C1 [Niederst, Matthew J.; Sequist, Lecia V.; Lockerman, Elizabeth L.; Garcia, Angel R.; Katayama, Ryohei; Costa, Carlotta; Ross, Kenneth N.; Moran, Teresa; Howe, Emily; Fulton, Linnea E.; Mulvey, Hillary E.; Mohamoud, Farhiya; Borger, Darrell R.; Ramaswamy, Sridhar; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Niederst, Matthew J.; Sequist, Lecia V.; Lockerman, Elizabeth L.; Garcia, Angel R.; Katayama, Ryohei; Costa, Carlotta; Ross, Kenneth N.; Moran, Teresa; Howe, Emily; Fulton, Linnea E.; Mulvey, Hillary E.; Mohamoud, Farhiya; Miyoshi, Norikatsu; Borger, Darrell R.; Ramaswamy, Sridhar; Shioda, Toshi; Getz, Gad; Engelman, Jeffrey A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Poirier, John T.; Rudin, Charles M.] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, New York, NY 10065 USA.
[Mermel, Craig H.; Ramaswamy, Sridhar; Getz, Gad] Broad Inst MIT & Harvard, Canc Genome Comparat Anal Grp, Cambridge, MA 02142 USA.
[Mermel, Craig H.; Bernardo, Lindsay A.; Iafrate, Anthony J.; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Ctr Canc, Dept Pathol, Boston, MA 02114 USA.
[Bernardo, Lindsay A.; Iafrate, Anthony J.; Mino-Kenudson, Mari] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Miyoshi, Norikatsu; Shioda, Toshi] Massachusetts Gen Hosp, Ctr Canc, Mol Profiling Lab, Boston, MA 02114 USA.
[VanderLaan, Paul A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Costa, Daniel B.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, Boston, MA 02115 USA.
[Jaenne, Pasi A.] Dana Farber Canc Inst, Belfer Inst Appl Sci, Dept Med Oncol, Boston, MA 02215 USA.
[Jaenne, Pasi A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Jaenne, Pasi A.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Engelman, JA (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA.
EM jengelman@mgh.harvard.edu
OI Rudin, Charles/0000-0001-5204-3465; Costa, Daniel/0000-0002-0689-395X;
Poirier, John/0000-0001-9795-5644; VanderLaan, Paul/0000-0002-7234-5652
FU Lung Cancer Research Foundation; Uniting Against Lung Cancer;
NIH/National Cancer Institute [R01CA137008, 5R21CA156000, P50CA090578];
Lungevity; Department of Defense (CDMRP) [LC130190]; Targeting a Cure
for Lung Cancer; Piece of the Solution; MGH Thoracic Oncology Group
FX We thank Dr Nick Dyson for the constructs targeting GFP and RB and Dr
James Rocco and Dr William Michaud for supplying feeder cells and
helpful advice. This work was supported by the Lung Cancer Research
Foundation (Scientific Merit Award, M.J.N.), Uniting Against Lung Cancer
(L.V.S. and M.J.N.), NIH/National Cancer Institute (R01CA137008, J.A.E.,
5R21CA156000, L.V.S. and P50CA090578, D.B.C.), Lungevity (J.A.E. and
L.V.S.) Department of Defense (CDMRP LC130190, C.M.R and P.A.J.) and
philanthropic support from Targeting a Cure for Lung Cancer, Be a Piece
of the Solution, and the MGH Thoracic Oncology Group.
NR 37
TC 52
Z9 53
U1 2
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2015
VL 6
AR UNSP 6377
DI 10.1038/ncomms7377
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CF5YK
UT WOS:000352633100002
PM 25758528
ER
PT J
AU van Leeuwen, EM
Karssen, LC
Deelen, J
Isaacs, A
Medina-Gomez, C
Mbarek, H
Kanterakis, A
Trompet, S
Postmus, I
Verweij, N
van Enckevort, DJ
Huffman, JE
White, CC
Feitosa, MF
Bartz, TM
Manichaikul, A
Joshi, PK
Peloso, GM
Deelen, P
van Dijk, F
Willemsen, G
de Geus, EJ
Milaneschi, Y
Penninx, BWJH
Francioli, LC
Menelaou, A
Pulit, SL
Rivadeneira, F
Hofman, A
Oostra, BA
Franco, OH
Leach, IM
Beekman, M
de Craen, AJM
Uh, HW
Trochet, H
Hocking, LJ
Porteous, DJ
Sattar, N
Packard, CJ
Buckley, BM
Brody, JA
Bis, JC
Rotter, JI
Mychaleckyj, JC
Campbell, H
Duan, Q
Lange, LA
Wilson, JF
Hayward, C
Polasek, O
Vitart, V
Rudan, I
Wright, AF
Rich, SS
Psaty, BM
Borecki, IB
Kearney, PM
Stott, DJ
Cupples, LA
Jukema, JW
van der Harst, P
Sijbrands, EJ
Hottenga, JJ
Uitterlinden, AG
Swertz, MA
van Ommen, GJB
de Bakker, PIW
Slagboom, PE
Boomsma, DI
Wijmenga, C
van Duijn, CM
AF van Leeuwen, Elisabeth M.
Karssen, Lennart C.
Deelen, Joris
Isaacs, Aaron
Medina-Gomez, Carolina
Mbarek, Hamdi
Kanterakis, Alexandros
Trompet, Stella
Postmus, Iris
Verweij, Niek
van Enckevort, David J.
Huffman, Jennifer E.
White, Charles C.
Feitosa, Mary F.
Bartz, Traci M.
Manichaikul, Ani
Joshi, Peter K.
Peloso, Gina M.
Deelen, Patrick
van Dijk, Freerk
Willemsen, Gonneke
de Geus, Eco J.
Milaneschi, Yuri
Penninx, Brenda W. J. H.
Francioli, Laurent C.
Menelaou, Androniki
Pulit, Sara L.
Rivadeneira, Fernando
Hofman, Albert
Oostra, Ben A.
Franco, Oscar H.
Leach, Irene Mateo
Beekman, Marian
de Craen, Anton J. M.
Uh, Hae-Won
Trochet, Holly
Hocking, Lynne J.
Porteous, David J.
Sattar, Naveed
Packard, Chris J.
Buckley, Brendan M.
Brody, Jennifer A.
Bis, Joshua C.
Rotter, Jerome I.
Mychaleckyj, Josyf C.
Campbell, Harry
Duan, Qing
Lange, Leslie A.
Wilson, James F.
Hayward, Caroline
Polasek, Ozren
Vitart, Veronique
Rudan, Igor
Wright, Alan F.
Rich, Stephen S.
Psaty, Bruce M.
Borecki, Ingrid B.
Kearney, Patricia M.
Stott, David J.
Cupples, L. Adrienne
Jukema, J. Wouter
van der Harst, Pim
Sijbrands, Eric J.
Hottenga, Jouke-Jan
Uitterlinden, Andre G.
Swertz, Morris A.
van Ommen, Gert-Jan B.
de Bakker, Paul I. W.
Slagboom, P. Eline
Boomsma, Dorret I.
Wijmenga, Cisca
van Duijn, Cornelia M.
CA Genome Netherlands Consortium
TI Genome of the Netherlands population-specific imputations identify an
ABCA6 variant associated with cholesterol levels
SO NATURE COMMUNICATIONS
LA English
DT Article
ID WIDE ASSOCIATION; MUTATIONS; DISEASE
AB Variants associated with blood lipid levels may be population-specific. To identify low-frequency variants associated with this phenotype, population-specific reference panels may be used. Here we impute nine large Dutch biobanks (similar to 35,000 samples) with the population-specific reference panel created by the Genome of the Netherlands Project and perform association testing with blood lipid levels. We report the discovery of five novel associations at four loci (P value < 6.61 x 10(-4)), including a rare missense variant in ABCA6 (rs77542162, p.Cys1359Arg, frequency 0.034), which is predicted to be deleterious. The frequency of this ABCA6 variant is 3.65-fold increased in the Dutch and its effect (beta(LDL-C) = 0.135, beta(TC) = 0.140) is estimated to be very similar to those observed for single variants in well-known lipid genes, such as LDLR.
C1 [van Leeuwen, Elisabeth M.; Karssen, Lennart C.; Isaacs, Aaron; Hofman, Albert; Franco, Oscar H.; van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands.
[Deelen, Joris; Beekman, Marian; Slagboom, P. Eline] Leiden Univ, Med Ctr, Dept Mol Epidemiol, NL-2300 RC Leiden, Netherlands.
[Medina-Gomez, Carolina; Rivadeneira, Fernando; Uitterlinden, Andre G.] Erasmus MC, Dept Epidemiol & Internal Med, NL-3000 CA Rotterdam, Netherlands.
[Mbarek, Hamdi; Willemsen, Gonneke; de Geus, Eco J.; Hottenga, Jouke-Jan] Vrije Univ Amsterdam, Dept Biol Psychol, NL-1081 BT Amsterdam, Netherlands.
[Mbarek, Hamdi; Willemsen, Gonneke; de Geus, Eco J.; Hottenga, Jouke-Jan] EMGO, Inst Hlth & Care Res, NL-1081 BT Amsterdam, Netherlands.
[Kanterakis, Alexandros; Deelen, Patrick; van Dijk, Freerk; Swertz, Morris A.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet Genom Coordinat Ctr, NL-9700 RB Groningen, Netherlands.
[Trompet, Stella; Jukema, J. Wouter] Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands.
[Postmus, Iris] Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, NL-2300 RC Leiden, Netherlands.
[Verweij, Niek] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9700 RB Groningen, Netherlands.
[van Enckevort, David J.] BioAssist, Netherlands Bioinformat Ctr, NL-6500 HB Nijmegen, Netherlands.
[Huffman, Jennifer E.; Trochet, Holly; Hayward, Caroline; Vitart, Veronique; Wright, Alan F.] Univ Edinburgh, MRC Human Genet Unit, MRC IGMM, Edinburgh EH4 2XU, Midlothian, Scotland.
[White, Charles C.; Cupples, L. Adrienne] Boston Univ, Dept Biostat, Sch Publ Hlth, Boston, MA 02118 USA.
[Feitosa, Mary F.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63108 USA.
[Bartz, Traci M.] Univ Washington, Dept Biostat & Med, Seattle, WA 98101 USA.
[Manichaikul, Ani; Mychaleckyj, Josyf C.; Rich, Stephen S.] Univ Virginia, Dept Publ Hlth Sci, Ctr Publ Hlth Genom, Charlottesville, VA 22908 USA.
[Joshi, Peter K.; Campbell, Harry; Wilson, James F.; Rudan, Igor] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland.
[Peloso, Gina M.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02176 USA.
[Milaneschi, Yuri; Penninx, Brenda W. J. H.; de Craen, Anton J. M.] Vrije Univ Amsterdam, Dept Psychiat, Med Ctr Amsterdam,Neurosci Campus Amsterdam, GGZinGeest,EMGO,Inst Hlth & Care Res, NL-1081 HL Amsterdam, Netherlands.
[Francioli, Laurent C.; Menelaou, Androniki; Pulit, Sara L.; de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Dept Med Genet, Ctr Mol Med, NL-3584 CG Utrecht, Netherlands.
[Oostra, Ben A.] Erasmus MC, Dept Clin Genet, NL-3000 CA Rotterdam, Netherlands.
[Uh, Hae-Won] Leiden Univ, Med Ctr, Dept Genet Stat, NL-2300 RC Leiden, Netherlands.
[Hocking, Lynne J.] Univ Aberdeen, Div Appl Hlth Sci, Aberdeen AB25 2ZD, Scotland.
[Porteous, David J.] Univ Edinburgh, Ctr Genom & Expt Med, MRC IGMM, Edinburgh EH4 2XU, Midlothian, Scotland.
[Sattar, Naveed] Univ Glasgow, Fac Med, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8QQ, Lanark, Scotland.
[Packard, Chris J.] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow G12 8QQ, Lanark, Scotland.
[Buckley, Brendan M.] Univ Coll, Dept Pharmacol & Therapeut, Cork, Ireland.
[Brody, Jennifer A.; Bis, Joshua C.] Univ Washington, Dept Med, Seattle, WA 98101 USA.
[Rotter, Jerome I.] UCLA, Inst Translat Genom & Populat Sci, Los Angeles BioMed Res Inst Harbor, Med Ctr, Torrance, CA 90502 USA.
[Duan, Qing; Lange, Leslie A.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
[Polasek, Ozren] Univ Split, Fac Med, Dept Publ Hlth, Split 21000, Croatia.
[Psaty, Bruce M.] Univ Washington, Dept Med & Epidemiol, Seattle, WA 98101 USA.
[Borecki, Ingrid B.] Washington Univ, Sch Med, Dept Genet & Biostat, St Louis, MO 63108 USA.
[Cupples, L. Adrienne] Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA.
[Sijbrands, Eric J.] Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands.
[van Ommen, Gert-Jan B.] Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RC Leiden, Netherlands.
[de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Dept Epidemiol, NL-3584 CG Utrecht, Netherlands.
[Boomsma, Dorret I.] Vrije Univ Amsterdam, Dept Biol Psychol, NL-1081 BT Amsterdam, Netherlands.
[Wijmenga, Cisca] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, NL-9700 RB Groningen, Netherlands.
RP van Duijn, CM (reprint author), Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands.
EM c.vanduijn@erasmusmc.nl
RI Wilson, James F/A-5704-2009; Polasek, Ozren/B-6002-2011; Rivadeneira,
Fernando/O-5385-2015; Slagboom, P. Eline/R-4790-2016; Verweij,
Niek/A-4499-2017; Feitosa, Mary/K-8044-2012; Suchiman, H. Eka
D./F-5024-2017; de Bakker, Paul/B-8730-2009; Ye, Kai/B-3640-2012;
OI Wilson, James F/0000-0001-5751-9178; Polasek, Ozren/0000-0002-5765-1862;
Rivadeneira, Fernando/0000-0001-9435-9441; Slagboom, P.
Eline/0000-0002-2875-4723; Feitosa, Mary/0000-0002-0933-2410; Suchiman,
H. Eka D./0000-0002-7168-5516; de Bakker, Paul/0000-0001-7735-7858; van
Schaik, Barbera/0000-0002-5568-8127; Joshi, Peter/0000-0002-6361-5059;
Sijbrands, Eric/0000-0001-8857-7389; Hocking, Lynne
J/0000-0002-2414-2826; Beekman, Marian/0000-0003-0585-6206; Deelen,
Joris/0000-0003-4483-3701; Mbarek, Hamdi/0000-0002-1108-0371;
Medina-Gomez, Carolina/0000-0001-7999-5538; Verweij,
Niek/0000-0002-4303-7685; Wolffenbuttel, Bruce H.R./0000-0001-9262-6921;
Karssen, Lennart C./0000-0002-1959-342X; de Geus,
Eco/0000-0001-6022-2666
FU Netherlands Organization for Scientific Research [184021007]; NHLBI
[HHSN268201200036C, HHSN268200800007C, HHSN268200960009C, N01HC55222,
N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086,
5R01HL08770003, HL-54776, N01-HC-95159, N01-HC-95169, RR-024156,
N02.HL.6.4278]; NHLBI from the National Institute of Neurological
Disorders and Stroke (NINDS) [HL080295, HL087652, HL105756, HL103612];
National Institute on Aging (NIA) [AG023629]; European Commission FP-6
STRP [018947 (LSHG-CT-2006-01947)]; European Community's Seventh
Framework Programme (FP7) [HEALTH-F4-2007201413]; European Commission
under the programme 'Quality of Life and Management of the Living
Resources' of 5th Framework Programme [QLG2-CT2002- 01254]; Netherlands
Organisation for Scientific Research; Russian Foundation for Basic
Research [NWO-RFBR 047.017.043]; BBMRI-NL; Dutch government [NWO
184.021.007]; Netherlands Scientific Organization [NWO 480-05-003];
Dutch Brain Foundation; VU University Amsterdam; NIDDK [5R01DK06833603,
5R01DK07568102]; NHLBI Framingham Heart Study [N01-HC-25195]; Affymetrix
Inc for genotyping services [N02-HL-6-4278]; Robert Dawson Evans
Endowment of the Department of Medicine at the Boston University School
of Medicine and Boston Medical Center; National Heart, Lung, and Blood
Institute (NHLBI) [R01-HL-087700, R01-HL-088215]; Netherlands
Organization for Scientific Research (NWO); MagW/ZonMW
[Middelgroot-911-09-032, Spinozapremie 56-464-14192]; Geestkracht
programme of the Netherlands Organization for Health Research and
Development (Zon-MW) [10-000-1002]; Center for Medical Systems Biology
(CSMB, NWO Genomics); NBIC/BioAssist/RK [2008.024]; Biobanking and
Biomolecular Resources Research Infrastructure (BBMRI-NL) [184.021.007];
VU University's Institute for Health and Care Research (EMGO+);
Neuroscience Campus Amsterdam (NCA); European Science Foundation (ESF)
[EU/QLRT-200101254]; European Community's Seventh Framework Program
(FP7); ENGAGE [HEALTH-F4-2007-201413]; European Science Council (ERC)
[230374, 284167]; Genetic Association Information Network (GAIN) of the
Foundation for the National Institutes of Health, Rutgers University
Cell and DNA Repository [NIMH U24 MH068457-06]; Avera Institute, Sioux
Falls, South Dakota (USA); National Institutes of Health (NIH) [R01
HD042157-01A1, MH081802, 1RC2 MH089951, 1RC2 MH089995]; Dtuch Kidney
Foundation [E033]; EU [037697]; National Institutes of Health
[2R01LM010098]; Netherlands Organisation for Health Research and
Development [175.010.2007.006]; NWO VENI [916.761.70]; ZonMw
[90.700.441]; Dutch Inter University Cardiology Institute Netherlands
(ICIN); investigator-initiated grant obtained from Bristol-Myers Squibb;
Established Clinical Investigator of the Netherlands Heart Foundation
[2001 D 032]; seventh framework programme of the European commission
[223004]; Netherlands Genomics Initiative (Netherlands Consortium for
Healthy Aging) [050-060-810]; Erasmus Medical Center and Erasmus
University, Rotterdam, Netherlands Organization for the Health Research
and Development (ZonMw); Research Institute for Diseases in the Elderly
(RIDE); Ministry of Education, Culture and Science; Ministry for Health,
Welfare and Sports; European Commission (DG XII); Municipality of
Rotterdam; Netherlands Organisation of Scientific Research NWO
Investments [175.010.2005.011, 911-03-012]; Research Institute for
Diseases in the Elderly [014-93-015]; Netherlands Genomics Initiative
(NGI)/Netherlands Organisation for Scientific Research (NWO)
[050-060-810]
FX We especially thank all volunteers who participated in our study. This
study made use of data generated by the 'Genome of the Netherlands'
project, which is funded by the Netherlands Organization for Scientific
Research (grant no. 184021007). The data were made available as a
Rainbow Project of BBMRI-NL. Samples were contributed by LifeLines
(http://lifelines. nl/lifelines-research/general), the Leiden Longevity
Study (http://www. healthy-ageing. nl; http://www. langleven. net), the
Netherlands Twin Registry (NTR: http://www. tweelingenregister. org),
the Rotterdam studies (http://www. erasmus-epidemiology.
nl/rotterdamstudy) and the Genetic Research in Isolated Populations
programme (http://www. epib. nl/research/geneticepi/research. html#
gip). The sequencing was carried out in collaboration with the Beijing
Institute for Genomics (BGI).; We would like to thank all the members of
the CHARGE Lipids Working Group for their contribution in this project
(a full list of consortium members is provided in Supplementary Note
1).; Cardiovascular Health Study: This CHS research was supported by
NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268200960009C,
N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083,
N01HC85086; and NHLBI grants HL080295, HL087652, HL105756 and HL103612
with additional contribution from the National Institute of Neurological
Disorders and Stroke (NINDS). Additional support was provided through
AG023629 from the National Institute on Aging (NIA). A full list of CHS
investigators and institutions can be found at
http://www.chs-nhlbi.org/pi.htm.; The ERF study as a part of EuroSPAN
(European Special Populations Research Network) was supported by
European Commission FP-6 STRP grant number 018947 (LSHG-CT-2006-01947)
and also received funding from the European Community's Seventh
Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007201413
by the European Commission under the programme 'Quality of Life and
Management of the Living Resources' of 5th Framework Programme (no.
QLG2-CT2002- 01254). High-throughput analysis of the ERF data was
supported by joint grant from the Netherlands Organisation for
Scientific Research and the Russian Foundation for Basic Research
(NWO-RFBR 047.017.043). This research was financially supported by
BBMRI-NL, a Research Infrastructure financed by the Dutch government
(NWO 184.021.007). Statistical analyses for the ERF study were carried
out on the Genetic Cluster Computer (http://www. geneticcluster. org),
which is financially supported by the Netherlands Scientific
Organization (NWO 480-05-003 PI: Posthuma) along with a supplement from
the Dutch Brain Foundation and the VU University Amsterdam. We are
grateful to all study participants and their relatives, general
practitioners and neurologists for their contributions and to P. Veraart
for her help in genealogy, J. Vergeer for the supervision of the
laboratory work and P. Snijders for his help in data collection.; The
FamHS is funded by a NHLBI grant 5R01HL08770003, and NIDDK grants
5R01DK06833603 and 5R01DK07568102.; The Framingham Heart Study SHARe
Project for GWAS scan was supported by the NHLBI Framingham Heart Study
(Contract No. N01-HC-25195) and its contract with Affymetrix Inc for
genotyping services (Contract No. N02-HL-6-4278). DNA isolation and
biochemistry were partly supported by NHLBI HL-54776. A portion of this
research utilized the Linux Cluster for Genetic Analysis (LinGA-II)
funded by the Robert Dawson Evans Endowment of the Department of
Medicine at the Boston University School of Medicine and Boston Medical
Center. We are grateful to Han Chen for conducting the 1000G
imputation.; The Family Heart Study was supported by the by grants
R01-HL-087700 and R01-HL-088215 from the National Heart, Lung, and Blood
Institute (NHLBI).; MESA Whites and the MESA SHARe project are conducted
and supported by contracts N01-HC-95159 through N01-HC-95169 and
RR-024156 from the NHLBI. Funding for MESA SHARe genotyping was provided
by NHLBI Contract N02.HL.6.4278. MESA Family is conducted and supported
in collaboration with MESA investigators; support is provided by grants
and contracts R01HL071051, R01HL071205, R01HL071250, R01HL071251,
R01HL071252, R01HL071258 and R01HL071259. We thank the participants of
the MESA study, the Coordinating Center, MESA investigators and study
staff for their valuable contributions. A full list of participating
MESA investigators and institutions can be found at
http://www.mesa-nhlbi.org.; Netherland Twin Register (NTR) and
Netherlands Study of Depression and Anxiety (NESDA): Funding was
obtained from the Netherlands Organization for Scientific Research (NWO)
and MagW/ZonMW grants Middelgroot-911-09-032, Spinozapremie
56-464-14192, Geestkracht programme of the Netherlands Organization for
Health Research and Development (Zon-MW, grant number 10-000-1002),
Center for Medical Systems Biology (CSMB, NWO Genomics),
NBIC/BioAssist/RK(2008.024), Biobanking and Biomolecular Resources
Research Infrastructure (BBMRI-NL, 184.021.007), VU University's
Institute for Health and Care Research (EMGO+) and Neuroscience Campus
Amsterdam (NCA); the European Science Foundation (ESF,
EU/QLRT-200101254), the European Community's Seventh Framework Program
(FP7/2007-2013), ENGAGE (HEALTH-F4-2007-201413); the European Science
Council (ERC Advanced, 230374); and the European Research Council
(ERC-284167). Part of the genotyping and analyses were funded by the
Genetic Association Information Network (GAIN) of the Foundation for the
National Institutes of Health, Rutgers University Cell and DNA
Repository (NIMH U24 MH068457-06), the Avera Institute, Sioux Falls,
South Dakota (USA) and the National Institutes of Health (NIH R01
HD042157-01A1, MH081802, Grand Opportunity grants 1RC2 MH089951 and 1RC2
MH089995).; PREVEND genetics is supported by the Dtuch Kidney Foundation
(Grant E033), the EU project grant GENECURE (FP-6 LSHM CT 2006 037697),
the National Institutes of Health (grant 2R01LM010098), The Netherlands
Organisation for Health Research and Development (NWO-Groot grant
175.010.2007.006, NWO VENI grant 916.761.70, ZonMw grant 90.700.441) and
the Dutch Inter University Cardiology Institute Netherlands (ICIN).; The
PROSPER study was supported by an investigator-initiated grant obtained
from Bristol-Myers Squibb. J. W. J is an Established Clinical
Investigator of the Netherlands Heart Foundation (grant 2001 D 032).
Genotyping was supported by the seventh framework programme of the
European commission (grant 223004) and by the Netherlands Genomics
Initiative (Netherlands Consortium for Healthy Aging grant
050-060-810).; The Rotterdam Study is funded by Erasmus Medical Center
and Erasmus University, Rotterdam, Netherlands Organization for the
Health Research and Development (ZonMw), the Research Institute for
Diseases in the Elderly (RIDE), the Ministry of Education, Culture and
Science, the Ministry for Health, Welfare and Sports, the European
Commission (DG XII) and the Municipality of Rotterdam. We are grateful
to the study participants, the staff from the Rotterdam Study and the
participating general practitioners and pharmacists.; The generation and
management of GWAS genotype data for the Rotterdam Study is supported by
the Netherlands Organisation of Scientific Research NWO Investments (nr.
175.010.2005.011, 911-03-012). This study is funded by the Research
Institute for Diseases in the Elderly (014-93-015; RIDE2), the
Netherlands Genomics Initiative (NGI)/Netherlands Organisation for
Scientific Research (NWO) project no. 050-060-810. We thank Pascal Arp,
Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters for
their help in creating the GWAS database.
NR 22
TC 7
Z9 7
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2015
VL 6
AR UNSP 6065
DI 10.1038/ncomms7065
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CF5ZF
UT WOS:000352635400001
PM 25751400
ER
PT J
AU Collaco, JM
Aherrera, AD
Breysse, PN
Winickoff, JP
Klein, JD
McGrath-Morrow, SA
AF Collaco, Joseph M.
Aherrera, Angela D.
Breysse, Patrick N.
Winickoff, Jonathan P.
Klein, Jonathan D.
McGrath-Morrow, Sharon A.
TI Hair Nicotine Levels in Children With Bronchopulmonary Dysplasia
SO PEDIATRICS
LA English
DT Article
ID SECONDHAND SMOKE EXPOSURE; BIRTH-WEIGHT INFANTS; TOBACCO-SMOKE;
CIGARETTE-SMOKE; PRETERM INFANTS; DISEASE; REHOSPITALIZATION; MORBIDITY;
GROWTH; WOMEN
AB BACKGROUND: Tobacco smoke exposure (TSE) may increase respiratory morbidities in young children with bronchopulmonary dysplasia (BPD). Rapid respiratory rates, close proximity to a smoking caregiver, and increased dermal absorption of tobacco smoke components can contribute to systemic exposure. In this study, hair nicotine levels were used as a biomarker of chronic TSE in young children with BPD to determine if hair nicotine levels correlate with caregiver self-report of TSE and respiratory morbidities.
METHODS: From 2012 to 2014, hair nicotine levels were measured from consecutive children seen in a BPD outpatient clinic and compared with caregiver questionnaires on household smoking. The relationship between respiratory morbidities and self-reported TSE or hair nicotine level was assessed.
RESULTS: The mean hair nicotine level from 117 children was 3.1 +/- 13.2 ng/mg. Hair nicotine levels were significantly higher in children from smoking households by caregiver self-report compared with caregivers who reported no smoking (8.2 +/- 19.7 ng/mg vs 1.8 +/- 10.7; P < .001). In households that reported smoking, hair nicotine levels were higher in children with a primary caregiver who smoked compared with a primary caregiver who did not smoke. Among children with BPD who required respiratory support (n = 50), a significant association was found between higher log hair nicotine levels and increased hospitalizations and limitation of activity.
CONCLUSIONS: Chronic TSE is common in children with BPD, with hair nicotine levels being more likely to detect TSE than caregiver self-report. Hair nicotine levels were also a better predictor of hospitalization and activity limitation in children with BPD who required respiratory support at outpatient presentation.
C1 [Collaco, Joseph M.; Aherrera, Angela D.; McGrath-Morrow, Sharon A.] Johns Hopkins Sch Med, Eudowood Div Pediat Resp Sci, Baltimore, MD USA.
[Breysse, Patrick N.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Collaco, Joseph M.; Breysse, Patrick N.; Winickoff, Jonathan P.; Klein, Jonathan D.; McGrath-Morrow, Sharon A.] Amer Acad Pediat, Julius B Richmond FAMRI Ctr Excellence, Elk Grove Village, IL USA.
[Winickoff, Jonathan P.] Massachusetts Gen Hosp, Div Gen Pediat, Boston, MA 02114 USA.
[Winickoff, Jonathan P.] Harvard Univ, Sch Med, Boston, MA USA.
RP Collaco, JM (reprint author), Eudowood Div Pediat Resp Sci, David M Rubenstein Bldg,200 North Wolfe St, Baltimore, MD 21287 USA.
EM mcollac1@jhmi.edu
FU Center of Excellence grant from the Flight Attendant Medical Research
Institute; Johns Hopkins Center of Excellence grant from the Flight
Attendant Medical Research Institute
FX Funded by a Center of Excellence grant to the American Academy of
Pediatrics from the Flight Attendant Medical Research Institute and a
Johns Hopkins Center of Excellence grant from the Flight Attendant
Medical Research Institute.
NR 27
TC 5
Z9 5
U1 0
U2 3
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD MAR
PY 2015
VL 135
IS 3
BP E678
EP E686
DI 10.1542/peds.2014-2501
PG 9
WC Pediatrics
SC Pediatrics
GA CF0BD
UT WOS:000352206600016
PM 25647675
ER
PT J
AU Speltz, ML
Collett, BR
Wallace, ER
Starr, JR
Cradock, MM
Buono, L
Cunningham, M
Kapp-Simon, K
AF Speltz, Matthew L.
Collett, Brent R.
Wallace, Erin R.
Starr, Jacqueline R.
Cradock, Mary Michaeleen
Buono, Lauren
Cunningham, Michael
Kapp-Simon, Kathleen
TI Intellectual and Academic Functioning of School-Age Children With
Single-Suture Craniosynostosis
SO PEDIATRICS
LA English
DT Article
ID NONSYNDROMIC CRANIOSYNOSTOSIS; INFANTS; NEURODEVELOPMENT; PRESSURE;
OUTCOMES; BRAIN
AB OBJECTIVE: We compared the developmental status of school-age children with single-suture craniosynostosis (case group) and unaffected children (control group). Within the case group we compared the performance of children distinguished by location of suture fusion (sagittal, metopic, unicoronal, lambdoid).
METHODS: We administered standardized tests of intelligence, reading, spelling, and math to 182 case participants and 183 control participants. This sample represented 70% of those tested during infancy before case participants had corrective surgery.
RESULTS: After adjustment for demographics, case participants' average scores were lower than those of control participants on all measures. The largest observed differences were in Full-Scale IQ and math computation, where case participants' adjusted mean scores were 2.5 to 4 points lower than those of control participants (Ps ranged from.002 to .09). Adjusted mean case-control differences on other measures of achievement were modest, although case deficits became more pronounced after adjustment for participation in developmental interventions. Among case participants, 58% had no discernible learning problem (score <25th percentile on a standardized achievement test). Children with metopic, unicoronal, and lambdoid synostosis tended to score lower on most measures than did children with sagittal fusions (Ps ranged from, <.001 to .82).
CONCLUSIONS: The developmental delays observed among infants with single-suture craniosynostosis are partially evident at school age, as manifested by lower average scores than those of control participants on measures of IQ and math. However, case participants' average scores were only slightly lower than those of control participants on reading and spelling measures, and the frequency of specific learning problems was comparable. Among case participants, those with unicoronal and lambdoid fusions appear to be the most neurodevelopmentally vulnerable.
C1 [Speltz, Matthew L.; Collett, Brent R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Cunningham, Michael] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
[Speltz, Matthew L.; Collett, Brent R.; Wallace, Erin R.] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA 98121 USA.
[Starr, Jacqueline R.] Forsyth Inst, Dept Clin & Translat Res, Cambridge, MA USA.
[Starr, Jacqueline R.] Harvard Univ, Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, Boston, MA 02115 USA.
[Cradock, Mary Michaeleen] St Louis Childrens Hosp, Dept Psychol, St Louis, MO 63178 USA.
[Cradock, Mary Michaeleen] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
[Buono, Lauren] Childrens Healthcare Atlanta, Ctr Craniofacial Disorders, Atlanta, GA USA.
[Cunningham, Michael] Seattle Childrens Hosp, Craniofacial Ctr, Seattle, WA USA.
[Kapp-Simon, Kathleen] Northwestern Univ, Dept Surg, Chicago, IL USA.
[Kapp-Simon, Kathleen] Shriners Hosp Children, Chicago, IL USA.
RP Speltz, ML (reprint author), Seattle Childrens Res Inst, 2001 8th Ave,Suite 600,Mailstop CW8-6, Seattle, WA 98121 USA.
EM matt.speltz@seattlechildrens.org
FU National Institutes of Health (NIH) from the National Institute of
Dental and Craniofacial Research [R01 DE 13813, R01 DE 018227]; Jean
Renny Endowment for Craniofacial Medicine; National Institutes of Health
(NIH)
FX All phases of this study were supported by National Institutes of Health
(NIH) grant R01 DE 13813 (Dr Speltz) and R01 DE 018227 (Dr Cunningham)
from the National Institute of Dental and Craniofacial Research. Dr
Cunningham was also supported by the Jean Renny Endowment for
Craniofacial Medicine. Funded by the National Institutes of Health
(NIH).
NR 44
TC 14
Z9 14
U1 0
U2 8
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD MAR
PY 2015
VL 135
IS 3
BP E615
EP E623
DI 10.1542/peds.2014-1634
PG 9
WC Pediatrics
SC Pediatrics
GA CF0BD
UT WOS:000352206600009
PM 25713274
ER
PT J
AU Yang, F
Petsalaki, E
Rolland, T
Hill, DE
Vidal, M
Roth, FP
AF Yang, Fan
Petsalaki, Evangelia
Rolland, Thomas
Hill, David E.
Vidal, Marc
Roth, Frederick P.
TI Protein Domain-Level Landscape of Cancer-Type-Specific Somatic Mutations
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; EPIDERMAL GROWTH-FACTOR; P53 TUMOR-SUPPRESSOR;
HEPATOCELLULAR-CARCINOMA; PROSTATE-CANCER; GENOMIC ANALYSIS; HUMAN
BREAST; LUNG-CANCER; ESOPHAGEAL ADENOCARCINOMA; INACTIVATING MUTATIONS
AB Identifying driver mutations and their functional consequences is critical to our understanding of cancer. Towards this goal, and because domains are the functional units of a protein, we explored the protein domain-level landscape of cancer-type-specific somatic mutations. Specifically, we systematically examined tumor genomes from 21 cancer types to identify domains with high mutational density in specific tissues, the positions of mutational hotspots within these domains, and the functional and structural context where possible. While hotspots corresponding to specific gain-of-function mutations are expected for oncoproteins, we found that tumor suppressor proteins also exhibit strong biases toward being mutated in particular domains. Within domains, however, we observed the expected patterns of mutation, with recurrently mutated positions for oncogenes and evenly distributed mutations for tumor suppressors. For example, we identified both known and new endometrial cancer hotspots in the tyrosine kinase domain of the FGFR2 protein, one of which is also a hotspot in breast cancer, and found new two hotspots in the Immunoglobulin I-set domain in colon cancer. Thus, to prioritize cancer mutations for further functional studies aimed at more precise cancer treatments, we have systematically correlated mutations and cancer types at the protein domain level.
C1 [Yang, Fan; Roth, Frederick P.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
[Yang, Fan; Petsalaki, Evangelia; Roth, Frederick P.] Univ Toronto, Donnelly Ctr, Toronto, ON, Canada.
[Yang, Fan; Petsalaki, Evangelia; Roth, Frederick P.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada.
[Rolland, Thomas; Hill, David E.; Vidal, Marc; Roth, Frederick P.] Dana Farber Canc Inst, CCSB, Boston, MA 02115 USA.
[Rolland, Thomas] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Roth, Frederick P.] Canadian Inst Adv Res, Toronto, ON, Canada.
[Roth, Frederick P.] Univ Toronto, Dept Comp Sci, Toronto, ON, Canada.
RP Yang, F (reprint author), Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
EM fritz.roth@utoronto.ca
RI Roth, Frederick/H-6308-2011;
OI Petsalaki, Evangelia/0000-0002-8294-2995; Roth,
Frederick/0000-0002-6628-649X
FU NIH/NHGRI Center of Excellence in Genome Science award [HG004233];
NIH/NHGRI [HG001715]; Canada Excellence Research Chairs Program; Avon
Foundation; Ontario Research Fund - Research Excellence Award; Canadian
Institute for Advanced Research Fellowship
FX This project was supported by an NIH/NHGRI Center of Excellence in
Genome Science award (HG004233) and benefitted from NIH/NHGRI award
HG001715 (both to MV, DEH, and FPR). FPR was also supported by the
Canada Excellence Research Chairs Program, by the Avon Foundation, by an
Ontario Research Fund - Research Excellence Award, and by a Canadian
Institute for Advanced Research Fellowship. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 143
TC 15
Z9 15
U1 2
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-734X
EI 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD MAR
PY 2015
VL 11
IS 3
AR UNSP e1004147
DI 10.1371/journal.pcbi.1004147
PG 30
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA CE9XB
UT WOS:000352195700038
PM 25794154
ER
PT J
AU Siedner, MJ
Gostin, LO
Cranmer, HH
Kraemer, JD
AF Siedner, Mark J.
Gostin, Lawrence O.
Cranmer, Hilarie H.
Kraemer, John D.
TI Strengthening the Detection of and Early Response to Public Health
Emergencies: Lessons from the West African Ebola Epidemic
SO PLOS MEDICINE
LA English
DT Article
ID COMMUNITY ADVISORY BOARDS; GLOBAL HEALTH; VIRUS DISEASE
C1 [Siedner, Mark J.; Cranmer, Hilarie H.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Siedner, Mark J.; Cranmer, Hilarie H.] Harvard Univ, Sch Med, Boston, MA USA.
[Gostin, Lawrence O.; Kraemer, John D.] Georgetown Univ, ONeill Inst Natl & Global Hlth Law, Washington, DC USA.
[Kraemer, John D.] Georgetown Univ, Dept Hlth Syst Adm, Washington, DC USA.
RP Siedner, MJ (reprint author), Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
EM msiedner@mgh.harvard.edu
FU NIMH NIH HHS [K23 MH099916]
NR 33
TC 12
Z9 12
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD MAR
PY 2015
VL 12
IS 3
AR e1001804
DI 10.1371/journal.pmed.1001804
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA CE8MI
UT WOS:000352096300012
PM 25803303
ER
PT J
AU Dinter, J
Duong, E
Lai, NY
Berberich, MJ
Kourjian, G
Bracho-Sanchez, E
Chu, D
Su, H
Zhang, SC
Le Gall, S
AF Dinter, Jens
Duong, Ellen
Lai, Nicole Y.
Berberich, Matthew J.
Kourjian, Georgio
Bracho-Sanchez, Edith
Chu, Duong
Su, Hang
Zhang, Shao Chong
Le Gall, Sylvie
TI Variable Processing and Cross-presentation of HIV by Dendritic Cells and
Macrophages Shapes CTL Immunodominance and Immune Escape
SO PLOS PATHOGENS
LA English
DT Article
ID MHC CLASS-I; T-LYMPHOCYTE EPITOPES; VIRUS TYPE-1 INFECTION; CONTROLS
PHAGOSOMAL PH; ANTIGEN PRESENTATION; PEPTIDE STABILITY; VIRAL
REPLICATION; VACCINE DESIGN; CUTTING EDGE; RESPONSES
AB Dendritic cells (DCs) and macrophages (Mos) internalize and process exogenous HIV-derived antigens for cross-presentation by MHC-I to cytotoxic CD8(+) T cells (CTL). However, how degradation patterns of HIV antigens in the cross-presentation pathways affect immunodominance and immune escape is poorly defined. Here, we studied the processing and cross-presentation of dominant and subdominant HIV-1 Gag-derived epitopes and HLA-restricted mutants by monocyte-derived DCs and Mos. The cross-presentation of HIV proteins by both DCs and Mos led to higher CTL responses specific for immunodominant epitopes. The low CTL responses to subdominant epitopes were increased by pretreatment of target cells with peptidase inhibitors, suggestive of higher intracellular degradation of the corresponding peptides. Using DC and Mo cell extracts as a source of cytosolic, endosomal or lysosomal proteases to degrade long HIV peptides, we identified by mass spectrometry cell-specific and compartment-specific degradation patterns, which favored the production of peptides containing immunodominant epitopes in all compartments. The intracellular stability of optimal HIV-1 epitopes prior to loading onto MHC was highly variable and sequence-dependent in all compartments, and followed CTL hierarchy with immunodominant epitopes presenting higher stability rates. Common HLA-associated mutations in a dominant epitope appearing during acute HIV infection modified the degradation patterns of long HIV peptides, reduced intracellular stability and epitope production in cross-presentation-competent cell compartments, showing that impaired epitope production in the cross-presentation pathway contributes to immune escape. These findings highlight the contribution of degradation patterns in the cross-presentation pathway to HIV immunodominance and provide the first demonstration of immune escape affecting epitope cross-presentation.
C1 [Dinter, Jens; Duong, Ellen; Lai, Nicole Y.; Berberich, Matthew J.; Kourjian, Georgio; Bracho-Sanchez, Edith; Chu, Duong; Su, Hang; Zhang, Shao Chong; Le Gall, Sylvie] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ragon Inst MGH MIT & Harvard, Cambridge, MA 02138 USA.
RP Dinter, J (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ragon Inst MGH MIT & Harvard, Cambridge, MA 02138 USA.
EM sylvie_legall@hms.harvard.edu
FU NIAID [R01 AI084753, R01 AI084106]; Ernst Schering Foundation
FX The project was funded by grants R01 AI084753 and R01 AI084106 from
NIAID to SLG. JD is funded in part by a Ph.D. training fellowship from
the Ernst Schering Foundation. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 76
TC 9
Z9 9
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAR
PY 2015
VL 11
IS 3
AR UNSP e1004725
DI 10.1371/journal.ppat.1004725
PG 22
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA CE9ZI
UT WOS:000352201900045
PM 25781895
ER
PT J
AU Moutsopoulos, NM
Chalmers, NI
Barb, JJ
Abusleme, L
Greenwell-Wild, T
Dutzan, N
Paster, BJ
Munson, PJ
Fine, DH
Uzel, G
Holland, SM
AF Moutsopoulos, Niki M.
Chalmers, Natalia I.
Barb, Jennifer J.
Abusleme, Loreto
Greenwell-Wild, Teresa
Dutzan, Nicolas
Paster, Bruce J.
Munson, Peter J.
Fine, Daniel H.
Uzel, Gulbu
Holland, Steven M.
TI Subgingival Microbial Communities in Leukocyte Adhesion Deficiency and
Their Relationship with Local Immunopathology
SO PLOS PATHOGENS
LA English
DT Article
ID AGGRESSIVE PERIODONTITIS; AGGREGATIBACTER-ACTINOMYCETEMCOMITANS;
IDENTIFICATION MICROARRAY; PORPHYROMONAS-GINGIVALIS; REFRACTORY
PERIODONTITIS; INFECTION; INFLAMMATION; RESPONSES; CHILDREN; HEALTH
AB Leukocyte Adhesion Deficiency I (LAD-I) is a primary immunodeficiency caused by single gene mutations in the CD18 subunit of beta 2 integrins which result in defective transmigration of neutrophils into the tissues. Affected patients suffer from recurrent life threatening infections and severe oral disease (periodontitis). Microbial communities in the local environment (subgingival plaque) are thought to be the triggers for inflammatory periodontitis, yet little is known regarding the microbial communities associated with LAD-I periodontitis. Here we present the first comprehensive characterization of the subgingival communities in LAD-I, using a 16S rRNA gene-based microarray, and investigate the relationship of this tooth adherent microbiome to the local immunopathology of periodontitis. We show that the LAD subgingival microbiome is distinct from that of health and Localized Aggressive Periodontitits. Select periodontitis-associated species in the LAD microbiome included Parvimonas micra, Porphyromonas endodontalis, Eubacterium brachy and Treponema species. Pseudomonas aeruginosa, a bacterium not typically found in subgingival plaque is detected in LAD-I. We suggest that microbial products from LAD-associated communities may have a role in stimulating the local inflammatory response. We demonstrate that bacterial LPS translocates into the lesions of LAD-periodontitis potentially triggering immunopathology. We also show in in vitro assays with human macrophages and in vivo in animal models that microbial products from LAD-associated subgingival plaque trigger IL-23-related immune responses, which have been shown to dominate in patient lesions. In conclusion, our current study characterizes the subgingival microbial communities in LAD-periodontitis and supports their role as triggers of disease pathogenesis.
C1 [Moutsopoulos, Niki M.; Abusleme, Loreto; Greenwell-Wild, Teresa; Dutzan, Nicolas] Natl Inst Dent & Craniofacial Res, Oral Immun & Inflammat Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.
[Chalmers, Natalia I.] Natl Inst Dent & Craniofacial Res, Clin Res Core, NIH, Bethesda, MD USA.
[Barb, Jennifer J.; Munson, Peter J.] NIH, Ctr Informat Technol, Bethesda, MD 20892 USA.
[Paster, Bruce J.] Forsyth Inst, Cambridge, MA USA.
[Paster, Bruce J.] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA.
[Fine, Daniel H.] Rutgers State Univ, Rutgers Sch Dent Med, Newark, NJ 07102 USA.
[Uzel, Gulbu; Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA.
RP Moutsopoulos, NM (reprint author), Natl Inst Dent & Craniofacial Res, Oral Immun & Inflammat Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.
EM nmoutsop@mail.nih.gov
FU Intramural Research Program of the NIH; National Institute of Dental and
Craniofacial Research (NIDCR); National Institute of Allergy and
Infectious Diseases (NIAID)
FX This research was supported in part by the Intramural Research Program
of the NIH, National Institute of Dental and Craniofacial Research
(NIDCR) and National Institute of Allergy and Infectious Diseases
(NIAID). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 47
TC 10
Z9 10
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAR
PY 2015
VL 11
IS 3
AR e1004698
DI 10.1371/journal.ppat.1004698
PG 19
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA CE9ZI
UT WOS:000352201900027
PM 25741691
ER
PT J
AU Freer, PE
AF Freer, Phoebe E.
TI Mammographic Breast Density: Impact on Breast Cancer Risk and
Implications for Screening
SO RADIOGRAPHICS
LA English
DT Article
ID DIGITAL MAMMOGRAPHY; DIAGNOSTIC-ACCURACY; ASYMPTOMATIC WOMEN; 1ST
EVALUATION; ELEVATED RISK; FAMILIAL RISK; ULTRASOUND; TOMOSYNTHESIS;
MRI; US
AB Mammographic breast density is rapidly becoming a hot topic in both the medical literature and the lay press. In the United States, recent legislative changes in 19 states now require radiologists to notify patients regarding breast density as well as the possible need for supplemental screening. Federal legislation regarding breast density notification has been introduced, and its passage is likely on the horizon. An understanding of the context, scientific evidence, and controversies surrounding the topic of breast density as a risk factor for breast cancer is critical for radiologists. The current state of evidence is presented regarding supplemental screening for women with dense breasts, including the use of digital breast tomo-synthesis, whole-breast ultrasonography, and gadolinium-enhanced magnetic resonance imaging. A review of current practice guidelines and additional sources of information will improve radiologists' understanding of the relevant subject of breast density and enable them to respond appropriately to questions from patients, clinicians, and the media. (C) RSNA, 2015.
C1 Massachusetts Gen Hosp, MGH Imaging, Dept Radiol, Boston, MA 02114 USA.
RP Freer, PE (reprint author), Massachusetts Gen Hosp, MGH Imaging, Dept Radiol, 15 Pk Man St,Wang Bldg,ACC 240, Boston, MA 02114 USA.
EM pfreer@partners.org
OI Freer, Phoebe/0000-0001-6886-7100
NR 84
TC 18
Z9 18
U1 0
U2 13
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0271-5333
J9 RADIOGRAPHICS
JI Radiographics
PD MAR-APR
PY 2015
VL 35
IS 2
BP 302
EP 315
DI 10.1148/rg.352140106
PG 14
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CF4YR
UT WOS:000352561000001
PM 25763718
ER
PT J
AU Gunn, AJ
Mangano, MD
Choy, G
Sahani, DV
AF Gunn, Andrew J.
Mangano, Mark D.
Choy, Garry
Sahani, Dushyant V.
TI Rethinking the Role of the Radiologist: Enhancing Visibility through
Both Traditional and Nontraditional Reporting Practices
SO RADIOGRAPHICS
LA English
DT Article
ID REFERRING PHYSICIANS; PREFERENCES; COMMUNICATION; STYLE
AB The written radiology report is the primary method by which the radiologist communicates examination findings to the referring physician and the patient. Unfortunately, despite recent efforts to improve radiology reporting practices, dissatisfaction with regard to traditional reporting practices continues among referring physicians and patients. Moreover, the current reporting paradigm limits the amount of interaction that radiologists can have with patients and referring physicians. To address these issues, organizational efforts have been made by the Radiological Society of North America and the American College of Radiology to educate the public about the role of the radiologist in patient care, provide resources for individuals to learn more about the practice of radiology, and assist radiologists in creating a more "patient-centered" practice. In addition, individual radiologists may want to consider making adjustments to their reporting practices to improve communication of examination findings and increase patient awareness of the radiologist's role in clinical care. Many opportunities exist for radiologists to make such changes, both within the traditional reporting model (decreasing barriers to communication, educating patients) and with implementation of various nontraditional reporting practices (eg, delivering examination results directly to patients, receiving structured feedback on reports, establishing a diagnostic radiology consultation clinic). The authors provide guidance for radiologists who wish to enhance their visibility in clinical care with use of both traditional and nontraditional reporting practices. (C) RSNA, 2015
C1 [Gunn, Andrew J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Gunn, AJ (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
EM ajgunnmd@gmail.com
NR 38
TC 11
Z9 11
U1 1
U2 3
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0271-5333
J9 RADIOGRAPHICS
JI Radiographics
PD MAR-APR
PY 2015
VL 35
IS 2
BP 416
EP 423
DI 10.1148/rg.352140042
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CF4YR
UT WOS:000352561000009
PM 25763726
ER
PT J
AU Kwak, JJ
Tirumani, SH
Van den Abbeele, AD
Koo, PJ
Jacene, HA
AF Kwak, Jennifer J.
Tirumani, Sree Harsha
Van den Abbeele, Annick D.
Koo, Phillip J.
Jacene, Heather A.
TI Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response
Patterns and Immunerelated Adverse Events
SO RADIOGRAPHICS
LA English
DT Article
ID METASTATIC MELANOMA; IN-VIVO; IPILIMUMAB; THERAPY; BLOCKADE; ANTIBODY;
CRITERIA; SAFETY; CTLA-4
AB Cancer immunotherapy is changing the imaging evaluation of cancer treatment response and treatment-related toxic effects. New emerging patterns of treatment response and treatment-related toxic effects after treatment with immunomodulating agents have been observed. Treatment response after immunomodulatory therapy can be associated with significantly delayed decrease in tumor size, and new or enlarging tumors observed soon after completion of treatment may not reflect disease progression. In addition, activation of the immune system to fight cancer may lead to unwanted autoimmune-mediated toxic effects that could be mistaken for metastatic disease or misdiagnosed as a non-treatment-related process and delay appropriate clinical management. Radiologists must recognize the novel treatment response patterns and the wide range of autoimmune toxic effects, which should not be mistaken for treatment failure or metastatic disease progression. (C) RSNA, 2015
C1 [Kwak, Jennifer J.; Koo, Phillip J.] Univ Colorado, Sch Med, Dept Radiol, Aurora, CO 80045 USA.
[Tirumani, Sree Harsha; Van den Abbeele, Annick D.; Jacene, Heather A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA.
[Tirumani, Sree Harsha; Van den Abbeele, Annick D.; Jacene, Heather A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
RP Kwak, JJ (reprint author), Univ Colorado, Sch Med, Dept Radiol, Anschutz Med Campus,12700 E 19th Ave,Room C278, Aurora, CO 80045 USA.
EM jen.j.kwak@gmail.com
NR 22
TC 8
Z9 8
U1 0
U2 4
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0271-5333
J9 RADIOGRAPHICS
JI Radiographics
PD MAR-APR
PY 2015
VL 35
IS 2
BP 424
EP 437
DI 10.1148/rg.352140121
PG 14
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CF4YR
UT WOS:000352561000010
PM 25763727
ER
PT J
AU Tirumani, SH
Fairchild, A
Krajewski, KM
Nishino, M
Howard, SA
Baheti, AD
Rosenthal, MH
Jagannathan, JP
Shinagare, AB
Ramaiya, NH
AF Tirumani, Sree Harsha
Fairchild, Alexandra
Krajewski, Katherine M.
Nishino, Mizuki
Howard, Stephanie A.
Baheti, Akshay D.
Rosenthal, Michael H.
Jagannathan, Jyothi P.
Shinagare, Atul B.
Ramaiya, Nikhil H.
TI Anti-VEGF Molecular Targeted Therapies in Common Solid Malignancies:
Comprehensive Update for Radiologists
SO RADIOGRAPHICS
LA English
DT Article
ID RENAL-CELL CARCINOMA; GASTROINTESTINAL STROMAL TUMORS; ADVANCED
HEPATOCELLULAR-CARCINOMA; VENOUS THROMBOEMBOLIC EVENTS; RESPONSE
EVALUATION CRITERIA; COLORECTAL LIVER METASTASES; CONTRAST-ENHANCED CT;
SOFT-TISSUE SARCOMAS; LUNG-CANCER; ANTIANGIOGENIC THERAPY
AB Angiogenesis is an essential component of the growth and dissemination of solid malignancies and is mediated by several proangiogenic factors. The most widely studied proangiogenic factor is vascular endothelial growth factor (VEGF). A major class of molecular targeted therapies (MTTs) inhibit the VEGF axis and are referred to as antiangiogenic MTTs. There are two main types of anti-VEGF MTTs: drugs targeting circulating VEGF and drugs interfering with the activity of the VEGF receptors. The cancers against which antiangiogenic MTTs have had the greatest effect are gliomas, non-small cell lung cancer, colorectal cancer, hepatocellular carcinoma, renal cell carcinoma, and gastrointestinal stromal tumor. These cancers respond to antiangiogenic MTTs in a different way than they respond to conventional chemotherapy. Instead of the traditional Response Evaluation Criteria in Solid Tumors (RECIST), each of these cancers therefore requires its own individualized treatment response criteria (TRC). Examples of individualized TRC include the Response Assessment in Neurooncology (RANO) criteria for gliomas, modified RECIST for hepatocellular carcinoma, and Morphology, Attenuation, Size, and Structure (MASS) criteria for renal cell carcinoma. Furthermore, antiangiogenic MTTs have a unique spectrum of class-specific and drug-specific toxic effects, some of which can be detected at imaging. Increasing use of antiangiogenic MTTs in clinical practice necessitates that radiologists be aware of these drugs, their response patterns, and TRC as well as their toxic effect profiles. (C) RSNA, 2015
C1 [Tirumani, Sree Harsha; Krajewski, Katherine M.; Nishino, Mizuki; Howard, Stephanie A.; Baheti, Akshay D.; Rosenthal, Michael H.; Jagannathan, Jyothi P.; Shinagare, Atul B.; Ramaiya, Nikhil H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, Boston, MA 02215 USA.
[Tirumani, Sree Harsha; Fairchild, Alexandra; Krajewski, Katherine M.; Nishino, Mizuki; Howard, Stephanie A.; Baheti, Akshay D.; Rosenthal, Michael H.; Jagannathan, Jyothi P.; Shinagare, Atul B.; Ramaiya, Nikhil H.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02215 USA.
RP Tirumani, SH (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA.
EM Sreeharsha_Tiru-mani@DFCI.HARVARD.EDU
FU RSNA; General Electric; National Cancer Institute; Harvard Medical
School
FX A.B.S. Activities related to the present article: disclosed no relevant
relationships. Activities not related to the present article: research
grant from RSNA. Other activities: disclosed no relevant relationships.
K.M.K. Activities related to the present article: disclosed no relevant
relationships. Activities not related to the present article: grants
from General Electric. Other activities: disclosed no relevant
relationships. M.N. Activities related to the present article: disclosed
no relevant relationships. Activities not related to the present
article: grants from the National Cancer Institute and Harvard Medical
School. Other activities: disclosed no relevant relationships.
NR 88
TC 7
Z9 8
U1 0
U2 0
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0271-5333
J9 RADIOGRAPHICS
JI Radiographics
PD MAR-APR
PY 2015
VL 35
IS 2
BP 455
EP 474
DI 10.1148/rg.352140119
PG 20
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CF4YR
UT WOS:000352561000012
PM 25763729
ER
PT J
AU Scheinfeld, MH
Dym, AA
Spektor, M
Avery, LL
Dym, RJ
Amanatullah, DF
AF Scheinfeld, Meir H.
Dym, Akiva A.
Spektor, Michael
Avery, Laura L.
Dym, R. Joshua
Amanatullah, Derek F.
TI Acetabular Fractures: What Radiologists Should Know and How 3D CT Can
Aid Classification
SO RADIOGRAPHICS
LA English
DT Article
ID PERCUTANEOUS SCREW FIXATION; COMPUTED-TOMOGRAPHY; HETEROTOPIC
OSSIFICATION; POSTERIOR WALL; CONVENTIONAL RADIOGRAPHY; OPERATIVE
TREATMENT; MANAGEMENT; INJURY; INDOMETHACIN; STABILITY
AB Correct recognition, description, and classification of acetabular fractures is essential for efficient patient triage and treatment. Acetabular fractures may result from high-energy trauma or low-energy trauma in the elderly. The most widely used acetabular fracture classification system among radiologists and orthopedic surgeons is the system of Judet and Letournel, which includes five elementary (or elemental) and five associated fractures. The elementary fractures are anterior wall, posterior wall, anterior column, posterior column, and transverse. The associated fractures are all combinations or partial combinations of the elementary fractures and include transverse with posterior wall, T-shaped, associated both column, anterior column or wall with posterior hemitransverse, and posterior column with posterior wall. The most unique fracture is the associated both column fracture, which completely dissociates the acetabular articular surface from the sciatic buttress. Accurate categorization of acetabular fractures is challenging because of the complex three-dimensional (3D) anatomy of the pelvis, the rarity of certain acetabular fracture variants, and confusing nomenclature. Comparing a 3D image of the fractured acetabulum with a standard diagram containing the 10 Judet and Letournel categories of acetabular fracture and using a flowchart algorithm are effective ways of arriving at the correct fracture classification. Online supplemental material is available for this article. (C) RSNA, 2015.radiographics.rsna.org
C1 [Scheinfeld, Meir H.; Dym, R. Joshua] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Radiol, Div Emergency Radiol, Bronx, NY 10467 USA.
[Dym, Akiva A.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Spektor, Michael] Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06510 USA.
[Avery, Laura L.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp,Div Emergency Radiol, Boston, MA 02115 USA.
[Amanatullah, Derek F.] Stanford Univ, Dept Orthoped Surg, Palo Alto, CA 94304 USA.
RP Scheinfeld, MH (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Radiol, Div Emergency Radiol, 111 E 210 St, Bronx, NY 10467 USA.
EM mscheinf@montefiore.org
FU AONA; Trimed; Acumed; DePuy-Synthes; Medscape; Sanofi
FX D.F.A. Activities related to the present article: disclosed no relevant
relationships. Activities not related to the present article: grants
from AONA, Trimed, Acumed, and DePuy-Synthes and personal fees from
Medscape and Sanofi. Other activities: disclosed no relevant
relationships.
NR 86
TC 3
Z9 5
U1 3
U2 5
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0271-5333
J9 RADIOGRAPHICS
JI Radiographics
PD MAR-APR
PY 2015
VL 35
IS 2
BP 555
EP 577
DI 10.1148/rg.352140098
PG 23
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CF4YR
UT WOS:000352561000021
PM 25763739
ER
PT J
AU Yi, JS
Federation, AJ
Qi, J
Dhe-Paganon, S
Hadler, M
Xu, X
St Pierre, R
Varca, AC
Wu, L
Marineau, JJ
Smith, WB
Souza, A
Chory, EJ
Armstrong, SA
Bradner, JE
AF Yi, Joanna S.
Federation, Alexander J.
Qi, Jun
Dhe-Paganon, Sirano
Hadler, Michael
Xu, Xiang
St Pierre, Roodolph
Varca, Anthony C.
Wu, Lei
Marineau, Jason J.
Smith, William B.
Souza, Amanda
Chory, Emma J.
Armstrong, Scott A.
Bradner, James E.
TI Structure-Guided DOT1L Probe Optimization by Label-Free Ligand
Displacement
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID MIXED-LINEAGE LEUKEMIA; HISTONE METHYLTRANSFERASE DOT1L; H3K79
METHYLATION; INHIBITORS; POTENT; LEUKEMOGENESIS; CHROMATIN; CELLS
AB The DOT1L lysine methyltransferase has emerged as a validated therapeutic target in MLL-rearranged (MLLr) acute leukemias. Although S-adenosylmethionine competitive inhibitors have demonstrated pharmacological proof-of-principle in MLLr-leukemia, these compounds require further optimization to improve cellular potency and pharmacokinetic stability. Limiting DOT1L inhibitor discovery and ligand optimization have been complex biochemical methods often using radionucleotides and cellular methods requiring prolonged culture. We therefore developed a new suite of assay technologies that allows comparative assessment of chemical tools for DOT1L in a miniaturized format. Coupling these assays with structural information, we developed new insights into DOT1L ligand binding and identified several functionalized probes with increased cellular potency (IC50 values similar to 10 nM) and excellent selectivity for DOT1L. Together these assay technologies define a platform capability for discovery and optimization of small-molecule DOT1L inhibitors.
C1 [Yi, Joanna S.; Federation, Alexander J.; Qi, Jun; St Pierre, Roodolph; Varca, Anthony C.; Marineau, Jason J.; Smith, William B.; Souza, Amanda; Chory, Emma J.; Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Yi, Joanna S.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Yi, Joanna S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Dhe-Paganon, Sirano] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Hadler, Michael; Armstrong, Scott A.] Mem Sloan Kettering Canc Ctr, Dept Pediat, Human Oncol & Pathogenesis Program, New York, NY 10021 USA.
[Xu, Xiang] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Bradner, James E.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Wu, Lei] Shanghai ChemPartner Co Ltd, Shanghai, Peoples R China.
RP Bradner, JE (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM James_Bradner@dfci.harvard.edu
FU U.S. National Institutes of Health [R01 CA176745]; William Lawrence &
Blanche Hughes Foundation; Leukemia & Lymphoma Society SCOR; American
Society of Hematology-Scholar Award
FX We thank R. Paranal for his assistance in developing the high content
assay; we thank C. Ott for helpful discussions and D. Buckley for
thoughtful review of the manuscript. This work was funded by the U.S.
National Institutes of Health grant R01 CA176745, the William Lawrence &
Blanche Hughes Foundation, the Leukemia & Lymphoma Society SCOR grant,
and the American Society of Hematology-Scholar Award.
NR 23
TC 7
Z9 7
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD MAR
PY 2015
VL 10
IS 3
BP 667
EP 674
DI 10.1021/cb500796d
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CE1FY
UT WOS:000351558700003
PM 25397901
ER
PT J
AU Iaconelli, J
Huang, JH
Berkovitch, SS
Chattopadhyay, S
Mazitschek, R
Schreiber, SL
Haggarty, SJ
Karmacharya, R
AF Iaconelli, Jonathan
Huang, Joanne H.
Berkovitch, Shaunna S.
Chattopadhyay, Shrikanta
Mazitschek, Ralph
Schreiber, Stuart L.
Haggarty, Stephen J.
Karmacharya, Rakesh
TI HDAC6 Inhibitors Modulate Lys49 Acetylation and Membrane Localization of
beta-Catenin in Human iPSC-Derived Neuronal Cells
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID CHROMATIN-MEDIATED NEUROPLASTICITY; HISTONE DEACETYLASE INHIBITORS;
SYNAPTIC PLASTICITY; NUCLEAR-LOCALIZATION; MOUSE MODEL; PHOSPHORYLATION;
PROTEIN; ACTIVATION; MECHANISMS; DISEASE
AB We examined the effects of isoform-specific histone deacetylase (HDAC) inhibitors on beta-catenin posttranslational modifications in neural progenitor cells (NPCs) derived from human induced pluripotent stem cells (iPSCs). beta-catenin is a multifunctional protein with important roles in the developing and adult central nervous system. Activation of the Wnt pathway results in stabilization and nuclear translocation of beta-catenin, resulting in activation of multiple target genes. In addition, beta-catenin forms a complex with cadherins at the plasma membrane as part of the adherens junctions. The N-terminus of beta-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3 beta (GSK3 beta). beta-Catenin phosphorylated at these sites is recognized by beta-transducin repeat-containing protein (beta TrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of beta-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1 alpha (CK1 alpha) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of beta-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of beta-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of beta-catenin, it results in increased membrane localization of beta-catenin.
C1 [Iaconelli, Jonathan; Huang, Joanne H.; Berkovitch, Shaunna S.; Haggarty, Stephen J.; Karmacharya, Rakesh] Harvard Univ, Ctr Human Genet Res, Ctr Expt Drugs & Diagnost, Psychiat & Neurodev Genet Unit,Med Sch, Boston, MA 02114 USA.
[Iaconelli, Jonathan; Huang, Joanne H.; Berkovitch, Shaunna S.; Chattopadhyay, Shrikanta; Mazitschek, Ralph; Haggarty, Stephen J.; Karmacharya, Rakesh] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Iaconelli, Jonathan; Huang, Joanne H.; Berkovitch, Shaunna S.; Chattopadhyay, Shrikanta; Mazitschek, Ralph; Schreiber, Stuart L.; Karmacharya, Rakesh] Broad Inst Harvard & MIT, Ctr Sci Therapeut, Cambridge, MA 02142 USA.
[Karmacharya, Rakesh] McLean Hosp, Schizophrenia & Bipolar Disorder Program, Belmont, MA 02478 USA.
[Chattopadhyay, Shrikanta] Harvard Univ, MGH Canc Ctr, Sch Med, Boston, MA 02114 USA.
[Mazitschek, Ralph] Harvard Univ, Ctr Syst Biol, Sch Med, Boston, MA 02114 USA.
[Schreiber, Stuart L.] Harvard Univ, Howard Hughes Med Inst, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
RP Karmacharya, R (reprint author), Harvard Univ, Ctr Human Genet Res, Ctr Expt Drugs & Diagnost, Psychiat & Neurodev Genet Unit,Med Sch, Boston, MA 02114 USA.
EM karmacharya@mcb.harvard.edu
OI Haggarty, Stephen J./0000-0002-7872-168X
FU National Institute of Mental Health Clinical Scientist Development Award
[K08MH086846]; Brain and Behavior Research Foundation; Steve Willis and
Elissa Freud; National Institute of General Medical Sciences Award
[GM038627]; National Cancer Institute [P50CA086355]; National Institute
of Mental Health [R33MH087896]; National Institute of Drug Abuse Award
[R01DA028301]
FX We thank S. Sheridan and B. Ghosh for helpful discussions, K. Hennig for
technical assistance, and M. Bray for assistance with CellProfiler image
analysis. This work was supported by the National Institute of Mental
Health Clinical Scientist Development Award K08MH086846 (to R.K.), the
Brain and Behavior Research Foundation Young Investigator Award (to
R.K.), by Steve Willis and Elissa Freud (to R.K.), the National
Institute of General Medical Sciences Award GM038627 (to S.L.S.), the
National Cancer Institute Award P50CA086355 (to R.M.), the National
Institute of Mental Health Award R33MH087896 (to S.J.H.), and the
National Institute of Drug Abuse Award R01DA028301 (to S.J.H.).
NR 57
TC 9
Z9 10
U1 1
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD MAR
PY 2015
VL 10
IS 3
BP 883
EP 890
DI 10.1021/cb500838r
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CE1FY
UT WOS:000351558700027
PM 25546293
ER
PT J
AU Lee, K
Shao, HL
Weissleder, R
Lee, H
AF Lee, Kyungheon
Shao, Huilin
Weissleder, Ralph
Lee, Hakho
TI Acoustic Purification of Extracellular Microvesicles
SO ACS NANO
LA English
DT Article
DE nanotechnology; microvesicles; nanoparticle separation; microfluidics;
acoustic wave
ID RED-BLOOD-CELLS; LARGE ONCOSOMES; VESICLES; EXOSOMES; MICROPARTICLES;
SEPARATION; PARTICLES; THERAPY; WAVES
AB Microvesicles (MVs) are an increasingly important source for biomarker discovery and clinical diagnostics. The small size of MVs and their presence in complex biological environment, however, pose technical challenges in sample preparation, particularly when sample volumes are small. We herein present an acoustic nanofilter system that size-specifically separates MVs in a continuous and contact-free manner. The separation uses ultrasound standing waves to exert differential acoustic force on MVs according to their size and density. By optimizing the design of the ultrasound transducers and underlying electronics, we were able to achieve a high separation yield and resolution. The "filter size-cutoff' can be controlled electronically in situ, which enables versatile MV-size selection. We applied the acoustic nanofilter to isolate nanoscale (<200 nm) vesicles from cell culture media as well as MVs in stored red blood cell products. With the capacity for rapid and contact-free MV isolation, the developed system could become a versatile preparatory tool for MV analyses.
C1 [Lee, Kyungheon; Shao, Huilin; Weissleder, Ralph; Lee, Hakho] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
RP Lee, H (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,CPZN 5206, Boston, MA 02114 USA.
EM hlee@mgh.harvard.edu
RI Lee, Kyungheon/E-3863-2013
FU NIH [R01 HL113156, P01 CA069246, U54 CA151884]; DoD OCRP
[W81XWH-14-1-0279]; Basic Science Research Program through the National
Research Foundation of Korea (NRF) - Ministry of Education
[2012R1A6A3A03040166]
FX The authors thank X. O. Breakefield (Massachusetts General Hospital) for
access to and assistance with the NTA. The acoustic device was
fabricated using the facilities at the Center for Nanoscale Systems
(CNS) at Harvard University (National Science Foundation award
ECS-0335765). This work was supported in parts by NIH Grants R01
HL113156 (H.L.), P01 CA069246 (R.W.), U54 CA151884 (R.W.), and DoD OCRP
Award W81XWH-14-1-0279 (H.L.). This research was also partially
supported by Basic Science Research Program through the National
Research Foundation of Korea (NRF) funded by the Ministry of Education
2012R1A6A3A03040166 (K.L.)
NR 31
TC 27
Z9 27
U1 9
U2 56
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD MAR
PY 2015
VL 9
IS 3
BP 2321
EP 2327
DI 10.1021/nn506538f
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA CE4HN
UT WOS:000351791800010
PM 25672598
ER
PT J
AU Montgomerie, JZ
Lawrence, AE
LaMotte, AD
Taft, CT
AF Montgomerie, John Z.
Lawrence, Amy E.
LaMotte, Adam D.
Taft, Casey T.
TI The link between posttraumatic stress disorder and firearm violence: A
review
SO AGGRESSION AND VIOLENT BEHAVIOR
LA English
DT Review
DE PTSD; Firearm; violence; Mental illness; Mass shooting
ID NATIONAL COMORBIDITY SURVEY; DSM-IV DISORDERS; 3-YEAR FOLLOW-UP; SURVEY
REPLICATION; VETERANS-AFFAIRS; POLICE OFFICERS; COMBAT VETERANS; PTSD
SYMPTOMS; SUICIDE; SCHOOL
AB The relationship between firearm violence and mental illness has been a longstanding issue, and one that has received recent national attention due to highly publicized shootings. However, no prior reviews have focused on the relationship between firearm violence and posttraumatic stress disorder (PTSD) specifically. The current review examines evidence of PTSD as both a consequence of and risk factor for firearm violence. The studies reviewed suggest elevated rates of PTSD among those exposed to firearm violence, with particularly high levels of PTSD found among witnesses of mass shootings and firearm injury survivors. Additionally, these studies indicate that certain factors, such as closer proximity to the incident and closer relationship to the victims, increase one's risk for developing PTSD. Although there is a dearth of research on PTSD as a risk factor for perpetration of firearm violence, the available evidence suggests a significant connection between the two. Gaps in the current literature are discussed, as well as directions for future study. Firearm violence remains a significant public health concern, and identifying its impacts and potential risk factors such as PTSD will be crucial for interventions aimed at addressing this problem. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Montgomerie, John Z.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90089 USA.
[Lawrence, Amy E.; LaMotte, Adam D.; Taft, Casey T.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Taft, Casey T.] Boston Univ, Sch Med, Boston, MA 02215 USA.
RP Montgomerie, JZ (reprint author), Univ So Calif, Keck Sch Med, 1975 Zonal Ave, Los Angeles, CA 90089 USA.
EM Johnmont@usc.edu
NR 59
TC 0
Z9 0
U1 4
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-1789
EI 1873-6335
J9 AGGRESS VIOLENT BEH
JI Aggress. Violent Behav.
PD MAR-APR
PY 2015
VL 21
BP 39
EP 44
DI 10.1016/j.avb.2015.01.009
PG 6
WC Criminology & Penology; Psychology, Multidisciplinary
SC Criminology & Penology; Psychology
GA CE4GW
UT WOS:000351790100005
ER
PT J
AU Williston, SK
Taft, CT
VanHaasteren, KO
AF Williston, Sarah Krill
Taft, Casey T.
VanHaasteren, Kayla O.
TI Military veteran perpetrators of intimate partner violence: Challenges
and barriers to coordinated intervention
SO AGGRESSION AND VIOLENT BEHAVIOR
LA English
DT Article
DE Veterans; Trauma; PTSD; Intimate partner violence; Diversion programs
ID POSTTRAUMATIC-STRESS-DISORDER; DOMESTIC VIOLENCE; ANGER; AGGRESSION;
CARE; INVOLVEMENT; DEPLOYMENT; PATTERNS; SOLDIERS; BEHAVIOR
AB Intimate partner violence (IPV) is a significant concern among recently returning Veterans. In this paper, we discuss the etiology of IPV in this population and the intersections between Veteran healthcare and criminal justice system policies regarding Veteran IPV. We describe the current socio-political context in which clinical interventions and criminal justice diversion policies and pilot programs are emerging. Challenges to coordinating prevention and intervention across Veteran healthcare and criminal justice systems are discussed and highlighted via material on a Veteran-specific IPV intervention, and we discuss strategies for overcoming coordination challenges as well as areas for further innovation. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Williston, Sarah Krill] Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA.
[Taft, Casey T.; VanHaasteren, Kayla O.] VA Boston Healthcare Syst, Behav Hlth Sci Div, Natl Ctr PTSD, Boston, MA USA.
[Taft, Casey T.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA.
RP Williston, SK (reprint author), UMASS Boston, Dept Psychol, 100 Morrissey Blvd, Boston, MA 02125 USA.
EM Sarah.Kri11001@umb.edu
NR 47
TC 0
Z9 0
U1 3
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-1789
EI 1873-6335
J9 AGGRESS VIOLENT BEH
JI Aggress. Violent Behav.
PD MAR-APR
PY 2015
VL 21
BP 55
EP 60
DI 10.1016/j.avb.2015.01.008
PG 6
WC Criminology & Penology; Psychology, Multidisciplinary
SC Criminology & Penology; Psychology
GA CE4GW
UT WOS:000351790100007
ER
PT J
AU Yang, J
Song, Y
Wang, HX
Liu, CN
Li, ZZ
Liu, Y
Kong, YW
AF Yang, Jing
Song, Yang
Wang, Hongxin
Liu, Chunna
Li, Zhongzhe
Liu, Ying
Kong, Yawei
TI Insulin Treatment Prevents the Increase in D-Serine in Hippocampal CA1
Area of Diabetic Rats
SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS
LA English
DT Article
DE insulin; d-serine; long-term potentiation; water maze; serine racemase
ID LONG-TERM POTENTIATION; MORRIS WATER MAZE; SYNAPTIC PLASTICITY;
NMDA-RECEPTORS; SPATIAL MEMORY; AMINO-ACIDS; BRAIN; RACEMASE; MICE;
GLUTAMATE
AB Purpose: Diabetes is a high risk factor for dementia. Employing a diabetic rat model, the present study was designed to determine whether the content of d-serine (d-Ser) in hippocampus is associated with the impairment of spatial learning and memory ability.
Methods: Diabetes was induced by a single intravenous injection of streptozotocin (STZ). The insulin treatment began 3 days after STZ injection.
Results: We found that both water maze learning and hippocampal CA1 long-term potentiation (LTP) were impaired in diabetic rats. The contents of glutamate, d-Ser, and serine racemase in the hippocampus of diabetic rats were significantly higher than those in the control group. Insulin treatment prevented the STZ-induced impairment in water maze learning and hippocampal CA1-LTP in diabetic rats and also maintained the contents of glutamate, d-Ser, and serine racemase at the normal range in hippocampus.
Conclusions: These results suggest that insulin treatment has a potent protection effect on CA1-LTP, spatial learning and memory ability of the diabetic rats in vivo. Furthermore, insulin may take effect by inhibiting the overactivation of N-methyl-d-aspartate receptors, which play a critical role in neurotoxicity.
C1 [Yang, Jing; Song, Yang; Wang, Hongxin; Liu, Chunna; Li, Zhongzhe; Liu, Ying] Liaoning Med Univ, Prov Key Lab Cardiovasc & Cerebrovasc Drug Basic, Jinzhou 121001, Peoples R China.
[Kong, Yawei] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med,Div Plast & Reconstruct Surg, Boston, MA USA.
RP Yang, J (reprint author), Liaoning Med Univ, Prov Key Lab Cardiovasc & Cerebrovasc Drug Basic, Jinzhou 121001, Peoples R China.
EM yangjing@lnmu.edu.cn
FU Liaoning Province science and technology plan project, China
[2013225305]
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
supported by the grant No. 2013225305 from Liaoning Province science and
technology plan project, China.
NR 42
TC 2
Z9 2
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-3175
EI 1938-2731
J9 AM J ALZHEIMERS DIS
JI Am. J. Alzheimers Dis. Other Dement.
PD MAR
PY 2015
VL 30
IS 2
BP 201
EP 208
DI 10.1177/1533317514545379
PG 8
WC Geriatrics & Gerontology; Clinical Neurology
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA CE3EA
UT WOS:000351707000012
PM 25118332
ER
PT J
AU Hsieh, YH
Leung, FW
AF Hsieh, Yu-Hsi
Leung, Felix W.
TI The Ideal Insertion Method for Colonoscopy Is in the Eye of the Beholder
Response
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Letter
ID MINIMALLY SEDATED COLONOSCOPY; CONTROLLED-TRIAL
C1 [Hsieh, Yu-Hsi] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Med, Div Gastroenterol, Chiayi 62247, Taiwan.
[Hsieh, Yu-Hsi] Tzu Chi Univ, Sch Med, Hualien, Taiwan.
[Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hill, CA USA.
[Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Hsieh, YH (reprint author), Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Med, Div Gastroenterol, 2 Minsheng Rd, Chiayi 62247, Taiwan.
EM hsieh.yuhsi@msa.hinet.net
NR 5
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD MAR
PY 2015
VL 110
IS 3
BP 475
EP 476
DI 10.1038/ajg.2015.15
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CE6AF
UT WOS:000351917100022
PM 25743719
ER
PT J
AU Karaosmanoglu, AD
Khawaja, RDA
Onur, MR
Kalra, MK
AF Karaosmanoglu, Ali Devrim
Khawaja, Ranish Deedar Ali
Onur, Mehmet Ruhi
Kalra, Mannudeep K.
TI CT and MRI of Aortic Coarctation: Pre- and Postsurgical Findings
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE aortic coarctation; congenital heart disease; CT; MRI
ID CONGENITAL HEART-DISEASE; ANGIOGRAPHY; ADULT; ECHOCARDIOGRAPHY;
IMPLANTATION; MANAGEMENT; ANOMALIES; PREGNANCY; SPECTRUM
AB OBJECTIVE. The purpose of this article is to summarize the roles of CT and MRI in the diagnosis and follow-up of patients with aortic coarctation.
CONCLUSION. Aortic coarctation is a common congenital heart disease accounting for approximately 6-8% of congenital heart defects. Despite its deceptively simple anatomic presentation, it is a complex medical problem with several associated anatomic and physiologic abnormalities. CT and MRI may provide very accurate information of the coarctation anatomy and other associated cardiac abnormalities.
C1 [Karaosmanoglu, Ali Devrim] Hacettepe Univ, Sch Med, Dept Radiol, Ankara, Turkey.
[Khawaja, Ranish Deedar Ali; Kalra, Mannudeep K.] Massachusetts Gen Hosp, Div Cardiac Imaging, Boston, MA 02114 USA.
[Khawaja, Ranish Deedar Ali; Kalra, Mannudeep K.] Harvard Univ, Sch Med, Boston, MA USA.
[Onur, Mehmet Ruhi] Firat Univ, Sch Med, Dept Radiol, TR-23169 Elazig, Turkey.
RP Karaosmanoglu, AD (reprint author), Hacettepe Univ, Sch Med, Dept Radiol, Ankara, Turkey.
EM alidevrim76@yahoo.com
NR 38
TC 0
Z9 0
U1 0
U2 2
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
EI 1546-3141
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAR
PY 2015
VL 204
IS 3
BP W224
EP W233
DI 10.2214/AJR.14.12529
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CE1UU
UT WOS:000351598800001
PM 25714305
ER
PT J
AU Krajewski, KM
Nishino, M
Ramaiya, NH
Choueiri, TK
AF Krajewski, Katherine M.
Nishino, Mizuki
Ramaiya, Nikhil H.
Choueiri, Toni K.
TI RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell
Carcinoma Receiving Vascular Endothelial Growth Factor-Targeted Therapy
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE CT; renal cell carcinoma; Response Evaluation Criteria in Solid Tumors
(RECIST); tumor response assessment; vascular endothelial growth
factor-targeted therapy
ID RESPONSE EVALUATION CRITERIA; ADVANCED GASTRIC-CANCER; GUIDELINE VERSION
1.1; COMPUTED-TOMOGRAPHY; TUMOR RESPONSE; SOLID TUMORS; ATTENUATION;
SUNITINIB; EVALUATE; TRIAL
AB OBJECTIVE. Response Evaluation Criteria in Solid Tumors (RECIST) is the most widely accepted method to objectively assess response to therapy in renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy. Both RECIST 1.0 and 1.1 have been used to assess response to VEGF-targeted therapies; however, systematic comparisons are lacking.
MATERIALS AND METHODS. Sixty-two patients with metastatic RCC treated with VEGF-targeted therapies were retrospectively studied. Tumor measurements and response assessment according to RECIST 1.1 and RECIST 1.0 were compared, including the number of target lesions, baseline measurements, response at each follow-up, best overall response, and time to progression (TTP). Morphologic changes and new enhancement were also assessed over the course of treatment, and TTP was evaluated using morphologic change criteria in combination with RECIST 1.1.
RESULTS. The number of target lesions according to RECIST 1.1 was significantly fewer than by RECIST 1.0 (median, 2 vs 4; p < 0.0001). At first imaging follow-up, the percentage change of the sums of the diameter measurements by RECIST 1.1 and RECIST 1.0 were highly concordant (R = 0.857; mean shrinkage, 12.1% by RECIST 1.1 vs 10.8% by RECIST 1.0). Best response assessment was highly concordant between the two criteria (weighted. = 0.819). There was no evidence of a difference in TTP by the two criteria, with a median TTP of 8.9 months (95% CI for the median, 5.5-13.9) by RECIST 1.1 and 8.9 months (95% CI for the median, 5.8-13.6) by RECIST 1.0. The median TTP by RECIST 1.1 alone was 8.9 months compared with 5.6 months for RECIST 1.1 and morphologic changes combined.
CONCLUSION. RECIST 1.1 and RECIST 1.0 response assessments were overall highly concordant in patients with RCC treated with VEGF-targeted therapy, with fewer target lesions according to RECIST 1.1 but no difference in TTP.
C1 [Krajewski, Katherine M.; Nishino, Mizuki; Ramaiya, Nikhil H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Imaging, Boston, MA 02115 USA.
[Krajewski, Katherine M.; Nishino, Mizuki; Ramaiya, Nikhil H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Choueiri, Toni K.] Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA.
[Choueiri, Toni K.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Krajewski, KM (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Imaging, 450 Brookline Ave, Boston, MA 02115 USA.
EM kmkrajewski@partners.org
FU GE Healthcare; Association of University Radiologists; National Cancer
Institute [1K23CA157631]; Pfizer; Trust family; Loker Pinard; Michael
Brigham funds for Kidney Cancer Research
FX K. M. Krajewski received a research grant from GE Healthcare and the
Association of University Radiologists. M. Nishino received support from
the National Cancer Institute (grant 1K23CA157631). T. K. Choueiri
serves on the advisory boards for Pfizer, Aveo, GlaxoSmithKline, and
Novartis and has received research support from Pfizer, the Trust
family, Loker Pinard, and Michael Brigham funds for Kidney Cancer
Research.
NR 27
TC 4
Z9 4
U1 0
U2 0
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
EI 1546-3141
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAR
PY 2015
VL 204
IS 3
BP W282
EP W288
DI 10.2214/AJR.14.13236
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CE1UU
UT WOS:000351598800009
PM 25714313
ER
PT J
AU Rehani, MM
AF Rehani, Madan M.
TI What Makes and Keeps Radiation Risks Associated With CT a Hot Topic?
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Editorial Material
DE carcinogenic risks of CT; CT; radiation risks of CT; skin injuries in CT
ID COMPUTED-TOMOGRAPHY
C1 [Rehani, Madan M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rehani, Madan M.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Rehani, MM (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
EM madan.rehani@gmail.com
NR 10
TC 0
Z9 0
U1 0
U2 0
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
EI 1546-3141
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAR
PY 2015
VL 204
IS 3
BP W234
EP W235
DI 10.2214/AJR.14.12860
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CE1UU
UT WOS:000351598800002
PM 25714306
ER
PT J
AU Tedeschi, V
Rathmell, JP
Eisenach, JC
AF Tedeschi, Vicki
Rathmell, James P.
Eisenach, James C.
TI Finding and Getting What You Want When You Want It Just Got Easier at
Anesthesiology
SO ANESTHESIOLOGY
LA English
DT Editorial Material
C1 [Tedeschi, Vicki] Anesthesiol Editorial Off, Schaumburg, IL USA.
[Rathmell, James P.] Harvard Med Syst, Massachusetts Gen Hosp, Dept Anesthesiol & Crit Care Med, Boston, MA USA.
[Eisenach, James C.] Wake Forest Sch Med, Dept Anesthesiol, Winston Salem, NC 27157 USA.
RP Eisenach, JC (reprint author), Wake Forest Sch Med, Dept Anesthesiol, Winston Salem, NC 27157 USA.
EM Editor-in-Chief@asahq.org
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD MAR
PY 2015
VL 122
IS 3
BP 491
EP 494
DI 10.1097/ALN.0000000000000580
PG 4
WC Anesthesiology
SC Anesthesiology
GA CE3OY
UT WOS:000351737900005
PM 25603458
ER
PT J
AU Parker, MJ
Lovich, MA
Tsao, AC
Wei, AE
Wakim, MG
Maslov, MY
Tsukada, H
Peterfreund, RA
AF Parker, Michael J.
Lovich, Mark A.
Tsao, Amy C.
Wei, Abraham E.
Wakim, Matthew G.
Maslov, Mikhail Y.
Tsukada, Hisashi
Peterfreund, Robert A.
TI Computer Control of Drug Delivery by Continuous Intravenous Infusion
Bridging the Gap between Intended and Actual Drug Delivery
SO ANESTHESIOLOGY
LA English
DT Article
ID DEAD-VOLUME; IN-VITRO; DYNAMICS
AB Background: Intravenous drug infusion driven by syringe pumps may lead to substantial temporal lags in achieving steady-state delivery at target levels when using very low flow rates (microinfusion). This study evaluated computer algorithms for reducing temporal lags via coordinated control of drug and carrier flows.
Methods: Novel computer control algorithms were developed based on mathematical models of fluid flow. Algorithm 1 controlled initiation of drug infusion and algorithm 2 controlled changes to ongoing steady-state infusions. These algorithms were tested in vitro and in vivo using typical high and low dead volume infusion system architectures. One syringe pump infused a carrier fluid and a second infused drug. Drug and carrier flowed together via a manifold through standard central venous catheters. Samples were collected in vitro for quantitative delivery analysis. Parameters including left ventricular max dP/dt were recorded in vivo.
Results: Regulation by algorithm 1 reduced delivery delay in vitro during infusion initiation by 69% (low dead volume) and 78% (high dead volume). Algorithmic control in vivo measuring % change in max dP/dt showed similar results (55% for low dead volume and 64% for high dead volume). Algorithm 2 yielded greater precision in matching the magnitude and timing of intended changes in vivo and in vitro.
Conclusions: Compared with conventional methods, algorithm-based computer control of carrier and drug flows can improve drug delivery by pump-driven intravenous infusion to better match intent. For norepinephrine infusions, the amount of drug reaching the bloodstream per time appears to be a dominant factor in the hemodynamic response to infusion.
C1 [Parker, Michael J.] Beth Israel Deaconess Med Ctr, Dept Med, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA.
[Lovich, Mark A.; Wei, Abraham E.; Wakim, Matthew G.; Maslov, Mikhail Y.] Steward St Elizabeths Med Ctr, Dept Anesthesiol & Pain Med, Boston, MA USA.
[Tsukada, Hisashi] Steward St Elizabeths Med Ctr, Dept Med, Div Pulmonol, Boston, MA USA.
[Tsao, Amy C.; Peterfreund, Robert A.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Parker, MJ (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Pulm Crit Care & Sleep Med,Dept Med, 25 Shattuck St,Room 307D, Boston, MA 02115 USA.
EM michael_parker@hms.harvard.edu
NR 11
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD MAR
PY 2015
VL 122
IS 3
BP 647
EP 658
DI 10.1097/ALN.0000000000000519
PG 12
WC Anesthesiology
SC Anesthesiology
GA CE3OY
UT WOS:000351737900018
PM 25419684
ER
PT J
AU Mauck, RL
Burdick, JA
AF Mauck, Robert L.
Burdick, Jason A.
TI From Repair to Regeneration: Biomaterials to Reprogram the Meniscus
Wound Microenvironment
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE Meniscus; Biomaterials; Wound healing; Regeneration; Scaffold;
Extracellular matrix
ID STEM-CELL DIFFERENTIATION; NECROSIS-FACTOR-ALPHA; HUMAN KNEE-JOINT;
IN-VITRO; NUCLEAR MECHANICS; HYALURONIC-ACID; SYNOVIAL-FLUID;
3-DIMENSIONAL HYDROGELS; NANOFIBROUS SCAFFOLDS; PARTIAL MENISCECTOMY
AB When the field of tissue engineering first arose, scaffolds were conceived of as inert three-dimensional structures whose primary function was to support cellularity and tissue growth. Since then, advances in scaffold and biomaterial design have evolved to not only guide tissue formation, but also to interact dynamically with and manipulate the wound environment. At present, these efforts are being directed towards strategies that directly address limitations in endogenous wound repair, with the goal of reprogramming the local wound environment (and the cells within that locality) from a state that culminates in an inferior tissue repair into a state in which functional regeneration is achieved. This review will address this approach with a focus on recent advances in scaffold design towards the resolution of tears of the knee meniscus as a case example. The inherent limitations to endogenous repair will be discussed, as will specific examples of how biomaterials are being designed to overcome these limitations. Examples will include design of fibrous scaffolds that promote colonization by modulating local extracellular matrix density and delivering recruitment factors. Furthermore, we will discuss scaffolds that are themselves modulated by the wound environment to alter porosity and modulate therapeutic release through precise coordination of scaffold degradation. Finally, we will close with emerging concepts in local control of cell mechanics to improve interstitial cell migration and so advance repair. Overall, these examples will illustrate how emergent features within a biomaterial can be tuned to manipulate and harness the local tissue microenvironment in order to promote robust regeneration.
C1 [Mauck, Robert L.] Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Burdick, Jason A.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.
[Mauck, Robert L.; Burdick, Jason A.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA.
RP Mauck, RL (reprint author), Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Perelman Sch Med, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA.
EM lemauck@mail.med.upenn.edu; burdick2@seas.upenn.edu
FU National Institutes of Health [R01 EB008722, AR056624]; Department of
Veterans Affairs [I01 RX000700, RX000174]
FX This work was supported with grants from the National Institutes of
Health (R01 EB008722 and AR056624) and the Department of Veterans
Affairs (I01 RX000700 and RX000174). The authors gratefully acknowledge
Dr. Brendon Baker, Dr. Matt Fisher, Dr. Lara Ionescu, Dr. Iris Kim, Dr.
Brendan Purcell, and Ms. Feini (Sylvia) Qu for their helpful input,
graphical design, and in depth discussions on this topic.
NR 122
TC 9
Z9 9
U1 3
U2 29
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0090-6964
EI 1573-9686
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD MAR
PY 2015
VL 43
IS 3
BP 529
EP 542
DI 10.1007/s10439-015-1249-z
PG 14
WC Engineering, Biomedical
SC Engineering
GA CE3QF
UT WOS:000351742500005
PM 25650096
ER
PT J
AU Davids, MS
Kim, H
Costello, C
Avigan, D
Chen, YB
Armand, P
Alyea, EP
Hedlund, J
McSweeney, P
Liguori, R
Ritz, J
Ball, E
Bashey, A
Soiffer, R
AF Davids, M. S.
Kim, H.
Costello, C.
Avigan, D.
Chen, Y. B.
Armand, P.
Alyea, E. P.
Hedlund, J.
McSweeney, P.
Liguori, R.
Ritz, J.
Ball, E.
Bashey, A.
Soiffer, R.
CA Blood Canc Res Partnership
TI Interim results of a multicenter phase I/Ib study of CTLA4 blockade with
ipilimumab for relapsed hematologic malignancies after allogeneic
hematopoietic cell transplantation
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the
European-Society-for-Blood-and-Marrow-Transplantation
CY MAR 22-25, 2015
CL Istanbul, TURKEY
SP European Soc Blood & Marrow Transplantat
C1 [Davids, M. S.; Kim, H.; Armand, P.; Alyea, E. P.; Liguori, R.; Ritz, J.; Soiffer, R.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA.
[Costello, C.; Ball, E.] Univ Calif San Diego, Moores Canc Ctr, Div BMT, La Jolla, CA 92093 USA.
[Avigan, D.] Beth Israel Deaconess Med Ctr, BMT Program, Boston, MA 02215 USA.
[Chen, Y. B.] Massachusetts Gen Hosp, Ctr Canc, BMT Program, Boston, MA USA.
[Hedlund, J.] New England Canc Specialists, Maine Ctr Canc Med, Scarborough, ME USA.
[McSweeney, P.] Colorado Blood Canc Inst, Denver, CO USA.
[Bashey, A.] Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD MAR
PY 2015
VL 50
SU 1
MA O141
BP S82
EP S82
PG 1
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA CE2GN
UT WOS:000351632900142
ER
PT J
AU Kekre, N
Kim, H
Thanarajasingam, G
Armand, P
Antin, J
Cutler, C
Nikiforow, S
Ho, V
Alyea, E
Koreth, J
Soiffer, R
AF Kekre, N.
Kim, H.
Thanarajasingam, G.
Armand, P.
Antin, J.
Cutler, C.
Nikiforow, S.
Ho, V.
Alyea, E.
Koreth, J.
Soiffer, R.
TI Immunosuppression Taper as the Sole Therapy for Early Relapse is
Effective after Reduced Intensity Allogeneic Hematopoietic Cell
Transplantation
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the
European-Society-for-Blood-and-Marrow-Transplantation
CY MAR 22-25, 2015
CL Istanbul, TURKEY
SP European Soc Blood & Marrow Transplantat
C1 [Kekre, N.; Kim, H.; Armand, P.; Antin, J.; Cutler, C.; Nikiforow, S.; Ho, V.; Alyea, E.; Koreth, J.; Soiffer, R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Thanarajasingam, G.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD MAR
PY 2015
VL 50
SU 1
MA P667
BP S453
EP S454
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA CE2GN
UT WOS:000351632902280
ER
PT J
AU Khera, N
Albelda, R
Hahn, T
Salas-Coronado, D
Marcellot, L
Tucker-Seeley, R
Odejide, O
Soiffer, R
Abel, G
AF Khera, N.
Albelda, R.
Hahn, T.
Salas-Coronado, D.
Marcellot, L.
Tucker-Seeley, R.
Odejide, O.
Soiffer, R.
Abel, G.
TI Association of Psycho social Outcomes with Familial Financial Hardship
after Hematopoietic Cell Transplantation
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the
European-Society-for-Blood-and-Marrow-Transplantation
CY MAR 22-25, 2015
CL Istanbul, TURKEY
SP European Soc Blood & Marrow Transplantat
C1 [Khera, N.] Mayo Clin, Phoenix, AZ USA.
[Albelda, R.] Univ Massachusetts, Boston, MA 02125 USA.
[Hahn, T.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Salas-Coronado, D.; Marcellot, L.; Tucker-Seeley, R.; Odejide, O.; Soiffer, R.; Abel, G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD MAR
PY 2015
VL 50
SU 1
MA P606
BP S423
EP S423
PG 1
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA CE2GN
UT WOS:000351632902219
ER
PT J
AU Khera, N
Chai, X
Duong, H
Inamoto, Y
Chen, G
Mayer, S
Arora, M
Palmer, J
Flowers, M
Cutler, C
Lukez, A
Arai, S
Lazaryan, A
Pusic, I
Krupski, MC
Wood, W
Lee, S
Pidala, J
AF Khera, N.
Chai, X.
Duong, H.
Inamoto, Y.
Chen, G.
Mayer, S.
Arora, M.
Palmer, J.
Flowers, M.
Cutler, C.
Lukez, A.
Arai, S.
Lazaryan, A.
Pusic, I.
Krupski, M. C.
Wood, W.
Lee, S.
Pidala, J.
TI Prospective Longitudinal Study of Late Acute Graft Versus Host Disease
after Hematopoietic Cell Transplantation: A Report from Chronic GVHD
Consortium
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the
European-Society-for-Blood-and-Marrow-Transplantation
CY MAR 22-25, 2015
CL Istanbul, TURKEY
SP European Soc Blood & Marrow Transplantat
C1 [Khera, N.; Palmer, J.] Mayo Clin, Phoenix, AZ USA.
[Chai, X.; Flowers, M.; Lee, S.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Duong, H.] Cleveland Clin, Cleveland, OH 44106 USA.
[Inamoto, Y.] Natl Canc Ctr, Tokyo, Japan.
[Chen, G.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Mayer, S.] Weill Cornell Med Coll, New York, NY USA.
[Arora, M.; Lazaryan, A.] Univ Minnesota, Minneapolis, MN USA.
[Cutler, C.; Lukez, A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Arai, S.] Stanford Univ, Palo Alto, CA 94304 USA.
[Pusic, I.] Washington Univ, St Louis, MO 63130 USA.
[Krupski, M. C.] Vanderbilt Univ, Nashville, TN 37235 USA.
[Wood, W.] Univ N Carolina, Chapel Hill, NC USA.
[Pidala, J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD MAR
PY 2015
VL 50
SU 1
MA P528
BP S384
EP S385
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA CE2GN
UT WOS:000351632902143
ER
PT J
AU Kim, JW
Lee, J
Kim, BS
Chong, SY
Jung, CW
Kim, YK
Mun, YC
Jo, DY
Lee, HG
Won, JH
Park, JS
Lee, JH
Moon, JH
Do, YR
Cheong, JW
Lee, JH
Yhim, HY
Kim, H
Yoon, SS
AF Kim, J. -W.
Lee, J.
Kim, B. -S.
Chong, S. Y.
Jung, C. W.
Kim, Y. -K.
Mun, Y. -C.
Jo, D. -Y.
Lee, H. G.
Won, J. -H.
Park, J. S.
Lee, J. H.
Moon, J. H.
Do, Y. R.
Cheong, J. -W.
Lee, J. -H.
Yhim, H. -Y.
Kim, H.
Yoon, S. -S.
CA Korean Soc Blood Marrow
TI Impact of stem cell dose and performance status on cord blood
transplantation outcome in adult patients with advanced hematologic
diseases: 13-year experience in Korea
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the
European-Society-for-Blood-and-Marrow-Transplantation
CY MAR 22-25, 2015
CL Istanbul, TURKEY
SP European Soc Blood & Marrow Transplantat
C1 [Kim, J. -W.; Yoon, S. -S.] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
[Lee, J.; Kim, B. -S.] Daegu Fatima Hosp, Dept Internal Med, Daegu, South Korea.
[Chong, S. Y.] Bundang CHA Hosp, Dept Internal Med, Songnam, South Korea.
[Jung, C. W.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Internal Med, Seoul, South Korea.
[Kim, Y. -K.] Chonnam Natl Univ, Hwasun Hosp, Dept Internal Med, Gwangju, South Korea.
[Mun, Y. -C.] Ewha Womans Univ, Mokdong Hosp, Dept Internal Med, Seoul, South Korea.
[Jo, D. -Y.] Chungnam Natl Univ Hosp, Dept Internal Med, Taejon, South Korea.
[Lee, H. G.] Konkuk Univ Hosp, Dept Internal Med, Seoul, South Korea.
[Won, J. -H.] Soon Chun Hyang Univ Hosp, Dept Internal Med, Seoul, South Korea.
[Park, J. S.] Ajou Univ Hosp, Dept Internal Med, Suwon, South Korea.
[Lee, J. H.] Gachon Univ, Gil Hosp, Dept Internal Med, Inchon, South Korea.
[Moon, J. H.] Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea.
[Do, Y. R.] Dongsan Med Ctr, Dept Internal Med, Daegu, South Korea.
[Cheong, J. -W.] Yonsei Univ, Severance Hosp, Dept Internal Med, Seoul 120749, South Korea.
[Lee, J. -H.] Asan Med Ctr, Dept Internal Med, Seoul, South Korea.
[Yhim, H. -Y.] Chonbuk Natl Univ Hosp, Dept Internal Med, Jeonju, South Korea.
[Kim, H.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD MAR
PY 2015
VL 50
SU 1
MA P465
BP S354
EP S355
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA CE2GN
UT WOS:000351632902083
ER
PT J
AU Kotsiou, E
Guinan, E
Gribben, J
Davies, J
AF Kotsiou, E.
Guinan, E.
Gribben, J.
Davies, J.
TI Phenotypic and functional stability of regulatory T cells expanded after
alloanergization with costimulatory molecule blockade
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the
European-Society-for-Blood-and-Marrow-Transplantation
CY MAR 22-25, 2015
CL Istanbul, TURKEY
SP European Soc Blood & Marrow Transplantat
C1 [Kotsiou, E.; Gribben, J.; Davies, J.] Barts Canc Inst, Ctr Hematooncol, London, England.
[Guinan, E.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Guinan, E.] Dana Farber Canc Inst, Dept Pediat, Boston, MA 02115 USA.
[Guinan, E.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD MAR
PY 2015
VL 50
SU 1
MA P502
BP S373
EP S373
PG 1
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA CE2GN
UT WOS:000351632902120
ER
PT J
AU Madenci, AL
Stetson, A
Weldon, C
Lehmann, L
AF Madenci, A. L.
Stetson, A.
Weldon, C.
Lehmann, L.
TI Safety of peritoneal and pleural drain placement in pediatric stem cell
transplant recipients with severe veno-occlusive disease
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the
European-Society-for-Blood-and-Marrow-Transplantation
CY MAR 22-25, 2015
CL Istanbul, TURKEY
SP European Soc Blood & Marrow Transplantat
C1 [Madenci, A. L.; Weldon, C.] Boston Childrens Hosp, Dept Surg, Boston, MA USA.
[Madenci, A. L.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Stetson, A.; Weldon, C.; Lehmann, L.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Lehmann, L.] Boston Childrens Hosp, Dept Med, Div Hematol Oncol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD MAR
PY 2015
VL 50
SU 1
MA P256
BP S244
EP S245
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA CE2GN
UT WOS:000351632901251
ER
PT J
AU Nicolini, FE
DeAngelo, DJ
Abruzzese, E
Apperley, JF
Holyoake, TL
Larson, RA
Lustgarten, S
Rivera, VM
Clackson, T
Conlon, MG
Haluska, FG
Talpaz, M
Cortes, JE
AF Nicolini, F. E.
DeAngelo, D. J.
Abruzzese, E.
Apperley, J. F.
Holyoake, T. L.
Larson, R. A.
Lustgarten, S.
Rivera, V. M.
Clackson, T.
Conlon, M. G.
Haluska, F. G.
Talpaz, M.
Cortes, J. E.
TI Ponatinib for Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome
Positive Acute Lymphoblastic Leukemia (Ph plus ALL) With History of Stem
Cell Transplantation (SCT): Efficacy and Safety Results of the PACE
Trial
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the
European-Society-for-Blood-and-Marrow-Transplantation
CY MAR 22-25, 2015
CL Istanbul, TURKEY
SP European Soc Blood & Marrow Transplantat
C1 [Nicolini, F. E.] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France.
[DeAngelo, D. J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Abruzzese, E.] Univ Roma Tor Vergata, S Eugenio Hosp, Rome, Italy.
[Apperley, J. F.] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, London, England.
[Holyoake, T. L.] Univ Glasgow, Inst Canc Sci, Paul OGorman Leukaemia Res Ctr, Glasgow, Lanark, Scotland.
[Larson, R. A.] Univ Chicago, Chicago, IL 60637 USA.
[Lustgarten, S.; Rivera, V. M.; Clackson, T.; Conlon, M. G.; Haluska, F. G.] ARIAD Pharmaceut Inc, Cambridge, MA USA.
[Talpaz, M.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Cortes, J. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
RI Holyoake, Tessa/M-3668-2015
OI Holyoake, Tessa/0000-0002-0608-6066
NR 0
TC 0
Z9 0
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD MAR
PY 2015
VL 50
SU 1
MA P744
BP S490
EP S490
PG 1
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA CE2GN
UT WOS:000351632902352
ER
PT J
AU Richardson, PG
Smith, AR
Triplett, BM
Kernan, NA
Grupp, SA
Antin, JH
Lehmann, L
Miloslavsky, M
Hume, R
Hannah, AL
Nejadnik, B
Soiffer, RJ
AF Richardson, P. G.
Smith, A. R.
Triplett, B. M.
Kernan, N. A.
Grupp, S. A.
Antin, J. H.
Lehmann, L.
Miloslavsky, M.
Hume, R.
Hannah, A. L.
Nejadnik, B.
Soiffer, R. J.
TI Defibrotide for Pediatric and Adult Patients with Hepatic Veno-occlusive
Disease: Interim Age Subgroup Survival Analysis From an Ongoing Expanded
Access Program in the US
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the
European-Society-for-Blood-and-Marrow-Transplantation
CY MAR 22-25, 2015
CL Istanbul, TURKEY
SP European Soc Blood & Marrow Transplantat
C1 [Richardson, P. G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancy,Dept Med Oncol,Jerome Lipp, Boston, MA 02115 USA.
[Smith, A. R.] Univ Minnesota, Div Pediat Blood & Marrow Transplantat, Minneapolis, MN USA.
[Triplett, B. M.] St Jude Childrens Res Hosp, Bone Marrow Transplantat & Cellular Therapy, Memphis, TN 38105 USA.
[Kernan, N. A.] Mem Sloan Kettering Canc Ctr, Pediat BMT Serv, New York, NY 10021 USA.
[Grupp, S. A.] Childrens Hosp Philadelphia, Pediat Oncol, Philadelphia, PA 19104 USA.
[Antin, J. H.; Soiffer, R. J.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Dept Med Oncol, Stem Cell Bone Marrow Transplantat Program,Div He, Boston, MA 02115 USA.
[Lehmann, L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancy,Dept Med Oncol,Ctr Stem Ce, Boston, MA 02115 USA.
[Miloslavsky, M.; Hume, R.; Hannah, A. L.; Nejadnik, B.] Jazz Pharmaceut Inc, Palo Alto, CA USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD MAR
PY 2015
VL 50
SU 1
MA O127
BP S74
EP S75
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA CE2GN
UT WOS:000351632900128
ER
PT J
AU Richardson, PG
Smith, AR
Triplett, BM
Kernan, NA
Grupp, SA
Antin, JH
Lehmann, L
Miloslavsky, M
Hume, R
Hannah, AL
Nejadnik, B
Soiffer, RJ
AF Richardson, P. G.
Smith, A. R.
Triplett, B. M.
Kernan, N. A.
Grupp, S. A.
Antin, J. H.
Lehmann, L.
Miloslavsky, M.
Hume, R.
Hannah, A. L.
Nejadnik, B.
Soiffer, R. J.
TI Defibrotide for Hepatic Veno-Occlusive Disease Following Allogeneic or
Autologous Hematopoietic Stem Cell Transplant: Interim Subgroup Survival
Analysis From an Ongoing US Study
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the
European-Society-for-Blood-and-Marrow-Transplantation
CY MAR 22-25, 2015
CL Istanbul, TURKEY
SP European Soc Blood & Marrow Transplantat
C1 [Richardson, P. G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancy,Dept Med Oncol,Jerome Lipp, Boston, MA 02115 USA.
[Smith, A. R.] Univ Minnesota, Div Pediat Blood & Marrow Transplantat, Minneapolis, MN USA.
[Triplett, B. M.] St Jude Childrens Res Hosp, Bone Marrow Transplantat & Cellular Therapy, Memphis, TN 38105 USA.
[Kernan, N. A.] Mem Sloan Kettering Canc Ctr, Pediat BMT Serv, New York, NY 10021 USA.
[Grupp, S. A.] Childrens Hosp Philadelphia, Pediat Oncol, Philadelphia, PA 19104 USA.
[Antin, J. H.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Dept Med Oncol, Stem Cell Bone Marrow Transplantat Program,Div He, Boston, MA 02115 USA.
[Lehmann, L.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Dept Med Oncol, Ctr Stem Cell Transplantat,Div Hematol Malignancy, Boston, MA 02115 USA.
[Miloslavsky, M.; Hume, R.; Hannah, A. L.; Nejadnik, B.; Soiffer, R. J.] Jazz Pharmaceut Inc, Palo Alto, CA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD MAR
PY 2015
VL 50
SU 1
MA O058
BP S34
EP S35
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA CE2GN
UT WOS:000351632900059
ER
PT J
AU Vij, R
Hars, V
Blum, W
Shore, T
Rapoport, A
Shea, T
Hoke, E
Stone, R
Friedman, P
Owzar, K
Devine, S
AF Vij, R.
Hars, V.
Blum, W.
Shore, T.
Rapoport, A.
Shea, T.
Hoke, E.
Stone, R.
Friedman, P.
Owzar, K.
Devine, S.
TI CALGB 100801 (Alliance): A phase II multi-center study of azacitidine
(AZA) following allogeneic transplantation using a "test dose'' targeted
busulfan conditioning regimen for high risk myelodysplasia and older
patients with acute myeloid leukemia
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the
European-Society-for-Blood-and-Marrow-Transplantation
CY MAR 22-25, 2015
CL Istanbul, TURKEY
SP European Soc Blood & Marrow Transplantat
C1 [Vij, R.] Washington Univ, Sect BMT & Leukemia, Sch Med, St Louis, MO 63130 USA.
[Hars, V.; Hoke, E.] Duke Univ, Alliance Stat & Data Ctr, Durham, NC 27706 USA.
[Blum, W.; Devine, S.] Ohio State Univ, Columbus, OH 43210 USA.
[Shore, T.] Weill Med Coll, New York, NY USA.
[Rapoport, A.] Univ Maryland, Baltimore, MD 21201 USA.
[Shea, T.] Univ N Carolina, Chapel Hill, NC USA.
[Stone, R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Friedman, P.] Univ Chicago, Chicago, IL 60637 USA.
[Owzar, K.] Alliance Stat & Data Ctr, Durham, NC USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD MAR
PY 2015
VL 50
SU 1
MA P640
BP S440
EP S441
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA CE2GN
UT WOS:000351632902253
ER
PT J
AU Yuan, A
Chai, X
Martins, F
Cutler, C
Lee, S
Treister, N
AF Yuan, A.
Chai, X.
Martins, F.
Cutler, C.
Lee, S.
Treister, N.
TI Oral chronic graft-versus-host disease outcomes and resource
utilization: a subanalysis from the chronic GVHD Consortium
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the
European-Society-for-Blood-and-Marrow-Transplantation
CY MAR 22-25, 2015
CL Istanbul, TURKEY
SP European Soc Blood & Marrow Transplantat
C1 [Yuan, A.; Treister, N.] Brigham & Womens Hosp, Div Oral Med & Dent, Boston, MA 02115 USA.
[Yuan, A.; Treister, N.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Chai, X.; Lee, S.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Martins, F.] Univ Sao Paulo, Sch Dent, Dept Oral Pathol, Sao Paulo, Brazil.
[Cutler, C.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD MAR
PY 2015
VL 50
SU 1
MA P092
BP S162
EP S163
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA CE2GN
UT WOS:000351632901088
ER
PT J
AU Burstein, HJ
AF Burstein, H. J.
TI Endocrine therapy for post-menopausal patients: type and duration
SO BREAST
LA English
DT Meeting Abstract
ID ADJUVANT TAMOXIFEN; METAANALYSIS; TRIALS
C1 [Burstein, H. J.] Harvard Univ, Sch Med, Breast Oncol Ctr, Dana Farber Canc Inst, Boston, MA USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
EI 1532-3080
J9 BREAST
JI Breast
PD MAR
PY 2015
VL 24
SU 1
MA PG 11.02
BP S21
EP S22
PG 2
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA CE4IT
UT WOS:000351795000040
ER
PT J
AU Garber, J
AF Garber, J.
TI Using germline genetics in the management of breast cancer patients and
their families
SO BREAST
LA English
DT Meeting Abstract
C1 [Garber, J.] Dana Farber Canc Inst, Ctr Canc Genet & Prevent, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
EI 1532-3080
J9 BREAST
JI Breast
PD MAR
PY 2015
VL 24
SU 1
MA PG 6.01
BP S10
EP S11
PG 2
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA CE4IT
UT WOS:000351795000021
ER
PT J
AU Partridge, A
AF Partridge, A.
TI Management of breast cancer in very young women
SO BREAST
LA English
DT Meeting Abstract
C1 [Partridge, A.] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
EI 1532-3080
J9 BREAST
JI Breast
PD MAR
PY 2015
VL 24
SU 1
MA PG 13.01
BP S24
EP S24
PG 1
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA CE4IT
UT WOS:000351795000046
ER
PT J
AU Regan, M
AF Regan, M.
TI Predicting benefit of endocrine therapy
SO BREAST
LA English
DT Meeting Abstract
C1 [Regan, M.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
EI 1532-3080
J9 BREAST
JI Breast
PD MAR
PY 2015
VL 24
SU 1
MA PG 11.03
BP S22
EP S22
PG 1
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA CE4IT
UT WOS:000351795000041
ER
PT J
AU Winer, E
AF Winer, E.
TI Tailoring the chemotherapy regimen in patients with triple negative
subtypes
SO BREAST
LA English
DT Meeting Abstract
C1 [Winer, E.] Dana Farber Canc Inst, Div Womens Canc, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
EI 1532-3080
J9 BREAST
JI Breast
PD MAR
PY 2015
VL 24
SU 1
MA PG 12.01
BP S22
EP S22
PG 1
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA CE4IT
UT WOS:000351795000042
ER
PT J
AU Javidi-Sharifi, N
Traer, E
Martinez, J
Gupta, A
Taguchi, T
Dunlap, J
Heinrich, MC
Corless, CL
Rubin, BP
Druker, BJ
Tyner, JW
AF Javidi-Sharifi, Nathalie
Traer, Elie
Martinez, Jacqueline
Gupta, Anu
Taguchi, Takehiro
Dunlap, Jennifer
Heinrich, Michael C.
Corless, Christopher L.
Rubin, Brian P.
Druker, Brian J.
Tyner, Jeffrey W.
TI Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor
Cell Growth and Drug Resistance
SO CANCER RESEARCH
LA English
DT Article
ID PROSTATE-CANCER; FACTOR RECEPTOR-3; LUNG-CANCER; B-RAF; SURVIVAL;
LEUKEMIA; IMATINIB; MUTATION; KINASE; MECHANISMS
AB Kinase inhibitors such as imatinib have dramatically improved outcomes for patients with gastrointestinal stromal tumor (GIST), but many patients develop resistance to these treatments. Although in some patients this event corresponds with mutations in the GIST driver oncogenic kinase KIT, other patients develop resistance without KIT mutations. In this study, we address this patient subset in reporting a functional dependence of GIST on the FGF receptor FGFR3 and its crosstalk with KIT in GIST cells. Addition of the FGFR3 ligand FGF2 to GIST cells restored KIT phosphorylation during imatinib treatment, allowing sensitive cells to proliferate in the presence of the drug. FGF2 expression was increased in imatinib-resistant GIST cells, the growth of which was blocked by RNAi-mediated silencing of FGFR3. Moreover, combining KIT and FGFR3 inhibitors synergized to block the growth of imatinib-resistant cells. Signaling crosstalk between KIT and FGFR3 activated the MAPK pathway to promote resistance to imatinib. Clinically, an IHC analysis of tumor specimens from imatinib-resistant GIST patients revealed a relative increase in FGF2 levels, with a trend toward increased expression in imatinib-naive samples consistent with possible involvement in drug resistance. Our findings provide a mechanistic rationale to evaluate existing FGFR inhibitors and multikinase inhibitors that target FGFR3 as promising strategies to improve treatment of patients with GIST with de novo or acquired resistance to imatinib. (C)2014 AACR.
C1 [Javidi-Sharifi, Nathalie; Traer, Elie; Martinez, Jacqueline; Dunlap, Jennifer; Heinrich, Michael C.; Corless, Christopher L.; Druker, Brian J.; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA.
[Javidi-Sharifi, Nathalie; Traer, Elie; Heinrich, Michael C.; Druker, Brian J.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA.
[Gupta, Anu; Rubin, Brian P.] Lerner Res Inst, Dept Mol Genet, Cleveland, OH USA.
[Taguchi, Takehiro] Kochi Univ, Grad Sch Kuroshio Sci, Div Human Hlth & Med Sci, Nankoku, Kochi, Japan.
[Dunlap, Jennifer; Corless, Christopher L.] Oregon Hlth & Sci Univ, Depat Anat Pathol, Portland, OR 97239 USA.
[Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA.
[Rubin, Brian P.] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA.
[Rubin, Brian P.] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA.
[Druker, Brian J.] Howard Hughes Med Inst, Portland, OR USA.
[Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97239 USA.
RP Tyner, JW (reprint author), Oregon Hlth & Sci Univ, Knight Canc Inst, 3181 Southwest Sam Jackson Pk Rd,Mailcode L592, Portland, OR 97239 USA.
EM tynerj@ohsu.edu
FU Oregon Clinical and Translational Research Institute (OCTRI); National
Center for Advancing Translational Sciences (NCATS) [TL1 RR024159]; NIH;
NIH Roadmap for Medical Research; V Foundation for Cancer Research;
Leukemia and Lymphoma Society; Gabrielle's Angel Foundation for Cancer
Research; National Cancer Institute [5R00CA151457-04, 1R01CA183974-01];
Life Raft Group
FX N. Javidi-Sharifi was supported by the Oregon Clinical and Translational
Research Institute (OCTRI), grant number TL1 RR024159 from the National
Center for Advancing Translational Sciences (NCATS), a component of the
NIH, and NIH Roadmap for Medical Research. B.J. Druker was an
investigator of the Howard Hughes Medical Institute. J.W. Tyner was
supported by grants from the V Foundation for Cancer Research, The
Leukemia and Lymphoma Society, the Gabrielle's Angel Foundation for
Cancer Research, and the National Cancer Institute (5R00CA151457-04;
1R01CA183974-01). B.P. Rubin and A. Gupta were supported by the Life
Raft Group.
NR 34
TC 15
Z9 15
U1 2
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 1
PY 2015
VL 75
IS 5
BP 880
EP 891
DI 10.1158/0008-5472.CAN-14-0573
PG 12
WC Oncology
SC Oncology
GA CE6GG
UT WOS:000351934100012
PM 25432174
ER
PT J
AU Sepulcre, J
AF Sepulcre, Jorge
TI An OP4 Functional Stream in the Language-Related Neuroarchitecture
SO CEREBRAL CORTEX
LA English
DT Article
DE auditory-motor (A M) interface; functional connectivity; graph theory;
language; network
ID HUMAN BRAIN; CEREBRAL-CORTEX; SPEECH ARTICULATION; ARCUATE FASCICULUS;
CORTICAL NETWORK; AUDITORY-CORTEX; CONNECTIVITY; ORGANIZATION; PATHWAYS;
AREAS
AB Sensory comprehension and motor production of language symbols form the basis of human speech. Classical neuroanatomy has pointed to Wernicke's and Broca's areas as playing important roles in the integration of these 2 functions. However, recent studies have proposed that more direct pathways may exist between auditory input and motor output, bypassing Wernicke's and Broca's areas. We used functional network analyses to investigate potential auditorymotor (A-M) couplings between language-related cortices. We found that operculum parietale (OP) interconnectivity in region OP-4 seems to play a critical role in the A-M integration of the brain. This finding supports a novel landscape in the functional neuroarchitecture that sustains language in humans.
C1 [Sepulcre, Jorge] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Sepulcre, Jorge] Harvard Univ, Sch Med, Boston, MA USA.
[Sepulcre, Jorge] Massachusetts Gen Hosp, Athinioula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA.
[Sepulcre, Jorge] Harvard Univ, Sch Med, Charlestown, MA USA.
RP Sepulcre, J (reprint author), Harvard Univ, 52 Oxford St,Northwest Bldg,280-02, Cambridge, MA 02138 USA.
EM sepulcre@nmr.mgh.harvard.edu
NR 66
TC 5
Z9 5
U1 2
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1047-3211
EI 1460-2199
J9 CEREB CORTEX
JI Cereb. Cortex
PD MAR
PY 2015
VL 25
IS 3
BP 658
EP 666
DI 10.1093/cercor/bht256
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA CE6GW
UT WOS:000351935800008
PM 24084124
ER
PT J
AU Pascual, B
Masdeu, JC
Hollenbeck, M
Makris, N
Insausti, R
Ding, SL
Dickerson, BC
AF Pascual, Belen
Masdeu, Joseph C.
Hollenbeck, Mark
Makris, Nikos
Insausti, Ricardo
Ding, Song-Lin
Dickerson, Bradford C.
TI Large-Scale Brain Networks of the Human Left Temporal Pole: A Functional
Connectivity MRI Study
SO CEREBRAL CORTEX
LA English
DT Article
DE anterior temporal lobe; brain anatomy; cytoarchitecture; language;
resting-state fMRI
ID KLUVER-BUCY-SYNDROME; MEDIAL PREFRONTAL NETWORKS; COMPARATIVE
CYTOARCHITECTONIC ANALYSIS; MONKEY MACACA-FASCICULARIS;
DISTORTION-CORRECTED FMRI; MULTIPLE SYSTEM ATROPHY; HUMAN
CEREBRAL-CORTEX; OLD-WORLD MONKEY; RHESUS-MONKEY; SEMANTIC MEMORY
AB The most rostral portion of the human temporal cortex, the temporal pole (TP), has been described as "enigmatic" because its functional neuroanatomy remains unclear. Comparative anatomy studies are only partially helpful, because the human TP is larger and cytoarchitectonically more complex than in nonhuman primates. Considered by Brodmann as a single area (BA 38), the human TP has been recently parceled into an array of cytoarchitectonic subfields. In order to clarify the functional connectivity of subregions of the TP, we undertook a study of 172 healthy adults using resting-state functional connectivity MRI. Remarkably, a hierarchical cluster analysis performed to group the seeds into distinct subsystems according to their large-scale functional connectivity grouped 87.5% of the seeds according to the recently described cytoarchitectonic subregions of the TP. Based on large-scale functional connectivity, there appear to be 4 major subregions of the TP: 1) dorsal, with predominant connectivity to auditory/somatosensory and language networks; 2) ventromedial, predominantly connected to visual networks; 3) medial, connected to paralimbic structures; and 4) anterolateral, connected to the default-semantic network. The functional connectivity of the human TP, far more complex than its known anatomic connectivity in monkey, is concordant with its hypothesized role as a cortical convergence zone.
C1 [Pascual, Belen; Hollenbeck, Mark; Dickerson, Bradford C.] Massachusetts Gen Hosp, MGH Frontotemporal Dementia Unit, Alzheimers Dis Res Ctr, Dept Neurol,Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Pascual, Belen; Hollenbeck, Mark; Makris, Nikos; Dickerson, Bradford C.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Masdeu, Joseph C.] NIH, Sect Integrat Neuroimaging, Bethesda, MD 20892 USA.
[Makris, Nikos] Massachusetts Gen Hosp, Ctr Morphometr Anal, Dept Psychiat, Charlestown, MA 02129 USA.
[Makris, Nikos] Massachusetts Gen Hosp, Ctr Morphometr Anal, Dept Neurol, Charlestown, MA 02129 USA.
[Makris, Nikos] Massachusetts Gen Hosp, Ctr Morphometr Anal, Dept Radiol Serv, Charlestown, MA 02129 USA.
[Makris, Nikos; Dickerson, Bradford C.] Massachusetts Gen Hosp, Ctr Neural Syst Invest, Dept Neurol, Charlestown, MA 02129 USA.
[Makris, Nikos; Dickerson, Bradford C.] Massachusetts Gen Hosp, Ctr Neural Syst Invest, Dept Psychiat, Charlestown, MA 02129 USA.
[Insausti, Ricardo] Univ Castilla La Mancha, Ctr Human Neuroanat Lab, Dept Hlth Sci, Sch Med, Albacete 02071, Spain.
[Ding, Song-Lin] Allen Inst Brain Sci, Seattle, WA 98103 USA.
RP Dickerson, BC (reprint author), MGH Frontotemporal Dementia Unit, 149 13th St,Suite 2691, Charlestown, MA 02129 USA.
EM bradd@nmr.mgh.harvard.edu
FU National Institute on Aging [P50-AG005134]; National Institute of
Neurological Disorders and Stroke [R21-NS077059]
FX Supported by grants from the National Institute on Aging (P50-AG005134)
and National Institute of Neurological Disorders and Stroke
(R21-NS077059).
NR 151
TC 34
Z9 35
U1 8
U2 34
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1047-3211
EI 1460-2199
J9 CEREB CORTEX
JI Cereb. Cortex
PD MAR
PY 2015
VL 25
IS 3
BP 680
EP 702
DI 10.1093/cercor/bht260
PG 23
WC Neurosciences
SC Neurosciences & Neurology
GA CE6GW
UT WOS:000351935800010
PM 24068551
ER
PT J
AU Deutsch, MB
Mendez, MF
AF Deutsch, Mariel B.
Mendez, Mario F.
TI Neurocognitive Features Distinguishing Primary Central Nervous System
Lymphoma from Other Possible Causes of Rapidly Progressive Dementia
SO COGNITIVE AND BEHAVIORAL NEUROLOGY
LA English
DT Review
DE dementia; lymphoma; neurologic manifestations; neuropsychiatry
ID PRIMARY CNS LYMPHOMA; CEREBRI; LEUKOENCEPHALOPATHY; MANIFESTATIONS;
DIAGNOSIS; SURVIVAL
AB Objective: Define the neurocognitive features of primary central nervous system lymphoma (PCNSL) presenting with dementia, and compare with other causes of rapidly progressive dementia (RPD).
Background: PCNSL can present as an RPD. Differentiating PCNSL from other RPDs is critical because lymphomatous dementia may be reversible, and untreated PCNSL is fatal.
Methods: We performed a meta-analysis of case reports of dementia from PCNSL (between 1950 and 2013); 20 patients (14 with lymphomatosis cerebri) met our criteria. We compared these patients to a case series of patients with RPD from Creutzfeldt-Jakob disease and other non-PCNSL etiologies (Sala et al, 2012. Alzheimer Dis Assoc Disord. 26:267-271).
Results: Median age was 66 years (range 41 to 81); 70% were men. Time from symptom onset to evaluation was <6 months in 65%. No patients had seizures; 5% had headaches; 45% had non-aphasic speech difficulty. There was significantly more memory impairment in patients with PCNSL than other RPDs and significantly less myoclonus and parkinsonism. Behavioral changes and cerebellar signs were not significantly different. Significantly more patients with PCNSL than other RPDs had white matter changes; significantly fewer had atrophy. Elevated CSF protein and pleocytosis were more frequent in PCNSL; patients with other RPDs tended to have normal CSF +/- 14-3-3 protein.
Conclusions: Unlike patients with RPD from other causes, those with PCNSL commonly present with impaired memory, apathy, and abnormal speech and gait, without headache, seizure, or myoclonus. White matter changes and CSF abnormalities pre-dominate. Improved clinical awareness of PCNSL can prompt earlier diagnosis and treatment.
C1 [Deutsch, Mariel B.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Deutsch, Mariel B.; Mendez, Mario F.] Vet Affairs Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA 90073 USA.
RP Deutsch, MB (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Neurobehav Unit 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM marielbrooke@ucla.edu
OI Deutsch, Mariel/0000-0003-1228-8868
FU National Institute on Aging [5R01AG034499]
FX Supported in part by National Institute on Aging Grant 5R01AG034499
(M.F.M.).
NR 30
TC 2
Z9 3
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1543-3633
EI 1543-3641
J9 COGN BEHAV NEUROL
JI Cogn. Behav. Neurol.
PD MAR
PY 2015
VL 28
IS 1
BP 1
EP 10
PG 10
WC Behavioral Sciences; Clinical Neurology
SC Behavioral Sciences; Neurosciences & Neurology
GA CE5NI
UT WOS:000351882000001
PM 25812125
ER
PT J
AU Ahnen, DJ
Bresalier, RS
Levin, B
Kaunitz, JD
AF Ahnen, Dennis J.
Bresalier, Robert S.
Levin, Bernard
Kaunitz, Jonathan D.
TI CRC Screening, Past, Present, and Future: A Tribute to Emmet Keeffe
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Editorial Material
C1 [Ahnen, Dennis J.] Univ Colorado, Sch Med, Denver, CO 80204 USA.
[Ahnen, Dennis J.] Gastroenterol Rockies, Boulder, CO USA.
[Bresalier, Robert S.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Levin, Bernard] New York City Colon Canc Control Coalit, New York, NY USA.
[Kaunitz, Jonathan D.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
[Kaunitz, Jonathan D.] UCLA Sch Med, Los Angeles, CA USA.
RP Ahnen, DJ (reprint author), Univ Colorado, Sch Med, Denver, CO 80204 USA.
EM dennis.ahnen@ucdenver.edu
FU NCI NIH HHS [R01 CA068099]
NR 5
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD MAR
PY 2015
VL 60
IS 3
SI SI
BP 589
EP 591
DI 10.1007/s10620-015-3603-2
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CE5GC
UT WOS:000351858100001
PM 25724168
ER
PT J
AU Chacko, L
Macaron, C
Burke, CA
AF Chacko, Lyssa
Macaron, Carole
Burke, Carol A.
TI Colorectal Cancer Screening and Prevention in Women
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Review
DE Colorectal cancer; Colorectal cancer prevention; Colorectal cancer
screening; Colorectal cancer and women
ID BODY-MASS INDEX; RANDOMIZED CONTROLLED-TRIAL; SESSILE SERRATED ADENOMAS;
ESTROGEN PLUS PROGESTIN; HIGH-FIBER DIET; COLON-CANCER;
CIGARETTE-SMOKING; NEGATIVE COLONOSCOPY; DIABETES-MELLITUS; FOLLOW-UP
AB Colorectal cancer (CRC) is one of the leading cancers and cause of cancer deaths in American women and men. Females and males share a similar lifetime cumulative risk of CRC however, substantial differences in risk factors, tumor biology, and effectiveness of cancer prevention services have been observed between them. This review distills the evidence documenting the unique variation observed between the genders relating to CRC risk factors, screening and prevention. Consistent evidence throughout the world demonstrates that women reach equivalent levels of adenomas and CRC as men but it occurs nearly a decade later in life than in their male counterparts. Women have a higher proportion of tumors which are hypermethylated, have microsatellite instability and located in the proximal colon suggesting the serrated pathway may be of greater consequence in them than in men. Other CRC risk factors such as smoking, diet and obesity have been shown to have disparate effects on women which may related to interactions between estrogen exposure, body fat distribution, and the biologic underpinnings of their tumors. There is data showing the uptake, choice, and efficacy of different CRC screening methods in women is dissimilar to that in men. The mortality benefit from FOBT, sigmoidoscopy, and protection from interval CRC by colonoscopy appears to be lower in women than men. A greater understanding of these gender idiosyncrasies will facilitate an personalized approach to CRC prevention and should ultimately lead to a reduced burden of disease.
C1 [Chacko, Lyssa] Denver Vet Affairs Med Ctr, Dept Gastroenterol & Hepatol, Denver, CO USA.
[Macaron, Carole; Burke, Carol A.] Cleveland Clin, Dept Gastroenterol & Hepatol, Cleveland, OH 44195 USA.
RP Burke, CA (reprint author), Cleveland Clin, Dept Gastroenterol & Hepatol, Desk A 30,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM Burkec1@ccf.org
NR 148
TC 3
Z9 3
U1 2
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD MAR
PY 2015
VL 60
IS 3
SI SI
BP 698
EP 710
DI 10.1007/s10620-014-3452-4
PG 13
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CE5GC
UT WOS:000351858100015
PM 25596719
ER
PT J
AU Inra, JA
Syngal, S
AF Inra, Jennifer A.
Syngal, Sapna
TI Colorectal Cancer in Young Adults
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Review
DE Colorectal cancer; Young adults; Colorectal cancer screening; Review
ID SOCIETY-TASK-FORCE; II COLON-CANCER; STAGE-II; UNITED-STATES;
MICROSATELLITE INSTABILITY; FERTILITY PRESERVATION; ADJUVANT
CHEMOTHERAPY; CHILDHOOD-CANCER; MYH MUTATIONS; RISK
AB The incidence and mortality rates of colorectal cancer (CRC) have been decreasing in adults over 50 years of age, however, these rates have been increasing in adults under 50. The majority of CRC in young adults is sporadic, and is likely due to behavioral and environmental causes, however the exact etiology still remains unclear. The minority of CRC in this population is due to inherited CRC syndromes. Young adults with CRC are often symptomatic (abdominal pain, rectal bleeding), and diagnosis is often delayed due to reasons such as under-utilized health care services, and physicians attributing symptoms to diagnoses other than CRC. Young adults with CRC often have more aggressive tumor characteristics, but they tend to have better survival rates when compared with older adults when matched for stage. Treatment is the same for young patients with CRC, however there are issues that arise in this population that do not necessarily affect older adults, such as the negative effect of chemotherapy/radiation on fertility. It is not clear that screening individuals for CRC at ages under 50 is beneficial or cost-effective. Further studies are needed regarding this topic.
C1 [Inra, Jennifer A.; Syngal, Sapna] Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA.
[Inra, Jennifer A.; Syngal, Sapna] Harvard Univ, Sch Med, Boston, MA 02163 USA.
[Syngal, Sapna] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA.
RP Syngal, S (reprint author), Harvard Univ, Sch Med, Boston, MA 02163 USA.
EM jinra@partners.org; sapna_syngal@dfci.harvard.edu
FU NCI [K24 113433]
FX The authors would like to thank Matthew Yurgelun, M. D. for thoughtful
review and suggestions. Supported by NCI Grant K24 113433.
NR 59
TC 13
Z9 15
U1 3
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD MAR
PY 2015
VL 60
IS 3
SI SI
BP 722
EP 733
DI 10.1007/s10620-014-3464-0
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CE5GC
UT WOS:000351858100017
PM 25480403
ER
PT J
AU Rodriguez-Diaz, E
Huang, Q
Cerda, SR
O'Brien, MJ
Bigio, IJ
Singh, SK
AF Rodriguez-Diaz, Eladio
Huang, Qin
Cerda, Sandra R.
O'Brien, Michael J.
Bigio, Irving J.
Singh, Satish K.
TI Endoscopic histological assessment of colonic polyps by using elastic
scattering spectroscopy
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID CONFOCAL LASER ENDOMICROSCOPY; DIFFUSE-REFLECTANCE SPECTROSCOPY;
DIMINUTIVE COLORECTAL POLYPS; WHITE-LIGHT; IN-VIVO; VIRTUAL
CHROMOENDOSCOPY; OPTICAL MAGNIFICATION; DIAGNOSTIC-ACCURACY;
BARRETTS-ESOPHAGUS; COMMUNITY PRACTICE
AB Background: Elastic-scattering spectroscopy (ESS) can assess in vivo and in real-time the scattering and absorption properties of tissue related to underlying pathologies.
Objectives: To evaluate the potential of ESS for differentiating neoplastic from non-neoplastic polyps during colonoscopy.
Design: Pilot study, retrospective data analysis.
Setting: Academic practice.
Patients: A total of 83 patients undergoing screening/surveillance colonoscopy.
Interventions: ESS spectra of 218 polyps (133 non-neoplastic, 85 neoplastic) were acquired during colonoscopy. Spectral data were correlated with the classification of biopsy samples by 3 GI pathologists. High-dimensional methods were used to design diagnostic algorithms.
Main Outcome Measurements: Diagnostic performance of ESS.
Results: Analysis of spectra from polyps of all sizes (N = 218) resulted in a sensitivity of 91.5%, specificity of 92.2%, and accuracy of 91.9% with a high-confidence rate of 90.4%. Restricting analysis to polyps smaller than 1 cm (n = 179) resulted in a sensitivity of 87.0%, specificity of 92.1%, and accuracy of 90.6% with a highconfidence rate of 89.3%. Analysis of polyps 5 mm or smaller (n = 157) resulted in a sensitivity of 86.8%, specificity of 91.2%, and accuracy of 90.1% with a high-confidence rate of 89.8%.
Limitations: Sample size, retrospective validation used to obtain performance estimates.
Conclusion: Results indicate that ESS permits accurate, real-time classification of polyps as neoplastic or nonneoplastic. ESS is a simple, low cost, clinically robust method with minimal impact on procedure flow, especially when integrated into standard endoscopic biopsy tools. Performance on polyps 5 mm or smaller indicates that ESS may, in theory, achieve Preservation and Incorporation of Valuable Endoscopic Innovations performance thresholds. ESS may one day prove to be a useful tool used in endoscopic screening and surveillance of colorectal cancer.
C1 [Rodriguez-Diaz, Eladio; Bigio, Irving J.; Singh, Satish K.] Boston Univ, Sch Med, Gastroenterol Sect, Dept Med, Boston, MA 02118 USA.
[Cerda, Sandra R.; O'Brien, Michael J.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA.
[Huang, Qin] Boston Univ, Coll Engn, Dept Pathol, Boston, MA 02118 USA.
[Singh, Satish K.] Boston Univ, Coll Engn, Med Serv, Gastroenterol Unit, Boston, MA 02118 USA.
[Rodriguez-Diaz, Eladio; Bigio, Irving J.; Singh, Satish K.] Boston Univ, Coll Engn, Dept Biomed Engn, VA Boston Healthcare Syst, Boston, MA 02118 USA.
RP Singh, SK (reprint author), Boston Univ, Sch Med, Gastroenterol Sect, Dept Med, Suite 504,650 Albany St, Boston, MA 02118 USA.
EM singhsk@bu.edu
FU VA CSRD MERIT Award [1I01CX000347]; NIH/NCI [U54 CA10467]; Wallace H.
Coulter Foundation; Center for the Integration of Medicine & Innovative
Technology (CIMIT)
FX The following author disclosed financial relationships relevant to this
article: Dr Singh is a consultant for Mauna Kea Technologies and
NinePoint Medical. All other authors disclosed no financial
relationships relevant to this article. This work was supported in part
by VA CSR&D MERIT Award 1I01CX000347 (S.K.S.), NIH/NCI grant U54 CA10467
(I.J.B., S.K.S.), and the Wallace H. Coulter Foundation (S.K.S., I.J.B.)
and the Center for the Integration of Medicine & Innovative Technology
(CIMIT) (S.K.S.).
NR 49
TC 1
Z9 1
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
EI 1097-6779
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD MAR
PY 2015
VL 81
IS 3
BP 539
EP 547
DI 10.1016/j.gie.2014.07.012
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CE2SI
UT WOS:000351666800006
PM 25257128
ER
PT J
AU Cadoni, S
Sanna, S
Gallittu, P
Argiolas, M
Fanari, V
Porcedda, ML
Erriu, M
Leung, FW
AF Cadoni, Sergio
Sanna, Stefano
Gallittu, Paolo
Argiolas, Mariangela
Fanari, Viviana
Porcedda, Maria L.
Erriu, Matteo
Leung, Felix W.
TI A randomized, controlled trial comparing real-time insertion pain during
colonoscopy confirmed water exchange to be superior to water immersion
in enhancing patient comfort
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID CARBON-DIOXIDE INSUFFLATION; UNSEDATED COLONOSCOPY; AIR INSUFFLATION;
AIDED COLONOSCOPY; MINIMAL SEDATION; US VETERANS; INFUSION; MEMORIES
AB Background: A recent American Society for Gastrointestinal Endoscopy Technology Status Evaluation Report recommended comparative studies of water-aided colonoscopy methods to refine the optimal insertion technique.
Objective: Air insufflation (AI), water immersion (WI), and water exchange (WE) were compared head-to-head to test the hypothesis that WE produces the least insertion pain.
Design: Patient-blinded, prospective, randomized, controlled trials.
Setting: Two community hospitals in Italy.
Patients: First-time diagnostic or screening colonoscopy in unsedated patients with the option of on-demand sedation.
Intervention: Colonoscopy with AI, WI, or WE.
Main Outcome Measurements: Real-time maximum insertion pain (0 = none, 10 = worst). To avoid interventional bias, the timing of recording was at the discretion of the nurse assistant. Adjunct measures were implemented to ensure patient perception of minimal discomfort. Recalled pain and patients' guess of insertion methods were recorded after colonoscopy.
Results: Results were merged for 576 randomized patients. Correct patient guesses lower than 33% confirmed adequate blinding. Significant correlation (Pearson coefficient 0.6, P < .0005) between real-time and recalled pain provided internal validation of the former as the primary outcome. Real-time pain (95% confidence interval [CI]: AI, 4.1 [3.7-4.5]; WI, 3.5 [3.0-3.9]; and WE, 2.5 [2.2-2.9] [P < .0005] was the lowest in the WE group. The proportions of patients completing unsedated colonoscopy based on the assigned methods were significantly different (WE, 74.7% vs WI, 62.4%; P = .009; vs AI, 65.3%; P = .04). WE required the least implementation of adjunct maneuvers.
Limitations: Unblinded colonoscopists.
Conclusion: The current findings with an internally validated primary outcome in adequately blinded patients support the hypothesis that WE is superior to WI in attenuating real-time insertion pain and enhancing completion of unsedated colonoscopy.
C1 [Cadoni, Sergio; Gallittu, Paolo] S Barbara Hosp, Digest Endoscopy Unit, I-09016 Iglesias, CI, Italy.
[Sanna, Stefano; Argiolas, Mariangela; Fanari, Viviana; Porcedda, Maria L.] NS di Bonaria Hosp, Digest Endoscopy Unit, San Gavino Monreale, Italy.
[Erriu, Matteo] Univ Cagliari, Dept Surg Sci, Cagliari, Italy.
[Leung, Felix W.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA.
[Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Cadoni, S (reprint author), S Barbara Hosp, Digest Endoscopy Unit, Via S Leonardo 1, I-09016 Iglesias, CI, Italy.
NR 27
TC 16
Z9 16
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
EI 1097-6779
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD MAR
PY 2015
VL 81
IS 3
BP 557
EP 566
DI 10.1016/j.gie.2014.07.029
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CE2SI
UT WOS:000351666800009
PM 25262100
ER
PT J
AU Cuthbertson, DW
Raol, N
Hicks, J
Green, L
Parke, R
AF Cuthbertson, David W.
Raol, Nikhila
Hicks, John
Green, Linda
Parke, Robert
TI Minor Salivary Gland Basal Cell Adenocarcinoma A Systematic Review and
Report of a New Case
SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Review
ID OF-THE-LITERATURE; SINGLE INSTITUTION EXPERIENCE; PAROTID-GLAND; TUMORS;
PALATE; POPULATION; CARCINOMAS; CANCER; INDIA; HEAD
AB IMPORTANCE Basal cell adenocarcinoma (BCAC) of the minor salivary gland is an extremely rare disease: the most recent substantive literature review reports only 25 cases. Owing to the rarity of this disease, it has not yet been well characterized in the literature.
OBJECTIVE We sought to expand the knowledge of minor salivary gland BCAC by performing an exhaustive literature review and adding to it a new case that is rare owing to the tumor's size, aggressive nature, and mixed histologic pattern. The review emphasizes epidemiologic patterns, diagnostic characteristics, treatment patterns, and expected prognosis for minor salivary gland BCAC.
EVIDENCE ACQUISITION In June 2012, PubMed was queried using the term "salivary gland basal cell adenocarcinoma," and the resultant articles were reviewed. Those specifically mentioning a minor salivary gland BCAC were included in this study. Those that did not differentiate minor salivary gland BCAC from major salivary gland BCAC were excluded. The search was not limited by language and included articles from North America, Europe, Africa, and Asia from 1978 to June 2012.
RESULTS The PubMed search resulted in 195 articles, of which 33 articles reported at least 1 case of minor salivary gland BCAC. We report herein 72 cases of minor salivary gland BCAC (71 cases from the literature review and 1 new case reported herein). The mean patient age at the time of presentation was 56 years (range, 24-90 years), and the disease showed no sex predilection. The most common location was the palate, and the average lesions size was 2.4 cm (range, 0.7-4.2 cm). The treatment modality of choice was wide local excision (n = 57; 79%). There was a high local recurrence rate (n = 30; 41%) but a low rate of distant metastasis (n = 8; 11%).
CONCLUSIONS AND RELEVANCE We present a comprehensive review of minor salivary gland BCAC, describing nearly 3 times as many cases as has been previously reported. This review characterizes a rare disease and increases awareness of the disease among otolaryngologists. Minor salivary gland BCAC is similar to major salivary gland BCAC and minor salivary gland tumors in general with regard to patient age, sex, tumor site, treatment modality, recurrence, metastasis, and mortality.
C1 [Cuthbertson, David W.; Raol, Nikhila; Parke, Robert] Baylor Coll Med, Bobby R Alford Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA.
[Hicks, John; Green, Linda] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
[Green, Linda; Parke, Robert] Michael E Debakey Dept Vet Affairs Med Ctr, Houston, TX USA.
RP Cuthbertson, DW (reprint author), Baylor Coll Med, Bobby R Alford Dept Otolaryngol Head & Neck Surg, One Baylor Plaza, Houston, TX 77030 USA.
EM dwcuthbe@bcm.edu
NR 45
TC 0
Z9 0
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6181
EI 2168-619X
J9 JAMA OTOLARYNGOL
JI JAMA Otolaryngol-Head Neck Surg.
PD MAR
PY 2015
VL 141
IS 3
BP 276
EP 283
DI 10.1001/jamaoto.2014.3344
PG 8
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA CE1PV
UT WOS:000351585000014
PM 25555241
ER
PT J
AU Nicksa, GA
Anderson, C
Fidler, R
Stewart, L
AF Nicksa, Grace A.
Anderson, Cristan
Fidler, Richard
Stewart, Lygia
TI Innovative Approach Using Interprofessional Simulation to Educate
Surgical Residents in Technical and Nontechnical Skills in High-Risk
Clinical Scenarios
SO JAMA SURGERY
LA English
DT Article
ID GRADUATE MEDICAL-EDUCATION; ACCREDITATION COUNCIL; PROGRAM DIRECTORS;
AMERICAN-COLLEGE; SURGERY; IMPLEMENTATION; CHALLENGES; BEHAVIOR; IMPACT
AB IMPORTANCE The Accreditation Council for Graduate Medical Education core competencies stress nontechnical skills that can be difficult to evaluate and teach to surgical residents. During emergencies, surgeons work in interprofessional teams and are required to perform certain procedures. To obtain proficiency in these skills, residents must be trained.
OBJECTIVE To educate surgical residents in leadership, teamwork, effective communication, and infrequently performed emergency surgical procedures with the use of interprofessional simulations.
DESIGN, SETTING, AND PARTICIPANTS SimMan 3GS was used to simulate high-risk clinical scenarios (15-20 minutes), followed by debriefings with real-time feedback (30 minutes). A modified Oxford Non-Technical Skills scale (score range, 1-4) was used to assess surgical resident performance during the first half of the academic year (July-December 2012) and the second half of the academic year (January-June 2013). Anonymous online surveys were used to solicit participant feedback. Simulations were conducted in the operating room, intensive care unit, emergency department, ward, and simulation center. A total of 43 surgical residents (postgraduate years [PGYs] 1 and 2) participated in interdisciplinary clinical scenarios, with other health care professionals (nursing, anesthesia, critical care, medicine, respiratory therapy, and pharmacy; mean number of nonsurgical participants/session: 4, range 0-9). Thirty seven surgical residents responded to the survey.
EXPOSURES Simulation of high-risk clinical scenarios: postoperative pulmonary embolus, pneumothorax, myocardial infarction, gastrointestinal bleeding, anaphylaxis with a difficult airway, and pulseless electrical activity arrest.
MAIN OUTCOMES AND MEASURES Evaluation of resident skills: communication, leadership, teamwork, problem solving, situation awareness, and confidence in performing emergency procedures (eg, cricothyroidotomy).
RESULTS A total of 31 of 35 (89%) of the residents responding found the sessions useful. Additionally, 28 of 33 (85%) reported improved confidence doing procedures and 29 of 37 (78%) reported knowing when the procedure should be applied. Oxford Non-Technical Skills evaluation demonstrated significant improvement in PGY 2 resident performance assessed during the 2 study periods: communication score increased from 3 to 3.71 (P = .01), leadership score increased from 2.77 to 3.86 (P < .001), teamwork score increased from 3.15 to 3.86 (P = .007), and procedural ability score increased from 2.23 to 3.43 (P = .03). There were no statistically significant improved scores in PGY 2 decision making or situation awareness. No improvements in skills were seen among PGY 1 participants.
CONCLUSIONS AND RELEVANCE The PGY 2 residents improved their skills, but the PGY 1 residents did not. Participants found interprofessional simulations to be realistic and a valuable educational tool. Interprofessional simulation provides a valuable means of educating surgical residents and evaluating their skills in real-life clinical scenarios.
C1 [Nicksa, Grace A.; Anderson, Cristan; Fidler, Richard; Stewart, Lygia] San Francisco VA Med Ctr, Dept Surg, San Francisco, CA 94121 USA.
[Nicksa, Grace A.; Anderson, Cristan; Stewart, Lygia] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94121 USA.
RP Stewart, L (reprint author), San Francisco VA Med Ctr, Dept Surg, 4150 Clement St, San Francisco, CA 94121 USA.
EM lygia.stewart@va.gov
NR 24
TC 10
Z9 12
U1 1
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD MAR
PY 2015
VL 150
IS 3
BP 201
EP 207
DI 10.1001/jamasurg.2014.2235
PG 7
WC Surgery
SC Surgery
GA CE2HQ
UT WOS:000351636800003
PM 25565037
ER
PT J
AU Shunk, KA
Zimmet, J
Cason, B
Speiser, B
Tseng, EE
AF Shunk, Kendrick A.
Zimmet, Jeffrey
Cason, Brian
Speiser, Bernadette
Tseng, Elaine E.
TI Development of a Veterans Affairs Hybrid Operating Room for
Transcatheter Aortic Valve Replacement in the Cardiac Catheterization
Laboratory
SO JAMA SURGERY
LA English
DT Article
ID HIGH-RISK PATIENTS; IMPLANTATION; SURGERY; OUTCOMES; STENOSIS;
MANAGEMENT; FACILITY; REGISTRY; PROGRAM
AB IMPORTANCE Transcatheter aortic valve replacement (TAVR) revolutionized the treatment of aortic stenosis. Developing a TAVR program with a custom-built hybrid operating room (HOR) outside the surgical operating room area poses unique challenges in Veterans Affairs (VA) institutions.
OBJECTIVE To present the process by which the San Francisco VA Medical Center developed a VA-approved TAVR program, in which an HOR exists in a cardiac catheterization laboratory, as a guideline for future programs.
DESIGN, SETTING, AND PARTICIPANTS Retrospective review of each required approval process for developing an HOR in a cardiac catheterization laboratory in a VA designated for complex surgery. Participants included San Francisco VA Medical Center health care professionals and individuals responsible for new program initiation in VA institutions.
EXPOSURES External reviews by industry vendors, the VA Central Office, and the Office for Construction, Facilities, and Management and an internal Healthcare Failure Mode and Effect Analysis.
MAIN OUTCOMES AND MEASURES The timeline for each process.
RESULTS Developing a TAVR program required vetting and approval from industry vendors, who provided training and expertise. Architectural plans for construction of the HOR began in 2010-2011, followed by approval from Edwards Lifesciences, Inc, in 2012 and fundamentals training on February 8 and 9, 2013. Following a pilot launch of the first VA TAVR program at the Houston VA Medical Center, subsequent programs were required to submit a plan to the VA Central Office for proposed restructuring of their clinical programs. After the San Francisco VA Medical Center proposal submission on February 3, 2013, a site visit consisting of a National Chief of Catheterization Laboratory Managers, a cardiac surgeon, and an interventional cardiologist with TAVR experience was conducted on April 12, 2013. During construction, HOR plans were inspected by the Office for Construction, Facilities, and Management followed by on-site inspection on August 8, 2013, to assess the adequacy of the HOR, newly built restricted corridors, equipment storage areas, and altered staff and patient flow patterns. Last, a Healthcare Failure Mode and Effect Analysis was performed to mitigate any negative effects of the HOR not being colocated in the surgical operating room area. Approval was then granted on November 13, 2013. Our first 10 TAVR cases were successfully completed as of April 2, 2014.
CONCLUSIONS AND RELEVANCE The primary factor for development of a successful TAVR program is integration of the heart valve team. Particular adaptations to the cardiac catheterization laboratory environment are required to accommodate an uncompromised HOR in which cardiac and vascular surgeons can be as comfortable as their interventional cardiology colleagues.
C1 [Shunk, Kendrick A.; Zimmet, Jeffrey] San Francisco VA Med Ctr, Div Cardiol, San Francisco, CA 94121 USA.
[Cason, Brian] San Francisco VA Med Ctr, Dept Anesthesia, San Francisco, CA USA.
[Speiser, Bernadette] Jesse Brown VA Med Ctr, Div Cardiol, Chicago, IL USA.
[Tseng, Elaine E.] San Francisco VA Med Ctr, Div Cardiothorac Surg, San Francisco, CA USA.
RP Tseng, EE (reprint author), UCSF Med Ctr, Div Cardiothorac Surg, 4150 Clement St,112D, San Francisco, CA 94121 USA.
EM elaine.tseng@va.gov
NR 22
TC 0
Z9 0
U1 1
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD MAR
PY 2015
VL 150
IS 3
BP 216
EP 222
DI 10.1001/jamasurg.2014.1404
PG 7
WC Surgery
SC Surgery
GA CE2HQ
UT WOS:000351636800007
PM 25588001
ER
PT J
AU Boudreaux-Kelly, M
Wilson, M
Bokhari, M
AF Boudreaux-Kelly, Monique
Wilson, Mark
Bokhari, Malak
TI Statistical Methods of Risk-Adjusted Statistical Process Control Charts
to Assess Surgical Performance in Consecutive Colorectal Operations at a
Single Institution
SO JAMA SURGERY
LA English
DT Letter
C1 [Boudreaux-Kelly, Monique] Res StatCore, Pittsburgh Res Off, Pittsburgh, PA USA.
[Wilson, Mark; Bokhari, Malak] VA Pittsburgh Healthcare Syst, Dept Surg, Pittsburgh, PA 15240 USA.
RP Bokhari, M (reprint author), VA Pittsburgh Healthcare Syst, Dept Surg, Univ Dr Campus 112 U, Pittsburgh, PA 15240 USA.
EM malak.bokhari@va.gov
NR 3
TC 0
Z9 0
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD MAR
PY 2015
VL 150
IS 3
BP 271
EP 272
DI 10.1001/jamasurg.2014.1773
PG 2
WC Surgery
SC Surgery
GA CE2HQ
UT WOS:000351636800016
PM 25606809
ER
PT J
AU Shapiro, M
Rashid, NU
Huang, Q
Galper, SL
Boosalis, VA
Whang, EE
Gold, JS
AF Shapiro, Mia
Rashid, Naim U.
Huang, Qin
Galper, Shira L.
Boosalis, Valia A.
Whang, Edward E.
Gold, Jason S.
TI Radiation Therapy for Unresectable Pancreatic Adenocarcinoma:
Population-Based Trends in Utilization and Survival Rates in the United
States
SO JAMA SURGERY
LA English
DT Letter
ID GEMCITABINE; CANCER; TRIAL
C1 [Shapiro, Mia; Whang, Edward E.; Gold, Jason S.] VA Boston Healthcare Syst, Surg Serv, West Roxbury, MA USA.
[Shapiro, Mia; Rashid, Naim U.; Huang, Qin; Galper, Shira L.; Whang, Edward E.; Gold, Jason S.] Harvard Univ, Sch Med, Boston, MA USA.
[Rashid, Naim U.] Dana Farber Canc Ctr, Boston, MA USA.
[Huang, Qin] VA Boston Healthcare Syst, Pathol Serv, West Roxbury, MA USA.
[Galper, Shira L.] VA Boston Healthcare Syst, Radiat Therapy Serv, West Roxbury, MA USA.
[Galper, Shira L.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Boosalis, Valia A.] VA Boston Healthcare Syst, Med Serv, West Roxbury, MA USA.
[Boosalis, Valia A.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Whang, Edward E.; Gold, Jason S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Gold, JS (reprint author), VA Boston Healthcare Syst 112, Surg Serv, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.
EM jgold4@partners.org
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD MAR
PY 2015
VL 150
IS 3
BP 274
EP 277
DI 10.1001/jamasurg.2014.1837
PG 5
WC Surgery
SC Surgery
GA CE2HQ
UT WOS:000351636800018
PM 25629219
ER
PT J
AU Smith, ER
Porter, KE
Messina, MG
Beyer, JA
Defever, ME
Foa, EB
Rauch, SAM
AF Smith, Erin R.
Porter, Katherine E.
Messina, Michael G.
Beyer, Jonathan A.
Defever, Mahrie E.
Foa, Edna B.
Rauch, Sheila A. M.
TI Prolonged Exposure for PTSD in a Veteran group: A pilot effectiveness
study
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Prolonged Exposure therapy; Group psychotherapy; PTSD; Veterans
ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; RAPE
VICTIMS; TRIAL
AB Previous research has consistently demonstrated that Prolonged Exposure (PE) therapy is an effective treatment for posttraumatic stress disorder (PTSD). Traditionally, PE has been studied and delivered on an individual basis. However, the growing number of Veterans in need of PTSD treatment has led to increased interest in group therapies as an efficient way to provide access to care. The current study examined a group and individual hybrid treatment that was developed based on PE principles. Treatment was 12 weeks in length and consisted of 12 one-hour group sessions focused on in vivo exposures, and an average of approximately five-hour long individual imaginal exposure sessions. Data for this study were derived from 67 veterans who participated in 12 cohorts of the Group PE. Significant reductions in PTSD and depression symptoms were found in both completers and intent-to-treat sample analyses. The clinical implications of these findings are discussed. Published by Elsevier Ltd.
C1 [Smith, Erin R.; Porter, Katherine E.; Rauch, Sheila A. M.] VA Ann Arbor Healthcare Syst, Mental Hlth Serv, Ann Arbor, MI 48105 USA.
[Smith, Erin R.; Porter, Katherine E.; Rauch, Sheila A. M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA.
[Messina, Michael G.] William S Middleton Mem Vet Adm Med Ctr, Mental Hlth Serv, Madison, WI USA.
[Messina, Michael G.] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Beyer, Jonathan A.] Jesse Brown VA Med Ctr, Mental Hlth Serv, Chicago, IL USA.
[Foa, Edna B.] Univ Penn, Philadelphia, PA 19104 USA.
RP Smith, ER (reprint author), VA Ann Arbor Healthcare Syst, 2215 Fuller Rd, Ann Arbor, MI 48105 USA.
EM Erin.Smith3@va.gov
RI Rauch, Sheila/K-4450-2015
OI Rauch, Sheila/0000-0001-9686-4011
FU CDA-2 Award from the Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Clinical Sciences
Research and Development
FX Dr. Rauch's contribution was based upon work supported by a CDA-2 Award
from the Department of Veterans Affairs, Veterans Health Administration,
Office of Research and Development, Clinical Sciences Research and
Development.
NR 33
TC 5
Z9 5
U1 3
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD MAR
PY 2015
VL 30
BP 23
EP 27
DI 10.1016/j.janxdis.2014.12.008
PG 5
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA CE2PX
UT WOS:000351658600005
PM 25594370
ER
PT J
AU Dadfar, N
Seyyedi, M
Forghani, R
Curtin, HD
AF Dadfar, Nazanin
Seyyedi, Mohammad
Forghani, Reza
Curtin, Hugh D.
TI Computed Tomography Appearance of Normal Nonossified Thyroid Cartilage
Implication for Tumor Invasion Diagnosis
SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY
LA English
DT Article
DE thyroid cartilage; nonossified; laryngeal cancer; CT scan
ID DUAL-ENERGY CT; SQUAMOUS-CELL CARCINOMA; LARYNGEAL CARCINOMA;
HYPOPHARYNGEAL CANCER; NEOPLASTIC INVASION; FRAMEWORK
AB Objective: The objective of this study was to determine the density and homogeneity of the nonossified thyroid cartilage (NOTC) on contrast-enhanced computed tomography (CT) providing preliminary information for future evaluation of cartilage invasion using dual-energy CT.
Methods: One hundred normal-larynx CT scans were evaluated for the density and homogeneity of NOTC.
Results: The density of the NOTC was homogeneous in all cases. Nonossified thyroid cartilage had higher mean density than contiguous muscle, but there was overlap. In 47 cases, a lucent area was observed at the junction of the ossified and NOTC but not within the NOTC itself. In 11 cases, ossification was observed in only 1 cortex of the thyroid cartilage. Cartilage at the anterior commissure was not ossified in 7 cases.
Conclusions: Nonossified thyroid cartilage has a homogeneous appearance on contrast-enhanced CT scans, but showed some normal variations that could be mistakenly reported as tumor invasion.
C1 [Dadfar, Nazanin; Curtin, Hugh D.] Massachusetts Eye & Ear Infirm, Dept Radiol, Boston, MA 02114 USA.
[Seyyedi, Mohammad] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Seyyedi, Mohammad] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Forghani, Reza] McGill Univ, Jewish Gen Hosp, Dept Radiol, Montreal, PQ H3T 1E2, Canada.
[Forghani, Reza] McGill Univ, Montreal, PQ, Canada.
RP Curtin, HD (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St Lobby, Boston, MA 02114 USA.
EM hugh_curtin@meei.harvard.edu
NR 24
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0363-8715
EI 1532-3145
J9 J COMPUT ASSIST TOMO
JI J. Comput. Assist. Tomogr.
PD MAR-APR
PY 2015
VL 39
IS 2
BP 240
EP 243
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CE2VC
UT WOS:000351677000018
PM 25564299
ER
PT J
AU Loboprabhu, S
Molinari, V
Asghar-Ali, AA
AF Loboprabhu, Sheila
Molinari, Victor
Asghar-Ali, Ali Abbas
TI Castaways: Addressing Hostility and Helplessness in Severely Lonely
Adults
SO JOURNAL OF PSYCHIATRIC PRACTICE
LA English
DT Article
DE hostility; helplessness; loneliness; validation; mentalization; reality
orientation; socialization
ID ATTACHMENT RELATIONSHIPS; LONELINESS; SELF; CHILDHOOD; PREDICTORS;
CHILDREN; BEHAVIOR; TRAUMA; MODEL; LIFE
AB Hostility and helplessness are recurrent themes in severely lonely adults, and they can be both causes and effects of subjective feelings of loneliness. Since many lonely patients report a history of abuse, hostile and helpless states of mind may reflect identification with hostile (aggressor) or helpless (passive) attachment figures. Hostile intrusiveness and helpless withdrawal by the parent are 2 distinct patterns of parent-child misattunement that can lead to infant disorganization via disrupted emotional communication and to loneliness later in life. Anxious-ambivalent lonely older adults tend to exhibit hyperactivating hostile behaviors (to deal with a core sense of powerlessness), whereas those with fearful-avoidant attachment styles exhibit deactivating helpless behaviors (to deflect intense underlying feelings of rage). Based on this model, we outline different treatment approaches for lonely persons with different attachment styles by describing the successful treatment of two severely lonely, suicidal veterans. We describe an approach to treating hostile and helpless behaviors in lonely patients, using validation, mentalization, reality orientation, and socialization. Validation provides a sense of safety and rapport. Mentalization allows the lonely individual to better appreciate his or her own mental processes and those of others. Reality orientation provides feedback to lonely individuals on whether their perceptions are accurate and reality-based and helps them appreciate the consequences their behavior may have for self and others. Finally, socialization reduces disenfranchisement by teaching/re-teaching individuals social skills that may have become impaired by prolonged isolation.
C1 [Loboprabhu, Sheila; Asghar-Ali, Ali Abbas] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA.
[Loboprabhu, Sheila; Asghar-Ali, Ali Abbas] Baylor Coll Med, Houston, TX 77030 USA.
[Molinari, Victor] Univ S Florida, Tampa, FL USA.
RP Loboprabhu, S (reprint author), Michael E DeBakey Dept Vet Affairs Med Ctr, Mental Hlth Care Line, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM SheilaM.Loboprabhu@va.gov
NR 45
TC 0
Z9 0
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1527-4160
EI 1538-1145
J9 J PSYCHIATR PRACT
JI J. Psychiatr. Pract.
PD MAR
PY 2015
VL 21
IS 2
BP 93
EP 106
DI 10.1097/01.pra.0000462602.94853.2f
PG 14
WC Psychiatry
SC Psychiatry
GA CE2TR
UT WOS:000351672100002
PM 25782760
ER
PT J
AU Heo, JY
Jeon, HJ
Fava, M
Mischoulon, D
Baer, L
Clam, A
Doorley, J
Pisoni, A
Papakostas, GI
AF Heo, Jung-Yoon
Jeon, Hong Jin
Fava, Maurizio
Mischoulon, David
Baer, Lee
Clam, Alisabet
Doorley, James
Pisoni, Angela
Papakostas, George I.
TI Efficacy of ziprasidone monotherapy in patients with anxious depression:
A 12-week, randomized, double-blind, placebo-controlled,
sequential-parallel comparison trial
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Ziprasidone; Major depressive disorder; Anxious depression; Efficacy;
Monotherapy
ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; STAR-ASTERISK-D; NONANXIOUS
DEPRESSION; CLINICAL-TRIALS; HUMAN BRAIN; DSM-IV; DISORDER; RECEPTORS;
RELEASE; BINDING
AB Anxious depression, defined as major depressive disorder (MDD) accompanied by high levels of anxiety, seems to be difficult to treat with traditional antidepressant monotherapy. The purpose of this study was to assess the efficacy of ziprasidone monotherapy in patients with anxious depression versus non-anxious depression. One hundred and twenty outpatients were enrolled in a 12-week study that was divided into two 6-week periods according to the sequential parallel comparison design. Patients were randomized in a 2:3:3 multi-ratio to receive ziprasidone for 12 weeks, placebo for 6 weeks, followed by ziprasidone for 6 weeks, or placebo for 12 weeks. Efficacy was measured according to the 17-item Hamilton Depression Rating Scale (HRDS-17), Quick Inventory of Depressive Symptomatology Self-Rated (QIDS-SR). Anxious depression was defined as a score of >= 7 on the HDRS-17 anxiety/somatization subscale. In phase I and II, ziprasidone monotherapy led to no significant changes compared with placebo on the HDRS-17 and QIDS-SR scores in patients with both anxious and non-anxious depression. In the pooled analysis, ziprasidone monotherapy also produced no significance on the HDRS-17 (Z = 0.25, P = 0.80) and QIDS-SR (Z = 0.43, P = 0.67) in patients with anxious depression. In conclusion, treatment with ziprasidone monotherapy may produce no significant improvement compared with placebo in patients with in anxious depression. Trial registration: ClinicalTrials.gov identifier: NCT00555997. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Heo, Jung-Yoon; Jeon, Hong Jin] Sungkyunkwan Univ, Dept Psychiat, Depress Ctr, Samsung Med Ctr,Sch Med, Seoul 135710, South Korea.
[Jeon, Hong Jin; Fava, Maurizio; Mischoulon, David; Baer, Lee; Clam, Alisabet; Doorley, James; Pisoni, Angela; Papakostas, George I.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA USA.
[Jeon, Hong Jin] Sungkyunkwan Univ, Dept Clin Res Design & Evaluat, SAIHST, Seoul 135710, South Korea.
[Jeon, Hong Jin] Sungkyunkwan Univ, Dept Med Device Management & Res, SAIHST, Seoul 135710, South Korea.
RP Jeon, HJ (reprint author), Sungkyunkwan Univ, Dept Psychiat, Depress Ctr, Samsung Med Ctr,Sch Med, 50 Irwon Dong, Seoul 135710, South Korea.
EM jeonhj@skku.edu
FU Pfizer Inc.; Basic Science Research Program through the National
Research Foundation of Korea (NRF) - Ministry of Education, Science and
Technology [2011-0013064]; Samsung Medical Center Clinical Research
Development Program (CRDP) [SMO1131461]
FX This trial was supported by Pfizer Inc. This research was also supported
by the Basic Science Research Program through the National Research
Foundation of Korea (NRF) funded by the Ministry of Education, Science
and Technology (No. 2011-0013064), and the Samsung Medical Center
Clinical Research Development Program (CRDP) Grant SMO1131461. They had
no further role in study design; in the collection, analysis and
interpretation of data; in the writing of the report; and in the
decision to submit the paper for publication.
NR 35
TC 1
Z9 1
U1 1
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
EI 1879-1379
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD MAR
PY 2015
VL 62
BP 56
EP 61
DI 10.1016/j.jpsychires.2015.01.007
PG 6
WC Psychiatry
SC Psychiatry
GA CE4GS
UT WOS:000351789700007
PM 25659187
ER
PT J
AU Zhang, CR
Cloonan, L
Fitzpatrick, KM
Kanakis, AS
Ayres, AM
Furie, KL
Rosand, J
Rost, NS
AF Zhang, Cathy R.
Cloonan, Lisa
Fitzpatrick, Kaitlin M.
Kanakis, Allison S.
Ayres, Alison M.
Furie, Karen L.
Rosand, Jonathan
Rost, Natalia S.
TI Determinants of White Matter Hyperintensity Burden Differ at the
Extremes of Ages of Ischemic Stroke Onset
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Leukoaraiosis; white matter disease; risk factor; acute cerebral
infarction; CT and MRI; risk factors for stroke
ID SMALL VESSEL DISEASE; LACUNAR STROKE; RISK-FACTORS; LEUKOARAIOSIS;
VOLUME; SUSCEPTIBILITY; PROGRESSION; HEMORRHAGE; SEVERITY; OLD
AB Background: Age is a well-known risk factor for both stroke and increased burden of white matter hyperintensity (WMH), as detected on magnetic resonance imaging (MRI) scans. However, in patients diagnosed with ischemic stroke (IS), WMH volume (WMHv) varies significantly across age groups. We sought to examine the determinants of WMH burden across the ages of stroke onset with the goal to uncover potential age-specific stroke prevention targets. Methods: Adult subjects from an ongoing hospital-based cohort study of IS patients with admission brain MRI were categorized as having early (< 55 years), late (> 75 years), or average (55-75 years) age of stroke onset. WMHv was measured using a previously validated, MRI-based semi-automated method and normalized for linear regression analyses. Results: Of 1008 IS subjects, 249 had early-onset stroke (24.7%), and 311 had late-onset stroke (30.9%). In multivariable analysis of WMHv using backward stepwise selection, only age (beta = .02, P = .018), hypertension (beta = .24, P = .049), and history of tobacco use (beta = .38, P = .001) were independently associated with WMHv in patients with early-onset stroke, whereas male sex (beta = -.30, P = .007), hyperlipidemia (beta = -.27, P = .015), and current alcohol use (beta = .23, P = .034) were independently associated with WMHv in patients with late-onset stroke. Conclusions: History of tobacco use is a strong independent predictor of WMH burden in patients with early-onset stroke, whereas age is no longer associated with WMHv in IS patients older than 75 years of age. These findings suggest that the major risk factors to target for stroke prevention differ across age groups and may be modifiable.
C1 [Zhang, Cathy R.; Cloonan, Lisa; Fitzpatrick, Kaitlin M.; Kanakis, Allison S.; Ayres, Alison M.; Rosand, Jonathan; Rost, Natalia S.] Massachusetts Gen Hosp, Dept Neurol, Stroke Serv, Boston, MA 02114 USA.
[Rosand, Jonathan; Rost, Natalia S.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Furie, Karen L.] Rhode Isl Hosp, Providence, RI USA.
RP Rost, NS (reprint author), Massachusetts Gen Hosp, Dept Neurol, Stroke Serv, 175 Cambridge St,Suite 300, Boston, MA 02114 USA.
EM nrost@partners.org
FU American Heart Association Bugher Foundation; Deane Institute for
Integrative Research in Atrial Fibrillation and Stroke; Massachusetts
General Hospital; National Institute of Neurological Disorders and
Stroke (NINDS) [K23 NS064052, R01 NS082285]; NINDS [5P50NS051343-04,
5R01NS059727, 5P50NS051343, R01NS063925, K23NS064052, R01NS082285]
FX This study was supported by project grants from the American Heart
Association Bugher Foundation, the Deane Institute for Integrative
Research in Atrial Fibrillation and Stroke, Massachusetts General
Hospital, and the National Institute of Neurological Disorders and
Stroke (NINDS grants K23 NS064052 and R01 NS082285). C.R.Z., L.C., K.F.,
A.K., and A.M.A. report no disclosures. K.L.F. is supported by the NINDS
(5P50NS051343-04). J.R. is supported by the NINDS (5R01NS059727,
5P50NS051343, R01NS063925) and the American Heart Association Bugher
Foundation. N.S.R. is supported by the NINDS (K23NS064052 and
R01NS082285).
NR 32
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD MAR
PY 2015
VL 24
IS 3
BP 649
EP 654
DI 10.1016/j.jstrokecerebrovasdis.2014.10.016
PG 6
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA CE5FB
UT WOS:000351855000027
PM 25576348
ER
PT J
AU Enguidanos, S
Kogan, AMC
Schreibeis-Baum, H
Lendon, J
Lorenz, K
AF Enguidanos, Susan
Kogan, Alexis M. Coulourides
Schreibeis-Baum, Hannah
Lendon, Jessica
Lorenz, Karl
TI "Because I Was Sick": Seriously Ill Veterans' Perspectives on Reason for
30-Day Readmissions
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE readmission; seriously ill; cancer; heart failure; palliative care
ID HOSPITAL READMISSION; PALLIATIVE CARE; MEDICARE BENEFICIARIES; COST
AB ObjectivesTo determine the perspectives of seriously ill individuals on reasons for 30-day hospital readmission.
DesignA prospective qualitative study was conducted employing individual interviews conducted at bedside.
SettingDepartment of Veterans Affairs Greater Los Angeles Healthcare System.
ParticipantsSeriously ill individuals with heart failure or cancer receiving inpatient palliative care and readmitted to the hospital within 30days of hospital discharge were recruited to participate. Nine were interviewed.
MeasurementsA semistructured interview protocol was used to elicit participant perspectives on readmission causes.
ResultsAll participants were male and had a mean age of 70.19.5. Participants were ethnically diverse (three African Americans, three Caucasians, three Hispanic or mixed ethnic background). Six lived alone, and four did not have caregiver support. Qualitative analysis of transcripts revealed three themes relating to reasons for hospital readmission: lack of caregiver support and motivation to provide self-care, acceptance of condition and desire for aggressive care, and access to care and poor quality of care.
ConclusionParticipants identified potentially avoidable reasons for hospital readmission as well as causes that require rethinking regarding how community support is targeted and delivered. Participant preference for aggressive care, inability to provide self-care, and lack of caregiver support suggest the need for new and innovative mechanisms to support seriously ill community-dwelling individuals.
C1 [Enguidanos, Susan; Kogan, Alexis M. Coulourides] Univ So Calif, Leonard Davis Sch Gerontol, Los Angeles, CA 90089 USA.
[Schreibeis-Baum, Hannah; Lendon, Jessica; Lorenz, Karl] US Dept Vet Affairs, Los Angeles, CA USA.
RP Enguidanos, S (reprint author), Univ So Calif, Davis Sch Gerontol, 3715 McClintock Ave, Los Angeles, CA 90089 USA.
EM Susan.Enguidanos@usc.edu
OI Enguidanos, Susan/0000-0002-5112-288X
FU National Palliative Care Research Center
FX This study was supported by a career development award from the National
Palliative Care Research Center. Hannah Schreibeis-Baum, Jessica Lendon,
and Karl Lorenz are employed by the VA, the site of the research study.
Susan Enguidanos and Alexis Coulourides Kogan received grant funds from
the National Palliative Care Research Center to conduct this research.
NR 26
TC 2
Z9 2
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAR
PY 2015
VL 63
IS 3
BP 537
EP 542
DI 10.1111/jgs.13238
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA CE3PO
UT WOS:000351740400015
PM 25732270
ER
PT J
AU Paquin, AM
Salow, M
Rudolph, JL
AF Paquin, Allison M.
Salow, Marci
Rudolph, James L.
TI Pharmacist Calls to Older Adults with Cognitive Difficulties After
Discharge in a Tertiary Veterans Affairs Medical Center: A Quality
Improvement Program
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE transitions in care; medication safety; medication reconciliation
ID HOSPITAL DISCHARGE; CARE; RECONCILIATION; DISCREPANCIES; PATIENT;
IMPACT; SCALE
AB ObjectivesTo evaluate the effect of the Pharmacological Intervention in Late Life (PILL) Service, which provides pharmacist telephone follow-up after discharge of older adults from the hospital, on postdischarge acute care utilization.
DesignRetrospective, secondary data analysis of a quality improvement project from 2010 to 2012.
SettingTertiary Veterans Affairs hospital.
ParticipantsParticipants were inpatients aged 65 and older with delirium risk or prescribed a dementia medication (N=501, mean age 79.58.0; 98% male).
MeasurementsPILL Service pharmacist telephone follow-up included a medication review and reconciliation within 5days after hospital discharge. The time of the pharmacist call was examined in relation to the outcomes of emergency and urgent care encounters, readmissions, and mortality within 60days.
ResultsThe average number of discharge medications was 14.8 +/- 5.7 with 2.8 +/- 2.2 medication changes and 1.4 +/- 1.8 discrepancies between medication order and instruction. After adjustment for age, number of medication changes, and number of discrepancies, every additional 5minutes of pharmacist call was associated with a 15% reduction in 60-day readmission (adjusted odds ratio (OR)=0.85, 95% confidence interval (95% CI)=0.75-0.97) but was not associated with emergency or urgent care encounters (adjusted OR=1.03, 95% CI=0.91-1.17) or mortality (adjusted OR=0.84, 95% CI=0.58-1.20).
ConclusionPharmacist-led medication review, reconciliation, and telephone calls after hospital discharge were associated with fewer 60-day hospital readmissions in this quality improvement program.
C1 [Paquin, Allison M.; Salow, Marci] VA Boston Healthcare Syst, Dept Pharm, Boston, MA USA.
[Paquin, Allison M.; Salow, Marci] Northeastern Univ, Dept Clin Pharm Practice, Boston, MA 02115 USA.
[Rudolph, James L.] VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA.
[Rudolph, James L.] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA.
[Rudolph, James L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Rudolph, JL (reprint author), VABHS GRECC, 150 S Huntington Ave, Boston, MA 02130 USA.
EM jrudolph@partners.org
FU VA Rehabilitation Career Development and Patient Safety Center of
Inquiry grants; Veterans Engineering Resource Network; Center for
Integration of Medicine and Innovative Technology; VA Central Office of
Geriatrics and Extended Care Non-institutional Alternatives to Extended
Care grant; American Society of Health-System Pharmacists Research and
Education Foundation
FX Drs. Paquin, Salow, and Rudolph are employees of the U.S. government.
The views expressed in this article are those of the authors and do not
necessarily represent the views of the Department of Veterans Affairs.
Dr. Rudolph is supported by VA Rehabilitation Career Development and
Patient Safety Center of Inquiry grants. Drs. Paquin, Salow, and Rudolph
have been supported by the VA grant described above. Dr. Paquin has
participated in research supported by the Veterans Engineering Resource
Network and the Center for Integration of Medicine and Innovative
Technology. Drs. Paquin and Rudolph had full access to study data and
take responsibility for the integrity and accuracy of this analysis.
None of the authors has any financial and personal conflicts to report.;
The project reported here was supported by the VA Central Office of
Geriatrics and Extended Care Non-institutional Alternatives to Extended
Care grant. The American Society of Health-System Pharmacists Research
and Education Foundation supported preparation of this manuscript.
NR 22
TC 2
Z9 2
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAR
PY 2015
VL 63
IS 3
BP 571
EP 577
DI 10.1111/jgs.13315
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA CE3PO
UT WOS:000351740400021
PM 25732548
ER
PT J
AU Kron, IL
Hung, J
Overbey, JR
Bouchard, D
Gelijns, AC
Moskowitz, AJ
Voisine, P
O'Gara, PT
Argenziano, M
Michler, RE
Gillinov, M
Puskas, JD
Gammie, JS
Mack, MJ
Smith, PK
Sai-Sudhakar, C
Gardner, TJ
Ailawadi, G
Zeng, X
O'Sullivan, K
Parides, MK
Swayze, R
Thourani, V
Rose, EA
Perrault, LP
Acker, MA
AF Kron, Irving L.
Hung, Judy
Overbey, Jessica R.
Bouchard, Denis
Gelijns, Annetine C.
Moskowitz, Alan J.
Voisine, Pierre
O'Gara, Patrick T.
Argenziano, Michael
Michler, Robert E.
Gillinov, Marc
Puskas, John D.
Gammie, James S.
Mack, Michael J.
Smith, Peter K.
Sai-Sudhakar, Chittoor
Gardner, Timothy J.
Ailawadi, Gorav
Zeng, Xin
O'Sullivan, Karen
Parides, Michael K.
Swayze, Roger
Thourani, Vinod
Rose, Eric A.
Perrault, Louis P.
Acker, Michael A.
CA CSTN Investigators
TI Predicting recurrent mitral regurgitation after mitral valve repair for
severe ischemic mitral regurgitation
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article
ID PAPILLARY-MUSCLE DYSFUNCTION; DILATED CARDIOMYOPATHY; HEART-FAILURE;
RESTRICTIVE ANNULOPLASTY; ECHOCARDIOGRAPHY; REPLACEMENT;
RECOMMENDATIONS; MECHANISM; DISEASE; SURGERY
AB Objectives: The Cardiothoracic Surgical Trials Network recently reported no difference in the primary end point of left ventricular end-systolic volume index at 1 year postsurgery in patients randomized to repair (n = 126) or replacement (n = 125) for severe ischemic mitral regurgitation. However, patients undergoing repair experienced significantly more recurrent mitral regurgitation than patients undergoing replacement (32.6% vs 2.3%). We examined whether baseline echo-cardiographic and clinical characteristics could identify those who will develop moderate/severe recurrent mitral regurgitation or die.
Methods: Our analysis includes 116 patients who were randomized to and received mitral valve repair. Logistic regression was used to estimate a model-based probability of recurrence or death from baseline factors. Receiver operating characteristic curves were constructed from these estimated probabilities to determine classification cut-points maximizing accuracy of prediction based on sensitivity and specificity.
Results: Of the 116 patients, 6 received a replacement before leaving the operating room; all other patients had mild or less mitral regurgitation on intraoperative echo-cardiogram after repair. During the 2-year follow-up period, 76 patients developed moderate/severe mitral regurgitation or died (53 mitral regurgitation recurrences, 13 mitral regurgitation recurrences and death, and 10 deaths). The mechanism for recurrent mitral regurgitation was largely mitral valve leaflet tethering. Our model (including age, body mass index, sex, race, effective regurgitant orifice area, basal aneurysm/dyskinesis, New York Heart Association class, history of coronary artery bypass grafting, percutaneous coronary intervention, or ventricular arrhythmias) yielded an area under the receiver operating characteristic curve of 0.82.
Conclusions: The model demonstrated good discrimination in identifying patients who will survive 2 years without recurrent mitral regurgitation after mitral valve repair. Although our results require validation, they offer a clinically relevant risk score for selection of surgical candidates for this procedure.
C1 [Kron, Irving L.; Ailawadi, Gorav] Univ Virginia, Sch Med, Div Thorac & Cardiovasc Surg, Charlottesville, VA 22908 USA.
[Hung, Judy; Zeng, Xin] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Overbey, Jessica R.; Gelijns, Annetine C.; Moskowitz, Alan J.; O'Sullivan, Karen; Parides, Michael K.; Rose, Eric A.] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, Int Ctr Hlth Outcomes & Innovat Res InCHOIR, New York, NY 10029 USA.
[Bouchard, Denis; Perrault, Louis P.] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada.
[Voisine, Pierre] Hop Laval, Inst Univ Cardiol Quebec, Montreal, PQ, Canada.
[O'Gara, Patrick T.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA.
[Argenziano, Michael] Columbia Univ, Coll Phys & Surg, Dept Surg, Div Cardiothorac Surg, New York, NY USA.
[Michler, Robert E.; Swayze, Roger] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Cardiothorac Surg, New York, NY USA.
[Gillinov, Marc] Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44195 USA.
[Puskas, John D.; Thourani, Vinod] Icahn Sch Med Mt Sinai, Mt Sinai Beth Israel, Cardiothorac Surg, Dept Cardiac Surg, New York, NY 10029 USA.
[Gammie, James S.] Univ Maryland, Dept Cardiac Surg, Baltimore, MD 21201 USA.
[Mack, Michael J.] Baylor Scott & White Hlth, Baylor Res Inst, Cardiothorac Surg, Plano, TX USA.
[Smith, Peter K.] Duke Univ, Div Cardiovasc & Thorac Surg, Durham, NC USA.
[Sai-Sudhakar, Chittoor] Ohio State Univ, Med Ctr, Cardiac Surg, Columbus, OH 43210 USA.
[Gardner, Timothy J.] Christiana Care Hlth Syst, Ctr Heart & Vasc Hlth, Newark, DE USA.
[Acker, Michael A.] Univ Penn, Dept Surg, Div Cardiovasc Surg, Sch Med, Philadelphia, PA 19104 USA.
RP Gelijns, AC (reprint author), Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, InCHOIR, New York, NY 10029 USA.
EM Annetine.gelijns@mountsinai.edu
OI Moskowitz, Alan/0000-0002-4412-9450; Browndyke,
Jeffrey/0000-0002-8573-7073
FU National Heart, Lung, and Blood Institute, Bethesda, Md; Canadian
Institutes of Health Research, Ottawa, Ontario; National Institute of
Neurological Diseases and Stroke, Bethesda, Md [7U01 HL088942]
FX Funded by a cooperative agreement of The National Heart, Lung, and Blood
Institute, Bethesda, Md; the Canadian Institutes of Health Research,
Ottawa, Ontario; and the National Institute of Neurological Diseases and
Stroke, Bethesda, Md (Grant 7U01 HL088942). (ClinicalTrials.gov number
NCT00807040).
NR 44
TC 38
Z9 39
U1 0
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD MAR
PY 2015
VL 149
IS 3
BP 752
EP +
DI 10.1016/j.jtcvs.2014.10.120
PG 11
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA CE6EX
UT WOS:000351930600040
PM 25500293
ER
PT J
AU Inaba, K
Nosanov, L
Menaker, J
Bosarge, P
Williams, L
Turay, D
Cachecho, R
de Moya, M
Bukur, M
Carl, J
Kobayashi, L
Kaminski, S
Beekley, A
Gomez, M
Skiada, D
AF Inaba, Kenji
Nosanov, Lauren
Menaker, Jay
Bosarge, Patrick
Williams, Lashonda
Turay, David
Cachecho, Riad
de Moya, Marc
Bukur, Marko
Carl, Jordan
Kobayashi, Leslie
Kaminski, Stephen
Beekley, Alec
Gomez, Mario
Skiada, Dimitra
CA AAST TL-Spine Multictr Study Grp
TI Prospective derivation of a clinical decision rule for thoracolumbar
spine evaluation after blunt trauma: An American Association for the
Surgery of Trauma Multi-Institutional Trials Group Study
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article; Proceedings Paper
CT 73rd Annual Meeting of the
American-Association-for-the-Surgery-of-Trauma / Clinical Congress of
Acute Care Surgery
CY SEP 09-13, 2014
CL Philadelphia, PA
SP Amer Assoc Surg Trauma
DE Thoracolumbar; spine; trauma; diagnostic; evaluation
ID LUMBAR SPINE; COMPUTED-TOMOGRAPHY; FRACTURES; INJURIES; RADIOGRAPHS;
CRITERIA; RISK; CLASSIFICATION; CLEARANCE; ACCURACY
AB BACKGROUND: Unlike the cervical spine (C-spine), where National Emergency X-Radiography Utilization Study (NEXUS) and the Canadian C-spine Rules can be used, evidence-based thoracolumbar spine (TL-spine) clearance guidelines do not exist. The aim of this study was to develop a clinical decision rule for evaluating the TL-spine after injury.
METHODS: Adult (>= 15 years) blunt trauma patients were prospectively enrolled at 13 US trauma centers (January 2012 to January 2014). Exclusion criteria included the following: C-spine injury with neurologic deficit, preexisting paraplegia/tetraplegia, and unevaluable examination. Remaining evaluable patients underwent TL-spine imaging and were followed up to discharge. The primary end point was a clinically significant TL-spine injury requiring TL-spine orthoses or surgical stabilization. Regression techniques were used to develop a clinical decision rule. Decision rule performance in identifying clinically significant fractures was tested.
RESULTS: Of 12,479 patients screened, 3,065 (24.6%) met inclusion criteria (mean [SD] age, 43.5 [19.8] years [range, 15-103 years]; male sex, 66.3%; mean [SD] Injury Severity Score [ISS], 8.8 [7.5]). The majority underwent computed tomography (93.3%), 6.3% only plain films, and 0.2% magnetic resonance imaging exclusively. TL-spine injury was identified in 499 patients (16.3%), of which 264 (8.6%) were clinically significant (29.2% surgery, 70.8% TL-spine orthosis). The majority was AO Type A1 282 (56.5%), followed by 67 (13.4%) A3, 43 (8.6%) B2, and 32 (6.4%) A4 injuries. The predictive ability of clinical examination (pain, midline tenderness, deformity, neurologic deficit), age, and mechanism was examined; positive clinical examination finding resulted in a sensitivity of 78.4% and a specificity of 72.9%. Addition of age of 60 years or older and high-risk mechanism (fall, crush, motor vehicle crash with ejection/rollover, unenclosed vehicle crash, auto vs. pedestrian) increased sensitivity to 98.9% with specificity of 29.0% for clinically significant injuries and 100.0% sensitivity and 27.3% specificity for injuries requiring surgery.
CONCLUSION: Clinical examination alone is insufficient for determining the need for imaging in evaluable patients at risk of TL-spine injury. Addition of age and high-risk mechanism results in a clinical decision-making rule with a sensitivity of 98.9% for clinically significant injuries. (Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.)
C1 [Inaba, Kenji; Nosanov, Lauren; Skiada, Dimitra] Univ So Calif, Div Trauma & Surg Crit Care, Los Angeles, CA 90033 USA.
[Turay, David] Loma Linda Univ, Dept Surg, Loma Linda, CA 92350 USA.
[Kobayashi, Leslie] Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, La Jolla, CA 92093 USA.
[Kaminski, Stephen] Santa Barbara Cottage Hosp, Trauma Serv, Santa Barbara, CA USA.
[Menaker, Jay] Univ Maryland, Sch Med, Dept Surg, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA.
[Bosarge, Patrick] Univ Alabama Birmingham, Div Trauma Burns & Surg Crit Care, Birmingham, AL USA.
[Williams, Lashonda] East Texas Med Ctr, Dept Trauma, Tyler, TX USA.
[Carl, Jordan] Univ Texas Southwestern Austin, Dept Surg, Austin, TX USA.
[Cachecho, Riad] Crozer Chester Med Ctr, Dept Surg, Upland, NY USA.
[Beekley, Alec] Thomas Jefferson Univ, Div Acute Care Surg, Philadelphia, PA 19107 USA.
[de Moya, Marc] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma, Boston, MA USA.
[Bukur, Marko] Florida Int Univ, Broward Gen Med Ctr, Miami, FL 33199 USA.
[Gomez, Mario] Lutheran Med Ctr, Div Trauma & Surg Crit Care, Brooklyn, NY USA.
RP Inaba, K (reprint author), Univ So Calif, LAC USC Med Ctr, Div Trauma & Surg Crit Care, IPT, 2051 Marengo St,C5L 100, Los Angeles, CA 90033 USA.
EM KInaba@surgery.usc.edu
NR 28
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD MAR
PY 2015
VL 78
IS 3
BP 459
EP 465
DI 10.1097/TA.0000000000000560
PG 7
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA CE8DQ
UT WOS:000352072000003
PM 25710414
ER
PT J
AU Dawes, AJ
Sacks, GD
Cryer, HG
Gruen, JP
Preston, C
Gorospe, D
Cohen, M
McArthur, DL
Russell, MM
Maggard-Gibbons, M
Ko, CY
AF Dawes, Aaron J.
Sacks, Greg D.
Cryer, H. Gill
Gruen, J. Peter
Preston, Christy
Gorospe, Deidre
Cohen, Marilyn
McArthur, David L.
Russell, Marcia M.
Maggard-Gibbons, Melinda
Ko, Clifford Y.
CA Los Angeles Cty Trauma Consortium
TI Intracranial pressure monitoring and inpatient mortality in severe
traumatic brain injury: A propensity score-matched analysis
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article; Proceedings Paper
CT 73rd Annual Meeting of the
American-Association-for-the-Surgery-of-Trauma / Clinical Congress of
Acute Care Surgery
CY SEP 09-13, 2014
CL Philadelphia, PA
SP Amer Assoc Surg Trauma
DE Traumatic brain injury; intracranial pressure monitoring; mortality;
propensity score
ID SEVERE HEAD-INJURY; EVIDENCE-BASED GUIDELINES; UNITED-STATES; CARE;
HOSPITALIZATION; IMPROVEMENT; MANAGEMENT; OUTCOMES; CENTERS
AB BACKGROUND: Although intracranial pressure (ICP) monitoring in severe traumatic brain injury (TBI) is recommended by the Brain Trauma Foundation, the benefits remain controversial. We sought to determine the impact of ICP monitor placement on inpatient mortality within a regional trauma system after correcting for selection bias through propensity score matching.
METHODS: Data were collected on all severe TBI cases presenting to 14 trauma centers during the 2-year study period (2009-2010). Inclusion criteria were as follows: blunt injury, Glasgow Coma Scale (GCS) score of 8 or lower in the emergency department, and abnormal intracranial findings on head computed tomography (CT). Two separate multivariate logistic regression models were used to predict ICP monitor placement and inpatient mortality after controlling for demographics, severity of injury, comorbidities, and TBI-specific variables (GCS score, pupil reactivity, international normalized ratio, and nine specific head CT findings). To account for selection bias, we developed a propensity score-matched model to estimate the "true'' effect of ICP monitoring on in-hospital mortality.
RESULT: A total of 844 patients met inclusion criteria; 22 died on arrival to the emergency department. Inpatient mortality was 38.8%; 46.0% of the patients underwent ICP monitor placement. Unadjusted mortality rates were significantly lower in the ICP monitoring group (30.7% vs. 45.7%, p < 0.001). ICP monitor placement was positively associated with CT findings of subdural hematoma, intraparenchymal contusion, and mass effect and negatively associated with age, alcoholism, and elevated international normalized ratio. After adjusting for selection bias via propensity score matching, ICP monitor placement was associated with an 8.3 percentage point reduction in the risk-adjusted mortality rate.
CONCLUSION: ICP monitor placement occurred in only 46% of eligible patients but was associated with significantly decreased mortality after adjusting for baseline risk profile and the propensity to undergo monitoring. As the individual impact of ICP monitoring may vary, future efforts must determine who stands to benefit from invasive monitoring techniques. (Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.)
C1 [Dawes, Aaron J.; Sacks, Greg D.; Cryer, H. Gill; Cohen, Marilyn; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[McArthur, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA.
[Dawes, Aaron J.; Sacks, Greg D.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA.
[Dawes, Aaron J.; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Gruen, J. Peter] Univ So Calif, Dept Neurosurg, Los Angeles, CA USA.
[Preston, Christy; Gorospe, Deidre] Cty Los Angeles, Dept Hlth Serv, Emergency Med Serv Agcy, Los Angeles, CA USA.
RP Dawes, AJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Ronald Reagan UCLA Med Ctr, 757 Westwood Plaza B7-11, Los Angeles, CA 90095 USA.
EM adawes@mednet.ucla.edu
OI Dawes, Aaron/0000-0003-4574-6765
FU VA Office of Academic Affiliations through the VA/Robert Wood Johnson
Clinical Scholars Program
FX A.J.D. was supported by the VA Office of Academic Affiliations through
the VA/Robert Wood Johnson Clinical Scholars Program.
NR 24
TC 11
Z9 11
U1 2
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD MAR
PY 2015
VL 78
IS 3
BP 492
EP 501
DI 10.1097/TA.0000000000000559
PG 10
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA CE8DQ
UT WOS:000352072000011
PM 25710418
ER
PT J
AU King, DR
Larentzakis, A
Ramly, EP
AF King, David Richard
Larentzakis, Andreas
Ramly, Elie P.
CA Boston Trauma Collaborative
TI Tourniquet use at the Boston Marathon bombing: Lost in translation
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE Tourniquet; bomb; Boston; extremity; prehospital
ID RESUSCITATION OUTCOMES CONSORTIUM; OPERATION IRAQI FREEDOM; HEMORRHAGE
CONTROL; MULTICENTER EVALUATION; PREHOSPITAL MODE; SEVERE INJURY; LIMB
TRAUMA; TRANSPORT; SURVIVAL; EXPERIENCE
AB BACKGROUND: The Boston Marathon bombing was the first major, modern US terrorist event with multiple, severe lower extremity injuries. First responders, including trained professionals and civilian bystanders, rushed to aid the injured. The purpose of this review was to determine how severely bleeding extremity injuries were treated in the prehospital setting in the aftermath of the Boston Marathon bombing.
METHODS: A database was created and populated by all the Boston Level I trauma centers following the Boston Marathon bombing. Data regarding specific injuries, extremities affected, demographics, prehospital interventions (including tourniquet types), and outcomes were extracted.
RESULTS: Of 243 injured, 152 patients presented to the emergency department within 24 hours. Of these 152 patients, there were 66 (63.6% female) experiencing at least one extremity injury, with age ranging from younger than 15 years to 71 years, and with a median Injury Severity Score (ISS) of 10 (range, 1-38). Of the 66 injured patients, 4 had upper limbs affected, 56 had injuries on the lower limbs only, and 6 had combined upper and lower limbs affected. The extremity Abbreviated Injury Scale (AIS) scores had a median of 3 (range, 1-4). There were 17 lower extremity traumatic amputations in 15 patients. In addition, there were 10 patients with 12 lower extremities experiencing major vascular injuries. Of 66 injured patients, 29 patients had recognized extremity exsanguination at the scene. In total, 27 tourniquets were applied: 16 of 17 traumatic amputations, 5 of 12 lower extremities with major vascular injuries, and 6 additional limbs with major soft tissue injury. All tourniquets were improvised, and no commercial, purpose-designed tourniquets were identified. Among all 243 patients, mortality was 0%.
CONCLUSION: After the Boston Marathon bombings, extremity exsanguination at the point of injury was either left untreated or treated with an improvised tourniquet in the prehospital environment. An effective, prehospital extremity hemorrhage control posture should be translated to all civilian first responders in the United States and should mirror the military's posture toward extremity bleeding control. The prehospital response to extremity exsanguination after the Boston Marathon bombing demonstrates that our current practice is an approach, lost in translation, from the battlefield to the homeland. (Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.)
C1 [King, David Richard; Larentzakis, Andreas; Ramly, Elie P.; Boston Trauma Collaborative] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Trauma,Emergency Surg,Surg Crit Care, Boston, MA 02141 USA.
RP King, DR (reprint author), Harvard Univ, Sch Med, US Army Joint Special Operat Command, Massachusetts Gen Hosp,Div Trauma Emergency Surg, 165 Cambridge St,Suite 810, Boston, MA 02141 USA.
EM dking3@mgh.harvard.edu
OI King, David/0000-0003-1028-1478
NR 28
TC 12
Z9 12
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD MAR
PY 2015
VL 78
IS 3
BP 594
EP 599
DI 10.1097/TA.0000000000000561
PG 6
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA CE8DQ
UT WOS:000352072000027
PM 25710432
ER
PT J
AU Rago, AP
Marini, J
Duggan, MJ
Beagle, J
Runyan, G
Sharma, U
Peev, M
King, DR
AF Rago, Adam P.
Marini, John
Duggan, Michael J.
Beagle, John
Runyan, Gem
Sharma, Upma
Peev, Miroslav
King, David R.
TI Diagnosis and deployment of a self-expanding foam for abdominal
exsanguination: Translational questions for human use
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE War; prehospital; hemorrhage; exsanguination; abdominal; foam; swine
ID COMBAT CASUALTY CARE; PREHOSPITAL TREATMENT; CLOSED-ABDOMEN; HEMORRHAGE;
ULTRASOUND; MODEL; SURVIVAL; WOUNDS; LETHAL; DEATH
AB BACKGROUND: We have previously described the hemostatic efficacy of a self-expanding polyurethane foam in lethal venous and arterial hemorrhage models. A number of critical translational questions remain, including prehospital diagnosis of hemorrhage, use with diaphragmatic injury, effects on spontaneous respiration, the role of omentum, and presence of a laparotomy on foam properties.
METHODS: In Experiment 1, diagnostic blood aspiration was attempted through a Veress needle before foam deployment during exsanguination (n = 53). In Experiment 2: a lethal hepatoportal injury/diaphragmatic laceration was created followed by foam (n = 6) or resuscitation (n = 10). In Experiment 3, the foam was deployed in naive, spontaneously breathing animals (n = 7), and respiration was monitored. In Experiments 4 and 5, the foam was deployed above (n = 6) and below the omentum (n = 6) and in naive animals (n = 6). Intra-abdominal pressure and organ contact were assessed.
RESULTS: In Experiment 1, blood was successfully aspirated from a Veress needle in 70% of lethal iliac artery injuries and 100% of lethal hepatoportal injuries. In Experiment 2, in the presence of a diaphragm injury, between 0 cc and 110 cc of foam was found within the pleural space. Foam treatment resulted in a survival benefit relative to the control group at 1 hour (p = 0.03). In Experiment 3, hypercarbia was observed: mean (SD) P-CO2 was 48 (9.4) mm Hg at baseline and 65 (14) mm Hg at 60 minutes. In Experiment 4, abdominal omentum seemed to influence organ contact and transport in two foam deployments. In Experiment 5, there was no difference in intra-abdominal pressure following foam deployment in the absence of a midline laparotomy.
CONCLUSION: In a series of large animal studies, we addressed key translational issues surrounding safe use of foam treatment. These additional data, from diagnosis to deployment, will guide human experiences with foam treatment for massive abdominal exsanguination where no other treatments are available. (Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.)
C1 [Duggan, Michael J.; Beagle, John; Peev, Miroslav; King, David R.] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Dept Surg, Boston, MA 02141 USA.
[Duggan, Michael J.; Beagle, John; Peev, Miroslav; King, David R.] Harvard Univ, Sch Med, Boston, MA USA.
[Rago, Adam P.; Marini, John; Sharma, Upma] Arsenal Med Inc, Watertown, MA USA.
RP King, DR (reprint author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02141 USA.
EM DKING3@mgh.harvard.edu
OI King, David/0000-0003-1028-1478
FU DARPA ARO [W911NF-10-C-0089, W911NF-12-C-0066]
FX This study was supported by DARPA ARO contracts W911NF-10-C-0089
W911NF-12-C-0066.
NR 20
TC 2
Z9 2
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD MAR
PY 2015
VL 78
IS 3
BP 607
EP 613
DI 10.1097/TA.0000000000000558
PG 7
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA CE8DQ
UT WOS:000352072000029
PM 25710434
ER
PT J
AU Purschke, M
Chuang, G
Le, M
Manstein, D
Avram, M
Anderson, RR
AF Purschke, Martin
Chuang, Gary
Le, Monica
Manstein, Dieter
Avram, Mathew
Anderson, R. Rox
TI LIDOCAINE-INDUCED POTENTIATION OF THERMAL DAMAGE IN KERATINOCYTES,
FIBROBLASTS, AND BASAL CELL CARCINOMA IN CULTURE
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
Univ Massachusetts, Sch Med, Worcester, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2015
VL 47
SU 26
MA 5
BP 2
EP 3
PG 2
WC Dermatology; Surgery
SC Dermatology; Surgery
GA CE8NN
UT WOS:000352099900006
ER
PT J
AU Wang, YC
Gu, Y
Dai, TH
AF Wang, Yucheng
Gu, Ying
Dai, Tianhong
TI ANTIMICROBIAL BLUE LIGHT INACTIVATION OF MULTIDRUG-RESISTANT
ACINETOBACTER BAUMANNII BIOFILMS
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
Chinese Peoples Liberat Army Gen Hosp, Beijing 100853, Peoples R China.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2015
VL 47
SU 26
MA 7
BP 3
EP 3
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA CE8NN
UT WOS:000352099900008
ER
PT J
AU Wang, RS
Ortega-Martinez, A
Purschke, M
Zhu, H
Anderson, RR
Kochevar, I
Franco, W
AF Wang, Ruisheng
Ortega-Martinez, Antonio
Purschke, Martin
Zhu, Hong
Anderson, R. Rox
Kochevar, Irene
Franco, Walfre
TI COLLAGEN CROSS-LINKS AS FLUORESCENT MARKER FOR BIOMECHANICAL
CHARACTERIZATION OF COLLAGENOUS TISSUES: FEASIBILITY STUDY
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Clarkson Univ, Potsdam, NY USA.
Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2015
VL 47
SU 26
MA 18
BP 7
EP 7
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA CE8NN
UT WOS:000352099900019
ER
PT J
AU Fan, B
Neel, V
Yaroslavsky, A
AF Fan, Bo
Neel, Victor
Yaroslavsky, Anna
TI COMBINING TERAHERTZ PULSED IMAGING IN FREQUENCY DOMAIN AND POLARIZATION
OPTICAL IMAGING FOR DELINEATING NONMELANOMA SKIN CANCERS
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Univ Massachusetts, Adv Biophoton Lab, Lowell, MA 01854 USA.
Massachusetts Gen Hosp Boston, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2015
VL 47
SU 26
MA 32
BP 11
EP 11
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA CE8NN
UT WOS:000352099900032
ER
PT J
AU Erlendsson, AM
Doukas, AG
Farinelli, WA
Bhayana, B
Anderson, RR
Haedersdal, M
AF Erlendsson, Andres M.
Doukas, Apostolos G.
Farinelli, William A.
Bhayana, Brijesh
Anderson, R. Rox
Haedersdal, Merete
TI PRESSURE ENHANCES FRACTIONAL LASER-ASSISTED DRUG DELIVERY
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
Univ Copenhagen, Bispebjerg Univ Hosp, Copenhagen, Denmark.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2015
VL 47
SU 26
MA 86
BP 30
EP 30
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA CE8NN
UT WOS:000352099900086
ER
PT J
AU Erlendsson, AM
Doukas, AG
Farinelli, WA
Eriksson, AH
Zibert, JR
Anderson, RR
Haedersdal, M
AF Erlendsson, Andres M.
Doukas, Apostolos G.
Farinelli, William A.
Eriksson, Andre H.
Zibert, John R.
Anderson, R. Rox
Haedersdal, Merete
TI RAPID DERMAL DEPOSITION OF INGENOL MEBUTATE USING PRESSURE AND ABLATIVE
FRACTIONAL LASER
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
LEO Pharma AS, Ballerup, Denmark.
Univ Copenhagen, Bispebjerg Univ Hosp, Copenhagen, Denmark.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2015
VL 47
SU 26
MA 87
BP 30
EP 30
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA CE8NN
UT WOS:000352099900087
ER
PT J
AU Kositratna, G
Manstein, D
AF Kositratna, Garuna
Manstein, Dieter
TI RAPID FIBRIN PLUG FORMATION WITHIN ABLATIVE FRACTIONAL CO2 LASER LESIONS
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 [Kositratna, Garuna; Manstein, Dieter] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2015
VL 47
SU 26
MA 88
BP 30
EP 31
PG 2
WC Dermatology; Surgery
SC Dermatology; Surgery
GA CE8NN
UT WOS:000352099900088
ER
PT J
AU Wang, Y
Gutierrez-Herrera, E
Ortega-Martinez, A
Farinelli, B
Doukas, A
Anderson, RR
Franco, W
AF Wang, Ying
Gutierrez-Herrera, Enoch
Ortega-Martinez, Antonio
Farinelli, Bill
Doukas, Apostolos
Anderson, R. Rox
Franco, Walfre
TI UV FLUORESCENCE EXCITATION IMAGING IN WOUND HEALING: WOUND SIZE AND
WOUND CLOSURE MEASUREMENTS
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 [Wang, Ying; Gutierrez-Herrera, Enoch; Ortega-Martinez, Antonio; Farinelli, Bill; Doukas, Apostolos; Anderson, R. Rox; Franco, Walfre] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2015
VL 47
SU 26
MA 146
BP 49
EP 49
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA CE8NN
UT WOS:000352099900145
ER
PT J
AU Levin, Y
Kositratna, G
Evers, M
Manstein, D
AF Levin, Yakir
Kositratna, Garuna
Evers, Michael
Manstein, Dieter
TI OPTIMIZATION OF LASER EXPOSURE PARAMETERS IN FRACTIONAL PHOTOTHERMOLYSIS
TO AVOID BULK HEATING
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 [Levin, Yakir; Kositratna, Garuna; Evers, Michael; Manstein, Dieter] Boston Univ, Massachusetts Gen Hosp, Boston, MA 02215 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2015
VL 47
SU 26
MA 155
BP 52
EP 52
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA CE8NN
UT WOS:000352099900154
ER
PT J
AU Zhang, W
Oda, T
Yu, Q
Jin, JO
AF Zhang, Wei
Oda, Tatsuya
Yu, Qing
Jin, Jun-O
TI Fucoidan from Macrocystis pyrifera Has Powerful Immune-Modulatory
Effects Compared to Three Other Fucoidans
SO MARINE DRUGS
LA English
DT Article
ID ASCOPHYLLUM-NODOSUM; DENDRITIC CELLS; SCAVENGER RECEPTOR; ADAPTIVE
IMMUNITY; BROWN SEAWEEDS; MATURATION; NEUTROPHILS; CYTOKINES; INNATE;
POLYSACCHARIDE
AB Fucoidan, a sulfated polysaccharide purified from brown algae, has a variety of immune-modulation effects, such as promoting activation of dendritic cells (DCs), natural killer (NK) cells and T cells, and enhancing anti-viral and anti-tumor responses. However, the immune-modulatory effect of fucoidan from different seaweed extracts has not been thoroughly analyzed and compared. We analyzed fucoidans obtained from Ascophyllum nodosum (A. nodosum), Macrocystis pyrifera (M. pyrifera), Undaria pinnatifida (U. pinnatifida) and Fucus vesiculosus (F. vesiculosus) for their effect on the apoptosis of human neutrophils, activation of mouse NK cells, maturation of spleen DCs, proliferation and activation of T cells, and the adjuvant effect in vivo. Fucoidans from M. pyrifera and U. pinnatifida strongly delayed human neutrophil apoptosis at low concentration, whereas fucoidans from A. nodosum and F. vesiculosus delayed human neutrophil apoptosis at higher concentration. Moreover, fucoidan from M. pyrifera promoted NK cell activation and cytotoxic activity against YAC-1 cells. In addition, M. pyrifera fucoidan induced the strongest activation of spleen DCs and T cells and ovalbumin (OVA) specific immune responses compared to other fucoidans. These data suggest that fucoidan from M. pyrifera can be potentially useful as a therapeutic agent for infectious diseases, cancer and an effective adjuvant for vaccine.
C1 [Zhang, Wei; Jin, Jun-O] Fudan Univ, Shanghai Med Coll, Shanghai Publ Hlth Clin Ctr, Shanghai 201508, Peoples R China.
[Oda, Tatsuya] Nagasaki Univ, Div Biochem, Fac Fisheries, Nagasaki, Nagasaki 8528521, Japan.
[Yu, Qing] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA 02142 USA.
RP Jin, JO (reprint author), Fudan Univ, Shanghai Med Coll, Shanghai Publ Hlth Clin Ctr, Shanghai 201508, Peoples R China.
EM weiwei061215@126.com; t-oda@nagasaki-u.ac.jp; qyu@forsyth.org;
junojin1@gmail.com
FU Research fund for International Young Scientists from National Natural
Science Foundation of China [81450110090]; Nagasaki University Major
Research Project (Research Initiative for Adaptation to Future Ocean
Change)
FX We thank the Shanghai Public Health Clinical Center animal facility for
maintaining animals. This study was supported by Research fund for
International Young Scientists from National Natural Science Foundation
of China (81450110090). Tatsuya Oda was supported by a fund from
Nagasaki University Major Research Project (Research Initiative for
Adaptation to Future Ocean Change).
NR 28
TC 8
Z9 9
U1 11
U2 42
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD MAR
PY 2015
VL 13
IS 3
BP 1084
EP 1104
DI 10.3390/md13031084
PG 21
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CE6EW
UT WOS:000351930500001
PM 25706632
ER
PT J
AU Bruinsma, BG
Uygun, K
Yarmush, ML
Saeidi, N
AF Bruinsma, Bote G.
Uygun, Korkut
Yarmush, Martin L.
Saeidi, Nima
TI Surgical models of Roux-en-Y gastric bypass surgery and sleeve
gastrectomy in rats and mice
SO NATURE PROTOCOLS
LA English
DT Article
ID INTENSIVE MEDICAL THERAPY; BARIATRIC SURGERY; ENERGY-EXPENDITURE; MOUSE
MODEL; OBESE RATS; METAANALYSIS; MORTALITY; WEIGHT; TRENDS; PREVALENCE
AB Bariatric surgery is the only definitive solution currently available for the present obesity pandemic. These operations typically involve reconfiguration of gastrointestinal tract anatomy and impose profound metabolic and physiological benefits, such as substantially reducing body weight and ameliorating type II diabetes. Therefore, animal models of these surgeries offer unique and exciting opportunities to delineate the underlying mechanisms that contribute to the resolution of obesity and diabetes. Here we describe a standardized procedure for mouse and rat models of Roux-en-Y gastric bypass (80-90 min operative time) and sleeve gastrectomy (30-45 min operative time), which, to a high degree, resembles operations in humans. We also provide detailed protocols for both pre- and postoperative techniques that ensure a high success rate in the operations. These protocols provide the opportunity to mechanistically investigate the systemic effects of the surgical interventions, such as regulation of body weight, glucose homeostasis and gut microbiome.
C1 [Bruinsma, Bote G.; Uygun, Korkut; Yarmush, Martin L.; Saeidi, Nima] Massachusetts Gen Hosp, Dept Surg, Ctr Engn Med, Boston, MA 02114 USA.
RP Yarmush, ML (reprint author), Massachusetts Gen Hosp, Dept Surg, Ctr Engn Med, Boston, MA 02114 USA.
EM myarmush@mgh.harvard.edu; nsaeidi@mgh.harvard.edu
FU US National Institutes of Health [DK095558]
FX This work was supported by US National Institutes of Health grant no.
DK095558 to N.S.
NR 38
TC 5
Z9 5
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
EI 1750-2799
J9 NAT PROTOC
JI Nat. Protoc.
PD MAR
PY 2015
VL 10
IS 3
DI 10.1038/nprot.2015.027
PG 13
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA CE6FE
UT WOS:000351931300010
PM 25719268
ER
PT J
AU Bruinsma, BG
Berendsen, TA
Izamis, ML
Yeh, H
Yarmush, ML
Uygun, K
AF Bruinsma, Bote G.
Berendsen, Tim A.
Izamis, Maria-Louisa
Yeh, Heidi
Yarmush, Martin L.
Uygun, Korkut
TI Supercooling preservation and transplantation of the rat liver
SO NATURE PROTOCOLS
LA English
DT Article
ID SUBNORMOTHERMIC MACHINE PERFUSION; COLD-STORAGE; POLYETHYLENE-GLYCOL;
CARDIAC DEATH; DONOR; INJURY; MODEL; HEPATOCYTES; TEMPERATURE; STRATEGY
AB he current standard for liver preservation involves cooling of the organ on ice (0-4 degrees C). Although it is successful for shorter durations, this method of preservation does not allow long-term storage of the liver. The gradual loss of hepatic viability during preservation puts pressure on organ sharing and allocation, may limit the use of suboptimal grafts and necessitates rushed transplantation to achieve desirable post-transplantation outcomes. In an attempt to improve and prolong liver viability during storage, alternative preservation methods are under investigation. For instance, ex vivo machine perfusion systems aim to sustain and even improve viability by supporting hepatic function at warm temperatures, rather than simply slowing down deterioration by cooling. Here we describe a novel subzero preservation technique that combines ex vivo machine perfusion with cryoprotectants to facilitate long-term supercooled preservation. The technique improves the preservation of rat livers to prolong storage times as much as threefold, which is validated by successful long-term recipient survival after orthotopic transplantation. This protocol describes how to load rat livers with cryoprotectants to prevent both intracellular and extracellular ice formation and to protect against hypothermic injury. Cryoprotectants are loaded ex vivo using subnormothermic machine perfusion (SNMP), after which livers can be cooled to -6 degrees C without freezing and kept viable for up to 96 h. Cooling to a supercooled state is controlled, followed by 3 h of SNSNMP recovery and orthotopic liver transplantation.
C1 [Bruinsma, Bote G.; Berendsen, Tim A.; Izamis, Maria-Louisa; Yarmush, Martin L.; Uygun, Korkut] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Ctr Engn Med,Med Sch, Boston, MA 02115 USA.
[Bruinsma, Bote G.] Univ Amsterdam, Acad Med Ctr, Dept Surg, Surg Lab, NL-1105 AZ Amsterdam, Netherlands.
[Yeh, Heidi] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA.
[Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ USA.
RP Yarmush, ML (reprint author), Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Ctr Engn Med,Med Sch, Boston, MA 02115 USA.
EM ireis@sbi.org; uygun.korkut@mgh.harvard.edu
FU US National Institutes of Health [R00DK080942, R01DK096075,
R01EB008678]; Shriners Hospitals for Children
FX Funding from the US National Institutes of Health (R00DK080942,
R01DK096075 and R01EB008678) and the Shriners Hospitals for Children is
gratefully acknowledged.
NR 31
TC 5
Z9 5
U1 1
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
EI 1750-2799
J9 NAT PROTOC
JI Nat. Protoc.
PD MAR
PY 2015
VL 10
IS 3
DI 10.1038/nprot.2015.011
PG 11
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA CE6FE
UT WOS:000351931300009
PM 25692985
ER
PT J
AU Brawner, BM
Reason, JL
Goodman, BA
Schensul, JJ
Guthrie, B
AF Brawner, Bridgette M.
Reason, Janaiya L.
Goodman, Bridget A.
Schensul, Jean J.
Guthrie, Barbara
TI Multilevel Drivers of Human Immunodeficiency Virus/Acquired Immune
Deficiency Syndrome Among Black Philadelphians Exploration Using
Community Ethnography and Geographic Information Systems
SO NURSING RESEARCH
LA English
DT Article
DE ethnography; geographic mapping; HIV; public health
ID SEXUALLY-TRANSMITTED-DISEASES; AFRICAN-AMERICAN WOMEN; HIV RISK;
NEIGHBORHOOD CONTEXT; UNITED-STATES; HEALTH; BEHAVIORS; HIV/AIDS;
PREVENTION; MEN
AB Background: Unequal human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) distribution is influenced by certain social and structural contexts that facilitate HIV transmission and concentrate HIV in disease epicenters. Thus, one of the first steps in designing effective community-level HIV/AIDS initiatives is to disentangle the influence of individual, social, and structural factors on HIV risk. Combining ethnographic methodology with geographic information systems mapping can allow for a complex exploration of multilevel factors within communities that facilitate HIV transmission in highly affected areas.
Objectives: We present the formative comparative community-based case study findings of an investigation of individual-, social-, and structural-level factors that contribute to the HIV/AIDS epidemic among Black Philadelphians.
Methods: Communities were defined using census tracts. The methodology included ethnographic and geographic information systems mapping, observation, informal conversations with residents and business owners, and secondary analyses of census tract-level data in four Philadelphia neighborhoods.
Results: Factors such as overcrowding, disadvantage, permeability in community boundaries, and availability and accessibility of health-related resources varied significantly. Furthermore, HIV/AIDS trended with social and structural inequities above and beyond the community's racial composition.
Discussion: This study was a first step to disentangle relationships between community-level factors and potential risk for HIV in an HIV epicenter. The findings also highlight stark sociodemographic differences within and across racial groups and further substantiate the need for comprehensive, community-level HIV prevention interventions. These findings from targeted U.S. urban communities have potential applicability for examining the distribution of HIV/AIDS in broader national and international geosocial contexts.
C1 [Brawner, Bridgette M.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Ctr Global Womens Hlth,Nursing, Philadelphia, PA 19104 USA.
[Brawner, Bridgette M.; Reason, Janaiya L.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA.
[Goodman, Bridget A.] Nazarbayev Univ, Grad Sch Educ, Astana, Kazakhstan.
[Schensul, Jean J.] Inst Community Res, Hartford, CT USA.
[Guthrie, Barbara] Northeastern Univ, Nursing PhD Program, Boston, MA 02115 USA.
RP Brawner, BM (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Ctr Global Womens Hlth, 418 Curie Blvd,4th Floor,Room 419, Philadelphia, PA 19104 USA.
EM brawnerb@nursing.upenn.edu
FU National Institute of Mental Health [R25MH087217]
FX The authors acknowledge that this study was funded by pilot funding
awarded to Dr. Brawner through the National Institute of Mental Health
R25MH087217 (Guthrie, Schensul, and Singer [PIs]).
NR 53
TC 2
Z9 2
U1 3
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-6562
EI 1538-9847
J9 NURS RES
JI Nurs. Res.
PD MAR-APR
PY 2015
VL 64
IS 2
BP 100
EP 110
DI 10.1097/NNR.0000000000000076
PG 11
WC Nursing
SC Nursing
GA CE2GS
UT WOS:000351633500372
PM 25738621
ER
PT J
AU Callans, K
Carroll, D
McDonough, A
Miller, B
Kelleher, A
Flanagan, J
Bleiler, C
AF Callans, Kevin
Carroll, Diane
McDonough, Annette
Miller, Brenda
Kelleher, Arlene
Flanagan, Jane
Bleiler, Carolyn
TI Family Experience in Caring for Their Child With an Artificial Airway in
the Home
SO NURSING RESEARCH
LA English
DT Meeting Abstract
C1 [Callans, Kevin; Carroll, Diane; Miller, Brenda; Kelleher, Arlene; Flanagan, Jane; Bleiler, Carolyn] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[McDonough, Annette] Univ Massachusetts Lowell, Lowell, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-6562
EI 1538-9847
J9 NURS RES
JI Nurs. Res.
PD MAR-APR
PY 2015
VL 64
IS 2
BP E54
EP E54
PG 1
WC Nursing
SC Nursing
GA CE2GS
UT WOS:000351633500142
ER
PT J
AU Griffith, C
AF Griffith, Catherine
TI Frail Older Adults' Experience of Participating in Clinical Trials
SO NURSING RESEARCH
LA English
DT Meeting Abstract
C1 [Griffith, Catherine] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-6562
EI 1538-9847
J9 NURS RES
JI Nurs. Res.
PD MAR-APR
PY 2015
VL 64
IS 2
BP E126
EP E126
PG 1
WC Nursing
SC Nursing
GA CE2GS
UT WOS:000351633500336
ER
PT J
AU Kim, M
Lee, H
Cooley, M
Sheldon, L
AF Kim, MinJin
Lee, Haeok
Cooley, Mary
Sheldon, Lisa
TI Attitude Toward HPV Vaccination Among Adolescents and Young Adults:
Concept Inventing and Situation-Specific Theory
SO NURSING RESEARCH
LA English
DT Meeting Abstract
C1 [Kim, MinJin; Lee, Haeok; Sheldon, Lisa] Univ Massachusetts Boston, Boston, MA USA.
[Cooley, Mary] Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-6562
EI 1538-9847
J9 NURS RES
JI Nurs. Res.
PD MAR-APR
PY 2015
VL 64
IS 2
BP E60
EP E60
PG 1
WC Nursing
SC Nursing
GA CE2GS
UT WOS:000351633500158
ER
PT J
AU Nipp, RD
Ryan, DP
AF Nipp, Ryan D.
Ryan, David P.
TI Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in
Metastatic Colorectal Cancer?
SO ONCOLOGIST
LA English
DT Editorial Material
ID PHASE-III TRIAL; INFUSIONAL FLUOROURACIL; OXALIPLATIN; FOLFIRI;
CHEMOTHERAPY; LEUCOVORIN; STATISTICS; IRINOTECAN; CETUXIMAB; RESECTION
C1 [Nipp, Ryan D.; Ryan, David P.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RP Nipp, RD (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA.
EM rnipp@partners.org
NR 24
TC 3
Z9 3
U1 0
U2 0
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD MAR
PY 2015
VL 20
IS 3
BP 236
EP 238
DI 10.1634/theoncologist.2014-0495
PG 3
WC Oncology
SC Oncology
GA CE6BB
UT WOS:000351919500002
PM 25660156
ER
PT J
AU Mulcahey, MK
Campbell, KJ
Golijanan, P
Gross, D
Provencher, MT
AF Mulcahey, Mary K.
Campbell, Kevin J.
Golijanan, Petar
Gross, Daniel
Provencher, Matthew T.
TI Posterior Bone Grafting for Glenoid Defects of the Shoulder
SO OPERATIVE TECHNIQUES IN SPORTS MEDICINE
LA English
DT Article
DE bone graft; posterior glenoid defect
ID RECURRENT ANTERIOR DISLOCATION; GLENOHUMERAL JOINT; POSTEROINFERIOR
INSTABILITY; ARTHROSCOPIC MANAGEMENT; EXCESSIVE RETROVERSION; JERK TEST;
SUBLUXATION; STABILITY; LESION; DIAGNOSIS
AB Posterior shoulder instability is a challenging clinical entity that requires a comprehensive history and physical examination, as well as relevant imaging studies, to confidently make the diagnosis. Posterior shoulder instability may cause significant shoulder dysfunction and pain. Several anatomical features contribute to posterior instability, including soft tissue lesions and posterior glenoid bone loss. Posterior shoulder stabilization with bone graft transfer procedures and glenoid osteotomies to restore the normal glenohumeral arc have been revisited in recent years to address posterior glenoid bone erosion and glenoid version issue. This review article provides a comprehensive description of posterior shoulder instability with a focus on the treatment of posterior glenoid bone defects and glenoid version issues. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Mulcahey, Mary K.] Drexel Univ, Hahnemann Univ Hosp, Coll Med, Dept Orthopaed Surg, Philadelphia, PA 19102 USA.
[Campbell, Kevin J.] Rush Univ, Univ Med Ctr, Dept Orthopaed, Chicago, IL 60612 USA.
[Golijanan, Petar; Gross, Daniel] Massachusetts Gen Hosp, Sports Med & Surg, Boston, MA 02114 USA.
[Provencher, Matthew T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Sports Med & Surg, Boston, MA 02115 USA.
RP Mulcahey, MK (reprint author), Drexel Univ, Hahnemann Univ Hosp, Coll Med, Dept Orthopaed Surg, 245 N 15th St,Mail Stop 420, Philadelphia, PA 19102 USA.
EM mary.mulcahey.md@gmail.com
NR 67
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1060-1872
EI 1557-9794
J9 OPER TECHN SPORT MED
JI Oper. Tech. Sports Med.
PD MAR
PY 2015
VL 23
IS 1
BP 32
EP 42
DI 10.1053/j.otsm.2014.09.011
PG 11
WC Sport Sciences; Surgery
SC Sport Sciences; Surgery
GA CE4FN
UT WOS:000351786600006
ER
PT J
AU Choi, HR
Siliski, JM
Malchau, H
Kwon, YM
AF Choi, Ho-Rim
Siliski, John M.
Malchau, Henrik
Kwon, Young-Min
TI Effect of Repeated Manipulation on Range of Motion in Patients With
Stiff Total Knee Arthroplasty
SO ORTHOPEDICS
LA English
DT Article
ID FLEXION; ANESTHESIA; MANAGEMENT; TKA
AB Although manipulation under anesthesia (MUA) has been considered effective first-line treatment for stiff total knee arthroplasty (TKA), there is no consensus regarding the usefulness of repeated MUA. The purpose of this study was to investigate the usefulness of repeated MUA performed for patients in whom satisfactory range of motion (ROM) was not achieved by MUA. The authors retrospectively reviewed 15 patients who underwent repeated MUA after failure of initial MUA for stiff TKA. Demographic and ROM data were collected. A final ROM of less than 90 degrees was considered a failed manipulation (failure group) and a final ROM of 90 degrees or more was considered a successful manipulation (success group). Average pre-repeated MUA ROM (72.3 degrees +/- 19.5 degrees) immediately improved to 112.3 degrees +/- 9.7 degrees (P<.001) in the operating room, and final ROM was 89.6 degrees +/- 23.9 degrees, an overall gain of 17.3 degrees (P=.04). However, despite this overall ROM increase, a successful final ROM (90 degrees or more) was achieved in approximately half of patients (7 of 13; 54%). There were no significant differences in demographics between the success and failure groups, except that there was significantly less pre-TKA ROM in the failure group (P=.02). There were no complications related to either the first or the repeated MUA procedures. The findings of this study suggest that repeated MUA can improve overall ROM for stiff TKA. The success rate of repeated MUA was less than that of primary MUA; however, it is a useful treatment modality for stiff TKA. Decreased pre-TKA ROM appeared to be associated with poor outcomes after repeated MUA.
C1 Massachusetts Gen Hosp, Harris Orthoped Lab, Boston, MA 02114 USA.
[Kwon, Young-Min] Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA.
RP Kwon, YM (reprint author), Massachusetts Gen Hosp, Dept Orthoped Surg, 55 Fruit St,Yawkey 3B, Boston, MA 02114 USA.
EM kwon.young-min@mgh.harvard.edu
FU Biomet; Stryker
FX Drs Choi, Malchau, and Kwon have no relevant financial relationships to
disclose. Dr Siliski is a paid consultant for Biomet and Stryker.
NR 12
TC 1
Z9 2
U1 1
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0147-7447
EI 1938-2367
J9 ORTHOPEDICS
JI Orthopedics
PD MAR
PY 2015
VL 38
IS 3
BP E157
EP E162
DI 10.3928/01477447-20150305-51
PG 6
WC Orthopedics
SC Orthopedics
GA CE9HT
UT WOS:000352155600002
PM 25760501
ER
PT J
AU Parisi, T
Burroughs, B
Kwon, YM
AF Parisi, Thomas
Burroughs, Brian
Kwon, Young-Min
TI Modular Hip Implant Fracture at the Stem-Sleeve Interface
SO ORTHOPEDICS
LA English
DT Article
ID FEMORAL STEMS; FRETTING WEAR; FAILURE; NECK; ARTHROPLASTY; PROSTHESIS;
COMPONENT; JUNCTION
AB The use of modular implants in femoral stem design has grown increasingly popular over the last decade because of the theoretical advantage of more flexibility and optimization of femoral anteversion, limb length, and femoral component offset. With the benefit of increased surgical flexibility, however, modularity also carries the theoretical risks of fretting at the modular surfaces, sequelae of wear debris, and possible failure and fracture of the stem at the modular junction. Indeed, there have been an increasing number of reports of modular implants failing due to fracture at modular junctions. The S-ROM prosthesis (DePuy Orthopaedics, Inc, Warsaw, Indiana), however, has a stellar clinical record and has been used with good results in both primary and revision total hip arthroplasty. Only a single case of S-ROM failure at the stem-sleeve interface has been reported in the orthopedic literature. The aim of this case report was to present a succinct history of proximal modularity in total hip arthroplasty and to describe the only known case of this type of catastrophic failure in an S-ROM prosthesis with a metal-on-metal bearing. Despite a low level of serum metal ions on presentation, scanning electron microscopy showed findings consistent with corrosive processes and pseudotumor was seen at revision surgery.
C1 [Parisi, Thomas; Burroughs, Brian; Kwon, Young-Min] Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA 02114 USA.
RP Parisi, T (reprint author), Massachusetts Gen Hosp, Dept Orthopaed, 55 Fruit St, Boston, MA 02114 USA.
EM tparisi@partners.org
NR 22
TC 3
Z9 3
U1 1
U2 9
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0147-7447
EI 1938-2367
J9 ORTHOPEDICS
JI Orthopedics
PD MAR
PY 2015
VL 38
IS 3
BP E234
EP E239
DI 10.3928/01477447-20150305-91
PG 6
WC Orthopedics
SC Orthopedics
GA CE9HT
UT WOS:000352155600014
PM 25760513
ER
PT J
AU Manchikanti, L
Falco, FJE
Helm, S
Hirsch, JA
AF Manchikanti, Laxmaiah
Falco, Frank J. E.
Helm, Standiford, II
Hirsch, Joshua A.
TI First, Do No Harm by Adopting Evidence-Based Policy Initiatives: The
Overselling of ICD-10 by Congress with High Expectations
SO PAIN PHYSICIAN
LA English
DT Article
ID ELECTRONIC HEALTH RECORDS; UNITED-STATES; IMPLEMENTATION; METAMORPHOSIS;
MEDICINE; READY; CARE
C1 [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA.
[Falco, Frank J. E.] Mid Atlantic Spine & Pain Phys, Newark, DE USA.
[Falco, Frank J. E.] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA.
[Helm, Standiford, II] Helm Ctr Pain Management, Laguna Hills, CA USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Manchikanti, L (reprint author), 2831 Lone Oak Rd, Paducah, KY 42003 USA.
EM drlm@thepainmd.com
FU Cephalon/Teva; AstraZeneca; Purdue Pharma, LP
FX Dr. Manchikanti has provided limited consulting services to Semnur
Pharmaceuticals, Incorporated, which is developing nonparticulate
steroids. Dr. Falco is a consultant for St. Jude Medical Inc. and Joimax
Inc. Dr. Helm is a clinical investigator with Epimed and receives
research support from Cephalon/Teva, AstraZeneca, and Purdue Pharma, LP.
He has attended an advisory group meeting for Activas. Dr. Hirsch is a
consultant for Medtronic.
NR 46
TC 8
Z9 8
U1 0
U2 0
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD MAR-APR
PY 2015
VL 18
IS 2
BP E107
EP E113
PG 7
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA CE1GL
UT WOS:000351560000010
PM 25794209
ER
PT J
AU Manchikanti, L
Falco, FJE
Singh, V
Hirsch, JA
AF Manchikanti, Laxmaiah
Falco, Frank J. E.
Singh, Vijay
Hirsch, Joshua A.
TI Elusive "Doc Fix": Groundhog Day 2015 for Sustainable Growth Rate (SGR)
SO PAIN PHYSICIAN
LA English
DT Article
ID ELECTRONIC HEALTH RECORDS; ICD-10; ADOPTION; CARE
C1 [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA.
[Falco, Frank J. E.] Mid Atlantic Spine & Pain Phys, Newark, DE USA.
[Falco, Frank J. E.] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA.
[Singh, Vijay] Spine Pain Diagnost Associates, Niagara, WI USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Manchikanti, L (reprint author), 2831 Lone Oak Rd, Paducah, KY 42003 USA.
EM drlm@thepainmd.com
NR 21
TC 3
Z9 3
U1 0
U2 0
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD MAR-APR
PY 2015
VL 18
IS 2
BP E101
EP E105
PG 5
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA CE1GL
UT WOS:000351560000009
PM 25794208
ER
PT J
AU Manchikanti, L
Pampati, V
Falco, FJE
Hirsch, JA
AF Manchikanti, Laxmaiah
Pampati, Vidyasagar
Falco, Frank J. E.
Hirsch, Joshua A.
TI An Updated Assessment of Utilization of Interventional Pain Management
Techniques in the Medicare Population: 2000-2013
SO PAIN PHYSICIAN
LA English
DT Article
DE Chronic pain; chronic spinal pain; interventional pain management;
interventional techniques; epidural injections; facet joint
interventions; sacroiliac joint injections
ID LOW-BACK-PAIN; MANAGING CHRONIC PAIN; UNITED-STATES; EPIDURAL
INJECTIONS; GLOBAL BURDEN; HEALTH-STATUS; EPIDEMIOLOGY; PREVALENCE;
TRENDS; GROWTH
AB Background: The rapid increase in the prevalence of chronic pain and disability, and the explosion of interventional pain management associated health care costs are a major concern for our community. Further, the increasing utilization of numerous modalities of treatments in managing chronic pain, continue to escalate at a pace which may not be sustainable. There are multiple regulations in place to control the growth of health care expenditures which seem to have been largely ineffective. Among the various modalities utilized in managing chronic pain, interventional techniques have shown a significant increase in their utilization in the face of continued debate with respect to the accuracy of diagnostic interventions and the efficacy of therapeutic interventions.
Objective: To update and assess the utilization of interventional techniques in chronic pain management in fee-for-service Medicare population.
Study Design: An updated analysis of the growth of interventional techniques in managing chronic pain in fee-for-service Medicare beneficiaries from 2000 through 2013.
Methods: The data were derived and analyzed utilizing the Centers for Medicare and Medicaid Services (CMS) Physician Supplier Procedure Summary Master Data from 2000 through 2013.
Results: From 2000 through 2013, in fee-for-service Medicare beneficiaries, the overall utilization of interventional techniques services increased 236% at an annual average growth of 9.8%, whereas the per 100,000 Medicare population utilization increased 156% with an annual average growth of 7.5%. During this period, the US population increased 12% with an annual average increase of 0.9%, whereas those above 65 years of age increased 27% with an annual average increase of 1.9%. Total Medicare beneficiaries increased 31% with an annual average increase of 2.1%, with an overall increase of 64% for those above 65 years of age, an increase of 26%, constituting 17% of the US population in 2013.
The overall increases in epidural and adhesiolysis procedures were 165% compared to 102% per 100,000 fee-for-service population with annual average increases of 7.8% and 5.6%. Facet joint and sacroiliac joint injections increased 417% for services with an annual average increase of 13.5%, whereas the rate per 100,000 fee-for-service Medicare beneficiaries increased 295% with an annual average increase of 11.1%.
Limitations: Limitations of this assessment include the lack of inclusion of participants from Medicare Advantage plans, lack of appropriate available data for state-wide utilization, and potential errors in documentation, coding, and billing.
Conclusion: This update once again shows a significant increase in interventional techniques in fee-for-service Medicare beneficiaries from 2000 through 2013 with an increase of 156% per 100,000 Medicare population with an annual average increase of 7.5%. During this period the Medicare population increased 31% with an annual average increase of 2.1%.
C1 [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA.
[Pampati, Vidyasagar] Univ Louisville, Louisville, KY 40292 USA.
[Falco, Frank J. E.] Mid Atlantic Spine & Pain Phys, Newark, DE USA.
[Falco, Frank J. E.] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Manchikanti, L (reprint author), 2831 Lone Oak Rd, Paducah, KY 42003 USA.
EM drlm@thepainmd.com
NR 72
TC 25
Z9 25
U1 1
U2 10
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD MAR-APR
PY 2015
VL 18
IS 2
BP E115
EP E127
PG 13
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA CE1GL
UT WOS:000351560000011
PM 25794210
ER
PT J
AU Vedak, P
Nazarian, RM
Kroshinsky, D
AF Vedak, Priyanka
Nazarian, Rosalynn M.
Kroshinsky, Daniela
TI A Case of Eczematid-Like Purpura of Doucas and Kapetanakis in a Child
SO PEDIATRIC DERMATOLOGY
LA English
DT Article
AB Eczematid-like purpura of Doucas and Kapetanakis is a subtype of the pigmented purpuric dermatoses, a group of uncommon dermatoses of unclear etiology characterized by purpura, petechiae, and hyperpigmentation. The Doucas and Kapetanakis subtype is rare in children, and its subtle findings can initially be overlooked and mistaken for other, more common dermatologic disorders in this age group. We present a case eczematid-like purpura of Doucas and Kapetanakis in an 11-year-old boy initially treated as eczema.
C1 [Vedak, Priyanka; Kroshinsky, Daniela] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02115 USA.
[Nazarian, Rosalynn M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA.
[Nazarian, Rosalynn M.; Kroshinsky, Daniela] Harvard Univ, Sch Med, Boston, MA USA.
RP Kroshinsky, D (reprint author), Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02115 USA.
EM dkroshinsky@partners.org
NR 5
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-8046
EI 1525-1470
J9 PEDIATR DERMATOL
JI Pediatr. Dermatol.
PD MAR-APR
PY 2015
VL 32
IS 2
BP 291
EP 292
DI 10.1111/pde.12507
PG 2
WC Dermatology; Pediatrics
SC Dermatology; Pediatrics
GA CE3RZ
UT WOS:000351747500036
PM 25641544
ER
PT J
AU Moye, J
Rouse, SJ
AF Moye, Jennifer
Rouse, Susan J.
TI Posttraumatic Stress in Older Adults When Medical Diagnoses or
Treatments Cause Traumatic Stress
SO PSYCHIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Posttraumatic stress disorder (PTSD); Geriatric; Cardiac; Cancer
ID MYOCARDIAL-INFARCTION; CARDIAC-ARREST; DISORDER; PTSD; VETERANS;
SURVIVORS; CANCER; CARE; CONSEQUENCES; COMORBIDITY
AB Most older patients adapt after catastrophic medical diagnoses and treatments, but a significant number may develop posttraumatic stress disorder (PTSD) symptoms. PTSD symptoms create added burden for the individual, family, and health care system for the patient's recovery. Medical-related PTSD may be underdiagnosed by providers who may be unaware that these health problems can lead to PTSD symptoms. Treatment research is lacking, but pharmacologic and nonpharmacologic approaches to treatment may be extrapolated and adjusted from the literature focusing on younger adults. Additional study is needed.
C1 [Moye, Jennifer; Rouse, Susan J.] VA Boston Healthcare Syst, Brockton, MA 02301 USA.
[Moye, Jennifer] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
RP Moye, J (reprint author), VA Boston Healthcare Syst, Brockton Div, 940 Belmont St, Brockton, MA 02301 USA.
EM jennifer.moye@va.gov
RI Moye, Jennifer/F-2240-2017
OI Moye, Jennifer/0000-0002-3434-347X
FU Department of Veterans Affairs Rehabilitation Research and Development
Service [5101RX000104-02]
FX Disclosure: This material is the result of work supported with resources
and the use of facilities at the Boston VA Medical Center. Dr J. Moye
received funding for research from the Department of Veterans Affairs
Rehabilitation Research and Development Service #5101RX000104-02.
NR 48
TC 1
Z9 1
U1 2
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0193-953X
EI 1558-3147
J9 PSYCHIAT CLIN N AM
JI Psychiatr. Clin. North Amer.
PD MAR
PY 2015
VL 38
IS 1
BP 45
EP 57
DI 10.1016/j.psc.2014.11.003
PG 13
WC Psychiatry
SC Psychiatry
GA CE4MM
UT WOS:000351804700004
PM 25725568
ER
PT J
AU Stoddard, FJ
Ryan, CM
Schneider, JC
AF Stoddard, Frederick J., Jr.
Ryan, Colleen M.
Schneider, Jeffrey C.
TI Physical and Psychiatric Recovery from Burns
SO PSYCHIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Rehabilitation; Resilience; Recovery; Body image; Posttraumatic stress
disorder; Depression; Hypertrophic scar; Burn reconstruction
ID SPINAL-CORD-INJURY; HETEROTOPIC BONE-FORMATION; ELECTRICAL BURNS; HEALED
BURNS; DOUBLE-BLIND; HIP-REPLACEMENT; GROWTH-HORMONE; FOLLOW-UP;
CHILDREN; OSSIFICATION
AB Burn injuries pose complex biopsychosocial challenges to recovery and improved comprehensive care. The physical and emotional sequelae of burns differ, depending on burn severity, individual resilience, and stage of development when they occur. Most burn survivors are resilient and recover, whereas some are more vulnerable and have complicated outcomes. Physical rehabilitation is affected by orthopedic, neurologic, and metabolic complications and disabilities. Psychiatric recovery is affected by pain, mental disorders, substance abuse, and burn stigmatization. Individual resilience, social supports, and educational or occupational achievements affect outcomes.
C1 [Stoddard, Frederick J., Jr.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Ryan, Colleen M.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Schneider, Jeffrey C.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA 02129 USA.
RP Schneider, JC (reprint author), Harvard Univ, Sch Med, Spaulding Rehabil Hosp, 300 1st Ave, Boston, MA 02129 USA.
EM jcschneider@partners.org
NR 103
TC 1
Z9 1
U1 4
U2 17
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0193-953X
EI 1558-3147
J9 PSYCHIAT CLIN N AM
JI Psychiatr. Clin. North Amer.
PD MAR
PY 2015
VL 38
IS 1
BP 105
EP 120
DI 10.1016/j.psc.2014.11.001
PG 16
WC Psychiatry
SC Psychiatry
GA CE4MM
UT WOS:000351804700008
PM 25725572
ER
PT J
AU Saffer, BY
Lanting, SC
Koehle, MS
Klonsky, ED
Iverson, GL
AF Saffer, Boaz Y.
Lanting, Shawnda C.
Koehle, Michael S.
Klonsky, E. David
Iverson, Grant L.
TI Assessing cognitive impairment using PROMIS (R) applied
cognition-abilities scales in a medical outpatient sample
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Patient-Reported Outcomes Measurement Information System (PROMIS (R));
Self-reported cognition; Depression; Anxiety
ID GENERALIZED ANXIETY DISORDER; PATIENT-REPORTED OUTCOMES; DEPRESSION;
GAD-7
AB Having a brief, standardized, reliable, and valid self-rated test of perceived cognitive functioning could be beneficial in psychiatry clinical practice, research, and clinical trials. The PROMIS (R) Applied Cognition-Abilities scales were developed, evaluated, and distributed by the National Institutes of Health to measure perceived cognitive functioning. This study examines several aspects of the reliability and validity of the PROMIS (R) Applied Cognition-Abilities eight and four-item scales in a sample of adult and older adult medical outpatients (N=148). Internal consistency reliability was high for both PROMIS (R) cognition scales. The brief four-item scale was highly correlated with the full eight-item scale (r(s)=0.98). There was a moderate correlation between the PROMIS (R) Applied Cognition-Abilities scales and measures of depression (PHQ-9) and anxiety (GAD-7). Subgroups of participants screening positively for depression or anxiety reported significantly worse cognitive functioning than medical controls, with large effect sizes. The base rates of individual items endorsed by depressed, anxious, and control participants are reported. More than 42% of depressed and anxious participants reported problems with their memory and concentration compared with fewer than 8% of medical controls. The field would benefit from studies using the PROMIS (R) Applied Cognition-Abilities scales in more demographically diverse samples and with other established measures of cognition. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Saffer, Boaz Y.; Lanting, Shawnda C.; Koehle, Michael S.; Iverson, Grant L.] Copeman Healthcare Ctr, Vancouver, BC, Canada.
[Saffer, Boaz Y.; Klonsky, E. David] Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada.
[Lanting, Shawnda C.; Koehle, Michael S.] Univ British Columbia, Sch Kinesiol, Vancouver, BC V6T 1Z4, Canada.
[Koehle, Michael S.] Univ British Columbia, Div Sport Med, Dept Family Practice, Vancouver, BC V6T 1Z4, Canada.
[Iverson, Grant L.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA.
[Iverson, Grant L.] Red Sox Fdn, Boston, MA USA.
[Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA.
RP Saffer, BY (reprint author), Univ British Columbia, Dept Psychol, 2136 West Mall, Vancouver, BC V6T 1Z4, Canada.
EM boazsaffer@hotmail.com
NR 20
TC 4
Z9 4
U1 1
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD MAR
PY 2015
VL 226
IS 1
BP 169
EP 172
DI 10.1016/j.psychres.2014.12.043
PG 4
WC Psychiatry
SC Psychiatry
GA CE6SV
UT WOS:000351969400024
PM 25639374
ER
PT J
AU Rai, A
Nimeh, T
Sood, A
Thirumavalavan, N
Thurmond, PE
Azadzoi, KM
Lerner, LB
AF Rai, Arun
Nimeh, Tony
Sood, Akshay
Thirumavalavan, Nannan
Thurmond, Portia E.
Azadzoi, Kazem M.
Lerner, Lori B.
TI Could Nocturia Be an Indicator of an Undiagnosed Sleep Disorder in Male
Veterans?
SO UROLOGY
LA English
DT Article
ID CHRONICALLY ISCHEMIC BLADDER; URINARY-TRACT SYMPTOMS; BERLIN
QUESTIONNAIRE; OVERACTIVE BLADDER; IDENTIFY PATIENTS; APNEA SYNDROME;
SEVERITY; POPULATION; PREVALENCE; FREQUENCY
AB OBJECTIVE To determine if men presenting with nocturia and/or voiding complaints may have undiagnosed symptoms of sleep-disordered breathing (SDB).
MATERIALS AND METHODS We conducted a cross-sectional study with men presenting to the Veterans Administration Boston Healthcare System Urology clinic between August 2012 and January 2013. Patients were asked to complete the American Urological Association symptom score and the Berlin sleep questionnaire to evaluate their voiding complaints and sleep quality. We performed univariable and multivariable statistical analyses to identify correlations between a positive Berlin score and voiding symptoms, with an emphasis on nocturia.
RESULTS A total 618 completed questionnaires were included. More than 65% of patients reported nocturia. Of those reporting nocturia, 55% also had a positive Berlin score. The American Urological Association symptom score components of frequency and nocturia, as well as body mass index and hypertension, were shown to be significant independent predictors of a positive Berlin questionnaire, suggesting high likelihood of SDB. Conversely, a positive Berlin questionnaire was a significant independent predictor of nocturia, suggesting high degree of correlation between the 2 conditions.
CONCLUSION Nocturia and other voiding symptoms, such as frequency, predict a positive Berlin score, and vice versa. Patients with a positive Berlin score may have an undiagnosed sleep disorder, the sequelae of which can lead to significant health consequences. If present, treatment of SDB can ameliorate voiding symptoms. Urologists should consider administration of the Berlin score in their office, particularly in patients refractory to treatment for their voiding complaints, and if positive, consider referral to a sleep specialist. Published by Elsevier Inc.
C1 Boston Med Ctr, Dept Urol, Boston, MA USA.
VA Boston Healthcare Syst, Dept Surg, West Roxbury, MA USA.
Vattikuti Urol Inst, Detroit, MI USA.
Boston Univ, Sch Med, Dept Urol, Boston, MA 02118 USA.
RP Lerner, LB (reprint author), Boston Univ, Sch Med, VA Boston Healthcare Syst, Urol Sect, 12 Water St, Hingham, MA 02043 USA.
EM Lerner_lori@hotmail.com
FU BLRD VA [I01 BX001428]
NR 30
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0090-4295
EI 1527-9995
J9 UROLOGY
JI Urology
PD MAR
PY 2015
VL 85
IS 3
BP 641
EP 646
DI 10.1016/j.urology.2014.10.055
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA CE6JJ
UT WOS:000351942400040
PM 25733279
ER
PT J
AU Barry, MJ
AF Barry, Michael J.
TI Is New Visual Prostate Symptom Score Useful as International Prostate
Symptom Score in the Evaluation of Men With Lower Urinary Tract
Symptoms? A Prospective Comparison of 2 Symptom Scores in Turkish
Society EDITORIAL COMMENT
SO UROLOGY
LA English
DT Editorial Material
C1 Massachusetts Gen Hosp, Med Practices Evaluat Ctr, Boston, MA 02114 USA.
RP Barry, MJ (reprint author), Massachusetts Gen Hosp, Med Practices Evaluat Ctr, Boston, MA 02114 USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0090-4295
EI 1527-9995
J9 UROLOGY
JI Urology
PD MAR
PY 2015
VL 85
IS 3
BP 657
EP 658
DI 10.1016/j.urology.2014.10.058
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA CE6JJ
UT WOS:000351942400044
PM 25733283
ER
PT J
AU Kim, E
Lee, Y
Lee, S
Park, SB
AF Kim, Eunha
Lee, Youngjun
Lee, Sanghee
Park, Seung Bum
TI Discovery, Understanding, and Bioapplication of Organic Fluorophore: A
Case Study with an Indolizine-Based Novel Fluorophore, Seoul-Fluor
SO ACCOUNTS OF CHEMICAL RESEARCH
LA English
DT Review
ID FLUORESCENCE PROBES; RATIONAL DESIGN; LIPID DROPLETS; CORE SKELETON;
QUANTUM YIELD; DYES; LIGHT; HETEROCYCLES; STRATEGIES; VISCOSITY
AB CONSPECTUS: Owing to its high sensitivity and great applicability, the fluorescence phenomenon has been considered as an inevitable research tool in the modem scientific fields of chemistry, biology, materials science, biomedical science, and their interfaces. Many strategies have been pursued to understand and manipulate the photophysical properties of fluorescent materials, but the scientific community has been focused on the repeated application of existing organic fluorophores or the identification of unique fluorescence properties in a trial-and-error basis without systematic studies. Moreover, recent studies are emphasizing the necessity of deeper understanding about the structure photophysical property relationship of organic fluorophores for the development of better fluorescent probes. Herein, we provide an overview of a novel fluorescent molecular framework, Seoul-Fluor, which can be rationally engineered to furnish a wide variety of fluorophores in terms of the photophysical properties. Seoul-Fluor is built on an indolizine-based fluorescent platform with three different positions to introduce various substituents: R-1 and R-2 substituents for electronic perturbation; R-3 substituent as a functional handle for bioconjugation. Over the past decade, we have demonstrated that the Seoul-Fluor system has (i) tunable and predictable emission wavelength covering a full visible-color range; (ii) controllable quantum yield via photoinduced electron transfer phenomenon; and (iii) environment-sensitive fluorogenic properties that can be modified through intramolecular charge transfer processes. We convincingly demonstrated the prediction of photophysical properties, that is, emission wavelength and quantum yield, through the construction of a systematic set of analogues and the subsequent analysis of their photophysical properties without the highly sophisticated theoretical support. Guided, by quantifiable parameters such as the Hammett substituent constants or energy levels of the molecular orbitals, this unique organic fluorophore can serve as a versatile molecular platform for the development of novel fluorescent switchable biosensors and filuorogenic bioprobes. In this Account,;we will discuss the discovery and recent progress made on Seoul-Fluor, the rational design of Seoul-Fluor-based bioprobes, and their practical applications to specific biological processes that are facilitated by systematic studies of the structure photophysical property relationships.
C1 [Kim, Eunha] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Kim, Eunha] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Lee, Youngjun; Lee, Sanghee; Park, Seung Bum] Seoul Natl Univ, Dept Chem, Ctr Chem Prote, Seoul 151747, South Korea.
RP Park, SB (reprint author), Seoul Natl Univ, Dept Chem, Ctr Chem Prote, Seoul 151747, South Korea.
EM sbpark@snu.ac.kr
FU Creative Research Initiative Grant - National Research Foundation of
Korea (NRF) [2014R1A3A2030423]; Bio & Medical Technology Development
Program - National Research Foundation of Korea (NRF) [2012M3A9C4048780]
FX This work was supported by the Creative Research Initiative Grant
(2014R1A3A2030423) and the Bio & Medical Technology Development Program
(2012M3A9C4048780) funded by the National Research Foundation of Korea
(NRF). E.K and S.L. are grateful for BK21 Postdoctoral Scholarship, and
Y.L. is grateful for a BK21 Scholarship.
NR 43
TC 27
Z9 27
U1 13
U2 89
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0001-4842
EI 1520-4898
J9 ACCOUNTS CHEM RES
JI Accounts Chem. Res.
PD MAR
PY 2015
VL 48
IS 3
BP 538
EP 547
DI 10.1021/ar500370v
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA CD8EB
UT WOS:000351326900006
PM 25695375
ER
PT J
AU Gandhi, PU
Motiwala, SR
Belcher, AM
Gaggin, HK
Weiner, RB
Baggish, AL
Fiuzat, M
Rocca, HPBL
Januzzi, JL
AF Gandhi, Parul U.
Motiwala, Shweta R.
Belcher, Arianna M.
Gaggin, Hanna K.
Weiner, Rory B.
Baggish, Aaron L.
Fiuzat, Mona
Rocca, Hans-Peter Brunner-La
Januzzi, James L., Jr.
TI Galectin-3 and mineralocorticoid receptor antagonist use in patients
with chronic heart failure due to left ventricular systolic dysfunction
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID NATRIURETIC PEPTIDE; THERAPY PROTECT; HF-ACTION
AB Background Galectin-3 is a prognostic heart failure biomarker associated with aldosterone-induced myocardial fibrosis; mineralocorticoid receptor antagonists (MRAs) may reduce such fibrosis. We sought to examine outcomes of patients with heart failure with reduced ejection fraction (HFrEF) as a function of galectin-3 and MRA therapy.
Methods A total of 151 patients with chronic HFrEF were categorized by baseline galectin-3 and subsequent MRA therapy trends with regard to cardiovascular (CV) events, left ventricular remodeling, safely, and quality of life, over a mean of 10 months.
Results Although galectin-3 >20 ng/mL was associated with doubling in adjusted risk for CV events, regardless of MRA treatment, there was no difference in CV event rates with regard to MRA use patterns, independent of galectin-3 concentrations. Specifically, in patients with elevated galectin-3 treated with intensified MRA therapy, a significant difference was not detected in CV event rates (P = .79) or the cumulative number of such events (P = .76). Adjusted analysis revealed no difference in time to first CV event if MRA was added/intensified in those with elevated galectin-3 (hazard ratio 0.99, 95% CI 0.97-1.02, P = .74); similarly, cumulative MRA dose was not a specific predictor of benefit. In those with elevated galectin-3, MRA therapy did not affect left ventricular remodeling indices or quality of life at follow-up; these patients had the highest rates of treatment-related adverse events with intensified MRA use. Regardless of MRA use, elevated galectin-3 was associated with more significant renal dysfunction.
Conclusions Among patients with chronic HFrEF and elevated galectin-3 concentrations, we found no specific benefit from addition or intensification of MRA therapy.
C1 [Gandhi, Parul U.; Belcher, Arianna M.; Gaggin, Hanna K.; Weiner, Rory B.; Baggish, Aaron L.; Januzzi, James L., Jr.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Motiwala, Shweta R.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Fiuzat, Mona] Duke Univ, Med Ctr, Durham, NC USA.
[Rocca, Hans-Peter Brunner-La] Maastricht Univ, Med Ctr, Dept Cardiol, NL-6200 MD Maastricht, Netherlands.
RP Januzzi, JL (reprint author), Massachusetts Gen Hosp, 32 Fruit St,Yawkey 5984, Boston, MA 02114 USA.
EM jjanuzzi@partners.org
FU Dennis and Marilyn Barry Fellowship in Cardiology; Clark Fund for
Cardiac Research Innovation; Roman W. DeSanctis Clinical Scholar
Endowment
FX Drs Gandhi and Motiwala are supported by the Dennis and Marilyn Barry
Fellowship in Cardiology, Dr Gaggin is supported in part by the Clark
Fund for Cardiac Research Innovation, and Dr Januzzi is supported in
part by the Roman W. DeSanctis Clinical Scholar Endowment.
NR 21
TC 5
Z9 8
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD MAR
PY 2015
VL 169
IS 3
BP 404
EP 411
DI 10.1016/j.ahj.2014.12.012
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CE0ID
UT WOS:000351486800013
PM 25728731
ER
PT J
AU Cefalo, P
Weinberg, I
Hawkins, BM
Hariharan, P
Okechukwu, I
Parry, BA
Chang, YC
Rosovsky, R
Liu, SW
Jaff, MR
Kabrhel, C
AF Cefalo, Philip
Weinberg, Ido
Hawkins, Beau M.
Hariharan, Praveen
Okechukwu, Ikenna
Parry, Blair A.
Chang, Yuchiao
Rosovsky, Rachel
Liu, Shan W.
Jaff, Michael R.
Kabrhel, Christopher
TI A Comparison of Patients Diagnosed With Pulmonary Embolism Who Are >= 65
Years With Patients < 65 Years
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID DEEP-VEIN THROMBOSIS; NATRIURETIC PEPTIDE LEVELS; LOW-RISK PATIENTS;
AGE; PREDICTION; GENDER; IMPACT; OLDER; RULE
AB Recent studies have highlighted differences in how older patients respond to high-risk pulmonary embolism (PE) and treatment. However, guidelines for PE risk stratification and treatment are not based on age, and data are lacking for older patients. We characterized the impact of age on clinical features, risk stratification, treatment, and outcomes in a sample of patients with PE in the emergency department. We performed an observational cohort study of 547 consecutive patients with PE in the emergency department from 2005 to 2011 in an urban tertiary hospital. We used bivariate proportions and multivariable logistic regression to compare clinical presentation, risk category, treatment, and outcomes in patients >= 65 years with those <65 years. The mean age was 58 +/- 17 years, 276(50%) were women, and 210 (38%) were >= 65 years. PE was more severe in patients >= 65 years (massive 14% vs 5%, submassive 48% vs 25%, and low risk 38% vs 70%, p <0.0001), with submassive PE being the most common presentation in patients >= 65 years. However, subanalysis removing natriuretic peptides from the definition of submassive PE negated this finding. Treatment with parenteral anticoagulation (88% vs 90%, p = 0.32), thrombolytic therapy (5% vs 4%, p = 0.87), and inferior vena cava filter (4% vs 4%, p = 0.73) were similar among age groups. Patients >= 65 years had higher 30-day mortality (11% vs 3%, p <0.001). In conclusion, patients >= 65 years present with more severe PE and have higher mortality, although treatment patterns were similar to younger patients. Age-specific guideline definitions of submassive PE may better identify high-risk patients. (c) 2015 Elsevier Inc. All rights reserved.
C1 [Cefalo, Philip] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA.
[Cefalo, Philip; Hariharan, Praveen; Okechukwu, Ikenna; Parry, Blair A.; Rosovsky, Rachel; Liu, Shan W.; Kabrhel, Christopher] Massachusetts Gen Hosp, Dept Emergency Med, Ctr Vasc Emergencies, Boston, MA 02114 USA.
[Weinberg, Ido; Jaff, Michael R.] Massachusetts Gen Hosp, Div Cardiol & Vasc Med, Dept Med, Inst Heart Vasc & Stroke Care, Boston, MA 02114 USA.
[Hawkins, Beau M.] Univ Oklahoma, Hlth Sci Ctr, Cardiovasc Dis Sect, Dept Internal Med, Oklahoma City, OK USA.
[Chang, Yuchiao] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Rosovsky, Rachel] Massachusetts Gen Hosp, Dept Med, Div Hematol & Oncol, Boston, MA 02114 USA.
[Kabrhel, Christopher] Massachusetts Gen Hosp, Inst Heart Vasc & Stroke Care, Boston, MA 02114 USA.
RP Kabrhel, C (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Ctr Vasc Emergencies, Boston, MA 02114 USA.
EM ckabrhel@partners.org
OI Kabrhel, Christopher/0000-0002-8699-7176
FU Harvard Milton fund, Boston, Massachusetts
FX This work was supported by a grant from the Harvard Milton fund, Boston,
Massachusetts. This sponsor had no role in study design, data collection
or analysis, or in the writing of the report.
NR 28
TC 0
Z9 2
U1 0
U2 3
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD MAR 1
PY 2015
VL 115
IS 5
BP 681
EP 686
DI 10.1016/j.amjcard.2014.12.025
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CD4CG
UT WOS:000351029600022
PM 25586333
ER
PT J
AU Lawrence, LA
Mulligan, JK
Roach, C
Pasquini, WN
Soler, ZM
Banglawala, SM
Karnezis, TT
Gudis, DA
Schlosser, RJ
AF Lawrence, Lauren A.
Mulligan, Jennifer K.
Roach, Catherine
Pasquini, Whitney N.
Soler, Zachary M.
Banglawala, Sarfaraz M.
Karnezis, Tom T.
Gudis, David A.
Schlosser, Rodney J.
TI Superoxide dismutase reduces the inflammatory response to Aspergillus
and Alternaria in human sinonasal epithelial cells derived from patients
with chronic rhinosinusitis
SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
LA English
DT Article
ID EOSINOPHILIC CHRONIC RHINOSINUSITIS; NASAL POLYPS; IN-VITRO; AIRWAY
EPITHELIUM; OXIDATIVE STRESS; AIRBORNE FUNGI; EXPRESSION; ASTHMA;
FUMIGATUS; ANTIOXIDANTS
AB Background: Aspergillus fumigatus and Alternaria alternata are ubiquitous environmental fungal allergens that can exacerbate airway inflammation and contribute to the disease process in patients with chronic rhinosinusitis (CRS). These antigens have been shown to induce human sinonasal epithelial cells (HSNECs) to promote a proinflammatory response, but what is unclear is a means by which to reduce these effects. Inhaled pathogens can induce HSNECs to produce reactive oxygen species (ROS) that trigger cytokine production.
Objective: This study aimed to determine whether the free radical scavenger superoxide dismutase (SOD) could reduce HSNEC-derived inflammation, as measured by interleukin (IL)-6 and IL-8 production, in response to Aspergillus or Alternaria exposure.
Methods: Sinus tissue explants were collected at the time of surgery from control patients (n = 7) and patients with CRS with nasal polyps (CRSwNP) (n = 9). HSNECs were cultured from the explants and treated with Aspergillus, Alternaria, and SOD for 24 hours. Cell supernatants and lysates were collected, and IL-6 and IL-8 concentrations were measured using enzyme-linked immunosorbent assay.
Results: In control and CRSwNP HSNECs, Aspergillus and Alternaria both increased cytokine production (p < 0.05), as measured by IL-6 and IL-8 concentration. SOD treatment reduced the inflammatory response to fungal antigen exposure from CRSwNP HSNECs but not control HSNECs. In CRSwNP patients, SOD significantly decreased IL-6 and IL-8 production after Alternaria exposure and IL-8 after Aspergillus exposure (p < 0.05).
Conclusions: When HSNECs from CRSwNP patients are treated with SOD concurrently with Aspergillus or Alternaria, SOD treatment decreases the fungal antigen-induced inflammatory response. The ability to attenuate inflammation induced by common fungal allergens with SOD treatment could provide a novel therapeutic or preventative approach for patients with CRS or other allergic inflammatory airway diseases.
C1 [Lawrence, Lauren A.; Mulligan, Jennifer K.; Roach, Catherine; Pasquini, Whitney N.; Soler, Zachary M.; Banglawala, Sarfaraz M.; Karnezis, Tom T.; Gudis, David A.; Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA.
[Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Mulligan, Jennifer K.; Schlosser, Rodney J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Lawrence, LA (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge,MSC-550, Charleston, SC 29425 USA.
EM lawre194@gmail.com
FU Department of Veterans Affairs, Veterans Health Administration, Clinical
Sciences Research and Development Merit Award; CSRD [1I01CX000377-01A2];
Optinose; Intersect ENT; Flight Attendant Medical Research Institute
[092401]
FX This work was supported by the Department of Veterans Affairs, Veterans
Health Administration, Clinical Sciences Research and Development Merit
Award, and the CSRD Grant 1I01CX000377- 01A2. This material is the
result of work supported with resources and the use of facilities at the
Ralph H. Johnson VA Medical Center, Charleston, South Carolina; R J
Schlosser is a consultant for BrainLAB Inc. and Olympus and has been
provided grant support from Optinose and Intersect ENT; none of these
provided support for this investigation. Z M Soler is also consultant
for BrainLAB Inc., but no support was provided for this investigation. J
K Mulligan is funded by a grant from the Flight Attendant Medical
Research Institute (ID, 092401), which was not affiliated with this
investigation. The remaining authors have no conflicts of interest
pertaining to this article
NR 41
TC 1
Z9 1
U1 1
U2 2
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1945-8924
EI 1945-8932
J9 AM J RHINOL ALLERGY
JI Am. J. Rhinol. Allergy
PD MAR-APR
PY 2015
VL 29
IS 2
BP 89
EP 93
DI 10.2500/ajra.2015.29.4155
PG 5
WC Otorhinolaryngology
SC Otorhinolaryngology
GA CE3HL
UT WOS:000351717200007
PM 25785747
ER
PT J
AU Sedaghat, AR
Gray, ST
Caradonna, SD
Caradonna, DS
AF Sedaghat, Ahmad R.
Gray, Stacey T.
Caradonna, Scott D.
Caradonna, David S.
TI Clustering of chronic rhinosinusitis symptomatology reveals novel
associations with objective clinical and demographic characteristics
SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
LA English
DT Article
ID SINONASAL OUTCOME TEST; ALLERGIC RHINITIS; SINUS SURGERY; PATHOGENESIS;
SCORES
AB Background: Chronic rhinosinusitis (CRS) is associated with varied head and neck symptomatology and quality-of-life impairments that are not necessarily correlated with each other or with objective measures of disease.
Objective: To determine how clustering patterns of CRS symptoms associate with objective clinical findings.
Methods: Symptom scores from 193 Sinonasal Outcomes Test-22 (SNOT-22) questionnaires, from 177 consecutive CRS patients, were analyzed by principal component analysis (PCA) to uncover fewer and physiologically understandable latent components. Univariate and multivariate regressions were made with patients' demographic characteristics, nasal polyposis, comorbid allergic rhinitis, asthma, gastro-esophageal reflux disease (GERD) or depression, and Lund-Mackay scoring of sinus computed tomography (CT) results.
Results: Four principal components (PCs), heavily weighted on sleep symptoms, nasal symptoms, otologic symptoms, and emotional function symptoms, respectively, are found to primarily describe the variability in patients' SNOT-22 scores. SNOT-22 subset scores reflecting sleep, nasal, otologic, and emotional function symptoms were constructed from corresponding PCs. Only female gender associated with the total SNOT-22 score (p = 0.004), whereas only Lund-Mackay score associated with the nasal subset score (p = 0.015). Allergic rhinitis only associated with the otologic subset score (p = 0.005), whereas only asthma associated with the emotional function subset score (p = 0.027). None of the measured covariates were associated with the sleep subset score.
Conclusion: Variability in SNOT-22 scores from CRS patients may be explained by the independent presence of sleep, nasal, otologic, and emotional function symptoms, with which we find novel clinical and demographic associations. These findings may represent clinical evidence for distinct pathophysiologic processes that differentially cause specific CRS symptomatology.
C1 [Sedaghat, Ahmad R.; Gray, Stacey T.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Sedaghat, Ahmad R.; Caradonna, Scott D.; Caradonna, David S.] Beth Israel Deaconess Med Ctr, Div Otolaryngol, Boston, MA 02215 USA.
[Sedaghat, Ahmad R.; Gray, Stacey T.; Caradonna, David S.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
RP Sedaghat, AR (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM ahmad_sedaghat@meei.harvard.edu
NR 25
TC 9
Z9 9
U1 0
U2 3
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1945-8924
EI 1945-8932
J9 AM J RHINOL ALLERGY
JI Am. J. Rhinol. Allergy
PD MAR-APR
PY 2015
VL 29
IS 2
BP 100
EP 105
DI 10.2500/ajra.2015.29.4140
PG 6
WC Otorhinolaryngology
SC Otorhinolaryngology
GA CE3HL
UT WOS:000351717200009
PM 25785749
ER
PT J
AU Miyake, MM
Bleier, BS
AF Miyake, Marcel Menon
Bleier, Benjamin S.
TI The blood-brain barrier and nasal drug delivery to the central nervous
system
SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
LA English
DT Article
ID INTRAVENOUS DELIVERY; CEREBROSPINAL-FLUID; BACTERIAL-MENINGITIS;
OLFACTORY PATHWAY; RAT-BRAIN; INTRANASAL; MICRODIALYSIS; TRANSPORT;
CHEMOTHERAPY; FLUORESCEIN
AB Background: The blood-brain barrier (BBB) is a highly efficient system that separates the central nervous system (CNS) from general circulation and promotes selective transport of molecules that are essential for brain function. However, it also limits the distribution of systemically administered therapeutics to the brain; therefore, there is a restricted number of drugs available for the treatment of brain disorders. Several drug-targeting strategies have been developed to attempt to bypass the BBB, but none has proved sufficiently effective in reaching the brain.
Methods: The objective of this study is to generally review these strategies of drug administration to the CNS.
Results: Noninvasive methods of drug delivery, such as chemical and biologic transport systems, do not represent a feasible platform, whereas for most drugs, it is still not possible to achieve therapeutic levels within the brain tissue after intravenous or oral administration, and the use of higher potency or more concentrated doses may cause serious toxic side effects. Direct intrathecal drug delivery through a catheter into the CNS also presents several problems. Intranasal drug delivery is a potential alternative method due to the direct transport into the cerebrospinal fluid (CSF) compartment along the olfactory pathway, but the study's conclusions are controversial. An endoscopic intranasal surgical procedure using established skull base surgery reconstruction techniques based on the use of a nasal mucosa surgical flap as the only obstacle between the nose and the subarachnoid space has appeared as a potential solution to increase the absorption of intranasal drugs to the CNS.
Conclusion: Despite extensive efforts to develop new techniques to cross the BBB, none has proved sufficiently effective in reaching the brain, whereas minimizing adverse effects and the endoscopic mucosal grafting technique offers new potential promise.
C1 [Miyake, Marcel Menon] Irmandade Santa Casa Misericordia Sao Paulo, Dept Otolaryngol, BR-04509020 Sao Paulo, Brazil.
[Bleier, Benjamin S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
RP Miyake, MM (reprint author), Irmandade Santa Casa Misericordia Sao Paulo, Rua Afonso Braz,525,Cj 22, BR-04509020 Sao Paulo, Brazil.
EM marcelmenon@yahoo.com.br
NR 68
TC 6
Z9 8
U1 5
U2 37
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1945-8924
EI 1945-8932
J9 AM J RHINOL ALLERGY
JI Am. J. Rhinol. Allergy
PD MAR-APR
PY 2015
VL 29
IS 2
BP 124
EP 127
DI 10.2500/ajra.2015.29.4149
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA CE3HL
UT WOS:000351717200013
PM 25785753
ER
PT J
AU Saha, S
Shaik, M
Johnston, G
Saha, SK
Berbiglia, L
Hicks, M
Gernand, J
Grewal, S
Arora, M
Wiese, D
AF Saha, Sukamal
Shaik, Mohammed
Johnston, Gregory
Saha, Supriya Kumar
Berbiglia, Lindsay
Hicks, Micheal
Gernand, Jill
Grewal, Sandeep
Arora, Madan
Wiese, David
TI Tumor size predicts long-term survival in colon cancer: an analysis of
the National Cancer Data Base
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
DE Colon cancer; Tumor size; Prognostic significance; Staging; Overall
survival
ID COLORECTAL-CANCER; PROGNOSTIC-FACTORS; METASTASIS; STAGE
AB BACKGROUND: American Joint Committee on Cancer uses tumor size for "T" staging of many solid tumors for its effect on prognosis. However, tumor size has not been incorporated in tumor (T), nodal status (N), metastasis (M) staging for colon cancer. Hence, the National Cancer Data Base was used to determine whether tumor size correlates with TNM staging and survival.
METHODS: For the 300,386 patients, tumor size was divided into S-1 (0 to 2 cm), S-2 (>2 to 4 cm), S-3 (>4 to 6 cm), and S-4 (>6 cm). Statistical comparison was done for TNM stage, grade, and nodal status with tumor size. Kaplan-Meier survival analysis was done for each "S" stage.
RESULTS: Of the 300,386 patients, 13% were classified as S-1, 39% S-2, 30% S-3 and 18% as S-4. Right colon was the most common site (48%). Tumor size positively correlated with grade, T stage, and nodal stage. Tumor size was inversely associated with survival.
CONCLUSION: Tumor size is positively correlated with important prognostic factors and negatively impacted survival. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Saha, Sukamal; Berbiglia, Lindsay; Hicks, Micheal; Gernand, Jill] McLaren Reg Med Ctr, Dept Surg, Flint, MI 48532 USA.
[Shaik, Mohammed] Michigan State Univ, Div Hematol Oncol, E Lansing, MI 48824 USA.
[Johnston, Gregory] McLaren Macomb, Dept Surg, Mt Clemens, MI USA.
[Saha, Supriya Kumar] Harvard Univ, Sch Med, Dept Hematol Oncol, Massachusettes Gen Hosp,Canc Ctr, Boston, MA USA.
[Grewal, Sandeep; Arora, Madan] McLaren Reg Med Ctr, Dept Hematol Oncol, Flint, MI 48532 USA.
[Wiese, David] McLaren Reg Med Ctr, Dept Pathol, Flint, MI 48532 USA.
RP Saha, S (reprint author), McLaren Reg Med Ctr, Dept Surg, Flint, MI 48532 USA.
EM ssahadr@aol.com
NR 13
TC 7
Z9 7
U1 2
U2 12
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
EI 1879-1883
J9 AM J SURG
JI Am. J. Surg.
PD MAR
PY 2015
VL 209
IS 3
BP 570
EP 574
DI 10.1016/j.amjsurg.2014.12.008
PG 5
WC Surgery
SC Surgery
GA CD6FB
UT WOS:000351183800027
PM 25601557
ER
PT J
AU Stappenbeck, CA
Luterek, JA
Kaysen, D
Rosenthal, CF
Gurrad, B
Simpson, TL
AF Stappenbeck, Cynthia A.
Luterek, Jane A.
Kaysen, Debra
Rosenthal, Christina F.
Gurrad, Bethann
Simpson, Tracy L.
TI A controlled examination of two coping skills for daily alcohol use and
PTSD symptom severity among dually diagnosed individuals
SO BEHAVIOUR RESEARCH AND THERAPY
LA English
DT Article
DE Coping behavior; Posttraumatic stress disorder; Alcohol dependence; Dual
diagnosis; Cognitive restructuring; Experiential acceptance
ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE DISORDERS; CONFIRMATORY
FACTOR-ANALYSIS; RELAPSE PREVENTION; THOUGHT SUPPRESSION; COCAINE ABUSE;
USE OUTCOMES; DEPENDENCE; THERAPY; EXPOSURE
AB Investigations of targeted coping skills could help guide initial treatment decisions for individuals with co-occurring posttraumatic stress disorder (PTSD) and alcohol dependence (AD) who often endorse worse coping skills than those with AD but not PTSD. Although improvement in coping skills is associated with enhanced alcohol use outcomes, no study has evaluated the utility of teaching specific coping skills in the context of comorbid PTSD/AD. We compared the effects of teaching two coping skills (cognitive restructuring [CR] and experiential acceptance [EA]) or an attention control condition on drinking and PTSD symptoms among 78 men and women with comorbid PTSD/AD during a 5-week daily follow-up assessment. Both CR and EA skills were associated with decreased drinking compared to control, and that change in drinking over time did not significantly differ between those who received CR and EA. Individuals who received CR skills, however, consumed less alcohol on a given day than those who received EA skills. Neither CR nor EA was associated with a decrease in PTSD symptom severity. These results provide preliminary support for clinicians to prioritize CR and EA skills during initial treatment sessions when working with individuals with PTSD/AD, and offer ideas for continued investigation and intervention refinement. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Stappenbeck, Cynthia A.; Kaysen, Debra; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98105 USA.
[Luterek, Jane A.; Rosenthal, Christina F.; Gurrad, Bethann; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Stappenbeck, CA (reprint author), Univ Washington, Box 354944, Seattle, WA 98105 USA.
EM cstappen@uw.edu
FU NIH/NIAAA [R21AA17130]
FX This study was supported in part by a grant from NIH/NIAAA (R21AA17130;
PI: Simpson) as well as by resources from the Center of Excellence in
Substance Abuse Treatment and Education (CESATE) at the VA Puget Sound
Health Care System.
NR 63
TC 3
Z9 3
U1 2
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0005-7967
EI 1873-622X
J9 BEHAV RES THER
JI Behav. Res. Ther.
PD MAR
PY 2015
VL 66
BP 8
EP 17
DI 10.1016/j.brat.2014.12.013
PG 10
WC Psychology, Clinical
SC Psychology
GA CD7CU
UT WOS:000351249200002
PM 25617814
ER
PT J
AU Iverson, KM
King, MW
Cunningham, KC
Resick, PA
AF Iverson, Katherine. M.
King, Matthew W.
Cunningham, Katherine C.
Resick, Patricia A.
TI Rape survivors' trauma-related beliefs before and after Cognitive
processing therapy: Associations with PTSD and depression symptoms
SO BEHAVIOUR RESEARCH AND THERAPY
LA English
DT Article
DE Cognitive distortions; Cognitive-behavioral therapy; Posttraumatic
stress disorder; Depression; Mixed-methods
ID POSTTRAUMATIC-STRESS-DISORDER; 5-YEAR FOLLOW-UP; INVENTORY; EXPOSURE;
VICTIMS
AB This study examined whether cognitive distortions (i.e., assimilated and overaccommodated thoughts) and realistic (i.e., accommodated) thoughts assessed from impact statements written 5-10 years after completing cognitive processing therapy (CPT) accurately predicted posttreatment maintenance or decline in treatment gains during the same period.
The sample included 50 women diagnosed with posttraumatic stress disorder (PTSD) secondary to rape who participated in a randomized clinical trial of CPT for PTSD. Cognitions were assessed via coding and analyses of participants' written impact statements at three time points: beginning of treatment, end of treatment, and at 5-10 years follow-up. Primary mental health outcomes were symptoms of PTSD (Clinician-Administered PTSD Scale) and depression (Beck Depression Inventory).
Changes in trauma-related beliefs between the end of treatment and long-term follow-up were associated with concomitant changes in PTSD and depression symptoms (effect sizes ranging from r = .35-.54). Declines in accommodated thinking and increases in overaccommodated thinking were associated with elevations in symptomatology. Improvement in accommodated thinking and declines in overaccommodated thinking were associated with lower PTSD and depression symptoms during this same time period.
Findings provided support for the role of changes in accommodated and overaccommodated thinking being associated with level of PTSD and depression many years after participating in CPT. Published by Elsevier Ltd.
C1 [Iverson, Katherine. M.; King, Matthew W.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Iverson, Katherine. M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Cunningham, Katherine C.] Univ Tulsa, Dept Psychol, Tulsa, OK 74104 USA.
[Resick, Patricia A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
RP Iverson, KM (reprint author), WHSD 116B 3 VA Boston Healthcare Syst, 150 South Huntington Ave,116B 3, Boston, MA 02130 USA.
EM Katherine.Iverson@va.gov
FU National Institute of Mental Health [NIH-1 R01-MH51509]; Department of
Veterans Affairs, Veterans Health Administration, Health Services
Research and Development (HSR&D) Service as part of her Career
Development Award [CDA 10-029]; Presidential Early Career Award for
Scientists and Engineers [USA 14-275]
FX This research was funded by a grant from the National Institute of
Mental Health (NIH-1 R01-MH51509) awarded to Patricia A. Resick. Dr.
Iverson's contribution to this manuscript was supported by the
Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development (HSR&D) Service as part of her Career
Development Award (CDA 10-029) and her Presidential Early Career Award
for Scientists and Engineers (USA 14-275). The views expressed in this
article are those of the authors and do not necessarily represent the
views of the Department of Veterans Affairs.
NR 25
TC 4
Z9 4
U1 3
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0005-7967
EI 1873-622X
J9 BEHAV RES THER
JI Behav. Res. Ther.
PD MAR
PY 2015
VL 66
BP 49
EP 55
DI 10.1016/j.brat.2015.01.002
PG 7
WC Psychology, Clinical
SC Psychology
GA CD7CU
UT WOS:000351249200006
PM 25698164
ER
PT J
AU Loggia, ML
Chonde, DB
Akeju, O
Arabasz, G
Catana, C
Edwards, RR
Hill, E
Hsu, S
Izquierdo-Garcia, D
Ji, RR
Riley, M
Wasan, AD
Zurcher, NR
Albrecht, DS
Vangel, MG
Rosen, BR
Napadow, V
Hooker, JM
AF Loggia, Marco L.
Chonde, Daniel B.
Akeju, Oluwaseun
Arabasz, Grae
Catana, Ciprian
Edwards, Robert R.
Hill, Elena
Hsu, Shirley
Izquierdo-Garcia, David
Ji, Ru-Rong
Riley, Misha
Wasan, Ajay D.
Zuercher, Nicole R.
Albrecht, Daniel S.
Vangel, Mark G.
Rosen, Bruce R.
Napadow, Vitaly
Hooker, Jacob M.
TI Evidence for brain glial activation in chronic pain patients
SO BRAIN
LA English
DT Article
DE chronic pain; C-11-PBR28; translocator protein (18kDa); TSPO;
neuroinflammation; glia
ID PROTEIN 18 KDA; PERIPHERAL BENZODIAZEPINE-RECEPTOR;
POSITRON-EMISSION-TOMOGRAPHY; LOW-DOSE NALTREXONE; EXPERIMENTAL
AUTOIMMUNE ENCEPHALOMYELITIS; IN-VITRO EVIDENCE; TRANSLOCATOR PROTEIN;
NEUROPATHIC PAIN; SPINAL-CORD; NERVE INJURY
AB Although substantial evidence has established that microglia and astrocytes play a key role in the establishment and maintenance of persistent pain in animal models, the role of glial cells in human pain disorders remains unknown. Here, using the novel technology of integrated positron emission tomography-magnetic resonance imaging and the recently developed radioligand C-11-PBR28, we show increased brain levels of the translocator protein (TSPO), a marker of glial activation, in patients with chronic low back pain. As the Ala147Thr polymorphism in the TSPO gene affects binding affinity for C-11-PBR28, nine patient-control pairs were identified from a larger sample of subjects screened and genotyped, and compared in a matched-pairs design, in which each patient was matched to a TSPO polymorphism-, age-and sex-matched control subject (seven Ala/Ala and two Ala/Thr, five males and four females in each group; median age difference: 1 year; age range: 29-63 for patients and 28-65 for controls). Standardized uptake values normalized to whole brain were significantly higher in patients than controls in multiple brain regions, including thalamus and the putative somatosensory representations of the lumbar spine and leg. The thalamic levels of TSPO were negatively correlated with clinical pain and circulating levels of the proinflammatory citokine interleukin-6, suggesting that TSPO expression exerts pain-protective/anti-inflammatory effects in humans, as predicted by animal studies. Given the putative role of activated glia in the establishment and or maintenance of persistent pain, the present findings offer clinical implications that may serve to guide future studies of the pathophysiology and management of a variety of persistent pain conditions.
C1 [Loggia, Marco L.; Chonde, Daniel B.; Arabasz, Grae; Catana, Ciprian; Hsu, Shirley; Izquierdo-Garcia, David; Riley, Misha; Zuercher, Nicole R.; Albrecht, Daniel S.; Vangel, Mark G.; Rosen, Bruce R.; Napadow, Vitaly; Hooker, Jacob M.] Harvard Univ, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA.
[Loggia, Marco L.; Edwards, Robert R.; Ji, Ru-Rong; Wasan, Ajay D.; Napadow, Vitaly] Massachusetts Gen Hosp, Dept Anesthesiol Perioperat & Pain Med, Brigham & Womens Hosp, Sch Med, Boston, MA 02155 USA.
[Akeju, Oluwaseun] MGH HMS, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Edwards, Robert R.; Wasan, Ajay D.] HMS, Brigham & Womens Hosp, Dept Psychiat, Medford, MA 02155 USA.
[Hill, Elena] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Ji, Ru-Rong] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27705 USA.
[Ji, Ru-Rong] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27705 USA.
[Wasan, Ajay D.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15206 USA.
[Wasan, Ajay D.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15206 USA.
[Rosen, Bruce R.] Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Napadow, Vitaly] Kyung Hee Univ, Dept Biomed Engn, Seoul 130872, South Korea.
RP Loggia, ML (reprint author), Massachusetts Gen Hosp, Bldg 149,Suite 2301, Charlestown, MA 02129 USA.
EM marco@nmr.mgh.harvard.edu
OI Ji, Ru-Rong/0000-0002-9355-3688
FU Harvard Catalyst Advanced Imaging Pilot Grant; National Centre for
Advancing Translational Science [1R21NS087472-01A1, 1UL1TR001102-01,
8UL1TR000170-05]; National Centre for Research Resources
[1UL1RR025758-04]; Harvard Clinical and Translational Science Centre;
Harvard University; academic healthcare centres
FX This project was supported by Harvard Catalyst Advanced Imaging Pilot
Grant (J.M.H.), 1R21NS087472-01A1 (M.L.L.) 1UL1TR001102-01,
8UL1TR000170-05, from the National Centre for Advancing Translational
Science, and 1UL1RR025758-04 from the National Centre for Research
Resources, Harvard Clinical and Translational Science Centre, and
financial contributions from Harvard University and its affiliated
academic healthcare centres. The content is solely the responsibility of
the authors and does not necessarily represent the official views of
Harvard Catalyst, Harvard University and its affiliated academic
healthcare centres, or the National Institutes of Health. The authors
have no conflicts of interest or competing financial interests to
declare.
NR 95
TC 60
Z9 62
U1 10
U2 34
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD MAR 1
PY 2015
VL 138
BP 604
EP 615
DI 10.1093/brain/awu377
PN 3
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CE0QY
UT WOS:000351510700018
PM 25582579
ER
PT J
AU Chebib, I
Hornicek, FJ
Nielsen, GP
Deshpande, V
AF Chebib, Ivan
Hornicek, Francis J.
Nielsen, G. Petur
Deshpande, Vikram
TI Cytomorphologic Features That Distinguish Schwannoma From Other
Low-Grade Spindle Cell Lesions
SO CANCER CYTOPATHOLOGY
LA English
DT Article
DE fine-needle aspiration biopsy; schwannoma; spindle cell neoplasm; low
grade; gastrointestinal stromal tumor; fibromatosis
ID FINE-NEEDLE-ASPIRATION; GASTROINTESTINAL STROMAL TUMOR; SOFT-TISSUE
TUMORS; NERVE SHEATH TUMOR; CYTOLOGIC FEATURES; BIOPSY DIAGNOSIS; CORE
BIOPSY; SARCOMAS; IMMUNOCYTOCHEMISTRY; EXPERIENCE
AB BACKGROUNDFine-needle aspiration biopsy of spindled mesenchymal lesions, including schwannomas, are challenging because of overlapping cytomorphological features. The objective of the current study was to identify key diagnostic cytological criteria for the diagnosis of schwannoma and to distinguish it from its common mimics.
METHODSA total of 58 schwannomas were evaluated and compared with 98 benign and low-grade spindle cell lesions, including 17 gastrointestinal stromal tumors and 20 fibromatosis cases. Biopsy confirmation was available for all cases. The authors semiquantitatively evaluated cellularity, quality of stroma (fibrous and fibrillar), the presence of single cells with bipolar cytoplasmic processes, and marked nuclear pleomorphism (in the absence of other features of malignancy). Nuclear features evaluated included fishhook-type nuclei, intranuclear inclusions, chromatin pattern, and nucleoli.
RESULTSSchwannomas demonstrated cohesive tissue fragments with fibrillary and occasionally fibrous stroma. The presence of intranuclear inclusions and marked nuclear pleomorphism and the absence of single cells with bipolar cytoplasmic processes emerged as statistically significant differences between the schwannoma and the nonschwannoma groups. When 5 criteria were present (high numbers of clusters, few to no single cells, fibrillary stroma, nuclei with pointed tips, and anisonucleosis) the sensitivity, specificity, positive predictive value, and negative predictive value for the diagnosis of schwannoma were 22%, 97%, 81%, and 68%, respectively.
CONCLUSIONSCohesive tissue fragments with fibrillary/fibrous stroma, intranuclear inclusions, marked nuclear pleomorphism, and the absence of spindled cells with bipolar cytoplasmic processes are strongly suggestive of schwannoma and assist in excluding potential mimics. Cancer (Cancer Cytopathol) 2015. (c) 2015 American Cancer Society. Cancer (Cancer Cytopathol) 2015;123:171-179. (c) 2014 American Cancer Society.
The objective of the current study was to identify key diagnostic cytological criteria for the diagnosis of schwannoma and to distinguish it from its common mimics. Cohesive tissue fragments with fibrillary/fibrous stroma, intranuclear inclusions, marked nuclear pleomorphism, and the absence of spindled cells with bipolar cytoplasmic processes are strongly suggestive of schwannoma and assist in excluding other low-grade spindle cell tumors from the diagnosis.
C1 [Chebib, Ivan; Nielsen, G. Petur; Deshpande, Vikram] Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA 02114 USA.
[Hornicek, Francis J.] Harvard Univ, Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Dept Orthopaed Surg,Med Sch, Boston, MA 02114 USA.
RP Chebib, I (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, WRN2,55 Fruit St, Boston, MA 02114 USA.
EM ichebib@partners.org
NR 39
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1934-662X
EI 1934-6638
J9 CANCER CYTOPATHOL
JI Cancer Cytopathol.
PD MAR
PY 2015
VL 123
IS 3
BP 171
EP 179
DI 10.1002/cncy.21506
PG 9
WC Oncology; Pathology
SC Oncology; Pathology
GA CD7ZN
UT WOS:000351315000006
PM 25641870
ER
PT J
AU Leonard, MK
Novak, M
McCorkle, JR
Yang, XWH
Belkin, A
Kaetzel, DM
AF Leonard, M. Katie
Novak, Marian
McCorkle, Joseph R.
Yang, Xiuwei H.
Belkin, Alexey
Kaetzel, David M.
TI The metastasis suppressor NME1 suppresses melanoma cell motility through
alterations in integrin repertoire and focal adhesion dynamics
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Meeting Abstract
C1 [Leonard, M. Katie; Belkin, Alexey; Kaetzel, David M.] Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.
[Leonard, M. Katie; Kaetzel, David M.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
[Novak, Marian] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA.
[McCorkle, Joseph R.] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA.
[Yang, Xiuwei H.] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA.
[Belkin, Alexey] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262-0898
EI 1573-7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD MAR
PY 2015
VL 32
IS 3
MA 69
BP 213
EP 214
PG 2
WC Oncology
SC Oncology
GA CE1VX
UT WOS:000351601900099
ER
PT J
AU Afnan, J
Snuderl, M
Small, J
AF Afnan, Jalil
Snuderl, Matija
Small, Juan
TI Intracranial, intradural aneurysmal bone cyst
SO CLINICAL IMAGING
LA English
DT Article
DE Aneurysmal bone cyst; Intracraniat; Intradural; Imaging; Pathology
AB Aneurysmal bone cysts (ABCs) are benign, expansile, blood-filled, osteolytic lesions with internal septations that may be intraosseous or extraosseous. The cysts may cause local mass effect, and changes in the regional vascular supply necessitating intervention. A case of an intracranial, intradural ABC in a young male patient with progressively severe headaches is presented. This is only the third recorded intradural case, the majority of these rare lesions being extracranial and only a minute fraction intracranial. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Afnan, Jalil] Lahey Hosp & Med Ctr, Dept Radiol, Burlington, MA 01803 USA.
[Snuderl, Matija] NYU, Langone Med Ctr, Dept Pathol, New York, NY 10003 USA.
[Small, Juan] Lahey Hosp & Med Ctr, Dept Neuroradiol, Burlington, MA 01803 USA.
[Small, Juan] Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA 02114 USA.
RP Small, J (reprint author), Lahey Hosp & Med Ctr, Dept Neuroradiol, 41 Mall Rd, Burlington, MA 01803 USA.
EM Juan.E.Small@Lahey.org
OI Snuderl, Matija/0000-0003-0752-0917
NR 16
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0899-7071
EI 1873-4499
J9 CLIN IMAG
JI Clin. Imaging
PD MAR-APR
PY 2015
VL 39
IS 2
BP 297
EP 299
DI 10.1016/j.clinimag.2014.11.004
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CE0HJ
UT WOS:000351484800024
PM 25482352
ER
PT J
AU Higgins, JM
AF Higgins, John M.
TI Red Blood Cell Population Dynamics
SO CLINICS IN LABORATORY MEDICINE
LA English
DT Article
DE Red blood cell population dynamics; Single-RBC measurements;
Mathematical modeling; RBC life span; RBC turnover; Diagnostic
applications; Predictive medicine; Personalized medicine
ID RETICULOCYTE; VESICULATION; ERYTHROCYTES; SURVIVAL; ANEMIA; VOLUME
AB Hematology analyzers provide a static snapshot of the circulating population of red blood cells (RBCs). The RBC population is rapidly changing, with more than 2 million RBCs turning over every second in the typical healthy adult. The static snapshot provided by the complete blood count does not capture many of the dynamic aspects of this population, such as the rate of RBC maturation and the rate of RBC turnover. By integrating basic science with hematology analyzer measurements, it is possible to estimate the rates of these dynamic processes, yielding new insights into human physiology, with potential diagnostic application.
C1 [Higgins, John M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Higgins, John M.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Higgins, John M.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
RP Higgins, JM (reprint author), Massachusetts Gen Hosp, Dept Pathol, 185 Cambridge St, Boston, MA 02114 USA.
EM higgins.john@mgh.harvard.edu
FU NIH Director's New Innovator Award [DP2DK098087]
FX The author was supported by an NIH Director's New Innovator Award
DP2DK098087.
NR 20
TC 2
Z9 2
U1 1
U2 13
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-2712
EI 1557-9832
J9 CLIN LAB MED
JI Clin. Lab. Med.
PD MAR
PY 2015
VL 35
IS 1
BP 43
EP +
DI 10.1016/j.cll.2014.10.002
PG 16
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA CD2YH
UT WOS:000350944400005
PM 25676371
ER
PT J
AU Keller, JB
Hedden, T
Thompson, TW
Anteraper, SA
Gabrieli, JDE
Whitfield-Gabrieli, S
AF Keller, Joseph B.
Hedden, Trey
Thompson, Todd W.
Anteraper, Sheeba A.
Gabrieli, John D. E.
Whitfield-Gabrieli, Susan
TI Resting-state anticorrelations between medial and lateral prefrontal
cortex: Association with working memory, aging, and individual
differences
SO CORTEX
LA English
DT Article
DE Default mode network; Working memory; Resting-state fMRI; Aging;
Functional connectivity
ID DEFAULT-MODE NETWORK; FUNCTIONAL CONNECTIVITY MRI; ANTI-CORRELATED
NETWORKS; GLOBAL SIGNAL REGRESSION; WHITE-MATTER INTEGRITY; HUMAN BRAIN;
COGNITIVE DECLINE; SENSORY STIMULATION; NOISE CORRECTION; SUBJECT MOTION
AB We examined how variation in working memory (WM) capacity due to aging or individual differences among young adults is associated with intrinsic or resting-state anticorrelations, particularly between (1) the medial prefrontal cortex (MPFC), a component of the default-mode network (DMN) that typically decreases in activation during external, attention-demanding tasks, and (2) the dorsolateral prefrontal cortex DLPFC, a component of the fronto-parietal control network that supports executive functions and WM and typically increases in activation during attention-demanding tasks. We compared the magnitudes of MPFC-DLPFC anticorrelations between healthy younger and older participants (Experiment 1) and related the magnitudes of these anticorrelations to individual differences on two behavioral measures of VIM capacity in two independent groups of young adults (Experiments 1 and 2). Relative to younger adults, older adults exhibited reductions in WM capacity and in MPFC-DLPFC anticorrelations. Within younger adults, greater MPFC-DLPFC anticorrelation at rest correlated with greater VIM capacity. These findings show that variation in MPFC-DLPFC anticorrelations, whether related to aging or to individual differences, may reflect an intrinsic functional brain architecture supportive of WM capacity. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Keller, Joseph B.; Thompson, Todd W.; Anteraper, Sheeba A.; Gabrieli, John D. E.; Whitfield-Gabrieli, Susan] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Keller, Joseph B.; Thompson, Todd W.; Anteraper, Sheeba A.; Gabrieli, John D. E.; Whitfield-Gabrieli, Susan] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA.
[Gabrieli, John D. E.] Inst Med Engn & Sci, Cambridge, MA USA.
[Hedden, Trey] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Hedden, Trey] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Keller, JB (reprint author), MIT, Dept Brain & Cognit Sci, 43 Vassar St,4033A, Cambridge, MA 02139 USA.
EM jkeller1@mit.edu
FU NIH/NIA [R21 AG030770]; NIH [T32 GM007484]; Barbara J. Weedon Fund
Fellowship at MIT; [K01 AG040197]
FX We thank Nina Wickens for her help in recruiting and testing
participants, and the staff of the Martinos Imaging Center at the
McGovern Institute at MIT for help in neuroimaging. This study was
supported by NIH/NIA grant R21 AG030770. Funding support for J.B.K was
provided by NIH grant T32 GM007484 and the Barbara J. Weedon Fund
Fellowship at MIT; support for T.H. was provided by grant K01 AG040197.
NR 69
TC 20
Z9 21
U1 3
U2 14
PU ELSEVIER MASSON
PI MILANO
PA VIA PALEOCAPA 7, 20121 MILANO, ITALY
SN 0010-9452
EI 1973-8102
J9 CORTEX
JI Cortex
PD MAR
PY 2015
VL 64
BP 271
EP 280
DI 10.1016/j.cortex.2014.12.001
PG 10
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA CD7CM
UT WOS:000351248400025
PM 25562175
ER
PT J
AU Hermayer, KL
Loftley, AS
Reddy, S
Narla, SN
Epps, NA
Zhu, YS
AF Hermayer, Kathie L.
Loftley, Aundrea S.
Reddy, Sumana
Narla, Satya Nandana
Epps, Nina A.
Zhu, Yusheng
TI Challenges of Inpatient Blood Glucose Monitoring: Standards, Methods,
and Devices to Measure Blood Glucose
SO CURRENT DIABETES REPORTS
LA English
DT Article
DE Glucose; Meter; Point of care; Hyperglycemia; Hypoglycemia; Hospital;
Arterial; Venous; Capillary; i-Stat; HemoCue; YSI; Critical illness;
Calibration; Continuous glucose monitoring; Maltose; Wired; Wireless;
FDA; CLIA
ID INTENSIVE INSULIN THERAPY; CRITICALLY-ILL PATIENTS; HEMATOCRIT; CARE;
MANAGEMENT; ACCURACY; METERS; HYPERGLYCEMIA; CAPILLARY; ARTERIAL
AB Glucose control in the hospital setting is very important. There is a high incidence of hyperglycemia, hypoglycemia, and glycemic variability in hospitalized patients. Safe insulin delivery and glucose control is dependent on reliable glucose meters and monitoring systems in the hospital. Different glucose monitoring systems use arterial, venous, central venous, and capillary blood samples. It is important for clinicians to be aware that there are limitations of specific point-of-care (POC) glucose meters and that situations exist whereby POC glucose meters as the sole measurement device should be avoided. POC meter devices are not approved by the Food and Drug Administration for use in critical care, although POC meter devices are commonly used in critical care settings and elsewhere. This review focuses on glucose assay principles, instrument technology, influences on glucose measurement, standards for glucose measurement, and an evaluation of different methods to measure blood glucose in the hospital setting.
C1 [Hermayer, Kathie L.; Loftley, Aundrea S.; Reddy, Sumana] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA.
[Hermayer, Kathie L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
[Narla, Satya Nandana; Zhu, Yusheng] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Epps, Nina A.] Med Univ S Carolina, Lab Serv Point Care Testing Qual & Safety, Charleston, SC 29425 USA.
RP Hermayer, KL (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,MSC 624, Charleston, SC 29425 USA.
EM hermayer@musc.edu; easona@musc.edu; reddysu@musc.edu; narlas@musc.edu;
eppsn@musc.edu; zhuyu@musc.edu
NR 38
TC 2
Z9 2
U1 3
U2 22
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1534-4827
EI 1539-0829
J9 CURR DIABETES REP
JI Curr. Diabetes Rep.
PD MAR
PY 2015
VL 15
IS 3
AR 10
DI 10.1007/s11892-015-0582-9
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CD6WZ
UT WOS:000351232400001
PM 25644818
ER
PT J
AU Sim, DA
Keane, PA
Tufail, A
Egan, CA
Aiello, LP
Silva, PS
AF Sim, Dawn A.
Keane, Pearse A.
Tufail, Adnan
Egan, Catherine A.
Aiello, Lloyd Paul
Silva, Paolo S.
TI Automated Retinal Image Analysis for Diabetic Retinopathy in
Telemedicine
SO CURRENT DIABETES REPORTS
LA English
DT Article
DE Automated retinal image analysis; Telemedicine; Diabetes mellitus;
Diabetic retinopathy
ID SIGNIFICANT MACULAR EDEMA; COLOR FUNDUS PHOTOGRAPHS; MICROANEURYSM
TURNOVER; SCREENING-PROGRAM; UNITED-STATES; RED LESIONS; EYE CARE;
DIAGNOSIS; PREVALENCE; SEVERITY
AB There will be an estimated 552 million persons with diabetes globally by the year 2030. Over half of these individuals will develop diabetic retinopathy, representing a nearly insurmountable burden for providing diabetes eye care. Telemedicine programmes have the capability to distribute quality eye care to virtually any location and address the lack of access to ophthalmic services. In most programmes, there is currently a heavy reliance on specially trained retinal image graders, a resource in short supply worldwide. These factors necessitate an image grading automation process to increase the speed of retinal image evaluation while maintaining accuracy and cost effectiveness. Several automatic retinal image analysis systems designed for use in telemedicine have recently become commercially available. Such systems have the potential to substantially improve the manner by which diabetes eye care is delivered by providing automated real-time evaluation to expedite diagnosis and referral if required. Furthermore, integration with electronic medical records may allow a more accurate prognostication for individual patients and may provide predictive modelling of medical risk factors based on broad population data.
C1 [Sim, Dawn A.; Aiello, Lloyd Paul; Silva, Paolo S.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA.
[Sim, Dawn A.; Aiello, Lloyd Paul; Silva, Paolo S.] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA.
[Sim, Dawn A.; Keane, Pearse A.; Tufail, Adnan; Egan, Catherine A.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
[Sim, Dawn A.; Keane, Pearse A.; Tufail, Adnan] UCL, Inst Ophthalmol, London, England.
[Silva, Paolo S.] Univ Philippines, Natl Inst Hlth, Philippine Eye Res Inst, Teleophthalmol & Image Reading Ctr, Manila, Philippines.
RP Silva, PS (reprint author), Harvard Univ, Sch Med, Dept Ophthalmol, One Joslin Pl, Boston, MA 02215 USA.
EM PaoloAntonio.Silva@joslin.havard.edu
FU Fight for Sight, UK [1987]; Moorfields Eye Hospital; National Institute
for Health Research (NIHR) Biomedical Research Centre based at
Moorfields Eye Hospital NHS Foundation Trust; UCL Institute of
Ophthalmology
FX The research was supported by a grant from Fight for Sight, UK (Grant
number 1987), The Special Trustees of Moorfields Eye Hospital and the
National Institute for Health Research (NIHR) Biomedical Research Centre
based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute
of Ophthalmology.
NR 74
TC 7
Z9 7
U1 1
U2 15
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1534-4827
EI 1539-0829
J9 CURR DIABETES REP
JI Curr. Diabetes Rep.
PD MAR
PY 2015
VL 15
IS 3
AR 14
DI 10.1007/s11892-015-0577-6
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CD6WZ
UT WOS:000351232400006
PM 25697773
ER
PT J
AU Psaros, C
Remmert, JE
Bangsberg, DR
Safren, SA
Smit, JA
AF Psaros, Christina
Remmert, Jocelyn E.
Bangsberg, David R.
Safren, Steven A.
Smit, Jennifer A.
TI Adherence to HIV Care After Pregnancy Among Women in Sub-Saharan Africa:
Falling Off the Cliff of the Treatment Cascade
SO CURRENT HIV/AIDS REPORTS
LA English
DT Editorial Material
ID TO-CHILD TRANSMISSION; IMMUNODEFICIENCY-VIRUS TRANSMISSION; FOLLOW-UP;
SOUTH-AFRICA; ANTIRETROVIRAL THERAPY; PMTCT PROGRAM; RURAL MALAWI;
SCALING-UP; PREVENTION; JOHANNESBURG
AB Increased access to testing and treatment means HIV can be managed as a chronic illness, though successful management requires continued engagement with the health care system. Most of the global HIV burden is in sub-Saharan Africa where rates of new infections are consistently higher in women versus men. Pregnancy is often the point at which an HIV diagnosis is made. While preventing mother to child transmission (PMTCT) interventions significantly reduce the rate of vertical transmission of HIV, women must administer ARVs to their infants, adhere to breastfeeding recommendations, and test their infants for HIV after childbirth. Some women will be expected to remain on the ARVs initiated during pregnancy, while others are expected to engage in routine testing so treatment can be reinitiated when appropriate. The postpartum period presents many barriers to sustained treatment adherence and engagement in care. While some studies have examined adherence to postpartum PMTCT guidelines, few have focused on continued engagement in care by the mother, and very few examine adherence beyond the 6-week postpartum visit. Here, we attempt to identify gaps in the research literature and make recommendations on how to address barriers to ongoing postpartum HIV care.
C1 [Psaros, Christina; Remmert, Jocelyn E.; Bangsberg, David R.; Safren, Steven A.] Massachusetts Gen Hosp, Boston, MA 02140 USA.
[Psaros, Christina; Bangsberg, David R.; Safren, Steven A.] Harvard Univ, Sch Med, Boston, MA USA.
[Bangsberg, David R.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Smit, Jennifer A.] Univ Witwatersrand, Fac Hlth Sci, Dept Obstet & Gynaecol, Maternal Adolescent & Child Hlth Res, Durban, South Africa.
[Smit, Jennifer A.] Univ KwaZulu Natal, Fac Hlth Sci, Sch Pharm & Pharmacol, Durban, South Africa.
RP Psaros, C (reprint author), Massachusetts Gen Hosp, 1 Bowdoin Sq,7th Floor, Boston, MA 02140 USA.
EM cpsaros@mgh.harvard.edu
FU NIMH NIH HHS [K23 MH096651, K24 MH094214, K24 MH087227]
NR 45
TC 9
Z9 9
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1548-3568
EI 1548-3576
J9 CURR HIV-AIDS REP
JI Curr. Hiv/Aids Rep.
PD MAR
PY 2015
VL 12
IS 1
BP 1
EP 5
DI 10.1007/s11904-014-0252-6
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA CD7XD
UT WOS:000351307700001
PM 25620530
ER
PT J
AU Chahroudi, A
Silvestri, G
Lichterfeld, M
AF Chahroudi, Ann
Silvestri, Guido
Lichterfeld, Mathias
TI T Memory Stem Cells and HIV: a Long-Term Relationship
SO CURRENT HIV/AIDS REPORTS
LA English
DT Article
DE HIV; SIV; Memory T cell; T memory stem cell; HIV-1 reservoir;
Persistence; Central memory; Effector memory; Stem cell; beta-Catenin
ID SIMIAN-IMMUNODEFICIENCY-VIRUS; NATURAL SIV HOSTS; LENTIVIRAL INFECTIONS;
PROGENITOR CELLS; WNT PATHWAY; IN-VIVO; EFFECTOR; RESERVOIR; DISEASE;
TRANSMISSION
AB In analogy to many tissues in which mature, terminally differentiated cells are continuously replenished by the progeny of less differentiated, long-lasting stem cells, it has been suspected that memory T lymphocytes might contain small numbers of stem cell-like cells. However, only recently have such cells been physically identified and isolated from humans, mice, and nonhuman primates. These cells, termed "T memory stem cells" (T-SCM), represent approximately 2-4% of all circulating T lymphocytes, seem to be extremely durable, and can rapidly differentiate into more mature central memory, effector memory, and effector T cells, while maintaining their own pool size through homeostatic self-renewal. Although it is becoming increasingly evident that that these cells have critical roles for T cell homeostasis and maintaining life-long cellular immunity against microbial pathogens during physiological conditions, they also seem intrinsically involved in many key aspects of HIV/SIV disease pathogenesis. Current data suggest that CD4+T-SCM cells represent a core element of the HIV-1 reservoir in patients treated with suppressive antiretroviral therapy (ART) and that relative resistance of CD4+ T-SCM cells to SIV represents a distinguishing feature of non-pathogenic SIV infection in natural hosts. This article summarizes recent studies investigating the role of T-SCM in HIV/SIV infection.
C1 [Chahroudi, Ann] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.
[Chahroudi, Ann; Silvestri, Guido] Yerkes Natl Primate Res Ctr, Atlanta, GA USA.
[Lichterfeld, Mathias] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Chahroudi, A (reprint author), Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.
EM ann.m.chahroudi@emory.edu
FU American Foundation for AIDS Research [108905-56-RGRL, 108302-51-RGRL];
NICHD Child Health Research Career Development Award [K12 HD072245];
Doris Duke Charitable Foundation [2009034]; NIH grant [AI098487,
AI106468, R37AI066998]
FX AC is supported by the American Foundation for AIDS Research (grant
108905-56-RGRL) and by an NICHD Child Health Research Career Development
Award (K12 HD072245). ML is supported by the American Foundation for
AIDS Research (grant 108302-51-RGRL), by the Doris Duke Charitable
Foundation (grant 2009034), and by NIH grants AI098487 and AI106468. GS
is supported by NIH grant R37AI066998.
NR 62
TC 6
Z9 6
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1548-3568
EI 1548-3576
J9 CURR HIV-AIDS REP
JI Curr. Hiv/Aids Rep.
PD MAR
PY 2015
VL 12
IS 1
BP 33
EP 40
DI 10.1007/s11904-014-0246-4
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA CD7XD
UT WOS:000351307700005
PM 25578055
ER
PT J
AU Gogela, NA
Lin, MV
Wisocky, JL
Chung, RT
AF Gogela, Neliswa A.
Lin, Ming V.
Wisocky, Jessica L.
Chung, Raymond T.
TI Enhancing Our Understanding of Current Therapies for Hepatitis C Virus
(HCV)
SO CURRENT HIV/AIDS REPORTS
LA English
DT Article
DE Direct-acting antivirals (DAAs); Protease inhibitors; NS5A inhibitors;
NS5B polymerase inhibitors; HCV/HIV co-infection
ID GENOTYPE 1 INFECTION; TREATMENT-NAIVE PATIENTS; SUSTAINED VIROLOGICAL
RESPONSE; PEGYLATED INTERFERON; RANDOMIZED-TRIAL; VIRAL-HEPATITIS;
NATURAL-HISTORY; PLUS RIBAVIRIN; UNITED-STATES; LIFE-CYCLE
AB Great progress has been made in understanding the HCV genome and its molecular virology. This understanding has culminated in the development of direct-acting antiviral (DAA) agents targeting HCV viral proteins. Telaprevir (TVR) and boceprevir (BOC) were the first DAAs introduced for treatment of genotype 1 HCV in 2011; when used in combination with pegylated interferon (pegIFN) and ribavirin (RBV), these protease inhibitors improved efficacy in patients with chronic HCV infection compared to the traditional dual therapy. However, this combination was associated with adverse events that often led to early termination of therapy. In late 2013, the FDA approved a second wave of DAAs, sofosbuvir (SOF) and simeprevir (SMV). The use of SOF with SMV opened the door for IFN-free combination regimens. This combination was highly efficacious and well tolerated in patients with HCV genotype 1. Sofosbuvir and ledipasvir (LDV) fixed-dose oral combination (FDC) therapy, and paritaprevir/ritonavir, ombitasvir and dasabuvir +/- RBV were recently approved, elevating sustained virologic response (SVR) rates to over 95%. We are anticipating the approval of additional IFN-free regimens with comparable efficacy and tolerability but with the addition of pangenotypic coverage, fewer drug-drug interactions, and a high barrier to resistance. This review will summarize current management for chronic HCV infection.
C1 [Gogela, Neliswa A.; Lin, Ming V.; Wisocky, Jessica L.; Chung, Raymond T.] Massachusetts Gen Hosp, Dept Med, Ctr Liver, Boston, MA 02114 USA.
[Gogela, Neliswa A.; Lin, Ming V.; Wisocky, Jessica L.; Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Div, Boston, MA 02114 USA.
[Lin, Ming V.; Chung, Raymond T.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Lin, Ming V.] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA.
RP Chung, RT (reprint author), Massachusetts Gen Hosp, Dept Med, Ctr Liver, 55 Fruit St, Boston, MA 02114 USA.
EM Chung.Raymond@mgh.harvard.edu
FU Gilead; AbbVie; MassBiologics; BMS (clinical trials)
FX Raymond T. Chung reports grant support from Gilead, AbbVie,
MassBiologics, and BMS (clinical trials).
NR 77
TC 11
Z9 11
U1 0
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1548-3568
EI 1548-3576
J9 CURR HIV-AIDS REP
JI Curr. Hiv/Aids Rep.
PD MAR
PY 2015
VL 12
IS 1
BP 68
EP 78
DI 10.1007/s11904-014-0243-7
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA CD7XD
UT WOS:000351307700008
PM 25761432
ER
PT J
AU Chen, HM
Fujita, M
AF Chen, Hui-min
Fujita, Mayumi
TI IL-37: A new player in immune tolerance
SO CYTOKINE
LA English
DT Editorial Material
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; ADAPTIVE IMMUNITY; DENDRITIC CELLS;
INTERLEUKIN 37; EXPRESSION; INNATE; DISEASE; PROTECTS; OBESITY; MEMBERS
C1 [Chen, Hui-min; Fujita, Mayumi] Univ Colorado, Dept Dermatol, Aurora, CO 80045 USA.
[Fujita, Mayumi] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA.
RP Fujita, M (reprint author), Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO 80045 USA.
EM Mayumi.Fujita@ucdenver.edu
FU NIAMS NIH HHS [P30AR057212]
NR 27
TC 7
Z9 8
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD MAR
PY 2015
VL 72
IS 1
BP 113
EP 114
DI 10.1016/j.cyto.2014.11.025
PG 2
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA CD8CI
UT WOS:000351322400017
PM 25592113
ER
PT J
AU Paciorkowski, AR
McDaniel, SS
Jansen, LA
Tully, H
Tuttle, E
Ghoneim, DH
Tupal, S
Gunter, SA
Vasta, V
Zhang, Q
Tran, T
Liu, YB
Ozelius, LJ
Brashear, A
Sweadner, KJ
Dobyns, WB
Hahn, S
AF Paciorkowski, Alex R.
McDaniel, Sharon S.
Jansen, Laura A.
Tully, Hannah
Tuttle, Emily
Ghoneim, Dalia H.
Tupal, Srinivasan
Gunter, Sonya A.
Vasta, Valeria
Zhang, Qing
Thao Tran
Liu, Yi B.
Ozelius, Laurie J.
Brashear, Allison
Sweadner, Kathleen J.
Dobyns, William B.
Hahn, Sihoun
TI Novel mutations in ATP1A3 associated with catastrophic early life
epilepsy, episodic prolonged apnea, and postnatal microcephaly
SO EPILEPSIA
LA English
DT Article
DE ATP1A3; Early life epilepsy; Apnea; Postnatal microcephaly; Na;
K-ATPase; Next-generation sequencing
ID ONSET DYSTONIA-PARKINSONISM; DE-NOVO MUTATIONS; RAPID-ONSET; ALTERNATING
HEMIPLEGIA; NA/K-ATPASE; CHILDHOOD; GENE; INTERNEURONS; NA,K-ATPASE;
SPECTRUM
AB Objective: Mutations of ATP1A3 have been associated with rapid onset dystonia-parkinsonism and more recently with alternating hemiplegia of childhood. Here we report onechild with catastrophic early life epilepsy and shortened survival, and another with epilepsy, episodic prolonged apnea, postnatal microcephaly, and severe developmental disability. Novel heterozygous mutations (p.Gly358Val and p.Ile363Asn) were identified in ATP1A3in these children.
Methods: Subjects underwent next-generation sequencing under a research protocol. Clinical data were collected retrospectively. The biochemical effects of the mutations on ATP1A3 protein function were investigated. Postmortem neuropathologic specimens from control and affected subjects were studied.
Results: The mutations localized to the P domain of the Na, K-ATPase alpha 3 protein, and resulted in significant reduction of Na, K-ATPase activity in vitro. We demonstrate in both control human brain tissue and that from the subject with the p.Gly358Val mutation that ATP1A3 immunofluorescence is prominently associated with interneurons in the cortex, which may provide some insight into the pathogenesis of the disease.
Significance: The findings indicate these mutations cause severe phenotypes of ATP1A3-related disorder spectrum that include catastrophic early life epilepsy, episodic apnea, and postnatal microcephaly.
C1 [Paciorkowski, Alex R.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.
[Paciorkowski, Alex R.] Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA.
[Paciorkowski, Alex R.] Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA.
[Paciorkowski, Alex R.; Tuttle, Emily; Ghoneim, Dalia H.] Univ Rochester, Med Ctr, Ctr Neural Dev & Dis, Rochester, NY 14642 USA.
[McDaniel, Sharon S.] Kaiser Permanente, Dept Pediat, San Francisco, CA USA.
[Jansen, Laura A.; Tupal, Srinivasan; Gunter, Sonya A.] Univ Virginia, Dept Neurol, Charlottesville, VA USA.
[Tully, Hannah] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Tully, Hannah; Vasta, Valeria; Zhang, Qing; Thao Tran; Hahn, Sihoun] Seattle Childrens Res Inst, Ctr Dev Therapeut, Seattle, WA USA.
[Liu, Yi B.; Sweadner, Kathleen J.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Ozelius, Laurie J.] Icahn Sch Med Mt Sinai, Dept Genet, New York, NY 10029 USA.
[Ozelius, Laurie J.] Icahn Sch Med Mt Sinai, Dept Genom Sci, New York, NY 10029 USA.
[Ozelius, Laurie J.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.
[Brashear, Allison] Wake Forest Sch Med, Dept Neurol, Winston Salem, NC USA.
[Sweadner, Kathleen J.] Harvard Univ, Sch Med, Boston, MA USA.
[Dobyns, William B.] Seattle Childrens Res Inst, Ctr Integrat Brain Res, Seattle, WA USA.
[Dobyns, William B.; Hahn, Sihoun] Univ Washington, Dept Pediat, Div Med Genet, Seattle, WA 98195 USA.
RP Paciorkowski, AR (reprint author), Univ Rochester, Med Ctr, Child Neurol, 601 Elmwood Ave, Rochester, NY 14642 USA.
EM alex_paciorkowski@urmc.rochester.edu
RI Brashear, Allison/G-3853-2015;
OI Dobyns, William/0000-0002-7681-2844; Vasta, Valeria/0000-0002-8148-1795
FU National Institute of Neurologic Disorders and Stroke (NINDS) of the
National Institutes of Health (NIH) [K08NS078054, K02NS072162,
R21NS081558, R01NS0 46616]; [LR11-328]
FX The authors would like to thank the two children and their parents for
participation in this study, and the parents of LR11-328 who provided
funding for the studies of ATP1A3 activity. We also wish to acknowledge
Dr. Raj Kapur, Seattle Children's Hospital, for his assistance with the
clinical neuropathology data. Research reported in this work was
supported by the National Institute of Neurologic Disorders and Stroke
(NINDS) of the National Institutes of Health (NIH) under award numbers
K08NS078054 (A.R.P), K02NS072162 (L.A.J.), R21NS081558 (K.J.S.), and
R01NS0 46616 (W.B.D.). The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
NIH.
NR 36
TC 16
Z9 16
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD MAR
PY 2015
VL 56
IS 3
BP 422
EP 430
DI 10.1111/epi.12914
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA CD6ZP
UT WOS:000351240300014
PM 25656163
ER
PT J
AU Karamichos, D
Zieske, JD
Sejersen, H
Sarker-Nag, A
Asara, JM
Hjortdal, J
AF Karamichos, D.
Zieske, J. D.
Sejersen, H.
Sarker-Nag, A.
Asara, John M.
Hjortdal, J.
TI Tear metabolite changes in keratoconus
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Keratoconus; Metabolomics; Oxidative stress; Rigid Gas Permeable lenses;
Pentacam
ID CONTACT-LENS WEAR; CORNEAL ALDEHYDE DEHYDROGENASE; OXIDATIVE STRESS;
RECURRENT KERATOCONUS; PATHOLOGICAL CORNEAS; PROTEINS; GLUTATHIONE;
THICKNESS; ACCUMULATION; EXPRESSION
AB While efforts have been made over the years, the exact cause of keratoconus (KC) remains unknown. The aim of this study was to identify alterations in endogenous metabolites in the tears of KC patients compared with age-matched healthy subjects. Three groups were tested: 1) Age-matched controls with no eye disease (N = 15), 2) KC - patients wearing Rigid Gas permeable lenses (N = 16), and 3) KC - No Correction (N = 14). All samples were processed for metabolomics analysis using LC-MS/MS. We identified a total of 296 different metabolites of which >40 were significantly regulated between groups. Glycolysis and gluconeogenesis had significant changes, such as 3-phosphoglycerate and 1,3 diphosphateglycerate. As a result the citric acid cycle (TCA) was also affected with notable changes in Isocitrate, aconitate, malate, and acetylphosphate, up regulated in Group 2 and/or 3. Urea cycle was also affected, especially in Group 3 where ornithine and aspartate were up-regulated by at least 3 fold. The oxidation state was also severely affected. Groups 2 and 3 were under severe oxidative stress causing multiple metabolites to be regulated when compared to Group 1. Group 2 and 3, both showed significant down regulation in GSH-to-GSSG ratio when compared to Group 1. Another indicator of oxidative stress, the ratio of lactate - pyruvate was also affected with Groups 2 and 3 showing at least a 2-fold up regulation. Overall, our data indicate that levels of metabolites related to urea cycle, TCA cycle and oxidative stress are highly altered in KC patients. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Karamichos, D.; Sarker-Nag, A.] Univ Oklahoma, Dean McGee Eye Inst, Ophthalmol, Oklahoma City, OK 73104 USA.
[Zieske, J. D.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
[Zieske, J. D.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Sejersen, H.; Hjortdal, J.] Aarhus Univ Hosp, Dept Ophthalmol, DK-8000 Aarhus C, Denmark.
[Asara, John M.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Signal Transduct,Mass Spectrometry Core, Boston, MA 02215 USA.
RP Karamichos, D (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, 608 Stanton L Young Blvd,DMEI PA-409, Oklahoma City, OK 73104 USA.
EM dimitrios-karamichos@ouhsc.edu; james_zieske@meei.harvard.edu;
henrseje@rm.dk; Akhee-SarkerNag@ouhsc.edu; jasara@bidmc.harvard.edu;
jesper.hjortdal@dadlnet.dk
RI karamichos, dimitrios/D-9651-2015
FU National Institutes of Health/National Eye Institute [5R01EY023568,
2P01CA120964]; Dana-Farber/Harvard Cancer Center Support Grant
[5P30CA006516]; Research to Prevent Blindness, (New York, NY USA)
FX The authors thank Min Yuan and Susanne Breitkopf for technical help with
mass spectrometry experiments. The authors would also like to thank Dr.
Robert E. Anderson for his input. This work was supported by National
Institutes of Health/National Eye Institute Grant 5R01EY023568 (D.K),
2P01CA120964 (J.M.A.) and Dana-Farber/Harvard Cancer Center Support
Grant 5P30CA006516 (J.M.A.). Also, supported, in part, by an
unrestricted grant from Research to Prevent Blindness, (New York, NY
USA). The Pentacam HR at Aarhus University Hospital was kindly donated
by Bagenkop-Nielsens Myopia Foundation.
NR 69
TC 6
Z9 6
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAR
PY 2015
VL 132
BP 1
EP 8
DI 10.1016/j.exer.2015.01.007
PG 8
WC Ophthalmology
SC Ophthalmology
GA CD6HJ
UT WOS:000351189900001
PM 25579606
ER
PT J
AU Parisi, LM
Gabbay, RA
AF Parisi, Laura M.
Gabbay, Robert A.
TI What Providers Want From the Primary Care Extension Service to
Facilitate Practice Transformation
SO FAMILY MEDICINE
LA English
DT Article
ID CENTERED MEDICAL HOME; HEALTH; IMPROVEMENT
AB BACKGROUND AND OBJECTIVES: While several experts have shared their visions of the Primary Care Extension Service (PCES) as called for in the Affordable Care Act (ACA), little is known about providers' perspective. We aimed to identify the most and least desired resources that primary care providers want from the PCES.
METHODS: A 70-question survey was administered to primary care providers (n=556) in Pennsylvania, one of four initial states chosen to develop the PCES infrastructure. Analysis focused on the highest and lowest ranked questions.
RESULTS: The most desired PCES services include (1) identifying and coordinating mental health services, (2) improving office efficiency, (3) increasing overall revenues, and (4) strategies to help implement evidence-based clinical guidelines. The least desired PCES services include (1) implementing e-prescribing, (2) implementing an electronic medical record (EMR) system, (3) implementing group visits, (4) recruiting new patients, and (5) implementing open or advanced access scheduling.
CONCLUSIONS: Despite expert models presented for the PCES, there is a critical need to ask primary care providers what they need from such a service. Our findings identified some divergences from key patient-centered medical home (PCMH) components, including the low ranking of services related to EMRs and increasing patient access. With interest growing in developing a PCES that would help spread innovation as outlined in the ACA, it's important to take a demand-side approach to the services providers most desire versus the more traditional supply-side approach that assumes the assistance providers need.
C1 [Parisi, Laura M.] Penn State Univ, Coll Med, University Pk, PA 16802 USA.
[Gabbay, Robert A.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Cambridge, MA 02138 USA.
RP Gabbay, RA (reprint author), Joslin Diabet Ctr, One Joslin Pl, Boston, MA 02215 USA.
EM gabbay@joslin.harvard.edu
FU Agency for Healthcare Research and Quality [U18HS020988]
FX This project was supported by grant number U18HS020988 from the Agency
for Healthcare Research and Quality. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the Agency for Healthcare Research and Quality
NR 34
TC 0
Z9 0
U1 1
U2 2
PU SOC TEACHERS FAMILY MEDICINE
PI LEAWOOD
PA 11400 TOMAHAWK CREEK PARKWAY, STE 540, LEAWOOD, KS 66207 USA
SN 0742-3225
EI 1938-3800
J9 FAM MED
JI Fam. Med.
PD MAR
PY 2015
VL 47
IS 3
BP 210
EP 216
PG 7
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA CD5HV
UT WOS:000351119500007
PM 25853532
ER
PT J
AU Springelkamp, H
Mishra, A
Hysi, PG
Gharahkhani, P
Hohn, R
Khor, CC
Bailey, JNC
Luo, XY
Ramdas, WD
Vithana, E
Koh, V
Yazar, S
Xu, L
Forward, H
Kearns, LS
Amin, N
Iglesias, AI
Sim, KS
van Leeuwen, EM
Demirkan, A
van der Lee, S
Loon, SC
Rivadeneira, F
Nag, A
Sanfilippo, PG
Schillert, A
de Jong, PTVM
Oostra, BA
Uitterlinden, AG
Hofman, A
Zhou, T
Burdon, KP
Spector, TD
Lackner, KJ
Saw, SM
Vingerling, JR
Teo, YY
Pasquale, LR
Wolfs, RCW
Lemij, HG
Tai, ES
Jonas, JB
Cheng, CY
Aung, T
Jansonius, NM
Klaver, CCW
Craig, JE
Young, TL
Haines, JL
MacGregor, S
Mackey, DA
Pfeiffer, N
Wong, TY
Wiggs, JL
Hewitt, AW
van Duijn, CM
Hammond, CJ
AF Springelkamp, Henriet
Mishra, Aniket
Hysi, Pirro G.
Gharahkhani, Puya
Hoehn, Rene
Khor, Chiea-Chuen
Bailey, Jessica N. Cooke
Luo, Xiaoyan
Ramdas, Wishal D.
Vithana, Eranga
Koh, Victor
Yazar, Seyhan
Xu, Liang
Forward, Hannah
Kearns, Lisa S.
Amin, Najaf
Iglesias, Adriana I.
Sim, Kar-Seng
van Leeuwen, Elisabeth M.
Demirkan, Ayse
van der Lee, Sven
Loon, Seng-Chee
Rivadeneira, Fernando
Nag, Abhishek
Sanfilippo, Paul G.
Schillert, Arne
de Jong, Paulus T. V. M.
Oostra, Ben A.
Uitterlinden, Andre G.
Hofman, Albert
Zhou, Tiger
Burdon, Kathryn P.
Spector, Timothy D.
Lackner, Karl J.
Saw, Seang-Mei
Vingerling, Johannes R.
Teo, Yik-Ying
Pasquale, Louis R.
Wolfs, Roger C. W.
Lemij, Hans G.
Tai, E-Shyong
Jonas, Jost B.
Cheng, Ching-Yu
Aung, Tin
Jansonius, Nomdo M.
Klaver, Caroline C. W.
Craig, Jamie E.
Young, Terri L.
Haines, Jonathan L.
MacGregor, Stuart
Mackey, David A.
Pfeiffer, Norbert
Wong, Tien-Yin
Wiggs, Janey L.
Hewitt, Alex W.
van Duijn, Cornelia M.
Hammond, Christopher J.
CA NEIGHBORHOOD Consortium
TI Meta-analysis of Genome-Wide Association Studies Identifies Novel Loci
Associated With Optic Disc Morphology
SO GENETIC EPIDEMIOLOGY
LA English
DT Article
DE GWAS; disc area; cup area; glaucoma
ID OPEN-ANGLE GLAUCOMA; OCULAR-TISSUES; GENE; GENOTYPES; TRAITS; NERVE;
ATOH7; SIZE
AB Primary open-angle glaucoma is the most common optic neuropathy and an important cause of irreversible blindness worldwide. The optic nerve head or optic disc is divided in two parts: a central cup (without nerve fibers) surrounded by the neuroretinal rim (containing axons of the retinal ganglion cells). The International Glaucoma Genetics Consortium conducted a meta-analysis of genome-wide association studies consisting of 17,248 individuals of European ancestry and 6,841 individuals of Asian ancestry. The outcomes of the genome-wide association studies were disc area and cup area. These specific measurements describe optic nerve morphology in another way than the vertical cup-disc ratio, which is a clinically used measurement, and may shed light on new glaucoma mechanisms. We identified 10 new loci associated with disc area (CDC42BPA, F5, DIRC3, RARB, ABI3BP, DCAF4L2, ELP4, TMTC2, NR2F2, and HORMAD2) and another 10 new loci associated with cup area (DHRS3, TRIB2, EFEMP1, FLNB, FAM101, DDHD1, ASB7, KPNB1, BCAS3, and TRIOBP). The new genes participate in a number of pathways and future work is likely to identify more functions related to the pathogenesis of glaucoma.
C1 [Springelkamp, Henriet; Amin, Najaf; Iglesias, Adriana I.; van Leeuwen, Elisabeth M.; Demirkan, Ayse; van der Lee, Sven; Rivadeneira, Fernando; Uitterlinden, Andre G.; Hofman, Albert; Klaver, Caroline C. W.; van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
[Springelkamp, Henriet; Ramdas, Wishal D.; Wolfs, Roger C. W.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
[Mishra, Aniket; Gharahkhani, Puya; MacGregor, Stuart] Royal Brisbane Hosp, QIMR Berghofer Med Res Inst, Stat Genet, Brisbane, Qld 4029, Australia.
[Hysi, Pirro G.; Nag, Abhishek; Spector, Timothy D.; Hammond, Christopher J.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London WC2R 2LS, England.
[Hoehn, Rene; Pfeiffer, Norbert] Univ Med Ctr Mainz, Dept Ophthalmol, Mainz, Germany.
[Hoehn, Rene; Lackner, Karl J.] Klin Pallas Olten, Olten, Switzerland.
[Khor, Chiea-Chuen; Vithana, Eranga; Koh, Victor; Loon, Seng-Chee; Saw, Seang-Mei; Cheng, Ching-Yu; Aung, Tin; Wong, Tien-Yin] Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore.
[Khor, Chiea-Chuen; Vithana, Eranga; Koh, Victor; Loon, Seng-Chee; Saw, Seang-Mei; Cheng, Ching-Yu; Aung, Tin; Wong, Tien-Yin] Natl Univ Hlth Syst, Singapore, Singapore.
[Khor, Chiea-Chuen; Sim, Kar-Seng] Genome Inst Singapore, Div Human Genet, Singapore, Singapore.
[Bailey, Jessica N. Cooke; Haines, Jonathan L.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
[Luo, Xiaoyan; Young, Terri L.] Duke Univ, Ctr Eye, Durham, NC USA.
[Vithana, Eranga; Saw, Seang-Mei; Cheng, Ching-Yu; Wong, Tien-Yin] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore.
[Vithana, Eranga; Saw, Seang-Mei; Vingerling, Johannes R.; Cheng, Ching-Yu; Aung, Tin; Wong, Tien-Yin] Singapore Natl Eye Ctr, Eye Res Inst, Singapore, Singapore.
[Yazar, Seyhan; Forward, Hannah; Sanfilippo, Paul G.; Mackey, David A.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
[Xu, Liang] Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
[Xu, Liang] Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.
[Kearns, Lisa S.; Sanfilippo, Paul G.; Hewitt, Alex W.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, CERA, Melbourne, Vic, Australia.
[Demirkan, Ayse] Leiden Univ, Dept Human Genet, Med Ctr, NL-2300 RA Leiden, Netherlands.
[Rivadeneira, Fernando; Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
[Rivadeneira, Fernando; Uitterlinden, Andre G.; Hofman, Albert] Netherlands Genom Initiat, Netherlands Consortium Hlth Ageing, The Hague, Netherlands.
[Schillert, Arne] Partner Site Hamburg Kiel Lubeck, DZHK German Ctr Cardiovasc Res, Lubeck, Germany.
[Schillert, Arne] Med Univ Lubeck, Inst Med Biometry & Stat, D-23538 Lubeck, Germany.
[de Jong, Paulus T. V. M.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
[de Jong, Paulus T. V. M.] Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands.
[de Jong, Paulus T. V. M.] Netherlands Inst Neurosci, Dept Retinal Signal Proc, Amsterdam, Netherlands.
[Oostra, Ben A.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands.
[Zhou, Tiger; Craig, Jamie E.] Flinders Univ S Australia, Dept Ophthalmol, Adelaide, SA 5001, Australia.
[Burdon, Kathryn P.; Mackey, David A.; Hewitt, Alex W.] Univ Tasmania, Menzies Res Inst Tasmania, Sch Med, Hobart, Tas, Australia.
[Saw, Seang-Mei; Teo, Yik-Ying; Tai, E-Shyong] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
[Saw, Seang-Mei; Teo, Yik-Ying; Tai, E-Shyong] Natl Univ Hlth Syst, Singapore, Singapore.
[Teo, Yik-Ying; Tai, E-Shyong] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117548, Singapore.
[Pasquale, Louis R.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Pasquale, Louis R.; Wiggs, Janey L.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Pasquale, Louis R.; Wiggs, Janey L.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Lemij, Hans G.] Rotterdam Eye Hosp, Glaucoma Serv, Rotterdam, Netherlands.
[Tai, E-Shyong] Natl Univ Singapore, Dept Med, Singapore 117548, Singapore.
[Tai, E-Shyong] Natl Univ Hlth Syst, Singapore, Singapore.
[Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Heidelberg, Germany.
[Jansonius, Nomdo M.] Univ Groningen, Univ Med Ctr Groningen, Dept Ophthalmol, Groningen, Netherlands.
RP Springelkamp, H (reprint author), Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
EM c.vanduijn@erasmusmc.nl
RI Macgregor, Stuart/C-6442-2009; Hewitt, Alex/D-1936-2013; Mackey,
David/H-5340-2014;
OI Macgregor, Stuart/0000-0001-6731-8142; Hewitt, Alex/0000-0002-5123-5999;
Mackey, David/0000-0001-7914-4709; Sim, Kar Seng/0000-0002-3822-7759;
Yazar, Seyhan/0000-0003-0994-6196; Gharahkhani,
Puya/0000-0002-4203-5952; Hohn, Rene /0000-0003-2870-1469; Tai, E
Shyong/0000-0003-2929-8966; Rivadeneira, Fernando/0000-0001-9435-9441;
Khor, Chiea Chuen/0000-0002-1128-4729; Hammond,
Christopher/0000-0002-3227-2620
FU Department of Health [SRF/01/010]; NEI NIH HHS [R01 EY011405, R01
EY013178, R01 EY015473, R01 EY022305, P30 EY014104, R01 EY004859, R01
EY023754]
NR 25
TC 14
Z9 14
U1 0
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-0395
EI 1098-2272
J9 GENET EPIDEMIOL
JI Genet. Epidemiol.
PD MAR
PY 2015
VL 39
IS 3
BP 207
EP 216
DI 10.1002/gepi.21886
PG 10
WC Genetics & Heredity; Mathematical & Computational Biology
SC Genetics & Heredity; Mathematical & Computational Biology
GA CD9ZW
UT WOS:000351462200008
PM 25631615
ER
PT J
AU Clark, RM
Lee, MS
Rauh-Hain, JA
Hall, T
Boruta, DM
del Carmen, MG
Goodman, A
Schorge, JO
Growdon, WB
AF Clark, Rachel M.
Lee, Malinda S.
Rauh-Hain, J. Alejandro
Hall, Tracilyn
Boruta, David M.
del Carmen, Marcela G.
Goodman, Annekathryn
Schorge, John O.
Growdon, Whitfield B.
TI Surgical Apgar Score and prediction of morbidity in women undergoing
hysterectomy for malignancy
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Surgical Apgar Score; Hysterectomy; Morbidity; Complications;
Gynecologic oncology
ID EPITHELIAL OVARIAN-CARCINOMA; HOSPITAL READMISSION; VALIDATION; SURGERY;
CARE; CYTOREDUCTION; POPULATION; ADMISSION; OUTCOMES; PATIENT
AB Objective. To validate whether Surgical Apgar Score can predict post-operative morbidity in patients undergoing hysterectomies for malignancies.
Methods. We conducted a retrospective cohort study of consecutive hysterectomies performed for cancer at a single academic institution between 2008 and 2010. The Surgical Apgar Score (SAS) was derived as previously reported. Pen-operative complications were as outlined by the American Board for Obstetrics and Gynecology, and then further subdivided into intra-operative and post-operative events. Univariate and multivariate logistic regressions were utilized.
Results. A total of 632 patients were identified. Of our cohort, 64% underwent surgery for cancer arising in the uterus, followed by ovary at 28.6% and cervix at 4%. Median patient age was 60 years old with a mean American Society of Anesthesiologists Physical Status Classification System (ASA) score of 2.5 and a median body mass index of 29. Average Surgical Apgar Score was 7.6. As SAS decreased, the risk of pen-operative complications increased (p < 0.01). On univariate analysis SAS could predict for both intra-operative and postoperative complications. However, on multivariate analyses SAS could not independently predict for any post-operative complications (OR 1.02, CI 0.47-2.17). In a multivariable model incorporating age, ASA class, SAS <4, disease site, bowel resection and laparotomy, only ASA class and laparotomy were able to predict for postoperative complication events.
Conclusions. Low Surgical Apgar Score significantly associates with morbidity in women undergoing hysterectomy for malignancy, but is unable to predict which patients will have postoperative complications. This renders the SAS less helpful for the creation of pen-operative metrics to guide post-operative care. (C) 2014 Elsevier Inc. All rights reserved.
C1 Massachusetts Gen Hosp, Div Gynecol Oncol, Vincent Dept Obstet & Gynecol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA.
RP Clark, RM (reprint author), 55 Fruit St, Boston, MA 02114 USA.
EM rmclark@partners.org
NR 30
TC 4
Z9 5
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD MAR
PY 2015
VL 136
IS 3
BP 516
EP 520
DI 10.1016/j.ygyno.2014.11.016
PG 5
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA CD6GJ
UT WOS:000351187300016
PM 25475542
ER
PT J
AU Schorge, JO
AF Schorge, John O.
TI y Cocytus: Have you begun your descent?
SO GYNECOLOGIC ONCOLOGY
LA English
DT Review
DE Mentoring; Professional development; Academic career
ID PROCRASTINATION; SURGERY
AB The vast majority of trainees entering a fellowship express a sincere interest in pursuing an 'academic career'. However, even the most dedicated souls will find their own path toward that worthy goal fraught with a number of unanticipated hazards-any one of which could result in a fullstop of professional advancement. Of interest, many of the obstacles are actually self-imposed, usually buried within the subconscious self. Without guidance of how to recognize and address these shortcomings, abandonment of one's original career trajectory may be seriously considered, and often acted upon. By the time any one of us has completed training, taken the boards, and gotten to this inflection point, we are at least in our mid- to late-30s. What then, is there to do, about this looming phenomenon, whenever it may occur? Perhaps we can draw comfort from a historical figure who has been there, and done that. His journey embodies the value of mentoring in traversing the succession of personal perils that are commonplace in today's professional environment (C) 2015 Elsevier Inc. All rights reserved.
C1 [Schorge, John O.] Massachusetts Gen Hosp, Vincent Gynecol Oncol Serv, Boston, MA 02114 USA.
RP Schorge, JO (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Vincent Gynecol Oncol Serv, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA.
EM jschorge@partners.org
NR 12
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD MAR
PY 2015
VL 136
IS 3
BP 582
EP 588
DI 10.1016/j.ygyno.2014.12.040
PG 7
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA CD6GJ
UT WOS:000351187300026
PM 25575482
ER
PT J
AU Coutinho, R
Clear, AJ
Mazzola, E
Owen, A
Greaves, P
Wilson, A
Matthews, J
Lee, A
Alvarez, R
da Silva, MG
Cabecadas, J
Neuberg, D
Calaminici, M
Gribben, JG
AF Coutinho, Rita
Clear, Andrew J.
Mazzola, Emanuele
Owen, Andrew
Greaves, Paul
Wilson, Andrew
Matthews, Janet
Lee, Abigail
Alvarez, Rute
da Silva, Maria Gomes
Cabecadas, Jose
Neuberg, Donna
Calaminici, Maria
Gribben, John G.
TI Revisiting the immune microenvironment of diffuse large B-cell lymphoma
using a tissue microarray and immunohistochemistry: robust semi-
automated analysis reveals CD3 and FoxP3 as potential predictors of
response to R-CHOP
SO HAEMATOLOGICA
LA English
DT Article
ID REGULATORY T-CELLS; TUMOR-ASSOCIATED MACROPHAGES; FOLLICULAR LYMPHOMA;
HODGKINS-LYMPHOMA; BIOMARKER CONSORTIUM; RITUXIMAB; SURVIVAL;
CHEMOTHERAPY; EXPRESSION; VALIDATION
AB Gene expression studies have identified the microenvironment as a prognostic player in diffuse large B- cell lymphoma. However, there is a lack of simple immune biomarkers that can be applied in the clinical setting and could be helpful in stratifying patients. Immunohistochemistry has been used for this purpose but the results are inconsistent. We decided to reinvestigate the immune microenvironment and its impact using immunohistochemistry, with two systems of image analysis, in a large set of patients with diffuse large B- cell lymphoma. Diagnostic tissue from 309 patients was arrayed onto tissue microarrays. Results from 161 chemoimmunotherapy- treated patients were used for outcome prediction. Positive cells, percentage stained area and numbers of pixels/ area were quantified and results were compared with the purpose of inferring consistency between the two semi- automated systems. Measurement cutpoints were assessed using a recursive partitioning algorithm classifying results according to survival. Kaplan- Meier estimators and Fisher exact tests were evaluated to check for significant differences between measurement classes, and for dependence between pairs of measurements, respectively. Results were validated by multivariate analysis incorporating the International Prognostic Index. The concordance between the two systems of image analysis was surprisingly high, supporting their applicability for immunohistochemistry studies. Patients with a high density of CD3 and FoxP3 by both methods had a better outcome. Automated analysis should be the preferred method for immunohistochemistry studies. Following the use of two methods of semi- automated analysis we suggest that CD3 and FoxP3 play a role in predicting response to chemoimmunotherapy in diffuse large B- cell lymphoma.
C1 [Coutinho, Rita; Clear, Andrew J.; Owen, Andrew; Greaves, Paul; Wilson, Andrew; Matthews, Janet; Lee, Abigail; Calaminici, Maria; Gribben, John G.] Queen Mary Univ, Barts Canc Inst, Dept Hematooncol, London, England.
[Mazzola, Emanuele] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Owen, Andrew; Lee, Abigail; Neuberg, Donna; Calaminici, Maria] Barts Hlth NHS Trust, Royal London Hosp, Dept Histopathol, London, England.
[Alvarez, Rute; da Silva, Maria Gomes] Portuguese Inst Oncol, Dept Hematol, Lisbon, Portugal.
[Cabecadas, Jose] Portuguese Inst Oncol, Dept Pathol, Lisbon, Portugal.
RP Coutinho, R (reprint author), Queen Mary Univ, Barts Canc Inst, Dept Hematooncol, London, England.
EM rittakoutinho@gmail.com
OI Greaves, Paul/0000-0002-3318-7233; Cabecadas, Jose/0000-0001-6232-1596;
Gomes da Silva, Maria/0000-0002-6993-2450
FU NCI NIH HHS [P01 CA081534, P01 CA81538]; PHS HHS [C1574/A6806]
NR 27
TC 8
Z9 8
U1 1
U2 9
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD MAR
PY 2015
VL 100
IS 3
BP 363
EP 369
DI 10.3324/haematol.2014.110189
PG 7
WC Hematology
SC Hematology
GA CD7OK
UT WOS:000351279900026
PM 25425693
ER
PT J
AU Evins, AE
Cather, C
Laffer, A
AF Evins, A. Eden
Cather, Corinne
Laffer, Alexandra
TI Treatment of Tobacco Use Disorders in Smokers with Serious Mental
Illness: Toward Clinical Best Practices
SO HARVARD REVIEW OF PSYCHIATRY
LA English
DT Article
DE bipolar; depression; nicotine use disorder; randomized controlled trial;
schizophrenia; severe mental illness; smoking cessation; tobacco use
ID PLACEBO-CONTROLLED TRIAL; SMOKING-CESSATION INTERVENTIONS; BIPOLAR
DISORDER; CIGARETTE-SMOKING; MAJOR DEPRESSION; DOUBLE-BLIND;
UNITED-STATES; SCHIZOAFFECTIVE DISORDER; SCHIZOPHRENIC SMOKERS; NICOTINE
DEPENDENCE
AB Addiction to tobacco-derived nicotine remains highly prevalent in the United States, with 18% using daily, and 53% of those with serious mental illness using daily. While smokers with serious mental illness have been excluded from most large nicotine-dependence treatment studies, a growing evidence base is available to guide clinicians in assisting their patients with psychiatric illness to quit smoking. The aim of this review is to present the evidence on safety and efficacy of smoking cessation interventions for those with serious mental illness. Smokers with schizophrenia spectrum disorders should receive varenicline or bupropion with or without nicotine replacement therapy in combination with behavioral treatment. Although more research is needed, preliminary evidence suggests that varenicline in combination with behavioral support is efficacious and well tolerated for smoking cessation for those with bipolar disorder and major depressive disorder. Controlled trials have found no evidence that in patients with serious mental illness, the use of pharmacotherapeutic cessation aids worsens psychiatric symptoms or increases the rate of psychiatric adverse events. Converging evidence indicates that a majority of smokers with serious mental illness want to quit smoking and that available pharmacotherapeutic cessation aids combined with behavioral support are both effective for, and well tolerated by, these smokers.
C1 [Evins, A. Eden; Cather, Corinne] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Evins, A. Eden; Cather, Corinne; Laffer, Alexandra] Massachusetts Gen Hosp, Ctr Addict Med, Dept Psychiat, Boston, MA 02114 USA.
RP Cather, C (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St,WACC812, Boston, MA 02114 USA.
EM ccather@mgh.harvard.edu
FU National Institute on Drug Abuse [R01 DA021245, K24 DA030443]
FX National Institute on Drug Abuse grant nos. R01 DA021245 and K24
DA030443 (Dr. Evins).
NR 77
TC 13
Z9 13
U1 2
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1067-3229
EI 1465-7309
J9 HARVARD REV PSYCHIAT
JI Harv. Rev. Psychiatr.
PD MAR-APR
PY 2015
VL 23
IS 2
BP 90
EP 98
DI 10.1097/HRP.0000000000000063
PG 9
WC Psychiatry
SC Psychiatry
GA CD9TQ
UT WOS:000351441700004
PM 25747922
ER
PT J
AU Sivashanker, K
Mufson, M
Mittal, L
Ross, E
Suzuki, J
AF Sivashanker, Karthik
Mufson, Michael
Mittal, Leena
Ross, Edgar
Suzuki, Joji
TI Challenges in Managing Acute on Chronic Pain in a Pregnant Woman at High
Risk for Opioid Use Disorder in the General Hospital Setting
SO HARVARD REVIEW OF PSYCHIATRY
LA English
DT Article
DE addiction; consultation-liaison psychiatry; dependence; opiate; opioid;
pain; pregnancy; psychosomatic; substance abuse
ID NEONATAL ABSTINENCE SYNDROME; CHRONIC NONMALIGNANT PAIN; DEPENDENT
PATIENTS; BREAST-MILK; BUPRENORPHINE; MANAGEMENT; METHADONE; WOMEN;
EXPOSURE; THERAPY
C1 [Sivashanker, Karthik] VA Boston Healthcare Syst, Dept Psychiat, Jamaica Plain, MA 02130 USA.
[Mufson, Michael; Mittal, Leena; Ross, Edgar; Suzuki, Joji] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Mittal, Leena; Suzuki, Joji] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA.
[Ross, Edgar] Brigham & Womens Hosp, Pain Management Ctr, Boston, MA 02115 USA.
RP Sivashanker, K (reprint author), VA Boston Healthcare Syst, Dept Psychiat, 251 Heath St,201, Jamaica Plain, MA 02130 USA.
EM sivashanker@gmail.com
NR 61
TC 0
Z9 0
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1067-3229
EI 1465-7309
J9 HARVARD REV PSYCHIAT
JI Harv. Rev. Psychiatr.
PD MAR-APR
PY 2015
VL 23
IS 2
BP 157
EP 166
DI 10.1097/HRP.0000000000000080
PG 10
WC Psychiatry
SC Psychiatry
GA CD9TQ
UT WOS:000351441700010
PM 25747928
ER
EF